<SEC-DOCUMENT>0001370368-20-000069.txt : 20200721
<SEC-HEADER>0001370368-20-000069.hdr.sgml : 20200721
<ACCEPTANCE-DATETIME>20200721093839
ACCESSION NUMBER:		0001370368-20-000069
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200721
DATE AS OF CHANGE:		20200721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		201037840

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a200721-6k.htm
<DESCRIPTION>6-K
<TEXT>

<html>
<head>
  <title>6-K</title>

</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#ffffff" text="#000000"">



   <div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<br>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 6-K</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">REPORT OF FOREIGN PRIVATE ISSUER</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">PURSUANT TO RULE 13a-16 or 15d-16 OF</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
    Report on Form 6-K dated
    July 21, 2020</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Commission File No. 1-15024)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="20%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Novartis AG</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">(Name of Registrant)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Lichtstrasse 35</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4056 Basel</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Switzerland</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="center" noshade size="1" width="20%">
</div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Form 20-F: <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form 40-F: <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yes: <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">No</font>: <font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-WEIGHT: bold">x</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yes: <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">No</font>: <font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-WEIGHT: bold">x</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yes: <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">No</font>: <font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-WEIGHT: bold">x</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>


<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Exhibits:</font>
<br />
<br />
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 11pt; FONT-WEIGHT: normal">

  <a href="a200721-99_1.htm" title="99.1 Financial Report Q2 2020">99.1 Financial Report Q2 2020</a>

<br />

 <a href="a200721-99_2.htm" title="99.2 Interim Financial Report">99.2 Interim Financial Report</a>
    <br />
</font>
    <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 11pt; FONT-WEIGHT: normal">
101.INS XBRL Instance Document
        <br />
101.SCH XBRL Taxonomy Extension Schema Document
        <br />
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
        <br />
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
        <br />
101.LAB XBRL Taxonomy Extension Label Linkbase Document
        <br />
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
        <br />


</div>


<br />




    <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Novartis AG</font></div>
</td>
</tr><tr>
<td valign="top" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="top" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:
July 21, 2020</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td colspan="2" valign="top" width="42%" style="BORDER-BOTTOM: black 0.5pt solid; TEXT-ALIGN: left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ PAUL PENEPENT</font></div>
</td>
</tr><tr>
<td valign="top" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paul Penepent</font></div>
</td>
</tr><tr>
<td valign="top" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Head Group Financial Reporting and Accounting</font></div>
</td>
</tr><tr>
<td valign="middle" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="center" noshade size="2" width="100%">
</div>





</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>a200721-99_1.htm
<DESCRIPTION>99.1 FINANCIAL REPORT Q2 2020
<TEXT>

<html>
<head>
  <title>99.1 Financial Report Q2 2020</title>

</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#ffffff" text="#000000"">



  <div id="HDR">
<div id="GLHDR" style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 100%; TEXT-ALIGN: right"></div>

<div style="WIDTH: 100%; TEXT-ALIGN: left">
<table id="1da8732496a249cc854a904f83fcfc20" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%" valign="top" align="left">
<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><img src="logo.jpg"></div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 12pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left"><font style="FONT-FAMILY: Arial">FINANCIAL RESULTS </font><font style="FONT-FAMILY: Arial">| </font>R&#201;SULTATS FINANCIERS <font style="FONT-FAMILY: Arial">| </font>FINANZERGEBNISSE</div>
</div>

<div style="FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 5%" valign="top">&#160; </td>
<td style="WIDTH: 22%" valign="top" align="left">
<div style="FONT-FAMILY: Arial; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-FAMILY: Arial; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-FAMILY: Arial; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9">Novartis&#160;International&#160;AG</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9">Novartis&#160;Global Communications</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font><font style="FONT-FAMILY: Arial; FONT-WEIGHT: normal">CH-4002 Basel</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font><font style="FONT-FAMILY: Arial; FONT-WEIGHT: normal">Switzerland</font></div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: normal; COLOR: #000000; TEXT-ALIGN: left">http://www.novartis.com</div>
</div>

<div style="FONT-FAMILY: Arial; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr>
</table>
</div>
</div>

<div style="FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"></div>

<div style="FONT-FAMILY: Arial">
<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 14pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.</div>

<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 14pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">
<table id="z889b9391a1804aaab3e26ddcc37b6e00" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9pt; VERTICAL-ALIGN: top; align: right">
<div style="margin-bottom: 4pt; font-size: 10pt; font-family: Symbol, serif; font-weight: bold; color: #000000; text-align: left;">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6%&#160; (cc<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">1</sup>, +3% USD) and core&#185; operating income growth of 19% (cc, +14% USD):</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z69a7b605f5e9456db2126e63e3595269" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 22.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Innovative Medicines grew sales 7% (cc, +5% USD) and core operating income 16% (cc, +11% USD)</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z51e25e95c7604e6387509df5338886aa" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 22.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Sandoz grew sales 1% (cc, -2% USD) and core operating income 26% (cc, +19% USD)</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z89d8a702f57340b0b42b61717841adda" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net sales in Q2 from continuing operations<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">2</sup> declined 1% (cc, -4% USD) largely reversing forward purchasing from Q1:</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zd6b8649f6f5448b8afa0fde9146cf1ab" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 22.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Key products continue growth, despite COVID-19, including: <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zolgensma</font> USD 205 million, <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font> USD 580 million (+40% cc), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font> USD 944 million (+12% cc), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Promacta/Revolade</font> USD 422 million (+23% cc), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray</font> USD 79 million and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kymriah</font> USD 118 million (+103% cc)</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z230d08bddf644778962fbd6fe55c26fe" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 22.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Sandoz Biopharmaceuticals grew 19% (cc, +16% USD), with double digit growth in the EU and US</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zc4cffb131cf143959a5846b88f399b0b" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 22.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">COVID-19 negatively impacted demand, particularly: <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Lucentis</font> and mature ophthalmology (approximately USD 0.3 billion), new patient starts in dermatology and Sandoz retail</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z7431fd6137604b76bfce8f9bf76475c1" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9.35pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Q2 core operating income grew 6% (cc, +1% USD) </font>due to lower spending and improved gross margin, driven by productivity and product mix, partly offset by lower sales</div>
</td>
</tr>
</table>
</div>

<div>
<table id="ze6c70ac873004e1191d44f37c6d17380" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9.35pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Q2 net income declined 4% (cc, -11% USD) </font>mainly due to higher impairments</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z7db68e12ba3d413482cd5bce41d23851" class="DSPFListTable" style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9.35pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Q2 free cash flow</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-WEIGHT: bold">1</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold"> of USD 3.6 billion (+1%), </font>as favorable working capital offset divestments in prior year</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z97da3708f6b540248ada25bfb6adceac" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Key Innovation Milestones:</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z8a1f346cc8fd4bed806351d89063fac4" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 23.05pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9.35pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Tabrecta</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">&#160;</font>approved in US for treatment of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">metastatic </font>NSCLC with exon 14 skipping mutation</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zdc01a8e0041f44a1a00097c38799005f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 23.05pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9.35pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Cosentyx</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">&#160;</font>approved in EU and US for treatment of active nr-axSpA</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z9ece77a054f84f2095f9bee4339cadb6" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 23.05pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9.35pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Zolgensma</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold"> IV </font>conditionally approved in EU for SMA children up to 21kg</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z1f7b0053c3bb42a8b772e754125021fa" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 23.05pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9.35pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Enerzair </font>received EC approval for treatment of uncontrolled asthma</div>
</td>
</tr>
</table>
</div>

<div>
<table id="ze6c3b3492b5b4304898e562f306cd2ad" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 22.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Entresto, Tabrecta, Mayzent, Enerzair and Atectura</font> simultaneously approved in <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Japan</font></div>
</td>
</tr>
</table>
</div>

<div>
<table id="z4ddd783f497a419cba7f176afd86912d" class="DSPFListTable" style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">
<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; COLOR: #000000; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Resolved legacy legal matters, </font>including the settlements related to FCPA and US speaker programs</div>
</td>
</tr>
</table>
</div>

<div>
<table id="ze97f74eaaad54ada8c8cb3d4ff6d01a7" class="DSPFListTable" style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">2020 guidance</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-WEIGHT: bold">3</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">&#160;for&#160;continuing operations tightened within prior guidance ranges &#8211; </font>Net sales expected to grow mid single digit; core operating income expected to grow low double digit</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Basel, July 21, 2020 - </font>commenting on the quarter, Vas Narasimhan, CEO of Novartis, said:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">&#8220;Novartis performed strongly in the first half, despite the impact from COVID-19, demonstrating the resilience and agility of our associates and operations. We continued to advance our broad range of efforts to support the COVID-19 pandemic response. Our growth drivers and launches continue their strong momentum, with </font>Cosentyx<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> and </font>Entresto<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> increasing market share in the US. We are on track to deliver on our commitment to drive consistent margin expansion and are excited by the progress of our deep mid to late stage pipeline to drive long-term growth&#8221;.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">&#160;</div>

<table id="zbb958f7e1d764f079ed7b22bfd54940e" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 19.88%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Key Figures</div>
</td>
<td style="WIDTH: 80.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="9">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">Continuing Operations</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 13.8%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.92%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 14.89%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net sales</div>
</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">11 347</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">11 764</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-1</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">23 630</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">22 870</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">6</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Operating income</div>
</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">2 352</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 663</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-12</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">5 096</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 905</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">11</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net income</div>
</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1 867</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 109</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">4 040</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 977</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">2</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">EPS (USD)</div>
</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">0.82</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0.91</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-3</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1.77</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.72</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">11</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Free cash flow</div>
</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3 631</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 612</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">5 652</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 481</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core operating income</div>
</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3 669</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 648</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">7 846</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 902</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core net income</div>
</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3 108</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 096</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">6 657</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 907</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">13</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">18</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core EPS (USD)</div>
</td>
<td style="WIDTH: 10.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1.36</div>
</td>
<td style="WIDTH: 13.26%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.34</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 2.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">2.92</div>
</td>
<td style="WIDTH: 12.14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2.55</div>
</td>
<td style="WIDTH: 6.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">15</div>
</td>
<td style="WIDTH: 5.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">19</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 2pt"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">1</sup> Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">2 </sup>Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions. <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">3 </sup>Please see detailed guidance assumptions on page 8 including the forecast assumption that we see a continuation of the return to normal global healthcare systems including prescription dynamics, particularly ophthalmology, in H2 2020. In addition, we assume that no&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Gilenya</font> and no <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Sandostatin</font> LAR generics enter in 2020 in the US.</div>

<div style="MARGIN-BOTTOM: 12pt; MARGIN-TOP: 2pt">&#160;</div>
</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">1</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left; MARGIN-TOP: 2pt">COVID-19 Update</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">The COVID-19 situation continues to evolve and is taking differing courses across the multitude of geographies that Novartis operates in. Our primary concerns remain the health and safety of our associates and patients while we also continue to take strong actions to help address the pandemic.</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">During the second quarter, COVID-19 had an impact on our business with forward purchasing from the first quarter largely reversing. Despite this our operations remain stable with record high customer service levels. Our cash collections continue to be according to our normal trade terms, and days sales outstanding at normal levels. Our product portfolio remains resilient despite COVID-19 negatively impacting sales in April and May, particularly: <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Lucentis </font>and mature ophthalmology, new patient starts in dermatology and Sandoz retail.&#160;Sales were mostly affected by lower new patient starts and significant reduction in patient visits to physicians. This impact showed improvement in the latter part of the quarter. Novartis is closely monitoring the situation and will provide an update with Q3 results. We implemented and embraced new ways of working, which include less travel and meeting costs. Novartis remains well positioned to meet its ongoing financial obligations and has sufficient liquidity to support our normal business activities.</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">At present drug development operations are continuing with manageable disruptions, with our SENSE and Site Cockpit digital technologies allowing us to proactively manage our clinical trials portfolio and rapidly mitigate site-level disruptions. Thus far, these measures have limited COVID-related impacts to our expected submission timelines over the next several years. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Phase III</font> clinical trials evaluating canakinumab in patients with pneumonia as a result of SARS-CoV-2 infection, and ruxolitinib in combination with standard of care compared to SoC alone, in collaboration with Incyte, are continuing. Data readouts from these studies are expected in the second half of 2020. We continue to support <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">35+</font> ongoing investigator-initiated trials<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"> involving 10 Novartis medicines</font>.</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">In July, Novartis launched a first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19. The new portfolio of 15 medicines from the Sandoz division addresses urgent unmet needs of low and lower middle income countries to treat patients with COVID-19 symptoms. The portfolio will be sold at no profit to governments in up to 79 eligible low and lower middle income countries during the pandemic and until a vaccine or curative treatment is available.</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Resolving legacy legal matters</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">We are continuing our long term journey to build trust with society and during the second quarter we resolved some of our legacy compliance issues. We finalized our USD 678 million settlement relating to a civil suit challenging speaker programs and other promotional events conducted in the US (2002 - 2011) as well as USD 51 million related to the company&#8217;s support of certain independent charitable co-pay foundations (2010 - 2014). Provisions for these settlements were previously made. Novartis has agreed to new corporate integrity obligations with the US Department of Health &amp; Human Services that will mean we will continue to evolve our approach to peer-to-peer medical education. Such education will transition towards a digital format in keeping with the changes that we have made and seen to be effective in recent months. All Foreign Corrupt Practices Act (FCPA) investigations into Novartis are now closed with the settlement that we have reached with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC). As part of the settlements, Novartis and certain of its current and former subsidiaries agreed to pay USD 234 million to the DOJ and USD 113 million to the SEC.</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">Financials</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">In order to comply with International Financial Reporting Standards (IFRS), Novartis has separated the Group&#8217;s reported financial data into &#8220;continuing&#8221; and &#8220;discontinued&#8221; operations. The results of the Alcon business in 2019 are reported as discontinued operations. See page 42 and Notes 2, 3 and 10 in the Condensed Interim Financial Report for a full explanation.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">The commentary below focuses on continuing operations including the businesses of Innovative Medicines and Sandoz, as well as the continuing Corporate functions. We also provide information on discontinued operations.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">2</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Continuing operations second quarter</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Net sales were USD 11.3 billion (-4%, -1% cc) in the second quarter. </font>Volume contributed 5 percentage points to sales growth driven by <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto, Zolgensma</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font>, partly offset by the impacts of COVID-19<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">. </font>Volume growth was offset by price erosion of 3 percentage points and negative impact from generic competition of 3 percentage points.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Operating income was USD 2.4 billion (-12%, -4% cc) mainly due to lower sales and higher impairments partly offset by lower spending and improved gross margin.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Net income was USD 1.9 billion </font>(-11%, -4% cc) mainly due to lower operating income. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">EPS was USD 0.82 (-10%, -3% cc), decreasing less than net income benefiting from lower weighted average number of shares outstanding.</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core operating income was USD 3.7 billion (+1%, +6% cc) due to lower spending and improved gross margin, driven by productivity and product mix, partly offset by lower sales.&#160;Core operating income margin was 32.3% of net sales, increasing by 1.3 percentage points (+2.1&#160;percentage points cc).</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core net income was USD 3.1 billion (0%, +5% cc) mainly driven by growth in core operating income. Core EPS was USD 1.36 (+1%, +6% cc), growing faster than core net income benefiting from lower weighted average number of shares outstanding.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Free cash flow from continuing operations amounted to USD 3.6 billion (+1%), broadly in line with the prior year quarter, as favorable working capital was offset by lower divestment proceeds.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Innovative Medicines</font> net sales were USD 9.2 billion (-1%, +1% cc). Pharmaceuticals BU sales grew 1% (cc), as the launch uptake of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zolgensma</font> and continuing momentum on <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font> were mostly offset by the negative impact of the COVID-19 pandemic, particularly in ophthalmology and new patient starts in&#160;dermatology. Oncology BU grew 1% (cc) as the continuing momentum on <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Promacta/Revolade, Kymriah, Kisqali </font>and<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Tafinlar + Mekinist</font> as well as the launch uptake of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray</font> was mostly offset by generic competition for <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Afinitor</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Exjade</font> and the negative impact of the COVID-19 pandemic, particularly in radioligand therapy. Generic competition had a negative impact of 4 percentage points, mainly driven by<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Afinitor, Exjade </font>and<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Travatan</font>, and net pricing had a negative impact of 4 percentage points. Volume contributed 9 percentage points to sales growth.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Sandoz</font> net sales were USD 2.2 billion (-11%, -9% cc) as volume declined 9 percentage points (cc) and pricing was in line with prior year, benefiting from favorable revenue deduction adjustments. The sales decline was due to COVID-19 negative impacts, mainly the reversal of Q1 forward purchasing and lower retail demand, some contract discontinuations in the US and a higher prior year base that included several first to market launches. The decline was partly offset by&#160;global sales of Biopharmaceuticals growing 19% (cc), driven by double digit growth in Europe and the US.</div>

<div style="MARGIN-BOTTOM: 6pt; MARGIN-TOP: 6pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Continuing operations first half</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Net sales were USD 23.6 billion (+3%, +6% cc) in the first half mainly driven by </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Entresto,</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Zolgensma </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">and </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Cosentyx</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">. </font>Volume contributed 11 percentage points to sales growth, despite being impacted by COVID-19<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">.&#160; </font>Strong volume growth was partly offset by price erosion of 3 percentage points and negative impact from generic competition of 2 percentage points.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Operating income was USD 5.1 billion (+4%, +11% cc) mainly driven by sales growth and lower legal expenses, partly offset by higher amortization and lower divestments.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Net income was USD 4.0 billion </font>(+2%, +9% cc) mainly driven by higher operating income, partly offset by higher financial expenses. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">EPS was USD 1.77 (+3%, +11% cc), growing faster than net income benefiting from lower weighted average number of shares outstanding.</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core operating income was USD 7.8 billion (+14%, +19% cc) mainly driven by higher sales and improved gross margin, partly offset by launch investments.&#160;Core operating income margin was 33.2% of net sales, increasing by 3.0 percentage points (+3.8&#160;percentage points cc).</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core net income was USD 6.7 billion (+13%, +18% cc) mainly driven by growth in core operating income. Core EPS was USD 2.92 (+15%, +19% cc), growing faster than core net income benefiting from lower weighted average number of shares outstanding.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">3</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Free cash flow from continuing operations amounted to USD 5.7 billion (+3%) compared to USD 5.5 billion in the prior year period. This increase was mainly driven by higher operating income adjusted for non-cash items and other adjustments, partly offset by lower divestment proceeds.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Innovative Medicines</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">net sales were USD 18.9 billion (+5%, +7% cc). Pharmaceuticals BU grew 8% (cc) driven by </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Entresto</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000"> (+50% cc), </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Zolgensma</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000"> (USD 0.4 billion), </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Cosentyx </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">(+15% cc) and the </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Xiidra</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000"> acquisition, partly offset by declines in </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Lucentis</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000"> and other ophthalmology products, driven mainly by lower demand due to COVID-19. Oncology BU grew 6% (cc) driven by </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Promacta/Revolade </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">(+28% cc),</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic"> Piqray</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000"> (USD 0.2 billion)</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">and</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic"> Kisqali</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000"> (+64% cc). Volume contributed 13 percentage points to sales growth. Generic competition had a negative impact of 3 percentage points. Net pricing had a negative impact of 3 percentage points.</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Sandoz</font> net sales were USD 4.7 billion (-2%, +1% cc). Volume growth of 3&#160;percentage points (cc), partially offset by 2 percentage points (cc) of price erosion, benefiting from favorable revenue deduction adjustments. Sales in Europe grew 5% (cc), while sales in the US declined 12%, driven by oral solids. Global sales of Biopharmaceuticals grew 25% (cc), driven by strong double digit growth in Europe and the US.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Discontinued operations</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Discontinued operations include the business of Alcon and certain corporate costs directly attributable to Alcon up to the spin-off date. As the Alcon spin-off was completed on April 9, 2019, the first half of the prior year includes three months of operating results of the divested business.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">In the first half of 2020, there were no activities related to discontinued operations. In the first half of 2019, discontinued operations net sales were USD 1.8 billion, operating income amounted to USD 71 million and net income from discontinued operations was USD 4.6 billion, including the non-taxable non-cash net gain on distribution of Alcon Inc. to Novartis AG shareholders which amounted to USD 4.7 billion. For further details see Note 2 &#8220;Distribution of Alcon Inc. to Novartis AG shareholders&#8221;, Note 3 &#8220;Significant transactions &#8211; Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders&#8221; and Note 10 &#8220;Discontinued operations&#8221;. &#160;&#160;&#160;&#160;&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Total Group first half</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">For the total Group, net income amounted to USD 4.0 billion compared to USD 8.6 billion in prior year, including the non-taxable non-cash net gain on distribution of Alcon Inc. Basic earnings per share was USD 1.77 compared to USD 3.70 in prior year. Cash flow from operating activities for the total Group amounted to USD 6.5 billion and free cash flow to USD 5.7 billion.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left; MARGIN-TOP: 12pt">Key growth drivers</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Underpinning our financial results in the quarter is a continued focus on key growth drivers (ranked in order of contribution to Q2 growth) including:</div>

<table id="z0903aa07909240ba978fc8c2a6334e11" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Zolgensma</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 205 million) driven by US sales as newborn screening continues to progress with 28 states representing 60% of newborns. Additional growth was driven by geographic expansion outside of US.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Entresto</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 580 million, +40% cc) delivered sustained growth and increased market share, driven by demand as the essential first choice therapy for HF patients.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Cosentyx</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 944 million, +12% cc) continued growth across indications and grew market share in the US. Growth was impacted by COVID-19 related disruption to dermatology and rheumatology practices.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Promacta/Revolade</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 422 million, +23% cc) grew at a double digit rate in most regions driven by increased use in chronic immune thrombocytopenia (ITP) and as first-line treatment for severe aplastic anemia (SAA) in the US.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Xiidra</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 79 million) was impacted by COVID-19 related disruption as ophthalmology visits declined significantly.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Piqray</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 79 million) grew in the US driven by strong demand.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Kymriah</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 118 million, +103% cc) grew strongly in Europe and US. More than 240 qualified treatment centers and 25 countries have coverage for at least one indication. The EMA approved manufacturing at Novartis owned facilities in Stein, Switzerland.</div>
</td>
</tr>
</table>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">4</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<table id="zf03595dd66104e498244809dcbab9b6e" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Kisqali</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 159 million, +49% cc) continued strong double-digit growth driven by demand in all geographies, benefiting from the impact of positive overall survival data from two pivotal Phase III trials (MONALEESA-7 and MONALEESA-3).</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Tafinlar + Mekinist</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 371 million, +12% cc) continued to show growth driven by demand in adjuvant melanoma as well as NSCLC.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Beovu</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 34 million) is approved in more than 30 countries. Post marketing cases termed as &#8220;retinal vasculitis&#8221; and/or &#8220;retinal vascular occlusion&#8221; that may result in severe vision loss, typically associated with intraocular inflammation and the current COVID-19 situation had an unfavorable impact on US sales.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Mayzent</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 34 million) grew vs. Q1&#8217;20 despite new patients starts being impacted by COVID-19. Patient uptake showed signs of improvement towards the end of Q2.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Adakveo</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">(USD 21 million) US launch is progressing well, with close to 100% brand awareness among hematologists. Payer coverage is expanding, including published Medicaid policies in 19 states and 85% coverage among commercial plans. The permanent J-code took effect&#160;July 1.</div>
</td>
</tr>

<tr style="HEIGHT: 35px">
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Biopharmaceuticals</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">(</font>USD 466 million<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">, +</font>19% cc<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">)</font> driven by continued double digit growth in Europe and the US<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"> (Biosimilars, biopharmaceutical contract manufacturing and </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Glatopa</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">).</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Emerging Growth Markets</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Which&#160;comprises all markets except the US, Canada, Western Europe, Japan, Australia and New Zealand,<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">&#160;</font>sales grew 5% (cc) including <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">China </font>(USD 625 million), which grew 20% (cc).</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net sales of the top 20 Innovative Medicines products in 2020</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<table id="z37d225a02bd44e6ea6c6ac931f860809" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 21.23%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% change</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 23.81%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Cosentyx</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;944</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">10</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">12</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 874</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">15</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Gilenya</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;738</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-9</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 510</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-5</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-4</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Entresto</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;580</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">38</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">40</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 149</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">48</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">50</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Tasigna</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;480</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;967</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">7</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Lucentis</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;401</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-25</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-24</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;888</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-17</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Promacta/Revolade</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;422</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">21</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">23</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;825</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">26</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">28</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Tafinlar + Mekinist</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;371</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">12</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;737</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">16</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Sandostatin</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;341</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-13</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;715</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Jakavi</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;310</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;628</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">16</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">20</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Gleevec/Glivec</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;288</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-8</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;617</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-2</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-STYLE: italic">Galvus </font>Group</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;279</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-13</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-8</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;617</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-3</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Xolair</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;289</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;596</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Afinitor/Votubia</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;266</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-34</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-33</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;562</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-27</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-STYLE: italic">Diovan </font>Group</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;268</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-5</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;542</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-STYLE: italic">Exforge </font>Group</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;238</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-5</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;496</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-7</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-3</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Ilaris</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;200</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">21</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">23</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;413</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">31</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">33</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Zolgensma</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;205</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;375</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Exjade/Jadenu</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;163</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-36</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-35</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;335</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-32</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-31</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Votrient</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;162</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-16</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-14</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;328</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-14</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Kisqali</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;159</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">43</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">49</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;320</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">58</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">64</div>
</td>
</tr>

<tr>
<td style="WIDTH: 27.15%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Top 20 products total</div>
</td>
<td style="WIDTH: 13.58%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">7 104</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">2</div>
</td>
<td style="WIDTH: 12.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;14 494</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 11.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">8</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">nm = not meaningful</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">5</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">R&amp;D Update - key developments from the second quarter</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left; MARGIN-TOP: 12pt">New approvals and regulatory update</div>

<table id="zaf0018a65f464c8094775617fb15c373" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Zolgensma</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">IV formulation</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">IT formulation</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Received EU conditional approval for patients with SMA and a clinical diagnosis of Type 1 or SMA patients with up to three copies of the SMN2 gene. The approval <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">covers babies and young children with SMA up to 21 kg. Commercial product was made available in the EU from July 1.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Continued dialogue with FDA on partial clinical hold. Plan to approach FDA for pre-BLA meeting with a BLA submission in 2021.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Tabrecta</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(Capmatinib)</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Tabrecta </font>(formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14). Approximately 4,000-5,000 patients are diagnosed with METex14 metastatic NSCLC each year in the US and may face poor prognoses due to presence of the mutation.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Enerzair Breezhaler </font>(QVM149)</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Received EC approval in July, as the first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma, including the first digital companion that can be prescribed with a treatment for uncontrolled asthma in the EU.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Cosentyx</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left">Received US and EU approval for treatment of patients with non-radiographic axSpA, the fourth indication after moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font> also received a positive CHMP opinion for the treatment of pediatric psoriasis.</div>

<div style="margin-bottom: 2pt; font-size: 10pt; font-family: Arial; color: #000000; text-align: left;">China health authority NMPA approved <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font> for the treatment of adults with ankylosing spondylitis.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Piqray</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray</font> in combination with fulvestrant received a positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Ilaris</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Granted a new indication in the US for active Still&#8217;s disease including Adult-Onset Still&#8217;s Disease (AOSD). This<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">&#160;</font>is the first FDA-approved treatment for AOSD.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Xolair</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Received a positive CHMP opinion for treatment of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled with intranasal corticosteroids.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Beovu</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">FDA approved label update to include additional safety information. The update includes characterization of adverse events, retinal vasculitis and retinal vascular occlusion, as part of the spectrum of intraocular inflammation observed in the HAWK&#160;and HARRIER trials and noted in the original prescribing information.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Ofatumumab</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">FDA extended its review of the sBLA for ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. Regulatory action is now expected&#160;in September 2020.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Entresto</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Tabrecta</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Mayzent</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Enerzair</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Atectura</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Japan MHLW simultaneously approved five new treatments for Japanese patients.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font> in chronic heart failure</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Tabrecta</font> for METex14 mutation-positive advanced and/or recurrent unresectable NSCLC</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Mayzent</font> in secondary progressive MS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Enerzair</font> (glycopyrronium bromide, indacaterol acetate, mometasone furoate)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Atectura</font> (indacaterol acetate, mometasone furoate) in different forms of asthma.</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 6pt; MARGIN-TOP: 12pt"><br>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">6</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left; MARGIN-TOP: 12pt">Regulatory submissions and filings</div>

<table id="z4bedb6695e2649fc97eae8de6f220960" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 20.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font> HFpEF</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 79.05%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">File accepted in the US.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Xiidra </font>EU</div>
</td>
<td style="WIDTH: 79.05%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Filing has been withdrawn following objections raised by the CHMP during the application process that Novartis recognized could not be resolved within the available timeframe.</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left; MARGIN-TOP: 12pt">Results from ongoing trials and other highlights</div>

<table id="z3a6563673dc645dd97b7106bdac5ef19" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Beovu</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">A post-hoc analysis presented at ARVO showed that lower levels of any fluid (intra-retinal fluid, sub-retinal fluid or pigment-epithelial detachment volume) were associated with better visual outcomes, suggesting that all three fluids are relevant for visual outcomes in wet AMD. In the post-hoc analysis, more patients on <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Beovu</font> experienced reduced levels of fluid.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Cosentyx</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Phase III PREVENT data show <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font> 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 52.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Ofatumumab</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">A post hoc analysis presented at European Academy of Neurology showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0&#8211;12 months) and second year (12&#8211;24 months) of treatment, respectively.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left">Kisqali</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left">MONALEESA-7 and MONALEESA-3 subgroup analysis presented during the 2020 ASCO Virtual Scientific Program showed <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kisqali</font> plus endocrine therapy extended life compared to endocrine therapy for patients with liver metastases &#8211; showing ~47% and 37% reduction in the risk of death in M7 and M3, respectively.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left">Tafinlar + Mekinist</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left">5-year data presented at the 2020 ASCO Virtual Scientific Program showed more than half of patients with BRAF-mutated advanced melanoma taking <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Tafinlar + Mekinist</font> were alive and free of a relapse.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Enerzair Breezhaler </font>(QVM149)</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Phase IIIb ARGON study met primary endpoint, demonstrating non-inferiority in improving quality of life in people with uncontrolled asthma compared to a free combination of two existing inhaled treatments, twice-daily Sal/Flu plus once-daily tiotropium (Tio).</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.46%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Adriforant</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(ZPL389)</div>
</td>
<td style="WIDTH: 79.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Based on a full review of an interim analysis of the Phase IIb ZEST trial, the efficacy data did not meet the pre-specified criteria to pursue adriforant (ZPL389) clinical trials in atopic dermatitis. The recommendation to stop the trial was not based on any safety concerns.</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 6pt; MARGIN-TOP: 12pt"><br>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">7</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 12pt">Capital structure and net debt</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Retaining a good balance between investment in the business, a strong capital structure and attractive shareholder returns remains a priority.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">During the first half of 2020, 25.6 million shares (for an equity value of USD 1.2 billion) were delivered as a result of options exercised and share deliveries related to participation plans of associates. In the same period, 1.6 million shares (for an equity value of USD 0.1 billion) were repurchased from associates. Consequently, the total number of shares outstanding increased by 24.0 million versus December 31, 2019. Novartis aims to offset the dilutive impact from equity based participation plans of associates over the remainder of the year. These treasury share transactions resulted in an equity increase of USD 1.1 billion and a net cash inflow of USD 0.7 billion, mainly related to option proceeds.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">In the second quarter of 2020, Novartis repaid the USD 1.0 billion, 4.4% coupon bond issued in March 2010 at maturity.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">As of June 30, 2020, the net debt increased by USD 10.6 billion to USD 26.5 billion versus December 31, 2019. The increase was mainly driven by the acquisition of The Medicines Company for USD 9.6 billion and the USD 7.0 billion annual dividend payment, partly offset by USD 5.7 billion free cash flow during the first half of 2020.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">As of Q2 2020, the long-term credit rating for the company is A1 with Moody&#8217;s Investors Service and AA- with S&amp;P Global Ratings.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">The Group has not experienced liquidity or cash flow disruptions during the first half of 2020 due to the COVID-19 pandemic. We believe that Novartis is well positioned to meet its ongoing financial obligations and has sufficient liquidity to support our normal business activities.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 12pt">2020 Outlook</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Barring unforeseen events</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9">Continuing operations</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">(Excluding Alcon from both 2019 and 2020)</font></div>

<div><br>
 &#160;</div>
</div>

<div><br>
</div>

<table id="zc639d64ce6a64956874f14594d2407bb" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 20.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net Sales</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 79.05%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Expected to grow mid single digit (cc)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">From a divisional perspective, we expect net sales performance (cc) in 2020 to be as follows:</div>

<div style="MARGIN-BOTTOM: 2pt; TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">&#8226;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Innovative Medicines: expected to grow mid single digit</font></div>

<div style="MARGIN-BOTTOM: 2pt; TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">&#8226;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Sandoz: expected to grow low single digit</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core operating income</div>
</td>
<td style="WIDTH: 79.05%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Expected to grow low double digit (cc)</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Our</font> guidance <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">assumes&#160;</font>that<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">&#160;</font>we see <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">a continuation</font> of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">the return to normal global healthcare systems including prescription dynamics, particularly ophthalmology, in H2 2020. In addition, we assume</font> that <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">no&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Gilenya</font> and no <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Sandostatin</font> LAR generics enter in 2020 in the US.</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Foreign exchange impact</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">If mid-July exchange rates prevail for the remainder of 2020, the foreign exchange impact for the year would be negative 1 to 2 percentage points on net sales and negative 4 percentage points on core operating income. The estimated impact of exchange rates on our results is provided monthly on our website.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">8</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 12pt">Key Figures</div>

<table id="zab0113c30da641e6bab0da169ba06fac" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 25.17%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Continuing operations&#185; &#178;</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">11 347</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">11 764</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">23 630</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">22 870</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Operating income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 352</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 663</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-12</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 096</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 905</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">11</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">As a % of sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">20.7</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">22.6</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">21.6</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">21.4</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core operating income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 669</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 648</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">7 846</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 902</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">As a % of sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">32.3</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">31.0</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">33.2</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">30.2</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 867</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 109</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 040</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 977</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">EPS (USD)</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0.82</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0.91</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-3</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.77</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.72</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">11</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core net income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 108</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 096</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 657</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 907</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">13</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">18</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core EPS (USD)</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.36</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.34</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2.92</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2.55</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">15</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Cash flows from<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font> operating activities</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 961</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 111</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">27</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 489</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 445</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">19</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Free cash flow</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 631</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 612</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 652</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 481</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Innovative Medicines</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9 188</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9 326</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">18 943</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">18 106</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Operating income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 033</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 564</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-21</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 788</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 673</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">As a % of sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">22.1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">27.5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">25.3</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">25.8</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core operating income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 301</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 306</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 908</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 228</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">11</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">As a % of sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">35.9</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">35.4</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">36.5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">34.4</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Sandoz</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 159</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2 438</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-9</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 687</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 764</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-2</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Operating income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">321</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">282</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">25</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">276</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">555</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-50</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-40</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">As</font> a % of sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">14.9</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">11.6</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">5.9</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">11.6</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core operating income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">475</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">501</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 148</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">962</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">19</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">As a % of sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">22.0</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">20.5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">24.5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">20.2</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Corporate</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Operating loss / income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-2</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-183</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">32</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-323</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core operating loss</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-107</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-159</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">33</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">34</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-210</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-288</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">27</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">28</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Discontinued operations</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net sales</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 777</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Operating&#160; income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">71</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core operating income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">350</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net Income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 691</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 590</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Total Group</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 18.71%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 867</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 800</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-73</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-70</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4 040</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">8 567</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-53</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-49</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">EPS (USD)</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0.82</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2.94</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-72</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-70</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.77</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3.70</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-52</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-49</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core net income</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 108</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 096</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 657</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 185</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">8</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core EPS (USD)</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.36</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1.34</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2.92</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">2.67</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">14</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Cash flows<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font> from operating activities</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 961</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 111</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">27</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">6 489</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 523</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">17</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Free cash flow</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 631</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3 612</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 652</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5 419</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.17%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left">nm = not meaningful</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 9.35%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">1</sup> Continuing operations include the businesses of Innovative Medicines and Sandoz Division including the US generic oral solids and dermatology portfolio as well as the continuing corporate functions and discontinued operations include the business of Alcon. See page 42 of the Condensed Interim Financial Report for full explanation.</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">2 </sup>Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 6pt">Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below:</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-VARIANT: normal; FONT-WEIGHT: normal; COLOR: #0000ff; FONT-STYLE: normal; TEXT-ALIGN: left"><u>https://ml-eu.globenewswire.com/resource/download/bed749ce-ebd9-4018-ab0d-27d775c7c2c8</u></div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">9</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">Disclaimer</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="margin-bottom: 2pt; font-size: 10pt; font-family: Arial; text-align: left; background-color: #ffffff;">
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify">This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as &#8220;continue,&#8221; &#8220;growth,&#8221; &#8220;expected,&#8221; &#8220;to grow,&#8221; &#8220;demonstrating,&#8221; &#8220;to advance,&#8221; &#8220;to support,&#8221; &#8220;increasing,&#8221; &#8220;to deliver,&#8221; &#8220;to drive,&#8221; &#8220;to evolve,&#8221; &#8220;remain,&#8221; &#8220;taking,&#8221; &#8220;to take,&#8221; &#8220;to help,&#8221; &#8220;trends,&#8221; &#8220;continuing,&#8221; &#8220;allowing,&#8221; &#8220;to start,&#8221; &#8220; evaluating,&#8221; &#8220;will,&#8221; &#8220;until,&#8221; &#8220;to build,&#8221; &#8220;evolve,&#8221; &#8220;launch,&#8221; &#8220;continued,&#8221; &#8220;continues,&#8221; &#8220;to progress,&#8221; &#8220;may,&#8221; &#8220;retaining,&#8221; &#8220;remains,&#8221; &#8220;believe,&#8221; &#8220;including,&#8221; &#8220;can,&#8221; &#8220;to create,&#8221; &#8220;to find,&#8221; &#8220;estimated,&#8221; &#8220;impact,&#8221; &#8220;ongoing,&#8221; &#8220;submissions,&#8221; &#8220;focus,&#8221; &#8220;launches,&#8221; &#8220;launch investments,&#8221; &#8220;innovation,&#8221; &#8220;potential,&#8221; &#8220;guidance,&#8221; &#8220;commitment,&#8221; &#8220;pipeline,&#8221; &#8220;aims,&#8221; &#8220;momentum,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;launched,&#8221; &#8220;on track,&#8221; &#8220;growing,&#8221; &#8220;progressing,&#8221; &#8220;expanding,&#8221; &#8220;pending,&#8221; &#8220;strongly,&#8221; &#8220;priority,&#8221; &#8220;filings,&#8221; &#8220;outlook,&#8221; &#8220;unforeseen,&#8221; &#8220;forecast,&#8221; &#8220;prevail,&#8221; &#8220;enter,&#8221; &#8220;to improve,&#8221; &#8220;transformative,&#8221; &#8220;innovative,&#8221; &#8220;inventive,&#8221; &#8220;manageable disruptions,&#8221; &#8220;expect,&#8221; &#8220;planned,&#8221; &#8220;working,&#8221; &#8220;monitoring,&#8221; &#8220;anticipated,&#8221; &#8220;continuously,&#8221; &#8220;on track,&#8221; or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding our estimates of the impact of past and future COVID-19 related forward purchasing on sales and on our performance; or regarding the impact of the COVID-19 pandemic on clinical trials, and research and development timelines;&#160;or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group&#8217;s liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding efforts to provide a not-for-profit portfolio of medicines for symptomatic treatment of COVID-19. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of the COVID-19 pandemic on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics, particularly ophthalmology, in the second half of 2020; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this press release; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and is expected to continue this year; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG&#8217;s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.</div>

<div>&#160;</div>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left">All product names appearing in italics are trademarks owned by or licensed to Novartis Group companies.</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left"><br>
 &#160;</div>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">10</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">About Novartis</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Novartis is reimagining medicine to improve and extend people&#8217;s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world&#8217;s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 145 nationalities work at Novartis around the world. Find out more at <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">https://www.novartis.com</font>.</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Novartis will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Novartis website. A replay will be available after the live webcast by visiting. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">https://www.novartis.com/investors/event-calendar</font></div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Detailed financial results accompanying this press release are included in the condensed interim financial report at the link below. Additional information is provided on Novartis divisions and pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found at. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">https://www.novartis.com/investors/event-calendar</font><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 14pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">Important dates</div>
</div>

<div style="MARGIN-BOTTOM: 2pt">
<table id="z15f71cfd104c429db56aea845e6a005a" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: auto" cellspacing="0" cellpadding="0" align="left" border="0">
<tr>
<td style="WIDTH: 150px; PADDING-BOTTOM: 3px">
<div>September 01, 2020</div>
</td>
<td style="WIDTH: 30px; PADDING-BOTTOM: 3px">&#160;</td>
<td style="WIDTH: 200px; PADDING-BOTTOM: 3px">
<div>ESG investor day</div>
</td>
</tr>

<tr>
<td style="WIDTH: 150px; PADDING-BOTTOM: 3px">
<div>October 27, 2020</div>
</td>
<td style="WIDTH: 30px; PADDING-BOTTOM: 3px">&#160;</td>
<td style="WIDTH: 200px; PADDING-BOTTOM: 3px">
<div>Third quarter results 2020</div>
</td>
</tr>

<tr>
<td style="WIDTH: 150px; PADDING-BOTTOM: 3px">
<div>November 24, 2020</div>
</td>
<td style="WIDTH: 30px; PADDING-BOTTOM: 3px">
<div>&#160;</div>
</td>
<td style="WIDTH: 200px; PADDING-BOTTOM: 3px">
<div>Capital Markets day</div>
</td>
</tr>
</table>

<br style="CLEAR: both">
</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">11</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">&#160;</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>



</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>a200721-99_2.htm
<DESCRIPTION>99.2 INTERIM FINANCIAL REPORT
<TEXT>

<html>
<head>
  <title>99.2 Interim Financial Report</title>

</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#ffffff" text="#000000"">




<div>
<div>
<div style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 100%; TEXT-ALIGN: right"></div>

<div style="WIDTH: 100%; TEXT-ALIGN: left">
<table id="2bdc99fb39704e459a4231a3d03535b4" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%" valign="top" align="left">
<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><img src="logo.jpg"></div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 5%" valign="top">&#160; </td>
<td style="WIDTH: 22%" valign="top" align="left">
<div style="FONT-FAMILY: Arial; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-FAMILY: Arial; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-FAMILY: Arial; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</div>

<div style="FONT-FAMILY: Arial; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr>
</table>
</div>
</div>

<div style="FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"></div>

<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 18pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left; MARGIN-TOP: 2pt">
<div style="FONT-SIZE: 18pt; FONT-FAMILY: Arial; FONT-WEIGHT: normal; COLOR: #0460a9; TEXT-ALIGN: left">Novartis Second Quarter and Half<font style="FONT-SIZE: 18pt; FONT-FAMILY: Arial">&#160;</font>Year 2020</div>

<div><br>
</div>

<div style="FONT-SIZE: 18pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Condensed interim financial report &#8211; Supplementary Data</div>

<div><br>
</div>

<br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div>
<table id="z0116bbc4e41e4cd486e421962f2bb485" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 200px" cellspacing="0" cellpadding="10" align="left" border="0">
<tr>
<td style="HEIGHT: 80px; WIDTH: 200px; VERTICAL-ALIGN: middle; TEXT-ALIGN: center; BACKGROUND-COLOR: #0070c0">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #ffffff; TEXT-ALIGN: left">Novartis&#160;Global Communications</div>
</td>
</tr>
</table>

<br style="CLEAR: both">
</div>

<div>&#160;</div>

<div>&#160;</div>

<div><br>
 &#160;</div>

<div>&#160;</div>

<div><br>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">1</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div>
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">Novartis Second Quarter and Half Year 2020<br>
 Condensed Interim Financial Report &#8211; Supplementary Data</div>
</div>

<table id="z38c78d78bfe143df8ed76abc612a403a" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">INDEX</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">Page</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">GROUP AND DIVISIONAL OPERATING PERFORMANCE</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Group</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">3</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Innovative Medicines</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Sandoz</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">14</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">CASH FLOW AND GROUP BALANCE SHEET</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">INNOVATION REVIEW</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">20</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Consolidated income statements</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">24</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Consolidated statements of comprehensive income</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Consolidated balance sheets</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">27</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Consolidated statements of changes in equity</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">28</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Consolidated statements of cash flows</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">31</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.85pt">Notes to condensed consolidated interim financial statements, including update on legal proceedings</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">33</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">SUPPLEMENTARY INFORMATION</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">54</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">CORE RESULTS</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Reconciliation from IFRS to core results</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">55</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Group</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">57</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Innovative Medicines</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">59</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Sandoz</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">60</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Corporate</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">61</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Discontinued operations</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">62</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">ADDITIONAL INFORMATION</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Income from associated companies</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">63</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Condensed consolidated changes in net debt / Share information</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">63</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Free cash flow</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">64</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 15.9pt">Effects of currency fluctuations</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">66</div>
</td>
</tr>

<tr>
<td style="WIDTH: 91.82%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">DISCLAIMER</div>
</td>
<td style="WIDTH: 8.18%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">68</div>
</td>
</tr>
</table>

<div><br>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">2</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">Novartis Second Quarter and Half Year 2020<br>
 Condensed Interim Financial Report &#8211; Supplementary Data</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 14pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Group</div>

<div><br>
</div>
</div>

<table id="z62d7de611c694db29f56d95f499d97de" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Key figures </font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;COLOR: #000000">1</sup></div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 14.75%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">% change</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 14.25%; VERTICAL-ALIGN: bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">2</sup></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">USDm</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">2</sup></div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net sales to third parties from continuing operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">11 347</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">11 764</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-1</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">23 630</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">22 870</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Divisional operating income from continuing operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">2 354</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">2 846</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-17</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">5 064</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">5 228</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-3</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Corporate income and expense, from continuing operations, net</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-2</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">-183</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">32</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">-323</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Operating income from continuing operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">2 352</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">2 663</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-12</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">5 096</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">4 905</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">11</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">As % of net sales</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">20.7</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; FONT-STYLE: italic; TEXT-ALIGN: right">22.6</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">21.6</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; FONT-STYLE: italic; TEXT-ALIGN: right">21.4</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Income from associated companies</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">183</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">176</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">306</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">256</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">20</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">20</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Interest expense</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-220</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">-205</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-7</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-459</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">-431</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-6</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-8</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Other financial income and expense</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-27</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-34</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">44</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Taxes</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-421</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">-525</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">20</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">13</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-869</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">-797</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-9</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">-17</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net income from continuing operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1 867</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">2 109</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">4 040</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">3 977</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">2</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">9</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Net income from discontinued operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">4 691</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">4 590</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net income</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1 867</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">6 800</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-73</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-70</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">4 040</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">8 567</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-53</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-49</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Basic earnings per share from continuing operations (USD)</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">0.82</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">0.91</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-3</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1.77</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">1.72</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">11</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Basic earnings per share from discontinued operations (USD)</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">2.03</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">1.98</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Basic earnings per share (USD)</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">0.82</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">2.94</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-72</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-70</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1.77</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">3.70</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-52</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-49</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Cash flows from operating activities from continuing operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3 961</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">3 111</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">27</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">6 489</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">5 445</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">19</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Free cash flow from continuing operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3 631</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">3 612</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">5 652</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">5 481</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom" colspan="2">&#160;</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr style="HEIGHT: 20px">
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core operating income from continuing operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3 669</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">3 648</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">7 846</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">6 902</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">19</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">As % of net sales</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">32.3</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; FONT-STYLE: italic; TEXT-ALIGN: right">31.0</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">33.2</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; FONT-STYLE: italic; TEXT-ALIGN: right">30.2</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core net income from continuing operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3 108</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">3 096</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">6 657</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">5 907</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">13</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">18</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core net income from discontinued operations</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">278</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core net income</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">3 108</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">3 096</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">6 657</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">6 185</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">8</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">12</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core basic earnings per share from continuing operations (USD)</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1.36</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">1.34</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">2.92</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">2.55</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">15</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">19</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Core basic earnings per share from discontinued operations (USD)</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #808080; TEXT-ALIGN: right">0.12</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core basic earnings per share (USD)</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1.36</div>
</td>
<td style="WIDTH: 7.64%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">1.34</div>
</td>
<td style="WIDTH: 7.69%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">6</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">2.92</div>
</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #808080; TEXT-ALIGN: right">2.67</div>
</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">9</div>
</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 39.15%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left">nm = not meaningful</div>
</td>
<td style="WIDTH: 8.57%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 6.35%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 8.97%; VERTICAL-ALIGN: bottom" colspan="2">&#160;</td>
<td style="WIDTH: 7.06%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.94%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.89%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 6.29%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">1</sup> Continuing operations include the businesses of Innovative Medicines and Sandoz Division including the US generic oral solids and dermatology portfolio and Corporate activities and discontinued operations include the business of Alcon. See page 42 for full explanation.</div>

<div style="MARGIN-BOTTOM: 4pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">2</sup> Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">COVID-19 Impacts</div>

<div><br>
</div>
</div>

<div>
<table id="z6f07928409ab4a8e82fd431876012a3a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">First half results, sales grew 6% (cc) and core operating income grew 19% (cc), are more representative of performance than Q2 as Q1 forward purchasing largely reversed.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z5f93d3d51fdf46b09340168d68fd7864" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Our operations remain stable with record high customer service levels. Product flow across country borders is working smoothly.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zdcd9e8870b8d47c784176b03a4521bf2" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Our cash collections continue to be according to our normal trade terms and days sales outstanding remains at normal levels.</div>
</td>
</tr>
</table>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">
<table id="z8be62bc31e084b639860cf25d13df360" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="font-size: 10pt; font-family: Arial; text-align: left;">Our product portfolio remains resilient despite COVID-19 negatively impacting demand in April and May, particularly: <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Lucentis</font> and mature ophthalmology (approximately USD 0.3 billion in Q2), new</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">3</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div>&#160;</div>

<div>
<table id="z3940fa265a10477da7d2ad129e98d7e7" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">patient starts in dermatology and Sandoz retail. There was some increase in demand for oral chronic treatments.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z62e4e982424d4bbc8e0a56c0cf5a66c5" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Sales were mostly affected by lower new patient starts and significant reduction in patient visits to physicians. This impact showed improvement in the latter part of the quarter. Novartis is closely monitoring the situation and will provide an update with Q3 results.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z269a5bbb94564a6c80a6d16e5b1bcf00" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">We implemented and embraced new ways of working, which include less travel and meeting costs.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zbbb9c9c6e0b44c2ba975853a5deaf64a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">At present drug development operations are continuing with manageable disruptions. Thus far, these measures have limited COVID-19 related impacts to our expected submission timelines over the next several years.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z94d32946ea25485599ee0fe7c52b00a2" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Novartis is well positioned to meet its ongoing financial obligations and has sufficient liquidity to support our normal business dynamics.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z1deb622c91c84f0eb68306308de086ec" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="font-size: 10pt; font-family: Arial; text-align: left;">First half dynamics are reflected in our full year guidance, which assumes that we see a continuation of the return to normal global healthcare systems including prescription dynamics, particularly ophthalmology, in H2 2020.</div>
</td>
</tr>
</table>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Financials</div>

<div style="TEXT-ALIGN: justify">In order to comply with International Financial Reporting Standards (IFRS), Novartis has separated the Group&#8217;s reported financial data into &#8220;continuing&#8221; and &#8220;discontinued&#8221; operations. The results of the Alcon business in 2019 are reported as discontinued operations. See page 42 and Notes 2, 3 and 10 for a full explanation.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">The commentary below focuses on continuing operations including the businesses of Innovative Medicines and Sandoz, as well as the continuing Corporate functions. We also provide information on discontinued operations.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Continuing operations second quarter</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Net sales</div>

<div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Net sales were USD 11.3 billion (-4%, -1% cc) in the second quarter. </font>Volume contributed 5 percentage points to sales growth driven by <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto, Zolgensma</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font>, partly offset by the impacts of COVID-19<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">. </font>Volume growth was offset by price erosion of 3 percentage points and negative impact from generic competition of 3 percentage points.</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Corporate income and expense, net</div>

<div style="TEXT-ALIGN: justify">Corporate income and expense, which includes the cost of Group headquarter and coordination functions, amounted to an expense of USD 2 million compared to an expense of USD 183 million in the second quarter of 2019, mainly driven by favorable contributions from the Novartis Venture Fund.</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Operating income</div>

<div style="TEXT-ALIGN: justify">Operating income was USD 2.4 billion (-12%, -4% cc) mainly due to lower sales and higher impairments, partly offset by lower spending and improved gross margin.</div>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core operating income was USD 3.7 billion (+1%, +6% cc) due to lower spending and improved gross margin, driven by productivity and product mix, partly offset by lower sales.&#160;Core operating income margin was 32.3% of net sales, increasing by 1.3 percentage points (+2.1&#160;percentage points cc).</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Income from associated companies</div>

<div style="TEXT-ALIGN: justify">Income from associated companies increased from USD 176 million in prior year to USD 183 million in the second quarter of 2020 driven by a higher estimated share of income from Roche Holding AG.</div>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Core income from associated companies increased from USD 253 million in prior year to USD 272 million in the second quarter of 2020 driven by a higher estimated core income contribution from Roche Holding AG for the current period.</div>
</div>

<div>
<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">4</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Interest expense and other financial income/expense</div>

<div style="FONT-WEIGHT: normal; TEXT-ALIGN: justify">Interest expense amounted to USD 220 million compared to prior year interest expense of USD 205 million. Other financial income and expense amounted to a loss of USD 27 million compared to prior year when they were negligible mainly due to lower interest income for the current period.</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Taxes</div>

<div style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">The tax rate for continuing operations in the second quarter was 18.4% compared to 19.9% in the prior year. The second quarter tax rate was negatively impacted by the effect of adjusting to the updated estimated full year tax rate. The prior year second quarter tax rate was impacted by the Swiss federal tax reform and a change to uncertain tax positions.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Excluding these impacts, the second quarter tax rate would have been 16.8% compared to 15.4% in the prior year. The increase from prior year was mainly the result of a change in profit mix.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">The core tax rate for continuing operations was 16.0% compared to 16.7% in prior year.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Net income, EPS and Free cash flow</div>

<div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Net income was USD 1.9 billion </font>(-11%, -4% cc) mainly due to lower operating income. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">EPS was USD 0.82 (-10%, -3% cc), decreasing less than net income benefiting from lower weighted average number of shares outstanding.</font></div>

<div style="TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">Core net income was USD 3.1 billion (0%, +5% cc) mainly driven by growth in core operating income. Core EPS was USD 1.36 (+1%, +6% cc), growing faster than core net income benefiting from lower weighted average number of shares outstanding.</div>

<div style="TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">Free cash flow from continuing operations amounted to USD 3.6 billion (+1%), broadly in line with the prior year quarter, as favorable working capital was offset by lower divestment proceeds.</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Continuing operations first half</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Net sales</div>

<div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Net sales were USD 23.6 billion (+3%, +6% cc) in the first half mainly driven by </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Entresto,</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Zolgensma </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">and </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; FONT-STYLE: italic">Cosentyx</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">. </font>Volume contributed 11 percentage points to sales growth, despite being impacted by COVID-19<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">. </font>Strong volume growth was partly offset by price erosion of 3 percentage points and negative impact from generic competition of 2 percentage points.</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Corporate income and expense, net</div>

<div style="TEXT-ALIGN: justify">Corporate income and expense, which includes the cost of Group headquarter and coordination functions, amounted to an income of USD 32 million, compared to an expense of USD 323 million in the first half of 2019, mainly driven by royalty settlement gain related to intellectual property rights and favorable contributions from the Novartis Venture Fund.</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Operating income</div>

<div style="TEXT-ALIGN: justify">Operating income was USD 5.1 billion (+4%, +11% cc) mainly driven by sales growth and lower legal expenses, partly offset by higher amortization and lower divestments.</div>

<div style="TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">Core operating income was USD 7.8 billion (+14%, +19% cc) mainly driven by higher sales and improved gross margin, partly offset by launch investments.&#160;Core operating income margin was 33.2% of net sales, increasing by 3.0 percentage points (+3.8&#160;percentage points cc).</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Income from associated companies</div>

<div style="TEXT-ALIGN: justify">Income from associated companies amounted to USD 306 million in the first half compared to USD 256 million in the prior year.</div>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">5</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">The share of income from Roche was USD 308 million compared to USD 257 million in the prior year. The estimated income for Roche Holding AG, net of amortization, was USD 372 million compared to USD 343 million in the prior year. This was partly offset by the negative prior year true up of USD 64 million in the first quarter of 2020, compared to a negative prior year true up of USD 129 million recognized in the first quarter of 2019. In addition, a USD 43 million income from the revaluation of the deferred tax liability, recognized upon initial accounting for the Roche investment, was recorded in the first quarter of 2019, following a change in the enacted tax rate in February 2019, of the Swiss Canton Basel-Stadt, effective January 1, 2019.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Core income from associated companies in the first half increased to USD 580 million compared to USD 531 million in prior year driven by a higher estimated core income contribution from Roche Holding AG. The core income contribution from Roche Holding AG increased to USD 582 million from USD 532 million in the prior year, driven by a higher estimated core income contribution from Roche for the current period. In addition a favorable prior year core income true up of USD 38 million was recorded in the first quarter of 2020, compared to a favorable true up of USD 32 million in the first quarter of 2019.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Interest expense and other financial income/expense</div>

<div style="TEXT-ALIGN: justify">Interest expense increased to USD 459 million from USD 431 million in the prior year, mainly due to an increase in interest expense from discounting long term liabilities.</div>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Other financial income and expense amounted to a loss of USD 34 million compared to an income of USD 44 million in prior year mainly due to lower interest income for the current period.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Taxes</div>

<div style="TEXT-ALIGN: justify">The tax rate for continuing operations in the first half was 17.7% compared to 16.7% in the prior year. The tax rate was negatively impacted by the effect of non-deductible legal settlement expenses in the first half and the impact of Swiss tax reform in the prior year.</div>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Excluding these impacts, the first half tax rate would have been 16.8% compared to 15.4% in the prior year. The increase from prior year was mainly the result of a change in profit mix.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">The core tax rate for continuing operations was 16.0% compared to 16.4% in prior year.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Net income, EPS and Free cash flow</div>

<div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">Net income was USD 4.0 billion </font>(+2%, +9% cc) mainly driven by higher operating income, partly offset by higher financial expenses. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">EPS was USD 1.77 (+3%, +11% cc), growing faster than net income benefiting from lower weighted average number of shares outstanding.</font></div>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core net income was USD 6.7 billion (+13%, +18% cc) mainly driven by growth in core operating income. Core EPS was USD 2.92 (+15%, +19% cc), growing faster than core net income benefiting from lower weighted average number of shares outstanding.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Free cash flow from continuing operations amounted to USD 5.7 billion (+3%) compared to USD 5.5 billion in the prior year period. This increase was mainly driven by higher operating income adjusted for non-cash items and other adjustments, partly offset by lower divestment proceeds.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Discontinued operations</div>

<div style="TEXT-ALIGN: justify">Discontinued operations include the business of Alcon and certain corporate costs directly attributable to Alcon up to the spin-off date. As the Alcon spin-off was completed on April 9, 2019, the first half of the prior year includes three months of operating results of the divested business.</div>

<div style="TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">In the first half of 2020, there were no activities related to discontinued operations. In the first half of 2019, discontinued operations net sales were USD 1.8 billion, operating income amounted to USD 71 million and net income from discontinued operations was USD 4.6 billion, including the non-taxable non-cash net gain on distribution of Alcon Inc. to Novartis AG shareholders which amounted to USD 4.7 billion. For further details see Note 2 &#8220;Distribution of Alcon Inc. to Novartis AG shareholders&#8221;, Note 3</div>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">6</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-VARIANT: normal; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">&#8220;Significant transactions &#8211; Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders&#8221; and Note 10 &#8220;Discontinued operations&#8221;.</div>

<div style="margin-bottom: 12pt; font-weight: bold; color: #0460a9; margin-top: 6pt; font-size: 10pt; font-family: Arial; text-align: left;">Total Group first half</div>

<div style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">For the total Group, net income amounted to USD 4.0 billion compared to USD 8.6 billion in prior year, including the non-taxable non-cash net gain on distribution of Alcon Inc. Basic earnings per share was USD 1.77 compared to USD 3.70 in prior year. Cash flow from operating activities for the total Group amounted to USD 6.5 billion and free cash flow to USD 5.7 billion.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">7</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div>
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold">Innovative Medicines</div>

<div>&#160;</div>
</div>

<table id="z1e19c1fa29e54f25aff76d87007ff7f7" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 22.36%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 12.59%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right; MARGIN-RIGHT: 1.65pt">Q2 2020</div>
</td>
<td style="WIDTH: 12.58%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right; MARGIN-RIGHT: 8.95pt">Q2 2019</div>
</td>
<td style="WIDTH: 12.6%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">% change</div>
</td>
<td style="WIDTH: 2.88%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right; MARGIN-RIGHT: 1.65pt">H1 2020</div>
</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right; MARGIN-RIGHT: 6.65pt">H1 2019</div>
</td>
<td style="WIDTH: 13.33%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.36%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 12.59%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 12.58%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right; MARGIN-RIGHT: 1.65pt">&#160;USD m</div>
</td>
<td style="WIDTH: 7.88%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 4.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 2.88%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 7.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.36%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net sales</div>
</td>
<td style="WIDTH: 12.59%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">9 188</div>
</td>
<td style="WIDTH: 12.58%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">9 326</div>
</td>
<td style="WIDTH: 7.88%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-1</div>
</td>
<td style="WIDTH: 4.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 2.88%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">18 943</div>
</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">18 106</div>
</td>
<td style="WIDTH: 7.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 5.92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.36%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Operating income</div>
</td>
<td style="WIDTH: 12.59%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">2 033</div>
</td>
<td style="WIDTH: 12.58%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">2 564</div>
</td>
<td style="WIDTH: 7.88%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-21</div>
</td>
<td style="WIDTH: 4.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-15</div>
</td>
<td style="WIDTH: 2.88%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">4 788</div>
</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">4 673</div>
</td>
<td style="WIDTH: 7.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">2</div>
</td>
<td style="WIDTH: 5.92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.36%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;&#160;As % of net sales</div>
</td>
<td style="WIDTH: 12.59%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">22.1</div>
</td>
<td style="WIDTH: 12.58%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">27.5</div>
</td>
<td style="WIDTH: 7.88%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 4.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 2.88%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">25.3</div>
</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">25.8</div>
</td>
<td style="WIDTH: 7.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 5.92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 26.28%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core operating income</div>
</td>
<td style="WIDTH: 8.68%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">3 301</div>
</td>
<td style="WIDTH: 12.58%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">3 306</div>
</td>
<td style="WIDTH: 7.88%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 4.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 2.88%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">6 908</div>
</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">6 228</div>
</td>
<td style="WIDTH: 7.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">11</div>
</td>
<td style="WIDTH: 5.92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.36%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;&#160;As % of net sales</div>
</td>
<td style="WIDTH: 12.59%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">35.9</div>
</td>
<td style="WIDTH: 12.58%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">35.4</div>
</td>
<td style="WIDTH: 7.88%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 4.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 2.88%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">36.5</div>
</td>
<td style="WIDTH: 11.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">34.4</div>
</td>
<td style="WIDTH: 7.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 5.92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">COVID-19 Impacts</div>

<div style="TEXT-ALIGN: justify">First half results are more representative of performance as Q1 forward purchasing largely reversed in Q2. In Q2 there was significant disruption to practices limiting patient access to treatments, particularly in our ophthalmology and dermatology businesses. New patient starts slowed in most therapeutic areas. Sales were mostly affected in April and May, and showed improvement in June. Despite this, H1 sales grew 7% (cc) with core operating income growing 16% (cc) driven by the launch uptake of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zolgensma</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray</font> as well as continuing momentum on <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Promacta/Revolade</font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kisqali, Kymriah</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Tafinlar </font>+<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Mekinist.</font> Spending was lower in Q2 due to the pandemic, as we implemented and embraced new ways of working, which include lower travel and meeting costs. We will closely monitor the impact of these trends on future quarters.</div>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Second quarter</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Net sales</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net sales were USD 9.2 billion (-1%, +1% cc) as continued uptake in launches and growth drivers were offset by the impact of the COVID-19 pandemic, particularly in ophthalmology and new patient starts in dermatology. Generic competition had a negative impact of 4 percentage points, mainly due to <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Afinitor, Exjade </font>and<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Travatan</font> and net pricing had a negative impact of 4 percentage points. Volume contributed 9 percentage points to sales growth.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">In the US <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; BACKGROUND-COLOR: #ffffff">(USD 3.5 billion) </font>sales <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; BACKGROUND-COLOR: #ffffff">grew 5% driven</font> by <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zolgensma, Entresto, Cosentyx</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray</font>. In Europe (USD 3.0 billion, -8%, -5% cc) sales declined despite continued strong performance of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto, Kymriah, Promacta </font>and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kisqali</font>. Japan sales were USD 0.6 billion (-8%, -10% cc). Emerging Growth Markets grew 1% (+9% cc), including double digit growth in China, with the launches of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto </font>and<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Cosentyx.</font></div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Pharmaceuticals BU sales were broadly in line with prior year (USD 5.6 billion, -1%, +1% cc). Continued growth momentum from <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zolgensma</font> (USD 205 million), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font> (USD 580 million, +38%, +40% cc) and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font> (USD 944 million, +10%, +12% cc) was offset by the negative impact of the COVID-19 pandemic, particularly in <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Lucentis</font> and mature ophthalmology (approximately USD 0.3 billion) and new patient starts in dermatology.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Oncology BU sales were also broadly in line with prior year (USD 3.5 billion, -2%, +1% cc). Strong performance of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Promacta/Revolade</font> (USD 422 million, +21%, +23% cc), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray </font>(USD 79 million), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kymriah </font>(USD 118 million, +103%, +103% cc) and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kisqali</font> (USD 159 million, +43%, +49% cc) was offset by generic competition for <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Afinitor</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Exjade</font> and the negative impact of the COVID-19 pandemic, particularly in radioligand therapy.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Operating income</div>

<div style="TEXT-ALIGN: justify">Operating income was USD 2.0 billion (-21%, -15% cc) mainly due to lower divestment gains and higher impairments, partly offset by lower legal expenses. Operating income margin was 22.1% of net sales decreasing 5.4 percentage points (-4.2 percentage points in cc).</div>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">8</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="margin-bottom: 6pt; font-size: 10pt; font-family: Arial; text-align: justify; margin-top: 6pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; BACKGROUND-COLOR: #ffffff">Core adjustments were USD 1.3 billion, mainly due to USD 0.7 billion for amortization. Core adjustments increased compared to prior year mainly due to lower divestment income and higher impairments and amortization, partly offset by lower legal provisions.</font></div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core operating income was USD 3.3 billion (0%, +5% cc) mainly driven by lower spending. Core operating income margin was 35.9% of net sales, increasing 0.5 percentage points (+1.3 percentage points cc). Core gross margin increased by 0.4 percentage points (cc). Core R&amp;D expenses as a percentage of net sales decreased by 0.7 percentage points (cc) mainly driven by productivity, portfolio prioritization and COVID-19 related spending impacts. Core SG&amp;A expenses declined by 1.0 percentage points (cc) benefiting from COVID-19 related spending impacts. Core Other Income and Expense net decreased the margin by 0.8 percentage points (cc), mainly due to the <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zolgensma </font>pre-launch inventory provision release in prior year.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">First half</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Net sales</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net sales were USD 18.9 billion (+5%, +7% cc). Pharmaceuticals BU grew 5% (+8% cc) driven by <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font> (USD 1.1 billion, +48%, +50% cc), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zolgensma</font> (USD 0.4 billion), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx </font>(USD 1.9 billion, +14%, +15% cc) and the <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Xiidra</font> acquisition, partly offset by declines in <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Lucentis</font> and other ophthalmology products, driven mainly by lower demand due to COVID-19. Oncology BU grew 4% (+6% cc) driven by <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Promacta/Revolade </font>(USD 0.8 billion, +26%, +28% cc),<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Piqray</font> (USD 0.2 billion)<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">&#160;</font>and<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Kisqali</font> (USD 0.3 billion, +58%, +64% cc). Volume contributed 13 percentage points to sales growth. Generic competition had a negative impact of 3 percentage points. Net pricing had a negative impact of 3 percentage points.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">The US (USD 7.1 billion, +12%) delivered strong performance of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zolgensma, Cosentyx</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font>. Europe sales (USD 6.4 billion, 0%, +3% cc) grew driven by <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto, Jakavi,</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #ff0000; FONT-STYLE: italic">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kymriah </font>and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kisqali</font>. Japan sales were USD 1.2 billion (0%, -2% cc). Emerging Growth Markets sales grew (+5%, +11% cc), led by double digit growth in China, including the launches of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Operating income</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Operating income was USD 4.8 billion (+2%, +9% cc), mainly driven by sales growth and lower legal expenses, partly offset by higher amortization and lower divestment gains. Operating income margin was 25.3% of net sales, decreasing 0.5 percentage points <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; BACKGROUND-COLOR: #ffffff">(+0.4 percentage points cc).</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; BACKGROUND-COLOR: #ffffff">Core adjustments were USD 2.1 billion, mainly due to USD 1.4 billion of amortization. Core adjustments increased compared to prior year mainly due to lower divestment income and higher amortization, partly offset by lower legal expenses.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core operating income was USD 6.9 billion (+11%, +16% cc) mainly driven by sales growth and lower spending due to COVID-19 impacts, partly offset by launch investments. Core operating income margin was 36.5% of net sales, increasing 2.1 percentage points (+2.8 percentage points cc). Core gross margin increased by 0.7 percentage points (cc) mainly driven by productivity. Core R&amp;D expenses as a percentage of net sales decreased by 1.3 percentage points (cc) mainly driven by the higher net sales, productivity and portfolio prioritization. Core SG&amp;A expenses declined by 1.2 percentage points (cc) benefiting from COVID-19 related spending impacts. Core Other Income and Expense net decreased the margin by 0.4 percentage points (cc).</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">9</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">ONCOLOGY BUSINESS UNIT</div>

<table id="z0c500346ee68497f817d203fce2cd8fe" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">Q2 2020</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">Q2 2019</div>
</td>
<td style="WIDTH: 11.89%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">% change</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">H1 2020</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">H1 2019</div>
</td>
<td style="WIDTH: 11.89%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;USD m</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;USD m</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">USD</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">cc</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;USD m</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;USD m</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">USD</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Tasigna</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;480</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;468</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">3</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">5</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;967</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;902</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">7</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Promacta/Revolade</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;422</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;349</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">21</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">23</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;825</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;656</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">26</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">28</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Tafinlar </font>+<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic"> Mekinist</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-STYLE: italic">1</sup></div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;371</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;340</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">12</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;737</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;637</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">16</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Sandostatin</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;341</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;403</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-13</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;715</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;795</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Jakavi</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;310</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;284</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">9</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;628</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;542</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">16</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">20</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Gleevec/Glivec</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;288</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;323</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-8</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;617</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;630</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-2</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Afinitor/Votubia</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;266</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;401</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-34</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-33</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;562</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;774</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-27</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Exjade/Jadenu</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;163</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;253</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-36</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-35</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;335</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;491</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-32</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-31</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Votrient</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;162</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;193</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-16</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-14</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;328</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;380</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-14</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Kisqali</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;159</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;111</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">43</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">49</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;320</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;202</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">58</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">64</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Lutathera</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;105</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;109</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-3</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;217</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;215</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Kymriah</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;118</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;58</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">103</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">103</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;211</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;103</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">105</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">106</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Piqray</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;79</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;6</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;153</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;6</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Adakveo</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;21</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;36</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Other</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;263</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;308</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-13</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;545</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;594</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-8</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-6</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.34%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Total Oncology business unit</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">3 548</div>
</td>
<td style="WIDTH: 9.68%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">3 606</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-2</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 2.85%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">7 196</div>
</td>
<td style="WIDTH: 10.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">6 927</div>
</td>
<td style="WIDTH: 6.37%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">6</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">1 </sup>Majority of sales for <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Mekinist </font>and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Tafinlar</font> are combination, but both can be used as monotherapy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">nm = not meaningful</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><br>
<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Tasigna</font> (USD 480 million, +3%, +5% cc) grew due to a strong performance in key markets including the US and China, partly offset by a decline in Europe.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Promacta/Revolade</font> (USD 422 million, +21%, +23% cc) grew at a double digit rate in most regions driven by increased use in chronic immune thrombocytopenia (ITP) and as first-line treatment for severe aplastic anemia (SAA) in the US.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Tafinlar </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">+</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic"> Mekinist</font> (USD 371 million, +9%, +12% cc), the worldwide leader in BRAF/MEK-inhibition, continued to show growth driven by demand in adjuvant melanoma as well as NSCLC.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Sandostatin</font> (USD 341 million, -15%, -13% cc) sales declined due to competitive pressure in Europe, US and Japan. The brand was also impacted by generic competition in Europe and the COVID-19 pandemic in the US.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Jakavi</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">&#160;</font>(USD 310 million, +9%, +14% cc) grew in all regions, driven by demand in the myelofibrosis and polycythemia vera indications.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Gleevec/Glivec</font> (USD 288 million, -11%, -8% cc) declined due to increased generic competition.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Afinitor/Votubia</font> (USD 266 million, -34%, -33% cc) declined due to generic competition in the US, Europe and Emerging Growth Markets.&#160;</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Exjade/Jadenu </font>(USD 163 million, -36%, -35% cc)<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">&#160;</font>declined due to pressure from generic competition in the US and other regions.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Votrient</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">&#160;</font>(USD 162 million, -16%, -14% cc) declined due to increased competition in Europe and the US.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Kisqali</font> (USD 159 million, +43%, +49% cc) continued strong double digit growth driven by demand in the US, strong uptake in Europe and other regions benefiting from the ongoing impact of positive overall survival data from two pivotal Phase III trials (MONALEESA-7 and MONALEESA-3).</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Lutathera</font> (USD 105 million, -4%, -3% cc) declined versus prior year due to the negative impact of the COVID-19 pandemic. There are almost 350 total centers now actively treating patients. Sales from all AAA brands (including <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Lutathera</font> and radiopharmaceutical diagnostic products) were USD 153 million.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Kymriah</font> (USD 118 million, +103%, +103% cc) grew strongly in Europe and US. More than 240 qualified treatment centers and 25 countries have coverage for at least one indication. The EMA approved commercial manufacturing of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kymriah</font> at the Novartis-owned facilities in Stein, Switzerland which will support existing manufacturing at the facility in Morris Plains, New Jersey, US.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Piqray </font>(USD 79 million) grew in the US driven by strong demand. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray</font> in combination with fulvestrant received a positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation. </div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">10</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray </font>is the first and only therapy specifically for the approximately 40% of HR+/HER2- advanced breast cancer patients who have a PIK3CA mutation, which is associated with poor prognosis. &#160;</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Adakveo </font>(USD 21 million)<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>US launch is progressing well, with close to 100% brand awareness among hematologists. Payer coverage decisions are expanding, including published Medicaid policies in 19 states and 85% coverage among commercial plans to date. The permanent J-code took effect&#160;July 1, which provides more confidence around the billing process. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Adakveo</font> was approved by the FDA following priority review as the first and only monthly therapy to reduce the frequency of pain crises, or vaso-occlusive crises (VOCs), in adults and pediatric patients aged 16 years and older with sickle cell disease.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">&#160;</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">PHARMACEUTICAL BUSINESS UNIT</div>

<div><br>
</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">IMMUNOLOGY, HEPATOLOGY and DERMATOLOGY</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">
<table id="z6f2f9760205348d6824fe58be645ffed" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 32%; VERTICAL-ALIGN: middle; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 11.21%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 11.53%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
<td style="WIDTH: 2.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.38%; VERTICAL-ALIGN: middle; TEXT-ALIGN: right">&#160;H1 2019</td>
<td style="WIDTH: 10.99%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 11.21%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.47%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 2.05%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 9.38%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.5%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Cosentyx</div>
</td>
<td style="WIDTH: 11.21%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;944</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;858</div>
</td>
<td style="WIDTH: 6.47%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">10</div>
</td>
<td style="WIDTH: 5.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">12</div>
</td>
<td style="WIDTH: 2.05%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 874</div>
</td>
<td style="WIDTH: 9.38%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 649</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 5.5%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">15</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Ilaris</div>
</td>
<td style="WIDTH: 11.21%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;200</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;165</div>
</td>
<td style="WIDTH: 6.47%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">21</div>
</td>
<td style="WIDTH: 5.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">23</div>
</td>
<td style="WIDTH: 2.05%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;413</div>
</td>
<td style="WIDTH: 9.38%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;316</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">31</div>
</td>
<td style="WIDTH: 5.5%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">33</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Total Immunology, Hepatology and Dermatology</div>
</td>
<td style="WIDTH: 11.21%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 144</div>
</td>
<td style="WIDTH: 10.45%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 023</div>
</td>
<td style="WIDTH: 6.47%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">12</div>
</td>
<td style="WIDTH: 5.28%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">13</div>
</td>
<td style="WIDTH: 2.05%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.91%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">2 287</div>
</td>
<td style="WIDTH: 9.38%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 965</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">16</div>
</td>
<td style="WIDTH: 5.5%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">18</div>
</td>
</tr>
</table>

<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Xolair</font> sales for all indications are reported in the Respiratory franchise</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Cosentyx</font> (USD 944 million, +10%, +12% cc) continued growth across indications and grew market share in the US. Growth was impacted by significant disruption to dermatology and rheumatology practices due to the COVID-19 pandemic. US sales grew 15% based on broad first line access across psoriasis, psoriatic arthritis and ankylosing spondylitis (AS). In April and June, respectively, <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx </font>received approval and launched in the EU and US for non-radiographic axial spondyloarthritis (nr-axSpA), its fourth major indication, which is now already launched in major markets including the US and Germany. In April, <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx </font>also became the first IL17A inhibitor approved in China for the treatment of AS. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Cosentyx</font> also received a positive CHMP opinion for pediatric psoriasis, reinforcing its strong safety profile.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Ilaris</font> (USD 200 million, +21%, +23% cc) sales were driven by strong double digit volume growth, particularly in Europe and the US. In June, <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Ilaris</font> was granted a new indication in the US for active Still&#8217;s disease including Adult-Onset Still&#8217;s Disease (AOSD); this is in addition to its previously-granted indication for systemic juvenile idiopathic arthritis (SJIA). <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Ilaris</font> is the first FDA-approved treatment for AOSD.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0070c0; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">OPHTHALMOLOGY</div>
</div>

<table id="z087534767cb54858ae567dcc0cf70411" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 32.44%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 10.25%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 9.92%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 12.3%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 12.3%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.44%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 10.25%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 9.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.44%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Lucentis</div>
</td>
<td style="WIDTH: 10.25%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;401</div>
</td>
<td style="WIDTH: 9.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;536</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-25</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-24</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;888</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 069</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-17</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.44%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Xiidra</div>
</td>
<td style="WIDTH: 10.25%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;79</div>
</td>
<td style="WIDTH: 9.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;169</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.44%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Beovu</div>
</td>
<td style="WIDTH: 10.25%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;34</div>
</td>
<td style="WIDTH: 9.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;102</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.44%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Other</div>
</td>
<td style="WIDTH: 10.25%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;423</div>
</td>
<td style="WIDTH: 9.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;638</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-34</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-32</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;974</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 266</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-23</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-21</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.44%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Total Ophthalmology</div>
</td>
<td style="WIDTH: 10.25%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;937</div>
</td>
<td style="WIDTH: 9.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 174</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-20</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-18</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">2 133</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">2 335</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-9</div>
</td>
<td style="WIDTH: 5.77%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-7</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify">nm = not meaningful</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Lucentis</font> (USD 401 million, -25%, -24% cc) declined double digit versus prior year, as did the market, due to the negative impact of the COVID-19 pandemic, which has significantly disrupted ophthalmology practices and limited patient access to treatment of retinal diseases. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Lucentis</font> sales started to recover in May with confirmed positive trend in June.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Xiidra </font>(USD 79 million) was impacted by COVID-19 as ophthalmology visits declined significantly. In the latter part of the quarter, the US dry eye market began to rebound as eye care practices began opening. A significant direct to consumer campaign was launched in the US in May with a new professional campaign rolling out over the summer. In an effort to support and expand patient access to care in the US, a new telemedicine program and new zero copay program launched at the end of June. Novartis has informed the European Medicines Agency of its decision to withdraw the centralized application for Marketing Authorization of <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Xiidra</font>.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">11</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Beovu </font>(USD 34 million) is now approved in more than 30 countries. Launches progress despite the operational challenges coming from the COVID-19 pandemic. Post marketing cases termed as &#8220;retinal vasculitis&#8221; and/or &#8220;retinal vascular occlusion&#8221; that may result in severe vision loss, typically associated with intraocular inflammation and the current COVID-19 situation had an unfavorable impact on US sales. Novartis initiated its own internal review of these post-marketing safety case reports including the establishment of an external Safety Review Committee (SRC) to provide an independent, objective review of these cases and a comparison with events seen in the brolucizumab Phase III trials (HAWK&#160;and HARRIER). Novartis also initiated a safety information update to <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Beovu </font>prescribing information worldwide and in June 2020, the FDA approved a label update for <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Beovu</font> to include additional safety information. Novartis has established a fully dedicated internal team collaborating with a coalition of top global experts to examine the root causes, risk factors, mitigation and potential treatment protocols. Novartis continues to believe <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Beovu</font> represents an important treatment option for patients with wet AMD, with an overall favorable benefit-risk profile.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Other ophthalmology</font> products declined due to the negative impact of the COVID-19 pandemic and generic impacts in the US, primarily for <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Travatan.</font></div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">NEUROSCIENCE<br>
</div>
</div>

<table id="zc17ccaafef944b31925606e8e595f18b" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 32.58%; VERTICAL-ALIGN: middle; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 9.97%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 12.34%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 12.29%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 9.97%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.8%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.74%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Gilenya</div>
</td>
<td style="WIDTH: 9.97%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;738</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;825</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 5.8%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-9</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 510</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 591</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-5</div>
</td>
<td style="WIDTH: 5.74%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-4</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Zolgensma</div>
</td>
<td style="WIDTH: 9.97%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;205</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;15</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.8%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;375</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;15</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.74%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Aimovig</div>
</td>
<td style="WIDTH: 9.97%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;33</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;24</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">38</div>
</td>
<td style="WIDTH: 5.8%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">45</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;69</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;42</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">64</div>
</td>
<td style="WIDTH: 5.74%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">72</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Mayzent</div>
</td>
<td style="WIDTH: 9.97%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;34</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;5</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.8%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;64</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;5</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 5.74%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Other</div>
</td>
<td style="WIDTH: 9.97%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;15</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;17</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-12</div>
</td>
<td style="WIDTH: 5.8%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-26</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;27</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;30</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 5.74%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.58%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Total Neuroscience</div>
</td>
<td style="WIDTH: 9.97%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 025</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;886</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">16</div>
</td>
<td style="WIDTH: 5.8%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">17</div>
</td>
<td style="WIDTH: 2.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">2 045</div>
</td>
<td style="WIDTH: 9.96%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 683</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">22</div>
</td>
<td style="WIDTH: 5.74%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">23</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 2pt">nm = not meaningful</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Gilenya </font>(USD 738 million, -11%, -9% cc) sales declined due to the impacts of the COVID-19 pandemic and increased competition. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Gilenya</font> remains the top prescribed high efficacy therapy in 40 countries around the world and the only one approved to treat pediatric RMS. Novartis is in US ANDA litigations with a generic manufacturer. In parallel, an appeal against a USPTO decision upholding the dosage regimen patent in IPR proceedings is ongoing.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Zolgensma</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">&#160;</font>(USD 205 million) newborn screening in the US continues to progress with 28 states representing 60% of newborns. Additional growth was driven by geographic expansion outside of the US. This includes the recent approval in Japan, with unrestricted reimbursement in place directly following approval by end of May; and approval in the EU, with immediate access to label in France (cohort ATU) and Germany, with the product in market as of July 1 and ~90% of patients covered through agreements already in place with sickness funds.&#160;We are in dialogue with all EU markets regarding our Day One access program, and have confidential agreements in place with five additional markets.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Mayzent </font>(USD 34 million) grew versus the first quarter despite new patients starts being impacted by COVID-19. Patient uptake is showing signs of improvement towards the end of Q2.&#160;&#160;Uptake is driven by important unmet needs in patients showing signs of progression despite being on other treatments. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Mayzent</font> is the first and only oral DMT studied and proven to delay disease progression in a broad SPMS patient population.&#160;In addition to the US and EU experience, <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Mayzent </font>is now approved in Australia, Canada, China and Japan, and could be approved in Switzerland.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Aimovig</font> (USD 33 million, +38%, +45% cc) is the most prescribed anti-CGRP worldwide, with more than 440,000 patients prescribed worldwide in the post-trial setting. It has now been launched for the preventive treatment of migraine in&#160;44&#160;countries and&#160;additional launches are underway.&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Aimovig</font> is co-commercialized with Amgen in the US, where Amgen records sales and Novartis has exclusive rights in all ex-US territories excluding Japan.&#160;The collaboration continues&#160;during&#160;the litigation&#160;between the companies and will remain in force&#160;until a final court resolution.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">12</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">CARDIOVASCULAR, RENAL AND METABOLISM</div>

<div><br>
</div>

<table id="z11b0b6cb0da14ee8a19819ab377a5472" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 26.51%; VERTICAL-ALIGN: middle; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 11.17%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 13.46%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
<td style="WIDTH: 3.19%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 13.38%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.51%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 11.17%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 7.14%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 6.32%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 3.19%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 7.14%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 6.24%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.51%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Entresto</div>
</td>
<td style="WIDTH: 11.17%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;580</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;421</div>
</td>
<td style="WIDTH: 7.14%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">38</div>
</td>
<td style="WIDTH: 6.32%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">40</div>
</td>
<td style="WIDTH: 3.19%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 149</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;778</div>
</td>
<td style="WIDTH: 7.14%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">48</div>
</td>
<td style="WIDTH: 6.24%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">50</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.51%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Other</div>
</td>
<td style="WIDTH: 11.17%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;6</div>
</td>
<td style="WIDTH: 7.14%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 6.32%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">nm</div>
</td>
<td style="WIDTH: 3.19%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;12</div>
</td>
<td style="WIDTH: 7.14%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-92</div>
</td>
<td style="WIDTH: 6.24%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-98</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.51%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Total Cardiovascular, Renal &amp; Metabolism</div>
</td>
<td style="WIDTH: 11.17%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;580</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;427</div>
</td>
<td style="WIDTH: 7.14%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">36</div>
</td>
<td style="WIDTH: 6.32%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">38</div>
</td>
<td style="WIDTH: 3.19%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 150</div>
</td>
<td style="WIDTH: 10.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;790</div>
</td>
<td style="WIDTH: 7.14%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">46</div>
</td>
<td style="WIDTH: 6.24%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">48</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 2pt">nm = not meaningful</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Entresto </font>(USD 580 million, +38%, +40% cc) delivered sustained growth and increased market share, driven by demand as the essential first choice therapy for HF patients. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto</font> was approved in Japan on June 29 and launch is expected in H2 2020 while in the US <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Entresto </font>filed with the FDA on April 22 an additional indication to treat HFpEF with a decision anticipated in Q1 2021. Novartis is in US ANDA litigation with generic manufacturers.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">RESPIRATORY<br>
</div>
</div>

<table id="z3de3845bfc3a407682b5a0fc165344e3" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 32.42%; VERTICAL-ALIGN: middle; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 12.3%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 12.3%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.42%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.42%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Xolair</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;289</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;290</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;596</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;571</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.42%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Ultibro</font> Group</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;149</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;166</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-7</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;309</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;323</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.42%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Other</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;6</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;5</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">20</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;10</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;12</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-17</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-18</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.42%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Total Respiratory</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;444</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;461</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-4</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;915</div>
</td>
<td style="WIDTH: 10.01%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;906</div>
</td>
<td style="WIDTH: 6.54%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 5.76%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">5</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Xolair</font> sales for all indications are reported in the Respiratory franchise</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Xolair </font>(USD 289 million, 0%, +4% cc) continued growth in constant currency in both indications, Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU). Novartis co-promotes <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Xolair </font>with Genentech in the US and share a portion of operating income, but we do not record any US sales.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Ultibro </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Group </font>(USD 149 million, -10%, -7% cc) sales declined due to competitive pressures in all regions. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Ultibro </font>Group consists of inhaled COPD therapies <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Ultibro</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Breezhaler</font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Seebri Breezhaler </font>and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Onbrez</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Breezhaler</font>.</div>

<div style="MARGIN-TOP: 6pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">ESTABLISHED MEDICINES</div>

<table id="zafe7ae1707c34d65a154145cdb8f280f" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">Q2 2020</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">Q2 2019</div>
</td>
<td style="WIDTH: 12.23%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">H1 2020</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">H1 2019</div>
</td>
<td style="WIDTH: 12.23%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Galvus</font> Group</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;279</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;320</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-13</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-8</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;617</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;635</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-3</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Diovan</font> Group</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;268</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;283</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-5</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;542</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;544</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">4</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Exforge</font> Group</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;238</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;264</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-10</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-5</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;496</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;531</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-7</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-3</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Zortress/Certican</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;106</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;124</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-12</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;233</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;240</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-3</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">0</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Neoral/Sandimmun(e)</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;96</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;110</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-13</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;197</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;213</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-8</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-5</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Voltaren/Cataflam</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;82</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;95</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-14</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;174</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;208</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-16</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Other</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;441</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;553</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-20</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-16</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;958</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">1 129</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-15</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">-12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 32.88%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Total Established Medicines</div>
</td>
<td style="WIDTH: 9.93%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 510</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1 749</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-14</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-9</div>
</td>
<td style="WIDTH: 2.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">&#160;</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">3 217</div>
</td>
<td style="WIDTH: 9.94%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">3 500</div>
</td>
<td style="WIDTH: 6.52%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-8</div>
</td>
<td style="WIDTH: 5.71%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1.5pt solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-5</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Galvus </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold">Group </font>(USD 279 million, -13%, -8% cc) declined primarily due to price reduction and inventory transfer cycle related to our co-promotion in Japan as well as generic competition in India.</div>

<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic">Diovan </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000">Group</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">(USD 268 million, -5%, 0% cc) declined</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">in Europe and Japan, partly offset by growth in Emerging Growth Markets.</font></div>

<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; FONT-STYLE: italic">Exforge</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold"> Group</font> (USD 238 million, -10%, -5% cc) declined in Europe due to generic competition, partly compensated by growth in Emerging Growth Markets.</div>

<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic">Zortress/Certican </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">(USD 106 million, -15%, -12% cc) </font>declined mainly due to generic competition in the US.</div>

<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic">Neoral/Sandimmun(e) </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">(USD 96 million, -13%, -11% cc) </font>declined mainly due to <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000">generic competition and mandatory price reductions.</font></div>

<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic">Voltaren/Cataflam</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000"> (USD 82 million, -14%, -11% cc) </font>declined mainly due to generic competition.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">13</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold">Sandoz</div>

<div><br>
</div>

<table id="z023fd29432614883a1eef99d420d3a82" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 26.48%; VERTICAL-ALIGN: top; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.72%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right; MARGIN-RIGHT: 1.65pt">Q2 2020</div>
</td>
<td style="WIDTH: 9.61%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right; MARGIN-RIGHT: 1.65pt">Q2 2019</div>
</td>
<td style="WIDTH: 15.64%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
<td style="WIDTH: 2.52%; VERTICAL-ALIGN: top; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.7%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right; MARGIN-RIGHT: 1.65pt">H1 2020</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right; MARGIN-RIGHT: 1.65pt">H1 2019</div>
</td>
<td style="WIDTH: 13.92%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">% change</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.48%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 9.61%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 8.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 7.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
<td style="WIDTH: 2.52%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right">&#160;</td>
<td style="WIDTH: 10.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD m</div>
</td>
<td style="WIDTH: 7.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">USD</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: right">cc</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.48%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net sales</div>
</td>
<td style="WIDTH: 10.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">2 159</div>
</td>
<td style="WIDTH: 9.61%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">2 438</div>
</td>
<td style="WIDTH: 8.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-11</div>
</td>
<td style="WIDTH: 7.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-9</div>
</td>
<td style="WIDTH: 2.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">4 687</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">4 764</div>
</td>
<td style="WIDTH: 7.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-2</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.48%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Operating income</div>
</td>
<td style="WIDTH: 10.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">321</div>
</td>
<td style="WIDTH: 9.61%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">282</div>
</td>
<td style="WIDTH: 8.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">14</div>
</td>
<td style="WIDTH: 7.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">25</div>
</td>
<td style="WIDTH: 2.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">276</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">555</div>
</td>
<td style="WIDTH: 7.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-50</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">-40</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.48%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;&#160;As % of net sales</div>
</td>
<td style="WIDTH: 10.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">14.9</div>
</td>
<td style="WIDTH: 9.61%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">11.6</div>
</td>
<td style="WIDTH: 8.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 7.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 2.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">5.9</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">11.6</div>
</td>
<td style="WIDTH: 7.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 26.48%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Core operating income</div>
</td>
<td style="WIDTH: 10.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">475</div>
</td>
<td style="WIDTH: 9.61%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">501</div>
</td>
<td style="WIDTH: 8.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">-5</div>
</td>
<td style="WIDTH: 7.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
<td style="WIDTH: 2.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">1 148</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">962</div>
</td>
<td style="WIDTH: 7.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">19</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.48%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;&#160;As % of net sales</div>
</td>
<td style="WIDTH: 10.72%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">22.0</div>
</td>
<td style="WIDTH: 9.61%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">20.5</div>
</td>
<td style="WIDTH: 8.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 7.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 2.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">24.5</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: right">20.2</div>
</td>
<td style="WIDTH: 7.57%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">COVID-19 Impacts</div>

<div><br>
</div>
</div>

<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">First half results are more representative of performance as Q1 forward purchasing largely reversed in Q2. In Q2 there was significant disruption to practices limiting patient access to treatments, especially to our retail business. Despite this, H1 sales grew 1% (cc) and core operating income grew 26% (cc).&#160; Spending was lower in both quarters as we implemented and embraced new ways of working, which include lower travel and meeting costs, as well as lower promotional activities. We will closely monitor the impact of these trends on future quarters.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Second quarter</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Net sales</div>

<div style="TEXT-ALIGN: justify">Sandoz net sales were USD 2.2 billion (-11%, -9% cc) in the second quarter with volume decline of 9 percentage points (cc) and pricing was in line with prior year, benefiting from favorable revenue deduction adjustments. The sales decline was due to COVID-19 negative impacts, mainly the reversal of Q1 forward purchasing and lower retail demand, some contract discontinuations in the US and a higher prior year base that included several first to market launches. The decline was partly offset by&#160;global sales of Biopharmaceuticals growing 19% (cc), driven by double digit growth in Europe and the US.</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Sales in Europe were USD 1.1 billion (-11%, -8% cc), impacted by COVID-19. Sales in the US were USD 508 million (-21%), impacted by the oral solids decline as well as US first-to-market launches in prior year. Sales in Asia / Africa / Australasia were USD 341 million (+2%, +4% cc) including the contribution from the Aspen Japan acquisition. Sales in Canada and Latin America were USD 180 million (-7%, +5% cc).</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Global sales of Biopharmaceuticals (biosimilars, biopharmaceutical contract manufacturing and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Glatopa</font>) grew to USD 466 million (+16%, +19% cc), driven by continued strong double-digit growth in Europe from <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Hyrimoz</font> (adalimumab), <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Erelzi</font> (etanercept) and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Zessly</font> (infliximab) and growth from <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Omnitrope</font> (somatropin). Launch roll-outs in other geographies also contributed to growth.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Retail sales were USD 1.6 billion (-17%, -14% cc), impacted by COVID-19. Total Anti-Infectives franchise sales were USD 251 million (-22%, -19% cc), including finished dosage forms sold under the Sandoz name (USD 134 million, -28%, -24% cc) and Anti-Infectives sold to third parties for sale under their own name (USD 117 million, -13%, -12% cc).</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Operating income</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Operating income was USD 321 million (+14%, +25% cc), mainly driven by lower restructuring expenses, continued gross margin improvements and lower costs, partly offset by the lower sales. Operating income margin increased by 4.3 percentage points in constant currencies; currency had a negative impact of 1.0 percentage points, resulting in a net increase of 3.3 percentage points to 14.9% of net sales.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core adjustments were USD&#160;154 million, including USD 70 million of amortization. Prior year core adjustments were USD 219 million. The change in core adjustments compared to prior year was driven by lower net restructuring expenses from Sandoz Transformation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Core operating income was USD 475 million (-5%, +1% cc) as lower spending linked to COVID-19, cost discipline and gross margin improvements were mostly offset by sales decline. Core operating income</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">14</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="TEXT-ALIGN: justify">margin improved by 2.2 percentage points in constant currencies, currency had a negative impact of 0.7 percentage points, resulting in a net increase of 1.5 percentage points to 22.0% of net sales. Core gross margin as a percentage of net sales increased by 2.0 percentage points (cc), driven by favorable product and geographic mix, ongoing productivity improvements and lower price erosion. Core R&amp;D expenses increased by 1.1&#160;percentage points (cc). Core SG&amp;A expenses decreased by 0.4&#160;percentage points (cc). Core Other Income and Expense decreased by 0.9&#160;percentage points (cc), mainly due to lower net legal settlement provisions.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">First half</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net sales</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net sales were USD 4.7 billion (-2%, +1% cc) with volume growth of 3&#160;percentage points (cc) partially offset by 2 percentage points (cc) of price erosion, benefiting from favorable revenue deduction adjustments. Excluding the US, net sales grew (+2%, +6% cc).</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Sales in Europe were USD 2.6 billion (+2%, +5% cc). Sales in the US were USD 1.1 billion (-12%), due to the volume decline in oral solids. Sales in Asia / Africa / Australasia were USD 675 million (+4%, +5% cc) including the contribution from the Aspen Japan acquisition. Sales in Canada and Latin America were USD 376 million (+1%, +12% cc).</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Global sales of Biopharmaceuticals (biosimilars, biopharmaceutical contract manufacturing and <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Glatopa</font>) grew to USD 916 million (+22%, +25% cc), driven by continued strong double digit growth in Europe and the US. Launch roll-outs in other geographies also contributed to growth.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Retail sales were USD 3.5 billion (-6%, -3% cc) as declines in the US were partly offset by growth in Europe. Total Anti-Infectives franchise sales were USD 582 million (-10%, -8% cc), including finished dosage forms sold under the Sandoz name (USD 356 million, -9%, -5% cc) and Anti-Infectives sold to third parties for sale under their own name (USD 226 million, -13%, -11% cc), which were impacted by a planned contract discontinuation.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Operating income</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Operating income was USD 276 million (-50%, -40% cc), impacted by USD 0.4 billion legal provisions and cumulative depreciation and amortization from the termination of the planned Aurobindo transaction. Operating income margin decreased by 4.7 percentage points in constant currencies; currency had a negative impact of 1.0 percentage points, resulting in a net decrease of 5.7 percentage points to 5.9% of net sales.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core adjustments were USD&#160;0.9 billion, including USD 0.2 billion of amortization and USD 0.4 billion legal settlements charges and provisions. Prior year core adjustments were USD 0.4 billion, which were impacted by net restructuring expenses from Sandoz Transformation.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Core operating income was USD 1.1 billion (+19%, +26% cc), driven by gross margin improvements, lower spending linked to COVID-19, cost discipline and sales growth. Core operating income margin was 24.5% of net sales, increasing 4.3 percentage points (4.9 percentage points cc). Core gross margin increased by 2.3 percentage points (cc), driven by favorable product and geographic mix along with ongoing productivity improvements and lower price erosion. Core R&amp;D expenses increased by 0.1&#160;percentage points (cc). Core SG&amp;A expenses decreased by 2.0&#160;percentage points (cc). Core Other Income and Expense decreased by 0.7&#160;percentage points (cc), mainly due to lower net legal settlement provisions.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">15</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold">GROUP CASH FLOW AND BALANCE SHEET</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 14pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Cash flow</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Second quarter</div>

<div style="TEXT-ALIGN: justify">Net cash flows from operating activities from continuing operations amounted to USD 4.0 billion, compared to USD 3.1 billion in the prior year quarter. This increase was mainly driven by favorable working capital and lower taxes paid, partly offset by higher provision payments including legal settlements.</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net cash outflows from investing activities from continuing operations amounted to USD 0.3 billion, compared to net cash inflows of USD 0.2 billion in the prior year quarter.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">The current year quarter cash outflows were mainly driven by USD 0.5 billion for the purchase of property, plant and equipment, intangible assets, financial assets and other non-current assets. These were partly offset by cash inflows of USD 0.2 billion mainly from the sale of financial and intangible assets.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">In the prior year quarter, net cash inflows of USD 0.2 billion from investing activities from continuing operations were mainly related to USD 1.0 billion in proceeds from the sale of property, plant and equipment (including the proceeds from the sale and leaseback of real estate), intangible assets and financial assets. These were partly offset by cash outflows of USD 0.5 billion for the purchase of property, plant and equipment, intangible assets and financial assets. Cash outflows for acquisitions and divestments of business, net, amounted to USD 0.3 billion (acquisition of IFM Tre, Inc.).</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net cash flows used in investing activities from discontinued operations amounted to USD 0.1 billion compared to USD 0.7 billion in the prior year quarter. The current year period includes payments related to the portfolio transformation transactions and payments attributable to the spin-off of the Alcon business. The prior year quarter mainly included the cash outflow of USD 0.6 billion due to the derecognized cash and cash equivalent following the completion of the spin-off of the Alcon business.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net cash flows used for financing activities from continuing operations amounted to USD 2.2 billion, compared to USD 2.7 billion in the prior year quarter.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">The current year quarter cash outflows includes mainly USD 1.2 billion from the net decrease in current financial debts and the repayment of a US dollar bond of USD 1.0 billion at maturity.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">In the prior year quarter, net cash outflows of USD 2.7 billion from financing activities from continuing operations mainly included the cash outflows for net treasury share transactions of USD 2.4 billion, the net repayment of financial debts of USD 0.8 billion, partly offset by other net financing cash inflows of USD 0.5 billion.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net cash inflows from financing activities from discontinued operations in the prior year quarter amounted to USD 2.7 billion, which included mainly the cash inflows of USD 3.2 billion from Alcon borrowings, partly offset by USD 0.1 billion in payments for Alcon transaction costs.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Free cash flow from continuing operations amounted to USD 3.6 billion (+1%), broadly in line with the prior year quarter, as favorable working capital was offset by lower divestment proceeds.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">First half</div>

<div style="TEXT-ALIGN: justify">Net cash flows from operating activities from continuing operations amounted to USD 6.5 billion, compared to USD 5.4 billion in the prior year period. This increase was driven by higher net income adjusted for non-cash items and other adjustments, including divestment gains, partly offset by higher provision payments including legal settlements.</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net cash outflows from investing activities from continuing operations amounted to USD 10.5 billion, compared to net cash inflows of USD 2.0 billion in the prior year period.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">16</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">The current year period cash outflows were mainly driven by the USD 9.9 billion used for the acquisitions and divestments of businesses, net (including the acquisition of The Medicines Company for USD 9.5 billion, net of cash acquired USD 0.1 billion, and the acquisition of Japanese business of Aspen Global Incorporated for USD 0.3 billion). Other investing activities cash outflows were USD 1.1 billion for the purchase of property, plant and equipment, intangible assets, financial assets and other non-current assets. These were partly offset by cash inflows of USD 0.5 billion mainly from the sale of financial assets (including the USD 0.2 billion proceeds from the sale of Alcon Inc. shares), of intangible assets and from the net proceeds from sales and purchases of marketable securities and commodities.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">In the prior year period, net cash inflows of USD 2.0 billion from investing activities from continuing operations were mainly related to USD 2.3 billion from the net sale of marketable securities and commodities, and of USD 1.3 billion in proceeds from the sale of property, plant and equipment (including the proceeds from the sale and leaseback of real estate), intangible assets and financial assets. These were partly offset by cash outflows of USD 1.2 billion for the purchase of property, plant and equipment, intangible assets and financial assets. Cash outflows for acquisitions and divestments of business, net, amounted to USD 0.4 billion including the acquisition of IFM Tre, Inc. (USD 0.3 billion).</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net cash flows used in investing activities from discontinued operations amounted to USD 0.1 billion compared to USD 1.1 billion in the prior year period. The current year period includes payments related to the portfolio transformation transactions and payments attributable to the spin-off of the Alcon business.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">The prior year period includes mainly the cash outflow for the acquisition of PowerVision, Inc. of USD 0.3 billion and USD 0.6 billion due to the derecognized cash and cash equivalent following the completion of Alcon spin-off, on April 9, 2019.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net cash flows used in financing activities from continuing operations amounted to USD 1.1 billion, compared to USD 13.0 billion in the prior year period.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">The current year period includes net cash inflows of USD 0.7 billion from net treasury share transactions and USD 5.4 billion from current and non-current financial debt; consisting of USD 4.9 billion from issuance of bonds denominated in US dollars (notional amount of USD 5.0 billion), USD 2.5 billion from the net increase in current financial debts and the repayment of two US dollar bonds totaling USD 2.0 billion at maturity. These net cash inflows were offset by cash outflows of USD 7.0 billion for the dividend payment and USD 0.3 billion for the net payments for lease liabilities and other financing cash flows.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">In the prior year period, net cash outflows of USD 13.0 billion from financing activities from continuing operations mainly included the cash outflows of USD 6.6 billion for the dividend payment, the repayment of a US dollar bond of USD 3.0 billion and for the net treasury share transactions of USD 2.4 billion. The net repayments of current financial debts amounted to USD 0.9 billion.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net cash inflows from financing activities from discontinued operations in the prior year period amounted to USD 3.3 billion, which included mainly the cash inflows of USD 3.5 billion from Alcon borrowings, partly offset by USD 0.2 billion payments for transaction costs.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Free cash flow from continuing operations amounted to USD 5.7 billion (+3%) compared to USD 5.5 billion in the prior year period. This increase was mainly driven by higher operating income adjusted for non-cash items and other adjustments, partly offset by lower divestment proceeds.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 14pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Balance sheet</div>

<div><br>
</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">In December 31, 2019, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reported as current assets and liabilities held for sale in the consolidated balance sheet. Novartis decided to retain the Sandoz US generic oral solids and dermatology businesses in March 2020, after mutual agreement with Aurobindo to terminate the transaction. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within the agreed timelines. As such, these assets and liabilities are reclassified to their respective consolidated balance sheet lines as from March 31, 2020, the prior year consolidated balance sheet is not restated (see Notes 2 and 3).</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">17</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Assets</div>

<div style="TEXT-ALIGN: justify">Total non-current assets of USD 99.9 billion at June 30, 2020, increased by USD 11.0 billion compared to December 31, 2019. Intangible assets other than goodwill increased by USD 7.9 billion mainly due to the acquisitions of The Medicines Company and of the Japanese business of Aspen Global Incorporated, net additions and the reclassification of the intangible assets of the disposal group held for sale of USD 0.3 billion, partially offset by amortization and impairments. Goodwill increased by USD 2.6 billion and deferred tax assets by USD 0.7 billion mainly due to the acquisition of The Medicines Company. Property, plant and equipment decreased by USD 0.1 billion, as the increase due to net additions and the reclassification of the property, plant and equipment of the disposal group held for sale of USD 0.1 billion were more than offset by depreciation. Investments in associated companies and financial assets decreased by USD 0.1 billion in total, while other non-current assets increased by USD 0.1 billion mainly due to an increase in the prepaid benefit costs of USD 0.1 billion, mainly resulting from actuarial losses primarily from changes in discount rates used to calculate the actuarial defined benefit obligations and valuation impact on plan assets. Right-of-use assets were broadly in line with December 31, 2019.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Total current assets of USD 23.9 billion at June 30, 2020, decreased by USD 5.6 billion compared to December 31, 2019. This was mainly driven by a decrease in cash and cash equivalents of USD 5.2 billion. Inventories increased by USD 0.9 billion, partly due to the reclassification of the inventory of the disposal group held for sale. Trade receivables decreased by USD 0.7 billion to USD 7.6 billion. Income tax receivables, other current assets and marketable securities, commodities, time deposits, and derivative financial instruments remained broadly in line with December 31, 2019.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Liabilities</div>

<div style="TEXT-ALIGN: justify">Total non-current liabilities of USD 40.5 billion increased by USD 5.9 billion compared to December 31, 2019. Long-term financial debts increased by USD 3.6 billion, mainly driven by the issuance of US dollar denominated bonds for a notional amount of USD 5.0 billion, partly offset by the reclassification from non-current to current financial debt of EUR 1.3 billion (USD 1.4 billion) bonds due in 2021. Deferred tax liabilities increased by USD 1.6 billion mainly due to the acquisition of The Medicines Company. Provisions and other non-current liabilities increased by USD 0.7 billion, principally due to an increase in pension liabilities of USD 0.6 billion, mainly resulting from actuarial losses primarily from changes in discount rates used to calculate the actuarial defined benefit obligations and valuation impact on plan assets. Lease liabilities were broadly in line compared to December 31, 2019.</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Total current liabilities of USD 29.4 billion increased by USD 1.1 billion compared to December 31, 2019. Financial debts and derivative financial instruments increased by USD 1.8 billion, due to the reclassification from non-current to current financial debt of EUR 1.3 billion (USD 1.4 billion) bonds due in 2021 and higher short-term borrowings, partly offset by the repayment at maturity of two US dollar bonds, totaling USD 2.0 billion. Current income tax liabilities increased by USD 0.4 billion. This net increase was partially offset by a decrease of USD 0.6 billion in trade payables and a decrease of USD 0.5 billion in provisions and other current liabilities. Lease liabilities were broadly in line compared to December 31, 2019.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Group equity</div>

<div style="TEXT-ALIGN: justify">The Group&#8217;s equity decreased by USD 1.7 billion to USD 53.9 billion at June 30, 2020 compared to December 31, 2019. This decrease was mainly due to the cash-dividend payment of USD 7.0 billion, net actuarial losses of USD 0.3 billion and purchase of treasury shares of USD 0.1 billion. This was partially offset by net income of USD 4.0 billion, the net effect of the exercise of options and employee transactions of USD 0.8 billion, equity-based compensation of USD 0.4 billion, favorable currency translation differences of USD 0.4 billion and the net favorable effect of fair value adjustments on financial instruments of USD 0.1 billion.</div>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Net debt and debt/equity ratio</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">The Group&#8217;s liquidity amounted to USD 6.3 billion at June 30, 2020, compared to USD 11.4 billion at December 31, 2019. Total non-current and current financial debts, including derivatives, amounted to USD 32.8 billion at June 30, 2020, compared to USD 27.4 billion at December 31, 2019. The debt/equity</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">18</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">ratio increased to 0.61:1 at June 30, 2020, compared to 0.49:1 at December 31, 2019. The net debt increased to USD 26.5 billion at June 30, 2020, compared to USD 15.9 billion at December 31, 2019.</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Group liquidity</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">We continuously track our liquidity positions and assets / liabilities profile. We have a strong balance sheet and related funding capabilities to meet our funding needs. The Group has not experienced liquidity or cash flow disruptions during the first half of 2020 due to COVID-19 pandemic, and maintains a cash and cash equivalents position of USD 5.9 billion as per June 30, 2020. We believe that our strong credit rating allows for continued access to short term funding in the US commercial paper market. The Group further has a committed credit facility of USD 6.0 billion as a backstop for the US commercial paper program, which was undrawn as of June 30, 2020, providing a further source of liquidity if needed. Novartis is well positioned to meet its ongoing financial obligations and has sufficient liquidity to support our normal business activities.</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">19</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold">Innovation Review</div>

<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold">&#160;</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify; MARGIN-TOP: 6pt">Benefiting from our continued focus on innovation, Novartis has one of the industry&#8217;s most innovative and inventive pipelines with more than 160 projects in clinical development.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Selected Innovative Medicines approvals: US, EU and Japan in Q2</div>
</div>

<table id="z0ed22962d07f43e89d5d92d02b6cc62b" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Product</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 25.67%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Active ingredient/<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font> Descriptor</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 34.23%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Indication</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 23.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Region</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Atectura Breezhaler</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(QMF149)</div>
</td>
<td style="WIDTH: 25.67%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">indacaterol/mometasone fuorate</div>
</td>
<td style="WIDTH: 34.23%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Asthma</div>
</td>
<td style="WIDTH: 23.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">EU &#8211; May</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">JP &#8211; June</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Cosentyx</div>
</td>
<td style="WIDTH: 25.67%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">secukinumab</div>
</td>
<td style="WIDTH: 34.23%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Non-radiographic axial spondyloarthritis</div>
</td>
<td style="WIDTH: 23.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">EU &#8211; April</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">US &#8211; June</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Enerzair Breezhaler (QVM149)</div>
</td>
<td style="WIDTH: 25.67%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">indacaterol acetate + mometasone fuorate + glycopyrronium bromide</div>
</td>
<td style="WIDTH: 34.23%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Asthma</div>
</td>
<td style="WIDTH: 23.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">EU &#8211; July</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">JP &#8211; June</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Entresto</div>
</td>
<td style="WIDTH: 25.67%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">valsartan/sacubitril</div>
</td>
<td style="WIDTH: 34.23%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Chronic heart failure</div>
</td>
<td style="WIDTH: 23.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">JP - June</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Mayzent</div>
</td>
<td style="WIDTH: 25.67%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">siponimod</div>
</td>
<td style="WIDTH: 34.23%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">SPMS</div>
</td>
<td style="WIDTH: 23.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">JP - June</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Tabrecta</div>
</td>
<td style="WIDTH: 25.67%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">capmatinib</div>
</td>
<td style="WIDTH: 34.23%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">NSCLC (cMET amp and mut)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">1</sup></div>
</td>
<td style="WIDTH: 23.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">US &#8211; May</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">JP &#8211; June</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Zolgensma</div>
</td>
<td style="WIDTH: 25.67%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 34.23%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Spinal Muscular Atrophy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(IV formulation)</div>
</td>
<td style="WIDTH: 23.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">EU &#8211; May conditional approval</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">1</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000"> indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).</font></div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Selected Innovative Medicines projects awaiting regulatory decisions</div>
</div>

<table id="z92ec54bdebb5427b987e5522362ae6bf" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 32.33%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: center">Completed submissions</div>
</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Product</div>
</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Indication</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">US</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">EU</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Japan</div>
</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">News update</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">BYL719</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Piqray</font> in US, alpelisib)</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">PIK3CA mutant HR+, HER2 (-) postmenopausal adv BC 2nd line (+fulv)</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Approved</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q4 2018</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">CHMP positive opinion &#8211; May 2020</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Cosentyx</div>
</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Non-radiographic axial spondyloarthritis</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Approved</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Approved</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q4 2019</div>
</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Phase III PREVENT data show significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to week 52</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Entresto</div>
</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Chronic heart failure with preserved ejection fraction</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q2 2020</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">- Filing accepted by FDA in June 2020</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">KJX839</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(inclisiran)</div>
</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Hyperlipidemia</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q4 2019</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q1 2020</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">OMB157</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(ofatumumab)</div>
</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Relapsing Multiple Sclerosis</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q4 2019</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q1 2020</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">FDA extend BLA review &#8211; regulatory action date September 2020</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">SEG101</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Adakveo</font> in US)</div>
</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Sickle cell disease</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Approved</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q2 2019</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.11%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Xolair</div>
</td>
<td style="WIDTH: 19.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Nasal polyps</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q3 2019</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Q4 2019</div>
</td>
<td style="WIDTH: 10.78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 32.54%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">CHMP positive opinion received &#8211; June 2020</font></div>
</td>
</tr>
</table>

<div><br>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">20</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-WEIGHT: bold">Selected Innovative Medicines pipeline projects</div>

<div><br>
</div>

<table id="z770afd82bdc34d27ad61c6abb95cf9bb" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Project/ <br>
 Compound</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Potential indication/ <br>
 Disease area</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">First planned <br>
 submissions</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Current <br>
 Phase</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">News update</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">ABL001</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Chronic myeloid leukemia 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">rd</sup>&#160; line</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid" rowspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">ACZ885<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font> (canakinumab)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Adjuvant NSCLC</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Enrollment ongoing</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">st</sup> line NSCLC</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Completed enrollment in Jan 2020</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">nd</sup> line NSCLC</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">- Enrollment complete</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Aimovig</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Pediatric migraine</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">AVXS-101 IT</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Spinal Muscular Atrophy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(IT formulation)</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">I / II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Continued dialogue with FDA on partial clinical hold</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Plan to approach FDA for pre-BLA meeting, with a BLA submission in 2021</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">AVXS-201</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Rett Syndrome</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">I</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top" rowspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">BYL719</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(alpelisib)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">PROS (PIK3CA-related overgrowth spectrum)</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2020</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Potential US filing in 2020 based on RWE data</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">HER2+ adv breast cancer</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Triple negative breast cancer</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Trial enrolled first patient in June 2020</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Head and neck squamous cell carcinoma</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Ovarian Cancer</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">CEE321</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Atopic dermatitis</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">I</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid" rowspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">CFZ533</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(iscalimab)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Renal Tx</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Liver Tx</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Sj&#246;gren&#8217;s syndrome</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Coartem</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Malaria uncomplicated, &lt;5kg patients</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Cosentyx</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Ankylosing spondylitis head-to-head vs. adalimumab</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2022</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Hidradenitis suppurativa</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2022</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Axial spondyloarthritis IV regimen</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2022</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Giant cell arteritis</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Lichen Planus</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Lupus Nephritis</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">CPK850</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Retinitis pigmentosa</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">CSJ117</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Asthma</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">ECF843</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Dry eye</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Entresto</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Post-acute myocardial infarction</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">INC280</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(capmatinib)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Solid Tumors</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Jakavi</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Acute graft-versus-host disease (GvHD)</div>
</td>
<td style="WIDTH: 15.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 9.27%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 4.5pt; TEXT-INDENT: -4.5pt">- Phase III results published in NEJM, confirming significant improvement in overall response</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Chronic graft-versus-host disease (GvHD) </div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Readout is on track for 2020</font></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">KAE609</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(cipargamin)</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Malaria uncomplicated</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Malaria severe</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">KAF156</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(ganaplacide)</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Malaria uncomplicated</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>
</table>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">21</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<table id="zb4309ee89f7a4477a4b33793bad2f721" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="HEIGHT: auto; WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: bold">Project/ <br>
 Compound</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: bold">Potential indication/ <br>
 Disease area</td>
<td style="HEIGHT: auto; WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: bold">First planned <br>
 submissions</td>
<td style="HEIGHT: auto; WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: bold">Current <br>
 Phase</td>
<td style="HEIGHT: auto; WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">News update</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Kisqali</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">+ endocrine therapy</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">HR+/HER2- early BC (adjuvant)</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2022</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Potential for registration as early as 2022 assuming positive, pre-planned interim analysis</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">KJX839</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(inclisiran)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">ORION-4: Secondary prevention of cardiovascular events in patients with elevated levels of LDLC</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Acquired from The Medicines Company in Jan 2020</font></div>

<div>&#160;</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">ORION-5: Evaluate inclisiran in subjects with a rare genetic condition: homozygous familial hypercholesterolemia (n=56)</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">July 2020: Preliminary&#160;analysis completed. Results inconclusive due to confounding factors. Trial continues with planned protocol amendment. Trial continues.&#160;Full results to be available in H2 2021</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">No impact on ongoing submissions</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Kymriah</font> (<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">tisagenlecleucel</font>)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">r/r Follicular lymphoma</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">r/r DLBCL in 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">st</sup> relapse</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">+ pembrolizumab</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">r/r DLBCL</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">LAM320</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Multi-drug resistant tuberculosis</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">III</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">WHO qualification only / US registration will not be pursued</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">LJC242</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(tropifexor + cenicriviroc)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Non-alcoholic steatohepatitis (NASH)</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">LJN452</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(tropifexor)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Non-alcoholic steatohepatitis (NASH)</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">FDA Fast Track designation</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">LMI070</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Spinal Muscular Atrophy</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">FDA Orphan designation, EMA Orphan status obtained</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Dose ranging study ongoing</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">LNA043</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Osteoarthritis</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">LNP023</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Paroxysmal nocturnal hemoglobinuria</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top" rowspan="2">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">IgA nephropathy</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Membranous nephropathy</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">C3 glomerulopathy</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">US orphan designation received</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Atypical haemolytic uraemic syndrome</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">LOU064</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(remibrutinib)</div>
</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Chronic Spontaneous Urticaria</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Readout expected in 2021</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 26.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Sj&#246;gren&#8217;s syndrome</div>
</td>
<td style="WIDTH: 14.22%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.24%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 33.19%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Lutathera</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">GEP-NET 1L G3</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">III</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">177</sup>Lu-PSMA-617</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Metastatic castration-resistant prostate cancer</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- Event driven trial. </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">H1 2021 readout</font></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">177</sup>Lu-PSMA-R2</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Prostate cancer</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">I</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">177</sup>Lu-NeoB</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Multiple Solid Tumor</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">I</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">LXE408</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Visceral leishmaniosis</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">MBG453</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Myelodysplastic syndrome</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Study initiated in June 2020</font></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Unfit AML</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Study expected to start in 2020</font></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">PDR001 + <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic">Tafinlar + Mekinist</font></div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Metastatic BRAF V600+ melanoma</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2020</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">- Expected submission in H2 2020</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">PDR001 Combo</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Malignant melanoma</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Enrollment ongoing</font></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">QBW251</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">COPD</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Phase IIb recruitment ongoing</font></div>
</td>
</tr>
</table>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">22</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="FONT-FAMILY: Arial">
<table id="z1b03ba3ed55f4c3383c0a3f5f9f4678d" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 29px">
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: bold">Project/ <br>
 Compound</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: bold">Potential indication/ <br>
 Disease area</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: bold">First planned <br>
 submissions</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: bold">Current <br>
 Phase</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt"><font style="FONT-WEIGHT: bold">News</font> update</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">QGE031</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(ligelizumab)</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Chronic Spontaneous Urticaria / Chronic</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Idiopathic Urticaria</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">Enrollment on track to complete in 2020</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">RTH258<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">&#160;</font>(brolucizumab)</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Diabetic macular edema</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2021</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">- Expected readout in H2 2020</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Retinal vein occlusion</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Diabetic retinopathy</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2023</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">SAF312</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Chronic ocular surface pain</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">TQJ230</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a)</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Trial initiated, FPFV in Q4 2019</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">UNR844</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Presbyopia</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">VAY736</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(ianalumab)</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Auto-immune hepatitis</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Primary Sj&#246;gren&#8217;s syndrome</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">FDA Fast Track designation</font></div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">VPM087</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">1st line colorectal cancer / 1st line renal cell carcinoma</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">I</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-STYLE: italic; TEXT-ALIGN: left">Xolair</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Food Allergy</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">2022</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">III</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 15.95%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">ZPL389</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">(adriforant)</div>
</td>
<td style="WIDTH: 25.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Atopic dermatitis</div>
</td>
<td style="WIDTH: 14.98%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">&#8805;2024</div>
</td>
<td style="WIDTH: 10.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left; MARGIN-LEFT: 2.3pt">II</div>
</td>
<td style="WIDTH: 32.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Project discontinued</font></div>
</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Selected Sandoz approvals and pipeline projects</div>
</div>

<table id="z98161be9ceac4601b1cb80c24ebbb5bc" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Project/ Compound</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 50.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">Potential indication/<font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><br>
</font> Disease area</div>
</td>
<td style="BORDER-TOP: #000000 1px solid; WIDTH: 33.08%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left">News update</div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">GP2411 (denosumab)</div>
</td>
<td style="WIDTH: 50.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Osteoporosis, skeletal-related in bone met. pts (same as originator)</div>
</td>
<td style="WIDTH: 33.08%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">In Phase III</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">First patient enrolled July 2019</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Insulin glargine, lispro, aspart</div>
</td>
<td style="WIDTH: 50.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Diabetes</div>
</td>
<td style="WIDTH: 33.08%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Collaboration with Gan &amp; Lee</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">natalizumab</div>
</td>
<td style="WIDTH: 50.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">Multiple sclerosis and Crohn&#8217;s disease</div>
</td>
<td style="WIDTH: 33.08%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Collaboration Polpharma Biologics</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 16.16%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">trastuzumab</div>
</td>
<td style="WIDTH: 50.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: left">HER2-positive cancer tumors</div>
</td>
<td style="WIDTH: 33.08%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Collaboration EirGenix</font></div>
</td>
</tr>
</table>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">23</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<a name="anchorId001660"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Condensed interim consolidated financial&nbsp;statements</p><a name="anchorId001663"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated income statements</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b> (unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 275</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 260</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;429</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;406</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;618</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;368</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;585</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;051</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 432</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 989</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;308</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;352</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;663</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -205</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;634</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -525</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;109</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc.  to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3, 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;800</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 6&nbsp;799</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding &#x2013; Basic (million)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;289</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;310</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Basic earnings per share from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 0.91</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Basic earnings per share from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2.03</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total basic earnings per share (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.94</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding &#x2013; Diluted (million)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;304</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;333</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Diluted earnings per share from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.81</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 0.90</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Diluted earnings per share from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2.01</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total diluted earnings per share (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.81</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.91</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">24</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0011271"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated income statements</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b> (unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;870</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to discontinued segment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;923</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 700</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 556</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&nbsp;151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;657</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;822</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;854</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;915</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&nbsp;501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4&nbsp;350</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 693</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;192</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;844</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;096</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;905</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -459</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -431</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;909</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;774</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -797</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;977</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain on distribution of Alcon Inc. <br>to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -101</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3, 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;567</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 4&nbsp;043</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 8&nbsp;565</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding &#x2013; Basic (million)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;281</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;312</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Basic earnings per share from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.72</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Basic earnings per share from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.98</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total basic earnings per share (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.70</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding &#x2013; Diluted (million)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;299</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;336</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Diluted earnings per share from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.70</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Diluted earnings per share from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.96</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total diluted earnings per share (USD)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.66</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.&nbsp;&nbsp;</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">25</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0011934"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of comprehensive income</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b> (unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;800</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Other comprehensive income to be eventually recycled into the consolidated income statement:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on debt securities, net of taxes</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total fair value adjustments on financial instruments, net of taxes</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -27</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 380</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items to eventually recycle</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 343</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 498</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Other comprehensive income never to be recycled into the consolidated income statement:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Actuarial gains/(losses) from defined benefit plans, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 319</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -387</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 173</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items never to be recycled</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 492</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -408</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;702</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;890</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 2&nbsp;703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 6&nbsp;888</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 2&nbsp;703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2&nbsp;298</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup>&nbsp;</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In Q2 2019, cumulative currency translation gains of USD 123 million were recycled into the consolidated income statement as a result of the Alcon spin-off (see Notes 2, 3 and 10).&nbsp;</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b> (unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;567</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Other comprehensive income to be eventually recycled into the consolidated income statement:</div>
      </td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on debt securities, net of taxes</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on deferred cash flow hedges, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total fair value adjustments on financial instruments, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of other comprehensive income recognized by associated companies, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -54</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 382</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 189</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items to eventually recycle</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 149</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Other comprehensive income never to be recycled into the consolidated income statement:</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Actuarial losses from defined benefit plans, net of taxes<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -293</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -890</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items never to be recycled</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -816</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;215</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;900</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 4&nbsp;219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 7&nbsp;898</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 4&nbsp;219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 3&nbsp;321</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 4&nbsp;577</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In H1 2019, cumulative currency translation gains of USD 123 million were recycled into the consolidated income statement as a result of the Alcon spin-off (see Notes 2, 3 and 10).</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Included in H1 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss pension plans that were previously recognized through other comprehensive income. This revaluation resulted from the Swiss canton Basel-Stadt tax reform, enacted in February 2019.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">26</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0012486"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated balance sheets </font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020<br> (unaudited)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019<br> (audited)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;955</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;640</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;677</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;524</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;669</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;787</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;575</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;644</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;601</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;909</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;475</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;518</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 866</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 738</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 99&nbsp;881</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 88&nbsp;866</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;904</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;982</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;644</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income tax receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 308</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, commodities, time deposits and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;917</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;733</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;680</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets without disposal group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;882</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;663</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Assets of disposal group held for sale</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 841</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;882</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;504</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 123&nbsp;763</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity and liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 913</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 936</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reserves</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52&nbsp;936</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54&nbsp;618</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Issued share capital and reserves attributable to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;812</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;474</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 77</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;885</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&nbsp;955</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;353</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;698</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;703</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;499</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;867</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;344</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;632</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 40&nbsp;496</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;555</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;820</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;424</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;875</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;031</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 258</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;571</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;194</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;858</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;338</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities without disposal group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;382</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities of disposal group held for sale</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;382</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;264</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 69&nbsp;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62&nbsp;819</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity and liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 123&nbsp;763</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">27</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0013409"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of changes in equity</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b> (unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Share<br> capital</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Treasury<br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Retained<br> earnings</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Total value<br> adjustments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Issued share <br> capital and <br> reserves <br> attributable <br> to Novartis <br> shareholders</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Non-<br> controlling<br> interests</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Total<br> equity</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at April 1, 2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 936</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -68</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;356</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5&nbsp;321</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&nbsp;903</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 74</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&nbsp;977</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 836</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 836</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 835</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 836</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;702</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 203</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 203</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 203</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees <br>as a result of the Alcon spin-off</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -74</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -74</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 206</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 206</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at June 30, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 913</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;495</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4&nbsp;559</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;812</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;885</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Share<br> capital</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Treasury<br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Retained<br> earnings</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Total value<br> adjustments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Issued share <br> capital and <br> reserves <br> attributable <br> to Novartis <br> shareholders</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Non-<br> controlling<br> interests</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Total<br> equity</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at April 1, 2019</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 944</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -63</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;518</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -5&nbsp;170</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;229</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;307</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;799</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;799</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;800</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 90</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;799</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;888</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;890</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend in kind</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2, 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;927</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;927</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;927</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;754</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;770</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;770</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 175</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 175</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 175</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees <br>as a result of the Alcon spin-off</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase obligation <br>under a share buyback trading plan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -2&nbsp;573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -2&nbsp;573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -2&nbsp;573</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of <br>consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -2&nbsp;672</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -2&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -2&nbsp;693</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at June 30, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 936</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -5&nbsp;088</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;504</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Included in Q2 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">28</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0015160"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of changes in equity</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half 2020</b> (unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Share<br> capital</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Treasury<br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Retained<br> earnings</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Total value<br> adjustments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Issued share <br> capital and <br> reserves <br> attributable <br> to Novartis <br> shareholders</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Non-<br> controlling<br> interests</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Total<br> equity</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at January 1, 2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 936</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -80</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59&nbsp;275</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4&nbsp;657</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 77</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;551</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;043</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;043</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 175</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;031</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;215</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;987</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -150</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 815</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 823</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 823</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 365</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 365</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees <br>as a result of the Alcon spin-off</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 29</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5&nbsp;811</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5&nbsp;881</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5&nbsp;881</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at June 30, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 913</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;495</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4&nbsp;559</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;812</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;885</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">29</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0015918"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of changes in equity</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half 2019</b> (unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Share<br> capital</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Treasury<br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Retained<br> earnings</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Total value<br> adjustments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Issued share <br> capital and <br> reserves <br> attributable <br> to Novartis <br> shareholders</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Non-<br> controlling<br> interests</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Total<br> equity</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at January 1, 2019, as previously reported</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 944</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -69</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 82&nbsp;191</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -4&nbsp;452</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;614</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;692</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in accounting policies</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated equity at January 1, 2019</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 944</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -69</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 82&nbsp;194</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -4&nbsp;452</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;617</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;695</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;565</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;565</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;567</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -613</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -667</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -667</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;511</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -613</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;898</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;900</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;645</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend in kind</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2, 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -23&nbsp;434</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -23&nbsp;434</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -23&nbsp;434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;955</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;972</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;972</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 197</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 443</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 447</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 447</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees <br>as a result of the Alcon spin-off</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase obligation <br>under a share buyback trading plan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -2&nbsp;289</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -2&nbsp;289</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -2&nbsp;289</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -253</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -253</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -253</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of<br>consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -35&nbsp;060</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -35&nbsp;089</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -35&nbsp;091</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at June 30, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 936</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -5&nbsp;088</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;504</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">30</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0017238"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of cash flows </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b> (unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;109</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adjustments to reconcile net income from continuing operations to net cash flows  from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of non-cash items and other adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;345</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;085</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest received</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -227</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -239</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial receipts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -303</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -560</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations before working capital <br>and provision changes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br> 3&nbsp;731</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> 3&nbsp;491</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -420</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -323</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in net current assets and other operating cash flow items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -57</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;961</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;111</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows from operating activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;961</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;111</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -238</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -279</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 648</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -161</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -45</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 142</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of interests in associated companies, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of businesses, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -286</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of marketable securities and commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -74</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -75</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of marketable securities and commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 69</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in/from investing activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 208</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in investing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -91</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -682</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows used in investing activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -425</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -474</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;368</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from exercised options and other treasury share transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;002</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -793</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payment of lease liabilities, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -74</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -69</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financing cash flows, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 532</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2&nbsp;172</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -2&nbsp;710</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in/from financing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;682</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows used in financing activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2&nbsp;185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -28</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents before effect of exchange rate changes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;351</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;609</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents of discontinued operations at March 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 499</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of exchange rate changes on cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net change in cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;389</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;184</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents at April 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;528</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;807</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents at June 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;917</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;991</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">31</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0018064"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of cash flows </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half </b>(unaudited)</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;977</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adjustments to reconcile net income from continuing operations to net cash flows  from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of non-cash items and other adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;101</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 489</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 463</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest received</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 140</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -321</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -406</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial receipts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -899</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -960</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations before working capital <br>and provision changes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br> 8&nbsp;790</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> 7&nbsp;309</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -824</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -516</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in net current assets and other operating cash flow items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;477</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;348</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;489</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;445</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from operating activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows from operating activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;489</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;523</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -475</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -561</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 812</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -460</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -498</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 281</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -154</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -48</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of interests in associated companies, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of businesses, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&nbsp;901</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -382</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of marketable securities and commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -345</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -120</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of marketable securities and commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 394</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;428</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in/from investing activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10&nbsp;461</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;959</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in investing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;105</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows used in/from investing activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10&nbsp;566</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 854</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends paid to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;645</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;590</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from exercised options and other treasury share transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 846</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;945</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;002</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;008</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;486</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -942</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payment of lease liabilities, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -91</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financing cash flows, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 71</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1&nbsp;146</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -13&nbsp;010</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in/from financing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;299</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows used in financing activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1&nbsp;172</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -9&nbsp;711</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents before effect of exchange rate changes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5&nbsp;249</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -3&nbsp;334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of exchange rate changes on cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net change in cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5&nbsp;195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -3&nbsp;280</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents at January 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;271</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents at June 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;917</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;991</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">32</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0018948"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Notes to the Condensed Interim Consolidated Financial Statements for&nbsp;the&nbsp;three-month and six-month period ended June 30, 2020 (unaudited)  </p><a name="anchorId0018956"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Basis of preparation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">These Condensed Interim Consolidated Financial Statements for the three-month and six-month period ended June 30, 2020, were prepared in accordance with International Accounting Standard 34 <i>Interim Financial Reporting </i>and accounting policies set out in the 2019 Annual Report published on January&nbsp;29, 2020.</div><a name="anchorId0018967"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Selected critical accounting policies</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s principal accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2019 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of &#xFB01;nancial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of assets and liabilities, including any contingent amounts, the distribution liability recognized in connection with the distribution of Alcon Inc. to Novartis AG shareholders, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions.  </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As disclosed in the 2019 Annual Report, goodwill, and acquired In-Process Research &amp; Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Group&#x2019;s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Group&#x2019;s results of operations and financial condition. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or&nbsp;held for distribution to owners</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are classified as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Distribution of Alcon Inc. </font>
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"> </font>
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">to Novartis AG shareholders</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&#x2019;s business (the &#x201C;Alcon business&#x201D;) to be reported as discontinued operations.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">33</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &#x201C;Other expense&#x201D; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &#x201C;Gain on distribution of Alcon Inc. to Novartis AG shareholders&#x201D; in the income statement of discontinued operations.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &#x201C;Level 3&#x201D; in the fair value hierarchy. The section &#x201C;&mdash;Impairment of goodwill and intangible assets&#x201D; in Note 1 to the Consolidated Financial Statements of the 2019 Annual Report provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional disclosures, refer to Notes 3 and 10.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">New IFRS standard effective as&nbsp;of&nbsp;January 1, 2020</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combination amendments</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired or disposed of should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the entity may choose to consider the transaction an acquisition of an asset or set of assets. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group.</div><a name="anchorId0019015"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Significant transactions</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of The&nbsp;Medicines Company</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 9.6 billion. The preliminary purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Results of operations since the date of acquisition were not material.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &ndash; acquisition of the Japanese business of Aspen Global Incorporated </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">34</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Aspen&#x2019;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consist of EUR 300 million (USD 331 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 120 million (USD 132 million), which AGI is eligible to receive upon the achievement of specified milestones.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was EUR 345 million (USD 381 million). The amount consisted of an initial cash payment of EUR 273 million (USD 301 million) and the fair value of contingent consideration of EUR 72 million (USD 80 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of approximately USD 309 million, consisting of USD 269 million intangible assets, USD 26 million other net assets, USD 14 million net deferred tax assets and goodwill of approximately USD 72 million. Results of operations since the date of acquisition were not material.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &ndash; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as regulatory approval from the US Federal Trade Commission was not obtained within the SAPA agreed timelines.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The cumulative amount of the depreciation on property, plant and equipment and amortization on intangible assets, not recorded in the consolidated income statement since the date of classification as held for sale, amounting to USD 38 million and USD 102 million, respectively, was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the Group&#x2019;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets of disposal group classified as held for sale</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 475</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 841</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities of disposal group classified as held for sale</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no cumulative income or expenses included in other comprehensive income relating to the disposal group.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2019</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">35</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April&nbsp;9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &#x201C;ALC.&#x201D; </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&#x2019;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&#x2019;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> April 8,<br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net assets derecognized<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -20&nbsp;025</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derecognition of distribution liability</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Difference between net assets and distribution liability</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;409</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Recognition of Alcon Inc. shares obtained <br>through consolidated foundations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 1&nbsp;273</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation gains recycled into the <br>consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 123</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs recognized in the  consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -114</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gain on distribution of Alcon Inc. to  Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> See Note 10 for additional information.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For additional disclosure on discontinued operations, refer to Note 10.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of IFM Tre, Inc. </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&#x2019;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gutdirected molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangibles, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of <i>Xiidra</i></font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with <i>Xiidra</i> (lifitegrast ophthalmic solution) 5% worldwide. <i>Xiidra</i> is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">36</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimated that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material.</div><a name="anchorId0019396"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Summary of equity attributable to Novartis AG shareholders </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Number of outstanding shares  (in millions)    </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Issued share capital and  reserves attributable to   Novartis AG shareholders  (in USD millions)</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;265.0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;614</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in accounting policy<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated equity at January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;617</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be cancelled</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -32.8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;819</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -153</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 823</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 365</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 447</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase obligation under a share buyback trading plan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;289</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;645</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend in kind to effect the spin-off of Alcon Inc.<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -23&nbsp;434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income of the period attributable to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;043</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;565</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income attributable to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -667</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -253</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at June 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;289.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;291.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;812</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;426</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In H1 2019, the impact of change in accounting policy includes USD 3 million related to the implementation of IFRS 16 Leases.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Included in H1 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. <br>This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Fair value of the dividend in kind of Alcon Inc. shares to Novartis AG shareholders (see Notes 2 and 3 for further details).</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> In H1 2019, Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Impact of hyperinflationary economies</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">37</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0019926"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Financial instruments </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value by hierarchy</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table illustrates the three hierarchical levels for valuing financial instruments at fair value as of June 30, 2020 and December&nbsp;31, 2019. For additional information on the hierarchies and other matters, please refer to the Consolidated Financial Statements in the 2019 Annual Report, published on January 29, 2020. </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 1</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 2</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 3</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative  financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   160</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   163</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 904</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 976</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 581</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;443</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;557</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 235</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 235</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 444</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 444</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 904</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 976</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;213</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;189</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit or loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 175</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 175</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;039</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;036</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;039</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;036</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -29</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -1&nbsp;065</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1&nbsp;185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -1&nbsp;250</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first half of 2020, there were no significant transfers from one level to the other and no significant transactions associated with level 3 financial instruments. During the second quarter of 2020, there were two non-significant transfers of equity securities from level 3 to level 1 for USD 26 million due to Initial Public Offerings.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of straight bonds amounted to USD 27.7 billion at June 30, 2020 (USD 23.7 billion at December 31, 2019) compared to the balance sheet value of USD 25.2 billion at June 30, 2020 (USD 22.2 billion at December 31, 2019). For all other financial assets and liabilities, the carrying amount is a reasonable approximation of the fair value. The carrying amount of financial assets included in the line total long-term financial investments of USD 2.1 billion at June 30, 2020 (USD 2.2 billion at December 31, 2019) is included in line &#x201C;Financial and other non-current assets&#x201D; of the consolidated balance sheets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In accordance with the consolidated foundations Alcon Inc. share divestment plans, Alcon Inc. shares with a fair value of USD 287 million were sold, or otherwise disposed of, in the first half of 2020 and the USD 16 million gain on disposal was transferred from other comprehensive income to retained earnings (second quarter : nil).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s exposure to financial risks has not changed significantly during the period and there have been no major changes to the risk management department or in any risk management policies.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">38</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current financial debt &ndash; issuance of bonds</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On February 11, 2020, Novartis issued the following straight bonds:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>Coupon</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Currency</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Nominal amount<br> (USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Maturity year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Issuer</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Issue price</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Carrying value<br> Jun 30, 2020<br> (USD millions)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.75%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.852%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 996</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.00%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.909%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.20%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.869%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;492</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.75%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2050</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97.712%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;213</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div><a name="anchorId00110922"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Details to the consolidated statements of&nbsp;cash&nbsp;flows </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.1. Reversal of non-cash items and other adjustments from continuing operations</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 319</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 371</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 601</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 958</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Losses/gains on disposal and other adjustments on property, plant and equipment; intangible assets; <br>financial assets; and other non-current assets, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -615</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 199</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 174</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -176</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 247</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 205</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;345</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;085</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 700</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 149</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;619</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 838</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;018</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets; <br>financial assets; and other non-current assets, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -684</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 377</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 372</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 797</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 493</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 387</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;101</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">39</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.2. Total amount of taxes paid </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first half of 2020, the total amount of taxes paid was USD 987 million (Q2 2020: USD 391 million), of which USD 899 million (Q2 2020: USD 303 million) was included within &#x201C;Net cash flows from operating activities from continuing operations&#x201D;, and USD 88 million (Q2 2020: USD 88 million) was included within &#x201C;Net cash flows used in investing activities from discontinued operations.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the first half of 2019, the total amount of taxes paid was USD 998 million (Q2 2019: USD 560 million), of which USD 960 million (Q2 2019: USD 560 million) was included within &#x201C;Net cash flows from operating activities from continuing operations&#x201D; and USD 38 million (Q2 2019: nil) was included within &#x201C;Net cash flows from operating activities from discontinued operations.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.3. Cash flows arising from acquisitions and divestments of businesses, net</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of business combinations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -32</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -407</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10&nbsp;030</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -486</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables and payables contingent consideration, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9&nbsp;888</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -367</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash flows from/used for divestments of businesses, net<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9&nbsp;901</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -382</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In the second quarter of 2020 and 2019, the USD 2 million represented the net cash inflows for previous years divestments.<br>During the first half of 2020, the USD 13 million included USD 15 million net cash outflows for previous years divestments (H1 2019: USD 15 million) and a prepaid sales price of USD 2 million for a business divestment.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 3 and 7 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.4. Cash and cash equivalents of discontinued operations at March 31, 2019</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents of discontinued operations at March 31, 2019,represents the amount of the Alcon business cash and cash equivalents included in the March 31, 2019, consolidated balance sheets in the line &#x201C;Assets related to discontinued operations.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For net cash flows used in investing activities from discontinued operations, see Note 10.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">40</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00111550"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Acquisition of businesses</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fair value of assets and liabilities arising from acquisitions:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 269</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;602</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 449</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 470</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables, marketable securities <br>and other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 109</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;928</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -101</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -144</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;569</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 411</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;537</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a  result of business combinations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   10&nbsp;030</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   486</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 3 details significant acquisitions of businesses, specifically, The Medicines Company and the Japanese business of AGI in 2020, and IFM Tre, Inc. in 2019. The goodwill arising out of these acquisitions is attributable to the buyer specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. Goodwill of USD 59 million in 2020 (2019: nil) is tax deductible.</div><a name="anchorId00111806"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Legal proceedings update </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings, including litigations, arbitrations and governmental investigations, that arise from time to time. Legal proceedings are inherently unpredictable. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F contains a summary as of the date of these reports of significant legal proceedings to which Novartis or its subsidiaries were a party. The following is a summary as of July 20, 2020 of significant developments in those proceedings, as well as any new significant proceedings commenced since the date of the 2019 Annual Report and 2019 Form 20-F.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Investigations and related litigations</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Government generic pricing antitrust investigations, antitrust class actions</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2016, Sandoz Inc. received grand jury subpoenas and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) in connection with alleged price fixing and market allocation of generic drugs in the US market as well as alleged False Claims Act violations. Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. agreed to pay USD 195 million and entered into a deferred prosecution agreement. The Sandoz resolution related to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. is also in negotiations with the DOJ Civil Division to resolve potential related claims and has recorded a provision of USD 186 million.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Southern District of New York (S.D.N.Y.) marketing practices investigation and litigation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, the US government filed a civil complaint in intervention to an individual <i>qui tam </i>action against Novartis Pharmaceuticals Corporation (NPC) in the United States District Court (USDC) for the S.D.N.Y. The complaint, as subsequently amended, asserted federal False Claims Act (FCA) and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications (<i>Lotrel</i>,&nbsp;<i>Starlix</i>&nbsp;and&nbsp;<i>Valturna</i>) allegedly serving as mechanisms to provide kickbacks to healthcare professionals (HCPs). Also in 2013, New York State filed a civil complaint in </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">41</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">intervention asserting similar claims. In July 2020, Novartis finalized its settlement agreement with the S.D.N.Y, the New York State Attorney General and the individual relator to resolve their claims. As part of this settlement, Novartis will pay USD 0.7 billion, and has agreed to new corporate integrity obligations with the Office of Inspector General of the US Department of Health &amp; Human Services. As of June 30, a provision in the amount of USD 0.7 billion remained accrued in the Innovative Medicines Division for this matter. As of July 20, 2020, USD 0.6 billion have been paid out of this provision.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">U.S. Government Foreign Corrupt Practices Act (FCPA) investigations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In June 2020, Novartis reached settlements with the DOJ and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by Novartis and its subsidiaries. These investigations were previously disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the headings &#x201C;Greece investigation,&#x201D; &#x201C;South Korea investigation&#x201D; and &#x201C;Asia/Russia investigation.&#x201D; As part of the coordinated resolution of these investigations, Novartis and certain of its current and former subsidiaries agreed to pay USD 0.3 billion. As of June 30, 2020, a provision in the amount of USD 0.1 billion remained accrued. As of July 20, 2020, USD 0.1 billion have been paid out of this provisions. To resolve the DOJ investigation, Novartis Hellas S.A.C.I. entered into a deferred prosecution agreement (&#x201C;Novartis Hellas DPA&#x201D;) pertaining to inappropriate economic benefits provided to Greek healthcare professionals from 2012 to 2015 in connection with the ophthalmology product <i>Lucentis</i>. The Novartis Hellas DPA also covers books and records issues pertaining to the <i>Lucentis</i> conduct and to conduct related to a 2009 epidemiological study. The resolutions contain no allegations relating to any bribery of Greek politicians, which is consistent with what Novartis found in its own internal investigation. Alcon Pte Ltd, a former Novartis subsidiary, has entered into a separate deferred prosecution agreement with the DOJ (&#x201C;Alcon DPA&#x201D;) pertaining to inappropriate economic benefits provided to Vietnamese healthcare professionals and books and records violations from 2011 to 2014 in Vietnam. This conduct related to a consultancy program run by a distributor in Vietnam. To resolve the SEC investigation, Novartis AG reached an agreement pertaining to internal controls and books and records violations in Greece, Vietnam and South Korea. The violations in Greece pertain to the <i>Lucentis</i>-related conduct covered in the Novartis Hellas DPA as well as controls issues with Novartis Hellas post-approval studies identified by internal review in 2012 and resolved by 2013. In Vietnam, the violations relate to the activities involving an Alcon distributor that are the subject of the Alcon DPA. In South Korea, the violations relate to conduct for which Novartis has already taken responsibility in South Korea, where Novartis is in the final stages of resolving these issues with the local authorities. The SEC agreement also addresses certain internal controls and books and records issues related to Alcon China&#x2019;s placement of surgical devices. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In addition to the matters described above, there have been other developments in the other legal matters described in Note 20 to the Consolidated Financial Statements contained in our 2019 Annual Report and 2019 Form 20-F.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.</div><a name="anchorId00111850"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Segmentation of key figures </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments, Innovative Medicines and Sandoz. In addition, we separately report Corporate activities.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision maker which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The reporting segments are as follows:</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Novartis Oncology consists of the global business franchise Oncology, and Novartis Pharmaceuticals consists of the global business franchises Ophthalmology; Immunology, Hepatology and Dermatology; Neuroscience; Respiratory; Cardiovascular, Renal and Metabolism; and Established Medicines.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">42</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services. Corporate includes the costs of the Group headquarters and those of corporate coordination functions in major countries, and items that are not specific to one segment. Further details are provided in Note 3 to the Consolidated Financial Statements of the 2019 Annual Report.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following the February 28, 2019, shareholders&#x2019; approval of the spin-off of the Alcon business, the Group reported its financial results as &#x201C;continuing operations&#x201D; and &#x201C;discontinued operations&#x201D; (refer to Notes 2, 3 and 10 for further details).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Continuing operations comprise the activities of Innovative Medicines and Sandoz Divisions and the continuing Corporate activities. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discontinued operations included in 2019 the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (see Notes&nbsp;2, 3 and 10).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Consolidated income statement </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative  Medicines</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -262</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;407</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;503</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;475</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -262</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 275</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 260</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;554</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;327</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;315</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 283</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 236</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;429</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;406</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;104</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;066</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;618</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;764</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;911</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -496</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -550</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;368</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;585</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;240</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;853</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -201</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -198</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;051</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 847</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 97</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 432</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 989</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -221</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -945</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -65</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -181</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -178</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -182</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;308</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;033</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;564</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 321</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 282</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;352</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;663</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 22.1%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 27.5%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 14.9%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11.6%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 20.7%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 22.6%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 174</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -205</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;634</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -525</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;109</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;800</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">43</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative  Medicines</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;870</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 409</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -449</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;352</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;532</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;779</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;840</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -449</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;923</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 507</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 511</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 700</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 556</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&nbsp;080</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4&nbsp;551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;614</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;591</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 485</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&nbsp;151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;657</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;779</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;492</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;200</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;283</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 200</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;822</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&nbsp;621</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&nbsp;564</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;016</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;854</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;915</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&nbsp;106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;958</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -395</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -392</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&nbsp;501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4&nbsp;350</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 326</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 922</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 693</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;192</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -562</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -269</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -319</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;844</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;788</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 276</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 555</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;096</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;905</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 25.3%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 25.8%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 5.9%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11.6%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 21.6%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 21.4%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 304</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -459</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -431</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;909</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;774</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -797</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;977</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain <br>on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> -101</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;567</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Additional consolidated balance sheet and income statement disclosure</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative  Medicines</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 81&nbsp;373</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;225</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;229</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;468</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;161</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30&nbsp;677</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 123&nbsp;763</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -14&nbsp;690</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -15&nbsp;332</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -3&nbsp;681</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -3&nbsp;804</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -51&nbsp;507</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -43&nbsp;683</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -69&nbsp;878</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -62&nbsp;819</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;885</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;537</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;537</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 66&nbsp;683</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;893</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;548</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;664</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;191</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;932</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 80&nbsp;422</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;489</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net operating assets are:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;485</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;632</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;943</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;888</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 527</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 549</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;955</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;257</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;835</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;767</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;524</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&nbsp;877</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27&nbsp;586</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;674</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;125</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;669</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;787</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the intangible asset impairment charges for continuing operations:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -500</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -20</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -509</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -466</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -478</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Q2 2020 and H1 2020 include an impairment of USD 485 million related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis. <br>H1 2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;D acquired through the 2015 Spinifex Pharmaceuticals Inc. acquisition.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">44</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region<sup>1</sup></font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br> cc<sup style="white-space: nowrap">  2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020<br> % of total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019<br> % of total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;964</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;515</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;336</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;123</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 586</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 666</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;909</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;279</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;255</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;130</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;269</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 52</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 508</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 642</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 333</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;621</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;796</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 538</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 642</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;094</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;487</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;023</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;978</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;439</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 766</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 860</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;530</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;817</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;897</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">45</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region<sup>1</sup></font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br> cc<sup style="white-space: nowrap">  2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020<br> % of total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019<br> % of total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;352</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;057</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;329</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;123</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;302</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;266</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;677</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;468</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;558</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;510</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;078</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;232</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 675</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 651</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 371</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;466</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;491</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;221</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;273</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;924</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;862</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;135</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;561</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;976</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;774</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;595</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;870</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;898</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;741</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">46</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by business franchise</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 468</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 422</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 349</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 371</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 340</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 310</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 284</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 266</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 253</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -35</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 111</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 263</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 308</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;548</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;606</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 944</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 858</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology, Hepatology and Dermatology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;144</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;023</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 536</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 423</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 937</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;174</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 825</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;025</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 886</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 580</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular, Renal and Metabolism</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 580</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 427</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 289</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 290</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Ultibro</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 444</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 268</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 283</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 238</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Voltaren/Cataflam</I></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;510</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;749</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;640</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;720</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">47</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 902</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 825</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 637</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 715</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 795</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 628</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 562</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 774</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 491</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 380</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 215</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 545</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 594</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;196</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;927</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;874</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;649</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 413</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology, Hepatology and Dermatology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;287</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;965</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 888</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;069</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 974</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;266</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;133</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;510</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;591</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 375</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;045</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;683</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 778</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -98</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular, Renal and Metabolism</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 790</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 46</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 596</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 571</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Ultibro</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 309</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 915</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 906</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 635</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 542</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 544</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 496</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 531</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 240</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 197</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 213</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Voltaren/Cataflam</I></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 208</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 958</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;747</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div>
      </td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">48</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales of the top 20 Innovative Medicines Division products in 2020 </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Brands</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Business franchise</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Key indication</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD/cc<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> cc<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> cc<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td width="12%" height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Cosentyx</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="12%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> Immunology,<br> Hepatology and<br> Dermatology</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="12%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br> spondylitis and <br> psoriatic arthritis<br> and non-radiographic<br> axial spondyloarthritis</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 614</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 15</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 330</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 944</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 10</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 12</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 416</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 322</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Entresto</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular,<br> Renal and <br> Metabolism</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> Chronic heart failure</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 308</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 41</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 580</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 221</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Lucentis</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related <br> macular degeneration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune <br> thrombocytopenia (ITP), <br> severe aplastic anemia (SAA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 212</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 210</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 422</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><br><I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic <br> and adjuvant melanoma; <br> advanced non-small cell <br> lung cancer (NSCLC)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 224</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 371</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Sandostatin</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors<br> and acromegaly</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 200</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 341</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Jakavi</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br> polycytomia vera (PV)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 310</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 310</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid<br> leukemia and GIST</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Xolair</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> Respiratory</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe Allergic Asthma (SAA) <br> and Chronic Spontaneous <br> Urticaria (CSU)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 289</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 289</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 266</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 234</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 268</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 236</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 238</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Ilaris</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology,<br> Hepatology and<br> Dermatology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,<br> TRAPS, HIDS/MKD, FMF,<br> SJIA, AOSD and gout)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 200</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Zolgensma</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy<br> (SMA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 205</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -35</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Kisqali</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   80</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   51</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   49</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;772</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;332</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;104</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 743</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;341</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;084</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;515</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">49</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales of the top 20 Innovative Medicines Division products in 2020 </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Brands</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Business franchise</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Key indication</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD/cc<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> cc<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> cc<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td width="12%" height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Cosentyx</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="12%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> Immunology,<br> Hepatology and<br> Dermatology</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="12%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br> spondylitis and <br> psoriatic arthritis<br> and non-radiographic<br> axial spondyloarthritis</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 1&nbsp;190</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 18</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 684</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 11</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 1&nbsp;874</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 14</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> <br> 15</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 804</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 706</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;510</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Entresto</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular,<br> Renal and <br> Metabolism</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> Chronic heart failure</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 601</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 548</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 1&nbsp;149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 48</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 50</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Lucentis</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related <br> macular degeneration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 888</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 888</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune <br> thrombocytopenia (ITP), <br> severe aplastic anemia (SAA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 399</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 825</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 28</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><br><I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic <br> and adjuvant melanoma; <br> advanced non-small cell <br> lung cancer (NSCLC)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 279</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 458</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> <br> 19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Sandostatin</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors<br> and acromegaly</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 413</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 302</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 715</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Jakavi</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br> polycytomia vera (PV)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 628</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 628</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid<br> leukemia and GIST</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 174</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 443</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Xolair</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> Respiratory</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe Allergic Asthma (SAA) <br> and Chronic Spontaneous <br> Urticaria (CSU)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 596</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 596</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 332</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 562</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 482</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 542</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 490</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 496</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Ilaris</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology,<br> Hepatology and<br> Dermatology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,<br> TRAPS, HIDS/MKD, FMF,<br> SJIA, AOSD and gout)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 413</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> <br> 33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><br>Zolgensma<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy<br> (SMA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 231</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 144</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 375</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -66</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 257</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 192</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Kisqali</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   86</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   97</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   320</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   64</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;463</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;031</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;494</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;594</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;855</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;449</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;057</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;886</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Includes a reclassification of export sales from the US into rest of the world in the amount of USD 44 million that were in Q1 2020 classified within US net sales. This reclassification has no impact on the reported Q1 2020 total <I>Zolgensma</I> net sales.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">50</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales by business franchise </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc<sup style="white-space: nowrap"> 2</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;576</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;903</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 466</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 134</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Of which USD 134 million (2019: USD 186 million) represents Anti-Infectives sold under Sandoz name</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc<sup style="white-space: nowrap"> 2</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;545</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;753</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 916</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 226</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Of which USD 356 million (2019: USD 390 million) represents Anti-Infectives sold under Sandoz name</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2020 and 2019.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Other revenue </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit sharing income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 209</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 209</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 182</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 251</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 275</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 260</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit sharing income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 407</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 350</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 407</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 351</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 69</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 121</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 507</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 511</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 700</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 556</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">51</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00124673"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Discontinued operations </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Discontinued operations included in 2019 the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Note 3 for further details). </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon eye care devices business researched, discovered, developed, manufactured, distributed and sold a broad range of eye care products. Alcon was organized into two global business franchises, Surgical and Vision Care. Alcon also provided services, training, education and technical support for both the Surgical and Vision Care businesses.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Consolidated income statement </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from discontinued <br>operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> 1&nbsp;777</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;809</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -860</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 949</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -638</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -142</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -113</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 4.0%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -159</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net loss from discontinued operations  before gain on distribution of Alcon Inc.  to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     -101</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc.  to Novartis AG shareholders<sup style="white-space: nowrap"> &nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> As the Alcon spin-off was completed on April 9, 2019, the Q2 2019 results of operations from the Alcon business were not material.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> See Note 3 for further details on the non-taxable non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders recognized on April 8, 2019, date of Distribution.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Supplemental disclosures related to&nbsp;the Alcon business distributed to&nbsp;Novartis AG shareholders</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash flows used in investing activities from&nbsp;discontinued operations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business in all periods.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments attributable to the spin-off of the Alcon business</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divested cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -628</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -628</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows attributable to the spin-off of the Alcon business</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -642</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -642</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other cash flows used in investing activities, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -463</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in investing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -91</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -682</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -1&nbsp;105</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash flows from financing activities from&nbsp;discontinued operations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first half of 2020, the net cash outflows from financing activities from discontinued operations of USD 26 million (Q2 2020: USD 13 million) was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis shareholders.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the first half of 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (Q2 2019: USD 2.7 billion) included mainly USD 3.5 billion (Q2 2019: USD 3.2 billion) from Alcon borrowings, partly offset by USD 0.2 billion (Q2 2019: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis shareholders (see Note 3).</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transaction closed in 2019 </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately-held, US-based medical device </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">52</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the net present value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets, of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 3.</div><a name="anchorId00125142"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Events subsequent to the June 30, 2020, consolidated balance sheet date</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In July 2020, Novartis paid USD 0.7 billion out of certain legal provisions. For additional information see Note 8.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">53</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00125148"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Supplementary information (unaudited)</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-IFRS disclosures</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core results</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s core results &ndash;including core operating income, core net income and core earnings per share &ndash; exclude fully the amortization and impairment charges of intangible assets, excluding software, net gains and losses on fund investments and equity securities valued at fair value through profit and loss, and certain acquisition and divestment related items. The following items that exceed a threshold of USD 25 million are also excluded: integration and divestment related income and expenses, divestment gains and losses, restructuring charges/releases and related items, legal related items, impairments of property, plant and equipment and financial assets, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a USD 25 million threshold.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that investor understanding of the Group&#x2019;s performance is enhanced by disclosing core measures of performance because, since they exclude items which can vary significantly from year to year, the core measures enable better comparison of business performance across years. For this same reason, Novartis uses these core measures in addition to IFRS and other measures as important factors in assessing the Group&#x2019;s performance. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following are examples of how these core measures are utilized:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In addition to monthly reports containing financial information prepared under International Financial Reporting Standards (IFRS), senior management receives a monthly analysis incorporating these core measures.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Annual budgets are prepared for both IFRS and core measures.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Despite the use of these measures by management in setting goals and measuring the Group&#x2019;s performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS. As a result, such measures have limits in usefulness to investors.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because of their non-standardized definitions, the core measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These core measures are presented solely to permit investors to more fully understand how the Group&#x2019;s management assesses underlying performance. These core measures are not, and should not be viewed as, a substitute for IFRS measures.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As an internal measure of Group performance, these core measures have limitations, and the Group&#x2019;s performance management process is not solely restricted to these metrics. A limitation of the core measures is that they provide a view of the Group&#x2019;s operations without including all events during a period, such as the effects of an acquisition, divestment, or amortization/impairments of purchased intangible assets and restructurings. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Constant currencies</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the relative values of non-US currencies to the US dollar can affect the Group&#x2019;s financial results and financial position. To provide additional information that may be useful to investors, including changes in sales volume, we present information about our net sales and various values relating to operating and net income that are adjusted for such foreign currency effects. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Constant currency calculations have the goal of eliminating two exchange rate effects so that an estimate can be made of underlying changes in the consolidated income statement excluding the impact of fluctuations in exchanges rates:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The impact of translating the income statements of consolidated entities from their non-USD functional currencies to USD; and</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The impact of exchange rate movements on the major transactions of consolidated entities performed in currencies other than their functional currency.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We calculate constant currency measures by translating the current year&#x2019;s foreign currency values for sales and other income statement items into USD using the average exchange rates from the prior year and comparing them to the prior year values in USD.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We use these constant currency measures in evaluating the Group&#x2019;s performance, since they may assist us in evaluating our ongoing performance from year to year. However, in performing our evaluation, we also consider equivalent measures of performance which are not affected by changes in the relative value of currencies.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Growth rate calculation</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For ease of understanding, Novartis uses a sign convention for its growth rates such that a reduction in operating expenses or losses compared to the prior year is shown as a positive growth.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net debt and free cash flow</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net debt and free cash flow are non-IFRS financial measures, which means they should not be interpreted as measures determined under IFRS. Net debt is presented as additional information because management believes it is a useful supplemental indicator of the Group&#x2019;s ability to pay dividends, to meet financial commitments and to invest in new strategic opportunities, including strengthening its balance sheet. Free cash flow is presented as additional information because management believes it is a useful supplemental indicator of the Group&#x2019;s ability to operate without reliance on additional borrowing or use of existing cash. Free cash flow is a measure of the net cash generated that is available for debt repayment, investment in strategic opportunities and for returning to shareholders. Cash flows in connection with the acquisition or divestment of subsidiaries, associated companies and non-controlling interests in subsidiaries are not taken into account to determine free cash flow. Free cash flow is not intended to be a substitute measure for net cash flows from operating activities as determined under IFRS.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">54</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">CORE RESULTS &ndash; Reconciliation from IFRS results to core results &ndash; Group</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">IFRS operating income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;033</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;564</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 321</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 282</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -183</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;352</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;663</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amortization of intangible assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 714</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 521</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 784</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 602</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment related to the Group-wide <br>rationalization of manufacturing sites</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 35</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total impairment charges</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisition or divestment of businesses and related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -42</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total acquisition or divestment of businesses  and related items, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   46</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divestment gains</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -598</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -593</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets - fair value adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring and related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -17</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 297</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Legal-related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 682</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 709</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additional income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -86</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -57</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -65</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additional expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 125</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 352</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;268</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 742</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 154</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;317</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 985</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 475</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -107</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;669</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;648</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 35.9%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 35.4%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 22.0%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 20.5%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 32.3%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 31.0%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 174</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to income from associated companies, net of tax</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 77</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -205</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes, adjusted for above items (core taxes)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -593</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -620</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;096</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income from discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;096</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income attributable to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;095</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic EPS from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.34</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic EPS from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic EPS (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.34</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For details on discontinued operations reconciliation from IFRS to core net income, please refer to page 61.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">55</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">CORE RESULTS &ndash; Reconciliation from IFRS results to core results &ndash; Group </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">IFRS operating income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;788</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;673</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 276</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 555</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -323</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;096</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;905</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amortization of intangible assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;432</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 978</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 233</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 160</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;665</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;138</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 509</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 429</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment related to the Group-wide <br>rationalization of manufacturing sites</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> 42</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total impairment charges</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 519</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 490</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisition or divestment of businesses and related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 157</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total acquisition or divestment of businesses  and related items, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divestment gains</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -148</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -624</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -622</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets - fair value adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring and related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 228</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 379</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 439</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Legal-related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 688</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 392</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 72</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 453</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 760</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additional income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -253</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -140</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -231</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -263</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additional expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 111</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 221</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 411</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 348</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;120</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;555</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 872</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 407</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -242</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;997</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;908</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;228</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;148</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 962</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -210</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;846</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;902</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 36.5%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 34.4%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 24.5%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 20.2%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 33.2%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 30.2%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 304</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to income from associated companies, net of tax</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 274</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 275</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 274</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 275</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -459</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -431</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes, adjusted for above items (core taxes)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;268</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;159</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;907</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income from discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income attributable to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;660</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;183</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic EPS from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.55</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic EPS from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic EPS (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.67</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For details on discontinued operations reconciliation from IFRS to core net income, please refer to page 62.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">56</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">CORE RESULTS &ndash; Reconciliation from IFRS results to core results &ndash; Group </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2020<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization <br> of intangible<br> assets<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2020<br> Core results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Q2 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;193</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 773</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;058</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;277</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;352</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 784</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 46</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;669</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;648</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 873</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 46</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;701</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;716</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes from continuing operations<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -593</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -620</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;096</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income from discontinued operations<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;096</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.34</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic EPS from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.34</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;429</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 773</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;564</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;723</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">            </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;368</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;318</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;515</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;010</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;054</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 432</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -223</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 214</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 178</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -251</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -274</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">            </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core income before taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 253</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">      </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to in-market products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies; income from associated companies includes USD 89 million for the Novartis share of the estimated Roche core items</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: research and development includes impairment charges related to intangible assets</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold, selling, general and administration, research and development and other expense include net charges related to acquisitions; other income and other expense include transitional service-fee income and expenses related to the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: cost of goods sold and other expense include restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include other restructuring income and charges and related items; selling, general and administration and other expense also include expenses related to COVID-19 donations; selling, general and administration also includes adjustments to provisions; research and development includes adjustments to contingent considerations; other income and other expense include fair value adjustments and divestment gains and losses on financial assets; other expense includes legal-related items; other financial income and expense includes a revaluation impact of a financial liability incurred through the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments of USD 1.4 billion to arrive at the core results before tax amounts to USD 172 million. The average tax rate on the adjustments is 12.2%, since the estimated quarterly core tax charge of 16.0% has been applied to the pre-tax income of the period.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;6&nbsp;</sup> For details on discontinued operations reconciliation from IFRS to core net income please refer to page 61.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;7&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">57</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">CORE RESULTS &ndash; Reconciliation from IFRS results to core results &ndash; Group </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2020<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization <br> of intangible <br> assets<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition <br> or divestment<br> of businesses<br> and related <br> items<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2020<br> Core results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> H1 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17&nbsp;179</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;640</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 42</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 45</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;942</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;049</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;096</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;665</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 411</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;846</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;902</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;909</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;939</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;925</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;066</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes from continuing operations<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;268</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;159</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;907</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income from discontinued operations<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.55</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic EPS from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.67</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">             </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 700</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 564</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 490</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&nbsp;151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;640</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 172</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&nbsp;252</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&nbsp;364</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">             </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;854</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&nbsp;773</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&nbsp;835</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&nbsp;501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 509</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -80</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&nbsp;044</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4&nbsp;018</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 693</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -406</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 231</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 794</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -510</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -628</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">             </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core income before taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 274</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 580</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 531</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 64</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">      </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to in-market products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies; income from associated companies includes USD 274 million for the Novartis share of the estimated Roche core items</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other expense includes impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold, selling, general and administration, research and development and other expense include net charges related to acquisitions; other income and other expense include transitional service-fee income and expenses related to the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: other revenues includes a settlement of royalties; cost of goods sold includes the cumulative amount of the depreciation up to December 31, 2019, recognized with the reclassification of property, plant and equipment out of assets of disposal group held for sale (see Note 3); cost of goods sold, other income and other expense include restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, research and development, other income and other expense include other restructuring income and charges and related items; selling, general and administration and other expense also include expenses related to COVID-19 donations; selling, general and administration also includes adjustments to provisions; research and development includes adjustments to contingent considerations; other income and other expense include fair value adjustments and divestment gains and losses on financial assets; other income also includes net gains from the divestment of products; other expense also includes a legal provision and legal-related items; other financial income and expense includes a revaluation impact of a financial liability incurred through the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments for continuing operations of USD 3.0 billion to arrive at the core results before tax amounts to USD 399 million. The average tax rate on the adjustments is 13.2%, since the estimated full year core tax charge of 16.0% has been applied to the pre-tax income of the period.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;6&nbsp;</sup> For details on discontinued operations reconciliation from IFRS to core net income please refer to page 62.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;7&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income, attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">58</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">CORE RESULTS &ndash; Reconciliation from IFRS results to core results &ndash; Innovative Medicines </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter </b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2020<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2020<br> Core results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Q2 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;104</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 703</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 47</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;865</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;962</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;033</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;306</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;554</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;767</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;764</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;848</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;240</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;809</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;856</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -221</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -115</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to in-market products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: research and development includes impairment charges related to intangible assets</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold, selling, general and administration, research and development and other expense include net charges related to acquisitions; other income and other expense include transitional service-fee income and expenses related to the Alcon spin-off</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: cost of goods sold and other expense include restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include other restructuring income and charges and related items; selling, general and administration includes expenses related to COVID-19 donations and adjustments to provisions; research and development includes adjustments to contingent considerations; other income and other expense include fair value adjustments on financial assets; other income also includes net gains from the divestment of financial assets</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half </b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2020<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2020<br> Core results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> H1 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;779</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;407</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;302</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;471</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;788</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;432</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 519</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;908</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;228</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&nbsp;080</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;407</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;557</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;506</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&nbsp;621</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&nbsp;564</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&nbsp;494</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&nbsp;106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 509</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -80</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&nbsp;649</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&nbsp;626</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 326</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -174</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 216</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -322</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to in-market products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: research and development includes impairment charges related to intangible assets; other expense includes impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold, selling, general and administration, research and development and other expense include net charges related to acquisitions; other income and other expense include transitional service-fee income and expenses related to the Alcon spin-off</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: cost of goods sold and other expense include restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, research and development, other income and other expense include other restructuring income and charges and related items; selling, general and administration includes expenses related to COVID-19 donations and adjustments to provisions; research and development includes adjustments to contingent considerations; other income and other expense include fair value adjustments on financial assets; other income also includes net gains from the divestment of products and financial assets; other expense includes legal-related items</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">59</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">CORE RESULTS &ndash; Reconciliation from IFRS results to core results &ndash; Sandoz </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter </b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2020<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2020<br> Core results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Q2 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;066</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;170</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;289</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 321</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 475</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 501</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;054</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;192</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -496</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -473</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -543</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -65</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -59</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to in-market products and other production-related intangible assets</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold includes net charges related to an acquisition</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Other items: cost of goods sold and other expense include restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, other income and other expense include restructuring income and charges and related items; selling, general and administration includes expenses related to COVID-19 donations and adjustments to provisions; other expense includes legal-related items</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half </b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2020<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2020<br> Core results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> H1 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;200</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 233</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 42</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 79</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;576</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;531</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 276</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;148</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 962</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;614</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&nbsp;238</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&nbsp;343</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;016</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -992</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;102</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -562</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 472</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -124</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to in-market products and other production-related intangible assets</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: cost of goods sold includes impairment charges related to intangible assets, other expense includes impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold includes net charges related to an acquisition</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: cost of goods sold includes the cumulative amount of the depreciation up to December 31, 2019, recognized with the reclassification of property, plant and equipment out of assets of disposal group held for sale (see Note 3);  cost of goods sold, other income and other expense include restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include other restructuring income and charges and related items; selling, general and administration also includes expenses related to COVID-19 donations and adjustments to provisions; other expense includes a legal provision and legal-related items</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">60</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">CORE RESULTS &ndash; Reconciliation from IFRS results to core results &ndash; Corporate</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter </b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2020<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization<br> of intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2020<br> Core results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Q2 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -107</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -159</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -178</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income and other expense include transitional service fee income and expenses related to the Alcon spin-off</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Other items: other income and other expense include fair value adjustments and divestment gains and losses on financial assets, and restructuring income and charges and related items; other expense also includes expenses related to COVID-19 donations</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2020<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization<br> of intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2020<br> Core results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> H1 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 200</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -136</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 64</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income/loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -210</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -288</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -269</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -182</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income and other expense include transitional service fee income and expenses related to the Alcon spin-off</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Other items: other revenues includes a settlement of royalties; other income and other expense include fair value adjustments and divestment gains and losses on financial assets, and restructuring income and charges and related items; other expense also includes adjustments to legal provisions and expenses related to COVID-19 donations</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">61</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">CORE RESULTS &ndash; Reconciliation from IFRS results to core results &ndash; Discontinued operations 2019</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter </b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2019<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization<br> of intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Q2 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations<br>before gain on distribution of Alcon Inc.<br>to Novartis AG shareholders<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.03</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">      </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Acquisition or divestment of businesses and related items represents the non-taxable non-cash gain related to the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> As the Alcon spin-off was completed on April 9, 2019, the Q2 results of operations from the Alcon business were not material.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2019<br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">     1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Impairments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Acquisition<br> or divestment<br> of businesses<br> and related<br> items<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Other <br> items<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> H1 2019<br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 949</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 165</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;123</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income of discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 350</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes of discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 337</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -59</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net loss/income from discontinued operations<br>before gain on distribution of Alcon Inc.<br>to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> <br> -101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br> <br> 278</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">            </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -860</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -686</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">            </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -624</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -136</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes amortization of acquired rights to in-market products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Acquisition or divestment of businesses and related items represents the non-taxable non-cash gain related to the distribution of Alcon Inc. (spin-off) to Novartis AG shareholders</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Other items: cost of goods sold, selling, general and administration, research and development and other expense include other restructuring charges and related items; research and development also includes amortization of option rights and the fair value adjustment of a contingent consideration liability; other income includes fair value adjustments on a financial asset; other expense also includes legal-related items</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments, excluding the non-taxable non-cash gain on the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders of USD 279 million to arrive at the core results before tax amounts to USD 100 million. The 2019 core tax rate excluding the effect of the gain on distribution of Alcon Inc. to Novartis AG shareholders is 17.5%.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">62</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income from associated companies</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Share of estimated Roche reported results</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 225</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 206</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 455</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 412</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Prior-year adjustment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> -129</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Amortization of additional intangible assets <br>recognized by Novartis on initial accounting <br>for the equity interest</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br> <br> -41</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> <br> <br> -29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br> <br> -83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> <br> <br> -69</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Partial release of deferred tax liability recognized</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 43</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income effect from Roche Holding AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 184</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 308</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 257</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 176</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core income from associated companies</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 183</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 176</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 306</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 256</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share of estimated Roche core adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 172</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 114</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche prior year adjustment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 161</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 253</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 580</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 531</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Condensed consolidated changes in net debt</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Change in cash and cash equivalents</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;389</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;184</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in marketable securities, commodities,  financial debts and financial derivatives</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;857</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   471</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Reduction in net debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;246</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;655</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt at April 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -29&nbsp;783</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -21&nbsp;541</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at June 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -26&nbsp;537</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -17&nbsp;886</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Change in cash and cash equivalents</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5&nbsp;195</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -3&nbsp;280</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in marketable securities, commodities,  financial debts and financial derivatives</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   -5&nbsp;404</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;578</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Increase in net debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10&nbsp;599</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -1&nbsp;702</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt at January 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15&nbsp;938</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -16&nbsp;184</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at June 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -26&nbsp;537</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -17&nbsp;886</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Components of net debt</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Jun 30, <br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debts</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -23&nbsp;955</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -20&nbsp;364</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current financial debts and derivative  financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   -8&nbsp;875</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -7&nbsp;857</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -32&nbsp;830</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -28&nbsp;221</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less liquidity:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;917</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;991</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, commodities, time deposits and derivative  financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     376</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     344</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liquidity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;293</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;335</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at June 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -26&nbsp;537</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -17&nbsp;886</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Share information </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Jun 30, <br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of shares outstanding</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;288&nbsp;979&nbsp;612</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;291&nbsp;765&nbsp;401</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Registered share price (CHF)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 82.42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 89.20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ADR price (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 87.34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 91.31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market capitalization (USD billions)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 198.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 209.7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market capitalization (CHF billions)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 188.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 204.4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Market capitalization is calculated based on the number of shares outstanding (excluding treasury shares). Market capitalization in USD is based on the market capitalization in CHF converted at the quarter end CHF/USD exchange rate.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">63</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Free cash flow </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;352</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;663</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments for non-cash items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;537</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;014</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 958</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -441</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income adjusted for non-cash items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;212</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;194</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial receipts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -237</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -211</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -303</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -560</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -420</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -323</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in inventory and trade receivables less trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 354</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -609</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other net current assets and other operating cash flow items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 296</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 552</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;961</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;111</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -238</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -279</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 648</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -161</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -45</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 142</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;631</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total free cash flow</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;631</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">64</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Free cash flow </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;096</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;905</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments for non-cash items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;986</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;467</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 838</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;018</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 322</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -312</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income adjusted for non-cash items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;242</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;078</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 489</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 463</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial receipts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 298</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -340</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -422</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -899</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -960</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -824</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -516</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in inventory and trade receivables less trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&nbsp;064</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&nbsp;306</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other net current assets and other operating cash flow items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -413</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -42</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;489</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;445</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -475</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -561</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 812</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -460</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -498</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 281</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -154</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -48</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;652</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;481</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Free cash flow from discontinued operations<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -62</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total free cash flow</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;652</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;419</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For the first half of 2020 free cash flow, proceeds from the sales of financial assets excludes the cash inflows from the sale of a portion of the Alcon Inc. shares recognized by certain consolidated foundations through the Alcon spin-off, which amounted to USD 232 million (H1 2019: nil). See Note 3.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> In the first half of 2019, the free cash flow from discontinued operation was a cash outflow of USD 62 million consisting of USD 78 million net cash inflows from operating activities from discontinued operations, USD 1.1 billion net cash flows used in investing activities from discontinued operations adjusted by USD 283 million of net cash outflows for acquisitions and divestments of businesses, by USD 642 million of cash outflows attributable to the spin-off of the Alcon business and by USD 40 million of other net investing cash outflows.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">65</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Effects of currency fluctuations</font>
</div><a name="anchorId00136030"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Principal currency translation rates</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD per unit)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Average <br> rates<br> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Average <br> rates<br> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Average <br> rates<br> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Average <br> rates<br> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Period-end <br> rates<br> Jun 30, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Period-end <br> rates<br> Jun 30, <br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 CHF</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.037</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.998</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.035</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.050</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.026</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 CNY</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.146</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.130</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.138</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 GBP</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.241</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.285</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.260</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.294</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.228</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.268</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">100 JPY</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.930</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.910</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.924</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.909</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.929</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.929</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">100 RUB</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.382</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.548</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.444</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.533</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.583</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Currency impact on key figures</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a summary of the currency impact on key Group figures due to their conversion into US dollars, the Group&#x2019;s reporting currency, of the financial data from entities reporting in non-US dollars. Constant currency (cc) calculations apply the exchange rates of the prior year period to the current period financial data for entities reporting in non-US dollars.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Second quarter</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Change in<br> USD %<br> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Change in<br>  constant<br>  currencies  %<br> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Percentage<br> point currency<br>  impact<br> Q2 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Change in<br> USD %<br> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in<br>  constant<br>  currencies  %<br> Q2 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Percentage<br> point currency<br>  impact<br> Q2 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Group &#x2013; Continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Corporate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">66</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Currency impact on key figures</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>First half</b></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Change in<br> USD %<br> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Change in<br>  constant<br>  currencies  %<br> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Percentage<br> point currency<br>  impact<br> H1 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Change in<br> USD %<br> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in<br>  constant<br>  currencies  %<br> H1 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Percentage<br> point currency<br>  impact<br> H1 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Group &#x2013; Continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Corporate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating loss/income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
  <font style="font-family:Arial,sans-serif; font-size:10pt; color:#000000;">67</font>
</div>
<div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt;">
  <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade>
</div>
<div style="WIDTH: 100%; TEXT-ALIGN: center; ">&#xA0;</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">Disclaimer</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="margin-bottom: 2pt; font-size: 10pt; font-family: Arial; text-align: left; background-color: #ffffff;">
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: justify">This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as &#8220;continue,&#8221; &#8220;growth,&#8221; &#8220;expected,&#8221; &#8220;to grow,&#8221; &#8220;demonstrating,&#8221; &#8220;to advance,&#8221; &#8220;to support,&#8221; &#8220;increasing,&#8221; &#8220;to deliver,&#8221; &#8220;to drive,&#8221; &#8220;to evolve,&#8221; &#8220;remain,&#8221; &#8220;taking,&#8221; &#8220;to take,&#8221; &#8220;to help,&#8221; &#8220;trends,&#8221; &#8220;continuing,&#8221; &#8220;allowing,&#8221; &#8220;to start,&#8221; &#8220; evaluating,&#8221; &#8220;will,&#8221; &#8220;until,&#8221; &#8220;to build,&#8221; &#8220;evolve,&#8221; &#8220;launch,&#8221; &#8220;continued,&#8221; &#8220;continues,&#8221; &#8220;to progress,&#8221; &#8220;may,&#8221; &#8220;retaining,&#8221; &#8220;remains,&#8221; &#8220;believe,&#8221; &#8220;including,&#8221; &#8220;can,&#8221; &#8220;to create,&#8221; &#8220;to find,&#8221; &#8220;estimated,&#8221; &#8220;impact,&#8221; &#8220;ongoing,&#8221; &#8220;submissions,&#8221; &#8220;focus,&#8221; &#8220;launches,&#8221; &#8220;launch investments,&#8221; &#8220;innovation,&#8221; &#8220;potential,&#8221; &#8220;guidance,&#8221; &#8220;commitment,&#8221; &#8220;pipeline,&#8221; &#8220;aims,&#8221; &#8220;momentum,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;launched,&#8221; &#8220;on track,&#8221; &#8220;growing,&#8221; &#8220;progressing,&#8221; &#8220;expanding,&#8221; &#8220;pending,&#8221; &#8220;strongly,&#8221; &#8220;priority,&#8221; &#8220;filings,&#8221; &#8220;outlook,&#8221; &#8220;unforeseen,&#8221; &#8220;forecast,&#8221; &#8220;prevail,&#8221; &#8220;enter,&#8221; &#8220;to improve,&#8221; &#8220;transformative,&#8221; &#8220;innovative,&#8221; &#8220;inventive,&#8221; &#8220;manageable disruptions,&#8221; &#8220;expect,&#8221; &#8220;planned,&#8221; &#8220;working,&#8221; &#8220;monitoring,&#8221; &#8220;anticipated,&#8221; &#8220;continuously,&#8221; &#8220;on track,&#8221; or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding our estimates of the impact of past and future COVID-19 related forward purchasing on sales and on our performance; or regarding the impact of the COVID-19 pandemic on clinical trials, and research and development timelines;&#160;or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group&#8217;s liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding efforts to provide a not-for-profit portfolio of medicines for symptomatic treatment of COVID-19. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of the COVID-19 pandemic on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics, particularly ophthalmology, in the second half of 2020; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this press release; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and is expected to continue this year; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG&#8217;s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.</div>

<div>&#160;</div>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left">All product names appearing in italics are trademarks owned by or licensed to Novartis Group companies.</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; COLOR: #000000; TEXT-ALIGN: left"><br>
 &#160;</div>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">68</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">
<div style="FONT-FAMILY: Arial">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">About Novartis</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Novartis is reimagining medicine to improve and extend people&#8217;s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world&#8217;s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 145 nationalities work at Novartis around the world. Find out more at <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">https://www.novartis.com</font>.</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Novartis will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Novartis website. A replay will be available after the live webcast by visiting. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">https://www.novartis.com/investors/event-calendar</font></div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: justify">Detailed financial results accompanying this press release are included in the condensed interim financial report at the link below. Additional information is provided on Novartis divisions and pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found at. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">https://www.novartis.com/investors/event-calendar</font><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 14pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 16pt; FONT-FAMILY: Arial; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 2pt">Important dates</div>
</div>

<div style="MARGIN-BOTTOM: 2pt">
<table id="z15f71cfd104c429db56aea845e6a005a" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; WIDTH: auto" cellspacing="0" cellpadding="0" align="left" border="0">
<tr>
<td style="WIDTH: 150px; PADDING-BOTTOM: 3px">
<div>September 01, 2020</div>
</td>
<td style="WIDTH: 30px; PADDING-BOTTOM: 3px">&#160;</td>
<td style="WIDTH: 200px; PADDING-BOTTOM: 3px">
<div>ESG investor day</div>
</td>
</tr>

<tr>
<td style="WIDTH: 150px; PADDING-BOTTOM: 3px">
<div>October 27, 2020</div>
</td>
<td style="WIDTH: 30px; PADDING-BOTTOM: 3px">&#160;</td>
<td style="WIDTH: 200px; PADDING-BOTTOM: 3px">
<div>Third quarter results 2020</div>
</td>
</tr>

<tr>
<td style="WIDTH: 150px; PADDING-BOTTOM: 3px">
<div>November 24, 2020</div>
</td>
<td style="WIDTH: 30px; PADDING-BOTTOM: 3px">
<div>&#160;</div>
</td>
<td style="WIDTH: 200px; PADDING-BOTTOM: 3px">
<div>Capital Markets day</div>
</td>
</tr>
</table>

<br style="CLEAR: both">
</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>

<div style="MARGIN-BOTTOM: 2pt"><br>
</div>
</div>

<div>
<div style="FONT-FAMILY: Arial">&#160;</div>

<div style="FONT-FAMILY: Arial">&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">69</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; TEXT-ALIGN: center">&#160;</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: Arial; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: Arial">&#160;</div>




</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>nvs-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfChangesInEquity" xlink:href="nvs-20200630.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetailsQ" xlink:href="nvs-20200630.xsd#disclosureAcquisitionOfBusinessesDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfComprehensiveIncome" xlink:href="nvs-20200630.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementsOfCashFlow" xlink:href="nvs-20200630.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfIncome" xlink:href="nvs-20200630.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/BalanceSheet" xlink:href="nvs-20200630.xsd#balanceSheet" xlink:type="simple"/>
   <link:calculationLink xlink:role="http://novartis.com/20200630/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Assets" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Assets" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Equity" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Equity" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Liabilities" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Liabilities" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets1" xlink:type="locator"/>
      <link:calculationArc order="10.2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssets1" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:calculationArc order="17.2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssets" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20200630/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromContinuingOperations" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromContinuingOperations" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:calculationArc order="1.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20200630/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCostsRecordedInEquityPaid" xlink:label="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20200630/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="2.8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20200630/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>nvs-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" xlink:href="nvs-20200630.xsd#disclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails2Q" xlink:href="nvs-20200630.xsd#disclosureSignificantTransactionsDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetailsQ" xlink:href="nvs-20200630.xsd#disclosureSignificantTransactionsDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails3Q" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsDetails3Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails2Q" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails1Q" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsDetails1Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetailsQ" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails9Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails9Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails8Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails8Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails7Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails7Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails6Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails6Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails5Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails5Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails4Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails4Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails3Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails3Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails2Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetailsQ" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" xlink:href="nvs-20200630.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetailsQ" xlink:href="nvs-20200630.xsd#disclosureAcquisitionOfBusinessesDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" xlink:href="nvs-20200630.xsd#disclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" xlink:href="nvs-20200630.xsd#disclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails4Q" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsDetails4Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails3Q" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsDetails3Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails2Q" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetailsQ" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersDetailsQ" xlink:href="nvs-20200630.xsd#disclosureSummaryOfEquityToShareholdersDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails1Q" xlink:href="nvs-20200630.xsd#disclosureSignificantTransactionsDetails1Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementsOfCashFlow" xlink:href="nvs-20200630.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfChangesInEquity" xlink:href="nvs-20200630.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/BalanceSheet" xlink:href="nvs-20200630.xsd#balanceSheet" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfComprehensiveIncome" xlink:href="nvs-20200630.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfIncome" xlink:href="nvs-20200630.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DocumentAndEntityInformation" xlink:href="nvs-20200630.xsd#documentAndEntityInformation" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
   <link:definitionLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GeographicalRegionsMember" xlink:label="lbl_GeographicalRegionsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GeographicalRegionsAxis" xlink:label="lbl_GeographicalRegionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GeographicalRegionsAxis" xlink:to="lbl_GeographicalRegionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonvestingMember" xlink:label="lbl_NonvestingMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonvestingAxis" xlink:label="lbl_NonvestingAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_NonvestingAxis" xlink:to="lbl_NonvestingMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DocumentAndEntityInformation" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentType" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AmendmentFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAnnualReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentTransitionReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentShellCompanyReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentPeriodEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalYearFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalPeriodFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_TradingSymbol" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityRegistrantName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCentralIndexKey" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CurrentFiscalYearEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCurrentReportingStatus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityVoluntaryFilers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFilerCategory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityPublicFloat" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityShellCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityEmergingGrowthCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityInteractiveDataCurrent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BasicEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_WeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DilutedEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_AdjustedWeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_CurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAndLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_StatementOfChangesInEquityTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ReductionOfIssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ChangesInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_YoYChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails1Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisposalGroupHeldForSaleLineItems" xlink:label="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentStatedMember" xlink:label="lbl_CurrentStatedMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_CurrentStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchasesValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongTermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails2Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_ClassesOfLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails3Q" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_StraightBondsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_FinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails4Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsOriginalCurrency" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_NotionalAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsIssuanceDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsMaturity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsLender" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsPremiumDiscount" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FinancialAssetsImpairedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_YoYChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefund" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetailsQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_LegalProceedingsProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NPCAndOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfReportableSegments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfBusinessUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfFranchises" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails2Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails3Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetOperatingAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails4Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZPL389Member" xlink:label="lbl_ZPL389Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZPL389Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails5Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CanadaAndLatinAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EstablishedMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EmergingGrowthMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails6Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BusinessUnitAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_OncologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_PharmaceuticalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_OphthalmologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_CardioMetabolicMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_EstablishedMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_COPDMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LutatheraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PiqrayMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XiidraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_BeovuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AimovigMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MayzentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SystaneGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TopicalOlopatadineGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MyforticMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_RitalinFocalinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails7Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_RestOfTheWorldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BusinessUnitAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_OncologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_PharmaceuticalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_OphthalmologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_CardioMetabolicMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_EstablishedMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_Top20ProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_RestOfPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReclassificationOfExportSales" xlink:label="lbl_ReclassificationOfExportSales" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ReclassificationOfExportSales" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails8Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RetailGenericsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_BiopharmaceuticalsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_AntiInfectivesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails9Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitSharingIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromRoyalties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_MilestoneIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenueOther" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ApplicableTaxRateExcludingExceptionalItems" xlink:label="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails1Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails2Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails3Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_IncomeStatementLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_OperatingIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenGlobalIncorporatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EliLillyAndCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKOncologyProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKVaccinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKTotalTransactionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CSLMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdmuneTheraputicsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IFMTreInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsUSDMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsEURMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RepaymentOfIntercompanyBalances" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquiree" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquireeFullYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCostsPaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ReversalOfImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialReceivableFromDivestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_MilestonePaymentAlreadyReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FuturePutOptionToSellBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PaymentPutOption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InterestExchanged" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerOrdinaryShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfOrdinarySharePerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ValueOfEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentCostToSell" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="53.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="54.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:definitionArc order="55.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="56.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:definitionArc order="57.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProformaNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:definitionArc order="58.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:definitionArc order="59.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="60.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="61.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:definitionArc order="62.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="63.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:definitionArc order="64.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="65.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:definitionArc order="66.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:definitionArc order="67.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialMilestoneMaximumPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:definitionArc order="68.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:definitionArc order="69.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:definitionArc order="70.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:definitionArc order="71.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="72.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:definitionArc order="73.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CustomaryPurchasePriceAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="74.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="75.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="76.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails2Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_AcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_DivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashOutflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PrepaidSalesPriceForABusinessDivestment" xlink:label="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:type="arc"/>
   </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>nvs-20200630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by MDD - e-reporting v3 -->
<!-- Created by MDD - Management Digital Data AG, Switzerland -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nvs="http://novartis.com/20200630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217">
  <link:schemaRef xlink:type="simple" xlink:href="nvs-20200630.xsd" />
  <xbrli:context id="Q_D-YTD-CurrentYear-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1-1-Year">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentQuarter-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:NovartisCapitalCorporationNewYorkUnitedStates1.752025Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:NovartisCapitalCorporationNewYorkUnitedStates1.752025Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:NovartisCapitalCorporationNewYorkUnitedStates2.002027Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:NovartisCapitalCorporationNewYorkUnitedStates2.002027Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:NovartisCapitalCorporationNewYorkUnitedStates2.202030Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:NovartisCapitalCorporationNewYorkUnitedStates2.202030Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:NovartisCapitalCorporationNewYorkUnitedStates2.752050Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:NovartisCapitalCorporationNewYorkUnitedStates2.752050Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PiqrayMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-06</xbrli:startDate>
      <xbrli:endDate>2020-01-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2BorrowingsUSDMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:BorrowingsUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2BorrowingsEURMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:BorrowingsEURMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-Alcon-4-April-9_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IFMTreInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IFMTreInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-07</xbrli:startDate>
      <xbrli:endDate>2019-05-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-08</xbrli:startDate>
      <xbrli:endDate>2019-05-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PowerVisionInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PowerVisionInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:LegalProceedingsProvisionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PiqrayMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PiqrayMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AdakveoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XiidraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2BeovuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2MayzentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2MayzentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PiqrayMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AdakveoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XiidraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2BeovuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2MayzentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2MayzentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2NPCAndOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:LegalProceedingsProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-July-20-2020_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2NPCAndOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:LegalProceedingsProvisionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-20</xbrli:startDate>
      <xbrli:endDate>2020-07-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:LegalProceedingsProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-July-20-2020_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:LegalProceedingsProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-20</xbrli:startDate>
      <xbrli:endDate>2020-07-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q2AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZPL389Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZPL389Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q2AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZPL389Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZPL389Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_dei-2019LegalEntityAxis_nvs-2020Q2SpinifexMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q2AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SpinifexMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-31</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IFMTreInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="Q_D-YTD-CurrentYear-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PowerVisionInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="EUR">
    <xbrli:measure>iso4217:EUR</xbrli:measure>
  </xbrli:unit>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">2000000</nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-12000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-54000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">382000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation id="fact_143760" contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">189000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">369000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">149000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-293000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans id="fact_143764" contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-890000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">99000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">74000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-194000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-816000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4215000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">7900000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4219000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">7898000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">4219000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">3321000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4577000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-4000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments>
  <nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">0</nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-38000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-27000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">380000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation id="fact_143785" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">525000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">343000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">498000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">319000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-387000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">173000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-21000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">492000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-408000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">2702000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">6890000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">2703000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">6888000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">2703000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">2298000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4590000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-1000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">123000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">123000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">944000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-63000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">51518000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-5170000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">47229000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1-1-Year_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">78000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1-1-Year" unitRef="USD" decimals="-6">47307000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6799000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6799000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">89000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">89000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">90000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6799000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">89000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6888000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ComprehensiveIncome>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-2927000000</nvs:DividendPaidNoncashAssetsDistribution>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-2927000000</nvs:DividendPaidNoncashAssetsDistribution>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-2927000000</nvs:DividendPaidNoncashAssetsDistribution>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">16000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">2754000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">2770000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2770000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">8000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-12000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">175000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">175000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">175000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">32000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">32000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">32000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:TaxesOnTreasuryShares id="fact_143843" contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">185000000</nvs:TaxesOnTreasuryShares>
  <nvs:TaxesOnTreasuryShares id="fact_143844" contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">185000000</nvs:TaxesOnTreasuryShares>
  <nvs:TaxesOnTreasuryShares id="fact_143845" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">185000000</nvs:TaxesOnTreasuryShares>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-2573000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-2573000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-2573000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TransactionCostsRecordedInEquity id="fact_143849" contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">301000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:TransactionCostsRecordedInEquity id="fact_143850" contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">301000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:TransactionCostsRecordedInEquity id="fact_143851" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">301000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">3000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-3000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-5000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">7000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-8000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-4000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-2672000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-7000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-2691000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-2693000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">936000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-67000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">55645000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-5088000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">51426000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">78000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">51504000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">936000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-68000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">55356000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-5321000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">50903000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">74000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentQuarter-1" unitRef="USD" decimals="-6">50977000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">1867000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">1867000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">0</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">836000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">836000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">835000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">1867000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">836000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">2703000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">0</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">9000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">9000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">23000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-31000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">203000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">203000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">203000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">8000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">8000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">74000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-74000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-23000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">31000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">272000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-74000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">206000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">206000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">913000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-37000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">57495000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4559000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">53812000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">73000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">944000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-69000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">82191000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-4452000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">78614000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">78000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">78692000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">944000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-69000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">82194000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-4452000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78617000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q2RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78695000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8565000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">8565000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-54000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-613000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-667000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-667000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8511000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-613000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">7898000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:DividendsPaid contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <ifrs-full:DividendsPaid contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <ifrs-full:DividendsPaid contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">17000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">2955000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">2972000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">2972000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">8000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-12000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">3000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">197000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">200000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">200000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">443000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">447000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">447000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">32000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">32000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">32000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:TaxesOnTreasuryShares contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">185000000</nvs:TaxesOnTreasuryShares>
  <nvs:TaxesOnTreasuryShares contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">185000000</nvs:TaxesOnTreasuryShares>
  <nvs:TaxesOnTreasuryShares contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">185000000</nvs:TaxesOnTreasuryShares>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-2289000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-2289000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-2289000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TransactionCostsRecordedInEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:TransactionCostsRecordedInEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:TransactionCostsRecordedInEquity contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">19000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-19000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-5000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">13000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">13000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">13000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-8000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-35060000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-23000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-35089000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-35091000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">936000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-80000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">59275000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4657000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">55474000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">77000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">55551000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4043000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">4043000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-12000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">188000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">176000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">175000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4031000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">188000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">4219000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-4000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:DividendsPaid contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <ifrs-full:DividendsPaid contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <ifrs-full:DividendsPaid contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">149000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">150000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">150000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">23000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-31000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ReductionOfIssuedCapital contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">8000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">815000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">823000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">823000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">5000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">360000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">365000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">365000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">29000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">29000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">29000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:TaxesOnTreasuryShares contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-30000000</nvs:TaxesOnTreasuryShares>
  <nvs:TaxesOnTreasuryShares contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-30000000</nvs:TaxesOnTreasuryShares>
  <nvs:TaxesOnTreasuryShares contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-30000000</nvs:TaxesOnTreasuryShares>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">90000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-90000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">9000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">9000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-23000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">43000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-5811000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q2TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-90000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-5881000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ChangesInEquity contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-5881000000</ifrs-full:ChangesInEquity>
  <ifrs-full:NumberOfSharesOutstanding contextRef="Q_I-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">2265000000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="Q_I-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">2311200000</ifrs-full:NumberOfSharesOutstanding>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">-32800000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:TreasurySharesAcquiredForCancellationValue contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">2819000000</nvs:TreasurySharesAcquiredForCancellationValue>
  <nvs:OtherSharePurchases contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">-1600000</nvs:OtherSharePurchases>
  <nvs:OtherSharePurchases contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">-1600000</nvs:OtherSharePurchases>
  <nvs:OtherSharePurchasesValue contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">150000000</nvs:OtherSharePurchasesValue>
  <nvs:OtherSharePurchasesValue contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">153000000</nvs:OtherSharePurchasesValue>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">5500000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:EquityBasedCompensationShares contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">10600000</nvs:EquityBasedCompensationShares>
  <nvs:EquityBasedCompensationShares contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">9500000</nvs:EquityBasedCompensationShares>
  <ifrs-full:NumberOfSharesOutstanding contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">2289000000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="Q_I-YTD-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">2291800000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:ProfitLoss contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4040000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">8567000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1867000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">6800000000</ifrs-full:ProfitLoss>
  <ifrs-full:Equity contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">53885000000</ifrs-full:Equity>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">23630000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">22870000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">53000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">23630000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">22923000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">700000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">556000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">7151000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">6657000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">17179000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">16822000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">6854000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">6915000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4501000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">4350000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">693000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">1192000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">1421000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">1844000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">5096000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">4905000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">306000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">256000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:InterestExpense contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">459000000</ifrs-full:InterestExpense>
  <ifrs-full:InterestExpense contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">431000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-34000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:OtherFinanceIncomeCost contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4909000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">4774000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">869000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">797000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4040000000</ifrs-full:ProfitLossFromContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">3977000000</ifrs-full:ProfitLossFromContinuingOperations>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-101000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">4590000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4043000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">8565000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">2000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:WeightedAverageShares contextRef="Q_D-YTD-CurrentYear" unitRef="Shares" decimals="-6">2281000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="Q_D-YTD-CurrentYear-1" unitRef="Shares" decimals="-6">2312000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations id="fact_144153" contextRef="Q_D-YTD-CurrentYear" unitRef="USDPerShares" decimals="2">1.77</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations id="fact_144154" contextRef="Q_D-YTD-CurrentYear-1" unitRef="USDPerShares" decimals="2">1.72</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations id="fact_144155" contextRef="Q_D-YTD-CurrentYear-1" unitRef="USDPerShares" decimals="2">1.98</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:BasicEarningsLossPerShare id="fact_144156" contextRef="Q_D-YTD-CurrentYear" unitRef="USDPerShares" decimals="2">1.77</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:BasicEarningsLossPerShare id="fact_144157" contextRef="Q_D-YTD-CurrentYear-1" unitRef="USDPerShares" decimals="2">3.70</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="Q_D-YTD-CurrentYear" unitRef="Shares" decimals="-6">2299000000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="Q_D-YTD-CurrentYear-1" unitRef="Shares" decimals="-6">2336000000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations id="fact_144160" contextRef="Q_D-YTD-CurrentYear" unitRef="USDPerShares" decimals="2">1.76</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations id="fact_144161" contextRef="Q_D-YTD-CurrentYear-1" unitRef="USDPerShares" decimals="2">1.70</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations id="fact_144162" contextRef="Q_D-YTD-CurrentYear-1" unitRef="USDPerShares" decimals="2">1.96</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:DilutedEarningsLossPerShare id="fact_144163" contextRef="Q_D-YTD-CurrentYear" unitRef="USDPerShares" decimals="2">1.76</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:DilutedEarningsLossPerShare id="fact_144164" contextRef="Q_D-YTD-CurrentYear-1" unitRef="USDPerShares" decimals="2">3.66</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">11347000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">11764000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">275000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">260000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">3429000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">3406000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">8193000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">8618000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">3368000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">3585000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">2441000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2051000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">432000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">989000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">464000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">1308000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">2352000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2663000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">183000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">176000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:InterestExpense contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">220000000</ifrs-full:InterestExpense>
  <ifrs-full:InterestExpense contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">205000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-27000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:OtherFinanceIncomeCost contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">0</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">2288000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2634000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">421000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">525000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1867000000</ifrs-full:ProfitLossFromContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2109000000</ifrs-full:ProfitLossFromContinuingOperations>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">4691000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1867000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">6799000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:WeightedAverageShares contextRef="Q_D-QoQ-CurrentYear" unitRef="Shares" decimals="-6">2289000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="Q_D-QoQ-CurrentYear-1" unitRef="Shares" decimals="-6">2310000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations id="fact_144202" contextRef="Q_D-QoQ-CurrentYear" unitRef="USDPerShares" decimals="2">0.82</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations id="fact_144203" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USDPerShares" decimals="2">0.91</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations id="fact_144204" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USDPerShares" decimals="2">2.03</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:BasicEarningsLossPerShare id="fact_144205" contextRef="Q_D-QoQ-CurrentYear" unitRef="USDPerShares" decimals="2">0.82</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:BasicEarningsLossPerShare id="fact_144206" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USDPerShares" decimals="2">2.94</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="Q_D-QoQ-CurrentYear" unitRef="Shares" decimals="-6">2304000000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="Q_D-QoQ-CurrentYear-1" unitRef="Shares" decimals="-6">2333000000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations id="fact_144209" contextRef="Q_D-QoQ-CurrentYear" unitRef="USDPerShares" decimals="2">0.81</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations id="fact_144210" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USDPerShares" decimals="2">0.90</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations id="fact_144211" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USDPerShares" decimals="2">2.01</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:DilutedEarningsLossPerShare id="fact_144212" contextRef="Q_D-QoQ-CurrentYear" unitRef="USDPerShares" decimals="2">0.81</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:DilutedEarningsLossPerShare id="fact_144213" contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USDPerShares" decimals="2">2.91</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">11955000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">12069000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:RightofuseAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">1640000000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">1677000000</ifrs-full:RightofuseAssets>
  <ifrs-full:Goodwill contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">29100000000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">26524000000</ifrs-full:Goodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">36669000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">28787000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">8575000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">8644000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:DeferredTaxAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">8601000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">7909000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:NoncurrentFinancialAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">2475000000</ifrs-full:NoncurrentFinancialAssets>
  <ifrs-full:NoncurrentFinancialAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">2518000000</ifrs-full:NoncurrentFinancialAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">866000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">738000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">99881000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">88866000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:Inventories contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">6904000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">5982000000</ifrs-full:Inventories>
  <ifrs-full:CurrentTradeReceivables contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">7644000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">8301000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTaxAssetsCurrent contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">308000000</ifrs-full:CurrentTaxAssetsCurrent>
  <ifrs-full:CurrentTaxAssetsCurrent contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">254000000</ifrs-full:CurrentTaxAssetsCurrent>
  <ifrs-full:OtherCurrentFinancialAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">376000000</ifrs-full:OtherCurrentFinancialAssets>
  <ifrs-full:OtherCurrentFinancialAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">334000000</ifrs-full:OtherCurrentFinancialAssets>
  <ifrs-full:CashAndCashEquivalents contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">5917000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">11112000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">2733000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">2680000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">23882000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
  <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">28663000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
  <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">841000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">23882000000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">29504000000</ifrs-full:CurrentAssets>
  <ifrs-full:Assets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">123763000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">118370000000</ifrs-full:Assets>
  <ifrs-full:IssuedCapital contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">913000000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">936000000</ifrs-full:IssuedCapital>
  <ifrs-full:TreasuryShares contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">37000000</ifrs-full:TreasuryShares>
  <ifrs-full:TreasuryShares contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">80000000</ifrs-full:TreasuryShares>
  <ifrs-full:OtherReserves contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">52936000000</ifrs-full:OtherReserves>
  <ifrs-full:OtherReserves contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">54618000000</ifrs-full:OtherReserves>
  <ifrs-full:EquityAttributableToOwnersOfParent contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">53812000000</ifrs-full:EquityAttributableToOwnersOfParent>
  <ifrs-full:EquityAttributableToOwnersOfParent contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">55474000000</ifrs-full:EquityAttributableToOwnersOfParent>
  <ifrs-full:NoncontrollingInterests contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">73000000</ifrs-full:NoncontrollingInterests>
  <ifrs-full:NoncontrollingInterests contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">77000000</ifrs-full:NoncontrollingInterests>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">23955000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">20353000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">1698000000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">1703000000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">7499000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">5867000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">7344000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">6632000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">40496000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">34555000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">4820000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">5424000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">8875000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">7031000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:CurrentLeaseLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">258000000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentLeaseLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">246000000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">2571000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
  <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">2194000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">12858000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">13338000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">29382000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">28233000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">31000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">29382000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">28264000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:Liabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">69878000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">62819000000</ifrs-full:Liabilities>
  <ifrs-full:EquityAndLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">123763000000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:EquityAndLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">118370000000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">169000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">475000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxAssets contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">11000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">2000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:Inventories contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">181000000</ifrs-full:Inventories>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">3000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">841000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:DeferredTaxLiabilities contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">2000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">4000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">25000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="Q_I-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">31000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">5202000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">4101000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">489000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">463000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">37000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">140000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">321000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">406000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">261000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">10000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">19000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">16000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">899000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">960000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">8790000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">7309000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">824000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">516000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-1477000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-1348000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">6489000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">5445000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">78000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">6489000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">5523000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">475000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">561000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">812000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">460000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">498000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">105000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">281000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">90000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">154000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">359000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">177000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">48000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">24000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">0</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">3000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-4000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-3000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-9901000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-382000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">345000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">120000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">394000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">2428000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-10461000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">1959000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-105000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-1105000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-10566000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">854000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
  <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">150000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">2590000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">846000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">200000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">4945000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">2002000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">3008000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">2486000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-942000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">142000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">91000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">5000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-142000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">71000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-1146000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-13010000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-26000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">3299000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-1172000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-9711000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-5249000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-3334000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">54000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">54000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-5195000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-3280000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="Q_I-CurrentYear-2" unitRef="USD" decimals="-6">13271000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">9991000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">2345000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2085000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">2000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">3000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">5000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">55000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">227000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">239000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">52000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">10000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">10000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-28000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">303000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">560000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">3731000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">3491000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">420000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">323000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">650000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-57000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">3961000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">3111000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">3961000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">3111000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">238000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">279000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">648000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">214000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">161000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">49000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">210000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">38000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">45000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">117000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">142000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">7000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">14000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-2000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-1000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">0</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-286000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">74000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">75000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">72000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">69000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-334000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">208000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-91000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-682000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-425000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-474000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">9000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2368000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">30000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1002000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">7000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-1169000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-793000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">74000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">69000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">5000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">52000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">532000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-2172000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-2710000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-13000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2682000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-2185000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-28000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1351000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">2609000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">38000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">76000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1389000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">3184000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="Q_I-CurrentQuarter-1" unitRef="USD" decimals="-6">4528000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="Q_I-CurrentQuarter-1-1-Year" unitRef="USD" decimals="-6">6807000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">700000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">719000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">154000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">149000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">2259000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1619000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">-127000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">-20000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">838000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">1018000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-55000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-684000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">377000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">372000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">-493000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-387000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">319000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">371000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">78000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">74000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1306000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">601000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">-166000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">-32000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">118000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">958000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">6000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-615000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">199000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">174000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">-247000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">-205000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">560000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">998000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">560000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">960000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">38000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">-2000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">-288000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">-9888000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">-367000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember" unitRef="USD" decimals="-6">2000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember" unitRef="USD" decimals="-6">-15000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">44000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">449000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">20000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">6000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">4000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">101000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">2000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
  <nvs:TradePayablesAndOtherLiabilities contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">9000000</nvs:TradePayablesAndOtherLiabilities>
  <nvs:IdentifiableAssetsAcquired contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">7569000000</nvs:IdentifiableAssetsAcquired>
  <nvs:IdentifiableAssetsAcquired contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">411000000</nvs:IdentifiableAssetsAcquired>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">75000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">10030000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">486000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">33000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">33000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">57000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">61000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">102000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">136000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">102000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">33000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">160000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">126000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">193000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">163000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">976000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">581000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">1443000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">1557000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">235000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">399000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">444000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">399000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">904000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">976000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">1218000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">1213000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">2122000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">2189000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">175000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1036000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1039000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1036000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">29000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">20000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">29000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">126000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">126000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1059000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1065000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1250000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:BorrowingsInterestRate contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" unitRef="Pure" decimals="4">0.0175</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" unitRef="Pure" decimals="5">0.99852</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BorrowingsInterestRate contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" unitRef="Pure" decimals="4">0.0200</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" unitRef="USD" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" unitRef="Pure" decimals="5">0.99909</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BorrowingsInterestRate contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" unitRef="Pure" decimals="4">0.0220</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" unitRef="USD" decimals="-6">1500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" unitRef="Pure" decimals="5">0.99869</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BorrowingsInterestRate contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" unitRef="Pure" decimals="4">0.0275</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" unitRef="USD" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" unitRef="Pure" decimals="5">0.97712</nvs:BorrowingsPremiumDiscount>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">9188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">9326000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2159000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2438000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">11347000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">11764000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">219000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">177000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">43000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">37000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-262000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-214000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">9407000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">9503000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2202000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2475000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-262000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-214000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">251000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">250000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">22000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">6000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">2000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">4000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2554000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2327000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1158000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1315000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-283000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-236000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">7104000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">7426000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1066000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1166000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">23000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">26000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2764000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2911000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">496000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">550000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">108000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">124000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2240000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">1853000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">201000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">198000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">154000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">847000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">17000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">45000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">261000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">97000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">221000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">945000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">65000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">181000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">178000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">182000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2033000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2564000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">321000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">282000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-183000000</ifrs-full:ProfitLossFromOperatingActivities>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="3">0.221</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="3">0.275</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="3">0.149</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="3">0.116</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-QoQ-CurrentYear" unitRef="Pure" decimals="3">0.207</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-QoQ-CurrentYear-1" unitRef="Pure" decimals="3">0.226</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">181000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">174000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">18943000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">18106000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">4687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">4764000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">409000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">426000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">92000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">76000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-501000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-449000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">19352000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">18532000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">4779000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">4840000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-501000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-449000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">507000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">511000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">35000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">34000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">158000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">11000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">5080000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">4551000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2614000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2591000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-543000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-485000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">14779000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">14492000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2200000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2283000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">200000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">47000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">5621000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">5564000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1016000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1112000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">217000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">239000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">4106000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">3958000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">395000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">392000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">326000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">922000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">49000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">82000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">318000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">188000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">590000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">1219000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">562000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">306000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">269000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">319000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">4788000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">4673000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">276000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">555000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">32000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-323000000</ifrs-full:ProfitLossFromOperatingActivities>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="3">0.253</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="3">0.258</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="3">0.059</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="3">0.116</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-YTD-CurrentYear" unitRef="Pure" decimals="3">0.216</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-YTD-CurrentYear-1" unitRef="Pure" decimals="3">0.214</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">304000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">254000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:NetOperatingAssets contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">66683000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">55893000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">12548000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">12664000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">80422000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">71489000000</nvs:NetOperatingAssets>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">9485000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">9632000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1943000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1888000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">527000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">549000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:Goodwill contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">21257000000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">18750000000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">7835000000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">7767000000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">8000000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">7000000</ifrs-full:Goodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">34877000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">27586000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1674000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1125000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">118000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">76000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1777000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">32000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1809000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:CostOfSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">860000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">949000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">638000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">142000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">15000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">113000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">71000000</ifrs-full:ProfitLossFromOperatingActivities>
  <nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="Pure" decimals="3">0.040</nvs:ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales>
  <ifrs-full:InterestExpense contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">10000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">58000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">159000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-101000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4691000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4590000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <nvs:NetAssetsDerecognized contextRef="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">20025000000</nvs:NetAssetsDerecognized>
  <ifrs-full:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed contextRef="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3409000000</ifrs-full:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed>
  <nvs:DistributionOfDividendToDividendBearingShares contextRef="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1273000000</nvs:DistributionOfDividendToDividendBearingShares>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">123000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:TransactionCosts contextRef="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">114000000</nvs:TransactionCosts>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-3000000</nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents>
  <nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-14000000</nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents>
  <nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-17000000</nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents>
  <nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-14000000</nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents>
  <nvs:DivestedCashAndCashEquivalents contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">628000000</nvs:DivestedCashAndCashEquivalents>
  <nvs:DivestedCashAndCashEquivalents contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">628000000</nvs:DivestedCashAndCashEquivalents>
  <nvs:CashFlowsAttributableToDivestedBusiness contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-3000000</nvs:CashFlowsAttributableToDivestedBusiness>
  <nvs:CashFlowsAttributableToDivestedBusiness contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-642000000</nvs:CashFlowsAttributableToDivestedBusiness>
  <nvs:CashFlowsAttributableToDivestedBusiness contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-17000000</nvs:CashFlowsAttributableToDivestedBusiness>
  <nvs:CashFlowsAttributableToDivestedBusiness contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-642000000</nvs:CashFlowsAttributableToDivestedBusiness>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-88000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-40000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-88000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-463000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <nvs:ProceedsFromCurrentAndNoncurrentBorrowings contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-8">3200000000</nvs:ProceedsFromCurrentAndNoncurrentBorrowings>
  <nvs:ProceedsFromCurrentAndNoncurrentBorrowings contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-8">3500000000</nvs:ProceedsFromCurrentAndNoncurrentBorrowings>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-8">-100000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-8">-200000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2964000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">3218000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.32</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.35</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">3515000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">3336000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2123000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2106000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">586000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">666000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">6909000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">7071000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.75</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.76</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2279000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">2255000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1130000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1269000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.52</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.52</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">508000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">642000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.26</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">333000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">180000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">194000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1621000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1796000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.75</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.74</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">538000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">642000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.26</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember" unitRef="USD" decimals="-6">4094000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember" unitRef="USD" decimals="-6">4487000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember" unitRef="Pure" decimals="2">0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">4023000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">3978000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.35</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">2464000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">2439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">766000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">860000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember" unitRef="USD" decimals="-6">8530000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember" unitRef="USD" decimals="-6">8867000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember" unitRef="Pure" decimals="2">0.75</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember" unitRef="Pure" decimals="2">0.75</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">2817000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">2897000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">6366000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">6352000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.35</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">7057000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">6329000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.37</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.35</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">4301000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">4123000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">1219000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">1302000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">14266000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">13638000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.75</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.75</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">4677000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">4468000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2558000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2510000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.55</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.53</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1078000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1232000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.26</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">675000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">651000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">371000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">3466000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">3491000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.74</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.73</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1221000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1273000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.26</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="2">0.27</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember" unitRef="USD" decimals="-6">8924000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember" unitRef="USD" decimals="-6">8862000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2019EuropeMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">8135000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">7561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">4976000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">4774000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">1595000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">1673000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2CanadaAndLatinAmericaMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember" unitRef="USD" decimals="-6">17732000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember" unitRef="USD" decimals="-6">17129000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember" unitRef="Pure" decimals="2">0.75</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EstablishedMarketsMember" unitRef="Pure" decimals="2">0.75</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">5898000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">5741000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2EmergingGrowthMarketsMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">2772000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">4332000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">7104000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="USD" decimals="-6">2084000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">5463000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">9031000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">14494000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="USD" decimals="-6">4449000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">468000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">349000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">403000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">340000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">323000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">284000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">401000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">253000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">193000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">111000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">109000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">58000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">1.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">308000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">3548000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">3606000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">638000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">937000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">1174000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">858000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">165000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">1144000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">1023000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">825000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">24000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">17000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">1025000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">886000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">421000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">6000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">580000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">427000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">290000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">166000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">5000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">444000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">461000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">320000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">283000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">264000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">124000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">110000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">95000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">553000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">1510000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">1749000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember" unitRef="USD" decimals="-6">5640000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember" unitRef="USD" decimals="-6">5720000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">902000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">656000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.26</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">795000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">637000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">774000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.27</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">491000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.32</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">380000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">202000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.58</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">215000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">103000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">1.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PiqrayMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">6000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">594000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">7196000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">6927000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">1069000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">1266000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">2133000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">2335000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">1649000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">316000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.31</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">2287000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">1965000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">1591000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">42000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">30000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">2045000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">1683000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">778000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.48</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">12000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">-0.92</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">1150000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">790000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.46</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">571000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">323000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">12000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">-0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">915000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">906000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">544000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">531000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">240000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">213000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">208000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">1129000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">3217000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">3500000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember" unitRef="USD" decimals="-6">11747000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember" unitRef="USD" decimals="-6">11179000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember" unitRef="USD" decimals="-6">1903000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember" unitRef="Pure" decimals="2">-0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember" unitRef="USD" decimals="-6">401000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember" unitRef="USD" decimals="-6">134000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">186000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">390000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember" unitRef="USD" decimals="-6">3753000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember" unitRef="USD" decimals="-6">752000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember" unitRef="Pure" decimals="2">0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember" unitRef="USD" decimals="-6">259000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:ProfitSharingIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">209000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">181000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">209000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">182000000</nvs:ProfitSharingIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">24000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">15000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">5000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">4000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">2000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">6000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">31000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">25000000</ifrs-full:RevenueFromRoyalties>
  <nvs:MilestoneIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">5000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">47000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">11000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">16000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">47000000</nvs:MilestoneIncome>
  <nvs:OtherRevenueOther contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">13000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">7000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">6000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-2000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">19000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">6000000</nvs:OtherRevenueOther>
  <nvs:ProfitSharingIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">407000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">350000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">1000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">407000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">351000000</nvs:ProfitSharingIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">54000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">49000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">13000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">7000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">158000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">13000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">225000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">69000000</ifrs-full:RevenueFromRoyalties>
  <nvs:MilestoneIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">25000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">98000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">11000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">23000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">36000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">121000000</nvs:MilestoneIncome>
  <nvs:OtherRevenueOther contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">21000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">14000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">11000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">3000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">-2000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">32000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">15000000</nvs:OtherRevenueOther>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">9600000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">7100000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">8500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">1400000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">2500000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:DivestmentDateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-8">800000000</nvs:DivestmentDateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-5">38000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-5">102000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-5">42000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:NetAssetsLiabilities contextRef="Q_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">23100000000</ifrs-full:NetAssetsLiabilities>
  <ifrs-full:OtherBorrowings contextRef="Q_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">3200000000</ifrs-full:OtherBorrowings>
  <ifrs-full:OtherBorrowings contextRef="Q_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2BorrowingsUSDMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">2800000000</ifrs-full:OtherBorrowings>
  <ifrs-full:OtherBorrowings contextRef="Q_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2BorrowingsEURMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">400000000</ifrs-full:OtherBorrowings>
  <nvs:AdditionalBorrowings contextRef="Q_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">300000000</nvs:AdditionalBorrowings>
  <ifrs-full:Borrowings contextRef="Q_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">3500000000</ifrs-full:Borrowings>
  <nvs:RepaymentOfIntercompanyBalances contextRef="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">-3100000000</nvs:RepaymentOfIntercompanyBalances>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-Transaction-Alcon-4-April-9_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">1300000000</ifrs-full:FinancialAssetsAtFairValue>
  <nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="Q_I-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.09</nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
  <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="Q_I-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">33000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
  <ifrs-full:GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination contextRef="Q_D-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">14000000</ifrs-full:GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="Q_I-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">361000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PercentageOfVotingEquityInterestsAcquired contextRef="Q_I-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.91</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="Q_D-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">285000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="Q_I-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">76000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="Q_I-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">355000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="Q_D-Transaction-IFM-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">39000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">3400000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">1900000000</nvs:PotentialMilestoneMaximumPayments>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">100000000</nvs:CustomaryPurchasePriceAdjustment>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">3700000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">3500000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">200000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">3600000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">3600000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">100000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:RevenueOfAcquireeFullYear contextRef="AR_D-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">300000000</nvs:RevenueOfAcquireeFullYear>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="Q_I-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">424000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="Q_D-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">289000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="Q_I-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">135000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="Q_I-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">418000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="Q_I-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">505000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="Q_I-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">93000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OtherNetAssets contextRef="Q_I-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">6000000</nvs:OtherNetAssets>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="Q_D-Transaction-PowerVision-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">6000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:NumberOfReportableSegments contextRef="Q_D-YTD-CurrentYear" unitRef="Pure" decimals="0">2</nvs:NumberOfReportableSegments>
  <nvs:NumberOfBusinessUnits contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="Pure" decimals="0">2</nvs:NumberOfBusinessUnits>
  <nvs:NumberOfFranchises contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="Pure" decimals="0">3</nvs:NumberOfFranchises>
  <nvs:AmountOfSettlementInPrinciple contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-5">195000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-5">186000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">580000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">5673000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">1149000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">11886000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">480000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">422000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">371000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">310000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">288000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">266000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">163000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.35</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">162000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">159000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.49</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">105000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">118000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">1.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PiqrayMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">79000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PiqrayMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">6000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AdakveoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">21000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">263000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">401000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XiidraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">79000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2BeovuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">34000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">423000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.32</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">944000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">200000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">205000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">15000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">33000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">0.45</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2MayzentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">34000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2MayzentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">5000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">15000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">-0.26</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.40</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">289000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">149000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">6000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">279000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">268000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">238000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">106000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">96000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">82000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">441000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">33000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">136000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">904000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">539000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">235000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q2ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">444000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q2GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q2AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">175000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1039000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">20000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q2DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">126000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">26000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-8">27700000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-8">23700000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-8">25200000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-8">22200000000</ifrs-full:FinancialLiabilities>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">614000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">330000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">416000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">322000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">308000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">272000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">221000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">259000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">401000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">212000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">210000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">147000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">224000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">200000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">141000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">310000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">70000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.27</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">218000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">279000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">289000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">163000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.37</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">103000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.27</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">34000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">234000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">2000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.50</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">236000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">95000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">105000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">105000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">100000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">34000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.71</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">129000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">72000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">90000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">79000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">80000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.51</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.63</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="USD" decimals="-6">743000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="USD" decimals="-6">1341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">1190000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">684000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">804000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">706000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">601000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">548000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.53</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.58</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">424000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">543000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">888000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">399000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">426000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.26</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.30</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">279000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">458000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">413000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">302000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">628000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">174000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">443000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">617000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">596000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">332000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">230000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">60000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">482000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">6000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">490000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">183000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.29</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">230000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.32</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">144000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">78000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.66</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">257000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">136000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">192000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">153000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.37</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">167000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.86</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.97</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="USD" decimals="-6">1594000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="USD" decimals="-6">2855000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">967000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">825000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.28</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">737000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">715000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">628000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">617000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">630000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">562000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.26</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">335000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.31</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">328000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">320000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.64</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">217000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LutatheraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">211000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2KymriahMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">1.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2PiqrayMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">153000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AdakveoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">36000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember" unitRef="USD" decimals="-6">545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2OncologyMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">413000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">888000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XiidraMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">169000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2BeovuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">102000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="USD" decimals="-6">974000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2OphthalmologyMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">1510000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">375000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">15000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">69000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">0.64</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2AimovigMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">0.72</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2MayzentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">64000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2MayzentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">5000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="USD" decimals="-6">27000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.50</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="USD" decimals="-6">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">-0.98</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2CardioMetabolicMember" unitRef="Pure" decimals="2">0.48</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">596000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">309000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2UltibroGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="USD" decimals="-6">10000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RespiratoryMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">617000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">496000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">233000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">197000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">174000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="USD" decimals="-6">958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember" unitRef="USD" decimals="-6">1576000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember" unitRef="USD" decimals="-6">466000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember" unitRef="Pure" decimals="2">0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember" unitRef="USD" decimals="-6">117000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">134000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">356000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember" unitRef="USD" decimals="-6">3545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2RetailGenericsMember" unitRef="Pure" decimals="2">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember" unitRef="USD" decimals="-6">916000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2BiopharmaceuticalsMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember" unitRef="USD" decimals="-6">226000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2AntiInfectivesMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">16000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember" unitRef="USD" decimals="-6">2000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember" unitRef="USD" decimals="-6">-13000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">26000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">269000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">8602000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">470000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
  <nvs:FinancialAndOtherAssets contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">49000000</nvs:FinancialAndOtherAssets>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">84000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">109000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">76000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">1928000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">32000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
  <nvs:TradePayablesAndOtherLiabilities contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">144000000</nvs:TradePayablesAndOtherLiabilities>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">2537000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:BondsIssued contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" unitRef="USD" decimals="-6">996000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" unitRef="USD" decimals="-6">1245000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" unitRef="USD" decimals="-6">1492000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" unitRef="USD" decimals="-6">1213000000</ifrs-full:BondsIssued>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="Shares" decimals="-5">300000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <ifrs-full:DividendsPayable contextRef="Q_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-8">26400000000</ifrs-full:DividendsPayable>
  <ifrs-full:IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners contextRef="Q_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-9">3000000000</ifrs-full:IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners>
  <nvs:PercentageOfEquityInterestSharesReceived contextRef="Q_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="Pure" decimals="3">0.047</nvs:PercentageOfEquityInterestSharesReceived>
  <ifrs-full:RevenueOfAcquiree contextRef="AR_D-Transaction-Takeda-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">200000000</ifrs-full:RevenueOfAcquiree>
  <nvs:AmountOfSettlementInPrinciple contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2NPCAndOthersMember" unitRef="USD" decimals="-8">700000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2NPCAndOthersMember" unitRef="USD" decimals="-8">700000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="Q_D-July-20-2020_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2NPCAndOthersMember" unitRef="USD" decimals="-8">600000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
  <nvs:AmountOfSettlementInPrinciple contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember" unitRef="USD" decimals="-8">300000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember" unitRef="USD" decimals="-8">100000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="Q_D-July-20-2020_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019LegalProceedingsProvisionMember" unitRef="USD" decimals="-8">100000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="Q_D-QoQ-CurrentYear" unitRef="USD" decimals="-6">391000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="Q_D-YTD-CurrentYear" unitRef="USD" decimals="-6">987000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">59000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
  <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes contextRef="Q_I-YTD-CurrentYear-1" unitRef="USD" decimals="-6">0</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
  <nvs:NetOperatingAssets contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">1191000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">2932000000</nvs:NetOperatingAssets>
  <ifrs-full:Assets contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">81373000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">16229000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">26161000000</ifrs-full:Assets>
  <ifrs-full:Liabilities contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">14690000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">3681000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">51507000000</ifrs-full:Liabilities>
  <ifrs-full:NetDebt contextRef="Q_I-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">26537000000</ifrs-full:NetDebt>
  <ifrs-full:NetDebt contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">26537000000</ifrs-full:NetDebt>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">500000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">20000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">509000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">466000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">42000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">12000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">500000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-QoQ-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">22000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">551000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">478000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q2AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZPL389Member" unitRef="USD" decimals="-6">485000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q2AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZPL389Member" unitRef="USD" decimals="-6">485000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-QoQ-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q2RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc contextRef="Q_D-YTD-Change_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2ChangeOverPeriodAxis_nvs-2020Q2PoPChangeMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2RestOfPortfolioMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-5">-26000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-5">-13000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="Q_D-YTD-CurrentYear-1_dei-2019LegalEntityAxis_nvs-2020Q2SpinifexMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q2AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">416000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:TaxReformImpactOnDeferredTaxOnTreasuryShares contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">69000000</nvs:TaxReformImpactOnDeferredTaxOnTreasuryShares>
  <nvs:TaxReformImpactOnDeferredTaxOnTreasuryShares contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">69000000</nvs:TaxReformImpactOnDeferredTaxOnTreasuryShares>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2AlconMember" unitRef="USD" decimals="-6">287000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="Q_D-QoQ-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">32000000</nvs:CashFlowFromNetIdentifiableAssets>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="Q_D-QoQ-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">407000000</nvs:CashFlowFromNetIdentifiableAssets>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">10030000000</nvs:CashFlowFromNetIdentifiableAssets>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="Q_D-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">486000000</nvs:CashFlowFromNetIdentifiableAssets>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="Q_D-QoQ-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">17000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="Q_D-QoQ-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">88000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">77000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="Q_D-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">88000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="Q_D-QoQ-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">-13000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="Q_D-QoQ-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">3000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">-65000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="Q_D-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">3000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="0">85</nvs:CashOfferPerOrdinaryShare>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-TheMedicinesCompany-2_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-8">9600000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="EUR" decimals="-6">300000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">331000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="EUR" decimals="-6">27000000</nvs:CustomaryPurchasePriceAdjustment>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">30000000</nvs:CustomaryPurchasePriceAdjustment>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="EUR" decimals="-6">120000000</nvs:PotentialMilestoneMaximumPayments>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">132000000</nvs:PotentialMilestoneMaximumPayments>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="EUR" decimals="-6">345000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">381000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="EUR" decimals="-6">273000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">301000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="EUR" decimals="-6">72000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">80000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">309000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">269000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">26000000</nvs:OtherNetAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">14000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">72000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:RightOfUseAssetsAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">32000000</nvs:RightOfUseAssetsAsOfAcquisitionDate>
  <nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">44000000</nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate>
  <nvs:AcquiredCashAndCashEquivalents contextRef="Q_I-YTD-CurrentYear" unitRef="USD" decimals="-6">76000000</nvs:AcquiredCashAndCashEquivalents>
  <nvs:FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="Q_I-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2AcquisitionsMember" unitRef="USD" decimals="-6">-34000000</nvs:FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
  <nvs:NetCashOutflowsFromDivestments contextRef="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember" unitRef="USD" decimals="-6">15000000</nvs:NetCashOutflowsFromDivestments>
  <nvs:NetCashOutflowsFromDivestments contextRef="Q_D-YTD-CurrentYear-1_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember" unitRef="USD" decimals="-6">15000000</nvs:NetCashOutflowsFromDivestments>
  <nvs:ReclassificationOfExportSales contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q2ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember_nvs-2020Q2BusinessUnitAxis_nvs-2020Q2PharmaceuticalMember_nvs-2020Q2FranchiseAxis_nvs-2020Q2NeuroscienceMember_nvs-2020Q2ProductPortfolioAxis_nvs-2020Q2Top20ProductsMember" unitRef="USD" decimals="-6">44000000</nvs:ReclassificationOfExportSales>
  <nvs:PrepaidSalesPriceForABusinessDivestment contextRef="Q_D-YTD-CurrentYear_nvs-2020Q2AcquisitionsAndDivestmentsAxis_nvs-2020Q2DivestmentsMember" unitRef="USD" decimals="-6">2000000</nvs:PrepaidSalesPriceForABusinessDivestment>
  <ifrs-full:DividendsPayable contextRef="Q_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">23434000000</ifrs-full:DividendsPayable>
  <ifrs-full:NetDebt contextRef="Q_I-CurrentYear-1" unitRef="USD" decimals="-6">15938000000</ifrs-full:NetDebt>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">303000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">899000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:Assets contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">71225000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">16468000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">30677000000</ifrs-full:Assets>
  <ifrs-full:Liabilities contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember" unitRef="USD" decimals="-6">15332000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember" unitRef="USD" decimals="-6">3804000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">43683000000</ifrs-full:Liabilities>
  <ifrs-full:NetDebt contextRef="Q_I-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q2CorporateMember" unitRef="USD" decimals="-6">15938000000</ifrs-full:NetDebt>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities contextRef="Q_D-QoQ-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">88000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">88000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations contextRef="Q_D-QoQ-CurrentYear-1" unitRef="USD" decimals="-6">499000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations>
  <nvs:ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI contextRef="Q_D-YTD-CurrentYear-1" unitRef="USD" decimals="-6">-358000000</nvs:ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <dei:EntityRegistrantName contextRef="Q_D-YTD-CurrentYear">NOVARTIS AG</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="Q_D-YTD-CurrentYear">0001114448</dei:EntityCentralIndexKey>
  <dei:DocumentType contextRef="Q_D-YTD-CurrentYear">6-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="Q_D-YTD-CurrentYear">2020-06-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag contextRef="Q_D-YTD-CurrentYear">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Q_D-YTD-CurrentYear">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalYearFocus contextRef="Q_D-YTD-CurrentYear">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="Q_D-YTD-CurrentYear">Q2</dei:DocumentFiscalPeriodFocus>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <ifrs-full:BorrowingsMaturity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member">2025</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates1.752025Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <ifrs-full:BorrowingsMaturity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member">2027</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.002027Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <ifrs-full:BorrowingsMaturity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member">2030</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.202030Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <ifrs-full:BorrowingsMaturity contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member">2050</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q2NovartisCapitalCorporationNewYorkUnitedStates2.752050Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <nvs:DetailedInformationAboutSignificantTransaction contextRef="Q_D-YTD-CurrentYear_dei-2019LegalEntityAxis_nvs-2020Q2TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels. The fair value of the total purchase consideration was USD 9.6 billion. The preliminary purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. Results of operations since the date of acquisition were not material.</nvs:DetailedInformationAboutSignificantTransaction>
  <nvs:DetailedInformationAboutSignificantTransaction contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2SandozMember">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval. In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as regulatory approval from the US Federal Trade Commission was not obtained within the SAPA agreed timelines. The cumulative amount of the depreciation on property, plant and equipment and amortization on intangible assets, not recorded in the consolidated income statement since the date of classification as held for sale, amounting to USD 38 million and USD 102 million, respectively, was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement. As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated. In the Group&#x2019;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following: There are no cumulative income or expenses included in other comprehensive income relating to the disposal group.</nvs:DetailedInformationAboutSignificantTransaction>
  <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;1. Basis of preparation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;These Condensed Interim Consolidated Financial Statements for the three-month and six-month period ended June 30, 2020, were prepared in accordance with International Accounting Standard 34 &lt;i&gt;Interim Financial Reporting &lt;/i&gt;and accounting policies set out in the 2019 Annual Report published on January&amp;nbsp;29, 2020. &lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;2. Selected critical accounting policies&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&amp;#x2019;s principal accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2019 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The preparation of &amp;#xfb01;nancial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of assets and liabilities, including any contingent amounts, the distribution liability recognized in connection with the distribution of Alcon Inc. to Novartis AG shareholders, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As disclosed in the 2019 Annual Report, goodwill, and acquired In-Process Research &amp;amp; Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Group&amp;#x2019;s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Group&amp;#x2019;s results of operations and financial condition. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or&amp;nbsp;held for distribution to owners&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are classified as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Distribution of Alcon Inc. &lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt; &lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;to Novartis AG shareholders&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&amp;#x2019;s business (the &amp;#x201c;Alcon business&amp;#x201d;) to be reported as discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &amp;#x201c;Other expense&amp;#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &amp;#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&amp;#x201d; in the income statement of discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&amp;#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&amp;#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in Note 1 to the Consolidated Financial Statements of the 2019 Annual Report provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional disclosures, refer to Notes 3 and 10.&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;New IFRS standard effective as&amp;nbsp;of&amp;nbsp;January 1, 2020&lt;/font&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combination amendments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired or disposed of should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the entity may choose to consider the transaction an acquisition of an asset or set of assets. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. &lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <nvs:DisclosureOfSignificantTransactionsTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;3. Significant transactions&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of The&amp;nbsp;Medicines Company&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&amp;#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&amp;#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 9.6 billion. The preliminary purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Results of operations since the date of acquisition were not material.&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &amp;ndash; acquisition of the Japanese business of Aspen Global Incorporated &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Aspen&amp;#x2019;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price consist of EUR 300 million (USD 331 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 120 million (USD 132 million), which AGI is eligible to receive upon the achievement of specified milestones. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was EUR 345 million (USD 381 million). The amount consisted of an initial cash payment of EUR 273 million (USD 301 million) and the fair value of contingent consideration of EUR 72 million (USD 80 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of approximately USD 309 million, consisting of USD 269 million intangible assets, USD 26 million other net assets, USD 14 million net deferred tax assets and goodwill of approximately USD 72 million. Results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &amp;ndash; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as regulatory approval from the US Federal Trade Commission was not obtained within the SAPA agreed timelines. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The cumulative amount of the depreciation on property, plant and equipment and amortization on intangible assets, not recorded in the consolidated income statement since the date of classification as held for sale, amounting to USD 38 million and USD 102 million, respectively, was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the Group&amp;#x2019;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Assets of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Liabilities of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There are no cumulative income or expenses included in other comprehensive income relating to the disposal group. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG &lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; shareholders&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April&amp;nbsp;9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &amp;#x201c;ALC.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&amp;#x2019;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&amp;#x2019;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; April 8, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net assets derecognized &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derecognition of distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Difference between net assets and distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Recognition of Alcon Inc. shares obtained &lt;br&gt;&lt;/br&gt;through consolidated foundations &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;273 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation gains recycled into the &lt;br&gt;&lt;/br&gt;consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transaction costs recognized in the consolidated income statement&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; See Note 10 for additional information. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For additional disclosure on discontinued operations, refer to Note 10.&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of IFM Tre, Inc. &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&amp;#x2019;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gutdirected molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangibles, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of &lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;font-style:italic;"&gt;Xiidra&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with &lt;i&gt;Xiidra&lt;/i&gt; (lifitegrast ophthalmic solution) 5% worldwide. &lt;i&gt;Xiidra&lt;/i&gt; is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimated that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material. &lt;/div&gt;</nvs:DisclosureOfSignificantTransactionsTextBlock>
  <nvs:DisclosureOfEquityTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;4. Summary of equity attributable to Novartis AG shareholders &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Number of outstanding shares (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Issued share capital and reserves attributable to Novartis AG shareholders (in USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 55&amp;nbsp;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 78&amp;nbsp;614&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in accounting policy &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Restated equity at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 55&amp;nbsp;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 78&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be cancelled&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 823&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 365&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees as a result of the Alcon spin-off&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes on treasury share transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase of treasury share repurchase obligation under a share buyback trading plan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividends to shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;987&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend in kind to effect the spin-off of Alcon Inc. &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net income of the period attributable to shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;043&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;565&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other comprehensive income attributable to shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;667&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transaction costs, net of taxes &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at June 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;289.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;291.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&amp;nbsp;812&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 51&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In H1 2019, the impact of change in accounting policy includes USD 3 million related to the implementation of IFRS 16 Leases. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Included in H1 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. &lt;br&gt;&lt;/br&gt;This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Fair value of the dividend in kind of Alcon Inc. shares to Novartis AG shareholders (see Notes 2 and 3 for further details). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; In H1 2019, Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Impact of hyperinflationary economies &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfEquityTextBlock>
  <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;5. Financial instruments &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Fair value by hierarchy&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table illustrates the three hierarchical levels for valuing financial instruments at fair value as of June 30, 2020 and December&amp;nbsp;31, 2019. For additional information on the hierarchies and other matters, please refer to the Consolidated Financial Statements in the 2019 Annual Report, published on January 29, 2020. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 904&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;443&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 444&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 444&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 904&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit or loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;059&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first half of 2020, there were no significant transfers from one level to the other and no significant transactions associated with level 3 financial instruments. During the second quarter of 2020, there were two non-significant transfers of equity securities from level 3 to level 1 for USD 26 million due to Initial Public Offerings. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of straight bonds amounted to USD 27.7 billion at June 30, 2020 (USD 23.7 billion at December 31, 2019) compared to the balance sheet value of USD 25.2 billion at June 30, 2020 (USD 22.2 billion at December 31, 2019). For all other financial assets and liabilities, the carrying amount is a reasonable approximation of the fair value. The carrying amount of financial assets included in the line total long-term financial investments of USD 2.1 billion at June 30, 2020 (USD 2.2 billion at December 31, 2019) is included in line &amp;#x201c;Financial and other non-current assets&amp;#x201d; of the consolidated balance sheets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In accordance with the consolidated foundations Alcon Inc. share divestment plans, Alcon Inc. shares with a fair value of USD 287 million were sold, or otherwise disposed of, in the first half of 2020 and the USD 16 million gain on disposal was transferred from other comprehensive income to retained earnings (second quarter : nil). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s exposure to financial risks has not changed significantly during the period and there have been no major changes to the risk management department or in any risk management policies. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current financial debt &amp;ndash; issuance of bonds&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On February 11, 2020, Novartis issued the following straight bonds:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Coupon &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Currency &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Nominal amount &lt;br&gt;&lt;/br&gt; (USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Maturity year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issuer &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issue price &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Carrying value &lt;br&gt;&lt;/br&gt; Jun 30, 2020 &lt;br&gt;&lt;/br&gt; (USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.75%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.852%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.00%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.909%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.20%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.869%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.75%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 97.712%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
  <ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;6. Details to the consolidated statements of&amp;nbsp;cash&amp;nbsp;flows &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;6.1. Reversal of non-cash items and other adjustments from continuing operations&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 319&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 371&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Losses/gains on disposal and other adjustments on property, plant and equipment; intangible assets; &lt;br&gt;&lt;/br&gt;financial assets; and other non-current assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;615 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 525&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;085&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 700&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 154&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;619&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets; &lt;br&gt;&lt;/br&gt;financial assets; and other non-current assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;55 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;684 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 377&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 493&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 387&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;6.2. Total amount of taxes paid &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first half of 2020, the total amount of taxes paid was USD 987 million (Q2 2020: USD 391 million), of which USD 899 million (Q2 2020: USD 303 million) was included within &amp;#x201c;Net cash flows from operating activities from continuing operations&amp;#x201d;, and USD 88 million (Q2 2020: USD 88 million) was included within &amp;#x201c;Net cash flows used in investing activities from discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During the first half of 2019, the total amount of taxes paid was USD 998 million (Q2 2019: USD 560 million), of which USD 960 million (Q2 2019: USD 560 million) was included within &amp;#x201c;Net cash flows from operating activities from continuing operations&amp;#x201d; and USD 38 million (Q2 2019: nil) was included within &amp;#x201c;Net cash flows from operating activities from discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;6.3. Cash flows arising from acquisitions and divestments of businesses, net&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of business combinations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;030&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;486&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Receivables and payables contingent consideration, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;367&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash flows from/used for divestments of businesses, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;901&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;382&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In the second quarter of 2020 and 2019, the USD 2 million represented the net cash inflows for previous years divestments. &lt;br&gt;&lt;/br&gt;During the first half of 2020, the USD 13 million included USD 15 million net cash outflows for previous years divestments (H1 2019: USD 15 million) and a prepaid sales price of USD 2 million for a business divestment. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Notes 3 and 7 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;6.4. Cash and cash equivalents of discontinued operations at March 31, 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents of discontinued operations at March 31, 2019,represents the amount of the Alcon business cash and cash equivalents included in the March 31, 2019, consolidated balance sheets in the line &amp;#x201c;Assets related to discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For net cash flows used in investing activities from discontinued operations, see Note 10. &lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
  <ifrs-full:DisclosureOfBusinessCombinationsExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;7. Acquisition of businesses&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Fair value of assets and liabilities arising from acquisitions:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 449&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 470&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables, marketable securities &lt;br&gt;&lt;/br&gt;and other current assets &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 109 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;928&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;144&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;569&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of business combinations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 486&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Note 3 details significant acquisitions of businesses, specifically, The Medicines Company and the Japanese business of AGI in 2020, and IFM Tre, Inc. in 2019. The goodwill arising out of these acquisitions is attributable to the buyer specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. Goodwill of USD 59 million in 2020 (2019: nil) is tax deductible. &lt;/div&gt;</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
  <nvs:LegalProceedingsUpdateTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;8. Legal proceedings update &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings, including litigations, arbitrations and governmental investigations, that arise from time to time. Legal proceedings are inherently unpredictable. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F contains a summary as of the date of these reports of significant legal proceedings to which Novartis or its subsidiaries were a party. The following is a summary as of July 20, 2020 of significant developments in those proceedings, as well as any new significant proceedings commenced since the date of the 2019 Annual Report and 2019 Form 20-F. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Investigations and related litigations&lt;/font&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Government generic pricing antitrust investigations,&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; antitrust class actions&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2016, Sandoz Inc. received grand jury subpoenas and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) in connection with alleged price fixing and market allocation of generic drugs in the US market as well as alleged False Claims Act violations. Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. agreed to pay USD 195 million and entered into a deferred prosecution agreement. The Sandoz resolution related to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&amp;#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. is also in negotiations with the DOJ Civil Division to resolve potential related claims and has recorded a provision of USD 186 million. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Southern District of New York (S.D.N.Y.) marketing practices investigation and litigation&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2013, the US government filed a civil complaint in intervention to an individual &lt;i&gt;qui tam &lt;/i&gt;action against Novartis Pharmaceuticals Corporation (NPC) in the United States District Court (USDC) for the S.D.N.Y. The complaint, as subsequently amended, asserted federal False Claims Act (FCA) and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications ( &lt;i&gt;Lotrel&lt;/i&gt;,&amp;nbsp; &lt;i&gt;Starlix&lt;/i&gt;&amp;nbsp;and&amp;nbsp; &lt;i&gt;Valturna&lt;/i&gt;) allegedly serving as mechanisms to provide kickbacks to healthcare professionals (HCPs). Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. In July 2020, Novartis finalized its settlement agreement with the S.D.N.Y, the New York State Attorney General and the individual relator to resolve their claims. As part of this settlement, Novartis will pay USD 0.7 billion, and has agreed to new corporate integrity obligations with the Office of Inspector General of the US Department of Health &amp;amp; Human Services. As of June 30, a provision in the amount of USD 0.7 billion remained accrued in the Innovative Medicines Division for this matter. As of July 20, 2020, USD 0.6 billion have been paid out of this provision. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;U.S. Government Foreign Corrupt Practices Act (FCPA) investigations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In June 2020, Novartis reached settlements with the DOJ and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by Novartis and its subsidiaries. These investigations were previously disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the headings &amp;#x201c;Greece investigation,&amp;#x201d; &amp;#x201c;South Korea investigation&amp;#x201d; and &amp;#x201c;Asia/Russia investigation.&amp;#x201d; As part of the coordinated resolution of these investigations, Novartis and certain of its current and former subsidiaries agreed to pay USD 0.3 billion. As of June 30, 2020, a provision in the amount of USD 0.1 billion remained accrued. As of July 20, 2020, USD 0.1 billion have been paid out of this provisions. To resolve the DOJ investigation, Novartis Hellas S.A.C.I. entered into a deferred prosecution agreement (&amp;#x201c;Novartis Hellas DPA&amp;#x201d;) pertaining to inappropriate economic benefits provided to Greek healthcare professionals from 2012 to 2015 in connection with the ophthalmology product &lt;i&gt;Lucentis&lt;/i&gt;. The Novartis Hellas DPA also covers books and records issues pertaining to the &lt;i&gt;Lucentis&lt;/i&gt; conduct and to conduct related to a 2009 epidemiological study. The resolutions contain no allegations relating to any bribery of Greek politicians, which is consistent with what Novartis found in its own internal investigation. Alcon Pte Ltd, a former Novartis subsidiary, has entered into a separate deferred prosecution agreement with the DOJ (&amp;#x201c;Alcon DPA&amp;#x201d;) pertaining to inappropriate economic benefits provided to Vietnamese healthcare professionals and books and records violations from 2011 to 2014 in Vietnam. This conduct related to a consultancy program run by a distributor in Vietnam. To resolve the SEC investigation, Novartis AG reached an agreement pertaining to internal controls and books and records violations in Greece, Vietnam and South Korea. The violations in Greece pertain to the &lt;i&gt;Lucentis&lt;/i&gt;-related conduct covered in the Novartis Hellas DPA as well as controls issues with Novartis Hellas post-approval studies identified by internal review in 2012 and resolved by 2013. In Vietnam, the violations relate to the activities involving an Alcon distributor that are the subject of the Alcon DPA. In South Korea, the violations relate to conduct for which Novartis has already taken responsibility in South Korea, where Novartis is in the final stages of resolving these issues with the local authorities. The SEC agreement also addresses certain internal controls and books and records issues related to Alcon China&amp;#x2019;s placement of surgical devices. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;In addition to the matters described above, there have been other developments in the other legal matters described in Note 20 to the Consolidated Financial Statements contained in our 2019 Annual Report and 2019 Form 20-F. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided. &lt;/div&gt;</nvs:LegalProceedingsUpdateTextBlock>
  <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;9. Segmentation of key figures &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments, Innovative Medicines and Sandoz. In addition, we separately report Corporate activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision maker which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The reporting segments are as follows:&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Novartis Oncology consists of the global business franchise Oncology, and Novartis Pharmaceuticals consists of the global business franchises Ophthalmology; Immunology, Hepatology and Dermatology; Neuroscience; Respiratory; Cardiovascular, Renal and Metabolism; and Established Medicines. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services. Corporate includes the costs of the Group headquarters and those of corporate coordination functions in major countries, and items that are not specific to one segment. Further details are provided in Note 3 to the Consolidated Financial Statements of the 2019 Annual Report. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Following the February 28, 2019, shareholders&amp;#x2019; approval of the spin-off of the Alcon business, the Group reported its financial results as &amp;#x201c;continuing operations&amp;#x201d; and &amp;#x201c;discontinued operations&amp;#x201d; (refer to Notes 2, 3 and 10 for further details). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Continuing operations comprise the activities of Innovative Medicines and Sandoz Divisions and the continuing Corporate activities. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discontinued operations included in 2019 the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (see Notes&amp;nbsp;2, 3 and 10). &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Consolidated income statement &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;347&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 177&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;503&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;347&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 251&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 275&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;327&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 236&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;406&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;911&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;496&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;368&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;240&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;853&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;198&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;051&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 154&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 847&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 261&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 97&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 989&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;945&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;033&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;564&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;663&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;as % of net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 22.1%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 27.5%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 14.9%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 20.7%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 22.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;525&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;687&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;630&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;870&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;449&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;532&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;840&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;449&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;923&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 511&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;080&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;614&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;591&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 17&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;822&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;564&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;854&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;395&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 693&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;192&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;844&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;788&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 276&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 555&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;096&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;905&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;as % of net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 25.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 25.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 5.9%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 21.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 21.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 254&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;909&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;040&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain &lt;br&gt;&lt;/br&gt;on distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;040&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;567&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Additional consolidated balance sheet and income statement disclosure&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 81&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;225&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;161&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 123&amp;nbsp;763&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 118&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;690&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;681&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&amp;nbsp;507&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;69&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&amp;nbsp;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;537&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;537&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 66&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;664&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;191&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 80&amp;nbsp;422&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net operating assets are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;485&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 527&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 549&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;955&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&amp;nbsp;257&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&amp;nbsp;877&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&amp;nbsp;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the intangible asset impairment charges for continuing operations:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;478&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Q2 2020 and H1 2020 include an impairment of USD 485 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis. &lt;br&gt;&lt;/br&gt;H1 2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;amp;D acquired through the 2015 Spinifex Pharmaceuticals Inc. acquisition. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by region&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:6pt; color:#000000; font-weight:bold; vertical-align:super;"&gt;1&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020 &lt;br&gt;&lt;/br&gt; % of total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019 &lt;br&gt;&lt;/br&gt; % of total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;964&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 666&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;909&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 508&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 180&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;796&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;094&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;978&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 766&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;347&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;897&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by region&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:6pt; color:#000000; font-weight:bold; vertical-align:super;"&gt;1&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020 &lt;br&gt;&lt;/br&gt; % of total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019 &lt;br&gt;&lt;/br&gt; % of total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;232&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 675&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 651&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 371&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;924&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;862&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;870&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;741&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales by business franchise &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 422&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 349&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 371&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 310&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 253&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 162&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Oncology business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;606&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 944&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 858&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;144&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 886&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 427&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 444&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 461&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 238&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Voltaren/Cataflam&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Pharmaceuticals business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;640&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;720&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 967&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 902&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 637&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 795&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 380&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 545&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 594&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Oncology business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 413&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;965&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 974&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;591&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 375&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 69&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;045&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 778&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 596&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 571&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 309&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 496&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 240&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Voltaren/Cataflam&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Pharmaceuticals business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;747&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales of the top 20 Innovative Medicines Division products in 2020 &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; US&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of world&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD/cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="12%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="12%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Immunology, &lt;br&gt;&lt;/br&gt; Hepatology and &lt;br&gt;&lt;/br&gt; Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="12%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and &lt;br&gt;&lt;/br&gt; psoriatic arthritis &lt;br&gt;&lt;/br&gt; and non-radiographic &lt;br&gt;&lt;/br&gt; axial spondyloarthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 614 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 330 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 944 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 10 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 416&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 322&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, &lt;br&gt;&lt;/br&gt; Renal and &lt;br&gt;&lt;/br&gt; Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 308 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 272 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 41 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 580 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 40 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Lucentis &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Ophthalmology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related &lt;br&gt;&lt;/br&gt; macular degeneration &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 401 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 401 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune &lt;br&gt;&lt;/br&gt; thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 212 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 210 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 422 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic &lt;br&gt;&lt;/br&gt; and adjuvant melanoma; &lt;br&gt;&lt;/br&gt; advanced non-small cell &lt;br&gt;&lt;/br&gt; lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 147 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 224 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 371 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Sandostatin &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors &lt;br&gt;&lt;/br&gt; and acromegaly &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 200 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 141 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 341 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycytomia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 310 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 310 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Gleevec/Glivec &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid &lt;br&gt;&lt;/br&gt; leukemia and GIST &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 70 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;27 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 218 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 288 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe Allergic Asthma (SAA) &lt;br&gt;&lt;/br&gt; and Chronic Spontaneous &lt;br&gt;&lt;/br&gt; Urticaria (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 289 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 289 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 236&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 238&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, &lt;br&gt;&lt;/br&gt; Hepatology and &lt;br&gt;&lt;/br&gt; Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, &lt;br&gt;&lt;/br&gt; SJIA, AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 105 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 200 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Zolgensma &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Neuroscience &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy &lt;br&gt;&lt;/br&gt; (SMA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 105 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 100 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 205 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 90&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 162&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;772&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 743&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;084&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales of the top 20 Innovative Medicines Division products in 2020 &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; US&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of world&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD/cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="12%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="12%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Immunology, &lt;br&gt;&lt;/br&gt; Hepatology and &lt;br&gt;&lt;/br&gt; Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="12%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and &lt;br&gt;&lt;/br&gt; psoriatic arthritis &lt;br&gt;&lt;/br&gt; and non-radiographic &lt;br&gt;&lt;/br&gt; axial spondyloarthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;190 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 684 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;874 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 706&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, &lt;br&gt;&lt;/br&gt; Renal and &lt;br&gt;&lt;/br&gt; Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 601 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 43 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 548 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 53 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 58 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;149 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 48 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 50 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 967&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Lucentis &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Ophthalmology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related &lt;br&gt;&lt;/br&gt; macular degeneration &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 888 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 888 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune &lt;br&gt;&lt;/br&gt; thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 399 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 426 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 26 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 30 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 825 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 26 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 28 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic &lt;br&gt;&lt;/br&gt; and adjuvant melanoma; &lt;br&gt;&lt;/br&gt; advanced non-small cell &lt;br&gt;&lt;/br&gt; lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 279 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 458 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 737 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Sandostatin &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors &lt;br&gt;&lt;/br&gt; and acromegaly &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 413 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 302 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 715 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;10 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycytomia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 628 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 628 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Gleevec/Glivec &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid &lt;br&gt;&lt;/br&gt; leukemia and GIST &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 174 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 443 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 617 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe Allergic Asthma (SAA) &lt;br&gt;&lt;/br&gt; and Chronic Spontaneous &lt;br&gt;&lt;/br&gt; Urticaria (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 596 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 596 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 496&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, &lt;br&gt;&lt;/br&gt; Hepatology and &lt;br&gt;&lt;/br&gt; Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, &lt;br&gt;&lt;/br&gt; SJIA, AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 183 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 29 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 230 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 32 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 413 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 33 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Zolgensma &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Neuroscience &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy &lt;br&gt;&lt;/br&gt; (SMA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 231 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 144 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 375 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 257&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 192&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 97&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;494&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;594&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;855&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;449&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;886&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Includes a reclassification of export sales from the US into rest of the world in the amount of USD 44 million that were in Q1 2020 classified within US net sales. This reclassification has no impact on the reported Q1 2020 total &lt;i&gt;Zolgensma&lt;/i&gt; net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales by business franchise &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; cc &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;576&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;903&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Of which USD 134 million (2019: USD 186 million) represents Anti-Infectives sold under Sandoz name &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; cc &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;545&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;753&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 226&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Of which USD 356 million (2019: USD 390 million) represents Anti-Infectives sold under Sandoz name &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The product portfolio of Sandoz is widely spread in 2020 and 2019.&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Other revenue &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 209&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 209&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 182&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 251&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 275&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 350&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 225&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 69&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 511&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
  <ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;10. Discontinued operations &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Discontinued operations included in 2019 the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Note 3 for further details). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Alcon eye care devices business researched, discovered, developed, manufactured, distributed and sold a broad range of eye care products. Alcon was organized into two global business franchises, Surgical and Vision Care. Alcon also provided services, training, education and technical support for both the Surgical and Vision Care businesses. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;"&gt;Consolidated income statement &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from discontinued &lt;br&gt;&lt;/br&gt;operations &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;777 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;as % of net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 4.0%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net loss from discontinued operations before gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; As the Alcon spin-off was completed on April 9, 2019, the Q2 2019 results of operations from the Alcon business were not material. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; See Note 3 for further details on the non-taxable non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders recognized on April 8, 2019, date of Distribution. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Supplemental disclosures related to&amp;nbsp;the Alcon business distributed to&amp;nbsp;Novartis AG shareholders&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Cash flows &lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;used in investing activities from&amp;nbsp;discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business in all periods. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Divested cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other cash flows used in investing activities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net cash flows used in investing activities from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;682&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Cash flows from financing activities from&amp;nbsp;discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first half of 2020, the net cash outflows from financing activities from discontinued operations of USD 26 million (Q2 2020: USD 13 million) was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis shareholders. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During the first half of 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (Q2 2019: USD 2.7 billion) included mainly USD 3.5 billion (Q2 2019: USD 3.2 billion) from Alcon borrowings, partly offset by USD 0.2 billion (Q2 2019: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis shareholders (see Note 3). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transaction closed in 2019 &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately-held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the net present value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets, of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 3. &lt;/div&gt;</ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or&amp;nbsp;held for distribution to owners&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are classified as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
  <nvs:DistributionByWayOfDivindendInKindToShareholders contextRef="Q_D-YTD-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Distribution of Alcon Inc. &lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt; &lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;to Novartis AG shareholders&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&amp;#x2019;s business (the &amp;#x201c;Alcon business&amp;#x201d;) to be reported as discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &amp;#x201c;Other expense&amp;#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &amp;#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&amp;#x201d; in the income statement of discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&amp;#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&amp;#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in Note 1 to the Consolidated Financial Statements of the 2019 Annual Report provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional disclosures, refer to Notes 3 and 10.&lt;/div&gt;</nvs:DistributionByWayOfDivindendInKindToShareholders>
  <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;New IFRS standard effective as&amp;nbsp;of&amp;nbsp;January 1, 2020&lt;/font&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combination amendments&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired or disposed of should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the entity may choose to consider the transaction an acquisition of an asset or set of assets. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
  <nvs:DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Assets of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Liabilities of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock>
  <nvs:DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; April 8, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net assets derecognized &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derecognition of distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Difference between net assets and distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Recognition of Alcon Inc. shares obtained &lt;br&gt;&lt;/br&gt;through consolidated foundations &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;273 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation gains recycled into the &lt;br&gt;&lt;/br&gt;consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transaction costs recognized in the consolidated income statement&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; See Note 10 for additional information. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock>
  <nvs:SummaryOfTreasurySharesMovementsTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Number of outstanding shares (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Issued share capital and reserves attributable to Novartis AG shareholders (in USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 55&amp;nbsp;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 78&amp;nbsp;614&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in accounting policy &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Restated equity at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 55&amp;nbsp;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 78&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be cancelled&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 823&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 365&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees as a result of the Alcon spin-off&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes on treasury share transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase of treasury share repurchase obligation under a share buyback trading plan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividends to shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;987&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend in kind to effect the spin-off of Alcon Inc. &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net income of the period attributable to shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;043&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;565&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other comprehensive income attributable to shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;667&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transaction costs, net of taxes &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at June 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;289.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;291.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&amp;nbsp;812&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 51&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In H1 2019, the impact of change in accounting policy includes USD 3 million related to the implementation of IFRS 16 Leases. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Included in H1 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. &lt;br&gt;&lt;/br&gt;This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Fair value of the dividend in kind of Alcon Inc. shares to Novartis AG shareholders (see Notes 2 and 3 for further details). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; In H1 2019, Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Impact of hyperinflationary economies &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:SummaryOfTreasurySharesMovementsTableTextBlock>
  <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 904&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;443&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 444&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 444&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 904&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit or loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;059&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
  <nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Coupon &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Currency &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Nominal amount &lt;br&gt;&lt;/br&gt; (USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Maturity year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issuer &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issue price &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Carrying value &lt;br&gt;&lt;/br&gt; Jun 30, 2020 &lt;br&gt;&lt;/br&gt; (USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.75%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.852%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.00%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.909%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.20%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.869%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.75%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 97.712%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock>
  <nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 319&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 371&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Losses/gains on disposal and other adjustments on property, plant and equipment; intangible assets; &lt;br&gt;&lt;/br&gt;financial assets; and other non-current assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;615 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 525&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;085&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 700&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 154&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;619&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets; &lt;br&gt;&lt;/br&gt;financial assets; and other non-current assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;55 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;684 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 377&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 493&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 387&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock>
  <nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of business combinations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;030&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;486&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Receivables and payables contingent consideration, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;367&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash flows from/used for divestments of businesses, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;901&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;382&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In the second quarter of 2020 and 2019, the USD 2 million represented the net cash inflows for previous years divestments. &lt;br&gt;&lt;/br&gt;During the first half of 2020, the USD 13 million included USD 15 million net cash outflows for previous years divestments (H1 2019: USD 15 million) and a prepaid sales price of USD 2 million for a business divestment. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock>
  <nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 449&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 470&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables, marketable securities &lt;br&gt;&lt;/br&gt;and other current assets &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 109 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;928&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;144&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;569&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of business combinations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 486&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock>
  <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;347&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 177&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;503&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;347&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 251&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 275&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;327&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 236&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;406&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;911&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;496&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;368&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;240&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;853&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;198&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;051&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 154&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 847&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 261&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 97&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 989&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;945&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;033&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;564&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;663&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;as % of net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 22.1%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 27.5%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 14.9%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 20.7%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 22.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;525&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;687&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;630&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;870&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;449&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;532&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;840&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;449&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;923&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 511&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;080&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;614&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;591&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 17&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;822&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;564&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;854&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;395&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 693&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;192&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;844&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;788&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 276&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 555&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;096&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;905&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;as % of net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 25.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 25.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 5.9%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 21.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 21.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 254&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;909&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;040&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain &lt;br&gt;&lt;/br&gt;on distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;040&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;567&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
  <nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by region&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:6pt; color:#000000; font-weight:bold; vertical-align:super;"&gt;1&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020 &lt;br&gt;&lt;/br&gt; % of total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019 &lt;br&gt;&lt;/br&gt; % of total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;964&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 666&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;909&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 508&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 180&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;796&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;094&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;978&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 766&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;347&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;897&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by region&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:6pt; color:#000000; font-weight:bold; vertical-align:super;"&gt;1&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020 &lt;br&gt;&lt;/br&gt; % of total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019 &lt;br&gt;&lt;/br&gt; % of total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;232&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 675&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 651&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 371&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;924&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;862&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;870&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;741&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales by business franchise &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 422&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 349&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 371&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 310&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 253&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 162&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Oncology business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;606&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 944&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 858&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;144&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 886&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 427&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 444&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 461&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 238&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Voltaren/Cataflam&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Pharmaceuticals business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;640&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;720&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 967&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 902&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 637&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 795&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 380&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 545&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 594&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Oncology business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 413&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;965&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 974&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;591&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 375&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 69&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;045&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 778&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 596&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 571&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 309&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 496&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 240&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Voltaren/Cataflam&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Pharmaceuticals business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;747&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2InnovativeMedicinesMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales of the top 20 Innovative Medicines Division products in 2020 &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; US&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of world&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD/cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="12%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="12%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Immunology, &lt;br&gt;&lt;/br&gt; Hepatology and &lt;br&gt;&lt;/br&gt; Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="12%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and &lt;br&gt;&lt;/br&gt; psoriatic arthritis &lt;br&gt;&lt;/br&gt; and non-radiographic &lt;br&gt;&lt;/br&gt; axial spondyloarthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 614 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 330 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 944 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 10 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 416&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 322&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, &lt;br&gt;&lt;/br&gt; Renal and &lt;br&gt;&lt;/br&gt; Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 308 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 272 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 41 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 580 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 40 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Lucentis &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Ophthalmology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related &lt;br&gt;&lt;/br&gt; macular degeneration &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 401 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 401 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune &lt;br&gt;&lt;/br&gt; thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 212 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 210 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 422 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic &lt;br&gt;&lt;/br&gt; and adjuvant melanoma; &lt;br&gt;&lt;/br&gt; advanced non-small cell &lt;br&gt;&lt;/br&gt; lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 147 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 224 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 371 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Sandostatin &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors &lt;br&gt;&lt;/br&gt; and acromegaly &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 200 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 141 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 341 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycytomia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 310 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 310 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Gleevec/Glivec &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid &lt;br&gt;&lt;/br&gt; leukemia and GIST &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 70 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;27 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 218 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 288 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe Allergic Asthma (SAA) &lt;br&gt;&lt;/br&gt; and Chronic Spontaneous &lt;br&gt;&lt;/br&gt; Urticaria (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 289 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 289 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 236&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 238&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, &lt;br&gt;&lt;/br&gt; Hepatology and &lt;br&gt;&lt;/br&gt; Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, &lt;br&gt;&lt;/br&gt; SJIA, AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 105 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 200 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Zolgensma &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Neuroscience &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy &lt;br&gt;&lt;/br&gt; (SMA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 105 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 100 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 205 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 90&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 162&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;772&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 743&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;084&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales of the top 20 Innovative Medicines Division products in 2020 &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; US&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of world&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD/cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; % &lt;br&gt;&lt;/br&gt; change &lt;br&gt;&lt;/br&gt; cc &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="12%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="12%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Immunology, &lt;br&gt;&lt;/br&gt; Hepatology and &lt;br&gt;&lt;/br&gt; Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="12%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and &lt;br&gt;&lt;/br&gt; psoriatic arthritis &lt;br&gt;&lt;/br&gt; and non-radiographic &lt;br&gt;&lt;/br&gt; axial spondyloarthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;190 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 684 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;874 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 706&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, &lt;br&gt;&lt;/br&gt; Renal and &lt;br&gt;&lt;/br&gt; Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 601 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 43 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 548 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 53 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 58 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;149 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 48 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 50 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 967&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Lucentis &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Ophthalmology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related &lt;br&gt;&lt;/br&gt; macular degeneration &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 888 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 888 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune &lt;br&gt;&lt;/br&gt; thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 399 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 426 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 26 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 30 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 825 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 26 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 28 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic &lt;br&gt;&lt;/br&gt; and adjuvant melanoma; &lt;br&gt;&lt;/br&gt; advanced non-small cell &lt;br&gt;&lt;/br&gt; lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 279 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 458 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 737 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Sandostatin &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors &lt;br&gt;&lt;/br&gt; and acromegaly &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 413 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 302 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;17 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 715 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;10 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycytomia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 628 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 628 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Gleevec/Glivec &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid &lt;br&gt;&lt;/br&gt; leukemia and GIST &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 174 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 443 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 617 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe Allergic Asthma (SAA) &lt;br&gt;&lt;/br&gt; and Chronic Spontaneous &lt;br&gt;&lt;/br&gt; Urticaria (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 596 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 596 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 496&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, &lt;br&gt;&lt;/br&gt; Hepatology and &lt;br&gt;&lt;/br&gt; Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, &lt;br&gt;&lt;/br&gt; SJIA, AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 183 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 29 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 230 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 32 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 413 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 33 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Zolgensma &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Neuroscience &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy &lt;br&gt;&lt;/br&gt; (SMA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 231 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 144 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 375 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; nm &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 257&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 192&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 97&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;494&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;594&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;855&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;449&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;886&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Includes a reclassification of export sales from the US into rest of the world in the amount of USD 44 million that were in Q1 2020 classified within US net sales. This reclassification has no impact on the reported Q1 2020 total &lt;i&gt;Zolgensma&lt;/i&gt; net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; cc &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;576&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;903&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Of which USD 134 million (2019: USD 186 million) represents Anti-Infectives sold under Sandoz name &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; % change&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD m&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; cc &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;545&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;753&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 226&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Of which USD 356 million (2019: USD 390 million) represents Anti-Infectives sold under Sandoz name &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The product portfolio of Sandoz is widely spread in 2020 and 2019.&lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;Second quarter&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 209&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 209&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 182&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 251&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 275&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; &lt;b&gt;First half&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 350&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 225&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 69&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 511&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock>
  <nvs:ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from discontinued &lt;br&gt;&lt;/br&gt;operations &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;777 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;as % of net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 4.0%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net loss from discontinued operations before gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; As the Alcon spin-off was completed on April 9, 2019, the Q2 2019 results of operations from the Alcon business were not material. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; See Note 3 for further details on the non-taxable non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders recognized on April 8, 2019, date of Distribution. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock>
  <nvs:CashFlowsUsedInInvestingActivitiesTableTextBlock contextRef="Q_D-YTD-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Divested cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other cash flows used in investing activities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net cash flows used in investing activities from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;682&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashFlowsUsedInInvestingActivitiesTableTextBlock>
  <nvs:DetailedInformationAboutSignificantTransaction contextRef="Q_D-YTD-CurrentYear_dei-2019LegalEntityAxis_nvs-2020Q2AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q2SandozMember">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020. Aspen&#x2019;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace. The purchase price consist of EUR 300 million (USD 331 million) upfront payment, less customary purchase price adjustment of EUR 29 million (USD 32 million), plus potential milestone payments of up to EUR 120 million (USD 132 million), which AGI is eligible to receive upon the achievement of specified milestones. The fair value of the total purchase consideration was EUR 342 million (USD 377 million). The amount consisted of an initial cash payment of EUR 271 million (USD 299 million) and the fair value of contingent consideration of EUR 71 million (USD 78 million), which they are eligible to receive upon the achievement of specified milestones. The preliminary purchase price allocation resulted in net identifiable assets of approximately USD 308 million, consisting of USD 269 million intangible assets, USD 26 million other net assets, USD 13 million net deferred tax assets and goodwill of approximately USD 69 million. Results of operations since the date of acquisition were not material.</nvs:DetailedInformationAboutSignificantTransaction>
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;11. Events subsequent to the June 30, 2020, consolidated balance sheet date&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In July 2020, Novartis paid USD 0.7 billion out of certain legal provisions. For additional information see Note 8. &lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <ifrs-full:DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements contextRef="Q_D-YTD-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&amp;#x2019;s principal accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2019 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The preparation of &amp;#xfb01;nancial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of assets and liabilities, including any contingent amounts, the distribution liability recognized in connection with the distribution of Alcon Inc. to Novartis AG shareholders, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As disclosed in the 2019 Annual Report, goodwill, and acquired In-Process Research &amp;amp; Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Group&amp;#x2019;s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Group&amp;#x2019;s results of operations and financial condition. &lt;/div&gt;</ifrs-full:DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements>
  <nvs:DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock contextRef="Q_D-YTD-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Jun 30, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Dec 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 81&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;225&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;161&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 123&amp;nbsp;763&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 118&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;690&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;681&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&amp;nbsp;507&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;69&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&amp;nbsp;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;537&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;537&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 66&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;664&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;191&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 80&amp;nbsp;422&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net operating assets are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;485&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;943&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 527&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 549&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;955&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&amp;nbsp;257&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&amp;nbsp;877&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&amp;nbsp;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the intangible asset impairment charges for continuing operations:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Q2 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Q2 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; H1 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; H1 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;478&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Q2 2020 and H1 2020 include an impairment of USD 485 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis. &lt;br&gt;&lt;/br&gt;H1 2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;amp;D acquired through the 2015 Spinifex Pharmaceuticals Inc. acquisition. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock>
  <nvs:DetailedInformationAboutSignificantTransaction contextRef="Q_D-YTD-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q2AlconMember">On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.). The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets. The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April 9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &#x201C;ALC.&#x201D; The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019. On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates. At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&#x2019;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets. Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&#x2019;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income. The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of: For additional disclosure on discontinued operations, refer to Note 10.</nvs:DetailedInformationAboutSignificantTransaction>
  <nvs:DetailedInformationAboutSignificantTransaction contextRef="Q_D-YTD-CurrentYear-1_dei-2019LegalEntityAxis_nvs-2020Q2IFMTreInc.Member">On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&#x2019;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gutdirected molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule. The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangibles, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material.</nvs:DetailedInformationAboutSignificantTransaction>
  <nvs:DetailedInformationAboutSignificantTransaction contextRef="Q_D-YTD-CurrentYear-1_dei-2019LegalEntityAxis_nvs-2020Q2TakedaPharmaceuticalCompanyLimitedMember">On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with Xiidra (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. The fair value of the total purchase consideration is USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimates that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material.</nvs:DetailedInformationAboutSignificantTransaction>
  <nvs:DetailedInformationAboutSignificantTransaction contextRef="Q_D-YTD-CurrentYear-1_dei-2019LegalEntityAxis_nvs-2020Q2PowerVisionInc.Member">In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately-held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the net present value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets, of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition are not material. For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 3.</nvs:DetailedInformationAboutSignificantTransaction>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="fn_FN-OCI-2-85f5bc0f060c4ccbb89b159213b34a6c" xml:lang="en">In H1 2019, cumulative currency translation gains of USD 123 million were recycled into the consolidated income statement as a result of the Alcon spin-off (see Notes 2, 3 and 10).</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="fn_FN-OCI-3-a36c16a44d51405f90ffba81b2e33964" xml:lang="en">Included in H1 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss pension plans that were previously recognized through other comprehensive income. This revaluation resulted from the Swiss canton Basel-Stadt tax reform, enacted in February 2019.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="fn_FN-EQ-1-85f5bc0f060c4ccbb89b159213b34a4a" xml:lang="en">Included in Q2 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="fn_FN-EQ-2-85f5bc0f060c4ccbb89b159213b34a3b" xml:lang="en">Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" xml:lang="en">Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</link:footnote>
    <link:loc xlink:type="locator" xlink:href="#fact_143760" xlink:label="fact_143760" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143760" xlink:to="fn_FN-OCI-2-85f5bc0f060c4ccbb89b159213b34a6c" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_143764" xlink:label="fact_143764" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143764" xlink:to="fn_FN-OCI-3-a36c16a44d51405f90ffba81b2e33964" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_143785" xlink:label="fact_143785" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143785" xlink:to="fn_FN-OCI-2-85f5bc0f060c4ccbb89b159213b34a6c" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_143843" xlink:label="fact_143843" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143843" xlink:to="fn_FN-EQ-1-85f5bc0f060c4ccbb89b159213b34a4a" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_143844" xlink:label="fact_143844" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143844" xlink:to="fn_FN-EQ-1-85f5bc0f060c4ccbb89b159213b34a4a" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_143845" xlink:label="fact_143845" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143845" xlink:to="fn_FN-EQ-1-85f5bc0f060c4ccbb89b159213b34a4a" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_143849" xlink:label="fact_143849" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143849" xlink:to="fn_FN-EQ-2-85f5bc0f060c4ccbb89b159213b34a3b" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_143850" xlink:label="fact_143850" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143850" xlink:to="fn_FN-EQ-2-85f5bc0f060c4ccbb89b159213b34a3b" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_143851" xlink:label="fact_143851" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_143851" xlink:to="fn_FN-EQ-2-85f5bc0f060c4ccbb89b159213b34a3b" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144153" xlink:label="fact_144153" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144153" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144154" xlink:label="fact_144154" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144154" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144155" xlink:label="fact_144155" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144155" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144156" xlink:label="fact_144156" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144156" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144157" xlink:label="fact_144157" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144157" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144160" xlink:label="fact_144160" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144160" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144161" xlink:label="fact_144161" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144161" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144162" xlink:label="fact_144162" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144162" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144163" xlink:label="fact_144163" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144163" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144164" xlink:label="fact_144164" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144164" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144202" xlink:label="fact_144202" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144202" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144203" xlink:label="fact_144203" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144203" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144204" xlink:label="fact_144204" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144204" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144205" xlink:label="fact_144205" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144205" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144206" xlink:label="fact_144206" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144206" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144209" xlink:label="fact_144209" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144209" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144210" xlink:label="fact_144210" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144210" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144211" xlink:label="fact_144211" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144211" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144212" xlink:label="fact_144212" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144212" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
    <link:loc xlink:type="locator" xlink:href="#fact_144213" xlink:label="fact_144213" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="fact_144213" xlink:to="fn_IS-QoQ-FN-1-bc423247be1d480cb36de4c7a25d23b2" order="1" />
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>nvs-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
   <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
      <link:label id="id_33621d8b" xlink:label="lbl_CHF_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CHF" xlink:to="lbl_CHF_labels" xlink:type="arc"/>
      <link:label id="id_2109f0bd" xlink:label="lbl_label554299581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="lbl_CH" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CH" xlink:to="lbl_label554299581" xlink:type="arc"/>
      <link:label id="id_30237143" xlink:label="lbl_label807629123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentType" xlink:to="lbl_label807629123" xlink:type="arc"/>
      <link:label id="id_bb438c4" xlink:label="lbl_NoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_NoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_7fdd0dd5" xlink:label="lbl_NoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
      <link:label id="id_18b26df5" xlink:label="lbl_CurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssets" xlink:to="lbl_CurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_2d4bde06" xlink:label="lbl_CurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
      <link:label id="id_e8d83cc" xlink:label="lbl_Assets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Assets" xlink:to="lbl_Assets_labels" xlink:type="arc"/>
      <link:label id="id_1c011115" xlink:label="lbl_Assets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
      <link:label id="id_17d32c44" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasuryShares" xlink:to="lbl_TreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_210754dc" xlink:label="lbl_EquityAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_EquityAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_5c95b1b" xlink:label="lbl_EquityAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Issued share capital and reserves attributable to Novartis AG shareholders</link:label>
      <link:label id="id_6ada4c7f" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Equity" xlink:to="lbl_Equity_labels" xlink:type="arc"/>
      <link:label id="id_217508c4" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
      <link:label id="id_202888aa" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentProvisions" xlink:label="lbl_NoncurrentProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentProvisions" xlink:to="lbl_NoncurrentProvisions_labels" xlink:type="arc"/>
      <link:label id="id_30c761c7" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current provisions</link:label>
      <link:label id="id_70a3cca2" xlink:label="lbl_NoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_NoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_46c178af" xlink:label="lbl_NoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
      <link:label id="id_37698457" xlink:label="lbl_CurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_CurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_422c0184" xlink:label="lbl_CurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
      <link:label id="id_6a28968d" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Liabilities" xlink:to="lbl_Liabilities_labels" xlink:type="arc"/>
      <link:label id="id_35c7371a" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_6baaabed" xlink:label="lbl_EquityAndLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_EquityAndLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_3794ff9e" xlink:label="lbl_EquityAndLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
      <link:label id="id_5ecd50fe" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipment" xlink:to="lbl_PropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_5f7f6e84" xlink:label="lbl_label1602186884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Goodwill" xlink:to="lbl_label1602186884" xlink:type="arc"/>
      <link:label id="id_78569540" xlink:label="lbl_label2018940224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsOtherThanGoodwill" xlink:to="lbl_label2018940224" xlink:type="arc"/>
      <link:label id="id_600994ad" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssets" xlink:to="lbl_DeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_76aa2451" xlink:label="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentNonfinancialAssets" xlink:to="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_2dffac3d" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Inventories" xlink:to="lbl_Inventories_labels" xlink:type="arc"/>
      <link:label id="id_3b71d990" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_OtherCurrentFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_47798f64" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_CashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_c46389d" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapital" xlink:to="lbl_IssuedCapital_labels" xlink:type="arc"/>
      <link:label id="id_7fe108cb" xlink:label="lbl_OtherReserves_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherReserves" xlink:to="lbl_OtherReserves_labels" xlink:type="arc"/>
      <link:label id="id_62ed78ce" xlink:label="lbl_label1659730126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterests" xlink:to="lbl_label1659730126" xlink:type="arc"/>
      <link:label id="id_40cd0a97" xlink:label="lbl_label1087179415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other non-current payables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentPayables" xlink:label="lbl_NoncurrentPayables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentPayables" xlink:to="lbl_label1087179415" xlink:type="arc"/>
      <link:label id="id_314a7125" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilities" xlink:to="lbl_DeferredTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_15149ace" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentFinancialLiabilities" xlink:to="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_48a2d168" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_65fe4156" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_OtherCurrentFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4f6a78d8" xlink:label="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxLiabilitiesCurrent" xlink:to="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:type="arc"/>
      <link:label id="id_63598632" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_654cedce" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_288deb92" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
      <link:label id="id_b623bea" xlink:label="lbl_OtherReserves_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves</link:label>
      <link:label id="id_3c0375d2" xlink:label="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:label id="id_5eaf97e4" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_48a98684" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts</link:label>
      <link:label id="id_126c9e67" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative financial instruments</link:label>
      <link:label id="id_4f2ac258" xlink:label="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax liabilities</link:label>
      <link:label id="id_1abd43d3" xlink:label="lbl_label448611283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DocumentAndEntityInformationAbstract" xlink:label="lbl_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAndEntityInformationAbstract" xlink:to="lbl_label448611283" xlink:type="arc"/>
      <link:label id="id_3da2017e" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments accounted for using equity method</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentAccountedForUsingEquityMethod" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_6c3d0a" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in associated companies</link:label>
      <link:label id="id_551c0fc4" xlink:label="lbl_label1427902404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_label1427902404" xlink:type="arc"/>
      <link:label id="id_42437f89" xlink:label="lbl_label1111719817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_label1111719817" xlink:type="arc"/>
      <link:label id="id_6e6b7ee6" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:label id="id_47a37331" xlink:label="lbl_label1201894193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_label1201894193" xlink:type="arc"/>
      <link:label id="id_131d39b3" xlink:label="lbl_label320682419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAbstract" xlink:to="lbl_label320682419" xlink:type="arc"/>
      <link:label id="id_7f542d" xlink:label="lbl_label8344621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_label8344621" xlink:type="arc"/>
      <link:label id="id_622df1d" xlink:label="lbl_label102948637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_label102948637" xlink:type="arc"/>
      <link:label id="id_7ba5a5ef" xlink:label="lbl_label2074453487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_label2074453487" xlink:type="arc"/>
      <link:label id="id_88ddaa5" xlink:label="lbl_label143514277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_label143514277" xlink:type="arc"/>
      <link:label id="id_47732be6" xlink:label="lbl_label1198730214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_label1198730214" xlink:type="arc"/>
      <link:label id="id_47bd73ec" xlink:label="lbl_label1203598316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_label1203598316" xlink:type="arc"/>
      <link:label id="id_bca487e" xlink:label="lbl_PropertyPlantAndEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_PropertyPlantAndEquipmentMember_labels" xlink:type="arc"/>
      <link:label id="id_567bb83c" xlink:label="lbl_LandMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LandMember" xlink:to="lbl_LandMember_labels" xlink:type="arc"/>
      <link:label id="id_16f548da" xlink:label="lbl_LandMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
      <link:label id="id_a7eb90b" xlink:label="lbl_BuildingsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BuildingsMember" xlink:to="lbl_BuildingsMember_labels" xlink:type="arc"/>
      <link:label id="id_4d69998b" xlink:label="lbl_BuildingsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
      <link:label id="id_62ebaccc" xlink:label="lbl_ConstructionInProgressMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in progress [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConstructionInProgressMember" xlink:to="lbl_ConstructionInProgressMember_labels" xlink:type="arc"/>
      <link:label id="id_74f44044" xlink:label="lbl_ConstructionInProgressMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
      <link:label id="id_451f7511" xlink:label="lbl_MachineryMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MachineryMember" xlink:to="lbl_MachineryMember_labels" xlink:type="arc"/>
      <link:label id="id_50dda083" xlink:label="lbl_MachineryMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and other equipment</link:label>
      <link:label id="id_6f28e51b" xlink:label="lbl_label1864951067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_label1864951067" xlink:type="arc"/>
      <link:label id="id_7c438c3d" xlink:label="lbl_label2084801597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_label2084801597" xlink:type="arc"/>
      <link:label id="id_5e0af6ee" xlink:label="lbl_label1577776878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_label1577776878" xlink:type="arc"/>
      <link:label id="id_345f7738" xlink:label="lbl_GrossCarryingAmountMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossCarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember_labels" xlink:type="arc"/>
      <link:label id="id_77df9cb5" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at beginning of period</link:label>
      <link:label id="id_4145517b" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at end of period</link:label>
      <link:label id="id_1f5560c5" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers from construction in progress, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_7baa32ee" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
      <link:label id="id_3eb55d39" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_31501db" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_53833bce" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_648c3365" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:label id="id_5803c369" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_54f4afbb" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
      <link:label id="id_f07d187" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationPropertyPlantAndEquipment" xlink:to="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_57f67848" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_6a50bcb" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_4bc845d6" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:label id="id_6bc0d1d9" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_3cc1cda9" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of impairment charge</link:label>
      <link:label id="id_2b7f313a" xlink:label="lbl_label729755962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net book value of Property, plant and equipment under finance lease contracts</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:to="lbl_label729755962" xlink:type="arc"/>
      <link:label id="id_260ca259" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual commitments for acquisition of property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_34818382" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments for purchases of property, plant and equipment</link:label>
      <link:label id="id_54bcbe9d" xlink:label="lbl_BorrowingCostsCapitalised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing costs capitalised</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingCostsCapitalised" xlink:to="lbl_BorrowingCostsCapitalised_labels" xlink:type="arc"/>
      <link:label id="id_555c8c31" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalisation rate of borrowing costs eligible for capitalisation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:to="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:type="arc"/>
      <link:label id="id_4c298205" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsInterestRate" xlink:to="lbl_BorrowingsInterestRate_labels" xlink:type="arc"/>
      <link:label id="id_4611e1b4" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on borrowings for new additions</link:label>
      <link:label id="id_3caaa61e" xlink:label="lbl_BorrowingCostsCapitalised_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized borrowing costs</link:label>
      <link:label id="id_5cb7a23f" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization rate used to determine the amount of borrowing costs eligible for capitalization</link:label>
      <link:label id="id_556c754b" xlink:label="lbl_label1433171275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementTable" xlink:to="lbl_label1433171275" xlink:type="arc"/>
      <link:label id="id_17e10fbe" xlink:label="lbl_label241915143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementLineItems" xlink:to="lbl_label241915143" xlink:type="arc"/>
      <link:label id="id_556e2a5d" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_62e43be9" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_7abef04f" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:to="lbl_PropertyPlantAndEquipmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_37009913" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movements of property, plant and equipment</link:label>
      <link:label id="id_611528f2" xlink:label="lbl_label1628776690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories Disclosure [abstract]</link:label>
      <link:label id="id_7f461082" xlink:label="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="lbl_DisclosureOfInventoriesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInventoriesExplanatory" xlink:to="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6d592b5d" xlink:label="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_label1628776690" xlink:type="arc"/>
      <link:label id="id_47e475f1" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1795799b" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories by class</link:label>
      <link:label id="id_543a8d3d" xlink:label="lbl_label1413123389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_label1413123389" xlink:type="arc"/>
      <link:label id="id_781cb00d" xlink:label="lbl_label2015145997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryAxis" xlink:to="lbl_label2015145997" xlink:type="arc"/>
      <link:label id="id_b0e25e5" xlink:label="lbl_label185476581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryMember" xlink:to="lbl_label185476581" xlink:type="arc"/>
      <link:label id="id_1b583e85" xlink:label="lbl_InventoryRawMaterialsGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRawMaterialsGrossMember" xlink:to="lbl_InventoryRawMaterialsGrossMember_labels" xlink:type="arc"/>
      <link:label id="id_2bb8c828" xlink:label="lbl_InventoryRawMaterialsGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw material, consumables</link:label>
      <link:label id="id_9dcab16" xlink:label="lbl_InventoryWorkInProgressGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in progress, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryWorkInProgressGrossMember" xlink:to="lbl_InventoryWorkInProgressGrossMember_labels" xlink:type="arc"/>
      <link:label id="id_696df603" xlink:label="lbl_InventoryWorkInProgressGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
      <link:label id="id_5b4c39ad" xlink:label="lbl_label1531722157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished products</link:label>
      <link:label id="id_2f569fbd" xlink:label="lbl_label794206141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished goods, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryFinishedGoodsGrossMember" xlink:to="lbl_label794206141" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryFinishedGoodsGrossMember" xlink:to="lbl_label1531722157" xlink:type="arc"/>
      <link:label id="id_4819bb17" xlink:label="lbl_InventoryLineItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryLineItems_labels" xlink:type="arc"/>
      <link:label id="id_29f36af5" xlink:label="lbl_InventoryLineItems_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
      <link:label id="id_4b29af41" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of inventories recognised as expense during period</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:type="arc"/>
      <link:label id="id_2b41374" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of inventory recognized as expense</link:label>
      <link:label id="id_11cae639" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryWritedown2011" xlink:to="lbl_InventoryWritedown2011_labels" xlink:type="arc"/>
      <link:label id="id_1fa3a1d8" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory provisions</link:label>
      <link:label id="id_6f7b4a87" xlink:label="lbl_ReversalOfInventoryWritedown_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversed inventory Provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfInventoryWritedown" xlink:to="lbl_ReversalOfInventoryWritedown_labels" xlink:type="arc"/>
      <link:label id="id_56e8eb36" xlink:label="lbl_ReversalOfInventoryWritedown_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of inventory write-down</link:label>
      <link:label id="id_39ec1db2" xlink:label="lbl_label971775410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_label971775410" xlink:type="arc"/>
      <link:label id="id_58dc47d3" xlink:label="lbl_EarningsPerShareExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="lbl_EarningsPerShareExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareExplanatory" xlink:to="lbl_EarningsPerShareExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_20fad442" xlink:label="lbl_EarningsPerShareExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
      <link:label id="id_5ead42de" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5719e1f6" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
      <link:label id="id_531039b4" xlink:label="lbl_label1393572276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_label1393572276" xlink:type="arc"/>
      <link:label id="id_6cb953c7" xlink:label="lbl_label1824084935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_label1824084935" xlink:type="arc"/>
      <link:label id="id_1efe1d89" xlink:label="lbl_label519970185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing and discontinued operations [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_label519970185" xlink:type="arc"/>
      <link:label id="id_26f22885" xlink:label="lbl_label653404293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate continuing and discontinued operations [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_label653404293" xlink:type="arc"/>
      <link:label id="id_a503764" xlink:label="lbl_ContinuingOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing operations [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContinuingOperationsMember" xlink:to="lbl_ContinuingOperationsMember_labels" xlink:type="arc"/>
      <link:label id="id_64674183" xlink:label="lbl_DiscontinuedOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued operations [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember_labels" xlink:type="arc"/>
      <link:label id="id_7aa601bd" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit/loss attributable to shareholders of Novartis AG</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToOwnersOfParent" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_68d30e6d" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
      <link:label id="id_5a4aec87" xlink:label="lbl_WeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageShares" xlink:to="lbl_WeightedAverageShares_labels" xlink:type="arc"/>
      <link:label id="id_1d84ebe1" xlink:label="lbl_WeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding used in the basic earnings per share</link:label>
      <link:label id="id_4e4dd4b7" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on number of ordinary shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:type="arc"/>
      <link:label id="id_4486a95d" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</link:label>
      <link:label id="id_627adbc2" xlink:label="lbl_AdjustedWeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustedWeightedAverageShares" xlink:to="lbl_AdjustedWeightedAverageShares_labels" xlink:type="arc"/>
      <link:label id="id_3ec2f3b5" xlink:label="lbl_AdjustedWeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares in diluted earnings per share</link:label>
      <link:label id="id_75396e0c" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from continuing operation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_35298166" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share, Continuing operations</link:label>
      <link:label id="id_4d75874f" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_57208e0e" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share, Discontinued operations</link:label>
      <link:label id="id_3bf5aca3" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShare_labels" xlink:type="arc"/>
      <link:label id="id_51010c7c" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total basic earnings per share</link:label>
      <link:label id="id_48b2fef8" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_2cf2996b" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_4e26e1ff" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShare_labels" xlink:type="arc"/>
      <link:label id="id_28929982" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total diluted earnings per share</link:label>
      <link:label id="id_3969c29" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share, Continuing operations</link:label>
      <link:label id="id_aa58d2a" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share, Discontinued operations</link:label>
      <link:label id="id_10d604a9" xlink:label="lbl_label282461353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_label282461353" xlink:type="arc"/>
      <link:label id="id_6b10381b" xlink:label="lbl_label1796225051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="lbl_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfFinancialPositionAbstract" xlink:to="lbl_label1796225051" xlink:type="arc"/>
      <link:label id="id_40fad394" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:type="arc"/>
      <link:label id="id_43e147c6" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:label id="id_56bb2315" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_51b234f9" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
      <link:label id="id_4c34e5bc" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Movements of goodwill and intangible assets [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:to="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_49099ca4" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movements of goodwill and intangible assets</link:label>
      <link:label id="id_73128ea8" xlink:label="lbl_label1930596008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of net book values of goodwill and intangible assets by reporting segment</link:label>
      <link:label id="id_4a2c58f" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions used in the calculation of valuation [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:to="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77ac0526" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in the calculation of valuation</link:label>
      <link:label id="id_63728238" xlink:label="lbl_label1668448824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocation of net book values of goodwill and intangible assets by reporting segment [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:label="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:to="lbl_label1668448824" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:to="lbl_label1930596008" xlink:type="arc"/>
      <link:label id="id_db941d3" xlink:label="lbl_label230244819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of IncomeTax [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_label230244819" xlink:type="arc"/>
      <link:label id="id_21d3fbe0" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIncomeTaxExplanatory" xlink:to="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3e9356c7" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_78295b76" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Taxes [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeBeforeTaxesTableTextBlock" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeBeforeTaxesTableTextBlock" xlink:to="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4c349cd3" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_12bf41b8" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and deferred Income Tax Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:to="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_47b0c493" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and deferred income tax expense</link:label>
      <link:label id="id_553ce855" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of Tax Rate [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AnalysisOfTaxRateTableTextBlock" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfTaxRateTableTextBlock" xlink:to="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3410484d" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of tax rate</link:label>
      <link:label id="id_58de322f" xlink:label="lbl_label1490956847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_label1490956847" xlink:type="arc"/>
      <link:label id="id_643ddbd0" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of interest expense [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInterestExpenseExplanatory" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInterestExpenseExplanatory" xlink:to="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_54a1e622" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense and other financial income and expense</link:label>
      <link:label id="id_1f6de87d" xlink:label="lbl_InterestExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestExpenseTableTextBlock" xlink:label="lbl_InterestExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseTableTextBlock" xlink:to="lbl_InterestExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6f7654df" xlink:label="lbl_InterestExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_3d171b85" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Income and Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:to="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_94ad887" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_4a94ff2f" xlink:label="lbl_label1934317586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Deferred Tax Assets and Liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_label1934317586" xlink:type="arc"/>
      <link:label id="id_7354dcb2" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of deferred taxes [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:to="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7f591b1f" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets and liablities</link:label>
      <link:label id="id_1f4ff3aa" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_21fac415" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:label id="id_36d33958" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</link:label>
      <link:label id="id_59f2fa2f" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Differences On Which No Deferred Tax Assets Have Been Provided [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:to="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_73861c88" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax assets have been provided</link:label>
      <link:label id="id_34022912" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1ccd7026" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross value of tax-loss carry-forwards</link:label>
      <link:label id="id_3232a79c" xlink:label="lbl_label842180508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_label842180508" xlink:type="arc"/>
      <link:label id="id_4b3b4099" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3f1625ed" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant accounting policies</link:label>
      <link:label id="id_3d96e2f9" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of property, plant and equipment [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_56feb2c8" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of property, plant and equipment</link:label>
      <link:label id="id_8ac126c" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of Available-for-Use Intangible Assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4312f4e1" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of Available-for-Use Intangible Assets</link:label>
      <link:label id="id_16da82f9" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for subsidiaries [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_61c4e7e5" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scope of consolidation</link:label>
      <link:label id="id_2b17ff8e" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_57c3715e" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currencies</link:label>
      <link:label id="id_18360a81" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for business combinations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6b7df679" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of assets</link:label>
      <link:label id="id_9c406cf" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_634a44d" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property plant and equipment</link:label>
      <link:label id="id_785c05c7" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for goodwill [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_64f7217c" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_5fb6702a" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Intangible assets available-for-use [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27c2e0c0" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets available-for-use</link:label>
      <link:label id="id_980511b" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Intangible assets not yet available-for-use [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_31c63f04" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets not yet available-for-use</link:label>
      <link:label id="id_1a22e85b" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Impairment of goodwill and intangible assets [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5ecba446" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill and intangible assets</link:label>
      <link:label id="id_35764af6" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Impairment of associated companies accounted for at equity [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_547afa65" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of associated companies accounted for at equity</link:label>
      <link:label id="id_2741bbc2" xlink:label="lbl_label710888359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lbl_label710888359" xlink:type="arc"/>
      <link:label id="id_4c9d021c" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:type="arc"/>
      <link:label id="id_2dc53cba" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_4f18679b" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for trade and other receivables [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7ee3df7f" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_5def73f" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_63d0690f" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and environmental liabilities</link:label>
      <link:label id="id_7371c5cb" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for contingent liabilities and contingent assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_55214b7d" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_7e49b25a" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_23e7bf92" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans and other post retirement benefits</link:label>
      <link:label id="id_f50de43" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for treasury shares [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_21b13d04" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares</link:label>
      <link:label id="id_7b5ef0a7" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:type="arc"/>
      <link:label id="id_4f9fa5aa" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
      <link:label id="id_7912cc37" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_28239f2f" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
      <link:label id="id_20541755" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6b599b81" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
      <link:label id="id_1cb64794" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for government grants [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:type="arc"/>
      <link:label id="id_35eedb65" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants</link:label>
      <link:label id="id_11f1b42e" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for decommissioning, restoration and rehabilitation provisions [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_40e153e3" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
      <link:label id="id_2726a264" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_13936f53" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_4a557154" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for non-current assets or disposal groups classified as held for sale [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7d2f6bd5" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale or held for distribution to owners</link:label>
      <link:label id="id_27c082e4" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:type="arc"/>
      <link:label id="id_455ebc" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of adopting significant new IFRS standards</link:label>
      <link:label id="id_11c5047" xlink:label="lbl_label18632775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:label="lbl_PropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentAbstract" xlink:to="lbl_label18632775" xlink:type="arc"/>
      <link:label id="id_7e2f70e6" xlink:label="lbl_label2117038310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangeAxis" xlink:to="lbl_label2117038310" xlink:type="arc"/>
      <link:label id="id_6a60d490" xlink:label="lbl_label1784730768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesMember" xlink:to="lbl_label1784730768" xlink:type="arc"/>
      <link:label id="id_64d1e224" xlink:label="lbl_BottomOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BottomOfRangeMember" xlink:to="lbl_BottomOfRangeMember_labels" xlink:type="arc"/>
      <link:label id="id_5e09e4ca" xlink:label="lbl_TopOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TopOfRangeMember" xlink:to="lbl_TopOfRangeMember_labels" xlink:type="arc"/>
      <link:label id="id_28553079" xlink:label="lbl_ComputerEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="lbl_ComputerEquipmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComputerEquipmentMember" xlink:to="lbl_ComputerEquipmentMember_labels" xlink:type="arc"/>
      <link:label id="id_2be121a7" xlink:label="lbl_FurnitureAndVehiclesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and vehicles [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FurnitureAndVehiclesMember" xlink:label="lbl_FurnitureAndVehiclesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FurnitureAndVehiclesMember" xlink:to="lbl_FurnitureAndVehiclesMember_labels" xlink:type="arc"/>
      <link:label id="id_613b73ea" xlink:label="lbl_FurnitureAndVehiclesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and vehicles</link:label>
      <link:label id="id_593b0650" xlink:label="lbl_label1497040464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lbl_label1497040464" xlink:type="arc"/>
      <link:label id="id_42d9f411" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_3c815062" xlink:label="lbl_BrandNamesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brand names [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BrandNamesMember" xlink:label="lbl_BrandNamesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BrandNamesMember" xlink:to="lbl_BrandNamesMember_labels" xlink:type="arc"/>
      <link:label id="id_37b4dbd2" xlink:label="lbl_OtherIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsMember" xlink:to="lbl_OtherIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_7fe96854" xlink:label="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-based intangible assets [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TechnologybasedIntangibleAssetsMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_2340963a" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing related intangible assets [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketingRelatedIntangibleAssetsMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_44d0b847" xlink:label="lbl_CurrentlyMarketedProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsMember" xlink:to="lbl_CurrentlyMarketedProductsMember_labels" xlink:type="arc"/>
      <link:label id="id_796a6b5e" xlink:label="lbl_label2037017438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement location [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_label2037017438" xlink:type="arc"/>
      <link:label id="id_bc5c8b8" xlink:label="lbl_label197511352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement location [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_label197511352" xlink:type="arc"/>
      <link:label id="id_2aedaf69" xlink:label="lbl_label720220009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CostOfSalesMember" xlink:label="lbl_CostOfSalesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSalesMember" xlink:to="lbl_label720220009" xlink:type="arc"/>
      <link:label id="id_2449d337" xlink:label="lbl_label608817975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales or Research and Development [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CostOfSalesOrResearchAndDevelopmentMember" xlink:label="lbl_CostOfSalesOrResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSalesOrResearchAndDevelopmentMember" xlink:to="lbl_label608817975" xlink:type="arc"/>
      <link:label id="id_5073642b" xlink:label="lbl_label1349739563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestExpenseAbstract" xlink:label="lbl_InterestExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_label1349739563" xlink:type="arc"/>
      <link:label id="id_7fef39d4" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense due to unwinding of discount on provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:type="arc"/>
      <link:label id="id_1de5231e" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpense_labels" xlink:type="arc"/>
      <link:label id="id_f4773bc" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income/expense arising from discounting long-term liabilities</link:label>
      <link:label id="id_5a15aac0" xlink:label="lbl_label1549022431" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_7a288c00" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Interest Expense</link:label>
      <link:label id="id_55d5704a" xlink:label="lbl_label1440051274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income and expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_label1440051274" xlink:type="arc"/>
      <link:label id="id_1c654137" xlink:label="lbl_label476397879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income on forward contracts and options</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeOnForwardContractsAndOptions" xlink:to="lbl_label476397879" xlink:type="arc"/>
      <link:label id="id_545ae83" xlink:label="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on net monetary position</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnNetMonetaryPosition" xlink:to="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:type="arc"/>
      <link:label id="id_550f9fc0" xlink:label="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monetary loss from hyperinflation</link:label>
      <link:label id="id_76a4da02" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_26393d9c" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency result, net</link:label>
      <link:label id="id_32d2b6d5" xlink:label="lbl_label852670165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major components of tax expense (income) [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_label852670165" xlink:type="arc"/>
      <link:label id="id_66ab5be5" xlink:label="lbl_label1722506213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_label1722506213" xlink:type="arc"/>
      <link:label id="id_4667b9e2" xlink:label="lbl_label1181202914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_label1181202914" xlink:type="arc"/>
      <link:label id="id_3f3ab48" xlink:label="lbl_CountryOfDomicileMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of domicile [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryOfDomicileMember" xlink:to="lbl_CountryOfDomicileMember_labels" xlink:type="arc"/>
      <link:label id="id_14841da" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign countries [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ForeignCountriesMember" xlink:to="lbl_ForeignCountriesMember_labels" xlink:type="arc"/>
      <link:label id="id_56fc0dcb" xlink:label="lbl_CountryOfDomicileMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
      <link:label id="id_7d96a380" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
      <link:label id="id_58ec016" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ProfitLossBeforeTax_labels" xlink:type="arc"/>
      <link:label id="id_55d23fd3" xlink:label="lbl_AccountingProfit_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccountingProfit" xlink:to="lbl_AccountingProfit_labels" xlink:type="arc"/>
      <link:label id="id_1207c251" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before taxes from continuing operations</link:label>
      <link:label id="id_d3303df" xlink:label="lbl_AccountingProfit_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Income before taxes</link:label>
      <link:label id="id_5fb2cb43" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpenseContinuingOperations" xlink:to="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_477ea68" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:label id="id_4390e563" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpense" xlink:to="lbl_IncomeTaxExpense_labels" xlink:type="arc"/>
      <link:label id="id_c99559f" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Income Tax Expense</link:label>
      <link:label id="id_750153b3" xlink:label="lbl_label1963021235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of average effective tax rate and applicable tax rate [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:label="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:to="lbl_label1963021235" xlink:type="arc"/>
      <link:label id="id_5d2df8ac" xlink:label="lbl_ApplicableTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ApplicableTaxRate" xlink:to="lbl_ApplicableTaxRate_labels" xlink:type="arc"/>
      <link:label id="id_74bd6dfe" xlink:label="lbl_ApplicableTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
      <link:label id="id_2c804df7" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of credits and allowances</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:type="arc"/>
      <link:label id="id_1d59fda1" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax credits and allowances</link:label>
      <link:label id="id_682f727c" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of write off of deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:to="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_514b6bd9" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write off of deferred tax assets</link:label>
      <link:label id="id_6710a9a" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from write down and reversal of write down of invest subsidiaries</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:type="arc"/>
      <link:label id="id_175786ff" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write down and reversal of write down of investments in subsidiaries</link:label>
      <link:label id="id_574b8256" xlink:label="lbl_label1464566358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax benefits expiring in 2017</link:label>
      <link:label id="id_5de8eaa3" xlink:label="lbl_label1575545507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from benefits expiring</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromBenefitsExpiring" xlink:to="lbl_label1575545507" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromBenefitsExpiring" xlink:to="lbl_label1464566358" xlink:type="arc"/>
      <link:label id="id_536d84ea" xlink:label="lbl_label1131311877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of non-deductible losses in Venezuela</link:label>
      <link:label id="id_4741211a" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of adjustments for current tax of prior periods</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:type="arc"/>
      <link:label id="id_3fc4f53a" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of prior year items</link:label>
      <link:label id="id_665323a" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of other items</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_dea5852" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
      <link:label id="id_ee48bb4" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate continuing operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_37da283b" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for continuing operations</link:label>
      <link:label id="id_47841719" xlink:label="lbl_label1199839001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for discontinued operations</link:label>
      <link:label id="id_f9778dc" xlink:label="lbl_label261585116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:to="lbl_label261585116" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:to="lbl_label1199839001" xlink:type="arc"/>
      <link:label id="id_51bf64bc" xlink:label="lbl_AverageEffectiveTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRate" xlink:to="lbl_AverageEffectiveTaxRate_labels" xlink:type="arc"/>
      <link:label id="id_4e4514d0" xlink:label="lbl_AverageEffectiveTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
      <link:label id="id_65d06a2f" xlink:label="lbl_label1708157487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets and liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_label1708157487" xlink:type="arc"/>
      <link:label id="id_482aa0f2" xlink:label="lbl_label1210753266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_label1210753266" xlink:type="arc"/>
      <link:label id="id_75d207b8" xlink:label="lbl_label1976698808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_label1976698808" xlink:type="arc"/>
      <link:label id="id_1bb2f625" xlink:label="lbl_label464713253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensions and other benefit obligations of associates [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:to="lbl_label464713253" xlink:type="arc"/>
      <link:label id="id_6d0f55ad" xlink:label="lbl_InventoriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoriesMember" xlink:to="lbl_InventoriesMember_labels" xlink:type="arc"/>
      <link:label id="id_7e43c96a" xlink:label="lbl_label2118371690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax loss carryforwards [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxLossCarryforwardsMember" xlink:to="lbl_label2118371690" xlink:type="arc"/>
      <link:label id="id_112eae32" xlink:label="lbl_label288271922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets, provisions and accruals [member]</link:label>
      <link:label id="id_4d44190d" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_69dcdf60" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_65498be7" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilityAsset" xlink:to="lbl_DeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_46ad922f" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance</link:label>
      <link:label id="id_637b5bc7" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credited/(charged) to income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_50e2e919" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</link:label>
      <link:label id="id_54101181" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax relating to items credited (charged) directly to equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:type="arc"/>
      <link:label id="id_8409b0d" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charged to equity</link:label>
      <link:label id="id_5e5bb1e8" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_495f93f4" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credited/(charged) to other comprehensive income</link:label>
      <link:label id="id_22e658d6" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through business combinations, deferred tax liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_36e0af13" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_35a4b23c" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other movements deferred tax liability (asset)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6e9211d6" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_1e95490a" xlink:label="lbl_label513100042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting of deferred tax assets and liabilities within the same tax jurisdiction</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:to="lbl_label513100042" xlink:type="arc"/>
      <link:label id="id_7845a7b2" xlink:label="lbl_label2017830834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax assets have been provided [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:to="lbl_label2017830834" xlink:type="arc"/>
      <link:label id="id_76d7af65" xlink:label="lbl_label1993846629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InvestmentsInSubsidiariesMember" xlink:label="lbl_InvestmentsInSubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInSubsidiariesMember" xlink:to="lbl_label1993846629" xlink:type="arc"/>
      <link:label id="id_155fe654" xlink:label="lbl_label358606420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill from acquisitions [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GoodwillFromAcquisitionsMember" xlink:label="lbl_GoodwillFromAcquisitionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillFromAcquisitionsMember" xlink:to="lbl_label358606420" xlink:type="arc"/>
      <link:label id="id_2439e7db" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:type="arc"/>
      <link:label id="id_720fdd61" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax has been provided as they are permanent in nature</link:label>
      <link:label id="id_193f7081" xlink:label="lbl_label423587969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lbl_label423587969" xlink:type="arc"/>
      <link:label id="id_6b884d65" xlink:label="lbl_label1804094821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_label1804094821" xlink:type="arc"/>
      <link:label id="id_37fff575" xlink:label="lbl_label939521397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet treatment [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_label939521397" xlink:type="arc"/>
      <link:label id="id_53909ff0" xlink:label="lbl_label1401987056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet treatment [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_label1401987056" xlink:type="arc"/>
      <link:label id="id_439c0ffd" xlink:label="lbl_label1134301181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CapitalizedMember" xlink:to="lbl_label1134301181" xlink:type="arc"/>
      <link:label id="id_4f2ca3b1" xlink:label="lbl_label1328325553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not capitalized [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotCapitalizedMember" xlink:to="lbl_label1328325553" xlink:type="arc"/>
      <link:label id="id_2654c6dd" xlink:label="lbl_label643090141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year of expiry [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_label643090141" xlink:type="arc"/>
      <link:label id="id_4110ec53" xlink:label="lbl_label1091628115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year of expiry [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_label1091628115" xlink:type="arc"/>
      <link:label id="id_5e6070e2" xlink:label="lbl_label1583378658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One year [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OneYearMember" xlink:to="lbl_label1583378658" xlink:type="arc"/>
      <link:label id="id_4ad3dc4f" xlink:label="lbl_label1255398479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two years [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TwoYearsMember" xlink:to="lbl_label1255398479" xlink:type="arc"/>
      <link:label id="id_5915ca9f" xlink:label="lbl_label1494600351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three years [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThreeYearsMember" xlink:to="lbl_label1494600351" xlink:type="arc"/>
      <link:label id="id_7bb728cd" xlink:label="lbl_label2075601101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four years [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FourYearsMember" xlink:to="lbl_label2075601101" xlink:type="arc"/>
      <link:label id="id_742ed8cf" xlink:label="lbl_label1949227215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five years [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FiveYearsMember" xlink:to="lbl_label1949227215" xlink:type="arc"/>
      <link:label id="id_347afbb1" xlink:label="lbl_label880475057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">More than five years [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MoreThanFiveYearsMember" xlink:to="lbl_label880475057" xlink:type="arc"/>
      <link:label id="id_74c41296" xlink:label="lbl_label94266701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets</link:label>
      <link:label id="id_14f7a19b" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of tax loss carryforwards expired</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:type="arc"/>
      <link:label id="id_6a5eff98" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax loss carryforwards expired</link:label>
      <link:label id="id_70fd1364" xlink:label="lbl_label1895633764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset expected to have an impact on current taxes payable after more than 12 months</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:to="lbl_label1895633764" xlink:type="arc"/>
      <link:label id="id_522d9018" xlink:label="lbl_label1378717720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities expected to have an impact on current taxes payable after more than 12 months</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:to="lbl_label1378717720" xlink:type="arc"/>
      <link:label id="id_2f7867e" xlink:label="lbl_label49776254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unremitted earnings retained by consolidated entities for reinvestment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:to="lbl_label49776254" xlink:type="arc"/>
      <link:label id="id_5d6e151" xlink:label="lbl_label97968465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for income taxes on unremitted earnings</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:label="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:to="lbl_label97968465" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets1" xlink:type="locator"/>
      <link:label id="id_7db0af99" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net capital losses on available-for-sale securities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnAvailableforsaleFinancialAssets1" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_27062936" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on available-for-sale financial assets</link:label>
      <link:label id="id_71a78a3a" xlink:label="lbl_label1906805306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial and other non-current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_label1906805306" xlink:type="arc"/>
      <link:label id="id_52927dd" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial and other non-current assets [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:to="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4f2bb8aa" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other non-current assets</link:label>
      <link:label id="id_67e73888" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfFinancialAssetsTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:to="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_634e228d" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:label id="id_57b4381e" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:to="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6832ec2" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:label id="id_1f868b2b" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of minimum finance lease payments [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2e528ce3" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum finance lease payments</link:label>
      <link:label id="id_6a1e58d8" xlink:label="lbl_label1780373720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_label1780373720" xlink:type="arc"/>
      <link:label id="id_574b2687" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other current assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2fe53b2a" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_2f9ef8c8" xlink:label="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherCurrentAssetsTableTextBlock" xlink:label="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsTableTextBlock" xlink:to="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6c3d724c" xlink:label="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_229f76b0" xlink:label="lbl_CurrentValueAddedTaxReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value added tax receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentValueAddedTaxReceivables" xlink:to="lbl_CurrentValueAddedTaxReceivables_labels" xlink:type="arc"/>
      <link:label id="id_5dea7085" xlink:label="lbl_CurrentValueAddedTaxReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT Receivable</link:label>
      <link:label id="id_68e173a" xlink:label="lbl_label1024297901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Withholding tax recoverable</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WithholdingTaxRecoverable" xlink:to="lbl_label1024297901" xlink:type="arc"/>
      <link:label id="id_7437ef3d" xlink:label="lbl_label905656156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - third party</link:label>
      <link:label id="id_6210dea9" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses associated companies</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_2201baf2" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - associated companies</link:label>
      <link:label id="id_61baeb33" xlink:label="lbl_label1639639859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables associated companies</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReceivablesAssociatedCompanies" xlink:to="lbl_label1639639859" xlink:type="arc"/>
      <link:label id="id_3ac7e1da" xlink:label="lbl_label986178010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables and current assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherReceivablesAndCurrentAssets" xlink:to="lbl_label986178010" xlink:type="arc"/>
      <link:label id="id_4072377e" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_OtherCurrentNonfinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_e3db8e7" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial assets</link:label>
      <link:label id="id_d18502c" xlink:label="lbl_label219697196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_label219697196" xlink:type="arc"/>
      <link:label id="id_69021d0e" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:to="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4984da50" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash</link:label>
      <link:label id="id_24a0b3b8" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, timedeposits, and derivative financial instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_443173b3" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, timedeposits, and derivative financial instruments</link:label>
      <link:label id="id_34fe6088" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashAndCashEquivalentsTableTextBlock" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsTableTextBlock" xlink:to="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1b8f74ee" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_808126e" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instruments held</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtInstrumentsHeld" xlink:to="lbl_DebtInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_6e00ca4f" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
      <link:label id="id_22a6b8a5" xlink:label="lbl_EquityInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity instruments held</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityInstrumentsHeld" xlink:to="lbl_EquityInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_724851f6" xlink:label="lbl_EquityInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_419c6f6a" xlink:label="lbl_FundInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fund instruments held</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FundInstrumentsHeld" xlink:to="lbl_FundInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_53712316" xlink:label="lbl_FundInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fund investments</link:label>
      <link:label id="id_17079bd" xlink:label="lbl_label1789088932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commodities</link:label>
      <link:label id="id_6c508a7b" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term deposits, not classified as cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_24ec6e77" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits with original maturity more than 90 days</link:label>
      <link:label id="id_ef5ab87" xlink:label="lbl_DerivativeFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialAssets" xlink:to="lbl_DerivativeFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_4954716a" xlink:label="lbl_DerivativeFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial assets</link:label>
      <link:label id="id_57e2aa2d" xlink:label="lbl_InterestReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestReceivable" xlink:to="lbl_InterestReceivable_labels" xlink:type="arc"/>
      <link:label id="id_6996ac87" xlink:label="lbl_InterestReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on debt securities and time deposits</link:label>
      <link:label id="id_70ff77e4" xlink:label="lbl_Cash_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current accounts</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Cash" xlink:to="lbl_Cash_labels" xlink:type="arc"/>
      <link:label id="id_502a929f" xlink:label="lbl_Cash_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
      <link:label id="id_436c5591" xlink:label="lbl_label1131173265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="lbl_CashAndCashEquivalentsAbstract1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsAbstract1" xlink:to="lbl_label1131173265" xlink:type="arc"/>
      <link:label id="id_20053f5" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents</link:label>
      <link:label id="id_47b73cba" xlink:label="lbl_CashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and short term investments with original maturity less than 90 days</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashEquivalents" xlink:to="lbl_CashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_178a6550" xlink:label="lbl_CashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
      <link:label id="id_25a7d307" xlink:label="lbl_label631755527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities denominations [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DebtSecuritiesDenominationsAbstract" xlink:label="lbl_DebtSecuritiesDenominationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesDenominationsAbstract" xlink:to="lbl_label631755527" xlink:type="arc"/>
      <link:label id="id_6e4a0bf9" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt securities held</link:label>
      <link:label id="id_3758e5ae" xlink:label="lbl_ComputerEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
      <link:label id="id_487fbdc1" xlink:label="lbl_label1216331201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in deferred tax balance [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_label1216331201" xlink:type="arc"/>
      <link:label id="id_41df7536" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at beginning of period</link:label>
      <link:label id="id_2e28206a" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at end of period</link:label>
      <link:label id="id_4c171394" xlink:label="lbl_label1276580756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_label1276580756" xlink:type="arc"/>
      <link:label id="id_767010e4" xlink:label="lbl_ContingentConsiderationReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Receivable</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivable" xlink:to="lbl_ContingentConsiderationReceivable_labels" xlink:type="arc"/>
      <link:label id="id_1c964d9b" xlink:label="lbl_ContingentConsiderationReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables</link:label>
      <link:label id="id_1cc013c7" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_47c06050" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
      <link:label id="id_2038ebb3" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
      <link:label id="id_7a406b1b" xlink:label="lbl_NoncurrentLoansAndReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current loans and receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLoansAndReceivables" xlink:to="lbl_NoncurrentLoansAndReceivables_labels" xlink:type="arc"/>
      <link:label id="id_69fe82c8" xlink:label="lbl_NoncurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current trade receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentTradeReceivables" xlink:to="lbl_NoncurrentTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_56c9fa84" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets available-for-sale</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsAvailableforsale" xlink:to="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:type="arc"/>
      <link:label id="id_7f86a75a" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale long-term financial investments</link:label>
      <link:label id="id_416abfec" xlink:label="lbl_NoncurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term receivables from customers</link:label>
      <link:label id="id_614e0e43" xlink:label="lbl_NoncurrentLoansAndReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term loans, advances and security deposits</link:label>
      <link:label id="id_2adc1935" xlink:label="lbl_label719067445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_label719067445" xlink:type="arc"/>
      <link:label id="id_372134b4" xlink:label="lbl_OtherNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_OtherNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_36e85d79" xlink:label="lbl_OtherNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other non-current assets</link:label>
      <link:label id="id_3d890a89" xlink:label="lbl_label503420728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred compensation plans assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredCompensationPlansAssets" xlink:to="lbl_label503420728" xlink:type="arc"/>
      <link:label id="id_5743c2dd" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid post-employment benefit plans assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:type="arc"/>
      <link:label id="id_509c8962" xlink:label="lbl_label1352436066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaturityAxis" xlink:to="lbl_label1352436066" xlink:type="arc"/>
      <link:label id="id_36becdba" xlink:label="lbl_label918474170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_label918474170" xlink:type="arc"/>
      <link:label id="id_19bac06a" xlink:label="lbl_NotLaterThanOneYearMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotLaterThanOneYearMember" xlink:to="lbl_NotLaterThanOneYearMember_labels" xlink:type="arc"/>
      <link:label id="id_40351209" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_26dc6723" xlink:label="lbl_LaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsMember" xlink:to="lbl_LaterThanFiveYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_678942b3" xlink:label="lbl_NotLaterThanOneYearMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not later than one year</link:label>
      <link:label id="id_65bceee2" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Between one and five years</link:label>
      <link:label id="id_2043ab6e" xlink:label="lbl_LaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than five years</link:label>
      <link:label id="id_1c8984aa" xlink:label="lbl_FinanceLeaseProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease provision</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinanceLeaseProvision" xlink:label="lbl_FinanceLeaseProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseProvision" xlink:to="lbl_FinanceLeaseProvision_labels" xlink:type="arc"/>
      <link:label id="id_4a3761d0" xlink:label="lbl_FinanceLeaseProvision_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinanceLeaseReceivables" xlink:to="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:type="arc"/>
      <link:label id="id_5712ddf0" xlink:label="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current finance lease receivables</link:label>
      <link:label id="id_3c5105da" xlink:label="lbl_IncomeStatementAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="lbl_IncomeStatementAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAbstract" xlink:to="lbl_IncomeStatementAbstract_labels" xlink:type="arc"/>
      <link:label id="id_3f03b5f7" xlink:label="lbl_IncomeStatementAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statements [abstract]</link:label>
      <link:label id="id_6acd9405" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoods_labels" xlink:type="arc"/>
      <link:label id="id_3a842f2" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
      <link:label id="id_150c2b7f" xlink:label="lbl_OtherRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRevenue" xlink:to="lbl_OtherRevenue_labels" xlink:type="arc"/>
      <link:label id="id_127d952" xlink:label="lbl_OtherRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
      <link:label id="id_2760bdf6" xlink:label="lbl_CostOfSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSales" xlink:to="lbl_CostOfSales_labels" xlink:type="arc"/>
      <link:label id="id_2b80a016" xlink:label="lbl_CostOfSales_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
      <link:label id="id_57c5a20d" xlink:label="lbl_GrossProfit_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossProfit" xlink:to="lbl_GrossProfit_labels" xlink:type="arc"/>
      <link:label id="id_526b4f9e" xlink:label="lbl_GrossProfit_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit from continuing operations</link:label>
      <link:label id="id_39d76e39" xlink:label="lbl_SalesAndMarketingExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="lbl_SalesAndMarketingExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SalesAndMarketingExpense" xlink:to="lbl_SalesAndMarketingExpense_labels" xlink:type="arc"/>
      <link:label id="id_28a0f9b9" xlink:label="lbl_SalesAndMarketingExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketing and Sales</link:label>
      <link:label id="id_10d069b8" xlink:label="lbl_ResearchAndDevelopmentExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentExpense" xlink:to="lbl_ResearchAndDevelopmentExpense_labels" xlink:type="arc"/>
      <link:label id="id_6d2fdc24" xlink:label="lbl_ResearchAndDevelopmentExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
      <link:label id="id_57c6dbd9" xlink:label="lbl_label1472650201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIncome" xlink:to="lbl_label1472650201" xlink:type="arc"/>
      <link:label id="id_5f87ab8e" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_17803288" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income from continuing operations</link:label>
      <link:label id="id_1fe0c0c6" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_487c7d01" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from associated companies</link:label>
      <link:label id="id_36251eec" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromContinuingOperations" xlink:to="lbl_ProfitLossFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_6dd27571" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_706453ab" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_1efbdca8" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromDiscontinuedOperations" xlink:to="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_1ee0d5e9" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income/loss from discontinued operations</link:label>
      <link:label id="id_390e92f5" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_62e876b4" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_6b81cf74" xlink:label="lbl_ProfitLossAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToAbstract_labels" xlink:type="arc"/>
      <link:label id="id_1f2a4c4f" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_41604097" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_68a67dec" xlink:label="lbl_label1755741676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_label1755741676" xlink:type="arc"/>
      <link:label id="id_4e036998" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_fc632c9" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_6d6e73d7" xlink:label="lbl_label1835955159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings per share [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_label1835955159" xlink:type="arc"/>
      <link:label id="id_78a7e003" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_2685ed2a" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_506c062c" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_4ec1d679" xlink:label="lbl_label1321326201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_label1321326201" xlink:type="arc"/>
      <link:label id="id_28aa5281" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in the share capital [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MovementInTheShareCapitalTableTextBlock" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInTheShareCapitalTableTextBlock" xlink:to="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_61f390ae" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to movement in the share capital</link:label>
      <link:label id="id_696322e3" xlink:label="lbl_MovementInTheShareslTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in the shares [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MovementInTheShareslTableTextBlock" xlink:label="lbl_MovementInTheShareslTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInTheShareslTableTextBlock" xlink:to="lbl_MovementInTheShareslTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3b7d854" xlink:label="lbl_MovementInTheShareslTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to movement in the shares</link:label>
      <link:label id="id_21fc0b5b" xlink:label="lbl_label570166107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_label570166107" xlink:type="arc"/>
      <link:label id="id_69f171dc" xlink:label="lbl_label1777431004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_label1777431004" xlink:type="arc"/>
      <link:label id="id_66229f4a" xlink:label="lbl_label1713545034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_label1713545034" xlink:type="arc"/>
      <link:label id="id_6258cf3f" xlink:label="lbl_ClassesOfShareCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_ClassesOfShareCapitalMember_labels" xlink:type="arc"/>
      <link:label id="id_45684f10" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInEquity" xlink:to="lbl_ChangesInEquity_labels" xlink:type="arc"/>
      <link:label id="id_29e71b73" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in the year</link:label>
      <link:label id="id_4ed5effa" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMember" xlink:to="lbl_TreasurySharesMember_labels" xlink:type="arc"/>
      <link:label id="id_17794e38" xlink:label="lbl_OrdinarySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrdinarySharesMember" xlink:to="lbl_OrdinarySharesMember_labels" xlink:type="arc"/>
      <link:label id="id_b03287e" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesIssuedAndFullyPaid" xlink:to="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:type="arc"/>
      <link:label id="id_1d73737e" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesOutstanding" xlink:to="lbl_NumberOfSharesOutstanding_labels" xlink:type="arc"/>
      <link:label id="id_4825d127" xlink:label="lbl_label1210437927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of shares outstanding</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="lbl_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="lbl_label1210437927" xlink:type="arc"/>
      <link:label id="id_4881ff43" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at beginning of period</link:label>
      <link:label id="id_40051e5a" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at end of period</link:label>
      <link:label id="id_3bcbca2a" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid at beginning of period</link:label>
      <link:label id="id_733911db" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid at end of period</link:label>
      <link:label id="id_623febca" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share capital at beginning of period</link:label>
      <link:label id="id_35d913cc" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share capital at end of period</link:label>
      <link:label id="id_288f270c" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury shares at end of period</link:label>
      <link:label id="id_140833fe" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury shares at beginning of period</link:label>
      <link:label id="id_c7e7a97" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity at end of period</link:label>
      <link:label id="id_81b3b28" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity at beginning of period</link:label>
      <link:label id="id_102df8b6" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfTreasuryShares" xlink:to="lbl_PurchaseOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_151d9a8b" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale or issue of treasury shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOrIssueOfTreasuryShares" xlink:to="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_20b3b802" xlink:label="lbl_label548648962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_label548648962" xlink:type="arc"/>
      <link:label id="id_435514ee" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_176c4f1e" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events subsequent to the December 31 consolidated balance sheet date</link:label>
      <link:label id="id_34460981" xlink:label="lbl_label877005185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Typ [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_label877005185" xlink:type="arc"/>
      <link:label id="id_72e1dec5" xlink:label="lbl_label1927405253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_label1927405253" xlink:type="arc"/>
      <link:label id="id_1da2a9c4" xlink:label="lbl_label497199556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventMember" xlink:to="lbl_label497199556" xlink:type="arc"/>
      <link:label id="id_7f877b78" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_7b380046" xlink:label="lbl_label2067267654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_label2067267654" xlink:type="arc"/>
      <link:label id="id_16b78de2" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingencies [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:to="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4488d3fd" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:label id="id_2de2541f" xlink:label="lbl_label769807391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant transactions [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_label769807391" xlink:type="arc"/>
      <link:label id="id_157aa47d" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Significant transactions [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_17fcde6d" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant transactions</link:label>
      <link:label id="id_60f273a7" xlink:label="lbl_label1626502055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_label1626502055" xlink:type="arc"/>
      <link:label id="id_7edd823a" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7e94d6aa" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt</link:label>
      <link:label id="id_594cd676" xlink:label="lbl_label1498207862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_label1498207862" xlink:type="arc"/>
      <link:label id="id_716dfcd6" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4ab48078" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments</link:label>
      <link:label id="id_3d80ff4e" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current portion of non-current borrowings by type [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5bcb7f48" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-current portion of non-current borrowings by type</link:label>
      <link:label id="id_84597e5" xlink:label="lbl_label138778597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings</link:label>
      <link:label id="id_77855829" xlink:label="lbl_label2005227561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:to="lbl_label2005227561" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:to="lbl_label138778597" xlink:type="arc"/>
      <link:label id="id_689e379d" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current financial debt including current portion by maturity [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4824ba8c" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt including current portion by maturity</link:label>
      <link:label id="id_780939b8" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current financial debt including current portion by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_43204093" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt including current portion by currency</link:label>
      <link:label id="id_75f0b654" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of comparison of balance sheet and fair value of total non-current financial debt including current portion [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:to="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_18f19ce6" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comparison of balance sheet and fair value of total non-current financial debt including current portion</link:label>
      <link:label id="id_6962ebc4" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of collaerallized non-current financial debt and pledged assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:to="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1220efab" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaerallized non-current financial debt and pledged assets</link:label>
      <link:label id="id_4abca4e3" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1f8d2d9c" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative instruments</link:label>
      <link:label id="id_8188b7e" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Leasing commitments [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:to="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77b05f18" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasing commitments</link:label>
      <link:label id="id_6662e9d6" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of research and development commitments [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:to="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3f2ee562" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development and other intangible purchase commitments</link:label>
      <link:label id="id_2a65b84f" xlink:label="lbl_label711309391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing commitments [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LeasingCommitmentsAbstract" xlink:label="lbl_LeasingCommitmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeasingCommitmentsAbstract" xlink:to="lbl_label711309391" xlink:type="arc"/>
      <link:label id="id_1173f4bb" xlink:label="lbl_label292811963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under fixed term operating leases [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_label292811963" xlink:type="arc"/>
      <link:label id="id_59b1ae19" xlink:label="lbl_label1504816665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under fixed term operating leases [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_label1504816665" xlink:type="arc"/>
      <link:label id="id_a4d7aae" xlink:label="lbl_label172849838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lbl_label172849838" xlink:type="arc"/>
      <link:label id="id_717d4be6" xlink:label="lbl_label1904036838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lbl_label1904036838" xlink:type="arc"/>
      <link:label id="id_4d7a925b" xlink:label="lbl_label1299878491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lbl_label1299878491" xlink:type="arc"/>
      <link:label id="id_3b47450e" xlink:label="lbl_label994526478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lbl_label994526478" xlink:type="arc"/>
      <link:label id="id_4b9f759a" xlink:label="lbl_label1268741530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development and other intangible asset purchase commitments [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ResearchAndDevelopmentCommitmentsAbstract" xlink:label="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:to="lbl_label1268741530" xlink:type="arc"/>
      <link:label id="id_714a8ba3" xlink:label="lbl_label1900710819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under research and development and other intangible asset purchase [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_label1900710819" xlink:type="arc"/>
      <link:label id="id_36fa2fba" xlink:label="lbl_label922365882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under research and development and other intangible asset purchase [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_label922365882" xlink:type="arc"/>
      <link:label id="id_5ab4de42" xlink:label="lbl_label632134259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments under long-term research and development agreements</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:to="lbl_label632134259" xlink:type="arc"/>
      <link:label id="id_2ceef672" xlink:label="lbl_label753858162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:to="lbl_label753858162" xlink:type="arc"/>
      <link:label id="id_68d6c1f6" xlink:label="lbl_label1758904822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label1758904822" xlink:type="arc"/>
      <link:label id="id_797bb3cc" xlink:label="lbl_label2038150092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest bearning accounts of associates payable on demand</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:to="lbl_label2038150092" xlink:type="arc"/>
      <link:label id="id_7b1552fe" xlink:label="lbl_ShorttermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermBorrowings" xlink:to="lbl_ShorttermBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_5020629f" xlink:label="lbl_ShorttermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank and other financial debt</link:label>
      <link:label id="id_13e39c07" xlink:label="lbl_CommercialPapersIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommercialPapersIssued" xlink:to="lbl_CommercialPapersIssued_labels" xlink:type="arc"/>
      <link:label id="id_4fdebda8" xlink:label="lbl_CommercialPapersIssued_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Papers</link:label>
      <link:label id="id_46dd5b19" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfLongtermBorrowings" xlink:to="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_7558c2a6" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of non-current financial debt</link:label>
      <link:label id="id_36b8e550" xlink:label="lbl_label918086992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit derivative, fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CreditDerivativeFairValue" xlink:label="lbl_CreditDerivativeFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CreditDerivativeFairValue" xlink:to="lbl_label918086992" xlink:type="arc"/>
      <link:label id="id_3a9947a0" xlink:label="lbl_DerivativeFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialLiabilities" xlink:to="lbl_DerivativeFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_6dcd1b42" xlink:label="lbl_DerivativeFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative financial instruments</link:label>
      <link:label id="id_1dcb5ef8" xlink:label="lbl_WeightedAverageInterestRateAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate, associates</link:label>
      <link:label id="id_2863fd2b" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current financial debt and derivative financial instruments</link:label>
      <link:label id="id_5aca2f89" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_74374cb6" xlink:label="lbl_label1949781174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_label1949781174" xlink:type="arc"/>
      <link:label id="id_7edb9957" xlink:label="lbl_label2128320855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:to="lbl_label2128320855" xlink:type="arc"/>
      <link:label id="id_10bc1963" xlink:label="lbl_label280762723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_label280762723" xlink:type="arc"/>
      <link:label id="id_300b69ab" xlink:label="lbl_BondsIssued_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Straight bonds</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BondsIssued" xlink:to="lbl_BondsIssued_labels" xlink:type="arc"/>
      <link:label id="id_1e4e0830" xlink:label="lbl_BondsIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
      <link:label id="id_203f2415" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total including current portion of non-current financial debt</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Borrowings" xlink:to="lbl_Borrowings_labels" xlink:type="arc"/>
      <link:label id="id_1bc6ed35" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
      <link:label id="id_2e986311" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less current portion of non-current financial debt</link:label>
      <link:label id="id_355479bd" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current financial debts</link:label>
      <link:label id="id_162b1eed" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">The amount of outstanding funds that the entity is obligated to repay</link:label>
      <link:label id="id_9d2aa80" xlink:label="lbl_label164801152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years and not later than six years [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:to="lbl_label164801152" xlink:type="arc"/>
      <link:label id="id_adae114" xlink:label="lbl_LaterThanSixYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six years [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanSixYearsMember" xlink:to="lbl_LaterThanSixYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_2050f0fd" xlink:label="lbl_LaterThanSixYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than six years</link:label>
      <link:label id="id_7e44b35f" xlink:label="lbl_label72836716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_6a9e2b6" xlink:label="lbl_label111796918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_label111796918" xlink:type="arc"/>
      <link:label id="id_57bebc13" xlink:label="lbl_label1472117779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:to="lbl_label1472117779" xlink:type="arc"/>
      <link:label id="id_6cdc708" xlink:label="lbl_label114149128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_label114149128" xlink:type="arc"/>
      <link:label id="id_1ad42498" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, pledged as security</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:type="arc"/>
      <link:label id="id_4cf075ff" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debts covered by collateral</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:type="arc"/>
      <link:label id="id_cf0451a" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total amount of collateralized non-current financial debts</link:label>
      <link:label id="id_6e3a2d82" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net book value of property, plant and equipment pledged as collateral for non-current financial debts</link:label>
      <link:label id="id_139c747e" xlink:label="lbl_label329020542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_label329020542" xlink:type="arc"/>
      <link:label id="id_75a8b438" xlink:label="lbl_label1973990456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_label1973990456" xlink:type="arc"/>
      <link:label id="id_3e0c6c47" xlink:label="lbl_label1041001543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_label1041001543" xlink:type="arc"/>
      <link:label id="id_776f09d7" xlink:label="lbl_label2003765719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_label2003765719" xlink:type="arc"/>
      <link:label id="id_227fd573" xlink:label="lbl_label578803059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_label578803059" xlink:type="arc"/>
      <link:label id="id_40a70df4" xlink:label="lbl_label1084689908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.25% EUR 1 500 million bond 2009/2016 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.757% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:to="lbl_label1084689908" xlink:type="arc"/>
      <link:label id="id_59ab4811" xlink:label="lbl_label1504397329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:to="lbl_label1504397329" xlink:type="arc"/>
      <link:label id="id_57804983" xlink:label="lbl_label1468025219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:to="lbl_label1468025219" xlink:type="arc"/>
      <link:label id="id_7920acbc" xlink:label="lbl_label2032184508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:to="lbl_label2032184508" xlink:type="arc"/>
      <link:label id="id_3ab016cd" xlink:label="lbl_label984618701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:to="lbl_label984618701" xlink:type="arc"/>
      <link:label id="id_40a1b86b" xlink:label="lbl_label1084340331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:to="lbl_label1084340331" xlink:type="arc"/>
      <link:label id="id_78372e25" xlink:label="lbl_label2016882213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:to="lbl_label2016882213" xlink:type="arc"/>
      <link:label id="id_6e2b28f3" xlink:label="lbl_label1848322291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:to="lbl_label1848322291" xlink:type="arc"/>
      <link:label id="id_7c889c9" xlink:label="lbl_label130582985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:to="lbl_label130582985" xlink:type="arc"/>
      <link:label id="id_1321f0b" xlink:label="lbl_label20061963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:to="lbl_label20061963" xlink:type="arc"/>
      <link:label id="id_66ae9900" xlink:label="lbl_label1722718464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:to="lbl_label1722718464" xlink:type="arc"/>
      <link:label id="id_45d38312" xlink:label="lbl_label1171489554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:to="lbl_label1171489554" xlink:type="arc"/>
      <link:label id="id_63c4e1e7" xlink:label="lbl_label1673847271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:to="lbl_label1673847271" xlink:type="arc"/>
      <link:label id="id_497f0505" xlink:label="lbl_label1233061125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:to="lbl_label1233061125" xlink:type="arc"/>
      <link:label id="id_5233650c" xlink:label="lbl_label1379099916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:to="lbl_label1379099916" xlink:type="arc"/>
      <link:label id="id_5f125bc1" xlink:label="lbl_label1595038657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotionalAmount" xlink:to="lbl_label1595038657" xlink:type="arc"/>
      <link:label id="id_4a9f133" xlink:label="lbl_label78246195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, original currency</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsOriginalCurrency" xlink:to="lbl_label78246195" xlink:type="arc"/>
      <link:label id="id_3d3b01c0" xlink:label="lbl_BorrowingsMaturity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, maturity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsMaturity" xlink:to="lbl_BorrowingsMaturity_labels" xlink:type="arc"/>
      <link:label id="id_6970167" xlink:label="lbl_BorrowingsLender_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, lender</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsLender" xlink:to="lbl_BorrowingsLender_labels" xlink:type="arc"/>
      <link:label id="id_2d26d7a1" xlink:label="lbl_BorrowingsPremiumDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, premium discount</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsPremiumDiscount" xlink:to="lbl_BorrowingsPremiumDiscount_labels" xlink:type="arc"/>
      <link:label id="id_43d0ad58" xlink:label="lbl_label1137749336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_label1137749336" xlink:type="arc"/>
      <link:label id="id_5168eb51" xlink:label="lbl_label1365830481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_label1365830481" xlink:type="arc"/>
      <link:label id="id_6ac35618" xlink:label="lbl_label1791186456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_label1791186456" xlink:type="arc"/>
      <link:label id="id_34e65236" xlink:label="lbl_label887509558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_label887509558" xlink:type="arc"/>
      <link:label id="id_71bada1c" xlink:label="lbl_label1908070940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_label1908070940" xlink:type="arc"/>
      <link:label id="id_7515173f" xlink:label="lbl_label1964316479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level1OfFairValueHierarchyMember" xlink:to="lbl_label1964316479" xlink:type="arc"/>
      <link:label id="id_17ccd63f" xlink:label="lbl_label399300159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level2OfFairValueHierarchyMember" xlink:to="lbl_label399300159" xlink:type="arc"/>
      <link:label id="id_93d606b" xlink:label="lbl_label155017323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level3OfFairValueHierarchyMember" xlink:to="lbl_label155017323" xlink:type="arc"/>
      <link:label id="id_7c0df05a" xlink:label="lbl_OtherNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentFinancialDebt" xlink:to="lbl_OtherNoncurrentFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_3aec21a3" xlink:label="lbl_OtherNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_661a115" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_45aae97f" xlink:label="lbl_label1168828799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value by measurement basis [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_label1168828799" xlink:type="arc"/>
      <link:label id="id_374d1399" xlink:label="lbl_label927798169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value by measurement basis [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_label927798169" xlink:type="arc"/>
      <link:label id="id_5786569c" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying reported amount fair value disclosure [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:type="arc"/>
      <link:label id="id_53a58f58" xlink:label="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value disclosure item amounts [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueDisclosureItemAmountsMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:type="arc"/>
      <link:label id="id_5d4ffc36" xlink:label="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair values</link:label>
      <link:label id="id_749b453a" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet</link:label>
      <link:label id="id_670f6333" xlink:label="lbl_label1729061683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="lbl_StatementOfComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfComprehensiveIncomeAbstract" xlink:to="lbl_label1729061683" xlink:type="arc"/>
      <link:label id="id_2d51324" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_669b15d1" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:type="arc"/>
      <link:label id="id_624c557e" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income never to be recycled into the consolidated income statement</link:label>
      <link:label id="id_543798f6" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, available-for-sale financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_6e3138d0" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities, net of taxes</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:type="arc"/>
      <link:label id="id_f9a3fe1" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges, net of taxes</link:label>
      <link:label id="id_63d7965" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, financial instruments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:type="arc"/>
      <link:label id="id_57f5d574" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total fair value adjustments on financial instruments, net of taxes</link:label>
      <link:label id="id_4fc35e7b" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:type="arc"/>
      <link:label id="id_5227f572" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_6b11bff3" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_1e6e2048" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total of items to eventually recycle</link:label>
      <link:label id="id_485691e" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:type="arc"/>
      <link:label id="id_6465e8d4" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income to be eventually recycled into the consolidated income statement</link:label>
      <link:label id="id_2f7e508d" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_7c43d9ec" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans, net of taxes</link:label>
      <link:label id="id_20ffa710" xlink:label="lbl_ComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_27277ccb" xlink:label="lbl_ComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income</link:label>
      <link:label id="id_5e2ce732" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:type="arc"/>
      <link:label id="id_5ce83165" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to</link:label>
      <link:label id="id_37725a9f" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_31bd4ac6" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders of Novartis AG</link:label>
      <link:label id="id_77aebdaf" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_30557ca" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_3783d7c" xlink:label="lbl_ContinuingOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_411d9c7f" xlink:label="lbl_DiscontinuedOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_4c054c08" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_OtherFinanceIncomeCost_labels" xlink:type="arc"/>
      <link:label id="id_f2e2db3" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other financial income and expense from continuing operations</link:label>
      <link:label id="id_53dc86a1" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_12f9d391" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_76e0ee52" xlink:label="lbl_ProfitLossAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to</link:label>
      <link:label id="id_533d4513" xlink:label="lbl_label1396524307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="lbl_StatementOfCashFlowsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfCashFlowsAbstract" xlink:to="lbl_label1396524307" xlink:type="arc"/>
      <link:label id="id_1706da9a" xlink:label="lbl_label386325146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_label386325146" xlink:type="arc"/>
      <link:label id="id_23f6c7e5" xlink:label="lbl_label603375589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_label603375589" xlink:type="arc"/>
      <link:label id="id_37845a12" xlink:label="lbl_label931420690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_label931420690" xlink:type="arc"/>
      <link:label id="id_ba7f520" xlink:label="lbl_label160680069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityMember" xlink:to="lbl_label160680069" xlink:type="arc"/>
      <link:label id="id_3004ac5a" xlink:label="lbl_label805612634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_label805612634" xlink:type="arc"/>
      <link:label id="id_4221701b" xlink:label="lbl_label1109487643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterestsMember" xlink:to="lbl_label1109487643" xlink:type="arc"/>
      <link:label id="id_6ac2ea98" xlink:label="lbl_IssuedCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapitalMember" xlink:to="lbl_IssuedCapitalMember_labels" xlink:type="arc"/>
      <link:label id="id_37852f90" xlink:label="lbl_RetainedEarningsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetainedEarningsMember" xlink:to="lbl_RetainedEarningsMember_labels" xlink:type="arc"/>
      <link:label id="id_3014527f" xlink:label="lbl_label806638207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_label806638207" xlink:type="arc"/>
      <link:label id="id_7cb9019e" xlink:label="lbl_label2092499358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncome" xlink:to="lbl_label2092499358" xlink:type="arc"/>
      <link:label id="id_14c74049" xlink:label="lbl_DividendsPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPaid" xlink:to="lbl_DividendsPaid_labels" xlink:type="arc"/>
      <link:label id="id_55c8d5fc" xlink:label="lbl_DividendsPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
      <link:label id="id_290fddfc" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:type="arc"/>
      <link:label id="id_35016d1a" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:type="arc"/>
      <link:label id="id_4817c0e9" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_4d8eb67a" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total of other equity movements</link:label>
      <link:label id="id_67a41ed4" xlink:label="lbl_label1738809044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments related to divestments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:to="lbl_label1738809044" xlink:type="arc"/>
      <link:label id="id_63274027" xlink:label="lbl_IssuedCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
      <link:label id="id_403fccbc" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:label id="id_74d7e6ee" xlink:label="lbl_RetainedEarningsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
      <link:label id="id_b4d100c" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, fair value adjustments on deferred cash flow hedges</link:label>
      <link:label id="id_780100c2" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_62d0936a" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
      <link:label id="id_7b5cb6f6" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_39ba29d5" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
      <link:label id="id_1c3cdb2b" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_66b0d29c" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid</link:label>
      <link:label id="id_72973404" xlink:label="lbl_label1922511876" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from continuing operations before working capital and provision changes</link:label>
      <link:label id="id_2f19480a" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments out of provisions and other net cash movements in non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_2fccc455" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in net current assets and other operating cash flow items</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:type="arc"/>
      <link:label id="id_7e94f37" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_364038a2" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from continuing operations</link:label>
      <link:label id="id_2c0f5fb2" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_658b02cd" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from discontinued operations</link:label>
      <link:label id="id_77c3c41b" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4017c1c6" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net cash flows from operating activities</link:label>
      <link:label id="id_668e4218" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_6c172e00" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
      <link:label id="id_79511d66" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_5310686b" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4e39a447" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:label id="id_209f49b7" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of intangible assets, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2fc66d2d" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible assets</link:label>
      <link:label id="id_eed6ef4" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial assets, classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_7b96e87e" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of financial assets</link:label>
      <link:label id="id_674ec417" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of financial assets, classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3a72549d" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of financial assets</link:label>
      <link:label id="id_4799c790" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of other long-term assets, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_5d62cc13" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of other non-current assets</link:label>
      <link:label id="id_4b05fa70" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of other long-term assets, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2f0edb6a" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of other non-current assets</link:label>
      <link:label id="id_5354701a" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2333df3a" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities and commodities</link:label>
      <link:label id="id_8f147c1" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other cash receipts from sales of equity or debt instruments of other entities, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_c3ff34a" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable securities and commodities</link:label>
      <link:label id="id_220d8b31" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_1940f2ef" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities from continuing operations</link:label>
      <link:label id="id_bda8617" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_741f077b" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in/from investing activities from discontinued operations</link:label>
      <link:label id="id_34225142" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_140f33b4" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash flows used in investing activities</link:label>
      <link:label id="id_643efdb2" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:type="arc"/>
      <link:label id="id_6226a1d0" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of treasury shares</link:label>
      <link:label id="id_4f16d177" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options and other treasury share transactions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:type="arc"/>
      <link:label id="id_1e868ebc" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2bab504d" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net cash flows used in financing activities</link:label>
      <link:label id="id_5774a6d0" xlink:label="lbl_label1467262672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lbl_label1467262672" xlink:type="arc"/>
      <link:label id="id_649add65" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_605d8076" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net change in cash and cash equivalents</link:label>
      <link:label id="id_153736f0" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:label id="id_354ffdea" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:label id="id_433b1725" xlink:label="lbl_label1127946021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows before working capital and provision changes</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:to="lbl_label1127946021" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:to="lbl_label1922511876" xlink:type="arc"/>
      <link:label id="id_7f2f5c65" xlink:label="lbl_label2133810277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:to="lbl_label2133810277" xlink:type="arc"/>
      <link:label id="id_429c1826" xlink:label="lbl_BorrowingsIssuanceDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, issuance date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsIssuanceDate" xlink:to="lbl_BorrowingsIssuanceDate_labels" xlink:type="arc"/>
      <link:label id="id_2669d99c" xlink:label="lbl_label644471196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency, others [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyOthersMember" xlink:to="lbl_label644471196" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyOthersMember" xlink:to="lbl_label72836716" xlink:type="arc"/>
      <link:label id="id_27412435" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current portion of non-current financial debt</link:label>
      <link:label id="id_45c60d00" xlink:label="lbl_label1170607360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_label1170607360" xlink:type="arc"/>
      <link:label id="id_388165d3" xlink:label="lbl_label948004307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_label948004307" xlink:type="arc"/>
      <link:label id="id_7de10318" xlink:label="lbl_label2111898392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_label2111898392" xlink:type="arc"/>
      <link:label id="id_1b1dbf0c" xlink:label="lbl_label454934284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_label454934284" xlink:type="arc"/>
      <link:label id="id_1eb1092a" xlink:label="lbl_label514918698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_label514918698" xlink:type="arc"/>
      <link:label id="id_3d371bfe" xlink:label="lbl_label1027021822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsidiariesMember" xlink:to="lbl_label1027021822" xlink:type="arc"/>
      <link:label id="id_644266d7" xlink:label="lbl_label1682073303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating income [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingIncomeMember" xlink:to="lbl_label1682073303" xlink:type="arc"/>
      <link:label id="id_41ead269" xlink:label="lbl_TranscendMedicalIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transcend Medical Inc [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TranscendMedicalIncMember" xlink:to="lbl_TranscendMedicalIncMember_labels" xlink:type="arc"/>
      <link:label id="id_7cc6732" xlink:label="lbl_TranscendMedicalIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transcend Medical Inc.</link:label>
      <link:label id="id_5c37cd24" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selexys Pharmaceuticals Corporation [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelexysPharmaceuticalsCorporationMember" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:type="arc"/>
      <link:label id="id_26bb8728" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selexys Pharmaceuticals Corporation</link:label>
      <link:label id="id_f0f7125" xlink:label="lbl_ZiarcoGroupLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedMember" xlink:to="lbl_ZiarcoGroupLimitedMember_labels" xlink:type="arc"/>
      <link:label id="id_74cc0f0d" xlink:label="lbl_ZiarcoGroupLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited</link:label>
      <link:label id="id_2cf9a6d0" xlink:label="lbl_EncoreVisionIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionIncMember" xlink:to="lbl_EncoreVisionIncMember_labels" xlink:type="arc"/>
      <link:label id="id_14700202" xlink:label="lbl_EncoreVisionIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc.</link:label>
      <link:label id="id_4323a92b" xlink:label="lbl_EliLillyAndCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EliLillyAndCompanyMember" xlink:to="lbl_EliLillyAndCompanyMember_labels" xlink:type="arc"/>
      <link:label id="id_7d1163f7" xlink:label="lbl_EliLillyAndCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company</link:label>
      <link:label id="id_406cf0bb" xlink:label="lbl_GSKOncologyProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Oncology Products [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKOncologyProductsMember" xlink:to="lbl_GSKOncologyProductsMember_labels" xlink:type="arc"/>
      <link:label id="id_4dee8051" xlink:label="lbl_GSKOncologyProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Oncology Products</link:label>
      <link:label id="id_543b3534" xlink:label="lbl_GSKVaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Vaccines [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKVaccinesMember" xlink:to="lbl_GSKVaccinesMember_labels" xlink:type="arc"/>
      <link:label id="id_50145ee" xlink:label="lbl_GSKVaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Vaccines</link:label>
      <link:label id="id_258b2077" xlink:label="lbl_GSKConsumerHealthcareMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKConsumerHealthcareMember" xlink:to="lbl_GSKConsumerHealthcareMember_labels" xlink:type="arc"/>
      <link:label id="id_5cb81481" xlink:label="lbl_GSKConsumerHealthcareMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare</link:label>
      <link:label id="id_2c752dc" xlink:label="lbl_GSKTotalTransactionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Total Transaction [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKTotalTransactionMember" xlink:to="lbl_GSKTotalTransactionMember_labels" xlink:type="arc"/>
      <link:label id="id_366ab1d6" xlink:label="lbl_GSKTotalTransactionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Total Transaction</link:label>
      <link:label id="id_2144f8b2" xlink:label="lbl_CSLMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CSLMember" xlink:to="lbl_CSLMember_labels" xlink:type="arc"/>
      <link:label id="id_5f983746" xlink:label="lbl_CSLMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CSL</link:label>
      <link:label id="id_1961772e" xlink:label="lbl_SpinifexMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexMember" xlink:to="lbl_SpinifexMember_labels" xlink:type="arc"/>
      <link:label id="id_7bf72331" xlink:label="lbl_SpinifexMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spinifex</link:label>
      <link:label id="id_72aed040" xlink:label="lbl_AdmuneTheraputicsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Admune Theraputics [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdmuneTheraputicsMember" xlink:to="lbl_AdmuneTheraputicsMember_labels" xlink:type="arc"/>
      <link:label id="id_1b618d38" xlink:label="lbl_AdmuneTheraputicsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Admune Theraputics</link:label>
      <link:label id="id_2608381e" xlink:label="lbl_label638072862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lbl_label638072862" xlink:type="arc"/>
      <link:label id="id_6adf03f3" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_29fb9219" xlink:label="lbl_label704352793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_label704352793" xlink:type="arc"/>
      <link:label id="id_7589cc7b" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:type="arc"/>
      <link:label id="id_770a51dc" xlink:label="lbl_AdditionalRecognitionGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional recognition, goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalRecognitionGoodwill" xlink:to="lbl_AdditionalRecognitionGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_159fb0c8" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:type="arc"/>
      <link:label id="id_bb4840e" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_1f8e7785" xlink:label="lbl_label529430405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:to="lbl_label529430405" xlink:type="arc"/>
      <link:label id="id_7a59b5df" xlink:label="lbl_label2052699615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:to="lbl_label2052699615" xlink:type="arc"/>
      <link:label id="id_3ce5a3b3" xlink:label="lbl_label1021682611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:to="lbl_label1021682611" xlink:type="arc"/>
      <link:label id="id_4e581a" xlink:label="lbl_label5134362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of arrangement for contingent consideration arrangements and indemnification assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:to="lbl_label5134362" xlink:type="arc"/>
      <link:label id="id_3ebaa53a" xlink:label="lbl_label1052419386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions and other current liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_label1052419386" xlink:type="arc"/>
      <link:label id="id_280373ad" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions and other current liabilities explanatory [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:to="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_58be9555" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_6f3dfdd7" xlink:label="lbl_label1866333655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of acquisition of businesses [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_label1866333655" xlink:type="arc"/>
      <link:label id="id_74ec4e33" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of business combinations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:to="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1fdc2fef" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of businesses</link:label>
      <link:label id="id_32cb811d" xlink:label="lbl_label852197661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_label852197661" xlink:type="arc"/>
      <link:label id="id_503f4b80" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of employee benefits [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_4572e29d" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of provisions and other current liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7df1458c" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_330b4ffd" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for reduction of revenue [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProvisionsForReductionOfRevenueTableTextBlock" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:to="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2487cf91" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for reduction of revenue</link:label>
      <link:label id="id_cda5e36" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestructuringProvisionsMovementsTableTextBlock" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:to="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_50653a58" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements</link:label>
      <link:label id="id_51adf498" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from acquisitions [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_55fc13ca" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from acquisitions</link:label>
      <link:label id="id_43a17f70" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4ac74a65" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table</link:label>
      <link:label id="id_7580bb7" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5d57abea" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the net liability table</link:label>
      <link:label id="id_8f2e3e1" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans and other post-employment benefit [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_26221373" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</link:label>
      <link:label id="id_7b5fd886" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of assumptions used [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_83b4487" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal weighted average actuarial assumptions</link:label>
      <link:label id="id_5a767463" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of sensitivity analysis for actuarial assumptions [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7c6a492e" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions</link:label>
      <link:label id="id_40d21ce7" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of health care cost trend rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_28fc355" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The healthcare cost trend rate assumptions used for other post-employment benefits</link:label>
      <link:label id="id_37e4cfa4" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of allocation of plan assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_a47f671" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The weighted average plan asset allocation of funded defined benefit pension plans</link:label>
      <link:label id="id_14ebebe1" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expected benefit payments [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7cfc7cde" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The expected future cash flows in respect of pension and other post- employment benefit plans</link:label>
      <link:label id="id_5cc7b4f2" xlink:label="lbl_label1556591858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lbl_label1556591858" xlink:type="arc"/>
      <link:label id="id_751ab231" xlink:label="lbl_label1964683825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lbl_label1964683825" xlink:type="arc"/>
      <link:label id="id_4f2027d2" xlink:label="lbl_label1327507410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_label1327507410" xlink:type="arc"/>
      <link:label id="id_44180645" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_7b396a57" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_2a66227f" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired research and development intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_520a49db" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired research and development</link:label>
      <link:label id="id_79560b48" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2e2e2336" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_2367c616" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5161ba57" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_62ae6b6f" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_4affdfb9" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_5c47e1cf" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_59b962bd" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:label id="id_13b05f40" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_33b144aa" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_262ed31" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net assets recognized as a result of business combinations</link:label>
      <link:label id="id_7c2d8d71" xlink:label="lbl_label2083360113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill expected to be deductible for tax purposes</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:to="lbl_label2083360113" xlink:type="arc"/>
      <link:label id="id_1e18b9d2" xlink:label="lbl_label504936914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:to="lbl_label504936914" xlink:type="arc"/>
      <link:label id="id_77fdfffd" xlink:label="lbl_label2013134845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potentially refundable consideration from acquisition</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:to="lbl_label2013134845" xlink:type="arc"/>
      <link:label id="id_240ec6" xlink:label="lbl_label2363078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of potentially refundable contingent consideration</link:label>
      <link:label id="id_5bb1899c" xlink:label="lbl_label1538361756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract right of first negotiation term</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractRightOfFirstNegotiationTerm" xlink:to="lbl_label1538361756" xlink:type="arc"/>
      <link:label id="id_3eeb75f2" xlink:label="lbl_label1055618546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueOfAcquiree" xlink:to="lbl_label1055618546" xlink:type="arc"/>
      <link:label id="id_742dd0f8" xlink:label="lbl_label1949159672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree full year</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueOfAcquireeFullYear" xlink:to="lbl_label1949159672" xlink:type="arc"/>
      <link:label id="id_37ba66ca" xlink:label="lbl_label934962890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business assets arising from contingencies amount recognized</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:to="lbl_label934962890" xlink:type="arc"/>
      <link:label id="id_53d61f56" xlink:label="lbl_label1406541654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business assets arising from contingencies amount recognized other than at fair value</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:to="lbl_label1406541654" xlink:type="arc"/>
      <link:label id="id_6acd7a2d" xlink:label="lbl_label1791851053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent consideration arrangements, range of outcomes, value, high</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lbl_label1791851053" xlink:type="arc"/>
      <link:label id="id_c33fcc1" xlink:label="lbl_label204733633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent option arrangements, range of outcomes, value, high</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:to="lbl_label204733633" xlink:type="arc"/>
      <link:label id="id_22e7f31e" xlink:label="lbl_label585626398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent option arrangements, fee paid</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:to="lbl_label585626398" xlink:type="arc"/>
      <link:label id="id_4739cf42" xlink:label="lbl_label1194970946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="lbl_label1194970946" xlink:type="arc"/>
      <link:label id="id_7e1ee3b5" xlink:label="lbl_label2115953589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests contributed</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfVotingEquityInterestsContributed" xlink:to="lbl_label2115953589" xlink:type="arc"/>
      <link:label id="id_376f146e" xlink:label="lbl_TransactionRelatedCosts_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction related costs</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionRelatedCosts" xlink:to="lbl_TransactionRelatedCosts_labels" xlink:type="arc"/>
      <link:label id="id_2d34f9e9" xlink:label="lbl_TransactionRelatedCostsPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction related costs paid</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionRelatedCostsPaid" xlink:to="lbl_TransactionRelatedCostsPaid_labels" xlink:type="arc"/>
      <link:label id="id_7a2e51fc" xlink:label="lbl_label690911032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLoss" xlink:to="lbl_label690911032" xlink:type="arc"/>
      <link:label id="id_67f3701a" xlink:label="lbl_label1744007194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLoss" xlink:to="lbl_label1744007194" xlink:type="arc"/>
      <link:label id="id_7cff95a1" xlink:label="lbl_label2097124769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_label2097124769" xlink:type="arc"/>
      <link:label id="id_772301d6" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for taxes other than income taxes, current</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:type="arc"/>
      <link:label id="id_2dc3de10" xlink:label="lbl_ShorttermRestructuringProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current restructuring provision</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermRestructuringProvision" xlink:to="lbl_ShorttermRestructuringProvision_labels" xlink:type="arc"/>
      <link:label id="id_5b202ec3" xlink:label="lbl_ShorttermRestructuringProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions</link:label>
      <link:label id="id_6d2493bb" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued royalties payable classified as current</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_198471b1" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals for royalties</link:label>
      <link:label id="id_3eae10b2" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes other than income taxes</link:label>
      <link:label id="id_4d2d81e4" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term employee benefits accruals</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermEmployeeBenefitsAccruals" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:type="arc"/>
      <link:label id="id_28ce7ee" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accurals for compensation and benefits including social security</link:label>
      <link:label id="id_72d5fdf0" xlink:label="lbl_DeferredIncomeClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income classified as current</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="lbl_DeferredIncomeClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredIncomeClassifiedAsCurrent" xlink:to="lbl_DeferredIncomeClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_315adc93" xlink:label="lbl_DeferredIncomeClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
      <link:label id="id_dfd6824" xlink:label="lbl_ShorttermLegalProceedingsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current legal proceedings provision</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermLegalProceedingsProvision" xlink:label="lbl_ShorttermLegalProceedingsProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermLegalProceedingsProvision" xlink:to="lbl_ShorttermLegalProceedingsProvision_labels" xlink:type="arc"/>
      <link:label id="id_3dc37367" xlink:label="lbl_ShorttermLegalProceedingsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for product liabilities, governmental investigations and other legal matters</link:label>
      <link:label id="id_7364ea66" xlink:label="lbl_OtherCurrentPayables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current payables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentPayables" xlink:to="lbl_OtherCurrentPayables_labels" xlink:type="arc"/>
      <link:label id="id_53bd8e15" xlink:label="lbl_OtherCurrentPayables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables</link:label>
      <link:label id="id_16646c9e" xlink:label="lbl_label375680158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_label375680158" xlink:type="arc"/>
      <link:label id="id_236d2862" xlink:label="lbl_label594356322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_label594356322" xlink:type="arc"/>
      <link:label id="id_4ebad11d" xlink:label="lbl_label1320866077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_label1320866077" xlink:type="arc"/>
      <link:label id="id_40fd93ca" xlink:label="lbl_RefundsProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds provision [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RefundsProvisionMember" xlink:label="lbl_RefundsProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RefundsProvisionMember" xlink:to="lbl_RefundsProvisionMember_labels" xlink:type="arc"/>
      <link:label id="id_134ebfe2" xlink:label="lbl_RefundsProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deductions from revenue</link:label>
      <link:label id="id_5e5b3081" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProvisions" xlink:to="lbl_OtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_21da05f2" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provision at end of period</link:label>
      <link:label id="id_3b690ec5" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provision at beginning of period</link:label>
      <link:label id="id_7d787c31" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through loss of control of subsidiary, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_ff50d0a" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to discontinued operations</link:label>
      <link:label id="id_5bf5caac" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_2a95f348" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_27eafa" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional provisions, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalProvisionsOtherProvisions" xlink:to="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_2c66d271" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_fe1b238" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision used, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionUsedOtherProvisions" xlink:to="lbl_ProvisionUsedOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_36a5293f" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/utilizations</link:label>
      <link:label id="id_359f477c" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in offset against gross trade receivables</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_18735dbe" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_16f119f6" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_482a71cf" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused provision reversed, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnusedProvisionReversedOtherProvisions" xlink:to="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_28d3a14e" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_45b7ba0b" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_26660dfe" xlink:label="lbl_RestructuringProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provision [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionMember" xlink:to="lbl_RestructuringProvisionMember_labels" xlink:type="arc"/>
      <link:label id="id_23d5363a" xlink:label="lbl_RestructuringProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provision</link:label>
      <link:label id="id_79614e6" xlink:label="lbl_label127276262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_label127276262" xlink:type="arc"/>
      <link:label id="id_51cb80cd" xlink:label="lbl_label1372291277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_label1372291277" xlink:type="arc"/>
      <link:label id="id_2ea0d5c3" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables explanatory [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:to="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6dd7d3e3" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_2c1cad42" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for trade receivables [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProvisionsForTradeReceivablesTableTextBlock" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:to="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3b131312" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for trade receivables</link:label>
      <link:label id="id_2ef5991b" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables provision movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesProvisionMovementsTableTextBlock" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:to="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77f758ca" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables provision movements</link:label>
      <link:label id="id_5d967f7b" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overdue amounts and related provisions [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:to="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b0e9f8f" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue amounts and related provision</link:label>
      <link:label id="id_22339022" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables denominated in other currencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:to="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1c976f04" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables denominated in other currencies</link:label>
      <link:label id="id_3cb8d68f" xlink:label="lbl_label1018746511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_label1018746511" xlink:type="arc"/>
      <link:label id="id_43d6f278" xlink:label="lbl_label1138160248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_label1138160248" xlink:type="arc"/>
      <link:label id="id_4c9afaa7" xlink:label="lbl_label1285225127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_label1285225127" xlink:type="arc"/>
      <link:label id="id_3182649e" xlink:label="lbl_label830629022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_label830629022" xlink:type="arc"/>
      <link:label id="id_5ff48884" xlink:label="lbl_label1609861252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_label1609861252" xlink:type="arc"/>
      <link:label id="id_75e5081d" xlink:label="lbl_label123214748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesMember" xlink:to="lbl_label123214748" xlink:type="arc"/>
      <link:label id="id_2e086500" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivables" xlink:to="lbl_CurrentTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_79f9d46a" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total trade receivables, net</link:label>
      <link:label id="id_3425f2e0" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables related to discontinued operations</link:label>
      <link:label id="id_4ce7ed6d" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables charged to the consolidated income statement</link:label>
      <link:label id="id_53792c91" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Utilization of reversal of provisions for doubtful trade receivables</link:label>
      <link:label id="id_74c340b1" xlink:label="lbl_label1958953137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of overdue amounts [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_label1958953137" xlink:type="arc"/>
      <link:label id="id_6ce050f6" xlink:label="lbl_label1826640118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past due status [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_label1826640118" xlink:type="arc"/>
      <link:label id="id_3284c13a" xlink:label="lbl_label847561018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past due status [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_label847561018" xlink:type="arc"/>
      <link:label id="id_21859e37" xlink:label="lbl_label562404919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentMember" xlink:to="lbl_label562404919" xlink:type="arc"/>
      <link:label id="id_36a38547" xlink:label="lbl_label916686151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of overdue amounts [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_label916686151" xlink:type="arc"/>
      <link:label id="id_5fbcb687" xlink:label="lbl_label1606203015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of receivables denominated in various currencies [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_label1606203015" xlink:type="arc"/>
      <link:label id="id_2efadcc4" xlink:label="lbl_label788192452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:to="lbl_label788192452" xlink:type="arc"/>
      <link:label id="id_d85c974" xlink:label="lbl_label226871668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:to="lbl_label226871668" xlink:type="arc"/>
      <link:label id="id_5358f3b4" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year, provisions recorded</link:label>
      <link:label id="id_7e49d670" xlink:label="lbl_label2118768240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_label2118768240" xlink:type="arc"/>
      <link:label id="id_5081e337" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_172e52ca" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies</link:label>
      <link:label id="id_2f049798" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:to="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_678c8520" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies</link:label>
      <link:label id="id_171309e1" xlink:label="lbl_label387123681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_label387123681" xlink:type="arc"/>
      <link:label id="id_7e6d2d55" xlink:label="lbl_label2121084245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_label2121084245" xlink:type="arc"/>
      <link:label id="id_5b223713" xlink:label="lbl_label1528968979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NameOfSubsidiary" xlink:to="lbl_label1528968979" xlink:type="arc"/>
      <link:label id="id_2bc20f05" xlink:label="lbl_label734138117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal place of business of subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:to="lbl_label734138117" xlink:type="arc"/>
      <link:label id="id_5cbe6246" xlink:label="lbl_label1555980870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of incorporation of subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="lbl_label1555980870" xlink:type="arc"/>
      <link:label id="id_77c5a25c" xlink:label="lbl_label2009440860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lbl_label2009440860" xlink:type="arc"/>
      <link:label id="id_64c53647" xlink:label="lbl_label1690646087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held in subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:to="lbl_label1690646087" xlink:type="arc"/>
      <link:label id="id_5c37870a" xlink:label="lbl_label1547142922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share/paid-in capital</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharePaidinCapital" xlink:to="lbl_label1547142922" xlink:type="arc"/>
      <link:label id="id_3c7cb5b5" xlink:label="lbl_label1014805941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Societe par actions SANDOZ, Algiers [member]</link:label>
      <link:label id="id_1fee848b" xlink:label="lbl_label535725195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Argentina S.A., Buenos Aires [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:to="lbl_label535725195" xlink:type="arc"/>
      <link:label id="id_37e7fad0" xlink:label="lbl_label937949904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios S.A., Buenos Aires [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:to="lbl_label937949904" xlink:type="arc"/>
      <link:label id="id_3ea304fe" xlink:label="lbl_label1050871038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Holding AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RocheHoldingAGBaselMember" xlink:to="lbl_label1050871038" xlink:type="arc"/>
      <link:label id="id_6ed1f5c4" xlink:label="lbl_label1859253700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_label1859253700" xlink:type="arc"/>
      <link:label id="id_258b1d67" xlink:label="lbl_label629874023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_label629874023" xlink:type="arc"/>
      <link:label id="id_d3021ba" xlink:label="lbl_label221258170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_label221258170" xlink:type="arc"/>
      <link:label id="id_7226aa6a" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rest of the world</link:label>
      <link:label id="id_494ba6f4" xlink:label="lbl_label1229694708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlansMember" xlink:to="lbl_label1229694708" xlink:type="arc"/>
      <link:label id="id_1d4af2d7" xlink:label="lbl_label491451095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic defined benefit plans [member]</link:label>
      <link:label id="id_48d21535" xlink:label="lbl_label1221727541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign defined benefit plans [member]</link:label>
      <link:label id="id_53109a65" xlink:label="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of major plans, geographic</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConcentrationOfMajorPlansGeographic" xlink:to="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:type="arc"/>
      <link:label id="id_6dd86874" xlink:label="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of the major plans and the concentration of the Group's DBO by geography.</link:label>
      <link:label id="id_55c3f642" xlink:label="lbl_label1438905922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of plan amendments, curtailments and settlements</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:to="lbl_label1438905922" xlink:type="arc"/>
      <link:label id="id_5774006e" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, recognized net gain (loss) due to curtailments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:type="arc"/>
      <link:label id="id_1a9c795a" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Pre-tax curtailment gain (loss)</link:label>
      <link:label id="id_3ccdda27" xlink:label="lbl_label1020123687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_label1020123687" xlink:type="arc"/>
      <link:label id="id_66c824b2" xlink:label="lbl_label1724392626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement plan type [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_label1724392626" xlink:type="arc"/>
      <link:label id="id_1c17a6ba" xlink:label="lbl_label471312058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement plan type [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_label471312058" xlink:type="arc"/>
      <link:label id="id_2219e14f" xlink:label="lbl_PensionPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension plan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionPlanMember" xlink:to="lbl_PensionPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_35fad562" xlink:label="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPostemploymentBenefitPlansMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:type="arc"/>
      <link:label id="id_2e4ea0d1" xlink:label="lbl_PensionPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension plans</link:label>
      <link:label id="id_67c584f7" xlink:label="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans</link:label>
      <link:label id="id_3d342709" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit obligation, at present value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitObligationAtPresentValue" xlink:to="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_22ca7a55" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation at beginning of period</link:label>
      <link:label id="id_7de6506d" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation at end of period</link:label>
      <link:label id="id_30925057" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current service cost, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_38d91a7e" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current service cost</link:label>
      <link:label id="id_2bef8750" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, interest cost</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanInterestCost" xlink:to="lbl_DefinedBenefitPlanInterestCost_labels" xlink:type="arc"/>
      <link:label id="id_6cf59b38" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
      <link:label id="id_d5fe3e9" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.</link:label>
      <link:label id="id_4281521a" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpense" xlink:to="lbl_AdministrativeExpense_labels" xlink:type="arc"/>
      <link:label id="id_603d3cd8" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_48f72a8" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement losses/(gains) arising from changes in financial assumptions</link:label>
      <link:label id="id_3f236d51" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_78d171f" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement (gains) arising from changes in demographic assumptions</link:label>
      <link:label id="id_7a970ce2" xlink:label="lbl_label783050349" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Experience-related remeasurement losses/(gains)</link:label>
      <link:label id="id_783c6ad8" xlink:label="lbl_label220841955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_45220e6b" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from plan, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_1ebcfd45" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit payments</link:label>
      <link:label id="id_6368b27" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by plan participants, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_481bb1bf" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_8f2ae87" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, benefit obligation</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:type="arc"/>
      <link:label id="id_474719e9" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_26d72366" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan assets, at fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlanAssetsAtFairValue" xlink:to="lbl_PlanAssetsAtFairValue_labels" xlink:type="arc"/>
      <link:label id="id_753e351c" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at beginning of period</link:label>
      <link:label id="id_432fa1b8" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at end of period</link:label>
      <link:label id="id_5996aa5" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense (income), defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_f38ab5e" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:label id="id_72396f28" xlink:label="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Return on plan assets excluding interest income, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_3dae186e" xlink:label="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return on plan assets excluding interest income</link:label>
      <link:label id="id_66d6f9ff" xlink:label="lbl_label1273555602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_37b55377" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by employer, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_12bfbc9" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_2adf4a42" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Settlements, Plan Assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:type="arc"/>
      <link:label id="id_6615f676" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
      <link:label id="id_4cd3f00b" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:type="arc"/>
      <link:label id="id_410b8f27" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_c41cf6c" xlink:label="lbl_label205639532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in benefit obligation [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_label205639532" xlink:type="arc"/>
      <link:label id="id_3bf9f9ba" xlink:label="lbl_label1006238138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in fair value of plan assets [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_label1006238138" xlink:type="arc"/>
      <link:label id="id_290f00a6" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surplus (deficit) in plan</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SurplusDeficitInPlan" xlink:to="lbl_SurplusDeficitInPlan_labels" xlink:type="arc"/>
      <link:label id="id_9610a9f" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
      <link:label id="id_5aa411ee" xlink:label="lbl_label1520701934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_label1520701934" xlink:type="arc"/>
      <link:label id="id_161add1b" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_37321747" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net liability in the balance sheet at end of period</link:label>
      <link:label id="id_5bdc9111" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LimitationOnRecognitionOfFundSurplus" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_76d185b5" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus at beginning of period</link:label>
      <link:label id="id_1ada4e58" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus at end of period</link:label>
      <link:label id="id_6ef6a13c" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in limitation on recognition of fund surplus</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:to="lbl_ChangeInLimitationOnRecognitionOfFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_203a6ebf" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</link:label>
      <link:label id="id_5d578703" xlink:label="lbl_label1566017283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:label id="id_1c085865" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:to="lbl_label1566017283" xlink:type="arc"/>
      <link:label id="id_155f6c71" xlink:label="lbl_label358575217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_label358575217" xlink:type="arc"/>
      <link:label id="id_25ebb8ae" xlink:label="lbl_label636205230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in net liability [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_label636205230" xlink:type="arc"/>
      <link:label id="id_54f9f34f" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Net liability at end of period</link:label>
      <link:label id="id_56e703b2" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Net liability at beginning of period</link:label>
      <link:label id="id_4c3018ba" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense (income), net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_493d88c7" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
      <link:label id="id_58444b6a" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on remeasurement, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_b032860" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurements</link:label>
      <link:label id="id_16e626ad" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6f51c69e" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_3d05f86e" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:type="arc"/>
      <link:label id="id_594017b5" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_f5fa1d1" xlink:label="lbl_label257925585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognized in the consolidated balance sheet [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_label257925585" xlink:type="arc"/>
      <link:label id="id_5b08b7db" xlink:label="lbl_label1527298011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued benefit liability</link:label>
      <link:label id="id_1ec53fdb" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit pension plan, accrued benefit liability</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:to="lbl_label1527298011" xlink:type="arc"/>
      <link:label id="id_1b1c172d" xlink:label="lbl_label454825773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_label454825773" xlink:type="arc"/>
      <link:label id="id_574cbf67" xlink:label="lbl_label1464647527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation by type [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_label1464647527" xlink:type="arc"/>
      <link:label id="id_59c768c3" xlink:label="lbl_ObligationByTypeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation by type [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ObligationByTypeMember_labels" xlink:type="arc"/>
      <link:label id="id_e411de0" xlink:label="lbl_UnfundedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unfunded [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnfundedMember" xlink:to="lbl_UnfundedMember_labels" xlink:type="arc"/>
      <link:label id="id_206ca87f" xlink:label="lbl_ObligationByTypeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation by type</link:label>
      <link:label id="id_4964c411" xlink:label="lbl_UnfundedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded</link:label>
      <link:label id="id_15c93075" xlink:label="lbl_ActiveMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Active [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActiveMember" xlink:to="lbl_ActiveMember_labels" xlink:type="arc"/>
      <link:label id="id_4cc31394" xlink:label="lbl_ActiveMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Active</link:label>
      <link:label id="id_4cfa00d5" xlink:label="lbl_DeferredPensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred pensioners [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredPensionersMember" xlink:to="lbl_DeferredPensionersMember_labels" xlink:type="arc"/>
      <link:label id="id_452ea3f3" xlink:label="lbl_DeferredPensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred pensioners</link:label>
      <link:label id="id_9ccd7d0" xlink:label="lbl_PensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensioners [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionersMember" xlink:to="lbl_PensionersMember_labels" xlink:type="arc"/>
      <link:label id="id_77f4d5bf" xlink:label="lbl_PensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pensioners</link:label>
      <link:label id="id_41aa0977" xlink:label="lbl_label1101662583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plans disclosures [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_label1101662583" xlink:type="arc"/>
      <link:label id="id_70b19e47" xlink:label="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfDiscountRates" xlink:to="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:type="arc"/>
      <link:label id="id_30e2ed44" xlink:label="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
      <link:label id="id_228400f7" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of pension increases</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:type="arc"/>
      <link:label id="id_5ba9eb34" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of pension increase</link:label>
      <link:label id="id_4f7f1dac" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:type="arc"/>
      <link:label id="id_2cc2bb1f" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of salary increase</link:label>
      <link:label id="id_1baffc03" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of interest on savings account</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:type="arc"/>
      <link:label id="id_56eba13" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on savings account</link:label>
      <link:label id="id_646262cf" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit assumption life expectancy, male</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:type="arc"/>
      <link:label id="id_32829bee" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current life expectancy for a 65-year-old male</link:label>
      <link:label id="id_d9d966" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit assumption life expectancy, female</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:type="arc"/>
      <link:label id="id_5516dd19" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current life expectancy for a 65-year-old female</link:label>
      <link:label id="id_5918de81" xlink:label="lbl_label1494802049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_label1494802049" xlink:type="arc"/>
      <link:label id="id_689d3554" xlink:label="lbl_label1755133268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_label1755133268" xlink:type="arc"/>
      <link:label id="id_3e1a9660" xlink:label="lbl_label1041929824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_label1041929824" xlink:type="arc"/>
      <link:label id="id_2737de6b" xlink:label="lbl_label657972843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_label657972843" xlink:type="arc"/>
      <link:label id="id_70f6e61c" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:type="arc"/>
      <link:label id="id_1b153ebb" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
      <link:label id="id_761309a6" xlink:label="lbl_LifeExpectancyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Life expectancy [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LifeExpectancyMember" xlink:to="lbl_LifeExpectancyMember_labels" xlink:type="arc"/>
      <link:label id="id_527cf7bb" xlink:label="lbl_LifeExpectancyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life expectancy</link:label>
      <link:label id="id_70b51d3d" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of pension increases [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:type="arc"/>
      <link:label id="id_5b5a9ebb" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of pension increase</link:label>
      <link:label id="id_47824990" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of interest on savings account [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:type="arc"/>
      <link:label id="id_32d0ccd0" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on savings account</link:label>
      <link:label id="id_742d5c34" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:type="arc"/>
      <link:label id="id_795db79c" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary increase</link:label>
      <link:label id="id_72dd0a47" xlink:label="lbl_label1927088711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in actuarial assumption [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_label1927088711" xlink:type="arc"/>
      <link:label id="id_6778fca" xlink:label="lbl_label108498890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in actuarial assumption [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_label108498890" xlink:type="arc"/>
      <link:label id="id_47ad1e48" xlink:label="lbl_Decrease25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Decrease25BasisPointMember" xlink:to="lbl_Decrease25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_56d62cdb" xlink:label="lbl_Decrease25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point decrease</link:label>
      <link:label id="id_3867e568" xlink:label="lbl_Increase25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Increase25BasisPointMember" xlink:to="lbl_Increase25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_5197441d" xlink:label="lbl_Increase25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point increase</link:label>
      <link:label id="id_1471972b" xlink:label="lbl_Increase1YearMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase, 1 year [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Increase1YearMember" xlink:to="lbl_Increase1YearMember_labels" xlink:type="arc"/>
      <link:label id="id_4ce59d83" xlink:label="lbl_Increase1YearMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1 year increase</link:label>
      <link:label id="id_290932d1" xlink:label="lbl_label688468689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lbl_label688468689" xlink:type="arc"/>
      <link:label id="id_7dde43af" xlink:label="lbl_label2111718319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lbl_label2111718319" xlink:type="arc"/>
      <link:label id="id_a6a337a" xlink:label="lbl_label174732154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of health care cost trend rates [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_label174732154" xlink:type="arc"/>
      <link:label id="id_3aac73e2" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:type="arc"/>
      <link:label id="id_6a35725f" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare cost trend rate assumed for next year</link:label>
      <link:label id="id_41b83777" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed to Decline</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:type="arc"/>
      <link:label id="id_4f8e05fa" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
      <link:label id="id_6b154ebb" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:type="arc"/>
      <link:label id="id_1990f79d" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year that the rate reaches the ultimate trend rate</link:label>
      <link:label id="id_6d01266f" xlink:label="lbl_label1828791919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of allocation of plan assets [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_label1828791919" xlink:type="arc"/>
      <link:label id="id_546e2ee7" xlink:label="lbl_label1416507111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_label1416507111" xlink:type="arc"/>
      <link:label id="id_351e0eb0" xlink:label="lbl_label891162288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_label891162288" xlink:type="arc"/>
      <link:label id="id_124636b7" xlink:label="lbl_EquityInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity investments [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityInvestmentsMember" xlink:to="lbl_EquityInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_77cea25b" xlink:label="lbl_EquityInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_1387f503" xlink:label="lbl_DebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesMember" xlink:to="lbl_DebtSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_3f4271a5" xlink:label="lbl_DebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
      <link:label id="id_3fb49996" xlink:label="lbl_RealEstateMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real estate [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateMember" xlink:to="lbl_RealEstateMember_labels" xlink:type="arc"/>
      <link:label id="id_3b683c06" xlink:label="lbl_RealEstateMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Real estate</link:label>
      <link:label id="id_40e14f9f" xlink:label="lbl_AlternativeInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative investments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlternativeInvestmentsMember" xlink:to="lbl_AlternativeInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_63169a31" xlink:label="lbl_AlternativeInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alternative investments</link:label>
      <link:label id="id_2f33748b" xlink:label="lbl_CashAndOtherInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and other investments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndOtherInvestmentsMember" xlink:to="lbl_CashAndOtherInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_6087023c" xlink:label="lbl_CashAndOtherInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and other investments</link:label>
      <link:label id="id_36f85bd1" xlink:label="lbl_label922246097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, target plan asset allocations range minimum</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:to="lbl_label922246097" xlink:type="arc"/>
      <link:label id="id_568969aa" xlink:label="lbl_label1451846058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, target plan asset allocations range maximum</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:to="lbl_label1451846058" xlink:type="arc"/>
      <link:label id="id_73a6e694" xlink:label="lbl_label1940317844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, plan asset allocations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:to="lbl_label1940317844" xlink:type="arc"/>
      <link:label id="id_7df88f41" xlink:label="lbl_label2113441601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares held by defined benefit plan</link:label>
      <link:label id="id_638e4e2e" xlink:label="lbl_label1670270510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of shares held by defined benefit plan</link:label>
      <link:label id="id_1fe80675" xlink:label="lbl_label535299701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average duration of defined benefit obligation years</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:to="lbl_label535299701" xlink:type="arc"/>
      <link:label id="id_3b7d1376" xlink:label="lbl_label998052726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lbl_label998052726" xlink:type="arc"/>
      <link:label id="id_3dd16606" xlink:label="lbl_label1037133318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_label1037133318" xlink:type="arc"/>
      <link:label id="id_123e0aae" xlink:label="lbl_label306055854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_label306055854" xlink:type="arc"/>
      <link:label id="id_f1ad7e6" xlink:label="lbl_label253417446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="lbl_label253417446" xlink:type="arc"/>
      <link:label id="id_103a32b5" xlink:label="lbl_label272249525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expected benefit payments [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_label272249525" xlink:type="arc"/>
      <link:label id="id_3fa24799" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future benefit payment [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:type="arc"/>
      <link:label id="id_7a2e1ca0" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future employer contributions [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:type="arc"/>
      <link:label id="id_6e3282e0" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_723df25e" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future benefit payments</link:label>
      <link:label id="id_b004db7" xlink:label="lbl_label910647463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions, next fiscal year (estimated)</link:label>
      <link:label id="id_489bf9be" xlink:label="lbl_label839490648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future benefit payment</link:label>
      <link:label id="id_20bc42c3" xlink:label="lbl_label549208771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_12ce3901" xlink:label="lbl_label315504897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past service cost and gains losses arising from settlements, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:to="lbl_label315504897" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:to="lbl_label549208771" xlink:type="arc"/>
      <link:label id="id_47519d57" xlink:label="lbl_label1196531031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future employer contributions, next fiscal year</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lbl_label1196531031" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lbl_label910647463" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:to="lbl_label1014805941" xlink:type="arc"/>
      <link:label id="id_1b677399" xlink:label="lbl_label459764633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="lbl_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lbl_label459764633" xlink:type="arc"/>
      <link:label id="id_33287a64" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of discontinued operations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:to="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2e310112" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_6868ef6e" xlink:label="lbl_label1751707502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of details to the consolidated statements of cash flows [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_label1751707502" xlink:type="arc"/>
      <link:label id="id_6b1bab45" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Details to the consolidated statements of cash flows</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:to="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_d3696d1" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
      <link:label id="id_5827fd3a" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items from continuing operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:to="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4b12a0b7" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items from continuing operations</link:label>
      <link:label id="id_31e67efa" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:to="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3971a54e" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations</link:label>
      <link:label id="id_1118f1b5" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows arising from acquisitions and divestments of businesses [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:to="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4c64ba26" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows arising from acquisitions and divestments of businesses</link:label>
      <link:label id="id_4c022ee6" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:to="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5bd72b36" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from discontinued operations</link:label>
      <link:label id="id_2f1afbf8" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement segmentation [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5cbbe15" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement segmentation</link:label>
      <link:label id="id_5a01c254" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses included in net income [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExpensesIncludedInNetIncomeTableTextBlock" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpensesIncludedInNetIncomeTableTextBlock" xlink:to="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2004e8bf" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses included in net income</link:label>
      <link:label id="id_10dd18ca" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, sales to continuing segments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:type="arc"/>
      <link:label id="id_2d4849c4" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to continuing segments</link:label>
      <link:label id="id_398e8ede" xlink:label="lbl_label965643998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_label965643998" xlink:type="arc"/>
      <link:label id="id_136ba9dd" xlink:label="lbl_label325822941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentsMember" xlink:to="lbl_label325822941" xlink:type="arc"/>
      <link:label id="id_211fcf4d" xlink:label="lbl_VaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VaccinesMember" xlink:label="lbl_VaccinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VaccinesMember" xlink:to="lbl_VaccinesMember_labels" xlink:type="arc"/>
      <link:label id="id_5b74f3f8" xlink:label="lbl_ConsumerHealthMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Health [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsumerHealthMember" xlink:to="lbl_ConsumerHealthMember_labels" xlink:type="arc"/>
      <link:label id="id_56f765a5" xlink:label="lbl_CorporateMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CorporateMember" xlink:to="lbl_CorporateMember_labels" xlink:type="arc"/>
      <link:label id="id_18ef0ff6" xlink:label="lbl_VaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines</link:label>
      <link:label id="id_461a031f" xlink:label="lbl_ConsumerHealthMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Health</link:label>
      <link:label id="id_53139d8a" xlink:label="lbl_CorporateMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
      <link:label id="id_448d3c2a" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating income/loss of discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OperatingIncomeLossOfDiscontinuedOperations" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingIncomeLossOfDiscontinuedOperations" xlink:to="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_720983c3" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income/loss of discontinued operations</link:label>
      <link:label id="id_72fd7ee5" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense of discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeTaxExpenseOfDiscontinuedOperations" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpenseOfDiscontinuedOperations" xlink:to="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_28dd046" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense of discontinued operations</link:label>
      <link:label id="id_1f5a1a52" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
      <link:label id="id_6a72e089" xlink:label="lbl_label1785913481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="lbl_DepreciationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationExpense" xlink:to="lbl_label1785913481" xlink:type="arc"/>
      <link:label id="id_25726f06" xlink:label="lbl_label628256518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="lbl_AmortisationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortisationExpense" xlink:to="lbl_label628256518" xlink:type="arc"/>
      <link:label id="id_411f99ec" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_3b138d2b" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:type="arc"/>
      <link:label id="id_16efc802" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation of Novartis equity plans</link:label>
      <link:label id="id_1bd6fe9" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_1b76fc8a" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
      <link:label id="id_7b8e06f2" xlink:label="lbl_PropertyPlantAndEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_199a6c29" xlink:label="lbl_FinancialAssetsImpairedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets impaired [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsImpairedMember" xlink:to="lbl_FinancialAssetsImpairedMember_labels" xlink:type="arc"/>
      <link:label id="id_430aa9fa" xlink:label="lbl_FinancialAssetsImpairedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:label id="id_580bc98f" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:type="arc"/>
      <link:label id="id_12db58d" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments on:</link:label>
      <link:label id="id_7cae4caa" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_7ed21581" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net</link:label>
      <link:label id="id_353f4e60" xlink:label="lbl_AdjustmentsForSharebasedPayments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for share based payments</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForSharebasedPayments" xlink:to="lbl_AdjustmentsForSharebasedPayments_labels" xlink:type="arc"/>
      <link:label id="id_728a3fc5" xlink:label="lbl_AdjustmentsForSharebasedPayments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-settled compensation expense</link:label>
      <link:label id="id_71026a6c" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for change in provisions and other non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_7a811d6" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash change in provisions and other non-current liabilities</link:label>
      <link:label id="id_5215d26" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance income (cost)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForFinanceIncomeCost" xlink:to="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:type="arc"/>
      <link:label id="id_1e915c0" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net financial expense</link:label>
      <link:label id="id_162e6aad" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:type="arc"/>
      <link:label id="id_7b5bcf12" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) in inventories</link:label>
      <link:label id="id_672b8eea" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:type="arc"/>
      <link:label id="id_47cff5e1" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) in trade receivables</link:label>
      <link:label id="id_543bdc2c" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts payable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:type="arc"/>
      <link:label id="id_4059a0ed" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in trade payables</link:label>
      <link:label id="id_b388f81" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_64e8a2fc" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other net current assets and other operating cash flow items</link:label>
      <link:label id="id_63e2f9e4" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_118bdd59" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents, discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_671e3a1e" xlink:label="lbl_label1730034206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_label1730034206" xlink:type="arc"/>
      <link:label id="id_141b97fd" xlink:label="lbl_label337352701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_label337352701" xlink:type="arc"/>
      <link:label id="id_12050514" xlink:label="lbl_AcquisitionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsMember" xlink:to="lbl_AcquisitionsMember_labels" xlink:type="arc"/>
      <link:label id="id_7f5f8169" xlink:label="lbl_AcquisitionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
      <link:label id="id_415fd821" xlink:label="lbl_DivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentsMember" xlink:to="lbl_DivestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_7b19873c" xlink:label="lbl_DivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestments</link:label>
      <link:label id="id_177d8886" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAssetsMember" xlink:to="lbl_OtherAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_fdd065b" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets [member]</link:label>
      <link:label id="id_7f9f59b1" xlink:label="lbl_OtherIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_1a3864c5" xlink:label="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technologies</link:label>
      <link:label id="id_5b13ac00" xlink:label="lbl_BrandNamesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brand names</link:label>
      <link:label id="id_7d41899d" xlink:label="lbl_InventoriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_50dd9de4" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net identifiable assets (acquired) or divested</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowFromNetIdentifiableAssets" xlink:to="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:type="arc"/>
      <link:label id="id_4169909f" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow) from Net identifiable assets (acquired) or divested</link:label>
      <link:label id="id_6da3acb5" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), currency translation effects</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowCurrencyTranslationEffects" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowCurrencyTranslationEffects" xlink:to="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:type="arc"/>
      <link:label id="id_28a59cd9" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_6046e1a8" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4ec913e7" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), acquired/(divested) liquity</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowAcquiredDivestedLiquity" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowAcquiredDivestedLiquity" xlink:to="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:type="arc"/>
      <link:label id="id_470c377e" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired/(divested) liquity</link:label>
      <link:label id="id_50fcd8ec" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
      <link:label id="id_51ec5468" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow) from Net identifiable assets (acquired) or divested, currency translation effects, Acquired/(divested) liquidity and fair value of previously held equity interests.</link:label>
      <link:label id="id_33a842e" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash provided by refinancing of intercompany financial debt, net</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:to="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:type="arc"/>
      <link:label id="id_cbc3f6c" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refinancing of intercompany financial debt, net</link:label>
      <link:label id="id_2f2298e2" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash provided by refinancing of intercompany financial debt, net.</link:label>
      <link:label id="id_7e82bd81" xlink:label="lbl_CashInflowOutflowGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Goodwill</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowGoodwill" xlink:label="lbl_CashInflowOutflowGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowGoodwill" xlink:to="lbl_CashInflowOutflowGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_3c41ff79" xlink:label="lbl_CashInflowOutflowGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_4f404f29" xlink:label="lbl_label1329614633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestment gain</link:label>
      <link:label id="id_250b8244" xlink:label="lbl_label621511236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Divestment gain (loss)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowDivestmentGainLoss" xlink:label="lbl_CashInflowOutflowDivestmentGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowDivestmentGainLoss" xlink:to="lbl_label621511236" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowDivestmentGainLoss" xlink:to="lbl_label1329614633" xlink:type="arc"/>
      <link:label id="id_48ec9225" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes paid and other portfolio transformation related cash flows</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:to="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:type="arc"/>
      <link:label id="id_69b7f35f" xlink:label="lbl_label1773663071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables and payables contingent consideration, net</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:to="lbl_label1773663071" xlink:type="arc"/>
      <link:label id="id_66ca8618" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other payments and deferred consideration, net</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:type="arc"/>
      <link:label id="id_7403ad6c" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Deferred)/prepaid portion of sales price</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DeferredPrepaidPortionOfSalesPrice" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredPrepaidPortionOfSalesPrice" xlink:to="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:type="arc"/>
      <link:label id="id_7290427c" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">(Deferred)/prepaid portion of sales price to cash flows (used in) provided by acquisitions/divestments of businesses.</link:label>
      <link:label id="id_55c25b5" xlink:label="lbl_label1423033786" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows</link:label>
      <link:label id="id_35ffff76" xlink:label="lbl_label905969526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration paid</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPaid" xlink:to="lbl_label905969526" xlink:type="arc"/>
      <link:label id="id_344a7417" xlink:label="lbl_label877294615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_label877294615" xlink:type="arc"/>
      <link:label id="id_2a937996" xlink:label="lbl_label714307990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_label714307990" xlink:type="arc"/>
      <link:label id="id_e12f433" xlink:label="lbl_Change25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Change25BasisPointMember" xlink:to="lbl_Change25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_a3f5c53" xlink:label="lbl_Change25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point change</link:label>
      <link:label id="id_375463d0" xlink:label="lbl_label928277456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends payable, amount per share</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPayableAmountPerShare" xlink:to="lbl_label928277456" xlink:type="arc"/>
      <link:label id="id_43bd571e" xlink:label="lbl_label1136482078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be held</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeHeld" xlink:to="lbl_label1136482078" xlink:type="arc"/>
      <link:label id="id_57fc5a54" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be cancelled</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeCancelled" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:type="arc"/>
      <link:label id="id_324c0bd9" xlink:label="lbl_label843844569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share purchases</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSharePurchases" xlink:to="lbl_label843844569" xlink:type="arc"/>
      <link:label id="id_4ae190e3" xlink:label="lbl_SharepurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-purchase of treasury shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharepurchaseOfTreasuryShares" xlink:label="lbl_SharepurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharepurchaseOfTreasuryShares" xlink:to="lbl_SharepurchaseOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_191f6daa" xlink:label="lbl_label421490090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be held, equity impact</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesAcquiredToBeHeldValue" xlink:label="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:to="lbl_label421490090" xlink:type="arc"/>
      <link:label id="id_3ea88f28" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired for cancellation, equity impact</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredForCancellationValue" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:type="arc"/>
      <link:label id="id_6fbbc8cc" xlink:label="lbl_OtherSharePurchasesValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share purchases, equity impact</link:label>
      <link:label id="id_5d0bb4f" xlink:label="lbl_label97565519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_label97565519" xlink:type="arc"/>
      <link:label id="id_663e6f69" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1fe06852" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income</link:label>
      <link:label id="id_72bd6f82" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of comprehensive income [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:to="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3ec5912e" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
      <link:label id="id_72f6c7af" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of share value adjustments currency translation effects [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:to="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_570bfee5" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share value adjustments currency translation effects</link:label>
      <link:label id="id_55c48a63" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments financial instruments reconciliation [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:to="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_b6f9702" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments financial instruments reconciliation</link:label>
      <link:label id="id_56e22f6a" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plan amounts recognized in other comprehensive income [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:to="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_8052d36" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plan amounts recognized in other comprehensive income</link:label>
      <link:label id="id_639839a6" xlink:label="lbl_label1670920614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_label1670920614" xlink:type="arc"/>
      <link:label id="id_46f3d26a" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3abc74f9" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based participation plans for associates</link:label>
      <link:label id="id_36b95a30" xlink:label="lbl_label918116912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_label918116912" xlink:type="arc"/>
      <link:label id="id_4f551c1c" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRelatedPartyExplanatory" xlink:to="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2142f37a" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with related parties</link:label>
      <link:label id="id_21a37a9f" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-employment benefits for associates</link:label>
      <link:label id="id_250e99ed" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officer and director compensation [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OfficerAndDirectorCompensationTableTextBlock" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:to="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_30161311" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Officers and Non-Executive Directors Compensation</link:label>
      <link:label id="id_332db2e6" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_5ba16f3" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_23eec797" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4f141a24" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation, activity [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2cdc96dc" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation, activity</link:label>
      <link:label id="id_5c5154d5" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward</link:label>
      <link:label id="id_44099e5b" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options</link:label>
      <link:label id="id_2a634859" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options</link:label>
      <link:label id="id_2b301a02" xlink:label="lbl_label724572674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_label724572674" xlink:type="arc"/>
      <link:label id="id_499d66e9" xlink:label="lbl_label1235052265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_label1235052265" xlink:type="arc"/>
      <link:label id="id_4bff5af2" xlink:label="lbl_label1275026162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_label1275026162" xlink:type="arc"/>
      <link:label id="id_4175504c" xlink:label="lbl_label1098207308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_label1098207308" xlink:type="arc"/>
      <link:label id="id_52e5607c" xlink:label="lbl_label1390764156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel of entity or parent [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_label1390764156" xlink:type="arc"/>
      <link:label id="id_51571277" xlink:label="lbl_label1364660855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Executive Director [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonExecutiveDirectorMember" xlink:to="lbl_label1364660855" xlink:type="arc"/>
      <link:label id="id_77564460" xlink:label="lbl_label2002142304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_label2002142304" xlink:type="arc"/>
      <link:label id="id_7f01623c" xlink:label="lbl_label2130797116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for associates [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_label2130797116" xlink:type="arc"/>
      <link:label id="id_2d55a2fa" xlink:label="lbl_RocheHoldingAGMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Holding AG [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RocheHoldingAGMember" xlink:to="lbl_RocheHoldingAGMember_labels" xlink:type="arc"/>
      <link:label id="id_102c1151" xlink:label="lbl_label271323473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_label271323473" xlink:type="arc"/>
      <link:label id="id_7a1d10b6" xlink:label="lbl_label2048725174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_label2048725174" xlink:type="arc"/>
      <link:label id="id_4b6874" xlink:label="lbl_label4941940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lucentis [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LucentisMember" xlink:to="lbl_label4941940" xlink:type="arc"/>
      <link:label id="id_4da120c0" xlink:label="lbl_label1302405312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xolair [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_XolairMember" xlink:to="lbl_label1302405312" xlink:type="arc"/>
      <link:label id="id_40080a70" xlink:label="lbl_label1074268784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held in associate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:to="lbl_label1074268784" xlink:type="arc"/>
      <link:label id="id_4fef4e77" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net expense, royalties cost sharing and profit sharing</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:type="arc"/>
      <link:label id="id_5866119e" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:type="arc"/>
      <link:label id="id_32134034" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:type="arc"/>
      <link:label id="id_40914b3d" xlink:label="lbl_KeyManagementPersonnelCompensation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensation_labels" xlink:type="arc"/>
      <link:label id="id_34c1eea8" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-employment benefits</link:label>
      <link:label id="id_24fee3be" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
      <link:label id="id_5994538d" xlink:label="lbl_KeyManagementPersonnelCompensation_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_a202e7c" xlink:label="lbl_label169881212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech, Inc., USA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GenentechInc.USAMember" xlink:to="lbl_label169881212" xlink:type="arc"/>
      <link:label id="id_3ecec9c1" xlink:label="lbl_label1053739457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prof. Dr. Brody [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfDrBrodyMember" xlink:to="lbl_label1053739457" xlink:type="arc"/>
      <link:label id="id_60abf97a" xlink:label="lbl_label1621883258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prof. Dr. Zinkernagel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfDrZinkernagelMember" xlink:to="lbl_label1621883258" xlink:type="arc"/>
      <link:label id="id_707fbae9" xlink:label="lbl_label1887419113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Alex Krauer [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrAlexKrauerMember" xlink:to="lbl_label1887419113" xlink:type="arc"/>
      <link:label id="id_5f1c0cdd" xlink:label="lbl_label1595673821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Daniel Vasella [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrDanielVasellaMember" xlink:to="lbl_label1595673821" xlink:type="arc"/>
      <link:label id="id_49199deb" xlink:label="lbl_label1226415595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. James Bradner [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrJamesBradnerMember" xlink:to="lbl_label1226415595" xlink:type="arc"/>
      <link:label id="id_12139c9c" xlink:label="lbl_label303275164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, daily rate</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:to="lbl_label303275164" xlink:type="arc"/>
      <link:label id="id_34648bf4" xlink:label="lbl_label879004660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, annual guaranteed minimum</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:to="lbl_label879004660" xlink:type="arc"/>
      <link:label id="id_475cd1c7" xlink:label="lbl_label1197265351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, shares acquired</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:to="lbl_label1197265351" xlink:type="arc"/>
      <link:label id="id_7d46110e" xlink:label="lbl_label2101743886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, ownership interest acquired</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:to="lbl_label2101743886" xlink:type="arc"/>
      <link:label id="id_41061f2c" xlink:label="lbl_label1090920236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_label1090920236" xlink:type="arc"/>
      <link:label id="id_2d82d11f" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_2c74381f" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities</link:label>
      <link:label id="id_1315ebbc" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:type="arc"/>
      <link:label id="id_2feb765f" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges</link:label>
      <link:label id="id_41098a9f" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:type="arc"/>
      <link:label id="id_66cb76c9" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans</link:label>
      <link:label id="id_2dc02a48" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative currency translation effects [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:type="arc"/>
      <link:label id="id_167b29ff" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative currency translation effects</link:label>
      <link:label id="id_23f99baf" xlink:label="lbl_label603560879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_label603560879" xlink:type="arc"/>
      <link:label id="id_525fbfa4" xlink:label="lbl_label98094011" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Value adjustments on comprehensive income at end of period</link:label>
      <link:label id="id_5f2ad26f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial gains/losses from defined benefit plans</link:label>
      <link:label id="id_56084e2" xlink:label="lbl_label492438188" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total value adjustments</link:label>
      <link:label id="id_4f1abe21" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial instruments</link:label>
      <link:label id="id_44ea9064" xlink:label="lbl_label521267934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale financial investments</link:label>
      <link:label id="id_172d7365" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
      <link:label id="id_1d877185" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of marketable investments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GainLossOnSaleOfMarketableInvestments" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnSaleOfMarketableInvestments" xlink:to="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:type="arc"/>
      <link:label id="id_67ba82da" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities sold</link:label>
      <link:label id="id_2adbb944" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of other financial assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_24c923e8" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets sold</link:label>
      <link:label id="id_334897f4" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments during the year</link:label>
      <link:label id="id_36328be7" xlink:label="lbl_label909282279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remeasurements from defined benefit plans [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:label="lbl_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:to="lbl_label909282279" xlink:type="arc"/>
      <link:label id="id_598b1d0a" xlink:label="lbl_label1502289162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_label1502289162" xlink:type="arc"/>
      <link:label id="id_42afb056" xlink:label="lbl_label1118810198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_label1118810198" xlink:type="arc"/>
      <link:label id="id_4854e53b" xlink:label="lbl_GoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillMember" xlink:to="lbl_GoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_5a809ba7" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets other than Goodwill</link:label>
      <link:label id="id_6fcb9ca9" xlink:label="lbl_GoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_789924e3" xlink:label="lbl_CurrentlyMarketedProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_6768eaf7" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketing know-how</link:label>
      <link:label id="id_1878d8ce" xlink:label="lbl_label410573006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_label410573006" xlink:type="arc"/>
      <link:label id="id_5927b5e9" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsAndGoodwill" xlink:to="lbl_IntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_7c0ed12" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill at beginning of period</link:label>
      <link:label id="id_747bc8d6" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill at end of period</link:label>
      <link:label id="id_4eee4a8f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_4295643b" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_fd8bae8" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_2975d791" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
      <link:label id="id_37bb77c5" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_31d55821" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_4b244fff" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_c2fe7ed" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:label id="id_13c2a444" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_7e269b8c" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_3f53b387" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_6e93cf7f" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization charge</link:label>
      <link:label id="id_4895c20f" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_31bd23bf" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:label id="id_4c0505b8" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_3a8c745b" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of impairment charge</link:label>
      <link:label id="id_46823638" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
      <link:label id="id_71feba23" xlink:label="lbl_label1912519203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_label1912519203" xlink:type="arc"/>
      <link:label id="id_76bd9383" xlink:label="lbl_label1992135555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for segment consolidation items [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_label1992135555" xlink:type="arc"/>
      <link:label id="id_e23d9e6" xlink:label="lbl_label237230566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating segments [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingSegmentsMember" xlink:to="lbl_label237230566" xlink:type="arc"/>
      <link:label id="id_4e99f014" xlink:label="lbl_InnovativeMedicinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Medicines [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InnovativeMedicinesMember" xlink:to="lbl_InnovativeMedicinesMember_labels" xlink:type="arc"/>
      <link:label id="id_5cce9bca" xlink:label="lbl_InnovativeMedicinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Medicines</link:label>
      <link:label id="id_62947297" xlink:label="lbl_SandozMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozMember" xlink:to="lbl_SandozMember_labels" xlink:type="arc"/>
      <link:label id="id_2d171b79" xlink:label="lbl_SandozMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sandoz</link:label>
      <link:label id="id_19f7b763" xlink:label="lbl_AlconMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconMember" xlink:to="lbl_AlconMember_labels" xlink:type="arc"/>
      <link:label id="id_82cbe5b" xlink:label="lbl_AlconMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcon</link:label>
      <link:label id="id_40af0c2d" xlink:label="lbl_label1085213741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated amounts [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnallocatedAmountsMember" xlink:to="lbl_label1085213741" xlink:type="arc"/>
      <link:label id="id_2f427f57" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:type="arc"/>
      <link:label id="id_1f6b21d" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terminal Growth Rate</link:label>
      <link:label id="id_6e31860b" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate used in current measurement of fair value less costs of disposal</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:type="arc"/>
      <link:label id="id_59daa167" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate (post-tax)</link:label>
      <link:label id="id_32f31c92" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_6067b5a3" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges</link:label>
      <link:label id="id_6697be1e" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of justification for using growth rate that exceeds long-term average growth rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:type="arc"/>
      <link:label id="id_576cfb66" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of growth rate</link:label>
      <link:label id="id_645c105b" xlink:label="lbl_label1683755099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_label1683755099" xlink:type="arc"/>
      <link:label id="id_86ca8ac" xlink:label="lbl_label141338796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_label141338796" xlink:type="arc"/>
      <link:label id="id_3cced209" xlink:label="lbl_label1020187145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_label1020187145" xlink:type="arc"/>
      <link:label id="id_b0eee5a" xlink:label="lbl_label185527898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_label185527898" xlink:type="arc"/>
      <link:label id="id_7bf97c21" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Annual Incentive Plan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_2ae4d862" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_6fae6c02" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Leveraged Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_4b1054ab" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Employee Share Ownership Plan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_28d147a5" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation UK Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_43a6ccb8" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select" [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:type="arc"/>
      <link:label id="id_3073fb0" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Long-Term Performance Plan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_547a9da" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Long-Term Relative Performance Plan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_1f01ff40" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Special Share Awards [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:type="arc"/>
      <link:label id="id_89e9c6a" xlink:label="lbl_label144612458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:to="lbl_label144612458" xlink:type="arc"/>
      <link:label id="id_25616927" xlink:label="lbl_label627140903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of method of settlement for share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:label="lbl_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:to="lbl_label627140903" xlink:type="arc"/>
      <link:label id="id_7e605438" xlink:label="lbl_label2120242232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of vesting requirements for share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="lbl_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="lbl_label2120242232" xlink:type="arc"/>
      <link:label id="id_73de771d" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities from share-based payment transactions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:type="arc"/>
      <link:label id="id_41659fd5" xlink:label="lbl_label1097179093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_label1097179093" xlink:type="arc"/>
      <link:label id="id_70e32ac1" xlink:label="lbl_label1893935809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_label1893935809" xlink:type="arc"/>
      <link:label id="id_1e53f765" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOutstandingShareOptions" xlink:to="lbl_NumberOfOutstandingShareOptions_labels" xlink:type="arc"/>
      <link:label id="id_71aeacaf" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding at beginning of period</link:label>
      <link:label id="id_5962c0d" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding at end of period</link:label>
      <link:label id="id_7fce5b76" xlink:label="lbl_label2144230262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_label2144230262" xlink:type="arc"/>
      <link:label id="id_3d4fe5a6" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_18341635" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_1df4b58c" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_4c6be67e" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised or sold</link:label>
      <link:label id="id_476e4360" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options forfeited or expired</link:label>
      <link:label id="id_3c8a636c" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercisable</link:label>
      <link:label id="id_18fcb954" xlink:label="lbl_label419215700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_label419215700" xlink:type="arc"/>
      <link:label id="id_3e8e4697" xlink:label="lbl_label1049511575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_label1049511575" xlink:type="arc"/>
      <link:label id="id_2cfcdafb" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:type="arc"/>
      <link:label id="id_5fb4ce8d" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_6a904dd3" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Remeasurements from defined benefit plans, total after tax</link:label>
      <link:label id="id_77782278" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before taxes, gains (losses) on remeasurements of defined benefit plans</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_5e993e53" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans before tax</link:label>
      <link:label id="id_70219b11" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before taxes, gains (losses) on remeasurements of other post-employment benefit plans</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_24653928" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans before tax</link:label>
      <link:label id="id_2e31d75a" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, gains (losses) on remeasurements of defined and other post-employment benefit plans, taxation</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:type="arc"/>
      <link:label id="id_258900b0" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxation on above items</link:label>
      <link:label id="id_7496cde" xlink:label="lbl_label122252510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, shares acquired, price</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:to="lbl_label122252510" xlink:type="arc"/>
      <link:label id="id_77be955a" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value adjustment on comprehensive income</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_19d019b2" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Value adjustments on comprehensive income at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label98094011" xlink:type="arc"/>
      <link:label id="id_53394b08" xlink:label="lbl_label1396263688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on value adjustment on comprehensive income</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label1396263688" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label492438188" xlink:type="arc"/>
      <link:label id="id_5127c80" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total value adjustments attributable to Novartis shareholders [Member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:type="arc"/>
      <link:label id="id_11f1c5d1" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total value adjustments</link:label>
      <link:label id="id_4fa34414" xlink:label="lbl_label1336099860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plan, converted, Novartis share options [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:to="lbl_label1336099860" xlink:type="arc"/>
      <link:label id="id_47c79757" xlink:label="lbl_label1204262743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:to="lbl_label1204262743" xlink:type="arc"/>
      <link:label id="id_5c4a8ca3" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised</link:label>
      <link:label id="id_5368a3e4" xlink:label="lbl_label1399366628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_label1399366628" xlink:type="arc"/>
      <link:label id="id_54d97aaa" xlink:label="lbl_label1423538858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-vesting [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonvestingAxis" xlink:label="lbl_NonvestingAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonvestingAxis" xlink:to="lbl_label1423538858" xlink:type="arc"/>
      <link:label id="id_129e3bed" xlink:label="lbl_label312359917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-vesting [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonvestingMember" xlink:label="lbl_NonvestingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonvestingMember" xlink:to="lbl_label312359917" xlink:type="arc"/>
      <link:label id="id_768fac4" xlink:label="lbl_label124320452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-vested shares granted [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonvestedSharesGrantedMember" xlink:label="lbl_NonvestedSharesGrantedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonvestedSharesGrantedMember" xlink:to="lbl_label124320452" xlink:type="arc"/>
      <link:label id="id_2ded6718" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual incentive</link:label>
      <link:label id="id_5e84f23d" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share savings plans</link:label>
      <link:label id="id_47fd4dbd" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select</link:label>
      <link:label id="id_779d196a" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Performance Plan</link:label>
      <link:label id="id_39c41311" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Relative Performance Plan</link:label>
      <link:label id="id_1cf8204b" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special share awards</link:label>
      <link:label id="id_4b5d1837" xlink:label="lbl_label679367036" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value at grante date at end of period</link:label>
      <link:label id="id_569121e3" xlink:label="lbl_label1373999706" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, fair value at grante date</link:label>
      <link:label id="id_6bf6969c" xlink:label="lbl_label766376780" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, fair value at grante date</link:label>
      <link:label id="id_6a253a0a" xlink:label="lbl_label1695476906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, fair value at grante date</link:label>
      <link:label id="id_5dafe477" xlink:label="lbl_label1571808375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_label1571808375" xlink:type="arc"/>
      <link:label id="id_64b72c46" xlink:label="lbl_label1689726022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_label1689726022" xlink:type="arc"/>
      <link:label id="id_195ec04a" xlink:label="lbl_label425640010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_label425640010" xlink:type="arc"/>
      <link:label id="id_776b087e" xlink:label="lbl_label2003503230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material reconciling items [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaterialReconcilingItemsMember" xlink:to="lbl_label2003503230" xlink:type="arc"/>
      <link:label id="id_13fb62a8" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, sales to other segments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:type="arc"/>
      <link:label id="id_71f1654a" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to discontinued operations</link:label>
      <link:label id="id_425f6b3f" xlink:label="lbl_label1113549631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromInterest" xlink:to="lbl_label1113549631" xlink:type="arc"/>
      <link:label id="id_6ed59bdd" xlink:label="lbl_DepreciationAndAmortisationExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationAndAmortisationExpense" xlink:to="lbl_DepreciationAndAmortisationExpense_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:type="arc"/>
      <link:label id="id_60788cbc" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_2bf65413" xlink:label="lbl_NetOperatingAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetOperatingAssets" xlink:to="lbl_NetOperatingAssets_labels" xlink:type="arc"/>
      <link:label id="id_3832e6c2" xlink:label="lbl_NetOperatingAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net operating assets</link:label>
      <link:label id="id_216a6d7c" xlink:label="lbl_PurchaseOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of interests in associates</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfInterestsInAssociates" xlink:label="lbl_PurchaseOfInterestsInAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfInterestsInAssociates" xlink:to="lbl_PurchaseOfInterestsInAssociates_labels" xlink:type="arc"/>
      <link:label id="id_41f96a5e" xlink:label="lbl_PurchaseOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:label id="id_5e202521" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:type="arc"/>
      <link:label id="id_3b72597a" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtsAndDerivativeInstruments" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:type="arc"/>
      <link:label id="id_6e43b10" xlink:label="lbl_label1241182885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current income tax and deferred tax liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:to="lbl_label1241182885" xlink:type="arc"/>
      <link:label id="id_2c7e10a7" xlink:label="lbl_label102429242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales (in % of total net sales)</link:label>
      <link:label id="id_7f20a04d" xlink:label="lbl_SelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total of selected non-current assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssets" xlink:to="lbl_SelectedNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_615b5ab6" xlink:label="lbl_SelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</link:label>
      <link:label id="id_46b9a3b0" xlink:label="lbl_label1358337308" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</link:label>
      <link:label id="id_439913bb" xlink:label="lbl_label1134105531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_557072dd" xlink:label="lbl_label1433432797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other countries [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCountriesMember" xlink:to="lbl_label1433432797" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCountriesMember" xlink:to="lbl_label1134105531" xlink:type="arc"/>
      <link:label id="id_7879a2ba" xlink:label="lbl_label2021237434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical regions [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GeographicalRegionsAxis" xlink:label="lbl_GeographicalRegionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalRegionsAxis" xlink:to="lbl_label2021237434" xlink:type="arc"/>
      <link:label id="id_cd118fc" xlink:label="lbl_label215030012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical regions [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GeographicalRegionsMember" xlink:label="lbl_GeographicalRegionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalRegionsMember" xlink:to="lbl_label215030012" xlink:type="arc"/>
      <link:label id="id_56b7dac7" xlink:label="lbl_label1638353244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia/Africa/Australasia [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AsiaAfricaAustralasiaMember" xlink:to="lbl_label1638353244" xlink:type="arc"/>
      <link:label id="id_7ec1f871" xlink:label="lbl_label2126641265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEntitysRevenue" xlink:to="lbl_label2126641265" xlink:type="arc"/>
      <link:label id="id_4a42fa89" xlink:label="lbl_label1245903497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersAbstract" xlink:label="lbl_DisclosureOfMajorCustomersAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersAbstract" xlink:to="lbl_label1245903497" xlink:type="arc"/>
      <link:label id="id_77148ff4" xlink:label="lbl_label1997836276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_label1997836276" xlink:type="arc"/>
      <link:label id="id_3a785089" xlink:label="lbl_label980963465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_label980963465" xlink:type="arc"/>
      <link:label id="id_7a5a32d3" xlink:label="lbl_label2052731603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_label2052731603" xlink:type="arc"/>
      <link:label id="id_54ab46d" xlink:label="lbl_label88781933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_label88781933" xlink:type="arc"/>
      <link:label id="id_329eef9f" xlink:label="lbl_label849276831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LargestCustomerMember" xlink:to="lbl_label849276831" xlink:type="arc"/>
      <link:label id="id_3eacc0a0" xlink:label="lbl_label1051508896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecondLargestCustomerMember" xlink:to="lbl_label1051508896" xlink:type="arc"/>
      <link:label id="id_54e36398" xlink:label="lbl_label1424188312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThirdLargestCustomerMember" xlink:to="lbl_label1424188312" xlink:type="arc"/>
      <link:label id="id_51bc0ac2" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_76ba88df" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation of key figures</link:label>
      <link:label id="id_596e3d72" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3d44b3a2" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated income statements</link:label>
      <link:label id="id_910173d" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, balance sheet [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_f1f9461" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated balance sheets</link:label>
      <link:label id="id_68241853" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, by countries and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_8ba3eb7" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and total of selected non-current assets, by countries and regions</link:label>
      <link:label id="id_6d6e90e5" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, net sales by business franchise [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_11d66710" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales by business franchise</link:label>
      <link:label id="id_1b7ab5f2" xlink:label="lbl_label461026802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_label461026802" xlink:type="arc"/>
      <link:label id="id_15494420" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2bcfd6a6" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated companies</link:label>
      <link:label id="id_113707b2" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_38388c12" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates</link:label>
      <link:label id="id_27f02648" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates balance sheet [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_ebb669f" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates, balance sheet value</link:label>
      <link:label id="id_52795c5f" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates summarized financial information [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6a736cd0" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_467a3bcc" xlink:label="lbl_label1182415820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_label1182415820" xlink:type="arc"/>
      <link:label id="id_3a1d7e" xlink:label="lbl_label3808638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_label3808638" xlink:type="arc"/>
      <link:label id="id_6360193f" xlink:label="lbl_RocheHoldingAGMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche Holding AG, Switzerland</link:label>
      <link:label id="id_5e0c8ce9" xlink:label="lbl_label1577880809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK</link:label>
      <link:label id="id_197b34b2" xlink:label="lbl_label427504818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:to="lbl_label427504818" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:to="lbl_label1577880809" xlink:type="arc"/>
      <link:label id="id_49715fd2" xlink:label="lbl_OthersAssociatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others associates [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OthersAssociatesMember" xlink:to="lbl_OthersAssociatesMember_labels" xlink:type="arc"/>
      <link:label id="id_4dbe4327" xlink:label="lbl_OthersAssociatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_54a1c758" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of total comprehensive income of associates and joint ventures accounted for using equity method</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_33c07958" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income effect</link:label>
      <link:label id="id_4b6b0442" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet value</link:label>
      <link:label id="id_2f5ba89e" xlink:label="lbl_label794536094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfOwnershipInterestInAssociate" xlink:to="lbl_label794536094" xlink:type="arc"/>
      <link:label id="id_5dfb85ae" xlink:label="lbl_label1576764846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsReceived" xlink:to="lbl_label1576764846" xlink:type="arc"/>
      <link:label id="id_404e569d" xlink:label="lbl_label1078875805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates summarized financial information [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssociatesSummarizedFinancialInformationTable" xlink:label="lbl_AssociatesSummarizedFinancialInformationTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatesSummarizedFinancialInformationTable" xlink:to="lbl_label1078875805" xlink:type="arc"/>
      <link:label id="id_53734bbc" xlink:label="lbl_label1400064956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PurchasePriceAllocationAssociatesTable" xlink:label="lbl_PurchasePriceAllocationAssociatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchasePriceAllocationAssociatesTable" xlink:to="lbl_label1400064956" xlink:type="arc"/>
      <link:label id="id_6e7640ef" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revaluation increase (decrease), intangible assets other than goodwil</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_20824625" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis share of re-appraised intangible assets</link:label>
      <link:label id="id_3ec70a2" xlink:label="lbl_AdditionalRecognitionGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implicit Novartis goodwill</link:label>
      <link:label id="id_2f773be1" xlink:label="lbl_ShareOfEstimatedNetAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of estimated net assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ShareOfEstimatedNetAssets" xlink:label="lbl_ShareOfEstimatedNetAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfEstimatedNetAssets" xlink:to="lbl_ShareOfEstimatedNetAssets_labels" xlink:type="arc"/>
      <link:label id="id_7ae8d097" xlink:label="lbl_ShareOfEstimatedNetAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis share of estimated net assets</link:label>
      <link:label id="id_df32051" xlink:label="lbl_label234037329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value of share in net identifiable assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:label="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:to="lbl_label234037329" xlink:type="arc"/>
      <link:label id="id_2274c64a" xlink:label="lbl_label578078282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated equity accounting adjustments and translation effects less dividends received</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:label="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:to="lbl_label578078282" xlink:type="arc"/>
      <link:label id="id_4dcb8141" xlink:label="lbl_label1305182529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement effects [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_label1305182529" xlink:type="arc"/>
      <link:label id="id_139af9b9" xlink:label="lbl_label328923577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis share of current year consolidated net income</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfCurrentYearNetIncome" xlink:to="lbl_label328923577" xlink:type="arc"/>
      <link:label id="id_9a810fe" xlink:label="lbl_label162009342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior year adjustment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PriorYearAdjustment" xlink:to="lbl_label162009342" xlink:type="arc"/>
      <link:label id="id_78fa72de" xlink:label="lbl_label2029679326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of fair value adjustments relating to intangible assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_label2029679326" xlink:type="arc"/>
      <link:label id="id_691026f" xlink:label="lbl_label110166639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on Amortization of fair value adjustments relating to intangible assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_label110166639" xlink:type="arc"/>
      <link:label id="id_7f5dcb1f" xlink:label="lbl_label2136853279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about provisions and non-current liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_label2136853279" xlink:type="arc"/>
      <link:label id="id_ff7eee9" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions, contingent liabilities and contingent assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3d543140" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_55d4757f" xlink:label="lbl_label1439987071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:to="lbl_label1439987071" xlink:type="arc"/>
      <link:label id="id_5b6a3526" xlink:label="lbl_label1533687078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:to="lbl_label1533687078" xlink:type="arc"/>
      <link:label id="id_60a92ef1" xlink:label="lbl_label1621700337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, fiscal year maturity [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:to="lbl_label1621700337" xlink:type="arc"/>
      <link:label id="id_345b34eb" xlink:label="lbl_label878392555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:to="lbl_label878392555" xlink:type="arc"/>
      <link:label id="id_48374a1f" xlink:label="lbl_label1211583007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_label1211583007" xlink:type="arc"/>
      <link:label id="id_31459c86" xlink:label="lbl_label826645638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_label826645638" xlink:type="arc"/>
      <link:label id="id_2ad08cd6" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current net defined benefit liability</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:type="arc"/>
      <link:label id="id_7487a2cd" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans</link:label>
      <link:label id="id_74710a33" xlink:label="lbl_label1953565235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term employee benefits and deferred compensation</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:to="lbl_label1953565235" xlink:type="arc"/>
      <link:label id="id_26d5ce13" xlink:label="lbl_label651546131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other post-employment benefits</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPostemploymentBenefits" xlink:to="lbl_label651546131" xlink:type="arc"/>
      <link:label id="id_70976fa3" xlink:label="lbl_label304425068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental remediation provisions, non-current</link:label>
      <link:label id="id_5e14a65" xlink:label="lbl_label98650725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_5ed0917e" xlink:label="lbl_label1590727038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision [roll forward]</link:label>
      <link:label id="id_6aa8f98d" xlink:label="lbl_label448335871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_70108f36" xlink:label="lbl_label2143979670" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_52a74241" xlink:label="lbl_label1560928630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_57e9d2a0" xlink:label="lbl_label42481781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_5d09f298" xlink:label="lbl_label1902698328" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current provision</link:label>
      <link:label id="id_6048622c" xlink:label="lbl_label1615356460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, fiscal year maturity [abstract]</link:label>
      <link:label id="id_f98ea01" xlink:label="lbl_label1750372676" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total environmental remediation liability provisions</link:label>
      <link:label id="id_2ccb9fb2" xlink:label="lbl_label1351152500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within two years</link:label>
      <link:label id="id_78ad40b" xlink:label="lbl_label771700847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due later than two years, but within five years</link:label>
      <link:label id="id_7cc5fad5" xlink:label="lbl_label1968177093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due later than five years, but within ten years</link:label>
      <link:label id="id_6e61547b" xlink:label="lbl_label757561900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
      <link:label id="id_4bc380f7" xlink:label="lbl_label1271103735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions [roll forward]</link:label>
      <link:label id="id_68422c0a" xlink:label="lbl_label1583004694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to discontinued operations</link:label>
      <link:label id="id_efc629e" xlink:label="lbl_label1339267684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_6285ec7c" xlink:label="lbl_label1568927014" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_3f37b15b" xlink:label="lbl_label1379712140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_50e2f2bd" xlink:label="lbl_label1424862979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_73b301e7" xlink:label="lbl_label252843510" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Product liabilities government investigations other legal matters provisions at end of period</link:label>
      <link:label id="id_29a7abc" xlink:label="lbl_label438797926" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current provision</link:label>
      <link:label id="id_2ace6c03" xlink:label="lbl_label1363494370" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current product liabilities, governmental investigations and other legal matters provisions at end of period</link:label>
      <link:label id="id_39eddf10" xlink:label="lbl_label971890448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings provision [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsProvisionMember" xlink:to="lbl_label971890448" xlink:type="arc"/>
      <link:label id="id_1f2f7122" xlink:label="lbl_label523202850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solodyn [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SolodynMember" xlink:to="lbl_label523202850" xlink:type="arc"/>
      <link:label id="id_10d3ac94" xlink:label="lbl_label282307732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Lenses [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactLensesMember" xlink:to="lbl_label282307732" xlink:type="arc"/>
      <link:label id="id_3e0809a2" xlink:label="lbl_label1040714146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gleevec [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GleevecMember" xlink:to="lbl_label1040714146" xlink:type="arc"/>
      <link:label id="id_7edbae34" xlink:label="lbl_label2128326196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclast/Aclasta [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclastAclastaMember" xlink:to="lbl_label2128326196" xlink:type="arc"/>
      <link:label id="id_2b94eceb" xlink:label="lbl_label731180267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tekturna/Rasilez/Valturna [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TekturnaRasilezValturnaMember" xlink:to="lbl_label731180267" xlink:type="arc"/>
      <link:label id="id_6962e490" xlink:label="lbl_label1392715101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NAG and Novartis Pharma SpA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NAGAndNovartisPharmaSpAMember" xlink:to="lbl_label1392715101" xlink:type="arc"/>
      <link:label id="id_13f125ec" xlink:label="lbl_label400121727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">F Hoffman La Roche AG and Roche SpA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:to="lbl_label400121727" xlink:type="arc"/>
      <link:label id="id_5ce126b6" xlink:label="lbl_label1365859055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma K.K. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaKKMember" xlink:to="lbl_label1365859055" xlink:type="arc"/>
      <link:label id="id_4f6a2c55" xlink:label="lbl_label1494155554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NAG [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NAGMember" xlink:to="lbl_label1494155554" xlink:type="arc"/>
      <link:label id="id_514c724a" xlink:label="lbl_label201735145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NPC and others [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NPCAndOthersMember" xlink:to="lbl_label201735145" xlink:type="arc"/>
      <link:label id="id_41e7b3b9" xlink:label="lbl_label770853776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis NC [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNCMember" xlink:to="lbl_label770853776" xlink:type="arc"/>
      <link:label id="id_51394769" xlink:label="lbl_label1362708329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability contingency, loss exposure not accrued, number of cases</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:to="lbl_label1362708329" xlink:type="arc"/>
      <link:label id="id_241b918a" xlink:label="lbl_label605786506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability contingency, loss exposure not accrued, best estimate</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:to="lbl_label605786506" xlink:type="arc"/>
      <link:label id="id_2225e7d2" xlink:label="lbl_label572909522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="lbl_label572909522" xlink:type="arc"/>
      <link:label id="id_7a029719" xlink:label="lbl_label2046990105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of legal questions referred to court</link:label>
      <link:label id="id_5477d4dd" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, maximum fine</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:type="arc"/>
      <link:label id="id_4b15d12d" xlink:label="lbl_label1259721005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of putative cases referred to court</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:to="lbl_label1259721005" xlink:type="arc"/>
      <link:label id="id_2dbbe7e6" xlink:label="lbl_label767289318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of other cases referred to court</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:to="lbl_label767289318" xlink:type="arc"/>
      <link:label id="id_2ca8b224" xlink:label="lbl_label749253156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of states with alleged violations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:to="lbl_label749253156" xlink:type="arc"/>
      <link:label id="id_5f79ad81" xlink:label="lbl_label1601809793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of cases still pending</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:to="lbl_label1601809793" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:to="lbl_label2046990105" xlink:type="arc"/>
      <link:label id="id_206c121e" xlink:label="lbl_label543953438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="lbl_Revenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Revenue" xlink:to="lbl_label543953438" xlink:type="arc"/>
      <link:label id="id_16a8694f" xlink:label="lbl_label380135759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:to="lbl_label380135759" xlink:type="arc"/>
      <link:label id="id_37595e6f" xlink:label="lbl_label928603759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:to="lbl_label928603759" xlink:type="arc"/>
      <link:label id="id_3742c395" xlink:label="lbl_label927122325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:to="lbl_label927122325" xlink:type="arc"/>
      <link:label id="id_5358e820" xlink:label="lbl_label1398335520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:to="lbl_label1398335520" xlink:type="arc"/>
      <link:label id="id_7779807a" xlink:label="lbl_label2004451450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:to="lbl_label2004451450" xlink:type="arc"/>
      <link:label id="id_2af5dc98" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with former members of the Board of Directors [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:to="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3ade93c7" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with former members of the Board of Directors</link:label>
      <link:label id="id_3e931ad0" xlink:label="lbl_TotalFairValueAdjustmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total fair value adjustments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalFairValueAdjustmentsMember" xlink:to="lbl_TotalFairValueAdjustmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_5fef6f2d" xlink:label="lbl_TotalFairValueAdjustmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value adjustments</link:label>
      <link:label id="id_2b0a5355" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions at beginning of period</link:label>
      <link:label id="id_7633694e" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions at end of period</link:label>
      <link:label id="id_55d5426d" xlink:label="lbl_label1440039533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses, third party</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesThirdParty" xlink:to="lbl_label1440039533" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesThirdParty" xlink:to="lbl_label905656156" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:label id="id_4ecd5cc2" xlink:label="lbl_label1322081474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [abstract]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_label1322081474" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:label id="id_3ada3bfa" xlink:label="lbl_label987380730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_label987380730" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:label id="id_7e01564" xlink:label="lbl_label132126052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_label132126052" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="locator"/>
      <link:label id="id_545eb47a" xlink:label="lbl_label1415492730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one month and not later than three months [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:to="lbl_label1415492730" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember1" xlink:type="locator"/>
      <link:label id="id_7cfc55ea" xlink:label="lbl_label2096911850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearMember1" xlink:to="lbl_label2096911850" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="locator"/>
      <link:label id="id_22980743" xlink:label="lbl_label580388675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:to="lbl_label580388675" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="locator"/>
      <link:label id="id_1f823f0f" xlink:label="lbl_label528629519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:to="lbl_label528629519" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:label id="id_1d54f07" xlink:label="lbl_label30756615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one month [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotLaterThanOneMonthMember" xlink:to="lbl_label30756615" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities1" xlink:type="locator"/>
      <link:label id="id_69518" xlink:label="lbl_label431384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentLiabilities1" xlink:to="lbl_label431384" xlink:type="arc"/>
      <link:label id="id_7b946bcb" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past service cost and gains losses arising from settlements, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset1" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_11be10a7" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_529b4b2a" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from change in tax rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromChangeInTaxRate1" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:type="arc"/>
      <link:label id="id_9416195" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax rate change on current and deferred tax assets and liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="locator"/>
      <link:label id="id_753a14cc" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of expense not deductible in determining taxable profit tax loss</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:type="arc"/>
      <link:label id="id_4ff9c19a" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of disallowed expenditures</link:label>
      <link:label id="id_72f99baf" xlink:label="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of tax losses</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfTaxLosses1" xlink:to="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:type="arc"/>
      <link:label id="id_3858f2af" xlink:label="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of utilization of tax losses brought forward from prior periods</link:label>
      <link:label id="id_6100ccc9" xlink:label="lbl_OtherExpenseByFunction_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherExpenseByFunction" xlink:to="lbl_OtherExpenseByFunction_labels" xlink:type="arc"/>
      <link:label id="id_7b7f0633" xlink:label="lbl_OtherExpenseByFunction_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other expense, by function</link:label>
      <link:label id="id_295deb1d" xlink:label="lbl_label694020893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ParValuePerShare" xlink:to="lbl_label694020893" xlink:type="arc"/>
      <link:label id="id_223c2b0a" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_7418af90" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:label id="id_7592952b" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:label id="id_6a995f9c" xlink:label="lbl_label1788436380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxotere [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxotereMember" xlink:to="lbl_label1788436380" xlink:type="arc"/>
      <link:label id="id_578eb571" xlink:label="lbl_label1468970353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amiodarone [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmiodaroneMember" xlink:to="lbl_label1468970353" xlink:type="arc"/>
      <link:label id="id_3bc6fd49" xlink:label="lbl_label1002896713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of equity [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_label1002896713" xlink:type="arc"/>
      <link:label id="id_5120693" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of equity [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfEquityTextBlock" xlink:label="lbl_DisclosureOfEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEquityTextBlock" xlink:to="lbl_DisclosureOfEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6726d861" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
      <link:label id="id_3dc60187" xlink:label="lbl_DividendTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DividendTableTextBlock" xlink:label="lbl_DividendTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendTableTextBlock" xlink:to="lbl_DividendTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_258e3af2" xlink:label="lbl_DividendTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to Dividend</link:label>
      <link:label id="id_cb435c9" xlink:label="lbl_label213136841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmendmentFlag" xlink:to="lbl_label213136841" xlink:type="arc"/>
      <link:label id="id_5d388f3d" xlink:label="lbl_label1563987773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentPeriodEndDate" xlink:to="lbl_label1563987773" xlink:type="arc"/>
      <link:label id="id_1e619d64" xlink:label="lbl_label509713764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentFiscalYearFocus" xlink:to="lbl_label509713764" xlink:type="arc"/>
      <link:label id="id_7fb4d619" xlink:label="lbl_label2142557721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentFiscalPeriodFocus" xlink:to="lbl_label2142557721" xlink:type="arc"/>
      <link:label id="id_29f6dab9" xlink:label="lbl_label704043705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradingSymbol" xlink:to="lbl_label704043705" xlink:type="arc"/>
      <link:label id="id_30c984d" xlink:label="lbl_label51157069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityRegistrantName" xlink:to="lbl_label51157069" xlink:type="arc"/>
      <link:label id="id_387f1769" xlink:label="lbl_label947853161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCentralIndexKey" xlink:to="lbl_label947853161" xlink:type="arc"/>
      <link:label id="id_6f6c1fbf" xlink:label="lbl_label1869356991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFiscalYearEndDate" xlink:to="lbl_label1869356991" xlink:type="arc"/>
      <link:label id="id_6f81ea6f" xlink:label="lbl_label1870785135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityWellKnownSeasonedIssuer" xlink:to="lbl_label1870785135" xlink:type="arc"/>
      <link:label id="id_593907e" xlink:label="lbl_label93556862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCurrentReportingStatus" xlink:to="lbl_label93556862" xlink:type="arc"/>
      <link:label id="id_a350bde" xlink:label="lbl_label171248606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityVoluntaryFilers" xlink:to="lbl_label171248606" xlink:type="arc"/>
      <link:label id="id_1ebbff8e" xlink:label="lbl_label515637134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityFilerCategory" xlink:to="lbl_label515637134" xlink:type="arc"/>
      <link:label id="id_2df8f48d" xlink:label="lbl_label771290253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCommonStockSharesOutstanding" xlink:to="lbl_label771290253" xlink:type="arc"/>
      <link:label id="id_6a10c99a" xlink:label="lbl_label1779485082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityPublicFloat" xlink:to="lbl_label1779485082" xlink:type="arc"/>
      <link:label id="id_60ad1327" xlink:label="lbl_US_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_US" xlink:to="lbl_US_labels" xlink:type="arc"/>
      <link:label id="id_45b4f0b8" xlink:label="lbl_GB_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GB" xlink:to="lbl_GB_labels" xlink:type="arc"/>
      <link:label id="id_fa4133c" xlink:label="lbl_DE_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DE" xlink:to="lbl_DE_labels" xlink:type="arc"/>
      <link:label id="id_4fab4920" xlink:label="lbl_FR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FR" xlink:to="lbl_FR_labels" xlink:type="arc"/>
      <link:label id="id_2409370a" xlink:label="lbl_JP_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JP" xlink:to="lbl_JP_labels" xlink:type="arc"/>
      <link:label id="id_7e84627" xlink:label="lbl_US_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US</link:label>
      <link:label id="id_35cc0588" xlink:label="lbl_GB_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK</link:label>
      <link:label id="id_11499416" xlink:label="lbl_DE_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
      <link:label id="id_50732a2" xlink:label="lbl_FR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
      <link:label id="id_16ecebec" xlink:label="lbl_JP_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
      <link:label id="id_47d2ec01" xlink:label="lbl_IT_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IT" xlink:to="lbl_IT_labels" xlink:type="arc"/>
      <link:label id="id_3b372d9d" xlink:label="lbl_IT_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Italy</link:label>
      <link:label id="id_53d1a5ee" xlink:label="lbl_CA_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CA" xlink:to="lbl_CA_labels" xlink:type="arc"/>
      <link:label id="id_68cbde64" xlink:label="lbl_CA_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada</link:label>
      <link:label id="id_87623f2" xlink:label="lbl_USD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USD" xlink:to="lbl_USD_labels" xlink:type="arc"/>
      <link:label id="id_73a7c19e" xlink:label="lbl_USD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USD</link:label>
      <link:label id="id_78126268" xlink:label="lbl_EUR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EUR" xlink:to="lbl_EUR_labels" xlink:type="arc"/>
      <link:label id="id_70708ef7" xlink:label="lbl_EUR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EUR</link:label>
      <link:label id="id_12746a38" xlink:label="lbl_JPY_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JPY" xlink:to="lbl_JPY_labels" xlink:type="arc"/>
      <link:label id="id_7b8f8056" xlink:label="lbl_JPY_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JPY</link:label>
      <link:label id="id_7a7394c2" xlink:label="lbl_CNY_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China, Yuan Renminbi</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CNY" xlink:to="lbl_CNY_labels" xlink:type="arc"/>
      <link:label id="id_4d265dd0" xlink:label="lbl_CNY_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CNY</link:label>
      <link:label id="id_1c17f7c4" xlink:label="lbl_GBP_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GBP" xlink:to="lbl_GBP_labels" xlink:type="arc"/>
      <link:label id="id_1728da67" xlink:label="lbl_GBP_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GBP</link:label>
      <link:label id="id_436074ee" xlink:label="lbl_CHF_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHF</link:label>
      <link:label id="id_1da98c1e" xlink:label="lbl_label497650718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_label497650718" xlink:type="arc"/>
      <link:label id="id_12b84aa7" xlink:label="lbl_label314067623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_label314067623" xlink:type="arc"/>
      <link:label id="id_165ab5d4" xlink:label="lbl_label375043540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_label375043540" xlink:type="arc"/>
      <link:label id="id_238135db" xlink:label="lbl_label595670491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityDomain" xlink:to="lbl_label595670491" xlink:type="arc"/>
      <link:label id="id_1d17e2f2" xlink:label="lbl_label488104690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_label488104690" xlink:type="arc"/>
      <link:label id="id_1d7da856" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Need new ITEM here</link:label>
      <link:label id="id_751ef3e9" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">General and Administration</link:label>
      <link:label id="id_20c355f9" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in non-controling interests</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:type="arc"/>
      <link:label id="id_71d21c6b" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in non-controlling interests</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:label id="id_7d6a6449" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends received from associated companies and others</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4bdcb2fd" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received, classified as operating activities</link:label>
      <link:label id="id_d7b5832" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income received, classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_7e7ea58d" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial receipts</link:label>
      <link:label id="id_44baadd4" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs paid, classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_68d65042" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial payments</link:label>
      <link:label id="id_36d7aeb1" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of interests in associates</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:to="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:type="arc"/>
      <link:label id="id_df43529" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestments of interests in associated companies</link:label>
      <link:label id="id_789b89ac" xlink:label="lbl_label1718040268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of businesses, net</link:label>
      <link:label id="id_197c150c" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to shareholders of Novartis AG</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3ec8bcea" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:label id="id_7cc199f7" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from non-current financial debts</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromNoncurrentBorrowings" xlink:to="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_2e7bd9f2" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of non-current borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentsOfNoncurrentBorrowings" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_106de250" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of non-current financial debts</link:label>
      <link:label id="id_40f4d6a8" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from non-current borrowings</link:label>
      <link:label id="id_1bde8770" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) increase (decrease) in current borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_104baa70" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in current financial debts</link:label>
      <link:label id="id_367ad3ce" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing cash flows, net</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2a649f3d" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as financing activities</link:label>
      <link:label id="id_3f82a721" xlink:label="lbl_IncomeTaxesPaidRefund_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefund" xlink:to="lbl_IncomeTaxesPaidRefund_labels" xlink:type="arc"/>
      <link:label id="id_53191c38" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_16a1607" xlink:label="lbl_label23729671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfReportableSegments" xlink:to="lbl_label23729671" xlink:type="arc"/>
      <link:label id="id_ff1b344" xlink:label="lbl_label267498308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Business Units</link:label>
      <link:label id="id_19aaa924" xlink:label="lbl_label430614820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Franchises</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfFranchises" xlink:to="lbl_label430614820" xlink:type="arc"/>
      <link:label id="id_4ccf5884" xlink:label="lbl_AdditionsToRestructuringProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to restructuring provisions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionsToRestructuringProvisions" xlink:label="lbl_AdditionsToRestructuringProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToRestructuringProvisions" xlink:to="lbl_AdditionsToRestructuringProvisions_labels" xlink:type="arc"/>
      <link:label id="id_3b0ef23" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to property, plant and equipment</link:label>
      <link:label id="id_528839cf" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to intangible assets and goodwill</link:label>
      <link:label id="id_40106876" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties and other segments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:type="arc"/>
      <link:label id="id_7458433e" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales to third parties from continuing operations</link:label>
      <link:label id="id_541cacbc" xlink:label="lbl_label1411165372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties and other segments, as percent of total net sales</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:to="lbl_label1411165372" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:to="lbl_label102429242" xlink:type="arc"/>
      <link:label id="id_5aa03955" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected non-current assets, as percent</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_6c200908" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected non-current assets (in % of total selected non-current assets)</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:to="lbl_label1358337308" xlink:type="arc"/>
      <link:label id="id_6d471c75" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of investments in associates for which there are quoted market prices</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:to="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:type="arc"/>
      <link:label id="id_6319607c" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
      <link:label id="id_51c4430d" xlink:label="lbl_label1371816717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense, gross</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_label1371816717" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_label1549022431" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:label id="id_752e4898" xlink:label="lbl_label1965967512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend income</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromDividends" xlink:to="lbl_label1965967512" xlink:type="arc"/>
      <link:label id="id_6b7200d3" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss on commodities and available-for-sale securities, net</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:type="arc"/>
      <link:label id="id_4fa6704a" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of commodities and available-for-sale securities, net</link:label>
      <link:label id="id_6fd24c63" xlink:label="lbl_OtherFinanceCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance cost</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinanceCost" xlink:to="lbl_OtherFinanceCost_labels" xlink:type="arc"/>
      <link:label id="id_2d3e7598" xlink:label="lbl_OtherFinanceCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial expense</link:label>
      <link:label id="id_2b07fd1f" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), discontinuing operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_671db01c" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense from discontinued operations</link:label>
      <link:label id="id_772c2e3e" xlink:label="lbl_label1999384126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from non-deductible losses</link:label>
      <link:label id="id_199436bd" xlink:label="lbl_label429143741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation change in uncertain tax positions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lbl_label429143741" xlink:type="arc"/>
      <link:label id="id_80d3caa" xlink:label="lbl_label135085226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation other adjustments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lbl_label135085226" xlink:type="arc"/>
      <link:label id="id_2016529c" xlink:label="lbl_label538333852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation change in enacted tax rate</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lbl_label538333852" xlink:type="arc"/>
      <link:label id="id_2aa51152" xlink:label="lbl_label1640547073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:to="lbl_label1640547073" xlink:type="arc"/>
      <link:label id="id_596243a4" xlink:label="lbl_label1689586548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income net of tax exchange differences on translation related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:to="lbl_label1689586548" xlink:type="arc"/>
      <link:label id="id_1a035b8a" xlink:label="lbl_label436427658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business unit [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_label436427658" xlink:type="arc"/>
      <link:label id="id_7dfe6553" xlink:label="lbl_label2113824083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business unit [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_label2113824083" xlink:type="arc"/>
      <link:label id="id_1c8ae042" xlink:label="lbl_label478863426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OncologyMember" xlink:to="lbl_label478863426" xlink:type="arc"/>
      <link:label id="id_6b138679" xlink:label="lbl_label1796441721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmaceutical [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PharmaceuticalMember" xlink:to="lbl_label1796441721" xlink:type="arc"/>
      <link:label id="id_73d27a10" xlink:label="lbl_label1943173648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Franchise [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_label1943173648" xlink:type="arc"/>
      <link:label id="id_578f16d9" xlink:label="lbl_label1468995289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Franchise [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FranchiseMember" xlink:to="lbl_label1468995289" xlink:type="arc"/>
      <link:label id="id_7a3bb683" xlink:label="lbl_label2050733699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmology [member]</link:label>
      <link:label id="id_29ccb106" xlink:label="lbl_label701280518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeuroscienceMember" xlink:to="lbl_label701280518" xlink:type="arc"/>
      <link:label id="id_1b0191fc" xlink:label="lbl_label453087740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respiratory [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespiratoryMember" xlink:to="lbl_label453087740" xlink:type="arc"/>
      <link:label id="id_43a1daf0" xlink:label="lbl_label1134680816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular, Renal and Metabolism [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CardioMetabolicMember" xlink:to="lbl_label1134680816" xlink:type="arc"/>
      <link:label id="id_393ea837" xlink:label="lbl_label960407607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Medicines [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedMedicinesMember" xlink:to="lbl_label960407607" xlink:type="arc"/>
      <link:label id="id_5bf06316" xlink:label="lbl_label1542480662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product portfolio [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_label1542480662" xlink:type="arc"/>
      <link:label id="id_38b2f5ea" xlink:label="lbl_label951252458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product portfolio [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_label951252458" xlink:type="arc"/>
      <link:label id="id_77b41933" xlink:label="lbl_label2008291635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COPD [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_COPDMember" xlink:to="lbl_label2008291635" xlink:type="arc"/>
      <link:label id="id_7bd53aee" xlink:label="lbl_label2077571822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gleevec/Glivec [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GleevecGlivecMember" xlink:to="lbl_label2077571822" xlink:type="arc"/>
      <link:label id="id_b0600c4" xlink:label="lbl_label184942788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tasigna [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TasignaMember" xlink:to="lbl_label184942788" xlink:type="arc"/>
      <link:label id="id_3f81d4ef" xlink:label="lbl_label1065473263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandostatin [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandostatinMember" xlink:to="lbl_label1065473263" xlink:type="arc"/>
      <link:label id="id_b64c3a5" xlink:label="lbl_label191153061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Afinitor/Votubia [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AfinitorVotubiaMember" xlink:to="lbl_label191153061" xlink:type="arc"/>
      <link:label id="id_7ee4b441" xlink:label="lbl_label2128917569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exjade/Jadenu [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExjadeJadenuMember" xlink:to="lbl_label2128917569" xlink:type="arc"/>
      <link:label id="id_28e14893" xlink:label="lbl_label685852819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tafinlar + Mekinist [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TafinlarMekinistMember" xlink:to="lbl_label685852819" xlink:type="arc"/>
      <link:label id="id_67d8ca2f" xlink:label="lbl_label1742260783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promacta/Revolade [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PromactaRevoladeMember" xlink:to="lbl_label1742260783" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OphthalmologyMember" xlink:to="lbl_label2050733699" xlink:type="arc"/>
      <link:label id="id_647651d6" xlink:label="lbl_label1685475798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Votrient [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VotrientMember" xlink:to="lbl_label1685475798" xlink:type="arc"/>
      <link:label id="id_2746717b" xlink:label="lbl_label658927995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jakavi [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JakaviMember" xlink:to="lbl_label658927995" xlink:type="arc"/>
      <link:label id="id_72117eb7" xlink:label="lbl_label1913749175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kisqali [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KisqaliMember" xlink:to="lbl_label1913749175" xlink:type="arc"/>
      <link:label id="id_4dee8d50" xlink:label="lbl_label1307479376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProductsMember" xlink:to="lbl_label1307479376" xlink:type="arc"/>
      <link:label id="id_6a7a37e6" xlink:label="lbl_label1786394598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travoprost Group [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TravoprostGroupMember" xlink:to="lbl_label1786394598" xlink:type="arc"/>
      <link:label id="id_3e01b08f" xlink:label="lbl_label1040298127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Systane Group [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SystaneGroupMember" xlink:to="lbl_label1040298127" xlink:type="arc"/>
      <link:label id="id_3ffa23d" xlink:label="lbl_label67084861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Topical Olopatadine Group [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TopicalOlopatadineGroupMember" xlink:to="lbl_label67084861" xlink:type="arc"/>
      <link:label id="id_931b1f9" xlink:label="lbl_label154251769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cosentyx [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CosentyxMember" xlink:to="lbl_label154251769" xlink:type="arc"/>
      <link:label id="id_31cd0397" xlink:label="lbl_label835519383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neoral/Sandimmun(e) [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeoralSandimmunEMember" xlink:to="lbl_label835519383" xlink:type="arc"/>
      <link:label id="id_48585481" xlink:label="lbl_label1213748353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zortress/Certican [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZortressCerticanMember" xlink:to="lbl_label1213748353" xlink:type="arc"/>
      <link:label id="id_d8aed9" xlink:label="lbl_label14200537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ilaris [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IlarisMember" xlink:to="lbl_label14200537" xlink:type="arc"/>
      <link:label id="id_612117f4" xlink:label="lbl_label1629558772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Myfortic [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MyforticMember" xlink:to="lbl_label1629558772" xlink:type="arc"/>
      <link:label id="id_63153a75" xlink:label="lbl_label1662335605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilenya [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GilenyaMember" xlink:to="lbl_label1662335605" xlink:type="arc"/>
      <link:label id="id_79c9c9f8" xlink:label="lbl_label2043267576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ultibro Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UltibroBreezhalerMember" xlink:to="lbl_label2043267576" xlink:type="arc"/>
      <link:label id="id_39edf745" xlink:label="lbl_label971896645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seebri Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SeebriBreezhalerMember" xlink:to="lbl_label971896645" xlink:type="arc"/>
      <link:label id="id_3093cd1d" xlink:label="lbl_label814992669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Onbrez Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OnbrezBreezhalerMember" xlink:to="lbl_label814992669" xlink:type="arc"/>
      <link:label id="id_61b9d990" xlink:label="lbl_label1639569808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entresto [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntrestoMember" xlink:to="lbl_label1639569808" xlink:type="arc"/>
      <link:label id="id_ba5bf3e" xlink:label="lbl_label195411774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galvus Group [member]</link:label>
      <link:label id="id_4a18d85e" xlink:label="lbl_label1243142238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exforge Group [member]</link:label>
      <link:label id="id_75a7ce71" xlink:label="lbl_label1973931633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diovan Group [member]</link:label>
      <link:label id="id_2e0075fc" xlink:label="lbl_label771782140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voltaren/Cataflam [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VoltarenCataflamMember" xlink:to="lbl_label771782140" xlink:type="arc"/>
      <link:label id="id_5304aa12" xlink:label="lbl_label1392814610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exelon/Exelon Patch [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExelonExelonPatchMember" xlink:to="lbl_label1392814610" xlink:type="arc"/>
      <link:label id="id_10a15386" xlink:label="lbl_label279008134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ritalin/Focalin [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RitalinFocalinMember" xlink:to="lbl_label279008134" xlink:type="arc"/>
      <link:label id="id_26f1359c" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on disposals, property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_1c74ede2" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on disposals and derecognitions</link:label>
      <link:label id="id_22aa91df" xlink:label="lbl_label1255943452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated impairments on disposals and derecognition</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:to="lbl_label1255943452" xlink:type="arc"/>
      <link:label id="id_626451ea" xlink:label="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired research and development [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredResearchAndDevelopmentMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:type="arc"/>
      <link:label id="id_d6a6395" xlink:label="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired research and development</link:label>
      <link:label id="id_52b9d0b7" xlink:label="lbl_AlconBrandNameMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon brand name [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconBrandNameMember" xlink:to="lbl_AlconBrandNameMember_labels" xlink:type="arc"/>
      <link:label id="id_4db335d9" xlink:label="lbl_AlconBrandNameMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Alcon brand name</link:label>
      <link:label id="id_52290b49" xlink:label="lbl_label1378421577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross value of tax loss carry forwards expiring in future years</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:to="lbl_label1378421577" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:to="lbl_label94266701" xlink:type="arc"/>
      <link:label id="id_70e22198" xlink:label="lbl_label198642827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales, change in %</link:label>
      <link:label id="id_330af3ff" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders of Novartis AG</link:label>
      <link:label id="id_2b7d0eda" xlink:label="lbl_label729616090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative currency translation gains/losses recycled through income statement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:to="lbl_label729616090" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:type="locator"/>
      <link:label id="id_19f22bed" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired loss on financial assets transferred to the income statement</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:to="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_2ac3f739" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification adjustments on financial assets measured at fair value through other comprehensive income, net of tax</link:label>
      <link:label id="id_1bf8cda2" xlink:label="lbl_label469290402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, available-for-sale financial investments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:label="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:to="lbl_label469290402" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:to="lbl_label521267934" xlink:type="arc"/>
      <link:label id="id_523cf50c" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, maketable securities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:type="arc"/>
      <link:label id="id_64b0e4db" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
      <link:label id="id_37e931e5" xlink:label="lbl_FinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceLeaseReceivables" xlink:label="lbl_FinanceLeaseReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseReceivables" xlink:to="lbl_FinanceLeaseReceivables_labels" xlink:type="arc"/>
      <link:label id="id_f9fb296" xlink:label="lbl_FinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease receivables</link:label>
      <link:label id="id_18330ebd" xlink:label="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments from finance lease agreements</link:label>
      <link:label id="id_5342799f" xlink:label="lbl_label1396865439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDoubtfulReceivableMember" xlink:to="lbl_label1396865439" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Commodities" xlink:to="lbl_label1789088932" xlink:type="arc"/>
      <link:label id="id_2985d64f" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding share capital</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_OutstandingShareCapital_labels" xlink:type="arc"/>
      <link:label id="id_550535ae" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total outstanding share capital at beginning of period</link:label>
      <link:label id="id_75bd4d3d" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total outstanding share capital at end of period</link:label>
      <link:label id="id_551db3e0" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:label id="id_736416f8" xlink:label="lbl_IssuedCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital, movement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapitalMovement" xlink:to="lbl_IssuedCapitalMovement_labels" xlink:type="arc"/>
      <link:label id="id_58515153" xlink:label="lbl_IssuedCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital movement of period</link:label>
      <link:label id="id_416f3b0f" xlink:label="lbl_OutstandingShareCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding share capital, movement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_OutstandingShareCapitalMovement_labels" xlink:type="arc"/>
      <link:label id="id_578dd06d" xlink:label="lbl_OutstandingShareCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total shares outstanding movement of period</link:label>
      <link:label id="id_6cc370cc" xlink:label="lbl_label1824747724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares cancelled for capital reduction</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesCancelledForCapitalReduction" xlink:to="lbl_label1824747724" xlink:type="arc"/>
      <link:label id="id_138eeec4" xlink:label="lbl_TreasurySharesMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares, movement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesMovement" xlink:label="lbl_TreasurySharesMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMovement" xlink:to="lbl_TreasurySharesMovement_labels" xlink:type="arc"/>
      <link:label id="id_296c7c9b" xlink:label="lbl_TreasurySharesMovement_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total number of outstanding treasury shares</link:label>
      <link:label id="id_3fd2a1c9" xlink:label="lbl_SharepurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:label id="id_4f72913c" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares, equity impact</link:label>
      <link:label id="id_10472e97" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity impact of treasury share movements</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityImpactOfTreasuryShareMovements" xlink:label="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityImpactOfTreasuryShareMovements" xlink:to="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:type="arc"/>
      <link:label id="id_1cdf067d" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity impact of treasury share movements</link:label>
      <link:label id="id_495f6f85" xlink:label="lbl_label903405960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average interest rate on loans received</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageInterestRateOnLoansReceived" xlink:to="lbl_label903405960" xlink:type="arc"/>
      <link:label id="id_57858aea" xlink:label="lbl_label1766025212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio fixed rate financial debt to total financial debt</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:to="lbl_label1766025212" xlink:type="arc"/>
      <link:label id="id_10cf25f4" xlink:label="lbl_label1048419104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average interest rate on borrowings</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageInterestRateOnBorrowings" xlink:to="lbl_label1048419104" xlink:type="arc"/>
      <link:label id="id_2aee42a4" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, coupon</link:label>
      <link:label id="id_176fa55a" xlink:label="lbl_BorrowingsIssuanceDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issuance year</link:label>
      <link:label id="id_6ff69971" xlink:label="lbl_BorrowingsMaturity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, maturity year</link:label>
      <link:label id="id_7a5c6046" xlink:label="lbl_BorrowingsLender_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issuer</link:label>
      <link:label id="id_30da0d60" xlink:label="lbl_BorrowingsPremiumDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issue price</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationNonCurrent" xlink:to="lbl_label98650725" xlink:type="arc"/>
      <link:label id="id_38f01585" xlink:label="lbl_label955258245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Environmental remediation provisions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_label1590727038" xlink:type="arc"/>
      <link:label id="id_26f523d7" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvision" xlink:to="lbl_EnvironmentalProvision_labels" xlink:type="arc"/>
      <link:label id="id_2f8c0636" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Environmental liabilities provision at beginning of period</link:label>
      <link:label id="id_3ca05f15" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Environmental liabilities provision at end of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvision" xlink:to="lbl_label1750372676" xlink:type="arc"/>
      <link:label id="id_5bf2bac7" xlink:label="lbl_label1542634183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, payments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionPayments" xlink:to="lbl_label1542634183" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionPayments" xlink:to="lbl_label448335871" xlink:type="arc"/>
      <link:label id="id_1bbf0a1c" xlink:label="lbl_label465504796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, releases</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionReleases" xlink:to="lbl_label465504796" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionReleases" xlink:to="lbl_label2143979670" xlink:type="arc"/>
      <link:label id="id_30109c5e" xlink:label="lbl_label806394974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, additions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionAdditions" xlink:to="lbl_label806394974" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionAdditions" xlink:to="lbl_label1560928630" xlink:type="arc"/>
      <link:label id="id_6528e847" xlink:label="lbl_label1697179719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, foreign currency translation gain (loss)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1697179719" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:to="lbl_label42481781" xlink:type="arc"/>
      <link:label id="id_69c992c5" xlink:label="lbl_EnvironmentalProvisionCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, Current</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionCurrent" xlink:to="lbl_EnvironmentalProvisionCurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionCurrent" xlink:to="lbl_label1902698328" xlink:type="arc"/>
      <link:label id="id_76c21b8c" xlink:label="lbl_label1992432524" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current environmental remediation provisions at end of period</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label1992432524" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label955258245" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label304425068" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:label="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_label1615356460" xlink:type="arc"/>
      <link:label id="id_6deab0eb" xlink:label="lbl_label1844097259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, next two years</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:to="lbl_label1844097259" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:to="lbl_label1351152500" xlink:type="arc"/>
      <link:label id="id_54b46e40" xlink:label="lbl_label1421110848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, later than two years, but within five years</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:to="lbl_label1421110848" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:to="lbl_label771700847" xlink:type="arc"/>
      <link:label id="id_366842e4" xlink:label="lbl_label912802532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, later than five years, but within ten years</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:to="lbl_label912802532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:to="lbl_label1968177093" xlink:type="arc"/>
      <link:label id="id_53179e3c" xlink:label="lbl_label1394056764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, after ten years</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:to="lbl_label1394056764" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:to="lbl_label757561900" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_label1271103735" xlink:type="arc"/>
      <link:label id="id_5e9e598e" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:type="arc"/>
      <link:label id="id_1dcf084" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Product liabilities government investigations other legal matters provisions at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_label252843510" xlink:type="arc"/>
      <link:label id="id_71839c4e" xlink:label="lbl_label1904450638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:to="lbl_label1904450638" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:to="lbl_label1583004694" xlink:type="arc"/>
      <link:label id="id_53472504" xlink:label="lbl_label1397171460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, payments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:to="lbl_label1397171460" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:to="lbl_label1339267684" xlink:type="arc"/>
      <link:label id="id_3e905f98" xlink:label="lbl_label1049649048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, releases</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:to="lbl_label1049649048" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:to="lbl_label1568927014" xlink:type="arc"/>
      <link:label id="id_61e84c26" xlink:label="lbl_label1642613798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, additions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:to="lbl_label1642613798" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:to="lbl_label1379712140" xlink:type="arc"/>
      <link:label id="id_6c695b53" xlink:label="lbl_label1818843987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, foreign currency translation gain (loss)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1818843987" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1424862979" xlink:type="arc"/>
      <link:label id="id_54a4e6a7" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, current</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:to="lbl_label438797926" xlink:type="arc"/>
      <link:label id="id_acc6217" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, non-current</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:to="lbl_label1363494370" xlink:type="arc"/>
      <link:label id="id_d93a8b" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateAssociates" xlink:to="lbl_WeightedAverageInterestRateAssociates_labels" xlink:type="arc"/>
      <link:label id="id_6be37912" xlink:label="lbl_WeightedAverageInterestRateAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on interest bearning accounts of associates payable on demand.</link:label>
      <link:label id="id_1a1c62e1" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on Bank and other financial debt</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_1401b9c9" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on Bank and other financial debt</link:label>
      <link:label id="id_7df4e11d" xlink:label="lbl_EnvironmentalProvisionCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Environmental remediation liabilities</link:label>
      <link:label id="id_19219108" xlink:label="lbl_AccrualsClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses for goods and services received but not invoiced</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualsClassifiedAsCurrent" xlink:to="lbl_AccrualsClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_2731b8ee" xlink:label="lbl_AccrualsClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals classified as current</link:label>
      <link:label id="id_1dcdc504" xlink:label="lbl_ContingentConsiderationCurrentPortion_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration, current portion</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationCurrentPortion" xlink:to="lbl_ContingentConsiderationCurrentPortion_labels" xlink:type="arc"/>
      <link:label id="id_cecd050" xlink:label="lbl_ContingentConsiderationCurrentPortion_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent considerations</link:label>
      <link:label id="id_66cb3d62" xlink:label="lbl_label1724595554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for deduction from revenue [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_label1724595554" xlink:type="arc"/>
      <link:label id="id_62196d01" xlink:label="lbl_label1645833473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_label1645833473" xlink:type="arc"/>
      <link:label id="id_5c0c0960" xlink:label="lbl_RestructuringProvisionTransfers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provision transfers</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestructuringProvisionTransfers" xlink:label="lbl_RestructuringProvisionTransfers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionTransfers" xlink:to="lbl_RestructuringProvisionTransfers_labels" xlink:type="arc"/>
      <link:label id="id_2238ed4d" xlink:label="lbl_RestructuringProvisionTransfers_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:type="locator"/>
      <link:label id="id_78c7fbb0" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification adjustments on cash flow hedges, net of tax</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:to="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_b7c54f9" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized net losses on cash flow hedges transferred to the consolidated income statement</link:label>
      <link:label id="id_58b3a333" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables and deferred tax liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5a90c79" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_2856a2a3" xlink:label="lbl_IdentifiableAssetsAcquired_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_IdentifiableAssetsAcquired_labels" xlink:type="arc"/>
      <link:label id="id_205b065c" xlink:label="lbl_IdentifiableAssetsAcquired_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net identifiable assets acquired</link:label>
      <link:label id="id_62f623d2" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property plant and equipment recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_59f5d7c5" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_28728c08" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_4dd002d2" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_3be633c" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired divested research and development intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3369d331" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Acquired)/divested research and development</link:label>
      <link:label id="id_44229a8b" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technologies recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3e9ce44a" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technologies</link:label>
      <link:label id="id_33f9a377" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_52667216" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_2879f83e" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_64556efa" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:label id="id_63e0564e" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_7a3f0241" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_4427bc74" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_5681fbbf" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:label id="id_6359834c" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_47a6ced3" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_4d854151" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3ea67aa0" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts</link:label>
      <link:label id="id_1be55693" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_65a5731d" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_5d12057a" xlink:label="lbl_label1419113480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Animal health [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AnimalHealthMember" xlink:label="lbl_AnimalHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnimalHealthMember" xlink:to="lbl_label1419113480" xlink:type="arc"/>
      <link:label id="id_6ab963bf" xlink:label="lbl_label1790534591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of business</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromSaleOfBusiness" xlink:label="lbl_ProceedsFromSaleOfBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSaleOfBusiness" xlink:to="lbl_label1790534591" xlink:type="arc"/>
      <link:label id="id_2cda3a42" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in/from investing activities from discontinued operations</link:label>
      <link:label id="id_7f35ae76" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments at beginning of period</link:label>
      <link:label id="id_5e88cc26" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments at end of period</link:label>
      <link:label id="id_32b354fd" xlink:label="lbl_label1199806184" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair values and other changes</link:label>
      <link:label id="id_3eaf2bac" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfBondsDiscount" xlink:to="lbl_AmortizationOfBondsDiscount_labels" xlink:type="arc"/>
      <link:label id="id_4b9e2882" xlink:label="lbl_label1268656258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debts [member]</link:label>
      <link:label id="id_24db2ae3" xlink:label="lbl_label618343139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debts and derivative financial instruments [member]</link:label>
      <link:label id="id_20254569" xlink:label="lbl_label539313513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:to="lbl_label539313513" xlink:type="arc"/>
      <link:label id="id_4171dffa" xlink:label="lbl_label1097981946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech / Roche [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GenentechRocheMember" xlink:to="lbl_label1097981946" xlink:type="arc"/>
      <link:label id="id_21b59c45" xlink:label="lbl_label565550149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of contracts with related parties</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfContractsWithRelatedParties" xlink:to="lbl_label565550149" xlink:type="arc"/>
      <link:label id="id_140db491" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of executive commitee members</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers_labels" xlink:type="arc"/>
      <link:label id="id_12cdd92b" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Commitee members</link:label>
      <link:label id="id_4d39a061" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of non-executive directors</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:type="arc"/>
      <link:label id="id_2b93879e" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-executive directors</link:label>
      <link:label id="id_4c2ae7af" xlink:label="lbl_label1277880239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future benefit payment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:to="lbl_label1277880239" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:to="lbl_label839490648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:to="lbl_label2113441601" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:to="lbl_label1670270510" xlink:type="arc"/>
      <link:label id="id_2111657b" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative expense net defined benefit liability asset</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6b50d402" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:label id="id_2605ce0d" xlink:label="lbl_label637914637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in expreience related assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label637914637" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label783050349" xlink:type="arc"/>
      <link:label id="id_45a2931c" xlink:label="lbl_label1168282396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, foreign currency exchange rate gain (loss)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:to="lbl_label1168282396" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:to="lbl_label220841955" xlink:type="arc"/>
      <link:label id="id_329368f1" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:to="lbl_label1273555602" xlink:type="arc"/>
      <link:label id="id_5b9bb55e" xlink:label="lbl_label1536931166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years and not later than ten years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:to="lbl_label1536931166" xlink:type="arc"/>
      <link:label id="id_7cbb695f" xlink:label="lbl_label2092656991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_label2092656991" xlink:type="arc"/>
      <link:label id="id_675e88e3" xlink:label="lbl_label1734248675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_label1734248675" xlink:type="arc"/>
      <link:label id="id_6f8cf207" xlink:label="lbl_label1871507975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssets" xlink:to="lbl_label1871507975" xlink:type="arc"/>
      <link:label id="id_31c4b50a" xlink:label="lbl_label834974986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_label834974986" xlink:type="arc"/>
      <link:label id="id_3b500f38" xlink:label="lbl_label995102520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_label995102520" xlink:type="arc"/>
      <link:label id="id_5853963a" xlink:label="lbl_label1481872954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtAmortisedCostMember" xlink:to="lbl_label1481872954" xlink:type="arc"/>
      <link:label id="id_15228c3a" xlink:label="lbl_label354585658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsMember" xlink:to="lbl_label354585658" xlink:type="arc"/>
      <link:label id="id_2ea70" xlink:label="lbl_label191088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_label191088" xlink:type="arc"/>
      <link:label id="id_5fa2081d" xlink:label="lbl_label1604454429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_label1604454429" xlink:type="arc"/>
      <link:label id="id_7ddd290" xlink:label="lbl_label131977872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities [member]</link:label>
      <link:label id="id_36737cf8" xlink:label="lbl_label913538296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale long-term financial investments [member]</link:label>
      <link:label id="id_5632a636" xlink:label="lbl_label1446159926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet item [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_label1446159926" xlink:type="arc"/>
      <link:label id="id_77e6aae0" xlink:label="lbl_label2011605728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet item [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_label2011605728" xlink:type="arc"/>
      <link:label id="id_39f42abc" xlink:label="lbl_label972303036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquitySecuritiesMember" xlink:to="lbl_label972303036" xlink:type="arc"/>
      <link:label id="id_34461243" xlink:label="lbl_label877007427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fund investments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FundInvestmentsMember" xlink:to="lbl_label877007427" xlink:type="arc"/>
      <link:label id="id_3c80f6bd" xlink:label="lbl_label1015084733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets excluding pre-payments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:to="lbl_label1015084733" xlink:type="arc"/>
      <link:label id="id_71d621f1" xlink:label="lbl_label1909858801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivablesMember" xlink:to="lbl_label1909858801" xlink:type="arc"/>
      <link:label id="id_266ee04f" xlink:label="lbl_label644800591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued interest on debt securities and time deposits [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:to="lbl_label644800591" xlink:type="arc"/>
      <link:label id="id_462cba41" xlink:label="lbl_label1177336385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time deposits with original maturity more than 90 days [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:to="lbl_label1177336385" xlink:type="arc"/>
      <link:label id="id_1ada2efd" xlink:label="lbl_label450506493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term loans and receivables from customers and finance lease, advances, security deposits [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:to="lbl_label450506493" xlink:type="arc"/>
      <link:label id="id_7c347590" xlink:label="lbl_label2083812752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associated companies at fair value through profit and loss [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:to="lbl_label2083812752" xlink:type="arc"/>
      <link:label id="id_533b50d9" xlink:label="lbl_label1396396249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsMember" xlink:to="lbl_label1396396249" xlink:type="arc"/>
      <link:label id="id_551fe4b1" xlink:label="lbl_label1428153521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_label1428153521" xlink:type="arc"/>
      <link:label id="id_114f7584" xlink:label="lbl_label290420100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_label290420100" xlink:type="arc"/>
      <link:label id="id_3b35b195" xlink:label="lbl_label993374613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_label993374613" xlink:type="arc"/>
      <link:label id="id_68a64911" xlink:label="lbl_label1755728145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="lbl_label1755728145" xlink:type="arc"/>
      <link:label id="id_6d1d78f2" xlink:label="lbl_label1830648050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValueMember" xlink:to="lbl_label1830648050" xlink:type="arc"/>
      <link:label id="id_27bb9ea8" xlink:label="lbl_label666607272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Groups of financial assets/liabilities [axis]</link:label>
      <link:label id="id_7cf4bc91" xlink:label="lbl_label2096413841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Groups of financial assets/liabilities [member]</link:label>
      <link:label id="id_68ba85b6" xlink:label="lbl_label1757054390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueMember" xlink:to="lbl_label1757054390" xlink:type="arc"/>
      <link:label id="id_3cee5982" xlink:label="lbl_label1022253442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lbl_label1022253442" xlink:type="arc"/>
      <link:label id="id_2d611cc9" xlink:label="lbl_label761339081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lbl_label761339081" xlink:type="arc"/>
      <link:label id="id_2c7b189f" xlink:label="lbl_label746264735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_label746264735" xlink:type="arc"/>
      <link:label id="id_153859c4" xlink:label="lbl_label356014532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_label356014532" xlink:type="arc"/>
      <link:label id="id_14968138" xlink:label="lbl_label345407800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lbl_label345407800" xlink:type="arc"/>
      <link:label id="id_2576e32b" xlink:label="lbl_label628548395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lbl_label628548395" xlink:type="arc"/>
      <link:label id="id_5a840ece" xlink:label="lbl_label1518603982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lbl_label1518603982" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_label666607272" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_label2096413841" xlink:type="arc"/>
      <link:label id="id_4718921c" xlink:label="lbl_label1192792604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt [member]</link:label>
      <link:label id="id_1748f73f" xlink:label="lbl_label390657855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debt [member]</link:label>
      <link:label id="id_7d47f3b5" xlink:label="lbl_label2101867445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesMember" xlink:to="lbl_label2101867445" xlink:type="arc"/>
      <link:label id="id_1ed425bd" xlink:label="lbl_label517219773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest bearning accounts of associates payable on demand [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:to="lbl_label517219773" xlink:type="arc"/>
      <link:label id="id_7fb53de5" xlink:label="lbl_label2142584293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank and other financial debt [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BankAndOtherFinancialDebtMember" xlink:to="lbl_label2142584293" xlink:type="arc"/>
      <link:label id="id_36f483b7" xlink:label="lbl_label921994167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial paper [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommercialPaperMember" xlink:to="lbl_label921994167" xlink:type="arc"/>
      <link:label id="id_2993bf16" xlink:label="lbl_label697548566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current debt [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:to="lbl_label697548566" xlink:type="arc"/>
      <link:label id="id_7aa4522e" xlink:label="lbl_label2057589294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Straight bonds [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StraightBondsMember" xlink:to="lbl_label2057589294" xlink:type="arc"/>
      <link:label id="id_2e89197f" xlink:label="lbl_label780736895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other financial institutions [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:to="lbl_label780736895" xlink:type="arc"/>
      <link:label id="id_3cfbed2" xlink:label="lbl_label63946450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease obligations [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseObligationsMember" xlink:to="lbl_label63946450" xlink:type="arc"/>
      <link:label id="id_47b3aade" xlink:label="lbl_label1202957022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration and other financial liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:to="lbl_label1202957022" xlink:type="arc"/>
      <link:label id="id_74b2144b" xlink:label="lbl_label1957827659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, by type of contract [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_label1957827659" xlink:type="arc"/>
      <link:label id="id_11a7e82b" xlink:label="lbl_label296216619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instrument, nature of instrument [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_label296216619" xlink:type="arc"/>
      <link:label id="id_5a462aee" xlink:label="lbl_label1514547950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instrument, nature of instrument [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_label1514547950" xlink:type="arc"/>
      <link:label id="id_75469247" xlink:label="lbl_label1967559239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, at fair value currency related [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:to="lbl_label1967559239" xlink:type="arc"/>
      <link:label id="id_3583f9fa" xlink:label="lbl_label897841658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, principal amounts [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_label897841658" xlink:type="arc"/>
      <link:label id="id_102b0f85" xlink:label="lbl_label271257477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, principal amounts [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_label271257477" xlink:type="arc"/>
      <link:label id="id_3f464064" xlink:label="lbl_label1061568612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract or underlying principal amout [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:to="lbl_label1061568612" xlink:type="arc"/>
      <link:label id="id_24f6d45c" xlink:label="lbl_label620155996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Positive fair values [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PositiveFairValuesMember" xlink:to="lbl_label620155996" xlink:type="arc"/>
      <link:label id="id_42b35305" xlink:label="lbl_label1119048453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Negative fair values [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NegativeFairValuesMember" xlink:to="lbl_label1119048453" xlink:type="arc"/>
      <link:label id="id_4c8abefe" xlink:label="lbl_label1284161278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label1284161278" xlink:type="arc"/>
      <link:label id="id_5286c358" xlink:label="lbl_label1384563544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_label1384563544" xlink:type="arc"/>
      <link:label id="id_487fc207" xlink:label="lbl_label1216332295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilities" xlink:to="lbl_label1216332295" xlink:type="arc"/>
      <link:label id="id_453bddb" xlink:label="lbl_label72596955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstruments" xlink:to="lbl_label72596955" xlink:type="arc"/>
      <link:label id="id_397d852b" xlink:label="lbl_label964527403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, forward foreign exchange rate contracts</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:to="lbl_label964527403" xlink:type="arc"/>
      <link:label id="id_b3aed83" xlink:label="lbl_label188411267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, over-the-counter currency options</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:to="lbl_label188411267" xlink:type="arc"/>
      <link:label id="id_24aeca58" xlink:label="lbl_label615434840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, by currency contract [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_label615434840" xlink:type="arc"/>
      <link:label id="id_3d32bab6" xlink:label="lbl_label1026734774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_label1026734774" xlink:type="arc"/>
      <link:label id="id_3f252a8f" xlink:label="lbl_label1059400335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_label1059400335" xlink:type="arc"/>
      <link:label id="id_59852144" xlink:label="lbl_label1501897028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_label1501897028" xlink:type="arc"/>
      <link:label id="id_640cd1b3" xlink:label="lbl_label1678561715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recurring fair value measurement [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RecurringFairValueMeasurementMember" xlink:to="lbl_label1678561715" xlink:type="arc"/>
      <link:label id="id_6df52bda" xlink:label="lbl_label1844784090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, time deposits and derivative financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:to="lbl_label1844784090" xlink:type="arc"/>
      <link:label id="id_469d8a26" xlink:label="lbl_label1184729638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial investments and long-term loans [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:to="lbl_label1184729638" xlink:type="arc"/>
      <link:label id="id_3e1a7df6" xlink:label="lbl_label1041923574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total available-for-sale marketable securities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:to="lbl_label1041923574" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:to="lbl_label131977872" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:to="lbl_label913538296" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtMember" xlink:to="lbl_label1192792604" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialDebtMember" xlink:to="lbl_label390657855" xlink:type="arc"/>
      <link:label id="id_55c289f5" xlink:label="lbl_label1438812661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale financial investments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:to="lbl_label1438812661" xlink:type="arc"/>
      <link:label id="id_4af993b7" xlink:label="lbl_label1257870263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_label1257870263" xlink:type="arc"/>
      <link:label id="id_5b807bec" xlink:label="lbl_label1535146988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valued at amortized cost [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValuedAtAmortizedCostMember" xlink:to="lbl_label1535146988" xlink:type="arc"/>
      <link:label id="id_6163f2e6" xlink:label="lbl_label1633940198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_label1633940198" xlink:type="arc"/>
      <link:label id="id_39b2a3b6" xlink:label="lbl_label968008630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_label968008630" xlink:type="arc"/>
      <link:label id="id_2dde0229" xlink:label="lbl_label769524265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration payables [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPayablesMember" xlink:to="lbl_label769524265" xlink:type="arc"/>
      <link:label id="id_648479c6" xlink:label="lbl_label1686403526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialLiabilitiesMember" xlink:to="lbl_label1686403526" xlink:type="arc"/>
      <link:label id="id_7d19861f" xlink:label="lbl_label2098824735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:to="lbl_label2098824735" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare1" xlink:type="locator"/>
      <link:label id="id_6e8d8711" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends proposed, cash per share</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare1" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:type="arc"/>
      <link:label id="id_5643fad7" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share</link:label>
      <link:label id="id_65bb0a73" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends proposed</link:label>
      <link:label id="id_738a993" xlink:label="lbl_label121153939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease in fair value measurement liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:to="lbl_label121153939" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:to="lbl_label1199806184" xlink:type="arc"/>
      <link:label id="id_7ebb8632" xlink:label="lbl_label2126218802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, at fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValue" xlink:to="lbl_label2126218802" xlink:type="arc"/>
      <link:label id="id_5083795f" xlink:label="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValue" xlink:to="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:type="arc"/>
      <link:label id="id_2d43301f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, hedges of net investments in foreign operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:type="arc"/>
      <link:label id="id_43e5ded1" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedge</link:label>
      <link:label id="id_72a89a91" xlink:label="lbl_label1923652241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Australia Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_731902b7" xlink:label="lbl_label1931018935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_1867bb0f" xlink:label="lbl_label409451279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Australia) Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_3d795141" xlink:label="lbl_label1031360833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_5d546db3" xlink:label="lbl_label1565814195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Austria GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAustriaGmbHViennaMember" xlink:to="lbl_label1565814195" xlink:type="arc"/>
      <link:label id="id_2234921c" xlink:label="lbl_label573870620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaGmbHViennaMember" xlink:to="lbl_label573870620" xlink:type="arc"/>
      <link:label id="id_7dcc65cd" xlink:label="lbl_label2110547405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Ophthalmika GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconOphthalmikaGmbHViennaMember" xlink:to="lbl_label2110547405" xlink:type="arc"/>
      <link:label id="id_6649a095" xlink:label="lbl_label1716101269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz GmbH, Kundl [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozGmbHViennaMember" xlink:to="lbl_label1716101269" xlink:type="arc"/>
      <link:label id="id_2af5dc99" xlink:label="lbl_label720755864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:to="lbl_label720755864" xlink:type="arc"/>
      <link:label id="id_710ef91f" xlink:label="lbl_label1896806687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Bangladesh) Limited, Gazipur [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBangladeshLimitedGazipurMember" xlink:to="lbl_label1896806687" xlink:type="arc"/>
      <link:label id="id_33533709" xlink:label="lbl_label861091593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma NV, Vilvoorde [member]</link:label>
      <link:label id="id_6bd26090" xlink:label="lbl_label1808949392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon - Couvreur NV, Puurs [member]</link:label>
      <link:label id="id_471d9dcf" xlink:label="lbl_label1193123279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon NV, Vilvoorde [member]</link:label>
      <link:label id="id_61e985d" xlink:label="lbl_label102668381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz NV, Vilvoorde [member]</link:label>
      <link:label id="id_3d34517c" xlink:label="lbl_label1026838908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Securities Investment Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:to="lbl_label1026838908" xlink:type="arc"/>
      <link:label id="id_2e061bfd" xlink:label="lbl_label772152317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Biociencias S.A., Sao Paulo [member]</link:label>
      <link:label id="id_608a61f5" xlink:label="lbl_label1619681781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]</link:label>
      <link:label id="id_20501724" xlink:label="lbl_label542119716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:to="lbl_label542119716" xlink:type="arc"/>
      <link:label id="id_b170914" xlink:label="lbl_label186059028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Canada Inc., Mississauga, Ontario [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:to="lbl_label186059028" xlink:type="arc"/>
      <link:label id="id_3382e919" xlink:label="lbl_label864217369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Canada Inc., Mississauga, Ontario [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:to="lbl_label864217369" xlink:type="arc"/>
      <link:label id="id_4aad4cdd" xlink:label="lbl_label1252871389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Canada Inc., Boucherville, Quebec [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:to="lbl_label1252871389" xlink:type="arc"/>
      <link:label id="id_467b0e02" xlink:label="lbl_label1182469634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Chile S.A., Santiago de Chile [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:to="lbl_label1182469634" xlink:type="arc"/>
      <link:label id="id_4a31b636" xlink:label="lbl_label1244771894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios Chile Ltd., Santiago de Chile [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:to="lbl_label1244771894" xlink:type="arc"/>
      <link:label id="id_61f8aada" xlink:label="lbl_label1643686618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beijing Novartis Pharma Co., Ltd., Beijing [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:to="lbl_label1643686618" xlink:type="arc"/>
      <link:label id="id_344a1881" xlink:label="lbl_label877271169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:to="lbl_label877271169" xlink:type="arc"/>
      <link:label id="id_2c879a70" xlink:label="lbl_label747084400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:to="lbl_label747084400" xlink:type="arc"/>
      <link:label id="id_44f2dcf0" xlink:label="lbl_label1156766960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai Novartis Trading Ltd., Shanghai [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:to="lbl_label1156766960" xlink:type="arc"/>
      <link:label id="id_2b1815d1" xlink:label="lbl_label722998737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Hong Kong Limited, Hong Kong [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconHongKongLimitedHongKongMember" xlink:to="lbl_label722998737" xlink:type="arc"/>
      <link:label id="id_57ba8d14" xlink:label="lbl_label1471843604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:to="lbl_label1471843604" xlink:type="arc"/>
      <link:label id="id_252cd53d" xlink:label="lbl_label623695165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:to="lbl_label623695165" xlink:type="arc"/>
      <link:label id="id_65e89b36" xlink:label="lbl_label1709742902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis de Colombia S.A., Santafe de Bogota [member]</link:label>
      <link:label id="id_1522bd0" xlink:label="lbl_label22162384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member]</link:label>
      <link:label id="id_2d82460" xlink:label="lbl_label47719520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz d.o.o. farmaceutska industrija, Zagreb [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:to="lbl_label47719520" xlink:type="arc"/>
      <link:label id="id_c60eb2a" xlink:label="lbl_label207678250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisS.r.o.PragueMember" xlink:to="lbl_label207678250" xlink:type="arc"/>
      <link:label id="id_402474ef" xlink:label="lbl_label1076131055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:to="lbl_label1076131055" xlink:type="arc"/>
      <link:label id="id_f1c4dd" xlink:label="lbl_label15844573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.r.o.PragueMember" xlink:to="lbl_label15844573" xlink:type="arc"/>
      <link:label id="id_6ea1eef6" xlink:label="lbl_label1856106230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcareASCopenhagenMember" xlink:to="lbl_label1856106230" xlink:type="arc"/>
      <link:label id="id_2dbeb314" xlink:label="lbl_label767472404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Nordic A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNordicASCopenhagenMember" xlink:to="lbl_label767472404" xlink:type="arc"/>
      <link:label id="id_1e75de5c" xlink:label="lbl_label511041116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozASCopenhagenMember" xlink:to="lbl_label511041116" xlink:type="arc"/>
      <link:label id="id_574d51cf" xlink:label="lbl_label1464685007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ecuador S.A., Quito [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisEcuadorS.A.QuitoMember" xlink:to="lbl_label1464685007" xlink:type="arc"/>
      <link:label id="id_679520f0" xlink:label="lbl_label1737826544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma S.A.E., Cairo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaS.A.E.CairoMember" xlink:to="lbl_label1737826544" xlink:type="arc"/>
      <link:label id="id_575ca2d" xlink:label="lbl_label91605549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Egypt Pharma S.A.E., New Cairo City [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:to="lbl_label91605549" xlink:type="arc"/>
      <link:label id="id_37f4e561" xlink:label="lbl_label938796385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finland Oy, Espoo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinlandOyEspooMember" xlink:to="lbl_label938796385" xlink:type="arc"/>
      <link:label id="id_42a0d3e7" xlink:label="lbl_label1117836263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Groupe France S.A., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:to="lbl_label1117836263" xlink:type="arc"/>
      <link:label id="id_7ba00702" xlink:label="lbl_label2074085122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:to="lbl_label2074085122" xlink:type="arc"/>
      <link:label id="id_d3dae7a" xlink:label="lbl_label222146170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratoires Alcon S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:to="lbl_label222146170" xlink:type="arc"/>
      <link:label id="id_3116dc5e" xlink:label="lbl_label823581790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.A.S., Levallois-Perret [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.A.S.LevalloisPerretMember" xlink:to="lbl_label823581790" xlink:type="arc"/>
      <link:label id="id_6e409e90" xlink:label="lbl_label1849728656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Deutschland GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeutschlandGmbHWehrMember" xlink:to="lbl_label1849728656" xlink:type="arc"/>
      <link:label id="id_17634123" xlink:label="lbl_label392380707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma GmbH, Nuremberg [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaGmbHNurembergMember" xlink:to="lbl_label392380707" xlink:type="arc"/>
      <link:label id="id_1cd787d" xlink:label="lbl_label30242941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Produktions GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:to="lbl_label30242941" xlink:type="arc"/>
      <link:label id="id_401bb4ef" xlink:label="lbl_label1075557615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Business Services GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:to="lbl_label1075557615" xlink:type="arc"/>
      <link:label id="id_3672a73d" xlink:label="lbl_label913483581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharma GmbH, Freiburg im Breisgau [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:to="lbl_label913483581" xlink:type="arc"/>
      <link:label id="id_1fd8572e" xlink:label="lbl_label534271790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WaveLight GmbH, Erlangen [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WaveLightGmbHErlangenMember" xlink:to="lbl_label534271790" xlink:type="arc"/>
      <link:label id="id_4649f215" xlink:label="lbl_label1179251221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision GmbH, Grosswallstadt [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:to="lbl_label1179251221" xlink:type="arc"/>
      <link:label id="id_72338a4a" xlink:label="lbl_label1915980362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz International GmbH, Holzkirchen [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:to="lbl_label1915980362" xlink:type="arc"/>
      <link:label id="id_2c6debd5" xlink:label="lbl_label745401301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HEXAL AG, Holzkirchen [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HEXALAGHolzkirchenMember" xlink:to="lbl_label745401301" xlink:type="arc"/>
      <link:label id="id_3b790099" xlink:label="lbl_label997785753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salutas Pharma GmbH, Barleben [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SalutasPharmaGmbHBarlebenMember" xlink:to="lbl_label997785753" xlink:type="arc"/>
      <link:label id="id_5a59fba6" xlink:label="lbl_label1515846566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1 A Pharma GmbH, Oberhaching [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1APharmaGmbHOberhachingMember" xlink:label="lbl_A1APharmaGmbHOberhachingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1APharmaGmbHOberhachingMember" xlink:to="lbl_label1515846566" xlink:type="arc"/>
      <link:label id="id_63faa754" xlink:label="lbl_label1677371220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aeropharm GmbH, Rudolstadt [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AeropharmGmbHRudolstadtMember" xlink:to="lbl_label1677371220" xlink:type="arc"/>
      <link:label id="id_53a147c7" xlink:label="lbl_label1403078599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novista Insurance Limited, Gibraltar City [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:to="lbl_label1403078599" xlink:type="arc"/>
      <link:label id="id_2881adea" xlink:label="lbl_label679587306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:to="lbl_label679587306" xlink:type="arc"/>
      <link:label id="id_24c810e" xlink:label="lbl_label38568206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:to="lbl_label38568206" xlink:type="arc"/>
      <link:label id="id_20010fd1" xlink:label="lbl_label536940497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Hungary Healthcare Limited Liability Company, Budapest [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:to="lbl_label536940497" xlink:type="arc"/>
      <link:label id="id_3e0a5b35" xlink:label="lbl_label1040866101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Hungary Limited Liability Company, Budapest [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:to="lbl_label1040866101" xlink:type="arc"/>
      <link:label id="id_866e747" xlink:label="lbl_label140961607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis India Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIndiaLimitedMumbaiMember" xlink:to="lbl_label140961607" xlink:type="arc"/>
      <link:label id="id_5d283d4e" xlink:label="lbl_label1562918222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare Private Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:to="lbl_label1562918222" xlink:type="arc"/>
      <link:label id="id_209ec8c8" xlink:label="lbl_label547277000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (India) Private Limited, Bangalore [member]</link:label>
      <link:label id="id_2bccb2e" xlink:label="lbl_label45927214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Private Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPrivateLimitedMumbaiMember" xlink:to="lbl_label45927214" xlink:type="arc"/>
      <link:label id="id_30564a91" xlink:label="lbl_label810961553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PT. Novartis Indonesia, Jakarta [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PT.NovartisIndonesiaJakartaMember" xlink:to="lbl_label810961553" xlink:type="arc"/>
      <link:label id="id_bca100f" xlink:label="lbl_label197791759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PT. CIBA Vision Batam, Batam [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PT.CIBAVisionBatamBatamMember" xlink:to="lbl_label197791759" xlink:type="arc"/>
      <link:label id="id_4fcc5f83" xlink:label="lbl_label1338793859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ireland Limited, Dublin [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIrelandLimitedDublinMember" xlink:to="lbl_label1338793859" xlink:type="arc"/>
      <link:label id="id_74708b2c" xlink:label="lbl_label1953532716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:to="lbl_label1953532716" xlink:type="arc"/>
      <link:label id="id_169e129" xlink:label="lbl_label23716137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Ireland Limited, Cork City [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:to="lbl_label23716137" xlink:type="arc"/>
      <link:label id="id_1a15ed68" xlink:label="lbl_label437644648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Israel Ltd., Petach Tikva [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisIsraelLtd.PetachTikvaMember" xlink:label="lbl_NovartisIsraelLtd.PetachTikvaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIsraelLtd.PetachTikvaMember" xlink:to="lbl_label437644648" xlink:type="arc"/>
      <link:label id="id_79225a64" xlink:label="lbl_label2032294500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Optonol Ltd., Neve-Ilan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OptonolLtd.NeveIlanMember" xlink:to="lbl_label2032294500" xlink:type="arc"/>
      <link:label id="id_572859e2" xlink:label="lbl_label1462262242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farma S.p.A., Origgio [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFarmaS.p.A.OriggioMember" xlink:label="lbl_NovartisFarmaS.p.A.OriggioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaS.p.A.OriggioMember" xlink:to="lbl_label1462262242" xlink:type="arc"/>
      <link:label id="id_51e555ae" xlink:label="lbl_label1373984174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Italia S.p.A., Milan [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconItaliaS.p.A.MilanMember" xlink:to="lbl_label1373984174" xlink:type="arc"/>
      <link:label id="id_39182a7" xlink:label="lbl_label59867815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.p.A., Origgio [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.p.A.OriggioMember" xlink:to="lbl_label59867815" xlink:type="arc"/>
      <link:label id="id_23768229" xlink:label="lbl_label594969129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Industrial Products S.p.A., Rovereto [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:to="lbl_label594969129" xlink:type="arc"/>
      <link:label id="id_46070173" xlink:label="lbl_label1174864243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Holding Japan K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:to="lbl_label1174864243" xlink:type="arc"/>
      <link:label id="id_30b5637" xlink:label="lbl_label51074615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaK.K.TokyoMember" xlink:to="lbl_label51074615" xlink:type="arc"/>
      <link:label id="id_2358b28" xlink:label="lbl_label37063464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Japan Ltd., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconJapanLtd.TokyoMember" xlink:to="lbl_label37063464" xlink:type="arc"/>
      <link:label id="id_90ace63" xlink:label="lbl_label151703139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozK.K.TokyoMember" xlink:to="lbl_label151703139" xlink:type="arc"/>
      <link:label id="id_2d24611e" xlink:label="lbl_label757358878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Investments S.a r.l., Luxembourg City [member]</link:label>
      <link:label id="id_6373cce9" xlink:label="lbl_label1668533481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance S.A., Luxembourg City [member]</link:label>
      <link:label id="id_495a738b" xlink:label="lbl_label1230664587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Corporation (Malaysia) Sdn. Bhd., Kuala Lumpur [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:to="lbl_label1230664587" xlink:type="arc"/>
      <link:label id="id_30ea85e" xlink:label="lbl_label51292254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:to="lbl_label51292254" xlink:type="arc"/>
      <link:label id="id_2040f9e0" xlink:label="lbl_label541129184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:to="lbl_label541129184" xlink:type="arc"/>
      <link:label id="id_23d9a520" xlink:label="lbl_label601466144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farmaceutica, S.A. de C.V., Mexico City [member]</link:label>
      <link:label id="id_7bc6228f" xlink:label="lbl_label2076582543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios, S.A. de C.V., Mexico City [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label2076582543" xlink:type="arc"/>
      <link:label id="id_77370b0a" xlink:label="lbl_label2000096010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz, S.A. de C.V., Mexico City [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label2000096010" xlink:type="arc"/>
      <link:label id="id_7143fa4f" xlink:label="lbl_label1900280399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Maroc SA, Casablanca [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaMarocSACasablancaMember" xlink:to="lbl_label1900280399" xlink:type="arc"/>
      <link:label id="id_30236580" xlink:label="lbl_label807626112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Netherlands B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:to="lbl_label807626112" xlink:type="arc"/>
      <link:label id="id_1fa13a8d" xlink:label="lbl_label530659981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaB.V.ArnhemMember" xlink:to="lbl_label530659981" xlink:type="arc"/>
      <link:label id="id_6a5dd736" xlink:label="lbl_label1784534838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Nederland B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNederlandB.V.ArnhemMember" xlink:to="lbl_label1784534838" xlink:type="arc"/>
      <link:label id="id_89b7931" xlink:label="lbl_label144406833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz B.V., Almere [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozB.V.AlmereMember" xlink:to="lbl_label144406833" xlink:type="arc"/>
      <link:label id="id_7ae0d9be" xlink:label="lbl_label2061556158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis New Zealand Ltd, Auckland [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNewZealandLtdAucklandMember" xlink:to="lbl_label2061556158" xlink:type="arc"/>
      <link:label id="id_659fd8fc" xlink:label="lbl_label1704974588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Norge AS, Oslo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNorgeASOsloMember" xlink:to="lbl_label1704974588" xlink:type="arc"/>
      <link:label id="id_53e6555" xlink:label="lbl_label87975253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma (Pakistan) Limited, Karachi [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:to="lbl_label87975253" xlink:type="arc"/>
      <link:label id="id_2f1259ff" xlink:label="lbl_label789731839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma (Logistics), Inc., Panama City [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:to="lbl_label789731839" xlink:type="arc"/>
      <link:label id="id_51335372" xlink:label="lbl_label1362318194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Centroamerica S.A., Panama City [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:to="lbl_label1362318194" xlink:type="arc"/>
      <link:label id="id_240f2db1" xlink:label="lbl_label604974513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare Philippines, Inc., Manila [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisHealthcarePhilippinesInc.ManilaMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.ManilaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcarePhilippinesInc.ManilaMember" xlink:to="lbl_label604974513" xlink:type="arc"/>
      <link:label id="id_2050b70f" xlink:label="lbl_label542160655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Philippines Corporation, Manila [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozPhilippinesCorporationManilaMember" xlink:label="lbl_SandozPhilippinesCorporationManilaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPhilippinesCorporationManilaMember" xlink:to="lbl_label542160655" xlink:type="arc"/>
      <link:label id="id_5fffa6cd" xlink:label="lbl_label1610589901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Poland Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_74c896dd" xlink:label="lbl_label1959302877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Polska Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_712c39fe" xlink:label="lbl_label1898723838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Polska Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_4ba5de33" xlink:label="lbl_label1269161523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lek S.A., Strykow [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LekS.A.StrykowMember" xlink:to="lbl_label1269161523" xlink:type="arc"/>
      <link:label id="id_520521db" xlink:label="lbl_label1376068059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Portugal SGPS Lda., Porto Salvo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:to="lbl_label1376068059" xlink:type="arc"/>
      <link:label id="id_c95dd37" xlink:label="lbl_label211148087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]</link:label>
      <link:label id="id_881ce5c" xlink:label="lbl_label142724700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member]</link:label>
      <link:label id="id_1c2378c4" xlink:label="lbl_label472086724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Farmaceutica Lda., Porto Salvo [member]</link:label>
      <link:label id="id_4a9bb1ea" xlink:label="lbl_label1251717610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Services Romania S.R.L., Bucharest [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:to="lbl_label1251717610" xlink:type="arc"/>
      <link:label id="id_30d12469" xlink:label="lbl_label819012713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Romania S.R.L., Bucharest [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:to="lbl_label819012713" xlink:type="arc"/>
      <link:label id="id_1a1b1a89" xlink:label="lbl_label437983881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.R.L., Targu-Mures [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.R.L.TarguMuresMember" xlink:to="lbl_label437983881" xlink:type="arc"/>
      <link:label id="id_620cd72f" xlink:label="lbl_label1645008687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma LLC, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaLLCMoscowMember" xlink:to="lbl_label1645008687" xlink:type="arc"/>
      <link:label id="id_a4d4ccd" xlink:label="lbl_label172838093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Farmacevtika LLC, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:to="lbl_label172838093" xlink:type="arc"/>
      <link:label id="id_4f8c203f" xlink:label="lbl_label1334583359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZAO Sandoz, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZAOSandozMoscowMember" xlink:label="lbl_ZAOSandozMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZAOSandozMoscowMember" xlink:to="lbl_label1334583359" xlink:type="arc"/>
      <link:label id="id_3b17514" xlink:label="lbl_label61961492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Neva LLC, St. Petersburg [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:to="lbl_label61961492" xlink:type="arc"/>
      <link:label id="id_2d25f558" xlink:label="lbl_label757462360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:to="lbl_label757462360" xlink:type="arc"/>
      <link:label id="id_ef37254" xlink:label="lbl_label250835540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Singapore) Pte Ltd., Singapore [member]</link:label>
      <link:label id="id_27535d56" xlink:label="lbl_label659774806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_73caa11d" xlink:label="lbl_label1942659357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_5ac408db" xlink:label="lbl_label1522796763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_405feadd" xlink:label="lbl_label1080027869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Singapore Manufacturing Pte. Ltd., Singapore [member]</link:label>
      <link:label id="id_5ad357d3" xlink:label="lbl_label1523800019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member]</link:label>
      <link:label id="id_5654aaaa" xlink:label="lbl_label1448389290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_1f0269e9" xlink:label="lbl_label520251881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Slovakia s.r.o., Bratislava [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:to="lbl_label520251881" xlink:type="arc"/>
      <link:label id="id_3337da30" xlink:label="lbl_label859298352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lek Pharmaceuticals d.d., Ljubjana [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:to="lbl_label859298352" xlink:type="arc"/>
      <link:label id="id_24583ab1" xlink:label="lbl_label609761969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pharmaceuticals d.d., Ljubjana [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:to="lbl_label609761969" xlink:type="arc"/>
      <link:label id="id_25162424" xlink:label="lbl_label622208036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis South Africa (Pty) Ltd, Midrand [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:to="lbl_label622208036" xlink:type="arc"/>
      <link:label id="id_c4640a" xlink:label="lbl_label12870666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:to="lbl_label12870666" xlink:type="arc"/>
      <link:label id="id_44cecbf4" xlink:label="lbl_label1154403316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz South Africa (Pty) Ltd, Kempton Park [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:label="lbl_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:to="lbl_label1154403316" xlink:type="arc"/>
      <link:label id="id_51e9e54d" xlink:label="lbl_label1374283085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisKoreaLtd.SeoulMember" xlink:to="lbl_label1374283085" xlink:type="arc"/>
      <link:label id="id_2fbc9bcb" xlink:label="lbl_label800889803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconKoreaLtd.SeoulMember" xlink:to="lbl_label800889803" xlink:type="arc"/>
      <link:label id="id_3acd65c6" xlink:label="lbl_label986539462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozKoreaLtd.SeoulMember" xlink:to="lbl_label986539462" xlink:type="arc"/>
      <link:label id="id_2cb12411" xlink:label="lbl_label749806609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farmaceutica, S.A., Barcelona [member]</link:label>
      <link:label id="id_1788ee4f" xlink:label="lbl_label394849871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Cusi S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCusiS.A.BarcelonaMember" xlink:to="lbl_label394849871" xlink:type="arc"/>
      <link:label id="id_25c7e6c1" xlink:label="lbl_label633857729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Farmaceutica S.A., Madrid [member]</link:label>
      <link:label id="id_578d972e" xlink:label="lbl_label1468897070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Industrial Products S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozIndustrialProductsS.A.BarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIndustrialProductsS.A.BarcelonaMember" xlink:to="lbl_label1468897070" xlink:type="arc"/>
      <link:label id="id_6a673c57" xlink:label="lbl_label1785150551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:to="lbl_label1785150551" xlink:type="arc"/>
      <link:label id="id_6cfceac6" xlink:label="lbl_label1828514502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Sverige AB, Stockholm [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSverigeABStockholmMember" xlink:to="lbl_label1828514502" xlink:type="arc"/>
      <link:label id="id_1784eaf5" xlink:label="lbl_label394586869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalAGBaselMember" xlink:to="lbl_label394586869" xlink:type="arc"/>
      <link:label id="id_1cfce538" xlink:label="lbl_label486335800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Holding AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHoldingAGBaselMember" xlink:to="lbl_label486335800" xlink:type="arc"/>
      <link:label id="id_523c2f36" xlink:label="lbl_label1379675958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International Pharmaceutical AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:to="lbl_label1379675958" xlink:type="arc"/>
      <link:label id="id_31c15b81" xlink:label="lbl_label834755457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaAGBaselMember" xlink:to="lbl_label834755457" xlink:type="arc"/>
      <link:label id="id_6bb5d046" xlink:label="lbl_label1807077446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Services AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaServicesAGBaselMember" xlink:to="lbl_label1807077446" xlink:type="arc"/>
      <link:label id="id_151ca66f" xlink:label="lbl_label354199151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Schweizerhalle AG, Muttenz [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:to="lbl_label354199151" xlink:type="arc"/>
      <link:label id="id_7888d993" xlink:label="lbl_label2022234515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Stein AG, Stein [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSteinAGSteinMember" xlink:to="lbl_label2022234515" xlink:type="arc"/>
      <link:label id="id_46b0e62c" xlink:label="lbl_label1185998380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Schweiz AG, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSchweizAGRischMember" xlink:to="lbl_label1185998380" xlink:type="arc"/>
      <link:label id="id_175b3164" xlink:label="lbl_label391852388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Switzerland SA, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconSwitzerlandSARischMember" xlink:to="lbl_label391852388" xlink:type="arc"/>
      <link:label id="id_6dde1079" xlink:label="lbl_label1843269753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceuticals Ltd., Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:to="lbl_label1843269753" xlink:type="arc"/>
      <link:label id="id_2056dcf1" xlink:label="lbl_label542563569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozAGBaselMember" xlink:to="lbl_label542563569" xlink:type="arc"/>
      <link:label id="id_c4607df" xlink:label="lbl_label205916127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pharmaceuticals AG, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPharmaceuticalsAGRischMember" xlink:to="lbl_label205916127" xlink:type="arc"/>
      <link:label id="id_2bda8165" xlink:label="lbl_label735740261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Taiwan) Co., Ltd., Taipei [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:to="lbl_label735740261" xlink:type="arc"/>
      <link:label id="id_1cc3a1bc" xlink:label="lbl_label482582972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Thailand) Limited, Bangkok [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisThailandLimitedBangkokMember" xlink:to="lbl_label482582972" xlink:type="arc"/>
      <link:label id="id_1e10820d" xlink:label="lbl_label504398349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Thailand) Limited, Bangkok [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:to="lbl_label504398349" xlink:type="arc"/>
      <link:label id="id_76d30813" xlink:label="lbl_label1993541651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:label id="id_7653b21e" xlink:label="lbl_label1985196574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratuvarlari Ticaret A.S., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:to="lbl_label1985196574" xlink:type="arc"/>
      <link:label id="id_6083f415" xlink:label="lbl_label1619260437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:label id="id_2c3cd0a2" xlink:label="lbl_label742183074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]</link:label>
      <link:label id="id_775d02f4" xlink:label="lbl_label2002584308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Middle East FZE, Dubai [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisMiddleEastFZEDubaiMember" xlink:to="lbl_label2002584308" xlink:type="arc"/>
      <link:label id="id_629f2d5a" xlink:label="lbl_label1654599002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label1654599002" xlink:type="arc"/>
      <link:label id="id_24628050" xlink:label="lbl_label610435152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label610435152" xlink:type="arc"/>
      <link:label id="id_72101279" xlink:label="lbl_label1913655929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Grimsby Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:to="lbl_label1913655929" xlink:type="arc"/>
      <link:label id="id_41ed60da" xlink:label="lbl_label1106075866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Eye Care UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label1106075866" xlink:type="arc"/>
      <link:label id="id_61fe5165" xlink:label="lbl_label1644056933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozLimitedFrimleyCamberleyMember" xlink:to="lbl_label1644056933" xlink:type="arc"/>
      <link:label id="id_5fa82378" xlink:label="lbl_label1604854648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:to="lbl_label1604854648" xlink:type="arc"/>
      <link:label id="id_4687124a" xlink:label="lbl_label1183257162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCorporationEastHanoverNYMember" xlink:to="lbl_label1183257162" xlink:type="arc"/>
      <link:label id="id_739f0d6b" xlink:label="lbl_label1939803499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Corporation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:to="lbl_label1939803499" xlink:type="arc"/>
      <link:label id="id_6a2defad" xlink:label="lbl_label1781395373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:to="lbl_label1781395373" xlink:type="arc"/>
      <link:label id="id_2951cebe" xlink:label="lbl_label693227198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:to="lbl_label693227198" xlink:type="arc"/>
      <link:label id="id_10d13d66" xlink:label="lbl_label282148198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:to="lbl_label282148198" xlink:type="arc"/>
      <link:label id="id_2e63ddd" xlink:label="lbl_label48643549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institute for Functional Genomics, Inc., San Diego, CA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:to="lbl_label48643549" xlink:type="arc"/>
      <link:label id="id_13ee6af1" xlink:label="lbl_label334392049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:to="lbl_label334392049" xlink:type="arc"/>
      <link:label id="id_5eea5c27" xlink:label="lbl_label1592417319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Services, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:to="lbl_label1592417319" xlink:type="arc"/>
      <link:label id="id_51dba865" xlink:label="lbl_label1373349989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Holding Corporation, Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:to="lbl_label1373349989" xlink:type="arc"/>
      <link:label id="id_31a31f0b" xlink:label="lbl_label832773899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:to="lbl_label832773899" xlink:type="arc"/>
      <link:label id="id_c4acd60" xlink:label="lbl_label206228832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Refractivehorizons, LLC, Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:to="lbl_label206228832" xlink:type="arc"/>
      <link:label id="id_48c065e" xlink:label="lbl_label76285534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Research, Ltd., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconResearchLtd.FortWorthTXMember" xlink:to="lbl_label76285534" xlink:type="arc"/>
      <link:label id="id_17312f5" xlink:label="lbl_label24318709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Lensx, Inc., Aliso Viejo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:to="lbl_label24318709" xlink:type="arc"/>
      <link:label id="id_305f2824" xlink:label="lbl_label811542564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Inc., Princeton, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozInc.PrincetonNJMember" xlink:to="lbl_label811542564" xlink:type="arc"/>
      <link:label id="id_1810f51f" xlink:label="lbl_label403764511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eon Labs, Inc., Princeton, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EonLabsInc.PrincetonNJMember" xlink:to="lbl_label403764511" xlink:type="arc"/>
      <link:label id="id_1c839601" xlink:label="lbl_label478385665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fougera Pharmaceuticals Inc., Melville, NY [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:to="lbl_label478385665" xlink:type="arc"/>
      <link:label id="id_7af3c86c" xlink:label="lbl_label2062796908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis de Venezuela, S.A., Caracas [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:to="lbl_label2062796908" xlink:type="arc"/>
      <link:label id="id_51d78d0e" xlink:label="lbl_label1373080846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceutical, C.A., Caracas [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:to="lbl_label1373080846" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:to="lbl_label772152317" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:to="lbl_label1619681781" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:to="lbl_label1709742902" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:to="lbl_label22162384" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label601466144" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:to="lbl_label211148087" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:to="lbl_label142724700" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:to="lbl_label472086724" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:to="lbl_label749806609" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:to="lbl_label633857729" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:to="lbl_label1993541651" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:to="lbl_label1619260437" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:to="lbl_label742183074" xlink:type="arc"/>
      <link:label id="id_5219f8cb" xlink:label="lbl_label1377433803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments - additional disclosure [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_label1377433803" xlink:type="arc"/>
      <link:label id="id_7be99054" xlink:label="lbl_label2078904404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in fair value measurement [table]</link:label>
      <link:label id="id_373151e5" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:type="arc"/>
      <link:label id="id_3bebbf6d" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3, at beginning of period</link:label>
      <link:label id="id_fde9a71" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3, at end of period</link:label>
      <link:label id="id_38539773" xlink:label="lbl_label945002355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lbl_label945002355" xlink:type="arc"/>
      <link:label id="id_3f162228" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_34d2b17f" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments recognized in the consolidated statement of comprehensive income</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_1f17c4f4" xlink:label="lbl_label521651444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases fair value measurement assets</link:label>
      <link:label id="id_712f0e18" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsFairValueMeasurementAssets" xlink:to="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_6183f24" xlink:label="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationFairValueMeasurementAssets" xlink:to="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_21602cfa" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value gains and losses recognized in the consolidated income statement for assets and liabilities held</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:type="arc"/>
      <link:label id="id_d0e5228" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</link:label>
      <link:label id="id_28030b1e" xlink:label="lbl_label671288094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monitoring of net debt or liquidity based on contractual maturities [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_label671288094" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_label2078904404" xlink:type="arc"/>
      <link:label id="id_2f39f660" xlink:label="lbl_label792327776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity of net debt [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_label792327776" xlink:type="arc"/>
      <link:label id="id_58c89014" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debts</link:label>
      <link:label id="id_7d6c1038" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt</link:label>
      <link:label id="id_2fc36503" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial assets</link:label>
      <link:label id="id_54e7be06" xlink:label="lbl_label1424473606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities and time deposits [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:to="lbl_label1424473606" xlink:type="arc"/>
      <link:label id="id_2cb9fd3b" xlink:label="lbl_label750386491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commodities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommoditiesMember" xlink:to="lbl_label750386491" xlink:type="arc"/>
      <link:label id="id_31b4a926" xlink:label="lbl_label833923366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deriviative financial instruments and accrued interest [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:to="lbl_label833923366" xlink:type="arc"/>
      <link:label id="id_75dba3db" xlink:label="lbl_label1977328603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debt [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtMember" xlink:to="lbl_label1977328603" xlink:type="arc"/>
      <link:label id="id_24faa4a5" xlink:label="lbl_label620405925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debt - undiscounted [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtUndiscountedMember" xlink:to="lbl_label620405925" xlink:type="arc"/>
      <link:label id="id_2e5c234f" xlink:label="lbl_label777790287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three month and not later than twelve months [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:to="lbl_label777790287" xlink:type="arc"/>
      <link:label id="id_106ff37d" xlink:label="lbl_label275772285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label275772285" xlink:type="arc"/>
      <link:label id="id_7c18c756" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential outflows in various currencies - from financial derivative liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4ab97cb3" xlink:label="lbl_label1253670067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential inflows in various currencies - from financial derivative assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:to="lbl_label1253670067" xlink:type="arc"/>
      <link:label id="id_68a3968f" xlink:label="lbl_label1755551375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_label1755551375" xlink:type="arc"/>
      <link:label id="id_6f45bf77" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual interest on non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_60f25e47" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest on non-current liabilities</link:label>
      <link:label id="id_26c3488c" xlink:label="lbl_label650332300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_label650332300" xlink:type="arc"/>
      <link:label id="id_3ecf37ac" xlink:label="lbl_label1053767596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_label1053767596" xlink:type="arc"/>
      <link:label id="id_1d7eaa93" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:type="arc"/>
      <link:label id="id_4d7520d9" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to foreign currency exchange rates</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:type="arc"/>
      <link:label id="id_bc6d63c" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to equity market movements</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:type="arc"/>
      <link:label id="id_7e591031" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to interest rates</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:type="arc"/>
      <link:label id="id_1a9805f" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All financial instruments</link:label>
      <link:label id="id_2ef01715" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to foreign currency exchange rates</link:label>
      <link:label id="id_74cd5fab" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to equity market movements</link:label>
      <link:label id="id_3073f174" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to interest rates</link:label>
      <link:label id="id_69bd9251" xlink:label="lbl_WeightedAverageMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageMember" xlink:to="lbl_WeightedAverageMember_labels" xlink:type="arc"/>
      <link:label id="id_301d16c7" xlink:label="lbl_WeightedAverageMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average</link:label>
      <link:label id="id_2a5fb07c" xlink:label="lbl_TopOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">High</link:label>
      <link:label id="id_6654bf44" xlink:label="lbl_BottomOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Low</link:label>
      <link:label id="id_405da1b9" xlink:label="lbl_WorstCaseLossScenarioMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Worst case loss scenario [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WorstCaseLossScenarioMember" xlink:to="lbl_WorstCaseLossScenarioMember_labels" xlink:type="arc"/>
      <link:label id="id_2e992db9" xlink:label="lbl_WorstCaseLossScenarioMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Worst case loss scenario</link:label>
      <link:label id="id_4ee2f2eb" xlink:label="lbl_label1323496171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash receipts and payments fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:to="lbl_label1323496171" xlink:type="arc"/>
      <link:label id="id_2d2549bd" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Potential outflows in various currencies - from financial derivative liabilities</link:label>
      <link:label id="id_6773649" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_7a7f8744" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_5793c543" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance</link:label>
      <link:label id="id_786524e" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of provisions for doubtful trade receivables</link:label>
      <link:label id="id_6744ae33" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Publicly quoted market value of the Novartis interest</link:label>
      <link:label id="id_24696e1c" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current service cost</link:label>
      <link:label id="id_471bbf88" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
      <link:label id="id_1439e3a2" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:label id="id_2f35efb7" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select", outside North America [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:type="arc"/>
      <link:label id="id_58a34798" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select outside North America</link:label>
      <link:label id="id_5e36913a" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select", North America [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:type="arc"/>
      <link:label id="id_49d8c8f7" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select North America</link:label>
      <link:label id="id_7c2b7da9" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plans, granted to associates prior merger [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:type="arc"/>
      <link:label id="id_3be795e9" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_3e622c14" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, number of shares</link:label>
      <link:label id="id_179f71dc" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_13e82d94" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, number of shares</link:label>
      <link:label id="id_676b945a" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Number of Shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:type="arc"/>
      <link:label id="id_7c12048" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, number of shares</link:label>
      <link:label id="id_36172efd" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares at end of period</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_60b0a4e9" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares at beginning of period</link:label>
      <link:label id="id_3531edda" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:label id="id_5e461d76" xlink:label="lbl_label1581653366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_label1581653366" xlink:type="arc"/>
      <link:label id="id_7874e637" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income from associated companies</link:label>
      <link:label id="id_32b80bd7" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Other Share Awards [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:type="arc"/>
      <link:label id="id_18282520" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share awards</link:label>
      <link:label id="id_46ef7a38" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcon equity plans granted to associates prior merger</link:label>
      <link:label id="id_5f28436" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Shares</link:label>
      <link:label id="id_68171cd3" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leveraged Share Savings Plan (LSSP)</link:label>
      <link:label id="id_33a3b55c" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Share Ownership Plan (ESOP)</link:label>
      <link:label id="id_48de40b0" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK Share Savings Plan</link:label>
      <link:label id="id_71e8eb1f" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for product liabilities, governmental investigations and other legal matters</link:label>
      <link:label id="id_68f6d949" xlink:label="lbl_ShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share movements in period</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareMovements" xlink:to="lbl_ShareMovements_labels" xlink:type="arc"/>
      <link:label id="id_10047f77" xlink:label="lbl_ShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total movements</link:label>
      <link:label id="id_5da2c69" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net expense, royalties cost sharing and profit sharing</link:label>
      <link:label id="id_1b2e9a2e" xlink:label="lbl_label2088768931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net investment hedge [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetInvestmentHedgeMember" xlink:label="lbl_NetInvestmentHedgeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetInvestmentHedgeMember" xlink:to="lbl_label2088768931" xlink:type="arc"/>
      <link:label id="id_6aadffe9" xlink:label="lbl_label1789788137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options held by market maker</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:to="lbl_label1789788137" xlink:type="arc"/>
      <link:label id="id_29617d6b" xlink:label="lbl_label694254955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, contractual live</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsContractualLive" xlink:to="lbl_label694254955" xlink:type="arc"/>
      <link:label id="id_b107ceb" xlink:label="lbl_label185629931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, contractual live, remaining</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:to="lbl_label185629931" xlink:type="arc"/>
      <link:label id="id_292f5855" xlink:label="lbl_label690968661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, weighted average exercise price</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:to="lbl_label690968661" xlink:type="arc"/>
      <link:label id="id_1e74829a" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense from continuing operations</link:label>
      <link:label id="id_764458f" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in current financial debts</link:label>
      <link:label id="id_657faa04" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests and other financing cash flows</link:label>
      <link:label id="id_4f246ab" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_3f1c8d8f" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseFairValueMeasurementAssets" xlink:to="lbl_label521651444" xlink:type="arc"/>
      <link:label id="id_cca13ad" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid and other portfolio transformation related cash flows</link:label>
      <link:label id="id_7ef7b9ed" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments, deferred consideration and other adjustments, net</link:label>
      <link:label id="id_47b366a2" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred portion of sales price</link:label>
      <link:label id="id_547e2ca5" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:type="arc"/>
      <link:label id="id_73838734" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved</link:label>
      <link:label id="id_56c435e" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:label id="id_12b02f16" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:label id="id_26be22ce" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of non-cash items and other adjustments</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForReconcileProfitLoss" xlink:to="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_2cafaaf8" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reversal of non-cash items</link:label>
      <link:label id="id_4b753731" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss)</link:label>
      <link:label id="id_38c3816c" xlink:label="lbl_IncomeTaxesPaidRefund_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (paid)/refund</link:label>
      <link:label id="id_156023e7" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (paid)/refund, classified as investing activities</link:label>
      <link:label id="id_4b858d4a" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income taxes refund/(paid), classified as operating activities</link:label>
      <link:label id="id_486e2543" xlink:label="lbl_DepreciationAndAmortisationExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:label id="id_bf2d3c0" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:label id="id_555a0937" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_498c02d2" xlink:label="lbl_AdditionsToRestructuringProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to restructuring provisions</link:label>
      <link:label id="id_775477cb" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation of Novartis equity plans</link:label>
      <link:label id="id_408b9f0d" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income statement effect</link:label>
      <link:label id="id_2a46b40e" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of income taxed at reduced rates</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:type="arc"/>
      <link:label id="id_55aa23f7" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of income taxed at reduced rates</link:label>
      <link:label id="id_17e76531" xlink:label="lbl_label401040689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movements of property, plant and equipment [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_label401040689" xlink:type="arc"/>
      <link:label id="id_3d749f5d" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAssetsProvisionsAccrualsMember" xlink:to="lbl_label288271922" xlink:type="arc"/>
      <link:label id="id_5ac948f0" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets [member]</link:label>
      <link:label id="id_6dbb9ba2" xlink:label="lbl_label1841011618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lbl_label1841011618" xlink:type="arc"/>
      <link:label id="id_44d33d7" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, NonVested in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:type="arc"/>
      <link:label id="id_46c4badd" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value at grante date at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:to="lbl_label679367036" xlink:type="arc"/>
      <link:label id="id_1c16a93d" xlink:label="lbl_label471247165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:to="lbl_label471247165" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:to="lbl_label1695476906" xlink:type="arc"/>
      <link:label id="id_657887a0" xlink:label="lbl_label1702397856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:to="lbl_label1702397856" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:to="lbl_label1373999706" xlink:type="arc"/>
      <link:label id="id_6cec499" xlink:label="lbl_label114214041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:to="lbl_label114214041" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:to="lbl_label766376780" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:to="lbl_label250835540" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:to="lbl_label659774806" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:to="lbl_label1942659357" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:to="lbl_label1522796763" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:to="lbl_label1080027869" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:to="lbl_label1523800019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPteLtdSingaporeMember" xlink:to="lbl_label1448389290" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:to="lbl_label547277000" xlink:type="arc"/>
      <link:label id="id_3f303d9f" xlink:label="lbl_label1060126111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex Pharmaceuticals, Inc., Wilmington, NC [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:to="lbl_label1060126111" xlink:type="arc"/>
      <link:label id="id_7ab53501" xlink:label="lbl_label2058695937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc., New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionInc.NewYorkNYMember" xlink:to="lbl_label2058695937" xlink:type="arc"/>
      <link:label id="id_71637428" xlink:label="lbl_label1902343208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Investment Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:to="lbl_label1902343208" xlink:type="arc"/>
      <link:label id="id_631dbefb" xlink:label="lbl_label1662893819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Services Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:to="lbl_label1662893819" xlink:type="arc"/>
      <link:label id="id_682001cf" xlink:label="lbl_label1746928079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis B2 Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisB2Ltd.HamiltonMember" xlink:to="lbl_label1746928079" xlink:type="arc"/>
      <link:label id="id_60c6aa6" xlink:label="lbl_label101477030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis B3 Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisB3Ltd.HamiltonMember" xlink:to="lbl_label101477030" xlink:type="arc"/>
      <link:label id="id_4bc526b5" xlink:label="lbl_label1271211701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ciba-Geigy Japan Limited, Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:to="lbl_label1271211701" xlink:type="arc"/>
      <link:label id="id_518a9aeb" xlink:label="lbl_label1368038123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International Pharmaceutical Investment AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:to="lbl_label1368038123" xlink:type="arc"/>
      <link:label id="id_614bc25c" xlink:label="lbl_label1632354908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Bioventures AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBioventuresAGBaselMember" xlink:to="lbl_label1632354908" xlink:type="arc"/>
      <link:label id="id_8fecb9d" xlink:label="lbl_label150915997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Forschungsstiftung, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisForschungsstiftungBaselMember" xlink:to="lbl_label150915997" xlink:type="arc"/>
      <link:label id="id_600bda82" xlink:label="lbl_label1611389570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Stiftung fuer Kaderausbildung, Basel [member]</link:label>
      <link:label id="id_6fd3a22a" xlink:label="lbl_label1876140586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:to="lbl_label1876140586" xlink:type="arc"/>
      <link:label id="id_2d8acaf0" xlink:label="lbl_label764070640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Stiftung fuer Mensch und Umwelt, Basel [member]</link:label>
      <link:label id="id_7d992496" xlink:label="lbl_label2107188374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]</link:label>
      <link:label id="id_2bb02e62" xlink:label="lbl_label732966498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:to="lbl_label732966498" xlink:type="arc"/>
      <link:label id="id_6c99f32" xlink:label="lbl_label113876786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:to="lbl_label113876786" xlink:type="arc"/>
      <link:label id="id_7dfa0e77" xlink:label="lbl_label2113539703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vivacta Limited, Frimley/Camberley, Surrey [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:to="lbl_label2113539703" xlink:type="arc"/>
      <link:label id="id_5489f125" xlink:label="lbl_label1418326309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis US Foundation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUSFoundationNewYorkNYMember" xlink:to="lbl_label1418326309" xlink:type="arc"/>
      <link:label id="id_1c9b37d8" xlink:label="lbl_label479934424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corthera, Inc., San Mateo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CortheraInc.SanMateoCAMember" xlink:to="lbl_label479934424" xlink:type="arc"/>
      <link:label id="id_32e0fe6b" xlink:label="lbl_label853605995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CoStim Pharmaceuticals Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:to="lbl_label853605995" xlink:type="arc"/>
      <link:label id="id_39cff8c0" xlink:label="lbl_label969930944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Navigate BioPharma Services, Inc., Carlsbad, CA [member]</link:label>
      <link:label id="id_196cf67c" xlink:label="lbl_label426571388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation, East Hanover, NJ [member]</link:label>
      <link:label id="id_72f336af" xlink:label="lbl_label1928541871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ClarVista Medical, Inc., Aliso Viejo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:to="lbl_label1928541871" xlink:type="arc"/>
      <link:label id="id_55c01a35" xlink:label="lbl_label1438652981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transcend Medical, Inc., Lake Forest, IL [member]</link:label>
      <link:label id="id_4148f290" xlink:label="lbl_label1095299728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Triangle International Reinsurance Limited, Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:to="lbl_label1095299728" xlink:type="arc"/>
      <link:label id="id_75fcbca" xlink:label="lbl_label123718602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trinity River Insurance Co Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:to="lbl_label123718602" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:to="lbl_label1611389570" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:to="lbl_label764070640" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:to="lbl_label2107188374" xlink:type="arc"/>
      <link:label id="id_7fb34e52" xlink:label="lbl_label2142457426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:to="lbl_label2142457426" xlink:type="arc"/>
      <link:label id="id_48e7e2a8" xlink:label="lbl_RUB_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Russia, Rubles</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RUB" xlink:to="lbl_RUB_labels" xlink:type="arc"/>
      <link:label id="id_2b6714e7" xlink:label="lbl_RUB_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RUB</link:label>
      <link:label id="id_6b134c2" xlink:label="lbl_BRL_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRL</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BRL" xlink:to="lbl_BRL_labels" xlink:type="arc"/>
      <link:label id="id_19bb001f" xlink:label="lbl_BRL_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brazil, Brazil Real</link:label>
      <link:label id="id_26408b72" xlink:label="lbl_AUD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AUD" xlink:to="lbl_AUD_labels" xlink:type="arc"/>
      <link:label id="id_1c95476e" xlink:label="lbl_AUD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AUD</link:label>
      <link:label id="id_547736b0" xlink:label="lbl_CAD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CAD</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CAD" xlink:to="lbl_CAD_labels" xlink:type="arc"/>
      <link:label id="id_5eb5601a" xlink:label="lbl_CAD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
      <link:label id="id_58b8f0b8" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_435d0149" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates, net income effect [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_71b428a4" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates, net income effect</link:label>
      <link:label id="id_d71a4cc" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates summarized financial information</link:label>
      <link:label id="id_303f5b81" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates</link:label>
      <link:label id="id_3ea56c51" xlink:label="lbl_label1051028561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets/liabilities, expected to have impact on current taxes payable</link:label>
      <link:label id="id_549c77e3" xlink:label="lbl_label1419540451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of deferred tax assets and liabilities, expected to have impact on current taxes payable [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:to="lbl_label1419540451" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:to="lbl_label1051028561" xlink:type="arc"/>
      <link:label id="id_686d8bfd" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of unremitted earnings retained by consolidated entities for reinvestment [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:to="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4726a0d4" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unremitted earnings retained by consolidated entities for reinvestment</link:label>
      <link:label id="id_2be0cf3f" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of amount of inventory recognized as an expense in cost of goods sold [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:to="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_26e57cfe" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of inventory recognized as an expense in cost of goods sold</link:label>
      <link:label id="id_30833089" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of recognized amount of inventory provisions and reversals of inventory provision [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:to="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3124df13" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized amount of inventory provisions and reversals of inventory provision</link:label>
      <link:label id="id_4d23afdc" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross trade receivable from closely monitored countries [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:to="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5f55c02d" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross trade receivable from closely monitored countries</link:label>
      <link:label id="id_540d35ce" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities, breakdown by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:to="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_295129f0" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, breakdown by currency</link:label>
      <link:label id="id_22b42dd0" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of treasury shares movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:to="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7493f0ce" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related treasury shares movements</link:label>
      <link:label id="id_28836a6a" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:to="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77bb4dc1" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_63da54e2" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of liabilities arising from financing activities [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:to="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_ea1dc4a" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of liabilities arising from financing activities</link:label>
      <link:label id="id_ecb4868" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of asset allocation, investments in shares of Novartis AG [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6d5c5887" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset allocation, investments in shares of Novartis AG</link:label>
      <link:label id="id_583fe5ec" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined contribution plans [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4176cd8b" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plans</link:label>
      <link:label id="id_5864530c" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expense related to all equity-based participation and liabilities arising from equity-based payment transactions [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_19e39c55" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense related to all equity-based participation and liabilities arising from equity-based payment transactions</link:label>
      <link:label id="id_12c92048" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets and financial liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6a3159a6" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets and financial liabilities</link:label>
      <link:label id="id_5070bcfa" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_5e4ef11c" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:label id="id_4b298c60" xlink:label="lbl_label1261014112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract or underlying principal amount the derivative financial instruments, by currency</link:label>
      <link:label id="id_6bba442" xlink:label="lbl_label112960578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, contract or underlying principal amount the derivative financial instruments, by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:to="lbl_label112960578" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:to="lbl_label1261014112" xlink:type="arc"/>
      <link:label id="id_7def025f" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:to="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_77677ae5" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value by hierarchy</link:label>
      <link:label id="id_3e022541" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in fair value measurement [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:to="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1b36ee5a" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in fair value measurement</link:label>
      <link:label id="id_fde92c1" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of monitoring of net debt or liquidity based on contractual maturities [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:to="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2293ad67" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monitoring of net debt or liquidity based on contractual maturities</link:label>
      <link:label id="id_1cfe8d17" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments and accrued interest on derivative financial instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5ab7d205" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments</link:label>
      <link:label id="id_36cdbc5" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other contractual liabilities of the net debt or liquidity [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:to="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_36a9094b" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other contractual liabilities of the net debt or liquidity</link:label>
      <link:label id="id_6873d3e4" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_52a21cc6" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model</link:label>
      <link:label id="id_5cc8b03e" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model, average, high, and low VAR amounts [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_13881ac7" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model, average, high, and low VAR amounts</link:label>
      <link:label id="id_41e588b8" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model, worst case loss scenario [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7c01a973" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model, worst case loss scenario</link:label>
      <link:label id="id_5ec493de" xlink:label="lbl_KR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KR" xlink:to="lbl_KR_labels" xlink:type="arc"/>
      <link:label id="id_685d93ad" xlink:label="lbl_KR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South Korea</link:label>
      <link:label id="id_25a8beb4" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:label id="id_43c445c8" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_53037399" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares, equity impact</link:label>
      <link:label id="id_449dfef2" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments out of provisions and other net cash movements in non-current liabilities</link:label>
      <link:label id="id_5f336b49" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</link:label>
      <link:label id="id_1ebe8e22" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:type="arc"/>
      <link:label id="id_7c3b4ddb" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation</link:label>
      <link:label id="id_37f79dee" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of release of contingent consideration liability</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:type="arc"/>
      <link:label id="id_7767d800" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of release of contingent consideration liability</link:label>
      <link:label id="id_3fbded99" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:to="lbl_label1999384126" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:to="lbl_label1131311877" xlink:type="arc"/>
      <link:label id="id_7da827c0" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_45122075" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables charged to the consolidated income statement</link:label>
      <link:label id="id_3b199e63" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_9457980" xlink:label="lbl_label155548032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset and liability valuation [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_label155548032" xlink:type="arc"/>
      <link:label id="id_1c2a973a" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law deferred tax expense income recognised in profit or loss</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_44e2d573" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law deferred tax relating to components of other comprehensive income</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_31998635" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law increase decrease in deferred tax liability asset</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_3ecc5b67" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law increase decrease in current income tax liability</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:type="arc"/>
      <link:label id="id_16a647a9" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law change in deferred tax assets and liabilities and current tax liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_549d9bf8" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Items previously recognized in consolidated income statement</link:label>
      <link:label id="id_5370a381" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Items previously recognized in other comprehensive income</link:label>
      <link:label id="id_584b4926" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of deferred tax assets and liabilities</link:label>
      <link:label id="id_1d65bc0" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of current income tax liabilities</link:label>
      <link:label id="id_67c3f632" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of deferred tax assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_25c7d443" xlink:label="lbl_label633852995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact location [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_label633852995" xlink:type="arc"/>
      <link:label id="id_49f0b616" xlink:label="lbl_label1240512022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact location [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_label1240512022" xlink:type="arc"/>
      <link:label id="id_2bcc20cf" xlink:label="lbl_label734798031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementMember" xlink:to="lbl_label734798031" xlink:type="arc"/>
      <link:label id="id_5659c922" xlink:label="lbl_label1448724770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:to="lbl_label1448724770" xlink:type="arc"/>
      <link:label id="id_2a7f4c39" xlink:label="lbl_label712985657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted operating lease commitments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedOperatingLeaseCommitments" xlink:to="lbl_label712985657" xlink:type="arc"/>
      <link:label id="id_78817d05" xlink:label="lbl_label2021752069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution of business to joint venture</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionOfBusinessToJointVenture" xlink:to="lbl_label2021752069" xlink:type="arc"/>
      <link:label id="id_77130f8a" xlink:label="lbl_label1997737866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of income not subject to tax on the divestment gain on GSK investment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:to="lbl_label1997737866" xlink:type="arc"/>
      <link:label id="id_5b6d1716" xlink:label="lbl_label1533875990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:to="lbl_label1533875990" xlink:type="arc"/>
      <link:label id="id_11cc9e15" xlink:label="lbl_label298622485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to available-for-sale financia investments previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:to="lbl_label298622485" xlink:type="arc"/>
      <link:label id="id_7418c9fe" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:type="arc"/>
      <link:label id="id_12e2c645" xlink:label="lbl_label316851781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law effective tax rate after implemetation of new law changes</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:to="lbl_label316851781" xlink:type="arc"/>
      <link:label id="id_2bfd3952" xlink:label="lbl_label738015570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law tax on unremitted earnings period allowed for payment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:to="lbl_label738015570" xlink:type="arc"/>
      <link:label id="id_34cb50dd" xlink:label="lbl_label885739741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on unremitted earnings</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:to="lbl_label885739741" xlink:type="arc"/>
      <link:label id="id_73b04098" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:type="arc"/>
      <link:label id="id_75b59f04" xlink:label="lbl_label1713201135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through finance lease contracts property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:to="lbl_label1713201135" xlink:type="arc"/>
      <link:label id="id_3eec7519" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal group companies materiality of assets or sales to third parties</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:type="arc"/>
      <link:label id="id_c93c456" xlink:label="lbl_label211010646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible asset purchase commitments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangiblePurchaseCommitments" xlink:to="lbl_label211010646" xlink:type="arc"/>
      <link:label id="id_6759fd06" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development and other intangible asset purchase commitments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:type="arc"/>
      <link:label id="id_624861c8" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_2f002958" xlink:label="lbl_label788539736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments - narrative [table]</link:label>
      <link:label id="id_684e1ed4" xlink:label="lbl_label1749950164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open hedges for anticipated transactions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OpenHedgesForAnticipatedTransactions" xlink:to="lbl_label1749950164" xlink:type="arc"/>
      <link:label id="id_38f600d1" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:type="arc"/>
      <link:label id="id_24d61d6" xlink:label="lbl_label38625750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when pricing parameters for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:to="lbl_label38625750" xlink:type="arc"/>
      <link:label id="id_8d1d7d" xlink:label="lbl_label9248125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most significant foreign exchange losses</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostSignificantForeignExchangeLosses" xlink:to="lbl_label9248125" xlink:type="arc"/>
      <link:label id="id_75c586da" xlink:label="lbl_label1975879386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term financial debt with a carrying amount</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:to="lbl_label1975879386" xlink:type="arc"/>
      <link:label id="id_189f8e8f" xlink:label="lbl_label413109903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:to="lbl_label413109903" xlink:type="arc"/>
      <link:label id="id_19e141a6" xlink:label="lbl_label434192806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net investment hedge recognized in the income statement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:to="lbl_label434192806" xlink:type="arc"/>
      <link:label id="id_7d454e3e" xlink:label="lbl_label2101694014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upper limit on holdings on unrelated company</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:to="lbl_label2101694014" xlink:type="arc"/>
      <link:label id="id_1ccfbaa5" xlink:label="lbl_label483375781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper maximum borrowing amount</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:to="lbl_label483375781" xlink:type="arc"/>
      <link:label id="id_665a2289" xlink:label="lbl_label1717183113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt/equity ratio</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtEquityRatio" xlink:to="lbl_label1717183113" xlink:type="arc"/>
      <link:label id="id_5597d347" xlink:label="lbl_label1436013383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VAR estimate confidence interval</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VAREstimateConfidenceInterval" xlink:to="lbl_label1436013383" xlink:type="arc"/>
      <link:label id="id_42729374" xlink:label="lbl_label1114805108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper maximum amount outstanding</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:to="lbl_label1114805108" xlink:type="arc"/>
      <link:label id="id_6e4f3f5e" xlink:label="lbl_label1850687326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility committed</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityCommitted" xlink:to="lbl_label1850687326" xlink:type="arc"/>
      <link:label id="id_40060c01" xlink:label="lbl_label1074138113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty risk [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_label1074138113" xlink:type="arc"/>
      <link:label id="id_16edbe31" xlink:label="lbl_label384679473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's cash and cash equivalents held with financial institution</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:to="lbl_label384679473" xlink:type="arc"/>
      <link:label id="id_367e78c8" xlink:label="lbl_label914258120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VendorAxis" xlink:to="lbl_label914258120" xlink:type="arc"/>
      <link:label id="id_45057e7f" xlink:label="lbl_label1157987967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VendorMember" xlink:to="lbl_label1157987967" xlink:type="arc"/>
      <link:label id="id_bcf5c90" xlink:label="lbl_label198139024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LargestFinancialInstitutionMember" xlink:to="lbl_label198139024" xlink:type="arc"/>
      <link:label id="id_561f18c8" xlink:label="lbl_label1444878536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecondLargestFinancialInstitutionMember" xlink:to="lbl_label1444878536" xlink:type="arc"/>
      <link:label id="id_cbf0fed" xlink:label="lbl_label213848045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThirdLargestFinancialInstitutionMember" xlink:to="lbl_label213848045" xlink:type="arc"/>
      <link:label id="id_3a76e486" xlink:label="lbl_label980870278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre tax profit (loss) from divestment of business</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:to="lbl_label980870278" xlink:type="arc"/>
      <link:label id="id_5810372f" xlink:label="lbl_label1477457711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, divestment-date fair value</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:to="lbl_label1477457711" xlink:type="arc"/>
      <link:label id="id_4121b29e" xlink:label="lbl_label1092727454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential receivable from divestment</link:label>
      <link:label id="id_3cc9e79a" xlink:label="lbl_label1019864986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration received</link:label>
      <link:label id="id_5b569e4" xlink:label="lbl_label95775204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone payment already received</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MilestonePaymentAlreadyReceived" xlink:to="lbl_label95775204" xlink:type="arc"/>
      <link:label id="id_63dee19f" xlink:label="lbl_label1675551135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future put option to sell business</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FuturePutOptionToSellBusiness" xlink:to="lbl_label1675551135" xlink:type="arc"/>
      <link:label id="id_7e35f229" xlink:label="lbl_label2117464617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment put option</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentPutOption" xlink:to="lbl_label2117464617" xlink:type="arc"/>
      <link:label id="id_4b717d8e" xlink:label="lbl_label1265728910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest exchanged</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExchanged" xlink:to="lbl_label1265728910" xlink:type="arc"/>
      <link:label id="id_8fd1ef1" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in offset against gross trade receivables</link:label>
      <link:label id="id_2ef82d23" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit payments</link:label>
      <link:label id="id_7c796053" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised</link:label>
      <link:label id="id_64515558" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised or sold</link:label>
      <link:label id="id_79b0131b" xlink:label="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:label id="id_18855477" xlink:label="lbl_ClassesOfShareCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total outstanding shares</link:label>
      <link:label id="id_34b6a8cb" xlink:label="lbl_OrdinarySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Novartis shares</link:label>
      <link:label id="id_20b38808" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total treasury shares</link:label>
      <link:label id="id_5dca543c" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other institutions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:type="arc"/>
      <link:label id="id_3901e819" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other financial institutions</link:label>
      <link:label id="id_551ca7d0" xlink:label="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable, current</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivableCurrent" xlink:to="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:type="arc"/>
      <link:label id="id_15fc798c" xlink:label="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable</link:label>
      <link:label id="id_249fb0f8" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of divestments, other provisions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfDivestmentsOtherProvisions" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_77b9898f" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of divestments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_label788539736" xlink:type="arc"/>
      <link:label id="id_4241ab2c" xlink:label="lbl_GrossCarryingAmountMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount</link:label>
      <link:label id="id_1264a0dc" xlink:label="lbl_label308584668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers with net sales over five percent</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CustomersWithNetSalesOverFivePercent" xlink:to="lbl_label308584668" xlink:type="arc"/>
      <link:label id="id_2af199bf" xlink:label="lbl_label720476607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in acquisitions and divestments of businesses, classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label720476607" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1718040268" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1423033786" xlink:type="arc"/>
      <link:label id="id_2cbb9926" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment (loss) reversal of impairment loss recognised in profit or loss</link:label>
      <link:label id="id_eadbcd2" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:label id="id_36976720" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid benefit cost</link:label>
      <link:label id="id_1c757af9" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued share-based payments</link:label>
      <link:label id="id_79c38d68" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
      <link:label id="id_1dbfe68b" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_7bc2e092" xlink:label="lbl_label2076369042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables short-term [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:to="lbl_label2076369042" xlink:type="arc"/>
      <link:label id="id_1fd99bd1" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_2da8b675" xlink:label="lbl_label329619167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options excluded from the calculation</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OptionsExcludedFromTheCalculation" xlink:to="lbl_label329619167" xlink:type="arc"/>
      <link:label id="id_171116a0" xlink:label="lbl_label386995872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US commercial paper programs [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USCommercialPaperProgramsMember" xlink:to="lbl_label386995872" xlink:type="arc"/>
      <link:label id="id_1fb8b12f" xlink:label="lbl_label532197679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JP commercial paper programs [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JPCommercialPaperProgramsMember" xlink:to="lbl_label532197679" xlink:type="arc"/>
      <link:label id="id_68bfdd9c" xlink:label="lbl_label1757404572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper, number of programs</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:to="lbl_label1757404572" xlink:type="arc"/>
      <link:label id="id_4e21d3c" xlink:label="lbl_label81927484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when most significant parameters for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:to="lbl_label81927484" xlink:type="arc"/>
      <link:label id="id_5ccfc0db" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when POS for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:type="arc"/>
      <link:label id="id_17ec29fe" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (AAA) [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:type="arc"/>
      <link:label id="id_4991ae50" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (AAA)</link:label>
      <link:label id="id_69548c9f" xlink:label="lbl_label1767148703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Share capital in tender offer</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalInTenderOffer" xlink:to="lbl_label1767148703" xlink:type="arc"/>
      <link:label id="id_5c76d079" xlink:label="lbl_CashOfferPerOrdinaryShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash offer per ordinary share</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOfferPerOrdinaryShare" xlink:to="lbl_CashOfferPerOrdinaryShare_labels" xlink:type="arc"/>
      <link:label id="id_741421fb" xlink:label="lbl_CashOfferPerADS_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash offer per ADS</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOfferPerADS" xlink:to="lbl_CashOfferPerADS_labels" xlink:type="arc"/>
      <link:label id="id_4236be0f" xlink:label="lbl_label1110883855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of ordinary share per ADS</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOrdinarySharePerADS" xlink:to="lbl_label1110883855" xlink:type="arc"/>
      <link:label id="id_471c5e7e" xlink:label="lbl_label1193041534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of equity</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfEquity" xlink:to="lbl_label1193041534" xlink:type="arc"/>
      <link:label id="id_72ec4d21" xlink:label="lbl_label454367578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximal amount of share buyback programm</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximalAmountOfShareBuybackProgramm" xlink:to="lbl_label454367578" xlink:type="arc"/>
      <link:label id="id_6eb334f8" xlink:label="lbl_label1857238264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Annual Incentive</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAnnualIncentive" xlink:to="lbl_label1857238264" xlink:type="arc"/>
      <link:label id="id_5c74f412" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:type="arc"/>
      <link:label id="id_5ba6657f" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
      <link:label id="id_7ae769dd" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_49cb7900" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provisions and other current liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfBusinessUnits" xlink:to="lbl_label267498308" xlink:type="arc"/>
      <link:label id="id_8b05ce2" xlink:label="lbl_label145775842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties, change in percent</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:to="lbl_label145775842" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:to="lbl_label198642827" xlink:type="arc"/>
      <link:label id="id_5eb218a8" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI</link:label>
      <link:label id="id_4b99efa9" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax on above items</link:label>
      <link:label id="id_5952def9" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefits other than equity-based compensation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:type="arc"/>
      <link:label id="id_389a5b52" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonCurrentFinancialDebtsMember" xlink:to="lbl_label1268656258" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:to="lbl_label618343139" xlink:type="arc"/>
      <link:label id="id_6987695e" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IntangibleAssetImpairmentChargesTextBlock" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:to="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_76ff2ee3" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges</link:label>
      <link:label id="id_2dd3bece" xlink:label="lbl_label768851662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of share capital tendered at the expiration of the tender offer</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:to="lbl_label768851662" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:to="lbl_label2363078" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:to="lbl_label1019864986" xlink:type="arc"/>
      <link:label id="id_4875601b" xlink:label="lbl_TransactionRelatedCostsPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction related costs paid</link:label>
      <link:label id="id_5201dd1d" xlink:label="lbl_TransactionRelatedCosts_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction related costs</link:label>
      <link:label id="id_b9d0509" xlink:label="lbl_label770091111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of fair value adjustments relating to intangible assets tax</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:to="lbl_label770091111" xlink:type="arc"/>
      <link:label id="id_55cbca11" xlink:label="lbl_label1439418897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum margin percentage impact of commodity price change</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:to="lbl_label1439418897" xlink:type="arc"/>
      <link:label id="id_a88bf0e" xlink:label="lbl_label176733966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum holding in unrelated company</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximumHoldingInUnrelatedCompany" xlink:to="lbl_label176733966" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialReceivableFromDivestment" xlink:to="lbl_label1092727454" xlink:type="arc"/>
      <link:label id="id_2fe8aa88" xlink:label="lbl_CashOfferPerADS_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses the amount of cash Novartis paid to the owners of AAA per ADS.</link:label>
      <link:label id="id_74cb8111" xlink:label="lbl_CashOfferPerOrdinaryShare_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.</link:label>
      <link:label id="id_4036843c" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses a maximal amount.</link:label>
      <link:label id="id_64640b79" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses a limit.</link:label>
      <link:label id="id_177cac6" xlink:label="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This is a reclassification that can be debit or credit.</link:label>
      <link:label id="id_5fdbc2b7" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</link:label>
      <link:label id="id_314a813f" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</link:label>
      <link:label id="id_4962d3fd" xlink:label="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SellingGeneralAndAdministrativeExpense" xlink:to="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:type="arc"/>
      <link:label id="id_1f242104" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other changes, equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:type="arc"/>
      <link:label id="id_5aa89188" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_94ddbe4" xlink:label="lbl_label156097508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_label156097508" xlink:type="arc"/>
      <link:label id="id_4cdc11a9" xlink:label="lbl_label1289490857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported value [member]</link:label>
      <link:label id="id_501954f0" xlink:label="lbl_label1343837424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period [member]</link:label>
      <link:label id="id_22153d9b" xlink:label="lbl_label571817371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change to prior year-end [member]</link:label>
      <link:label id="id_dc043" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDebt1" xlink:to="lbl_NetDebt_labels2" xlink:type="arc"/>
      <link:label id="id_8969c68" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:label id="id_641074d9" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:label id="id_476a5a91" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1548f70e" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of preparation</link:label>
      <link:label id="id_2c18deb" xlink:label="lbl_label46239211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of preparation [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BasisOfPreparationAbstract" xlink:label="lbl_BasisOfPreparationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasisOfPreparationAbstract" xlink:to="lbl_label46239211" xlink:type="arc"/>
      <link:label id="id_2df428b0" xlink:label="lbl_label770975920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SelectedCriticalAccountingPoliciesAbstract" xlink:label="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:to="lbl_label770975920" xlink:type="arc"/>
      <link:label id="id_2a3a2ba4" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies</link:label>
      <link:label id="id_6b45f171" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of equity attributable to Novartis AG shareholders</link:label>
      <link:label id="id_2c2ab3f2" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
      <link:label id="id_4dd6c758" xlink:label="lbl_label1305921368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings update [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LegalProceedingsUpdateAbstract" xlink:label="lbl_LegalProceedingsUpdateAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsUpdateAbstract" xlink:to="lbl_label1305921368" xlink:type="arc"/>
      <link:label id="id_62d75963" xlink:label="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings update [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LegalProceedingsUpdateTextBlock" xlink:label="lbl_LegalProceedingsUpdateTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsUpdateTextBlock" xlink:to="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_47116fe6" xlink:label="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal proceedings update</link:label>
      <link:label id="id_6f65ab76" xlink:label="lbl_label1868934006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impacts of adoption of new IFRS standards [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:label="lbl_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:to="lbl_label1868934006" xlink:type="arc"/>
      <link:label id="id_73aff3ab" xlink:label="lbl_label200796173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impacts of adoption of new IFRS standards [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:label="lbl_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:to="lbl_label200796173" xlink:type="arc"/>
      <link:label id="id_9aad709" xlink:label="lbl_label162191113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for available-for-sale financial assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:to="lbl_label162191113" xlink:type="arc"/>
      <link:label id="id_59f07686" xlink:label="lbl_label1508931206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lbl_label1508931206" xlink:type="arc"/>
      <link:label id="id_4a00f82a" xlink:label="lbl_label1241577514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Revenue from Contracts with Customers [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:to="lbl_label1241577514" xlink:type="arc"/>
      <link:label id="id_68958299" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for other revenue [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_68991831" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:label id="id_5460feda" xlink:label="lbl_label1415642842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated balance sheet by the adoption of IFRS 15 [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:label="lbl_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:to="lbl_label1415642842" xlink:type="arc"/>
      <link:label id="id_5b4e8ef2" xlink:label="lbl_label1531875058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated statement of changes in equity by the adoption of IFRS 9 and IFRS 15 [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:label="lbl_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:to="lbl_label1531875058" xlink:type="arc"/>
      <link:label id="id_e7f3472" xlink:label="lbl_label243217522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments additional disclosures table by the adoption of IFRS 9 [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:to="lbl_label243217522" xlink:type="arc"/>
      <link:label id="id_71771d90" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales by region</link:label>
      <link:label id="id_4f219465" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, net sales of Top 20 products [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b8de385" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales of Top 20 products</link:label>
      <link:label id="id_45ec2147" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, other revenue [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7f01fd05" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:label id="id_1894478a" xlink:label="lbl_AveXisIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AveXis, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AveXisIncMember" xlink:to="lbl_AveXisIncMember_labels" xlink:type="arc"/>
      <link:label id="id_43b60602" xlink:label="lbl_AveXisIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AveXis, Inc.</link:label>
      <link:label id="id_6a7073ad" xlink:label="lbl_label1785754541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_label1785754541" xlink:type="arc"/>
      <link:label id="id_33459cb3" xlink:label="lbl_label860200115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently stated [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestatedMember" xlink:to="lbl_label860200115" xlink:type="arc"/>
      <link:label id="id_41804a67" xlink:label="lbl_label1098926695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously stated [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreviouslyStatedMember" xlink:to="lbl_label1098926695" xlink:type="arc"/>
      <link:label id="id_d0e08b6" xlink:label="lbl_label217930333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_label217930333" xlink:type="arc"/>
      <link:label id="id_4a438f95" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 9 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:type="arc"/>
      <link:label id="id_68a9252d" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, IFRS 9</link:label>
      <link:label id="id_3803c2cc" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 15 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:type="arc"/>
      <link:label id="id_7f440478" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, IFRS 15</link:label>
      <link:label id="id_6cbd5ed8" xlink:label="lbl_OCIReservesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI reserves [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OCIReservesMember" xlink:label="lbl_OCIReservesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OCIReservesMember" xlink:to="lbl_OCIReservesMember_labels" xlink:type="arc"/>
      <link:label id="id_37bd32c4" xlink:label="lbl_OCIReservesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCI reserves</link:label>
      <link:label id="id_3071cdbf" xlink:label="lbl_label812764607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retail Generics [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetailGenericsMember" xlink:to="lbl_label812764607" xlink:type="arc"/>
      <link:label id="id_22d00e67" xlink:label="lbl_label584060519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceuticals [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BiopharmaceuticalsMember" xlink:to="lbl_label584060519" xlink:type="arc"/>
      <link:label id="id_74e760f" xlink:label="lbl_label122582543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti Infectives [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AntiInfectivesMember" xlink:to="lbl_label122582543" xlink:type="arc"/>
      <link:label id="id_2e5631da" xlink:label="lbl_label777400794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgical [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SurgicalMember" xlink:label="lbl_SurgicalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SurgicalMember" xlink:to="lbl_label777400794" xlink:type="arc"/>
      <link:label id="id_5a63105" xlink:label="lbl_label94777605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vision Care [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VisionCareMember" xlink:label="lbl_VisionCareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VisionCareMember" xlink:to="lbl_label94777605" xlink:type="arc"/>
      <link:label id="id_33d2b620" xlink:label="lbl_label869447200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumables [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsumablesMember" xlink:label="lbl_ConsumablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsumablesMember" xlink:to="lbl_label869447200" xlink:type="arc"/>
      <link:label id="id_3fe1336c" xlink:label="lbl_label1071723372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implantables [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImplantablesMember" xlink:label="lbl_ImplantablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImplantablesMember" xlink:to="lbl_label1071723372" xlink:type="arc"/>
      <link:label id="id_6d32d4c6" xlink:label="lbl_label1832047814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment/Other [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquipmentOtherMember" xlink:label="lbl_EquipmentOtherMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquipmentOtherMember" xlink:to="lbl_label1832047814" xlink:type="arc"/>
      <link:label id="id_9208315" xlink:label="lbl_label153125653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmic OTC [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OphthalmicOTCMember" xlink:label="lbl_OphthalmicOTCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OphthalmicOTCMember" xlink:to="lbl_label153125653" xlink:type="arc"/>
      <link:label id="id_3d77d223" xlink:label="lbl_label1031262755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact lens care [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContactLensCareMember" xlink:label="lbl_ContactLensCareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactLensCareMember" xlink:to="lbl_label1031262755" xlink:type="arc"/>
      <link:label id="id_5ff6168e" xlink:label="lbl_label1609963150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top 20 products [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Top20ProductsMember" xlink:to="lbl_label1609963150" xlink:type="arc"/>
      <link:label id="id_1bc8878f" xlink:label="lbl_label466126735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of portfolio [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestOfPortfolioMember" xlink:to="lbl_label466126735" xlink:type="arc"/>
      <link:label id="id_60f02df8" xlink:label="lbl_label1626353144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromRoyalties" xlink:to="lbl_label1626353144" xlink:type="arc"/>
      <link:label id="id_132c5856" xlink:label="lbl_label321673302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit sharing income</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitSharingIncome" xlink:to="lbl_label321673302" xlink:type="arc"/>
      <link:label id="id_dd742a8" xlink:label="lbl_label232211112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone income</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MilestoneIncome" xlink:to="lbl_label232211112" xlink:type="arc"/>
      <link:label id="id_31af75cd" xlink:label="lbl_OtherRevenueOther_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue, other</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRevenueOther" xlink:to="lbl_OtherRevenueOther_labels" xlink:type="arc"/>
      <link:label id="id_41473bf" xlink:label="lbl_OtherRevenueOther_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_22e4d15f" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities, as a percentage from net sales</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:type="arc"/>
      <link:label id="id_3e5bb44f" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income as % of net sales</link:label>
      <link:label id="id_3761b8d8" xlink:label="lbl_label929151192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada and Latin America [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CanadaAndLatinAmericaMember" xlink:to="lbl_label929151192" xlink:type="arc"/>
      <link:label id="id_35dc7c05" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties, change in percent, cc</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:type="arc"/>
      <link:label id="id_2402bc9" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales, change in %, cc</link:label>
      <link:label id="id_11578a03" xlink:label="lbl_label290949635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Markets [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedMarketsMember" xlink:to="lbl_label290949635" xlink:type="arc"/>
      <link:label id="id_1e6859ac" xlink:label="lbl_label510155180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emerging Growth Markets [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmergingGrowthMarketsMember" xlink:to="lbl_label510155180" xlink:type="arc"/>
      <link:label id="id_395d61a2" xlink:label="lbl_label962421154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of the world [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestOfTheWorldMember" xlink:to="lbl_label962421154" xlink:type="arc"/>
      <link:label id="id_2aeb33db" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired to be cancelled</link:label>
      <link:label id="id_16be2f1a" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired for cancellation, equity impact</link:label>
      <link:label id="id_14bac1b3" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_10768f17" xlink:label="lbl_label276205335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.5% EUR 750 million 2018/2023 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A0.5EUR750Million20182023OfNovartisMember" xlink:label="lbl_A0.5EUR750Million20182023OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.5EUR750Million20182023OfNovartisMember" xlink:to="lbl_label276205335" xlink:type="arc"/>
      <link:label id="id_6c222bbb" xlink:label="lbl_label1814178747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% EUR 750 million 2018/2030 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1.375EUR750Million20182030OfNovartisMember" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.375EUR750Million20182030OfNovartisMember" xlink:to="lbl_label1814178747" xlink:type="arc"/>
      <link:label id="id_42e49e27" xlink:label="lbl_label1122278951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.7% EUR 750 million 2018/2038 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1.7EUR750Million20182038OfNovartisMember" xlink:label="lbl_A1.7EUR750Million20182038OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.7EUR750Million20182038OfNovartisMember" xlink:to="lbl_label1122278951" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GalvusGroupMember" xlink:to="lbl_label195411774" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiovanGroupMember" xlink:to="lbl_label1973931633" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExforgeGroupMember" xlink:to="lbl_label1243142238" xlink:type="arc"/>
      <link:label id="id_15727011" xlink:label="lbl_label359821329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immunology, Hepatology and Dermatology [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:to="lbl_label359821329" xlink:type="arc"/>
      <link:label id="id_86e5c43" xlink:label="lbl_label141450307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti Infectives sold under Sandoz name [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:to="lbl_label141450307" xlink:type="arc"/>
      <link:label id="id_194d5f34" xlink:label="lbl_label424501044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combinations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lbl_label424501044" xlink:type="arc"/>
      <link:label id="id_4f78aa77" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:type="arc"/>
      <link:label id="id_73e25c53" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_7e4ea322" xlink:label="lbl_label2119082786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_label2119082786" xlink:type="arc"/>
      <link:label id="id_306dde36" xlink:label="lbl_label812506678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy required by IFRSs [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_label812506678" xlink:type="arc"/>
      <link:label id="id_474e15ff" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of disposal group held for sale</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSharePurchasesValue" xlink:to="lbl_OtherSharePurchasesValue_labels" xlink:type="arc"/>
      <link:label id="id_6ae68310" xlink:label="lbl_label1793491728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lutathera [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LutatheraMember" xlink:to="lbl_label1793491728" xlink:type="arc"/>
      <link:label id="id_5ba5546c" xlink:label="lbl_label1537561708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kymriah [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KymriahMember" xlink:to="lbl_label1537561708" xlink:type="arc"/>
      <link:label id="id_6c54b8f7" xlink:label="lbl_label1817491703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of share capital tendered at the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label1817491703" xlink:type="arc"/>
      <link:label id="id_a269182" xlink:label="lbl_label170299778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid for share capital tendered at the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label170299778" xlink:type="arc"/>
      <link:label id="id_7317bbcb" xlink:label="lbl_label1930935243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total percentage of share capital tendered after the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label1930935243" xlink:type="arc"/>
      <link:label id="id_57adc4f7" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in Equity [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_281ffdcd" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in Equity</link:label>
      <link:label id="id_2cc49159" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity paid</link:label>
      <link:label id="id_7df5c0c1" xlink:label="lbl_label2113257665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with related parties [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionsWithRelatedPartiesAbstract" xlink:label="lbl_TransactionsWithRelatedPartiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithRelatedPartiesAbstract" xlink:to="lbl_label2113257665" xlink:type="arc"/>
      <link:label id="id_5c1d5da7" xlink:label="lbl_label1309162706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with related parties [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionsWithRelatedPartiesTextBlock" xlink:label="lbl_TransactionsWithRelatedPartiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithRelatedPartiesTextBlock" xlink:to="lbl_label1309162706" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCostsRecordedInEquityPaid" xlink:label="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquityPaid" xlink:to="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:type="arc"/>
      <link:label id="id_5de3849f" xlink:label="lbl_TransactionCostsRecordedInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquity" xlink:to="lbl_TransactionCostsRecordedInEquity_labels" xlink:type="arc"/>
      <link:label id="id_154fa58" xlink:label="lbl_label22346328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income recycled into the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:to="lbl_label22346328" xlink:type="arc"/>
      <link:label id="id_7c9a09e2" xlink:label="lbl_label2090469858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9 fund investments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:to="lbl_label2090469858" xlink:type="arc"/>
      <link:label id="id_36de49a0" xlink:label="lbl_label920537504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9 equity securities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:to="lbl_label920537504" xlink:type="arc"/>
      <link:label id="id_1e72baf" xlink:label="lbl_label31927215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pension Fund [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPensionFundMember" xlink:to="lbl_label31927215" xlink:type="arc"/>
      <link:label id="id_6d9924d1" xlink:label="lbl_label1838752977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility uncommitted</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityUncommitted" xlink:to="lbl_label1838752977" xlink:type="arc"/>
      <link:label id="id_60aed585" xlink:label="lbl_label1622070661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other net assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNetAssets" xlink:to="lbl_label1622070661" xlink:type="arc"/>
      <link:label id="id_25566515" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from changes in ownership interests in subsidiaries that do not result in loss of control</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:type="arc"/>
      <link:label id="id_73ce5e23" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_68208ecc" xlink:label="lbl_label1746964172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ocular health [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OcularHealthMember" xlink:label="lbl_OcularHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OcularHealthMember" xlink:to="lbl_label1746964172" xlink:type="arc"/>
      <link:label id="id_7d654567" xlink:label="lbl_label2103788903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:to="lbl_label2103788903" xlink:type="arc"/>
      <link:label id="id_a1b491f" xlink:label="lbl_label169560351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:to="lbl_label169560351" xlink:type="arc"/>
      <link:label id="id_1f1416" xlink:label="lbl_label2036758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:to="lbl_label2036758" xlink:type="arc"/>
      <link:label id="id_63baf8ea" xlink:label="lbl_label1673197802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications International SA, Geneve [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:to="lbl_label1673197802" xlink:type="arc"/>
      <link:label id="id_4bc832fa" xlink:label="lbl_label1271411450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Switzerland SA, Geneve [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:to="lbl_label1271411450" xlink:type="arc"/>
      <link:label id="id_2658ed55" xlink:label="lbl_label643362133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AveXis, Inc., Bannockburn, IL [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AveXisInc.BannockburnILMember" xlink:label="lbl_AveXisInc.BannockburnILMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AveXisInc.BannockburnILMember" xlink:to="lbl_label643362133" xlink:type="arc"/>
      <link:label id="id_358de13" xlink:label="lbl_label56155667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications S.A., Saint Genis Pouilly [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:to="lbl_label56155667" xlink:type="arc"/>
      <link:label id="id_480bc7a" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share</link:label>
      <link:label id="id_4f788787" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share</link:label>
      <link:label id="id_579c77e7" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_6e4a53e8" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets without disposal group</link:label>
      <link:label id="id_4c7ed954" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities other than liabilities included in disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_6f67d848" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities included in disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_41ef90c7" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group held for sale</link:label>
      <link:label id="id_15dcecbd" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities without disposal group</link:label>
      <link:label id="id_6be52fb3" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_2cc5f4f3" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_4201ce33" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total of items never to be recycled</link:label>
      <link:label id="id_3dedbea0" xlink:label="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administration</link:label>
      <link:label id="id_24ee551" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_50cb4109" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_24ba2cbb" xlink:label="lbl_label616180923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal group held for sale [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisposalGroupHeldForSaleAbstract" xlink:label="lbl_DisposalGroupHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupHeldForSaleAbstract" xlink:to="lbl_label616180923" xlink:type="arc"/>
      <link:label id="id_2e51c9a9" xlink:label="lbl_label777111977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities not classified as held for sale [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_label777111977" xlink:type="arc"/>
      <link:label id="id_54b5ab16" xlink:label="lbl_label1421191958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities classified as held for sale [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_label1421191958" xlink:type="arc"/>
      <link:label id="id_620a76ae" xlink:label="lbl_label1644852910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsHeldForSaleMember" xlink:label="lbl_NoncurrentAssetsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsHeldForSaleMember" xlink:to="lbl_label1644852910" xlink:type="arc"/>
      <link:label id="id_35b1993" xlink:label="lbl_label56301971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal groups classified as held for sale [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:to="lbl_label56301971" xlink:type="arc"/>
      <link:label id="id_775bbb23" xlink:label="lbl_label2002500387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities classified as held for sale [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_label2002500387" xlink:type="arc"/>
      <link:label id="id_76d4000c" xlink:label="lbl_label1993605132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal group held for sale [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisposalGroupHeldForSaleLineItems" xlink:label="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_label1993605132" xlink:type="arc"/>
      <link:label id="id_511c252" xlink:label="lbl_label85049938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets of disposal group classified as held for sale [abstract]</link:label>
      <link:label id="id_3a8a761b" xlink:label="lbl_label982152731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group classified as held for sale [abstract]</link:label>
      <link:label id="id_7ebdc3d3" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_196d02a3" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other current assets</link:label>
      <link:label id="id_2004a2a3" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other current liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_5c1266c3" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other current liabilities</link:label>
      <link:label id="id_1b44e5e7" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_753e354c" xlink:label="lbl_label1967011148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in cash settled share based payments liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:to="lbl_label1967011148" xlink:type="arc"/>
      <link:label id="id_3fb8017" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments, net</link:label>
      <link:label id="id_45184c03" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Non-controlling interests</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowNoncontrollingInterests" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowNoncontrollingInterests" xlink:to="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_3e6c4694" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_773be135" xlink:label="lbl_label1852230229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount recorded in equity related to hyperinflation</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:to="lbl_label1852230229" xlink:type="arc"/>
      <link:label id="id_73d5e167" xlink:label="lbl_label1851268028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:to="lbl_label1851268028" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:label id="id_1341dbff" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_346b395c" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4b1ad4e8" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2fcaf057" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_17118b46" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_1d85e3c0" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_4b8f7d44" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2918e43e" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:label id="id_5abfc6c6" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_40924196" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts</link:label>
      <link:label id="id_4016f674" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interest in acquiree recognised at acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2ea65efd" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_2375ce31" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, debt securities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:type="arc"/>
      <link:label id="id_56d0df79" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities, net of taxes</link:label>
      <link:label id="id_4663183e" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:label id="id_40c6b8fb" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:type="arc"/>
      <link:label id="id_3261fe4" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation, equity impact</link:label>
      <link:label id="id_cb4c548" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
      <link:label id="id_2a76513b" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCosts" xlink:to="lbl_TransactionCosts_labels" xlink:type="arc"/>
      <link:label id="id_19c4929e" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on divestment of interests in associated companies</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_2500459a" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on divestment</link:label>
      <link:label id="id_198075f2" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_3f9715cf" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities</link:label>
      <link:label id="id_76d81b48" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_57bce160" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities</link:label>
      <link:label id="id_1fb67de2" xlink:label="lbl_label532053474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification to presentation required under IFRS 9 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:to="lbl_label532053474" xlink:type="arc"/>
      <link:label id="id_714a2d9" xlink:label="lbl_label118792921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated Value Adjustments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestatedValueAdjustmentsMember" xlink:to="lbl_label118792921" xlink:type="arc"/>
      <link:label id="id_4587be64" xlink:label="lbl_label1595406142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, equity investments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:to="lbl_label1595406142" xlink:type="arc"/>
      <link:label id="id_2b6a8c9e" xlink:label="lbl_label858249235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, fund investments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:to="lbl_label858249235" xlink:type="arc"/>
      <link:label id="id_6be6dda0" xlink:label="lbl_label1810292128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="lbl_label1810292128" xlink:type="arc"/>
      <link:label id="id_ea4af2a" xlink:label="lbl_label245673770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_label245673770" xlink:type="arc"/>
      <link:label id="id_341eabcf" xlink:label="lbl_label874425295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_label874425295" xlink:type="arc"/>
      <link:label id="id_2ef67b59" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_2bbf6984" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_5be6a6ba" xlink:label="lbl_label1541842618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_label1541842618" xlink:type="arc"/>
      <link:label id="id_5b1cb05e" xlink:label="lbl_label1528606814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label1528606814" xlink:type="arc"/>
      <link:label id="id_131c72f5" xlink:label="lbl_label320631541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Listed equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ListedEquitySecuritiesMember" xlink:to="lbl_label320631541" xlink:type="arc"/>
      <link:label id="id_58943bff" xlink:label="lbl_label1486109695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-listed equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonlistedEquitySecuritiesMember" xlink:to="lbl_label1486109695" xlink:type="arc"/>
      <link:label id="id_466ea37d" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of assets of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_328aa9b8" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of disposal group classified as held for sale</link:label>
      <link:label id="id_663782d5" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of liabilities of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5f98604f" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group classified as held for sale</link:label>
      <link:label id="id_1786ac50" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_33784e41" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities measured at fair value through other comprehensive income</link:label>
      <link:label id="id_2785f328" xlink:label="lbl_EndocyteMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteMember" xlink:to="lbl_EndocyteMember_labels" xlink:type="arc"/>
      <link:label id="id_1ab891f2" xlink:label="lbl_EndocyteMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Endocyte</link:label>
      <link:label id="id_559cd899" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets, cash and cash equivalents [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_63b9b41c" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_172750e3" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets, marketable securities, commodities and non-current financial assets [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7ca31c97" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities and non-current financial assets</link:label>
      <link:label id="id_447d705c" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net sales and selected non-current assets, by countries and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_36daedff" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and selected non-current assets, by countries and regions</link:label>
      <link:label id="id_24f609b0" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net sales, by segements and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27432d26" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales by region</link:label>
      <link:label id="id_4192e6ea" xlink:label="lbl_label235032989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of change in accounting policy</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:to="lbl_label235032989" xlink:type="arc"/>
      <link:label id="id_457ba061" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestments aquisitions of interests in associated companies</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_49d2e101" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through classified as held for sale, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_625c07b4" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_6066a3c9" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through classified as held for sale, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_580b40b6" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_3af4fc23" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_6cd0a23e" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax balance related to disposal group held for sale</link:label>
      <link:label id="id_7f1eeac9" xlink:label="lbl_OtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherShareSales" xlink:to="lbl_OtherShareSales_labels" xlink:type="arc"/>
      <link:label id="id_7be3c1db" xlink:label="lbl_OtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:label id="id_6d6afa95" xlink:label="lbl_label1359067097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share sales, equity impact</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherShareSalesEquityImpact" xlink:label="lbl_OtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherShareSalesEquityImpact" xlink:to="lbl_label1359067097" xlink:type="arc"/>
      <link:label id="id_3b6caa8a" xlink:label="lbl_NumberOfOtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other share sales</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherShareSales" xlink:to="lbl_NumberOfOtherShareSales_labels" xlink:type="arc"/>
      <link:label id="id_6db1b7c2" xlink:label="lbl_NumberOfOtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:label id="id_2d79675e" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other share sales, equity impact</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfOtherShareSalesEquityImpact" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherShareSalesEquityImpact" xlink:to="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:type="arc"/>
      <link:label id="id_4f13fea7" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share sales, equity impact</link:label>
      <link:label id="id_35d72bee" xlink:label="lbl_label903293934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, debt securities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:to="lbl_label903293934" xlink:type="arc"/>
      <link:label id="id_269c946a" xlink:label="lbl_label647795818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, equity securities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeEquitySecurities" xlink:label="lbl_OtherComprehensiveIncomeEquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeEquitySecurities" xlink:to="lbl_label647795818" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1931018935" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1923652241" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1031360833" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label409451279" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaNVVilvoordeMember" xlink:to="lbl_label861091593" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozNVVilvoordeMember" xlink:to="lbl_label102668381" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCouvreurNVPuursMember" xlink:to="lbl_label1808949392" xlink:type="arc"/>
      <link:label id="id_20428b8c" xlink:label="lbl_label541232012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Belgium BVBA, Puurs [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:to="lbl_label541232012" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNVVilvoordeMember" xlink:to="lbl_label1193123279" xlink:type="arc"/>
      <link:label id="id_7f713e00" xlink:label="lbl_label2138127872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon AG, Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconAGFribourgMember" xlink:to="lbl_label2138127872" xlink:type="arc"/>
      <link:label id="id_3e12064" xlink:label="lbl_label65085540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications USA, Inc., New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:to="lbl_label65085540" xlink:type="arc"/>
      <link:label id="id_749e4361" xlink:label="lbl_label1956528993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Corporation LLC, Duluth, GA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:to="lbl_label1956528993" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:to="lbl_label426571388" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:to="lbl_label1610589901" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:to="lbl_label1898723838" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:to="lbl_label1959302877" xlink:type="arc"/>
      <link:label id="id_6d8d3375" xlink:label="lbl_label1837970293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Healthcare, S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:to="lbl_label1837970293" xlink:type="arc"/>
      <link:label id="id_3892d07e" xlink:label="lbl_label949145726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ophthalmics AG, Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisOphthalmicsAGFribourgMember" xlink:label="lbl_NovartisOphthalmicsAGFribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOphthalmicsAGFribourgMember" xlink:to="lbl_label949145726" xlink:type="arc"/>
      <link:label id="id_5097f514" xlink:label="lbl_label1352135956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Ukraine LLC, Kiev [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozUkraineLLCKievMember" xlink:to="lbl_label1352135956" xlink:type="arc"/>
      <link:label id="id_68b9cbd5" xlink:label="lbl_label1757006805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestment cost to sell</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentCostToSell" xlink:to="lbl_label1757006805" xlink:type="arc"/>
      <link:label id="id_3bde338f" xlink:label="lbl_label1004417935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of settlement in principle</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfSettlementInPrinciple" xlink:to="lbl_label1004417935" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:to="lbl_label969930944" xlink:type="arc"/>
      <link:label id="id_54d2c7cf" xlink:label="lbl_label1423099855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of products in portfolio to be sold</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfProductsInPortfolioToBeSold" xlink:to="lbl_label1423099855" xlink:type="arc"/>
      <link:label id="id_4f5a93ca" xlink:label="lbl_label1331336138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying value of the divested business</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingValueOfTheDivestedBusiness" xlink:to="lbl_label1331336138" xlink:type="arc"/>
      <link:label id="id_2bfacba6" xlink:label="lbl_label737856422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short term leases and low value leases</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShortTermLeasesAndLowValueLeases" xlink:to="lbl_label737856422" xlink:type="arc"/>
      <link:label id="id_1638753" xlink:label="lbl_label23299923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining lease commitments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemainingLeaseCommitments" xlink:to="lbl_label23299923" xlink:type="arc"/>
      <link:label id="id_3c454913" xlink:label="lbl_label1011173651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities to be recognized</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesToBeRecognized" xlink:to="lbl_label1011173651" xlink:type="arc"/>
      <link:label id="id_46c00732" xlink:label="lbl_label1186989874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets to be recognized</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsToBeRecognized" xlink:to="lbl_label1186989874" xlink:type="arc"/>
      <link:label id="id_5c114913" xlink:label="lbl_label1544636691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss/gain recorded on equity securities and fund investments at fair value through the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:to="lbl_label1544636691" xlink:type="arc"/>
      <link:label id="id_c04ac79" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities, net of taxes</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:type="arc"/>
      <link:label id="id_5fb3768f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) from investments in equity instruments</link:label>
      <link:label id="id_4dc28e6d" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseIncome" xlink:to="lbl_DeferredTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_77e968c5" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax income</link:label>
      <link:label id="id_2d4a780d" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxExpenseIncome" xlink:to="lbl_CurrentTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_bbe9642" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
      <link:label id="id_5ac027e9" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income effect</link:label>
      <link:label id="id_2c40f598" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated companies' movements in comprehensive income</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:to="lbl_label757358878" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:to="lbl_label1668533481" xlink:type="arc"/>
      <link:label id="id_3d20cd78" xlink:label="lbl_label1025559928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte, Inc., Lafayette, IN [member]</link:label>
      <link:label id="id_151d2726" xlink:label="lbl_label354232102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tear Film Innovations, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:to="lbl_label354232102" xlink:type="arc"/>
      <link:label id="id_1a32a075" xlink:label="lbl_label439525493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TrueVision Systems, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:to="lbl_label439525493" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TranscendMedicalInc.LakeForestILMember" xlink:to="lbl_label1438652981" xlink:type="arc"/>
      <link:label id="id_279b1df4" xlink:label="lbl_label664477172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Baltics SIA, Riga [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBalticsSIARigaMember" xlink:to="lbl_label664477172" xlink:type="arc"/>
      <link:label id="id_5e85347d" xlink:label="lbl_label1585788029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Biosciences Peru S.A., Lima [member]</link:label>
      <link:label id="id_62d68d5f" xlink:label="lbl_label1658228063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Overseas Investments AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:to="lbl_label1658228063" xlink:type="arc"/>
      <link:label id="id_254382a8" xlink:label="lbl_label625181352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japat AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JapatAGBaselMember" xlink:to="lbl_label625181352" xlink:type="arc"/>
      <link:label id="id_4cd3abe4" xlink:label="lbl_label1288940516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Management SA, Geneva [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconManagementSAGenevaMember" xlink:to="lbl_label1288940516" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteInc.LafayetteINMember" xlink:to="lbl_label1025559928" xlink:type="arc"/>
      <link:label id="id_68b5f06f" xlink:label="lbl_label1756754031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oriel Therapeutics, Inc., Durham, NC [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:to="lbl_label1756754031" xlink:type="arc"/>
      <link:label id="id_60eaa13f" xlink:label="lbl_label1625989439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WaveLight, Inc., Sterling, VA [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WaveLightInc.SterlingVAMember" xlink:to="lbl_label1625989439" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:to="lbl_label1585788029" xlink:type="arc"/>
      <link:label id="id_5bdf673e" xlink:label="lbl_label1541367614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares with restricted use</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesWithRestrictedUse" xlink:to="lbl_label1541367614" xlink:type="arc"/>
      <link:label id="id_7fb088b9" xlink:label="lbl_label2142275769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of revenues exempt from taxation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:to="lbl_label2142275769" xlink:type="arc"/>
      <link:label id="id_6108aeff" xlink:label="lbl_CurrentInterestPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current interest payable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentInterestPayable" xlink:to="lbl_CurrentInterestPayable_labels" xlink:type="arc"/>
      <link:label id="id_1fc5ed9f" xlink:label="lbl_CurrentInterestPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interests on financial debt</link:label>
      <link:label id="id_6b7c4e62" xlink:label="lbl_label1458816832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment for repurchase own shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentForRepurchaseOwnShares" xlink:to="lbl_label1458816832" xlink:type="arc"/>
      <link:label id="id_5e285341" xlink:label="lbl_label130728687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial asstets debt securities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:to="lbl_label130728687" xlink:type="arc"/>
      <link:label id="id_1f883fd2" xlink:label="lbl_label826017497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions included in disposal group prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:to="lbl_label826017497" xlink:type="arc"/>
      <link:label id="id_256b0374" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation charge prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_4b6e3676" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total financial investments</link:label>
      <link:label id="id_2b3e006" xlink:label="lbl_label1209757713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proforma net sales</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProformaNetSales" xlink:to="lbl_label1209757713" xlink:type="arc"/>
      <link:label id="id_2888ddc2" xlink:label="lbl_label680058306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Serelaxin [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SerelaxinMember" xlink:to="lbl_label680058306" xlink:type="arc"/>
      <link:label id="id_4e4f9507" xlink:label="lbl_label1313838343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CyPass [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CyPassMember" xlink:to="lbl_label1313838343" xlink:type="arc"/>
      <link:label id="id_52281715" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement adjustments of prior year</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:type="arc"/>
      <link:label id="id_68901646" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions prior year</link:label>
      <link:label id="id_12f0be52" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement adjustments of current year</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:type="arc"/>
      <link:label id="id_10001b20" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions current year</link:label>
      <link:label id="id_53e07f22" xlink:label="lbl_label1407221538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plans and program rebates [axis]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_label1407221538" xlink:type="arc"/>
      <link:label id="id_64c2e5e1" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, other provisions and increase (decrease) through net exchange differences, other provisions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_359d5a9f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of currency translation and business combinations</link:label>
      <link:label id="id_73fc698b" xlink:label="lbl_label1945921931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges related to disposal group held for sale</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:to="lbl_label1945921931" xlink:type="arc"/>
      <link:label id="id_6ee3c039" xlink:label="lbl_label1860419641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges related to disposal group held for sale to the date of reclassification</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:to="lbl_label1860419641" xlink:type="arc"/>
      <link:label id="id_4ed2e3f9" xlink:label="lbl_label1322443769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions included in disposal group to the date of reclassification</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:to="lbl_label1322443769" xlink:type="arc"/>
      <link:label id="id_7be11426" xlink:label="lbl_label1459075477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in from divestments of businesses classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1459075477" xlink:type="arc"/>
      <link:label id="id_63a31bcb" xlink:label="lbl_label625103893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets divested</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsDivested" xlink:to="lbl_label625103893" xlink:type="arc"/>
      <link:label id="id_7f3ccd67" xlink:label="lbl_label654491613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets divested</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsDivested" xlink:to="lbl_label654491613" xlink:type="arc"/>
      <link:label id="id_28fd0d0c" xlink:label="lbl_label2062437885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities divested</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesDivested" xlink:to="lbl_label2062437885" xlink:type="arc"/>
      <link:label id="id_217212a3" xlink:label="lbl_label1484079992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssets" xlink:to="lbl_label1484079992" xlink:type="arc"/>
      <link:label id="id_3b6cb989" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_411a4e68" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_481dd512" xlink:label="lbl_label1209914642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow outflow from net identifiable assets divested acquired</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:to="lbl_label1209914642" xlink:type="arc"/>
      <link:label id="id_2dad0e04" xlink:label="lbl_TradePayablesAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesAndOtherLiabilities" xlink:to="lbl_TradePayablesAndOtherLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_1551e337" xlink:label="lbl_TradePayablesAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities</link:label>
      <link:label id="id_29a54c7d" xlink:label="lbl_label698698877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow outflow from net identifiable assets currency translation effects liquidity and fair value of equity interests</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:to="lbl_label698698877" xlink:type="arc"/>
      <link:label id="id_72d7c22d" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_469e951e" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divested business</link:label>
      <link:label id="id_79d4ff23" xlink:label="lbl_label2044002083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of other financial assets sold</link:label>
      <link:label id="id_f9b4624" xlink:label="lbl_label261834276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, fair value through other comprehensive income [member]</link:label>
      <link:label id="id_3f7b625a" xlink:label="lbl_label1065050714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term financial investments, fair value through other comprehensive income [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label1065050714" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label261834276" xlink:type="arc"/>
      <link:label id="id_3373fda5" xlink:label="lbl_label863239589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_label863239589" xlink:type="arc"/>
      <link:label id="id_52f984e4" xlink:label="lbl_label1392084196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US-specific healthcare plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:to="lbl_label1392084196" xlink:type="arc"/>
      <link:label id="id_3a1be35a" xlink:label="lbl_label974906202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US-specific healthcare plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:to="lbl_label974906202" xlink:type="arc"/>
      <link:label id="id_52817cee" xlink:label="lbl_label1384217838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-healthcare plans and program-related rebates, returns and other deductions [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:to="lbl_label1384217838" xlink:type="arc"/>
      <link:label id="id_518b30b7" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge prior to classification to assets held for sale</link:label>
      <link:label id="id_611b2741" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_35974485" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise prices for outstanding share options [member]</link:label>
      <link:label id="id_3da6037c" xlink:label="lbl_label1034290044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">46.7</link:label>
      <link:label id="id_5698bfcb" xlink:label="lbl_label1452851147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 46.7 [member]</link:label>
      <link:label id="id_df65a83" xlink:label="lbl_label1098297979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">54.5</link:label>
      <link:label id="id_26baf973" xlink:label="lbl_label1238972312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.0</link:label>
      <link:label id="id_5d51017e" xlink:label="lbl_label1565589886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.6</link:label>
      <link:label id="id_7925df2" xlink:label="lbl_label127032818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.6 [member]</link:label>
      <link:label id="id_50442a73" xlink:label="lbl_label61576322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">66.0</link:label>
      <link:label id="id_77b11616" xlink:label="lbl_label2008094230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:to="lbl_label2008094230" xlink:type="arc"/>
      <link:label id="id_13923e74" xlink:label="lbl_label328351348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">46.4</link:label>
      <link:label id="id_26b025e5" xlink:label="lbl_label649078245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">53.7</link:label>
      <link:label id="id_15297d64" xlink:label="lbl_label355040612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.1</link:label>
      <link:label id="id_37ef180d" xlink:label="lbl_label938416141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">58.3</link:label>
      <link:label id="id_7963b4c" xlink:label="lbl_label127286092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">66.1</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.7Member" xlink:to="lbl_label1452851147" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.7Member" xlink:to="lbl_label1034290044" xlink:type="arc"/>
      <link:label id="id_7638cc32" xlink:label="lbl_label1983433778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 54.5 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice54.5Member" xlink:to="lbl_label1983433778" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice54.5Member" xlink:to="lbl_label1098297979" xlink:type="arc"/>
      <link:label id="id_625d280f" xlink:label="lbl_label1650272271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.0 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.0Member" xlink:to="lbl_label1650272271" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.0Member" xlink:to="lbl_label1238972312" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.6Member" xlink:to="lbl_label127032818" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.6Member" xlink:to="lbl_label1565589886" xlink:type="arc"/>
      <link:label id="id_7f8b8ef4" xlink:label="lbl_label2139852532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 66.0 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.0Member" xlink:to="lbl_label2139852532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.0Member" xlink:to="lbl_label61576322" xlink:type="arc"/>
      <link:label id="id_1c214787" xlink:label="lbl_label471943047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 46.4 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.4Member" xlink:to="lbl_label471943047" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.4Member" xlink:to="lbl_label328351348" xlink:type="arc"/>
      <link:label id="id_60064b00" xlink:label="lbl_label1611025152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 53.7 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice53.7Member" xlink:to="lbl_label1611025152" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice53.7Member" xlink:to="lbl_label649078245" xlink:type="arc"/>
      <link:label id="id_3d7bc5f9" xlink:label="lbl_label1031521785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.1 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.1Member" xlink:to="lbl_label1031521785" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.1Member" xlink:to="lbl_label355040612" xlink:type="arc"/>
      <link:label id="id_5312799d" xlink:label="lbl_label1393719709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 58.3 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice58.3Member" xlink:to="lbl_label1393719709" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice58.3Member" xlink:to="lbl_label938416141" xlink:type="arc"/>
      <link:label id="id_11afcf8b" xlink:label="lbl_label296734603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 66.1 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.1Member" xlink:to="lbl_label296734603" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.1Member" xlink:to="lbl_label127286092" xlink:type="arc"/>
      <link:label id="id_602d9a64" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of interests in associated companies, net</link:label>
      <link:label id="id_1640eef1" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payments</link:label>
      <link:label id="id_4305d26a" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities from discontinued operations</link:label>
      <link:label id="id_1cb46ce6" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings</link:label>
      <link:label id="id_45074031" xlink:label="lbl_label1158103089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments and accrued lease payments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaymentsAndAccruedLeasePayments" xlink:to="lbl_label1158103089" xlink:type="arc"/>
      <link:label id="id_1787fdbc" xlink:label="lbl_label1284506961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recycling of the Novartis share of other comprehensive income from associated companies</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:to="lbl_label1284506961" xlink:type="arc"/>
      <link:label id="id_7702ef73" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_135f3eb7" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payments</link:label>
      <link:label id="id_1765273e" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net assets recognized as a result of business combinations</link:label>
      <link:label id="id_4a08e514" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
      <link:label id="id_71e76093" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:label id="id_608223c4" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total Income Tax Expense</link:label>
      <link:label id="id_352bb146" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense from discontinued operations</link:label>
      <link:label id="id_6348f872" xlink:label="lbl_TransactionCostsRecordedInEquity_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_label85049938" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_label982152731" xlink:type="arc"/>
      <link:label id="id_31ca37cf" xlink:label="lbl_label835336143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:to="lbl_label835336143" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_43b1908f" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets or deferred tax liabilities related to disposal group held for sale</link:label>
      <link:label id="id_3b7e23ba" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued benefit liability</link:label>
      <link:label id="id_774651e9" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_5fb55436" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired for cancellation, equity impact</link:label>
      <link:label id="id_71230227" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:label id="id_757b03e4" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total equity impact of treasury share movements</link:label>
      <link:label id="id_9217c59" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:label id="id_eb62348" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_2ec0dcb9" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_48bf4d53" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_1a35a04f" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_39d0eccc" xlink:label="lbl_OtherSharePurchasesValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other share purchases, equity impact</link:label>
      <link:label id="id_5209e6b5" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
      <link:label id="id_2a14e1da" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_74f13ac0" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:label id="id_180b00c2" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in/from investing activities from continuing operations</link:label>
      <link:label id="id_aca6a21" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in non-current financial debts</link:label>
      <link:label id="id_5e5a2737" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net cash flows used in/from investing activities</link:label>
      <link:label id="id_12daaf08" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divested interest in associate</link:label>
      <link:label id="id_595a0496" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in discontinued operations</link:label>
      <link:label id="id_6f1acb28" xlink:label="lbl_label1864026920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term financial investments [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongTermFinancialInvestmentsMember" xlink:to="lbl_label1864026920" xlink:type="arc"/>
      <link:label id="id_24014c8f" xlink:label="lbl_label1836731146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_label1836731146" xlink:type="arc"/>
      <link:label id="id_7323afac" xlink:label="lbl_label1544871888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major plans percentage in group DBO pensions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:to="lbl_label1544871888" xlink:type="arc"/>
      <link:label id="id_192e72f5" xlink:label="lbl_label456555172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most signigicant countries percentage on group DBO post employment benefit plans</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:to="lbl_label456555172" xlink:type="arc"/>
      <link:label id="id_45e2937b" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:label id="id_7686c3c0" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
      <link:label id="id_4d6d4f53" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_764909d2" xlink:label="lbl_label949739114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent financial assets, total financial investments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_label949739114" xlink:type="arc"/>
      <link:label id="id_2ba0d9fa" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:label id="id_751d39ac" xlink:label="lbl_label1964849580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net income/loss from discontinued operations before gain on distribution</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:to="lbl_label1964849580" xlink:type="arc"/>
      <link:label id="id_3a463b8c" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:type="arc"/>
      <link:label id="id_2c57b1ca" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on distribution</link:label>
      <link:label id="id_291f69d6" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax on Pension plans previously recognized in OCI</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:to="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:type="arc"/>
      <link:label id="id_2f7fc540" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightofuseAssets" xlink:to="lbl_RightofuseAssets_labels" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:label id="id_6acaf180" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind distribution liability</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPayable" xlink:to="lbl_DividendsPayable_labels" xlink:type="arc"/>
      <link:label id="id_34ce2448" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends payable, non-cash assets distributions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="locator"/>
      <link:label id="id_484edcc4" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_7adfa754" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners of paren</link:label>
      <link:label id="id_590635ac" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of treasury shares</link:label>
      <link:label id="id_2476e743" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:label id="id_1ffd83cc" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in/from financing activities from discontinued operations</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:label id="id_6a49a8cd" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities from continuing operations</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_59187aa8" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, discontinued operations</link:label>
      <link:label id="id_1d15aff4" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, continuing operations</link:label>
      <link:label id="id_100aa035" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:type="arc"/>
      <link:label id="id_50620c89" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:label id="id_96ecbb0" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents of discontinued operations at end of prior period</link:label>
      <link:label id="id_2334b78" xlink:label="lbl_label36916088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of discontinued operations [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_label36916088" xlink:type="arc"/>
      <link:label id="id_76c64958" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sales to continuing and discontinued segments</link:label>
      <link:label id="id_36af0a7f" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales from continuing operations</link:label>
      <link:label id="id_58501f6b" xlink:label="lbl_label1481645931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period, YoY [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YoYChangeMember" xlink:to="lbl_label1481645931" xlink:type="arc"/>
      <link:label id="id_3ed48330" xlink:label="lbl_label1054114608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lbl_label1054114608" xlink:type="arc"/>
      <link:label id="id_43a1a553" xlink:label="lbl_label1134667091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_label1134667091" xlink:type="arc"/>
      <link:label id="id_3045b2a1" xlink:label="lbl_label809874081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VehiclesMember" xlink:to="lbl_label809874081" xlink:type="arc"/>
      <link:label id="id_64acc522" xlink:label="lbl_label1689044258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_label1689044258" xlink:type="arc"/>
      <link:label id="id_5367393f" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationRightofuseAssets" xlink:to="lbl_DepreciationRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_4a6ffe17" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_1b8dfafc" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Machinery &amp; equipment and other assets</link:label>
      <link:label id="id_2da47e8f" xlink:label="lbl_NoncurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilities" xlink:to="lbl_NoncurrentLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_5905e579" xlink:label="lbl_NoncurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:label id="id_328c2a61" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilities" xlink:to="lbl_CurrentLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_543a77a3" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:label id="id_234e965a" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities, net</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_e7d4ee5" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
      <link:label id="id_7097e6f" xlink:label="lbl_label118062703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="lbl_PresentationOfLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLesseeAbstract" xlink:to="lbl_label118062703" xlink:type="arc"/>
      <link:label id="id_171d0edf" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilities" xlink:to="lbl_LeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_1c665876" xlink:label="lbl_GrossLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilities" xlink:to="lbl_GrossLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_2c03c1ee" xlink:label="lbl_GrossLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease commitments</link:label>
      <link:label id="id_1b0667c7" xlink:label="lbl_label453404615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lesses [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PresentationOfLeasesForLessesTable" xlink:label="lbl_PresentationOfLeasesForLessesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLessesTable" xlink:to="lbl_label453404615" xlink:type="arc"/>
      <link:label id="id_72b5e1b" xlink:label="lbl_label120282651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PresentationOfLeasesForLesseeLineItems" xlink:label="lbl_PresentationOfLeasesForLesseeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLesseeLineItems" xlink:to="lbl_label120282651" xlink:type="arc"/>
      <link:label id="id_3a8f2f5a" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to short-term leases for which recognition exemption has been used</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:type="arc"/>
      <link:label id="id_3f6e27d0" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition exemption for short term leases</link:label>
      <link:label id="id_7a5f05cd" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to leases of low-value assets for which recognition exemption has been used</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:type="arc"/>
      <link:label id="id_3ae50249" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition exception for low value leases</link:label>
      <link:label id="id_375e4cce" xlink:label="lbl_label928926926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New lease arrangements</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NewLeaseArrangements" xlink:to="lbl_label928926926" xlink:type="arc"/>
      <link:label id="id_c8ad2dc" xlink:label="lbl_label210424540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted future lease payments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedFutureLeasePayments" xlink:to="lbl_label210424540" xlink:type="arc"/>
      <link:label id="id_75283e38" xlink:label="lbl_EffectOfDiscounting_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of discounting</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfDiscounting" xlink:to="lbl_EffectOfDiscounting_labels" xlink:type="arc"/>
      <link:label id="id_6ac0bebc" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
      <link:label id="id_6447e039" xlink:label="lbl_label1682432057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about leases for lessee [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_label1682432057" xlink:type="arc"/>
      <link:label id="id_3e0ced0d" xlink:label="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseOnLeaseLiabilities" xlink:to="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_7693425d" xlink:label="lbl_label1989362269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowForLeases" xlink:to="lbl_label1989362269" xlink:type="arc"/>
      <link:label id="id_26c71205" xlink:label="lbl_label650580485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to variable lease payments not included in measurement of lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="lbl_label650580485" xlink:type="arc"/>
      <link:label id="id_63dc6855" xlink:label="lbl_label1675389013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:to="lbl_label1675389013" xlink:type="arc"/>
      <link:label id="id_10622a16" xlink:label="lbl_label274868758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [table]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_label274868758" xlink:type="arc"/>
      <link:label id="id_24f1a439" xlink:label="lbl_label619815993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [line items]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_label619815993" xlink:type="arc"/>
      <link:label id="id_67bf33b0" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales to third parties of discontinued operations</link:label>
      <link:label id="id_327f346c" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income of discontinued operations</link:label>
      <link:label id="id_64213541" xlink:label="lbl_label1679897921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentStatedMember" xlink:label="lbl_CurrentStatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentStatedMember" xlink:to="lbl_label1679897921" xlink:type="arc"/>
      <link:label id="id_5ebed7b4" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of treasury shares, number of shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:to="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:type="arc"/>
      <link:label id="id_22f85f35" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of treasury shares</link:label>
      <link:label id="id_25cdb408" xlink:label="lbl_label634237960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed information about significant transaction</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DetailedInformationAboutSignificantTransaction" xlink:to="lbl_label634237960" xlink:type="arc"/>
      <link:label id="id_7eb3758e" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:type="arc"/>
      <link:label id="id_6db37ab5" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
      <link:label id="id_ff14c14" xlink:label="lbl_IFMTreInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IFM Tre, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IFMTreInc.Member" xlink:to="lbl_IFMTreInc.Member_labels" xlink:type="arc"/>
      <link:label id="id_5b8c5fe7" xlink:label="lbl_IFMTreInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IFM Tre, Inc.</link:label>
      <link:label id="id_33428670" xlink:label="lbl_PowerVisionInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PowerVision, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PowerVisionInc.Member" xlink:to="lbl_PowerVisionInc.Member_labels" xlink:type="arc"/>
      <link:label id="id_7001a921" xlink:label="lbl_PowerVisionInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PowerVision, Inc.</link:label>
      <link:label id="id_6bb5fe48" xlink:label="lbl_label1807089224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for prepayments and accrued lease payments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:to="lbl_label1807089224" xlink:type="arc"/>
      <link:label id="id_10d3bb4e" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:type="arc"/>
      <link:label id="id_e7bd10a" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:label id="id_390e560d" xlink:label="lbl_label957240845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToRightofuseAssets" xlink:to="lbl_label957240845" xlink:type="arc"/>
      <link:label id="id_f3aa39f" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) arising from sale and leaseback transactions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:type="arc"/>
      <link:label id="id_1dfe7c52" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains or losses from sales leaseback</link:label>
      <link:label id="id_50d6583f" xlink:label="lbl_label1356224575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherBorrowings" xlink:to="lbl_label1356224575" xlink:type="arc"/>
      <link:label id="id_589c1537" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in dividends payable through change in fair value of non-cash assets held for distribution to owners</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_1a2e3f6" xlink:label="lbl_NetAssetsLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetAssetsLiabilities" xlink:to="lbl_NetAssetsLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4d789f55" xlink:label="lbl_NetAssetsLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net assets</link:label>
      <link:label id="id_7d2cba5f" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease of distribution liability</link:label>
      <link:label id="id_24596c04" xlink:label="lbl_label609840132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential milestone maximum payments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialMilestoneMaximumPayments" xlink:to="lbl_label609840132" xlink:type="arc"/>
      <link:label id="id_3dc6ce5a" xlink:label="lbl_label1036439130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of employees associated with the product transfer</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:to="lbl_label1036439130" xlink:type="arc"/>
      <link:label id="id_3954535f" xlink:label="lbl_label961827679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional borrowings</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalBorrowings" xlink:to="lbl_label961827679" xlink:type="arc"/>
      <link:label id="id_43740ee2" xlink:label="lbl_label1131679458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of equity interest shares received</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEquityInterestSharesReceived" xlink:to="lbl_label1131679458" xlink:type="arc"/>
      <link:label id="id_79732968" xlink:label="lbl_label2037590376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between fair value of distribution liability and net assets at the date of distribution</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:to="lbl_label2037590376" xlink:type="arc"/>
      <link:label id="id_431c3dd4" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution of dividend to dividend bearing shares to consolidated foundations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:type="arc"/>
      <link:label id="id_ff7c4c3" xlink:label="lbl_label267896003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aimovig [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AimovigMember" xlink:to="lbl_label267896003" xlink:type="arc"/>
      <link:label id="id_4945ceaa" xlink:label="lbl_label1229311658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities and Right of use assets Disclosure Abstract</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:label="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:to="lbl_label1229311658" xlink:type="arc"/>
      <link:label id="id_79212b70" xlink:label="lbl_label2032216944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="lbl_DisclosureOfLeasesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLeasesExplanatory" xlink:to="lbl_label2032216944" xlink:type="arc"/>
      <link:label id="id_4b496242" xlink:label="lbl_ReductionOfIssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of issued capital</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReductionOfIssuedCapital" xlink:to="lbl_ReductionOfIssuedCapital_labels" xlink:type="arc"/>
      <link:label id="id_211a2da" xlink:label="lbl_ReductionOfIssuedCapital_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction of share capital</link:label>
      <link:label id="id_610df533" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:type="arc"/>
      <link:label id="id_169b45c8" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions, equity impact</link:label>
      <link:label id="id_76378de3" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through exercise of options shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:type="arc"/>
      <link:label id="id_4cd892b4" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions shares</link:label>
      <link:label id="id_1efc7c8b" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through share based payment transactions shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:to="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:type="arc"/>
      <link:label id="id_1d05cf3d" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity based compensation shares</link:label>
      <link:label id="id_1a5eff2" xlink:label="lbl_label27652082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentOfLeaseLiability" xlink:to="lbl_label27652082" xlink:type="arc"/>
      <link:label id="id_7a957c7" xlink:label="lbl_label128538567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate lease liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:to="lbl_label128538567" xlink:type="arc"/>
      <link:label id="id_50834b9f" xlink:label="lbl_label1350781855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movements of the right-of-use assets [roll forward]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_label1350781855" xlink:type="arc"/>
      <link:label id="id_4004db36" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets at beginning of period</link:label>
      <link:label id="id_63713767" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets at end of period</link:label>
      <link:label id="id_491fa8b0" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease contract terminations, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseContractTerminationsRightofuseAssets" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_43e3ea12" xlink:label="lbl_label79581278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through net exchange differences, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:to="lbl_label79581278" xlink:type="arc"/>
      <link:label id="id_750ea0e7" xlink:label="lbl_label1963892967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares delivered to divested business employees, equity impact</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:to="lbl_label1963892967" xlink:type="arc"/>
      <link:label id="id_23a4b8a2" xlink:label="lbl_TaxesOnTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on treasury shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesOnTreasuryShares" xlink:to="lbl_TaxesOnTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_2a977fac" xlink:label="lbl_label714571692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease incentives</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseIncentives" xlink:to="lbl_label714571692" xlink:type="arc"/>
      <link:label id="id_752a730a" xlink:label="lbl_label1965716234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow for leases</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowForLeases" xlink:label="lbl_CashInflowForLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowForLeases" xlink:to="lbl_label1965716234" xlink:type="arc"/>
      <link:label id="id_56ca2a36" xlink:label="lbl_NetAssetsDerecognized_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets derecognized</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetAssetsDerecognized" xlink:to="lbl_NetAssetsDerecognized_labels" xlink:type="arc"/>
      <link:label id="id_1b28c052" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of distribution liability</link:label>
      <link:label id="id_32e2fa92" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Difference between net assets and distribution liability</link:label>
      <link:label id="id_5a5595b5" xlink:label="lbl_label1515558325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution of dividend to dividend bearing shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionOfDividendToDividendBearingShares" xlink:to="lbl_label1515558325" xlink:type="arc"/>
      <link:label id="id_76193299" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recognized in the consolidated income statement</link:label>
      <link:label id="id_1fe7672a" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:type="arc"/>
      <link:label id="id_4fbc2a8c" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on distribution</link:label>
      <link:label id="id_1b6a6442" xlink:label="lbl_label459957314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net provisions for transaction costs recognized in the income statement</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:label="lbl_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:to="lbl_label459957314" xlink:type="arc"/>
      <link:label id="id_68457d8c" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows attributable to divested business</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsAttributableToDivestedBusiness" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:type="arc"/>
      <link:label id="id_4f1d6584" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other cash flows used in investing activities, net</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_1bf16062" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as investing activities</link:label>
      <link:label id="id_1d66e74c" xlink:label="lbl_label493283148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other non-current assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialAndOtherNoncurrentAssets" xlink:label="lbl_FinancialAndOtherNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherNoncurrentAssets" xlink:to="lbl_label493283148" xlink:type="arc"/>
      <link:label id="id_2b5de5f3" xlink:label="lbl_label727574003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesAndOtherCurrentAssets" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:to="lbl_label727574003" xlink:type="arc"/>
      <link:label id="id_54b5d55e" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current lease liabilities</link:label>
      <link:label id="id_5b8463eb" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables, provisions and other liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradePayablesProvisionsAndOtherLiabilities" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:to="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_cbbfa93" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentAndNoncurrentFinancialDebt" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNoncurrentFinancialDebt" xlink:to="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_2ce3e4d1" xlink:label="lbl_label753132753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets Disclosure and Lease liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:label="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_label753132753" xlink:type="arc"/>
      <link:label id="id_7eea5c8b" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of lease commitment and lease liability [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:to="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_179a66c8" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of lease commitment and lease liability</link:label>
      <link:label id="id_61aad0c8" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_41e189f8" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets</link:label>
      <link:label id="id_74f2bff0" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Right-of-use assets roll forward [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:to="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4b1c78b0" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Right-of-use assets roll forward</link:label>
      <link:label id="id_21983c62" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of right-of-use assets carrying value and depreciation charge [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:to="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3cad94ea" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of right-of-use assets carrying value and depreciation charge</link:label>
      <link:label id="id_59a39235" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of lease liability [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:to="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_16173223" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of lease liability</link:label>
      <link:label id="id_349af9f2" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional disclosures related to right-of-use assets and lease liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b0fa89e" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional disclosures related to right-of-use assets and lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:type="locator"/>
      <link:label id="id_41a9be15" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill recognised as of acquisition date</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5f4cbeb8" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_20d2348f" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_24522acb" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net financial expense</link:label>
      <link:label id="id_2dbe7019" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_665e2bc2" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_2124eb92" xlink:label="lbl_label556067730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilitiesMember" xlink:to="lbl_label556067730" xlink:type="arc"/>
      <link:label id="id_25d32b75" xlink:label="lbl_label634596213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilitiesMember" xlink:to="lbl_label634596213" xlink:type="arc"/>
      <link:label id="id_7905e1d7" xlink:label="lbl_label203360922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate, excluding exceptional items</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ApplicableTaxRateExcludingExceptionalItems" xlink:label="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:to="lbl_label203360922" xlink:type="arc"/>
      <link:label id="id_65b2ed83" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debt</link:label>
      <link:label id="id_2db983d5" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables, provisions and other liabilities</link:label>
      <link:label id="id_71df6444" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows Attributable to divested business before divested cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_43e3fc7" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments out of provisions for transaction costs attributable to the divested business</link:label>
      <link:label id="id_4fb71438" xlink:label="lbl_DivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divested cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestedCashAndCashEquivalents" xlink:to="lbl_DivestedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_74caa513" xlink:label="lbl_DivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Divested cash and cash equivalents</link:label>
      <link:label id="id_3a16e3f2" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax on Pension plans previously recognized in OCI</link:label>
      <link:label id="id_5bc61768" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares obtained through consolidated foundation</link:label>
      <link:label id="id_32f424a5" xlink:label="lbl_label854860965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customary purchase price adjustment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CustomaryPurchasePriceAdjustment" xlink:to="lbl_label854860965" xlink:type="arc"/>
      <link:label id="id_4b0dbe44" xlink:label="lbl_RepaymentOfIntercompanyBalances_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of intercompany balances</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentOfIntercompanyBalances" xlink:to="lbl_RepaymentOfIntercompanyBalances_labels" xlink:type="arc"/>
      <link:label id="id_3ce6e6d2" xlink:label="lbl_label1021765330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax reform impact on deferred tax on treasury shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:to="lbl_label1021765330" xlink:type="arc"/>
      <link:label id="id_1d9b087f" xlink:label="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend paid, non-cash assets distribution</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendPaidNoncashAssetsDistribution" xlink:to="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:type="arc"/>
      <link:label id="id_49b7a9d9" xlink:label="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind</link:label>
      <link:label id="id_4f1253e8" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net gain at completion of spin-off [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:to="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_cd2ba12" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gain at completion of spin-off</link:label>
      <link:label id="id_4a895e0" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of assets and liabilities of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_399cb44f" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities of disposal group classified as held for sale</link:label>
      <link:label id="id_333e63f1" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement, discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b60d5f0" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement, discontinued operations</link:label>
      <link:label id="id_6f1a698a" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of items included in net income from discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:to="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6b21ae09" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of items included in net income from discontinued operations</link:label>
      <link:label id="id_4a52c922" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net assets derecognized [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:to="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_54e8c608" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net assets derecognized</link:label>
      <link:label id="id_68686f96" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from divestments [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_74c77dde" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from divestments</link:label>
      <link:label id="id_3a5e6480" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:type="arc"/>
      <link:label id="id_2aebe53" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period</link:label>
      <link:label id="id_14e1d56d" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period</link:label>
      <link:label id="id_16d7d1ab" xlink:label="lbl_label383242667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lbl_label383242667" xlink:type="arc"/>
      <link:label id="id_364362e8" xlink:label="lbl_label910385896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lbl_label910385896" xlink:type="arc"/>
      <link:label id="id_3ff27324" xlink:label="lbl_label1072853796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lbl_label1072853796" xlink:type="arc"/>
      <link:label id="id_218c01ed" xlink:label="lbl_label562823661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lbl_label562823661" xlink:type="arc"/>
      <link:label id="id_7e9fd619" xlink:label="lbl_label2124404249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lbl_label2124404249" xlink:type="arc"/>
      <link:label id="id_726c27cc" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:type="arc"/>
      <link:label id="id_5f37a474" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at beginning of period</link:label>
      <link:label id="id_88d7a8d" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at end of period</link:label>
      <link:label id="id_4f1e5db1" xlink:label="lbl_label1327390129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="lbl_label1327390129" xlink:type="arc"/>
      <link:label id="id_738f9077" xlink:label="lbl_label1938788471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="lbl_label1938788471" xlink:type="arc"/>
      <link:label id="id_236bf45e" xlink:label="lbl_label594277470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lbl_label594277470" xlink:type="arc"/>
      <link:label id="id_1e452462" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_19961677" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases and right-of-use assets</link:label>
      <link:label id="id_7213f224" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for distribution by way of divindend in kind to shareholders</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:type="arc"/>
      <link:label id="id_73c6a1d7" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution by way of dividend in kind to shareholders</link:label>
      <link:label id="id_3b0bcb35" xlink:label="lbl_label373468922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aspen Global Incorporated</link:label>
      <link:label id="id_505899ea" xlink:label="lbl_TheMedicinesCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Medicines Company [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TheMedicinesCompanyMember" xlink:to="lbl_TheMedicinesCompanyMember_labels" xlink:type="arc"/>
      <link:label id="id_3d4865bf" xlink:label="lbl_TheMedicinesCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Medicines Company</link:label>
      <link:label id="id_26a553b7" xlink:label="lbl_label648369079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Piqray [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PiqrayMember" xlink:to="lbl_label648369079" xlink:type="arc"/>
      <link:label id="id_3dbe8202" xlink:label="lbl_label1035895298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xiidra [member]</link:label>
      <link:label id="id_725b9be" xlink:label="lbl_label119912894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zolgensma [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZolgensmaMember" xlink:to="lbl_label119912894" xlink:type="arc"/>
      <link:label id="id_7679d6e" xlink:label="lbl_label124231022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mayzent [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MayzentMember" xlink:to="lbl_label124231022" xlink:type="arc"/>
      <link:label id="id_18490fef" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through assets related to discontinued operations</link:label>
      <link:label id="id_c87ee03" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through reclassification to right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_479a229e" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Costs of assets related to discontinued operations</link:label>
      <link:label id="id_18f65009" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through assets related to discontinued operations, intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_4ee2113e" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to discontinued operations</link:label>
      <link:label id="id_6422c211" xlink:label="lbl_label1679999505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:to="lbl_label1679999505" xlink:type="arc"/>
      <link:label id="id_36a944c" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at beginning of period continuing operations</link:label>
      <link:label id="id_f49321b" xlink:label="lbl_label256455195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax balance related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:to="lbl_label256455195" xlink:type="arc"/>
      <link:label id="id_59b158e6" xlink:label="lbl_label1504794854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aspen Global Incorporated [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenGlobalIncorporatedMember" xlink:to="lbl_label1504794854" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenGlobalIncorporatedMember" xlink:to="lbl_label373468922" xlink:type="arc"/>
      <link:label id="id_3dc8af6f" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted finance lease payments to be received</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:to="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:type="arc"/>
      <link:label id="id_334ff648" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total future payments</link:label>
      <link:label id="id_4ca139f0" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unearned finance income relating to finance lease payments receivable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:to="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:type="arc"/>
      <link:label id="id_32f71aba" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unearned interest income</link:label>
      <link:label id="id_32d528ec" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum finace lease payments receivable at present value</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:to="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_200aacc" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments from finance lease agreements, at present value</link:label>
      <link:label id="id_5e2f001b" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_270f5b37" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</link:label>
      <link:label id="id_60c53887" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3255d072" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New leases</link:label>
      <link:label id="id_78469395" xlink:label="lbl_label2017891221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from non-current to current, net</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:to="lbl_label2017891221" xlink:type="arc"/>
      <link:label id="id_37080272" xlink:label="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:label id="id_22d1162d" xlink:label="lbl_label584128045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesMember" xlink:to="lbl_label584128045" xlink:type="arc"/>
      <link:label id="id_5bd2b859" xlink:label="lbl_label1540536409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration payable</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationPayable" xlink:label="lbl_ContingentConsiderationPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPayable" xlink:to="lbl_label1540536409" xlink:type="arc"/>
      <link:label id="id_11db2be0" xlink:label="lbl_label299576288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_label299576288" xlink:type="arc"/>
      <link:label id="id_358bdb60" xlink:label="lbl_label2144120781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 16 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:to="lbl_label2144120781" xlink:type="arc"/>
      <link:label id="id_5776de2" xlink:label="lbl_label91712994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, USD [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsUSDMember" xlink:to="lbl_label91712994" xlink:type="arc"/>
      <link:label id="id_37cf6b5c" xlink:label="lbl_label936340316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, EUR [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsEURMember" xlink:to="lbl_label936340316" xlink:type="arc"/>
      <link:label id="id_4e1f7ea0" xlink:label="lbl_FinanceLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseLiabilities" xlink:to="lbl_FinanceLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_495a6466" xlink:label="lbl_FinanceLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations</link:label>
      <link:label id="id_633ca478" xlink:label="lbl_label1664918648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity based compensation shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedCompensationShares" xlink:to="lbl_label1664918648" xlink:type="arc"/>
      <link:label id="id_79aa7a52" xlink:label="lbl_label2041215570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions shares</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:to="lbl_label2041215570" xlink:type="arc"/>
      <link:label id="id_6d34d6c2" xlink:label="lbl_label1832179394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions, equity impact</link:label>
      <link:label id="id_6fef109e" xlink:label="lbl_label1877938334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:to="lbl_label1877938334" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:to="lbl_label1832179394" xlink:type="arc"/>
      <link:label id="id_347a007d" xlink:label="lbl_OtherNoncurrentReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentReceivables" xlink:to="lbl_OtherNoncurrentReceivables_labels" xlink:type="arc"/>
      <link:label id="id_4871e871" xlink:label="lbl_OtherNoncurrentReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term receivables</link:label>
      <link:label id="id_4529bc84" xlink:label="lbl_label1160363140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares delivered to divested business employees</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:to="lbl_label1160363140" xlink:type="arc"/>
      <link:label id="id_5b371f8c" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, impact of business combinations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:type="arc"/>
      <link:label id="id_3787190c" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_4001cae9" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Impact of adoption of IFRS 16 Leases</link:label>
      <link:label id="id_2f708bd6" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial debts cash flows from continuing operations</link:label>
      <link:label id="id_7a3ed482" xlink:label="lbl_label2050937986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously reported finance lease obligation of divested business</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:to="lbl_label2050937986" xlink:type="arc"/>
      <link:label id="id_34924f0b" xlink:label="lbl_label882003723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in acquisitions and divestments of businesses classified as investing activities from continuing operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:to="lbl_label882003723" xlink:type="arc"/>
      <link:label id="id_15f358a7" xlink:label="lbl_label368269479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, options on equity securities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:to="lbl_label368269479" xlink:type="arc"/>
      <link:label id="id_61acf165" xlink:label="lbl_label1591563240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, damages claimed</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:to="lbl_label1591563240" xlink:type="arc"/>
      <link:label id="id_49032bd4" xlink:label="lbl_label1224944596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional amount of settlement in principle</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:to="lbl_label1224944596" xlink:type="arc"/>
      <link:label id="id_4b8a0c94" xlink:label="lbl_label1267338388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of resolved action</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfResolvedAction" xlink:to="lbl_label1267338388" xlink:type="arc"/>
      <link:label id="id_54d844bf" xlink:label="lbl_label1423459519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enoxaparin [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnoxaparinMember" xlink:to="lbl_label1423459519" xlink:type="arc"/>
      <link:label id="id_29f14990" xlink:label="lbl_label703678864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Manufacturing Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozManufacturingInc.Member" xlink:to="lbl_label703678864" xlink:type="arc"/>
      <link:label id="id_1755f369" xlink:label="lbl_label391508841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Novartis Institute for BioMedical Research Co.,Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:to="lbl_label391508841" xlink:type="arc"/>
      <link:label id="id_6dee5dc4" xlink:label="lbl_label1844338116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Technical Development Co., Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:to="lbl_label1844338116" xlink:type="arc"/>
      <link:label id="id_5443c473" xlink:label="lbl_label1413727347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLforCURE [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CELLforCUREMember" xlink:to="lbl_label1413727347" xlink:type="arc"/>
      <link:label id="id_4cf512" xlink:label="lbl_label5043474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Manufacturing GmbH [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisManufacturingGmbHMember" xlink:to="lbl_label5043474" xlink:type="arc"/>
      <link:label id="id_4471df2c" xlink:label="lbl_label1148313388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Hungary Healthcare Limited Liability Company [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:to="lbl_label1148313388" xlink:type="arc"/>
      <link:label id="id_424beb28" xlink:label="lbl_label1112271656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaced Accelerator Applications (Italy) S.r.l. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:to="lbl_label1112271656" xlink:type="arc"/>
      <link:label id="id_5fad9749" xlink:label="lbl_label1605211977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDB Holland BV [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IDBHollandBVMember" xlink:to="lbl_label1605211977" xlink:type="arc"/>
      <link:label id="id_50283594" xlink:label="lbl_label1344812436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaced Accelerator Applications Iberica, S.L.U. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:to="lbl_label1344812436" xlink:type="arc"/>
      <link:label id="id_6345aa6d" xlink:label="lbl_label1665509997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Imaging Equipment Ltd [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImagingEquipmentLtdMember" xlink:to="lbl_label1665509997" xlink:type="arc"/>
      <link:label id="id_2031baeb" xlink:label="lbl_label540130027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Inflammasome Research, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInflammasomeResearchInc.Member" xlink:to="lbl_label540130027" xlink:type="arc"/>
      <link:label id="id_1af84be1" xlink:label="lbl_label452479969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Technology LLC [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTechnologyLLCMember" xlink:to="lbl_label452479969" xlink:type="arc"/>
      <link:label id="id_388a06e4" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:type="arc"/>
      <link:label id="id_3b18f468" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration paid consisting of cash and cash equivalents upfront payment</link:label>
      <link:label id="id_47a0c115" xlink:label="lbl_label1201717525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partial release of deferred tax liability recognized</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:to="lbl_label1201717525" xlink:type="arc"/>
      <link:label id="id_300e3078" xlink:label="lbl_label464719186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesUndiscounted" xlink:to="lbl_label464719186" xlink:type="arc"/>
      <link:label id="id_34d806ab" xlink:label="lbl_label1619923269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most material lease with lease term extension</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:to="lbl_label1619923269" xlink:type="arc"/>
      <link:label id="id_53edcb" xlink:label="lbl_label5500363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows for short term and low value leases</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:to="lbl_label5500363" xlink:type="arc"/>
      <link:label id="id_30ae4b2" xlink:label="lbl_label51045554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows for payments of leases interest</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:to="lbl_label51045554" xlink:type="arc"/>
      <link:label id="id_5a4733e9" xlink:label="lbl_label1514615785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax reform effective tax rate after implemetation of new reform changes</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:to="lbl_label1514615785" xlink:type="arc"/>
      <link:label id="id_63ed288d" xlink:label="lbl_label1676486797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax reform effective blended tax rate after implemetation of new reform changes</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:to="lbl_label1676486797" xlink:type="arc"/>
      <link:label id="id_3af42b4" xlink:label="lbl_label2021190939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term receivables from finance subleases</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongTermReceivablesFromFinanceSubleases" xlink:to="lbl_label2021190939" xlink:type="arc"/>
      <link:label id="id_115b6ebf" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through liabilities related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_64b9f08d" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts and lease liabilities related to discontinued operations</link:label>
      <link:label id="id_a7c0098" xlink:label="lbl_label175898776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility short term</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityShortTerm" xlink:to="lbl_label175898776" xlink:type="arc"/>
      <link:label id="id_3f8e8cf1" xlink:label="lbl_label1066306801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_label1066306801" xlink:type="arc"/>
      <link:label id="id_44dffa85" xlink:label="lbl_label1155529349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_label1155529349" xlink:type="arc"/>
      <link:label id="id_7feaeddc" xlink:label="lbl_label167109794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [axis]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_label167109794" xlink:type="arc"/>
      <link:label id="id_2246514e" xlink:label="lbl_label2121837386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [member]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EuropeMember" xlink:to="lbl_label2121837386" xlink:type="arc"/>
      <link:label id="id_4c9a1836" xlink:label="lbl_label849028726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [member]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmericasMember" xlink:to="lbl_label849028726" xlink:type="arc"/>
      <link:label id="id_295e5e69" xlink:label="lbl_RightofuseAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightofuseAssetsMember" xlink:to="lbl_RightofuseAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_164ca513" xlink:label="lbl_RightofuseAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:label id="id_4947c6a9" xlink:label="lbl_label1229440681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beovu [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BeovuMember" xlink:to="lbl_label1229440681" xlink:type="arc"/>
      <link:label id="id_22f028b0" xlink:label="lbl_ConsiderationPaidReceived_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid (received)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsiderationPaidReceived" xlink:to="lbl_ConsiderationPaidReceived_labels" xlink:type="arc"/>
      <link:label id="id_3dc9426c" xlink:label="lbl_ConsiderationPaidReceived_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash inflows from divestment</link:label>
      <link:label id="id_56521fba" xlink:label="lbl_label1448222650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash outflows from divestments</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashOutflowsFromDivestments" xlink:to="lbl_label1448222650" xlink:type="arc"/>
      <link:label id="id_1d2114e2" xlink:label="lbl_label488707298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_label488707298" xlink:type="arc"/>
      <link:label id="id_45aec51d" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_6eb0eb0c" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
      <link:label id="id_6bada554" xlink:label="lbl_label1806542164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesMember" xlink:to="lbl_label1806542164" xlink:type="arc"/>
      <link:label id="id_61717448" xlink:label="lbl_label1634825288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilitiesMember" xlink:to="lbl_label1634825288" xlink:type="arc"/>
      <link:label id="id_2e9b8dad" xlink:label="lbl_label781946285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_label781946285" xlink:type="arc"/>
      <link:label id="id_508846a9" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:type="arc"/>
      <link:label id="id_420e4c77" xlink:label="lbl_label1108233335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:to="lbl_label1108233335" xlink:type="arc"/>
      <link:label id="id_5c23b63c" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities</link:label>
      <link:label id="id_77f7d595" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities undiscounted</link:label>
      <link:label id="id_16b54793" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense arising from write-down or reversal of write-down of deferred tax asset</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:to="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:type="arc"/>
      <link:label id="id_45e19527" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write-off of deferred tax assets</link:label>
      <link:label id="id_63e83d46" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charge prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_226b60a4" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge prior to classification to assets held for sale</link:label>
      <link:label id="id_557effd1" xlink:label="lbl_label1434386385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax on transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:to="lbl_label1434386385" xlink:type="arc"/>
      <link:label id="id_5c1a2168" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of write-off of deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_59102729" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write-off of deferred tax assets</link:label>
      <link:label id="id_3df76505" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from current and non-current borrowings</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_64441db" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payment</link:label>
      <link:label id="id_11959a05" xlink:label="lbl_label295016965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Uncalled capital commitments for investments in funds</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:to="lbl_label295016965" xlink:type="arc"/>
      <link:label id="id_12c8e5a0" xlink:label="lbl_label315155872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_label315155872" xlink:type="arc"/>
      <link:label id="id_73c71c69" xlink:label="lbl_label1942428777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tennessee class action [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TennesseeClassActionMember" xlink:to="lbl_label1942428777" xlink:type="arc"/>
      <link:label id="id_17248af4" xlink:label="lbl_label388270836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Massachusetts case [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MassachusettsCaseMember" xlink:to="lbl_label388270836" xlink:type="arc"/>
      <link:label id="id_23bc1d31" xlink:label="lbl_label599530801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAnnualReport" xlink:to="lbl_label599530801" xlink:type="arc"/>
      <link:label id="id_34b5e034" xlink:label="lbl_label884334644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityShellCompany" xlink:to="lbl_label884334644" xlink:type="arc"/>
      <link:label id="id_481345ce" xlink:label="lbl_label1209222606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityEmergingGrowthCompany" xlink:to="lbl_label1209222606" xlink:type="arc"/>
      <link:label id="id_448d1a1f" xlink:label="lbl_label1150097951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityInteractiveDataCurrent" xlink:to="lbl_label1150097951" xlink:type="arc"/>
      <link:label id="id_8e53da4" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash inflow from borrowings</link:label>
      <link:label id="id_39e22a7b" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Transaction cost payments</link:label>
      <link:label id="id_4f32f729" xlink:label="lbl_label1328740137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossDeferredTaxAssets" xlink:to="lbl_label1328740137" xlink:type="arc"/>
      <link:label id="id_182b8b94" xlink:label="lbl_GrossDeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossDeferredTaxLiabilities" xlink:to="lbl_GrossDeferredTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_3fcaf800" xlink:label="lbl_GrossDeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:label id="id_12baf088" xlink:label="lbl_label314241160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount borrowed under the credit facility</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountBorrowedUnderTheCreditFacility" xlink:to="lbl_label314241160" xlink:type="arc"/>
      <link:label id="id_24f2fc6a" xlink:label="lbl_ContingentConsiderationLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationLiabilities" xlink:to="lbl_ContingentConsiderationLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_596ae769" xlink:label="lbl_label1500178281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation case [axis]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_label1500178281" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_XiidraMember" xlink:to="lbl_label1035895298" xlink:type="arc"/>
      <link:label id="id_6dadd046" xlink:label="lbl_label1840107590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentTransitionReport" xlink:to="lbl_label1840107590" xlink:type="arc"/>
      <link:label id="id_287ed480" xlink:label="lbl_label679400576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentShellCompanyReport" xlink:to="lbl_label679400576" xlink:type="arc"/>
      <link:label id="id_6eada512" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:type="arc"/>
      <link:label id="id_b2dfb88" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment</link:label>
      <link:label id="id_4be49960" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:type="arc"/>
      <link:label id="id_7d4d613b" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</link:label>
      <link:label id="id_4eb0928b" xlink:label="lbl_TaxesOnTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes on treasury shares</link:label>
      <link:label id="id_22a0ea85" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of assets related to discontinued operations</link:label>
      <link:label id="id_15b36c9d" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease through reclassification to right-of-use assets</link:label>
      <link:label id="id_55dcd44c" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition exemption for short term leases</link:label>
      <link:label id="id_7a35ce5" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition exception for low value leases</link:label>
      <link:label id="id_40e677f7" xlink:label="lbl_EffectOfDiscounting_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of discounting</link:label>
      <link:label id="id_2d2e026c" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_1ac53b1b" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease contract terminations, right-of-use assets</link:label>
      <link:label id="id_e5f5961" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities undiscounted</link:label>
      <link:label id="id_7d7ce79e" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory provisions</link:label>
      <link:label id="id_42fb2d2e" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year, provisions recorded</link:label>
      <link:label id="id_4eb32c65" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_27322091" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from non-current financial debts</link:label>
      <link:label id="id_7e6f87d8" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:label id="id_25b1f7fc" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_4de13945" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:label id="id_148d311b" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_67019b8d" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_f7a5847" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</link:label>
      <link:label id="id_6e294aeb" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4bbdbc8c" xlink:label="lbl_ContingentConsiderationLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:label id="id_45ca4585" xlink:label="lbl_NetAssetsDerecognized_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net assets derecognized</link:label>
      <link:label id="id_42ccca61" xlink:label="lbl_label1120717409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entitys trade receivable</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEntitysTradeReceivable" xlink:to="lbl_label1120717409" xlink:type="arc"/>
      <link:label id="id_43ec36aa" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:label id="id_677ffa06" xlink:label="lbl_CashInflowForSaleAndLeaseback_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow for sale and leaseback</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowForSaleAndLeaseback" xlink:to="lbl_CashInflowForSaleAndLeaseback_labels" xlink:type="arc"/>
      <link:label id="id_5bdc50eb" xlink:label="lbl_SaleAndLeaseBackMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale and lease back [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleAndLeaseBackMember" xlink:to="lbl_SaleAndLeaseBackMember_labels" xlink:type="arc"/>
      <link:label id="id_73fe88ea" xlink:label="lbl_SaleAndLeaseBackMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale and leaseback</link:label>
      <link:label id="id_1b2ddb15" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentRefundsProvision" xlink:to="lbl_CurrentRefundsProvision_labels" xlink:type="arc"/>
      <link:label id="id_6f9ec2d7" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue</link:label>
      <link:label id="id_782da91f" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, at beginning of period</link:label>
      <link:label id="id_67f2691b" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, at end of period</link:label>
      <link:label id="id_376d9857" xlink:label="lbl_label929929303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, commodity purchase contract</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:to="lbl_label929929303" xlink:type="arc"/>
      <link:label id="id_4c17362a" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_328352cc" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of divestments</link:label>
      <link:label id="id_5a93baa1" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
      <link:label id="id_1917780" xlink:label="lbl_label26310528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of income not subject to tax on divestment gain</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:to="lbl_label26310528" xlink:type="arc"/>
      <link:label id="id_6025ab0" xlink:label="lbl_CashInflowForSaleAndLeaseback_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash inflow for sale and leaseback</link:label>
      <link:label id="id_642f7fec" xlink:label="lbl_label1680834540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Technical Development Co., Ltd., Changshu [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:to="lbl_label1680834540" xlink:type="arc"/>
      <link:label id="id_14fc3a32" xlink:label="lbl_label352074290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLforCURE, Les Ulis [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CELLforCURELesUlisMember" xlink:to="lbl_label352074290" xlink:type="arc"/>
      <link:label id="id_372a8238" xlink:label="lbl_label925532728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (Italy) S.r.l., Pozzilli [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:to="lbl_label925532728" xlink:type="arc"/>
      <link:label id="id_12a3185f" xlink:label="lbl_label312678495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Netherlands B.V., Amsterdam [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:to="lbl_label312678495" xlink:type="arc"/>
      <link:label id="id_495d47ae" xlink:label="lbl_label1230849966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma B.V., Amsterdam [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:to="lbl_label1230849966" xlink:type="arc"/>
      <link:label id="id_3b55a7b7" xlink:label="lbl_label995469239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDB Holland BV, Baarle-Nassau [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IDBHollandBVBaarleNassauMember" xlink:to="lbl_label995469239" xlink:type="arc"/>
      <link:label id="id_33884b38" xlink:label="lbl_label864570168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Saudi Ltd., Riyadh [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSaudiLtd.RiyadhMember" xlink:to="lbl_label864570168" xlink:type="arc"/>
      <link:label id="id_222bb2dd" xlink:label="lbl_label573289181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Iberica, S.L.U., Esplugues de Llobregat [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.EspluguesDeLlobregatMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.EspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.EspluguesDeLlobregatMember" xlink:to="lbl_label573289181" xlink:type="arc"/>
      <link:label id="id_10409dbe" xlink:label="lbl_label272670142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis UK Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUKLimitedLondonMember" xlink:to="lbl_label272670142" xlink:type="arc"/>
      <link:label id="id_63d11071" xlink:label="lbl_label1674645617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals UK Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:to="lbl_label1674645617" xlink:type="arc"/>
      <link:label id="id_19392a8e" xlink:label="lbl_label423176846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Grimsby Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGrimsbyLimitedLondonMember" xlink:to="lbl_label423176846" xlink:type="arc"/>
      <link:label id="id_7c7620c7" xlink:label="lbl_label2088116423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Imaging Equipment Ltd, London [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImagingEquipmentLtdLondonMember" xlink:to="lbl_label2088116423" xlink:type="arc"/>
      <link:label id="id_51082ea6" xlink:label="lbl_label1359490726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedLondonMember" xlink:to="lbl_label1359490726" xlink:type="arc"/>
      <link:label id="id_70da7012" xlink:label="lbl_label1893363730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:to="lbl_label1893363730" xlink:type="arc"/>
      <link:label id="id_1a5c8917" xlink:label="lbl_label442272023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:to="lbl_label442272023" xlink:type="arc"/>
      <link:label id="id_2db5a3fb" xlink:label="lbl_label766878715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis US Foundation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:to="lbl_label766878715" xlink:type="arc"/>
      <link:label id="id_5bd187f1" xlink:label="lbl_label1540458481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:to="lbl_label1540458481" xlink:type="arc"/>
      <link:label id="id_25dd15b1" xlink:label="lbl_label635246001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Inflammasome Research, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:to="lbl_label635246001" xlink:type="arc"/>
      <link:label id="id_561808b5" xlink:label="lbl_label1444415669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Technology LLC, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:to="lbl_label1444415669" xlink:type="arc"/>
      <link:label id="id_7ffed34c" xlink:label="lbl_label2147406668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:to="lbl_label2147406668" xlink:type="arc"/>
      <link:label id="id_4458c6ff" xlink:label="lbl_label1146668799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteInc.EastHanoverNJMember" xlink:to="lbl_label1146668799" xlink:type="arc"/>
      <link:label id="id_68546348" xlink:label="lbl_label1750360904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vaccines and Diagnostics, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:to="lbl_label1750360904" xlink:type="arc"/>
      <link:label id="id_2d054e5d" xlink:label="lbl_label755322461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex Pharmaceuticals, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:to="lbl_label755322461" xlink:type="arc"/>
      <link:label id="id_75833aa3" xlink:label="lbl_label1971534499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Manufacturing GmbH, Marburg [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisManufacturingGmbHMarburgMember" xlink:to="lbl_label1971534499" xlink:type="arc"/>
      <link:label id="id_3ce1ce66" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities, net</link:label>
      <link:label id="id_7d5a543d" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</link:label>
      <link:label id="id_264ae6cd" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:label id="id_541ef56a" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:label id="id_4edf1e96" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when POS for level 3 change more than 10%</link:label>
      <link:label id="id_2efc8f07" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of non-current financial debts</link:label>
      <link:label id="id_2d28f541" xlink:label="lbl_label757658945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of US tax reform legislation</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfUSTaxReformLegislation" xlink:to="lbl_label757658945" xlink:type="arc"/>
      <link:label id="id_3c578d43" xlink:label="lbl_AcquiredCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredCashAndCashEquivalents" xlink:to="lbl_AcquiredCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_25ec28ce" xlink:label="lbl_AcquiredCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:label id="id_4dc21030" xlink:label="lbl_label1304563760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of impact on adoption of IFRS 16</link:label>
      <link:label id="id_284baaac" xlink:label="lbl_label676047532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impact on adoption of IFRS 16 [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:label="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:to="lbl_label676047532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:to="lbl_label1304563760" xlink:type="arc"/>
      <link:label id="id_7cee5446" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement, additional information [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_43467410" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement, additional information</link:label>
      <link:label id="id_47cec299" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet, additional information [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetAdditionalInformationTableTextBlock" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:to="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_557771c9" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet, additional information</link:label>
      <link:label id="id_6c2f9126" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:to="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6c013712" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities</link:label>
      <link:label id="id_cd95e1f" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:to="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5424fa1a" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_71dfb6f6" xlink:label="lbl_label1910486774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ultibro Group [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UltibroGroupMember" xlink:to="lbl_label1910486774" xlink:type="arc"/>
      <link:label id="id_86983fb" xlink:label="lbl_label141132795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adakveo [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdakveoMember" xlink:to="lbl_label141132795" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_label1289490857" xlink:type="arc"/>
      <link:label id="id_4b6d4dbb" xlink:label="lbl_label1265454523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 1.75%, 2025 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:to="lbl_label1265454523" xlink:type="arc"/>
      <link:label id="id_506f7c31" xlink:label="lbl_label1349483569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.00%, 2027 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:to="lbl_label1349483569" xlink:type="arc"/>
      <link:label id="id_2f497fb1" xlink:label="lbl_label793345969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.20%, 2030 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:to="lbl_label793345969" xlink:type="arc"/>
      <link:label id="id_27dd04e2" xlink:label="lbl_label668796130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.75%, 2050 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:to="lbl_label668796130" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PoPChangeMember" xlink:to="lbl_label1343837424" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PoPYEChangeMember" xlink:to="lbl_label571817371" xlink:type="arc"/>
      <link:label id="id_baa97ec" xlink:label="lbl_CurrentTaxAssetsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, current</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxAssetsCurrent" xlink:to="lbl_CurrentTaxAssetsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_6f03bc65" xlink:label="lbl_CurrentTaxAssetsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
      <link:label id="id_1b60e90f" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_4606d526" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provisions and other non-current liabilities</link:label>
      <link:label id="id_f38218c" xlink:label="lbl_label255336844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZPL389 [member]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZPL389Member" xlink:label="lbl_ZPL389Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZPL389Member" xlink:to="lbl_label255336844" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfOtherFinancialAssetsSold" xlink:to="lbl_label2044002083" xlink:type="arc"/>
      <link:label id="id_4fe64fe" xlink:label="lbl_RepaymentOfIntercompanyBalances_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of intercompany balances</link:label>
      <link:label id="id_17ced1e3" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_78162c1a" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:label id="id_23e031e7" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non current lease liabilities as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5e1a35c1" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current lease liabilities</link:label>
      <link:label id="id_2d827166" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments attributable to the spin-off of the Alcon business</link:label>
      <link:label id="id_5854f481" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows attributable to the spin-off of the Alcon business</link:label>
      <link:label id="id_280cd5b1" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property, plant and equipment</link:label>
      <link:label id="id_4ae04f6d" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercised options and other treasury share transactions</link:label>
      <link:label id="id_72d55c39" xlink:label="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of equity interest in acquiree held by acquirer immediately before acquisition date</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:to="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_159a4c8" xlink:label="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_7db37c64" xlink:label="lbl_label2108914788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of export sales</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReclassificationOfExportSales" xlink:label="lbl_ReclassificationOfExportSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationOfExportSales" xlink:to="lbl_label2108914788" xlink:type="arc"/>
      <link:label id="id_72d8ae42" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
      <link:label id="id_6dee4a36" xlink:label="lbl_label1844333110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid sales price for a business divestment</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PrepaidSalesPriceForABusinessDivestment" xlink:label="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:to="lbl_label1844333110" xlink:type="arc"/>
      <link:label id="id_2eb8c37" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recognized in the consolidated income statement</link:label>
      <link:label id="id_548385d" xlink:label="lbl_label88619101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of other accounting policies relevant to understanding of financial statements [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:label="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:to="lbl_label88619101" xlink:type="arc"/>
      <link:label id="id_5af405db" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, balance sheet and income statement [table text block]</link:label>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_53a7d2c" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated balance sheets and income statement</link:label>
   </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>nvs-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSubsequentEventsQ" xlink:href="nvs-20200630.xsd#disclosureSubsequentEventsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails4Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails4Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails5Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails5Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails6Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails6Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails7Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails7Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails8Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails8Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails9Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails9Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesTablesQ" xlink:href="nvs-20200630.xsd#disclosureAcquisitionOfBusinessesTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ" xlink:href="nvs-20200630.xsd#disclosureDetailsConsolidatedStatementsCashFlowsTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsTablesQ" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersTablesQ" xlink:href="nvs-20200630.xsd#disclosureSummaryOfEquityToShareholdersTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsTablesQ" xlink:href="nvs-20200630.xsd#disclosureSignificantTransactionsTablesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesPoliciesQ" xlink:href="nvs-20200630.xsd#disclosureSelectedCriticalAccountingPoliciesPoliciesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails3Q" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsDetails3Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails4Q" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsDetails4Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsQ" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresQ" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesQ" xlink:href="nvs-20200630.xsd#disclosureAcquisitionOfBusinessesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsQ" xlink:href="nvs-20200630.xsd#disclosureDetailsConsolidatedStatementsCashFlowsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsQ" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersQ" xlink:href="nvs-20200630.xsd#disclosureSummaryOfEquityToShareholdersQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesQ" xlink:href="nvs-20200630.xsd#disclosureSelectedCriticalAccountingPoliciesQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsQ" xlink:href="nvs-20200630.xsd#disclosureSignificantTransactionsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails3Q" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsDetails3Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" xlink:href="nvs-20200630.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails2Q" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetailsQ" xlink:href="nvs-20200630.xsd#disclosureSignificantTransactionsDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails2Q" xlink:href="nvs-20200630.xsd#disclosureSignificantTransactionsDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails1Q" xlink:href="nvs-20200630.xsd#disclosureSignificantTransactionsDetails1Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails1Q" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsDetails1Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetailsQ" xlink:href="nvs-20200630.xsd#disclosureDiscontinuedOperationsDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersDetailsQ" xlink:href="nvs-20200630.xsd#disclosureSummaryOfEquityToShareholdersDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetailsQ" xlink:href="nvs-20200630.xsd#disclosureAcquisitionOfBusinessesDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" xlink:href="nvs-20200630.xsd#disclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" xlink:href="nvs-20200630.xsd#disclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" xlink:href="nvs-20200630.xsd#disclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails2Q" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetailsQ" xlink:href="nvs-20200630.xsd#disclosureFinancialInstrumentsDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails3Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails3Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails2Q" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetails2Q" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetailsQ" xlink:href="nvs-20200630.xsd#disclosureSegmentationOfKeyFiguresDetailsQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureLegalProceedingsUpdateQ" xlink:href="nvs-20200630.xsd#disclosureLegalProceedingsUpdateQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DisclosureBasisOfPreparationQ" xlink:href="nvs-20200630.xsd#disclosureBasisOfPreparationQ" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfChangesInEquity" xlink:href="nvs-20200630.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementsOfCashFlow" xlink:href="nvs-20200630.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfComprehensiveIncome" xlink:href="nvs-20200630.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/StatementOfIncome" xlink:href="nvs-20200630.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/BalanceSheet" xlink:href="nvs-20200630.xsd#balanceSheet" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20200630/role/DocumentAndEntityInformation" xlink:href="nvs-20200630.xsd#documentAndEntityInformation" xlink:type="simple"/>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DocumentAndEntityInformation" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DocumentAndEntityInformationAbstract" xlink:label="lbl_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentAndEntityInformationAbstract" xlink:to="lbl_DocumentInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_DocumentInformationLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentType" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AmendmentFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalPeriodFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCentralIndexKey" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCurrentReportingStatus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityPublicFloat" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentPeriodEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalYearFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_TradingSymbol" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityRegistrantName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CurrentFiscalYearEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityVoluntaryFilers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFilerCategory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAnnualReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityShellCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityEmergingGrowthCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityInteractiveDataCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentTransitionReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:presentationArc order="2.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentShellCompanyReport" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="lbl_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_CurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAndLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfFinancialPositionAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="5.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="5.9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="5.92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:presentationArc order="2.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="lbl_IncomeStatementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BasicEarningsPerShareAbstract" xlink:type="arc"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DilutedEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="13.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:presentationArc order="1.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:presentationArc order="16.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="16.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_AdjustedWeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_WeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="lbl_StatementOfComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfComprehensiveIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:presentationArc order="2.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:presentationArc order="4.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="1.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="lbl_StatementOfCashFlowsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfCashFlowsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:presentationArc order="32.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="38.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="39.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="40.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="41.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:presentationArc order="41.5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="7.2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="31.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="35.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="36.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="38.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:presentationArc order="37.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="24.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="34.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="38.45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="38.35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:presentationArc order="39.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="39.3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="37.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_YoYChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:presentationArc order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_StatementOfChangesInEquityTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_StatementOfChangesInEquityLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ChangesInEquity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems1" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems1" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:presentationArc order="10.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="6.2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems2" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems2" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:presentationArc order="10.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="7.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:presentationArc order="9.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="6.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ReductionOfIssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="6.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:presentationArc order="8.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:presentationArc order="9.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:presentationArc order="10.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureBasisOfPreparationQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BasisOfPreparationAbstract" xlink:label="lbl_BasisOfPreparationAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasisOfPreparationAbstract" xlink:to="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureLegalProceedingsUpdateQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LegalProceedingsUpdateTextBlock" xlink:label="lbl_LegalProceedingsUpdateTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LegalProceedingsUpdateAbstract" xlink:label="lbl_LegalProceedingsUpdateAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalProceedingsUpdateAbstract" xlink:to="lbl_LegalProceedingsUpdateTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfReportableSegments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfBusinessUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfFranchises" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails2Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails3Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetOperatingAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongTermFinancialInvestmentsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails2Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_ClassesOfLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FinancialAssetsImpairedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_YoYChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefund" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_AcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_DivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashOutflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PrepaidSalesPriceForABusinessDivestment" xlink:label="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetailsQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="11.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchasesValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:presentationArc order="8.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:presentationArc order="8.9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:presentationArc order="8.95" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="9.7" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:presentationArc order="9.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:presentationArc order="2.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="8.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="9.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentStatedMember" xlink:label="lbl_CurrentStatedMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_CurrentStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="1.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:presentationArc order="10.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetailsQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ApplicableTaxRateExcludingExceptionalItems" xlink:label="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails1Q" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails1Q" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisposalGroupHeldForSaleAbstract" xlink:label="lbl_DisposalGroupHeldForSaleAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisposalGroupHeldForSaleAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisposalGroupHeldForSaleLineItems" xlink:label="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails2Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionCosts" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetailsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_IncomeStatementLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_OperatingIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenGlobalIncorporatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EliLillyAndCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKOncologyProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKVaccinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKTotalTransactionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CSLMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdmuneTheraputicsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IFMTreInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsUSDMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsEURMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquiree" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquireeFullYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCostsPaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ReversalOfImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialReceivableFromDivestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:presentationArc order="35.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:presentationArc order="36.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_MilestonePaymentAlreadyReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:presentationArc order="37.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FuturePutOptionToSellBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:presentationArc order="38.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PaymentPutOption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:presentationArc order="39.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InterestExchanged" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="40.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="41.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:presentationArc order="42.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerOrdinaryShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:presentationArc order="43.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:presentationArc order="44.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfOrdinarySharePerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:presentationArc order="45.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ValueOfEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="46.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:presentationArc order="47.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="48.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="49.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:presentationArc order="50.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentCostToSell" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="51.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="52.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="53.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="54.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:presentationArc order="55.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="56.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:presentationArc order="57.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProformaNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:presentationArc order="58.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:presentationArc order="59.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="60.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="61.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:presentationArc order="62.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="63.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:presentationArc order="64.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="65.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:presentationArc order="66.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:presentationArc order="67.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialMilestoneMaximumPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:presentationArc order="68.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:presentationArc order="69.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:presentationArc order="70.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:presentationArc order="71.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="72.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:presentationArc order="73.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CustomaryPurchasePriceAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="74.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="74.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RepaymentOfIntercompanyBalances" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="74.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails2Q" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_LegalProceedingsProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NPCAndOthersMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails3Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:presentationArc order="47.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="48.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="49.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSignificantTransactionsQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SelectedCriticalAccountingPoliciesAbstract" xlink:label="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfEquityTextBlock" xlink:label="lbl_DisclosureOfEquityTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_DisclosureOfEquityTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails4Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsOriginalCurrency" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_NotionalAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsIssuanceDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsMaturity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsLender" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsPremiumDiscount" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails3Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_StraightBondsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_FinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesPoliciesQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:label="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSignificantTransactionsTablesQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersTablesQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsTablesQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesTablesQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ" xlink:type="extended">
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails9Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitSharingIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromRoyalties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_MilestoneIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenueOther" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails8Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RetailGenericsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_BiopharmaceuticalsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_AntiInfectivesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails7Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_RestOfTheWorldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BusinessUnitAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_OncologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_PharmaceuticalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_OphthalmologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_CardioMetabolicMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_EstablishedMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_Top20ProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_RestOfPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReclassificationOfExportSales" xlink:label="lbl_ReclassificationOfExportSales" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ReclassificationOfExportSales" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails6Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BusinessUnitAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_OncologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_PharmaceuticalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_OphthalmologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_CardioMetabolicMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_EstablishedMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_COPDMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LutatheraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PiqrayMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XiidraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_BeovuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AimovigMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MayzentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:presentationArc order="29.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SystaneGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:presentationArc order="35.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TopicalOlopatadineGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:presentationArc order="36.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MyforticMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:presentationArc order="37.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:presentationArc order="38.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_RitalinFocalinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:presentationArc order="39.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails5Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CanadaAndLatinAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EstablishedMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EmergingGrowthMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails4Q" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_ZPL389Member" xlink:label="lbl_ZPL389Member" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZPL389Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20200630.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20200630/role/DisclosureSubsequentEventsQ" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc"/>
   </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>nvs-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nvs="http://novartis.com/20200630" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" blockDefault="" elementFormDefault="qualified" finalDefault="" targetNamespace="http://novartis.com/20200630">
   <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
   <xsd:import namespace="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
   <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
   <xsd:annotation>
      <xsd:appinfo>

      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
	  <link:roleType id="documentAndEntityInformation" roleURI="http://novartis.com/20200630/role/DocumentAndEntityInformation">
            <link:definition>0001000 - Document - Document and Entity Information</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfIncome" roleURI="http://novartis.com/20200630/role/StatementOfIncome">
            <link:definition>1001000 - Statement - Consolidated income statements</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfComprehensiveIncome" roleURI="http://novartis.com/20200630/role/StatementOfComprehensiveIncome">
            <link:definition>1002000 - Statement - Consolidated statements of comprehensive income</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfChangesInEquity" roleURI="http://novartis.com/20200630/role/StatementOfChangesInEquity">
            <link:definition>1004000 - Statement - Consolidated statements of changes in equity</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="balanceSheet" roleURI="http://novartis.com/20200630/role/BalanceSheet">
            <link:definition>1003000 - Statement - Consolidated balance sheets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementsOfCashFlow" roleURI="http://novartis.com/20200630/role/StatementsOfCashFlow">
            <link:definition>1005000 - Statement - Consolidated cash flow statements</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentDetails" roleURI="http://novartis.com/20200630/role/DisclosurePropertyPlantAndEquipmentDetails">
            <link:definition>2400900 - Disclosure - Property, plant and equipment (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentDetails2" roleURI="http://novartis.com/20200630/role/DisclosurePropertyPlantAndEquipmentDetails2">
            <link:definition>2400901 - Disclosure - Property, plant and equipment (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipment" roleURI="http://novartis.com/20200630/role/DisclosurePropertyPlantAndEquipment">
            <link:definition>2100900 - Disclosure - Property, plant and equipment</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentTables" roleURI="http://novartis.com/20200630/role/DisclosurePropertyPlantAndEquipmentTables">
            <link:definition>2300900 - Disclosure - Property, plant and equipment (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventories" roleURI="http://novartis.com/20200630/role/DisclosureInventories">
            <link:definition>2101400 - Disclosure - Inventories</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventoriesTables" roleURI="http://novartis.com/20200630/role/DisclosureInventoriesTables">
            <link:definition>2301400 - Disclosure - Inventories (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventoriesDetails" roleURI="http://novartis.com/20200630/role/DisclosureInventoriesDetails">
            <link:definition>2401400 - Disclosure - Inventories (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShare" roleURI="http://novartis.com/20200630/role/DisclosureEarningsPerShare">
            <link:definition>2100700 - Disclosure - Earnings per share</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShareTables" roleURI="http://novartis.com/20200630/role/DisclosureEarningsPerShareTables">
            <link:definition>2300700 - Disclosure - Earnings per share (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShareDetails" roleURI="http://novartis.com/20200630/role/DisclosureEarningsPerShareDetails">
            <link:definition>2400700 - Disclosure - Earnings per share (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPolicies" roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfSignificantAccountingPolicies">
            <link:definition>2100100 - Disclosure - Significant accounting policies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpense" roleURI="http://novartis.com/20200630/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense">
            <link:definition>2100500 - Disclosure - Interest expense and other financial income and expense</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxes" roleURI="http://novartis.com/20200630/role/DisclosureTaxes">
            <link:definition>2100600 - Disclosure - Taxes</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssets" roleURI="http://novartis.com/20200630/role/DisclosureGoodwillAndIntangibleAssets">
            <link:definition>2101100 - Disclosure - Goodwill and intangible assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilities" roleURI="http://novartis.com/20200630/role/DisclosureDeferredTaxAssetsAndLiabilities">
            <link:definition>2101200 - Disclosure - Deferred tax assets and liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
            <link:definition>2200100 - Disclosure - Significant accounting policies (Policies)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
            <link:definition>2300100 - Disclosure - Significant accounting policies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" roleURI="http://novartis.com/20200630/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables">
            <link:definition>2300500 - Disclosure - Interest expense and other financial income and expense (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsTables" roleURI="http://novartis.com/20200630/role/DisclosureGoodwillAndIntangibleAssetsTables">
            <link:definition>2301100 - Disclosure - Goodwill and intangible assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesTables" roleURI="http://novartis.com/20200630/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables">
            <link:definition>2301200 - Disclosure - Deferred tax assets and liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails" roleURI="http://novartis.com/20200630/role/DisclosureSignificantAccountingPoliciesDetails">
            <link:definition>2400100 - Disclosure - Significant accounting policies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" roleURI="http://novartis.com/20200630/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails">
            <link:definition>2400500 - Disclosure - Interest expense and other financial income and expense (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" roleURI="http://novartis.com/20200630/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2">
            <link:definition>2400501 - Disclosure - Interest expense and other financial income and expense (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesTables" roleURI="http://novartis.com/20200630/role/DisclosureTaxesTables">
            <link:definition>2300600 - Disclosure - Taxes (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails" roleURI="http://novartis.com/20200630/role/DisclosureTaxesDetails">
            <link:definition>2400600 - Disclosure - Taxes (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureTaxesDetails2">
            <link:definition>2400601 - Disclosure - Taxes (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureTaxesDetails3">
            <link:definition>2400602 - Disclosure - Taxes (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails" roleURI="http://novartis.com/20200630/role/DisclosureGoodwillAndIntangibleAssetsDetails">
            <link:definition>2401100 - Disclosure - Goodwill and intangible assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails2" roleURI="http://novartis.com/20200630/role/DisclosureGoodwillAndIntangibleAssetsDetails2">
            <link:definition>2401101 - Disclosure - Goodwill and intangible assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://novartis.com/20200630/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails">
            <link:definition>2401200 - Disclosure - Deferred tax assets and liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2">
            <link:definition>2401201 - Disclosure - Deferred tax assets and liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3">
            <link:definition>2401202 - Disclosure - Deferred tax assets and liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails4" roleURI="http://novartis.com/20200630/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4">
            <link:definition>2401203 - Disclosure - Deferred tax assets and liabilities (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureSignificantAccountingPoliciesDetails2">
            <link:definition>2400101 - Disclosure - Significant accounting policies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssets" roleURI="http://novartis.com/20200630/role/DisclosureFinancialAndOtherNoncurrentAssets">
            <link:definition>2101300 - Disclosure - Financial and other non-current assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsTables" roleURI="http://novartis.com/20200630/role/DisclosureFinancialAndOtherNoncurrentAssetsTables">
            <link:definition>2301300 - Disclosure - Financial and other non-current assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails" roleURI="http://novartis.com/20200630/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails">
            <link:definition>2401300 - Disclosure - Financial and other non-current assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails2" roleURI="http://novartis.com/20200630/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2">
            <link:definition>2401301 - Disclosure - Financial and other non-current assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails3" roleURI="http://novartis.com/20200630/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3">
            <link:definition>2401302 - Disclosure - Financial and other non-current assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssets" roleURI="http://novartis.com/20200630/role/DisclosureOtherCurrentAssets">
            <link:definition>2101700 - Disclosure - Other current assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssetsTables" roleURI="http://novartis.com/20200630/role/DisclosureOtherCurrentAssetsTables">
            <link:definition>2301700 - Disclosure - Other current assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssetsDetails" roleURI="http://novartis.com/20200630/role/DisclosureOtherCurrentAssetsDetails">
            <link:definition>2401700 - Disclosure - Other current assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecurities" roleURI="http://novartis.com/20200630/role/DisclosureMarketableSecurities">
            <link:definition>2101600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesTables" roleURI="http://novartis.com/20200630/role/DisclosureMarketableSecuritiesTables">
            <link:definition>2301600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails" roleURI="http://novartis.com/20200630/role/DisclosureMarketableSecuritiesDetails">
            <link:definition>2401600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureMarketableSecuritiesDetails2">
            <link:definition>2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureMarketableSecuritiesDetails3">
            <link:definition>2401602 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebt" roleURI="http://novartis.com/20200630/role/DisclosureNonCurrentFinancialDebt">
            <link:definition>2101900 - Disclosure - Non-current financial debt</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactions" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactions">
            <link:definition>2100200 - Disclosure - Significant transactions</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" roleURI="http://novartis.com/20200630/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments">
            <link:definition>2102100 - Disclosure - Current financial debt and derivative financial instruments</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingencies" roleURI="http://novartis.com/20200630/role/DisclosureCommitmentsAndContingencies">
            <link:definition>2102800 - Disclosure - Commitments and contingencies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsDetails" roleURI="http://novartis.com/20200630/role/DisclosureSubsequentEventsDetails">
            <link:definition>2403100 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtTables" roleURI="http://novartis.com/20200630/role/DisclosureNonCurrentFinancialDebtTables">
            <link:definition>2301900 - Disclosure - Non-current financial debt (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" roleURI="http://novartis.com/20200630/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables">
            <link:definition>2302100 - Disclosure - Current financial debt and derivative financial instruments (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesTables" roleURI="http://novartis.com/20200630/role/DisclosureCommitmentsAndContingenciesTables">
            <link:definition>2302800 - Disclosure - Commitments and contingencies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails">
            <link:definition>2400200 - Disclosure - Significant transactions (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails" roleURI="http://novartis.com/20200630/role/DisclosureNonCurrentFinancialDebtDetails">
            <link:definition>2401900 - Disclosure - Non-current financial debt (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails2" roleURI="http://novartis.com/20200630/role/DisclosureNonCurrentFinancialDebtDetails2">
            <link:definition>2401901 - Disclosure - Non-current financial debt (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails3" roleURI="http://novartis.com/20200630/role/DisclosureNonCurrentFinancialDebtDetails3">
            <link:definition>2401902 - Disclosure - Non-current financial debt (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails4" roleURI="http://novartis.com/20200630/role/DisclosureNonCurrentFinancialDebtDetails4">
            <link:definition>2401903 - Disclosure - Non-current financial debt (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails5" roleURI="http://novartis.com/20200630/role/DisclosureNonCurrentFinancialDebtDetails5">
            <link:definition>2401904 - Disclosure - Non-current financial debt (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails6" roleURI="http://novartis.com/20200630/role/DisclosureNonCurrentFinancialDebtDetails6">
            <link:definition>2401905 - Disclosure - Non-current financial debt (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" roleURI="http://novartis.com/20200630/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails">
            <link:definition>2402100 - Disclosure - Current financial debt and derivative financial instruments (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetails" roleURI="http://novartis.com/20200630/role/DisclosureCommitmentsAndContingenciesDetails">
            <link:definition>2402800 - Disclosure - Commitments and contingencies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureCommitmentsAndContingenciesDetails2">
            <link:definition>2402801 - Disclosure - Commitments and contingencies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEvents" roleURI="http://novartis.com/20200630/role/DisclosureSubsequentEvents">
            <link:definition>2103100 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureProvisionsAndOtherCurrentLiabilities" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherCurrentLiabilities">
            <link:definition>2102200 - Disclosure - Provisions and other current liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinesses" roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionsOfBusinesses">
            <link:definition>2102400 - Disclosure - Acquisitions of businesses</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociates" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociates">
            <link:definition>2102500 - Disclosure - Post-employment benefits for associates</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesTables" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables">
            <link:definition>2302200 - Disclosure - Provisions and other current liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinessesTables" roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionsOfBusinessesTables">
            <link:definition>2302400 - Disclosure - Acquisitions of businesses (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesTables" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesTables">
            <link:definition>2302500 - Disclosure - Post-employment benefits for associates (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails">
            <link:definition>2402200 - Disclosure - Provisions and other current liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2">
            <link:definition>2402201 - Disclosure - Provisions and other current liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3">
            <link:definition>2402202 - Disclosure - Provisions and other current liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinessesDetails" roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionsOfBusinessesDetails">
            <link:definition>2402400 - Disclosure - Acquisitions of businesses (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails">
            <link:definition>2402500 - Disclosure - Post-employment benefits for associates (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails2" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2">
            <link:definition>2402501 - Disclosure - Post-employment benefits for associates (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails3" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3">
            <link:definition>2402502 - Disclosure - Post-employment benefits for associates (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails4" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4">
            <link:definition>2402503 - Disclosure - Post-employment benefits for associates (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails5" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5">
            <link:definition>2402504 - Disclosure - Post-employment benefits for associates (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails6" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6">
            <link:definition>2402505 - Disclosure - Post-employment benefits for associates (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails7" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7">
            <link:definition>2402506 - Disclosure - Post-employment benefits for associates (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails8" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8">
            <link:definition>2402507 - Disclosure - Post-employment benefits for associates (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails9" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9">
            <link:definition>2402508 - Disclosure - Post-employment benefits for associates (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails10" roleURI="http://novartis.com/20200630/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10">
            <link:definition>2402509 - Disclosure - Post-employment benefits for associates (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureTradeReceivablesDetails3">
            <link:definition>2401502 - Disclosure - Trade receivables (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureTradeReceivablesDetails2">
            <link:definition>2401501 - Disclosure - Trade receivables (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails" roleURI="http://novartis.com/20200630/role/DisclosureTradeReceivablesDetails">
            <link:definition>2401500 - Disclosure - Trade receivables (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesTables" roleURI="http://novartis.com/20200630/role/DisclosureTradeReceivablesTables">
            <link:definition>2301500 - Disclosure - Trade receivables (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivables" roleURI="http://novartis.com/20200630/role/DisclosureTradeReceivables">
            <link:definition>2101500 - Disclosure - Trade receivables</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails4" roleURI="http://novartis.com/20200630/role/DisclosureTradeReceivablesDetails4">
            <link:definition>2401503 - Disclosure - Trade receivables (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails5" roleURI="http://novartis.com/20200630/role/DisclosureTradeReceivablesDetails5">
            <link:definition>2401504 - Disclosure - Trade receivables (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" roleURI="http://novartis.com/20200630/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies">
            <link:definition>2103200 - Disclosure - Principal Group subsidiaries and associated companies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" roleURI="http://novartis.com/20200630/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables">
            <link:definition>2303200 - Disclosure - Principal Group subsidiaries and associated companies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" roleURI="http://novartis.com/20200630/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails">
            <link:definition>2403200 - Disclosure - Principal Group subsidiaries and associated companies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails2" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails2">
            <link:definition>2403001 - Disclosure - Discontinued operations (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails">
            <link:definition>2403000 - Disclosure - Discontinued operations (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsTables" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTables">
            <link:definition>2303000 - Disclosure - Discontinued operations (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperations" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperations">
            <link:definition>2103000 - Disclosure - Discontinued operations</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails4" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4">
            <link:definition>2402304 - Disclosure - Details to the consolidated cash flow statements (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails3" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3">
            <link:definition>2402303 - Disclosure - Details to the consolidated cash flow statements (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails2" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2">
            <link:definition>2402301 - Disclosure - Details to the consolidated cash flow statements (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails">
            <link:definition>2402300 - Disclosure - Details to the consolidated cash flow statements (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsTables" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedCashFlowStatementsTables">
            <link:definition>2302300 - Disclosure - Details to the consolidated statements of cash flows (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatements" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedCashFlowStatements">
            <link:definition>2102300 - Disclosure - Details to the consolidated statements of cash flows</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFigures" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFigures">
            <link:definition>2100300 - Disclosure - Segmentation of key figures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompanies" roleURI="http://novartis.com/20200630/role/DisclosureAssociatedCompanies">
            <link:definition>2100400 - Disclosure - Associated companies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncome" roleURI="http://novartis.com/20200630/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome">
            <link:definition>2100800 - Disclosure - Changes in consolidated statements of comprehensive income</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilities" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilities">
            <link:definition>2102000 - Disclosure - Provisions and other non-current liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociates" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociates">
            <link:definition>2102600 - Disclosure - Equity-based participation plans for associates</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedParties" roleURI="http://novartis.com/20200630/role/DisclosureTransactionsWithRelatedParties">
            <link:definition>2102700 - Disclosure - Transactions with related parties</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosures" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosures">
            <link:definition>2102900 - Disclosure - Financial instruments - additional disclosures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresTables" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTables">
            <link:definition>2300300 - Disclosure - Segmentation of key figures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesTables" roleURI="http://novartis.com/20200630/role/DisclosureAssociatedCompaniesTables">
            <link:definition>2300400 - Disclosure - Associated companies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" roleURI="http://novartis.com/20200630/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables">
            <link:definition>2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesTables" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables">
            <link:definition>2302000 - Disclosure - Provisions and other non-current liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesTables" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesTables">
            <link:definition>2302600 - Disclosure - Equity-based participation plans for associates (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesTables" roleURI="http://novartis.com/20200630/role/DisclosureTransactionsWithRelatedPartiesTables">
            <link:definition>2302700 - Disclosure - Transactions with related parties (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresTables" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables">
            <link:definition>2302900 - Disclosure - Financial instruments - additional disclosures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails">
            <link:definition>2400300 - Disclosure - Segmentation of key figures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails" roleURI="http://novartis.com/20200630/role/DisclosureAssociatedCompaniesDetails">
            <link:definition>2400400 - Disclosure - Associated companies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" roleURI="http://novartis.com/20200630/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails">
            <link:definition>2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2" roleURI="http://novartis.com/20200630/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2">
            <link:definition>2400801 - Disclosure - Changes in consolidated statements of comprehensive income (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" roleURI="http://novartis.com/20200630/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3">
            <link:definition>2400802 - Disclosure - Changes in consolidated statements of comprehensive income (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" roleURI="http://novartis.com/20200630/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4">
            <link:definition>2400803 - Disclosure - Changes in consolidated statements of comprehensive income (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails">
            <link:definition>2402000 - Disclosure - Provisions and other non-current liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails">
            <link:definition>2402600 - Disclosure - Equity-based participation plans for associates (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2">
            <link:definition>2402601 - Disclosure - Equity-based participation plans for associates (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3">
            <link:definition>2402602 - Disclosure - Equity-based participation plans for associates (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails4" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4">
            <link:definition>2402603 - Disclosure - Equity-based participation plans for associates (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails5" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5">
            <link:definition>2402604 - Disclosure - Equity-based participation plans for associates (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails6" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6">
            <link:definition>2402605 - Disclosure - Equity-based participation plans for associates (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails7" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails7">
            <link:definition>2402606 - Disclosure - Equity-based participation plans for associates (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails8" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails8">
            <link:definition>2402607 - Disclosure - Equity-based participation plans for associates (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails9" roleURI="http://novartis.com/20200630/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails9">
            <link:definition>2402608 - Disclosure - Equity-based participation plans for associates (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails" roleURI="http://novartis.com/20200630/role/DisclosureTransactionsWithRelatedPartiesDetails">
            <link:definition>2041200 - Disclosure - Transactions with related parties (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureTransactionsWithRelatedPartiesDetails2">
            <link:definition>2402701 - Disclosure - Transactions with related parties (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureTransactionsWithRelatedPartiesDetails3">
            <link:definition>2402702 - Disclosure - Transactions with related parties (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails">
            <link:definition>2402900 - Disclosure - Financial instruments - additional disclosures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails3" roleURI="http://novartis.com/20200630/role/DisclosureGoodwillAndIntangibleAssetsDetails3">
            <link:definition>2401102 - Disclosure - Goodwill and intangible assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails4" roleURI="http://novartis.com/20200630/role/DisclosureGoodwillAndIntangibleAssetsDetails4">
            <link:definition>2401103 - Disclosure - Goodwill and intangible assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureSegmentationOfKeyFiguresDetails2" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails2">
            <link:definition>2400302 - Disclosure - Segmentation of key figures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails3" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails3">
            <link:definition>2400303 - Disclosure - Segmentation of key figures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails4" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails4">
            <link:definition>2400304 - Disclosure - Segmentation of key figures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails5" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails5">
            <link:definition>2400305 - Disclosure - Segmentation of key figures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails6" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails6">
            <link:definition>2400306 - Disclosure - Segmentation of key figures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails7" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails7">
            <link:definition>2400307 - Disclosure - Segmentation of key figures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureAssociatedCompaniesDetails2">
            <link:definition>2400401 - Disclosure - Associated companies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureAssociatedCompaniesDetails3">
            <link:definition>2400402 - Disclosure - Associated companies (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails4" roleURI="http://novartis.com/20200630/role/DisclosureAssociatedCompaniesDetails4">
            <link:definition>2400403 - Disclosure - Associated companies (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails5" roleURI="http://novartis.com/20200630/role/DisclosureAssociatedCompaniesDetails5">
            <link:definition>2400404 - Disclosure - Associated companies (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails6" roleURI="http://novartis.com/20200630/role/DisclosureAssociatedCompaniesDetails6">
            <link:definition>2400405 - Disclosure - Associated companies (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2">
            <link:definition>2402001 - Disclosure - Provisions and other non-current liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3">
            <link:definition>2402002 - Disclosure - Provisions and other non-current liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4">
            <link:definition>2402003 - Disclosure - Provisions and other non-current liabilities (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5">
            <link:definition>2402004 - Disclosure - Provisions and other non-current liabilities (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails6" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails6">
            <link:definition>2402005 - Disclosure - Provisions and other non-current liabilities (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquity" roleURI="http://novartis.com/20200630/role/DisclosureEquity">
            <link:definition>2101800 - Disclosure - Equity</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityTables" roleURI="http://novartis.com/20200630/role/DisclosureEquityTables">
            <link:definition>2301800 - Disclosure - Equity (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails" roleURI="http://novartis.com/20200630/role/DisclosureEquityDetails">
            <link:definition>2401800 - Disclosure - Equity (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails2" roleURI="http://novartis.com/20200630/role/DisclosureEquityDetails2">
            <link:definition>2401801 - Disclosure - Equity (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails3" roleURI="http://novartis.com/20200630/role/DisclosureEquityDetails3">
            <link:definition>2401802 - Disclosure - Equity (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails4" roleURI="http://novartis.com/20200630/role/DisclosureEquityDetails4">
            <link:definition>2401803 - Disclosure - Equity (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementsOfCashFlowParenthetical" roleURI="http://novartis.com/20200630/role/StatementsOfCashFlowParenthetical">
            <link:definition>1005010 - Statement - Consolidated cash flow statements (Parenthetical)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails1" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails1">
            <link:definition>2400301 - Disclosure - Segmentation of key figures (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails5" roleURI="http://novartis.com/20200630/role/DisclosureEquityDetails5">
            <link:definition>2401804 - Disclosure - Equity (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails5" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5">
            <link:definition>2402305 - Disclosure - Details to the consolidated cash flow statements (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2">
            <link:definition>2402901 - Disclosure - Financial instruments - additional disclosures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3">
            <link:definition>2402902 - Disclosure - Financial instruments - additional disclosures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4">
            <link:definition>2402903 - Disclosure - Financial instruments - additional disclosures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:labelLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5">
            <link:definition>2402904 - Disclosure - Financial instruments - additional disclosures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6">
            <link:definition>2402905 - Disclosure - Financial instruments - additional disclosures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7">
            <link:definition>2402906 - Disclosure - Financial instruments - additional disclosures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8">
            <link:definition>2402907 - Disclosure - Financial instruments - additional disclosures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9">
            <link:definition>2402908 - Disclosure - Financial instruments - additional disclosures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10">
            <link:definition>2402909 - Disclosure - Financial instruments - additional disclosures (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11">
            <link:definition>2402910 - Disclosure - Financial instruments - additional disclosures (Details 11)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12">
            <link:definition>2402911 - Disclosure - Financial instruments - additional disclosures (Details 12)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13">
            <link:definition>2402912 - Disclosure - Financial instruments - additional disclosures (Details 13)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails5" roleURI="http://novartis.com/20200630/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5">
            <link:definition>2401204 - Disclosure - Deferred tax assets and liabilities (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails3" roleURI="http://novartis.com/20200630/role/DisclosureSignificantAccountingPoliciesDetails3">
            <link:definition>2400102 - Disclosure - Significant accounting policies (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureBasisOfPreparationQ" roleURI="http://novartis.com/20200630/role/DisclosureBasisOfPreparationQ">
            <link:definition>2010100 - Disclosure - Basis of preparation</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesQ" roleURI="http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesQ">
            <link:definition>2010200 - Disclosure - Selected critical accounting policies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsQ" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsQ">
            <link:definition>2010300 - Disclosure - Significant transactions</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersQ" roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersQ">
            <link:definition>2010400 - Disclosure - Summary of equity attributable to Novartis AG shareholders</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsQ" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsQ">
            <link:definition>2010500 - Disclosure - Financial instruments</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLegalProceedingsUpdateQ" roleURI="http://novartis.com/20200630/role/DisclosureLegalProceedingsUpdateQ">
            <link:definition>2010800 - Disclosure - Legal proceedings update</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsQ" roleURI="http://novartis.com/20200630/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsQ">
            <link:definition>2102900 - Disclosure - Impacts of adoption of new IFRS standards</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsQ" roleURI="http://novartis.com/20200630/role/DisclosureSubsequentEventsQ">
            <link:definition>2011100 - Disclosure - Subsequent events</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresQ" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresQ">
            <link:definition>2010900 - Disclosure - Segmentation of key figures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesPoliciesQ" roleURI="http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesPoliciesQ">
            <link:definition>2020200 - Disclosure - Selected critical accounting policies (Policies)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersTablesQ">
            <link:definition>2030400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsTablesQ">
            <link:definition>2030500 - Disclosure - Financial instruments (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsTablesQ">
            <link:definition>2302900 - Disclosure - Impacts of adoption of new IFRS standards (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ">
            <link:definition>2030900 - Disclosure - Segmentation of key figures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesDetailsQ">
            <link:definition>2040200 - Disclosure - Selected critical accounting policies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetailsQ">
            <link:definition>2040300 - Disclosure - Significant transactions (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersDetailsQ">
            <link:definition>2040400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetailsQ">
            <link:definition>2040500 - Disclosure - Financial instruments (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails2Q" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails2Q">
            <link:definition>2040501 - Disclosure - Financial instruments (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetailsQ">
            <link:definition>2402900 - Disclosure - Impacts of adoption of new IFRS standards (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails2Q" roleURI="http://novartis.com/20200630/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails2Q">
            <link:definition>2402901 - Disclosure - Impacts of adoption of new IFRS standards (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetailsQ">
            <link:definition>2040900 - Disclosure - Segmentation of key figures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails2Q" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails2Q">
            <link:definition>2040901 - Disclosure - Segmentation of key figures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails3Q" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails3Q">
            <link:definition>2040902 - Disclosure - Segmentation of key figures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails4Q" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails4Q">
            <link:definition>2040903 - Disclosure - Segmentation of key figures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails5Q" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails5Q">
            <link:definition>2040904 - Disclosure - Segmentation of key figures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails6Q" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails6Q">
            <link:definition>2040905 - Disclosure - Segmentation of key figures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails7Q" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails7Q">
            <link:definition>2040906 - Disclosure - Segmentation of key figures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails8Q" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails8Q">
            <link:definition>2040907 - Disclosure - Segmentation of key figures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails9Q" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails9Q">
            <link:definition>2040908 - Disclosure - Segmentation of key figures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails3Q" roleURI="http://novartis.com/20200630/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails3Q">
            <link:definition>2402902 - Disclosure - Impacts of adoption of new IFRS standards (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails4Q" roleURI="http://novartis.com/20200630/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails4Q">
            <link:definition>2402903 - Disclosure - Impacts of adoption of new IFRS standards (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails3Q" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails3Q">
            <link:definition>2040502 - Disclosure - Financial instruments (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails4Q" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails4Q">
            <link:definition>2040503 - Disclosure - Financial instruments (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" roleURI="http://novartis.com/20200630/role/DisclosureTransactionsWithRelatedPartiesDetails1">
            <link:definition>2402700 - Disclosure - Transaction with related parties (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails5Q" roleURI="http://novartis.com/20200630/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails5Q">
            <link:definition>2402904 - Disclosure - Impacts of adoption of new IFRS standards (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureTransactionsWithRelatedPartiesDetailsQ">
            <link:definition>2011100 - Disclosure - Transactions with related parties</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails8" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails8">
            <link:definition>2400308 - Disclosure - Segmentation of key figures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails9" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails9">
            <link:definition>2400309 - Disclosure - Segmentation of key figures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails10" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails10">
            <link:definition>2400310 - Disclosure - Segmentation of key figures (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDisposalGroupHeldForSaleDetails" roleURI="http://novartis.com/20200630/role/DisclosureDisposalGroupHeldForSaleDetails">
            <link:definition>2400202 - Disclosure - Significant transactions (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" roleURI="http://novartis.com/20200630/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14">
            <link:definition>2402913 - Disclosure - Financial instruments - additional disclosures (Details 14)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsTables" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsTables">
            <link:definition>2300200 - Disclosure - Significant transactions (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails11" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails11">
            <link:definition>2400311 - Disclosure - Segmentation of key figures - Top 20 (Details 11)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails12" roleURI="http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails12">
            <link:definition>2400312 - Disclosure - Segmentation of key figures - Net sales by region (Details 12)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails6" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6">
            <link:definition>2402302 - Disclosure - Details to the consolidated cash flow statements (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsQ" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsQ">
            <link:definition>2011000 - Disclosure - Discontinued operations</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsQ" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsQ">
            <link:definition>2010600 - Disclosure - Lease liabilities and right-of-use assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsQ" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsQ">
            <link:definition>2010600 - Disclosure - Details to the consolidated statements of cash flows</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsTablesQ">
            <link:definition>2030300 - Disclosure - Significant transactions (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsTablesQ">
            <link:definition>2030600 - Disclosure - Lease liability and Right-of-use assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ">
            <link:definition>2030600 - Disclosure - Details to the consolidated statements of cash flows (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ">
            <link:definition>2031000 - Disclosure - Discontinued operations (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetailsQ">
            <link:definition>2040600 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails1Q" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails1Q">
            <link:definition>2040601 - Disclosure - Lease liability and Right-of-use assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails2Q" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2Q">
            <link:definition>2040602 - Disclosure - Lease liability and Right-of-use assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails3Q" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3Q">
            <link:definition>2040603 - Disclosure - Lease liability and Right-of-use assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails1Q" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails1Q">
            <link:definition>2040301 - Disclosure - Significant transactions (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetailsQ">
            <link:definition>2041000 - Disclosure - Discontinued operations (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ">
            <link:definition>2040600 - Disclosure - Details to the consolidated statements of cash flows (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q">
            <link:definition>2040601 - Disclosure - Details to the consolidated statements of cash flows (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesQ" roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesQ">
            <link:definition>2010700 - Disclosure - Acquisition of businesses</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesTablesQ" roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesTablesQ">
            <link:definition>2030700 - Disclosure - Acquisition of businesses (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesDetailsQ" roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetailsQ">
            <link:definition>2040701 - Disclosure - Acquisition of businesses (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails1Q" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails1Q">
            <link:definition>2041001 - Disclosure - Discontinued operations (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails2Q" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails2Q">
            <link:definition>2041002 - Disclosure - Discontinued operations (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails4Q" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4Q">
            <link:definition>2040604 - Disclosure - Lease liability and Right-of-use assets (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails5Q" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5Q">
            <link:definition>2040605 - Disclosure - Lease liability and Right-of-use assets (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureSignificantTransactionsDetails2Q" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails2Q">
            <link:definition>2040302 - Disclosure - Significant transactions (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails3Q" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails3Q">
            <link:definition>2041003 - Disclosure - Discontinued operations (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureRightOfUseAssetsAndLeaseLiability" roleURI="http://novartis.com/20200630/role/DisclosureRightOfUseAssetsAndLeaseLiability">
            <link:definition>2101000 - Disclosure - Right-of-use assets and lease liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureRightOfUseAssetsAndLeaseLiabilityTables" roleURI="http://novartis.com/20200630/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables">
            <link:definition>2301000 - Disclosure - Right-of-use assets and lease liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails2" roleURI="http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails2">
            <link:definition>2400201 - Disclosure - Significant transactions (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails3" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails3">
            <link:definition>2403005 - Disclosure - Discontinued operations (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails4" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails4">
            <link:definition>2403003 - Disclosure - Discontinued operations (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails">
            <link:definition>2401000 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2">
            <link:definition>2401001 - Disclosure - Lease liability and Right-of-use assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3">
            <link:definition>2401002 - Disclosure - Lease liability and Right-of-use assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4">
            <link:definition>2401003 - Disclosure - Lease liability and Right-of-use assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5">
            <link:definition>2401004 - Disclosure - Lease liability and Right-of-use assets (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6">
            <link:definition>2401005 - Disclosure - Lease liability and Right-of-use assets (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails5" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails5">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403004 - Disclosure - Discontinued operations (Details 5)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails6" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails6">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403002 - Disclosure - Discontinued operations (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails7" roleURI="http://novartis.com/20200630/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2401006 - Disclosure - Lease liability and Right-of-use assets (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails7" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403006 - Disclosure - Discontinued operations (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails8" roleURI="http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails8">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403007 - Disclosure - Discontinued operations (Details 8)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" roleURI="http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040602 - Disclosure - Details to the consolidated statements of cash flows (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesDetails2Q" roleURI="http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetails2Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040702 - Disclosure - Acquisition of businesses (Details 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" roleURI="http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040800 - Disclosure - Provisions and other non-current liabilities (Details)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType></xsd:appinfo>
   </xsd:annotation>
   <xsd:element abstract="true" id="nvs_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" name="NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_StatementTable" name="StatementTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StatementLineItems" name="StatementLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentTableTextBlock" name="PropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoriesDisclosureAbstract" name="InventoriesDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfInventoryCurrentTableTextBlock" name="ScheduleOfInventoryCurrentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryCurrentTable" name="InventoryCurrentTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryAxis" name="InventoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryMember" name="InventoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryRawMaterialsGrossMember" name="InventoryRawMaterialsGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryWorkInProgressGrossMember" name="InventoryWorkInProgressGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryFinishedGoodsGrossMember" name="InventoryFinishedGoodsGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryLineItems" name="InventoryLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" name="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" name="DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" name="AssumptionsUsedInTheCalculationOfValuationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" name="AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfIncomeTaxAbstract" name="DisclosureOfIncomeTaxAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeBeforeTaxesTableTextBlock" name="IncomeBeforeTaxesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" name="CurrentAndDeferredIncomeTaxExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AnalysisOfTaxRateTableTextBlock" name="AnalysisOfTaxRateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" name="DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseTableTextBlock" name="InterestExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherFinancialIncomeAndExpenseTableTextBlock" name="OtherFinancialIncomeAndExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" name="DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" name="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" name="TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SignificantAccountingPoliciesAbstract" name="SignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" name="RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" name="DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" name="DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" name="DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" name="DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FurnitureAndVehiclesMember" name="FurnitureAndVehiclesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketingRelatedIntangibleAssetsMember" name="MarketingRelatedIntangibleAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentlyMarketedProductsMember" name="CurrentlyMarketedProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementLocationAxis" name="IncomeStatementLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementLocationMember" name="IncomeStatementLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CostOfSalesMember" name="CostOfSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CostOfSalesOrResearchAndDevelopmentMember" name="CostOfSalesOrResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InterestExpenseAbstract" name="InterestExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialIncomeAndExpenseAbstract" name="OtherFinancialIncomeAndExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeOnForwardContractsAndOptions" name="IncomeOnForwardContractsAndOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeTaxExpense" name="IncomeTaxExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfCreditsAndAllowances" name="TaxRateEffectOfCreditsAndAllowances" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfWriteOffOfDeferredTaxAssets" name="TaxRateEffectOfWriteOffOfDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" name="TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromBenefitsExpiring" name="TaxRateEffectFromBenefitsExpiring" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageEffectiveTaxRateContinuingOperations" name="AverageEffectiveTaxRateContinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageEffectiveTaxRateDiscontinuedOperations" name="AverageEffectiveTaxRateDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" name="PensionsAndOtherBenefitObligationsOfAssociatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoriesMember" name="InventoriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TaxLossCarryforwardsMember" name="TaxLossCarryforwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" name="IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" name="OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" name="TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InvestmentsInSubsidiariesMember" name="InvestmentsInSubsidiariesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GoodwillFromAcquisitionsMember" name="GoodwillFromAcquisitionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetTreatmentAxis" name="BalanceSheetTreatmentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetTreatmentMember" name="BalanceSheetTreatmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CapitalizedMember" name="CapitalizedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NotCapitalizedMember" name="NotCapitalizedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YearOfExpiryAxis" name="YearOfExpiryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YearOfExpiryMember" name="YearOfExpiryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OneYearMember" name="OneYearMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TwoYearsMember" name="TwoYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThreeYearsMember" name="ThreeYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FourYearsMember" name="FourYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FiveYearsMember" name="FiveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MoreThanFiveYearsMember" name="MoreThanFiveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueOfTaxLossCarryforwardsExpired" name="ValueOfTaxLossCarryforwardsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" name="DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" name="DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" name="UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" name="ProvisionForIncomeTaxesOnUnremittedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" name="DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" name="DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAssetsTableTextBlock" name="DisclosureOfFinancialAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" name="DisclosureOfOtherNoncurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" name="DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherCurrentAssetsTableTextBlock" name="OtherCurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WithholdingTaxRecoverable" name="WithholdingTaxRecoverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentPrepaidExpensesAssociatedCompanies" name="CurrentPrepaidExpensesAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ReceivablesAssociatedCompanies" name="ReceivablesAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherReceivablesAndCurrentAssets" name="OtherReceivablesAndCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" name="DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" name="DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" name="MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsTableTextBlock" name="CashAndCashEquivalentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FundInstrumentsHeld" name="FundInstrumentsHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DebtSecuritiesDenominationsAbstract" name="DebtSecuritiesDenominationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementInDeferredTaxBalanceRollForward" name="MovementInDeferredTaxBalanceRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationReceivable" name="ContingentConsiderationReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfOtherNoncurrentAssetsAbstract" name="DisclosureOfOtherNoncurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredCompensationPlansAssets" name="DeferredCompensationPlansAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrepaidPostemploymentBenefitPlansAssets" name="PrepaidPostemploymentBenefitPlansAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinanceLeaseProvision" name="FinanceLeaseProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MovementInTheShareCapitalTableTextBlock" name="MovementInTheShareCapitalTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MovementInTheShareslTableTextBlock" name="MovementInTheShareslTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventTypAxis" name="SubsequentEventTypAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventTypeMember" name="SubsequentEventTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventMember" name="SubsequentEventMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" name="DisclosureOfCommitmentsAndContingenciesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfSignificantTransactionsAbstract" name="DisclosureOfSignificantTransactionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfSignificantTransactionsTextBlock" name="DisclosureOfSignificantTransactionsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" name="DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" name="DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" name="DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" name="DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" name="DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" name="DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfLeasingCommitmentsTableTextBlock" name="DisclosureOfLeasingCommitmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" name="DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeasingCommitmentsAbstract" name="LeasingCommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" name="ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" name="ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ResearchAndDevelopmentCommitmentsAbstract" name="ResearchAndDevelopmentCommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" name="ScheduleForCommitmentsUnderResearchAndDevelopmentTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" name="ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentsUnderLongtermResearchAgreements" name="CommitmentsUnderLongtermResearchAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" name="CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" name="CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" name="InterestBearningAccountsOfAssociatesPayableOnDemand" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" name="LaterThanFiveYearsAndNotLaterThanSixYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanSixYearsMember" name="LaterThanSixYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialDebtsCoveredByCollateral" name="NoncurrentFinancialDebtsCoveredByCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" name="A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" name="A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" name="A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsLender" name="BorrowingsLender" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsPremiumDiscount" name="BorrowingsPremiumDiscount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherNoncurrentFinancialDebt" name="OtherNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_FairValueByMeasurementBasisAxis" name="FairValueByMeasurementBasisAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueByMeasurementBasisMember" name="FairValueByMeasurementBasisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CarryingReportedAmountFairValueDisclosureMember" name="CarryingReportedAmountFairValueDisclosureMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueDisclosureItemAmountsMember" name="FairValueDisclosureItemAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" name="OtherComprehensiveIncomeNetOfTaxFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" name="IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsRelatedToDivestments" name="FairValueAdjustmentsRelatedToDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" name="PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" name="ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" name="PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" name="ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" name="ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" name="CashFlowsBeforeWorkingCapitalAndProvisionChanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" name="A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsIssuanceDate" name="BorrowingsIssuanceDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrencyOthersMember" name="CurrencyOthersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OperatingIncomeMember" name="OperatingIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TranscendMedicalIncMember" name="TranscendMedicalIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SelexysPharmaceuticalsCorporationMember" name="SelexysPharmaceuticalsCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedMember" name="ZiarcoGroupLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionIncMember" name="EncoreVisionIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EliLillyAndCompanyMember" name="EliLillyAndCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKOncologyProductsMember" name="GSKOncologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKVaccinesMember" name="GSKVaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKConsumerHealthcareMember" name="GSKConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKTotalTransactionMember" name="GSKTotalTransactionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexMember" name="SpinifexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdmuneTheraputicsMember" name="AdmuneTheraputicsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" name="BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" name="DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" name="DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfAcquisitionOfBusinessesAbstract" name="DisclosureOfAcquisitionOfBusinessesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionsForReductionOfRevenueTableTextBlock" name="ProvisionsForReductionOfRevenueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RestructuringProvisionsMovementsTableTextBlock" name="RestructuringProvisionsMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" name="FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" name="DisclosureOfDefinedBenefitPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" name="DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" name="BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAssumptionsUsedTableTextBlock" name="ScheduleOfAssumptionsUsedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" name="ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" name="ScheduleOfHealthCareCostTrendRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" name="ScheduleOfAllocationOfPlanAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" name="ScheduleOfExpectedBenefitPaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" name="AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" name="AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" name="CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" name="AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" name="OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" name="TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PotentiallyRefundableConsiderationFromAcquisition" name="PotentiallyRefundableConsiderationFromAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueOfAcquireeFullYear" name="RevenueOfAcquireeFullYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" name="SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" name="SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" name="SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" name="SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" name="SaleOfBusinessContingentOptionArrangementsFeePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfVotingEquityInterestsContributed" name="PercentageOfVotingEquityInterestsContributed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionRelatedCosts" name="TransactionRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionRelatedCostsPaid" name="TransactionRelatedCostsPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" name="ProvisionsAndOtherCurrentLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" name="AccrualForTaxesOtherThanIncomeTaxesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" name="AccruedRoyaltiesPayableClassifiedAsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProvisionsForDeductionsFromRevenueRollForward" name="ProvisionsForDeductionsFromRevenueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangesInOffsetAgainstGrossTradeReceivables" name="ChangesInOffsetAgainstGrossTradeReceivables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestructuringProvisionsMovementsRollForward" name="RestructuringProvisionsMovementsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTradeReceivablesAbstract" name="DisclosureOfTradeReceivablesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" name="DisclosureOfTradeReceivablesExplanatoryTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionsForTradeReceivablesTableTextBlock" name="ProvisionsForTradeReceivablesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesProvisionMovementsTableTextBlock" name="TradeReceivablesProvisionMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" name="OverdueAmountsAndRelatedProvisionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" name="TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnalysisOfOverdueAmountsTable" name="AnalysisOfOverdueAmountsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnalysisOfOverdueAmountsLineItems" name="AnalysisOfOverdueAmountsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" name="DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" name="CurrentTradeReceivablesFromCloselyMonitoredCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" name="CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" name="PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharePaidinCapital" name="SharePaidinCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisArgentinaS.A.BuenosAiresMember" name="NovartisArgentinaS.A.BuenosAiresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosS.A.BuenosAiresMember" name="AlconLaboratoriosS.A.BuenosAiresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RocheHoldingAGBaselMember" name="RocheHoldingAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConcentrationOfMajorPlansGeographic" name="ConcentrationOfMajorPlansGeographic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" name="DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetirementPlanTypeAxis" name="RetirementPlanTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetirementPlanTypeMember" name="RetirementPlanTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionPlanMember" name="PensionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherPostemploymentBenefitPlansMember" name="OtherPostemploymentBenefitPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanInterestCost" name="DefinedBenefitPlanInterestCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" name="InterestExpenseIncomeDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" name="ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanSettlementsPlanAssets" name="DefinedBenefitPlanSettlementsPlanAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" name="DefinedBenefitPlanChangeInBenefitObligationRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" name="DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" name="DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LimitationOnRecognitionOfFundSurplus" name="LimitationOnRecognitionOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ChangeInLimitationOnRecognitionOfFundSurplus" name="ChangeInLimitationOnRecognitionOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestIncomeOnLimitationOfFundSurplus" name="InterestIncomeOnLimitationOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" name="DefinedBenefitPlanChangeInNetLiabilityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" name="AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" name="DefinedBenefitPensionPlanAccruedBenefitLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" name="BreakdownOfDefinedBenefitObligationForPensionPlansTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ObligationByTypeAxis" name="ObligationByTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ObligationByTypeMember" name="ObligationByTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UnfundedMember" name="UnfundedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActiveMember" name="ActiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeferredPensionersMember" name="DeferredPensionersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionersMember" name="PensionersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" name="ScheduleOfDefinedBenefitPlansDisclosuresTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" name="ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitAssumptionLifeExpectancyMale" name="DefinedBenefitAssumptionLifeExpectancyMale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitAssumptionLifeExpectancyFemale" name="DefinedBenefitAssumptionLifeExpectancyFemale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LifeExpectancyMember" name="LifeExpectancyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" name="ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangeInActuarialAssumptionAxis" name="ChangeInActuarialAssumptionAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangeInActuarialAssumptionMember" name="ChangeInActuarialAssumptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Decrease25BasisPointMember" name="Decrease25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Increase25BasisPointMember" name="Increase25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Increase1YearMember" name="Increase1YearMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfHealthCareCostTrendRatesTable" name="ScheduleOfHealthCareCostTrendRatesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" name="DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" name="DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" name="DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfAllocationOfPlanAssetsTable" name="ScheduleOfAllocationOfPlanAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RealEstateMember" name="RealEstateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlternativeInvestmentsMember" name="AlternativeInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CashAndOtherInvestmentsMember" name="CashAndOtherInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" name="DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" name="DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanPlanAssetAllocations" name="DefinedBenefitPlanPlanAssetAllocations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" name="WeightedAverageDurationOfDefinedBenefitObligationYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfExpectedBenefitPaymentsTable" name="ScheduleOfExpectedBenefitPaymentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" name="DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" name="DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" name="PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" name="DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SocieteParActionsSANDOZAlgiersMember" name="SocieteParActionsSANDOZAlgiersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" name="DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" name="AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" name="CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" name="CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" name="CashFlowsFromDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementSegmentationTableTextBlock" name="ConsolidatedIncomeStatementSegmentationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExpensesIncludedInNetIncomeTableTextBlock" name="ExpensesIncludedInNetIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsSalesToContinuingSegments" name="RevenueFromSaleOfGoodsSalesToContinuingSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VaccinesMember" name="VaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsumerHealthMember" name="ConsumerHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CorporateMember" name="CorporateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OperatingIncomeLossOfDiscontinuedOperations" name="OperatingIncomeLossOfDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeTaxExpenseOfDiscontinuedOperations" name="IncomeTaxExpenseOfDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" name="AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsAndDivestmentsAxis" name="AcquisitionsAndDivestmentsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsAndDivestmentsMember" name="AcquisitionsAndDivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsMember" name="AcquisitionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DivestmentsMember" name="DivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowCurrencyTranslationEffects" name="CashInflowOutflowCurrencyTranslationEffects" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowAcquiredDivestedLiquity" name="CashInflowOutflowAcquiredDivestedLiquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" name="CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowGoodwill" name="CashInflowOutflowGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowDivestmentGainLoss" name="CashInflowOutflowDivestmentGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" name="TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReceivablesAndPayablesContingentConsiderationNet" name="ReceivablesAndPayablesContingentConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherPaymentsAndDeferredConsiderationNet" name="OtherPaymentsAndDeferredConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredPrepaidPortionOfSalesPrice" name="DeferredPrepaidPortionOfSalesPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationPaid" name="ContingentConsiderationPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Change25BasisPointMember" name="Change25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendsPayableAmountPerShare" name="DividendsPayableAmountPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeHeld" name="TreasurySharesAcquiredToBeHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeCancelled" name="TreasurySharesAcquiredToBeCancelled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherSharePurchases" name="OtherSharePurchases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharepurchaseOfTreasuryShares" name="SharepurchaseOfTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeHeldValue" name="TreasurySharesAcquiredToBeHeldValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredForCancellationValue" name="TreasurySharesAcquiredForCancellationValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfComprehensiveIncomeTableTextBlock" name="ScheduleOfComprehensiveIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" name="ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" name="FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" name="ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OfficerAndDirectorCompensationTableTextBlock" name="OfficerAndDirectorCompensationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" name="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" name="ScheduleOfSharebasedCompensationActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonExecutiveDirectorMember" name="NonExecutiveDirectorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RocheHoldingAGMember" name="RocheHoldingAGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LucentisMember" name="LucentisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_XolairMember" name="XolairMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" name="NetExpenseRoyaltiesCostSharingAndProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GenentechInc.USAMember" name="GenentechInc.USAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProfDrBrodyMember" name="ProfDrBrodyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProfDrZinkernagelMember" name="ProfDrZinkernagelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrAlexKrauerMember" name="DrAlexKrauerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrDanielVasellaMember" name="DrDanielVasellaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrJamesBradnerMember" name="DrJamesBradnerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationDailyRate" name="KeyManagementPersonnelCompensationDailyRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" name="KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationSharesAcquired" name="KeyManagementPersonnelCompensationSharesAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" name="KeyManagementPersonnelCompensationOwnershipInterestAcquired" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" name="FairValueAdjustmentsOnMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" name="FairValueAdjustmentsOnDeferredCashFlowHedgesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActuarialLossesFromDefinedBenefitPlansMember" name="ActuarialLossesFromDefinedBenefitPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CumulativeCurrencyTranslationEffectsMember" name="CumulativeCurrencyTranslationEffectsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainLossOnSaleOfMarketableInvestments" name="GainLossOnSaleOfMarketableInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainLossOnSaleOfOtherFinancialAssets" name="GainLossOnSaleOfOtherFinancialAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RemeasurementsFromDefinedBenefitPlansLineItems" name="RemeasurementsFromDefinedBenefitPlansLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InnovativeMedicinesMember" name="InnovativeMedicinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozMember" name="SandozMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconMember" name="AlconMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentivePlanMember" name="EquityBasedParticipationAnnualIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationShareSavingsPlanMember" name="EquityBasedParticipationShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" name="EquityBasedParticipationLeveragedShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" name="EquityBasedParticipationEmployeeShareOwnershipPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationUKShareSavingsPlanMember" name="EquityBasedParticipationUKShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" name="EquityBasedParticipationNovartisEquityPlanSelectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermPerformancePlanMember" name="EquityBasedParticipationLongTermPerformancePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" name="EquityBasedParticipationLongTermRelativePerformancePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationSpecialShareAwardsMember" name="EquityBasedParticipationSpecialShareAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" name="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationRestrictedSharesMember" name="EquityBasedParticipationRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" name="OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" name="OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" name="OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" name="KeyManagementPersonnelCompensationSharesAcquiredPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueAdjustmentOnComprehensiveIncome" name="ValueAdjustmentOnComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" name="GainsLossesOnValueAdjustmentOnComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="TotalValueAdjustmentsAttributableToNovartisShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" name="AlconInc.EquityPlanConvertedNovartisShareOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" name="AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" name="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonvestingAxis" name="NonvestingAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonvestingMember" name="NonvestingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonvestedSharesGrantedMember" name="NonvestedSharesGrantedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" name="RevenueFromSaleOfGoodsSalesToOtherSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" name="ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetOperatingAssets" name="NetOperatingAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" name="CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialDebtsAndDerivativeInstruments" name="FinancialDebtsAndDerivativeInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" name="CurrentIncomeTaxAndDeferredTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_SelectedNoncurrentAssets" name="SelectedNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OtherCountriesMember" name="OtherCountriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GeographicalRegionsAxis" name="GeographicalRegionsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GeographicalRegionsMember" name="GeographicalRegionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AsiaAfricaAustralasiaMember" name="AsiaAfricaAustralasiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LargestCustomerMember" name="LargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SecondLargestCustomerMember" name="SecondLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThirdLargestCustomerMember" name="ThirdLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" name="DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" name="DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" name="DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" name="DisclosureOfAssociatesBalanceSheetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AssociatesSummarizedFinancialInformationTableTextBlock" name="AssociatesSummarizedFinancialInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PurchasePriceAllocationAssociatesTableTextBlock" name="PurchasePriceAllocationAssociatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" name="GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OthersAssociatesMember" name="OthersAssociatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssociatesSummarizedFinancialInformationTable" name="AssociatesSummarizedFinancialInformationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PurchasePriceAllocationAssociatesTable" name="PurchasePriceAllocationAssociatesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareOfEstimatedNetAssets" name="ShareOfEstimatedNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" name="CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" name="AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsolidatedIncomeStatementEffectsTable" name="ConsolidatedIncomeStatementEffectsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareOfCurrentYearNetIncome" name="ShareOfCurrentYearNetIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PriorYearAdjustment" name="PriorYearAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" name="AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" name="TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" name="DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" name="AccrualForEnvironmentalLossContingenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" name="AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" name="AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" name="OtherLongtermEmployeeBenefitsAndDeferredCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherPostemploymentBenefits" name="OtherPostemploymentBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SolodynMember" name="SolodynMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContactLensesMember" name="ContactLensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GleevecMember" name="GleevecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReclastAclastaMember" name="ReclastAclastaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TekturnaRasilezValturnaMember" name="TekturnaRasilezValturnaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NAGAndNovartisPharmaSpAMember" name="NAGAndNovartisPharmaSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FHoffmanLaRocheAGAndRocheSpAMember" name="FHoffmanLaRocheAGAndRocheSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaKKMember" name="NovartisPharmaKKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NAGMember" name="NAGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NPCAndOthersMember" name="NPCAndOthersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNCMember" name="NovartisNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" name="ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" name="ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" name="EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" name="A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" name="A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" name="TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalFairValueAdjustmentsMember" name="TotalFairValueAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentPrepaidExpensesThirdParty" name="CurrentPrepaidExpensesThirdParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TaxotereMember" name="TaxotereMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmiodaroneMember" name="AmiodaroneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfEquityAbstract" name="DisclosureOfEquityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfEquityTextBlock" name="DisclosureOfEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendTableTextBlock" name="DividendTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseInNoncontrolingInterests" name="IncreaseDecreaseInNoncontrolingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfReportableSegments" name="NumberOfReportableSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfFranchises" name="NumberOfFranchises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsToRestructuringProvisions" name="AdditionsToRestructuringProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdParties" name="RevenueFromSaleOfGoodsThirdParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" name="RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" name="SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" name="InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" name="ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxExpenseIncomeDiscontinuingOperations" name="TaxExpenseIncomeDiscontinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments" name="EffectiveIncomeTaxRateReconciliationOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" name="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" name="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" name="OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BusinessUnitAxis" name="BusinessUnitAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BusinessUnitMember" name="BusinessUnitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OncologyMember" name="OncologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PharmaceuticalMember" name="PharmaceuticalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FranchiseAxis" name="FranchiseAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FranchiseMember" name="FranchiseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeuroscienceMember" name="NeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RespiratoryMember" name="RespiratoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CardioMetabolicMember" name="CardioMetabolicMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedMedicinesMember" name="EstablishedMedicinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProductPortfolioMember" name="ProductPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_COPDMember" name="COPDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GleevecGlivecMember" name="GleevecGlivecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TasignaMember" name="TasignaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandostatinMember" name="SandostatinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AfinitorVotubiaMember" name="AfinitorVotubiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExjadeJadenuMember" name="ExjadeJadenuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TafinlarMekinistMember" name="TafinlarMekinistMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PromactaRevoladeMember" name="PromactaRevoladeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OphthalmologyMember" name="OphthalmologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VotrientMember" name="VotrientMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JakaviMember" name="JakaviMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KisqaliMember" name="KisqaliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherProductsMember" name="OtherProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TravoprostGroupMember" name="TravoprostGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SystaneGroupMember" name="SystaneGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TopicalOlopatadineGroupMember" name="TopicalOlopatadineGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CosentyxMember" name="CosentyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeoralSandimmunEMember" name="NeoralSandimmunEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZortressCerticanMember" name="ZortressCerticanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IlarisMember" name="IlarisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MyforticMember" name="MyforticMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GilenyaMember" name="GilenyaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UltibroBreezhalerMember" name="UltibroBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SeebriBreezhalerMember" name="SeebriBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OnbrezBreezhalerMember" name="OnbrezBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EntrestoMember" name="EntrestoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VoltarenCataflamMember" name="VoltarenCataflamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExelonExelonPatchMember" name="ExelonExelonPatchMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RitalinFocalinMember" name="RitalinFocalinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" name="AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" name="AccumulatedImpairmentsOnDisposalsAndDerecognitions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquiredResearchAndDevelopmentMember" name="AcquiredResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconBrandNameMember" name="AlconBrandNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" name="GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" name="CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" name="OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeMaketableSecurities" name="OtherComprehensiveIncomeMaketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionForDoubtfulReceivableMember" name="ProvisionForDoubtfulReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" name="CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_Commodities" name="Commodities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OutstandingShareCapital" name="OutstandingShareCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IssuedCapitalMovement" name="IssuedCapitalMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OutstandingShareCapitalMovement" name="OutstandingShareCapitalMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesCancelledForCapitalReduction" name="SharesCancelledForCapitalReduction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesMovement" name="TreasurySharesMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EquityImpactOfTreasuryShareMovements" name="EquityImpactOfTreasuryShareMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageInterestRateOnLoansReceived" name="AverageInterestRateOnLoansReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" name="RatioFixedRateFinancialDebtToTotalFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AverageInterestRateOnBorrowings" name="AverageInterestRateOnBorrowings" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationNonCurrent" name="ContingentConsiderationNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnvironmentalProvisionRollForward" name="EnvironmentalProvisionRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvision" name="EnvironmentalProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionPayments" name="EnvironmentalProvisionPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionReleases" name="EnvironmentalProvisionReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionAdditions" name="EnvironmentalProvisionAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" name="EnvironmentalProvisionForeignCurrencyTranslationGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionCurrent" name="EnvironmentalProvisionCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalRemediationProvisionNoncurrent" name="EnvironmentalRemediationProvisionNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" name="EnvironmentalProvisionFiscalYearMaturityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" name="EnvironmentalProvisionExpectedCashOutflowNextTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" name="EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" name="EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" name="EnvironmentalProvisionExpectedCashOutflowAfterTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateAssociates" name="WeightedAverageInterestRateAssociates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" name="WeightedAverageInterestRateOnBankAndOtherFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationCurrentPortion" name="ContingentConsiderationCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProvisionForDeductionFromRevenueTable" name="ProvisionForDeductionFromRevenueTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionsAndOtherCurrentLiabilitiesTable" name="ProvisionsAndOtherCurrentLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestructuringProvisionsMovementsTable" name="RestructuringProvisionsMovementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RestructuringProvisionTransfers" name="RestructuringProvisionTransfers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" name="TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IdentifiableAssetsAcquired" name="IdentifiableAssetsAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashFlowFromNetIdentifiableAssets" name="CashFlowFromNetIdentifiableAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" name="PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" name="TechnologiesRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" name="FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InventoryRecognisedAsOfAcquisitionDivestmentDate" name="InventoryRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" name="TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" name="CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" name="CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" name="TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnimalHealthMember" name="AnimalHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromSaleOfBusiness" name="ProceedsFromSaleOfBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfBondsDiscount" name="AmortizationOfBondsDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentPortionOfNoncurrentFinancialDebt" name="CurrentPortionOfNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GenentechRocheMember" name="GenentechRocheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfContractsWithRelatedParties" name="NumberOfContractsWithRelatedParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfExecutiveCommiteeMembers" name="RelatedPartiesNumberOfExecutiveCommiteeMembers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfNonexecutiveDirectors" name="RelatedPartiesNumberOfNonexecutiveDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" name="DefinedBenefitPlanExpectedFutureBenefitPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EmployerSharesHeldByDefinedBenefitPlan" name="EmployerSharesHeldByDefinedBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" name="ValueOfEmployerSharesHeldByDefinedBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" name="AdministrativeExpenseNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" name="ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CashAndCashEquivalentsMember" name="CashAndCashEquivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetItemAxis" name="BalanceSheetItemAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetItemMember" name="BalanceSheetItemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquitySecuritiesMember" name="EquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FundInvestmentsMember" name="FundInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" name="TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationReceivablesMember" name="ContingentConsiderationReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" name="AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" name="TimeDepositsWithOriginalMaturityMoreThan90DaysMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" name="LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="AssociatedCompaniesAtFairValueThroughProfitAndLossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsMember" name="DerivativeFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GroupsOfFinancialAssetsLiabilitiesAxis" name="GroupsOfFinancialAssetsLiabilitiesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GroupsOfFinancialAssetsLiabilitiesMember" name="GroupsOfFinancialAssetsLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TradePayablesMember" name="TradePayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" name="InterestBearningAccountsOfAssociatesPayableOnDemandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BankAndOtherFinancialDebtMember" name="BankAndOtherFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommercialPaperMember" name="CommercialPaperMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentPortionOfNoncurrentDebtMember" name="CurrentPortionOfNoncurrentDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StraightBondsMember" name="StraightBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" name="LiabilitiesToBanksAndOtherFinancialInstitutionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinanceLeaseObligationsMember" name="FinanceLeaseObligationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" name="ContingentConsiderationAndOtherFinancialLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" name="DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" name="DerivativeFinancialInstrumentNatureOfInstrumentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" name="DerivativeFinancialInstrumentNatureOfInstrumentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" name="DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsPrincipalAmountsAxis" name="FinancialInstrumentsPrincipalAmountsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsPrincipalAmountsMember" name="FinancialInstrumentsPrincipalAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContractOrUnderlyingPrincipalAmoutMember" name="ContractOrUnderlyingPrincipalAmoutMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PositiveFairValuesMember" name="PositiveFairValuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NegativeFairValuesMember" name="NegativeFairValuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" name="DisclosureOfDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstruments" name="DerivativeFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" name="DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" name="DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" name="DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInvestmentsAndLongtermLoansGroupMember" name="FinancialInvestmentsAndLongtermLoansGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalAvailableforsaleMarketableSecuritiesMember" name="TotalAvailableforsaleMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableForSaleMarketableSecuritiesMember" name="AvailableForSaleMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableforsaleLongtermFinancialInvestmentsMember" name="AvailableforsaleLongtermFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtMember" name="CurrentFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentFinancialDebtMember" name="NoncurrentFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableforsaleFinancialInvestmentsMember" name="AvailableforsaleFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ValuedAtAmortizedCostMember" name="ValuedAtAmortizedCostMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationPayablesMember" name="ContingentConsiderationPayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialLiabilitiesMember" name="OtherFinancialLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" name="ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" name="IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAustriaGmbHViennaMember" name="NovartisAustriaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaGmbHViennaMember" name="NovartisPharmaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconOphthalmikaGmbHViennaMember" name="AlconOphthalmikaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozGmbHViennaMember" name="SandozGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" name="EBEWEPharmaGes.m.b.HNfg.KGViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBangladeshLimitedGazipurMember" name="NovartisBangladeshLimitedGazipurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" name="NovartisSecuritiesInvestmentLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" name="NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCanadaInc.MississaugaOntarioMember" name="AlconCanadaInc.MississaugaOntarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" name="CIBAVisionCanadaInc.MississaugaOntarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozCanadaInc.BouchervilleQuebecMember" name="SandozCanadaInc.BouchervilleQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisChileS.A.SantiagoDeChileMember" name="NovartisChileS.A.SantiagoDeChileMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" name="AlconLaboratoriosChileLtd.SantiagoDeChileMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" name="BeijingNovartisPharmaCo.Ltd.BeijingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" name="NovartisPharmaceuticalsHKLimitedHongKongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" name="SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" name="ShanghaiNovartisTradingLtd.ShanghaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconHongKongLimitedHongKongMember" name="AlconHongKongLimitedHongKongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" name="AlconChinaOphthalmicProductCo.Ltd.BeijingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" name="SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" name="SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisS.r.o.PragueMember" name="NovartisS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" name="AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.r.o.PragueMember" name="SandozS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcareASCopenhagenMember" name="NovartisHealthcareASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNordicASCopenhagenMember" name="AlconNordicASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozASCopenhagenMember" name="SandozASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisEcuadorS.A.QuitoMember" name="NovartisEcuadorS.A.QuitoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaS.A.E.CairoMember" name="NovartisPharmaS.A.E.CairoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" name="SandozEgyptPharmaS.A.E.NewCairoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinlandOyEspooMember" name="NovartisFinlandOyEspooMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" name="NovartisGroupeFranceS.A.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" name="NovartisPharmaS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" name="LaboratoiresAlconS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.A.S.LevalloisPerretMember" name="SandozS.A.S.LevalloisPerretMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeutschlandGmbHWehrMember" name="NovartisDeutschlandGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaGmbHNurembergMember" name="NovartisPharmaGmbHNurembergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaProduktionsGmbHWehrMember" name="NovartisPharmaProduktionsGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBusinessServicesGmbHWehrMember" name="NovartisBusinessServicesGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaGmbHFreiburgImBreisgauMember" name="AlconPharmaGmbHFreiburgImBreisgauMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_WaveLightGmbHErlangenMember" name="WaveLightGmbHErlangenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionGmbHGrosswallstadtMember" name="CIBAVisionGmbHGrosswallstadtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozInternationalGmbHHolzkirchenMember" name="SandozInternationalGmbHHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_HEXALAGHolzkirchenMember" name="HEXALAGHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SalutasPharmaGmbHBarlebenMember" name="SalutasPharmaGmbHBarlebenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1APharmaGmbHOberhachingMember" name="A1APharmaGmbHOberhachingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AeropharmGmbHRudolstadtMember" name="AeropharmGmbHRudolstadtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovistaInsuranceLimitedGibraltarCityMember" name="NovistaInsuranceLimitedGibraltarCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" name="NovartisHellasS.A.C.I.MetamorphosisAthensMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" name="AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" name="NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" name="SandozHungaryLimitedLiabilityCompanyBudapestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIndiaLimitedMumbaiMember" name="NovartisIndiaLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcarePrivateLimitedMumbaiMember" name="NovartisHealthcarePrivateLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPrivateLimitedMumbaiMember" name="SandozPrivateLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PT.NovartisIndonesiaJakartaMember" name="PT.NovartisIndonesiaJakartaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PT.CIBAVisionBatamBatamMember" name="PT.CIBAVisionBatamBatamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIrelandLimitedDublinMember" name="NovartisIrelandLimitedDublinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" name="NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" name="AlconLaboratoriesIrelandLimitedCorkCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIsraelLtd.PetachTikvaMember" name="NovartisIsraelLtd.PetachTikvaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OptonolLtd.NeveIlanMember" name="OptonolLtd.NeveIlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaS.p.A.OriggioMember" name="NovartisFarmaS.p.A.OriggioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconItaliaS.p.A.MilanMember" name="AlconItaliaS.p.A.MilanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.p.A.OriggioMember" name="SandozS.p.A.OriggioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIndustrialProductsS.p.A.RoveretoMember" name="SandozIndustrialProductsS.p.A.RoveretoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHoldingJapanK.K.TokyoMember" name="NovartisHoldingJapanK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaK.K.TokyoMember" name="NovartisPharmaK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconJapanLtd.TokyoMember" name="AlconJapanLtd.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozK.K.TokyoMember" name="SandozK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" name="NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" name="AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" name="CIBAVisionJohorSdn.Bhd.KualaLumpurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" name="AlconLaboratoriosS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.A.DeC.V.MexicoCityMember" name="SandozS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaMarocSACasablancaMember" name="NovartisPharmaMarocSACasablancaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNetherlandsB.V.ArnhemMember" name="NovartisNetherlandsB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaB.V.ArnhemMember" name="NovartisPharmaB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNederlandB.V.ArnhemMember" name="AlconNederlandB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozB.V.AlmereMember" name="SandozB.V.AlmereMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNewZealandLtdAucklandMember" name="NovartisNewZealandLtdAucklandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNorgeASOsloMember" name="NovartisNorgeASOsloMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaPakistanLimitedKarachiMember" name="NovartisPharmaPakistanLimitedKarachiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaLogisticsInc.PanamaCityMember" name="NovartisPharmaLogisticsInc.PanamaCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCentroamericaS.A.PanamaCityMember" name="AlconCentroamericaS.A.PanamaCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcarePhilippinesInc.ManilaMember" name="NovartisHealthcarePhilippinesInc.ManilaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPhilippinesCorporationManilaMember" name="SandozPhilippinesCorporationManilaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LekS.A.StrykowMember" name="LekS.A.StrykowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPortugalSGPSLda.PortoSalvoMember" name="NovartisPortugalSGPSLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" name="NovartisPharmaServicesRomaniaS.R.L.BucharestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconRomaniaS.R.L.BucharestMember" name="AlconRomaniaS.R.L.BucharestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.R.L.TarguMuresMember" name="SandozS.R.L.TarguMuresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaLLCMoscowMember" name="NovartisPharmaLLCMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconFarmacevtikaLLCMoscowMember" name="AlconFarmacevtikaLLCMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZAOSandozMoscowMember" name="ZAOSandozMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNevaLLCSt.PetersburgMember" name="NovartisNevaLLCSt.PetersburgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" name="SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSlovakiaS.r.o.BratislavaMember" name="NovartisSlovakiaS.r.o.BratislavaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LekPharmaceuticalsD.d.LjubjanaMember" name="LekPharmaceuticalsD.d.LjubjanaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPharmaceuticalsD.d.LjubjanaMember" name="SandozPharmaceuticalsD.d.LjubjanaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSouthAfricaPtyLtdMidrandMember" name="NovartisSouthAfricaPtyLtdMidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" name="AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozSouthAfricaPtyLtdKemptonParkMember" name="SandozSouthAfricaPtyLtdKemptonParkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisKoreaLtd.SeoulMember" name="NovartisKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconKoreaLtd.SeoulMember" name="AlconKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozKoreaLtd.SeoulMember" name="SandozKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCusiS.A.BarcelonaMember" name="AlconCusiS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIndustrialProductsS.A.BarcelonaMember" name="SandozIndustrialProductsS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" name="AbadiaRetuertaS.A.SardonDeDueroValladolidMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSverigeABStockholmMember" name="NovartisSverigeABStockholmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalAGBaselMember" name="NovartisInternationalAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHoldingAGBaselMember" name="NovartisHoldingAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalPharmaceuticalAGBaselMember" name="NovartisInternationalPharmaceuticalAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaAGBaselMember" name="NovartisPharmaAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaServicesAGBaselMember" name="NovartisPharmaServicesAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" name="NovartisPharmaSchweizerhalleAGMuttenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSteinAGSteinMember" name="NovartisPharmaSteinAGSteinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSchweizAGRischMember" name="NovartisPharmaSchweizAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconSwitzerlandSARischMember" name="AlconSwitzerlandSARischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalsLtd.FribourgMember" name="AlconPharmaceuticalsLtd.FribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozAGBaselMember" name="SandozAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPharmaceuticalsAGRischMember" name="SandozPharmaceuticalsAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTaiwanCo.Ltd.TaipeiMember" name="NovartisTaiwanCo.Ltd.TaipeiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisThailandLimitedBangkokMember" name="NovartisThailandLimitedBangkokMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesThailandLimitedBangkokMember" name="AlconLaboratoriesThailandLimitedBangkokMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" name="AlconLaboratuvarlariTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisMiddleEastFZEDubaiMember" name="NovartisMiddleEastFZEDubaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUKLimitedFrimleyCamberleyMember" name="NovartisUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" name="NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" name="NovartisGrimsbyLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" name="AlconEyeCareUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozLimitedFrimleyCamberleyMember" name="SandozLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" name="GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCorporationEastHanoverNYMember" name="NovartisCorporationEastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceCorporationNewYorkNYMember" name="NovartisFinanceCorporationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkNYMember" name="NovartisCapitalCorporationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" name="NovartisPharmaceuticalsCorporationEastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" name="NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" name="NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" name="NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisServicesInc.EastHanoverNYMember" name="NovartisServicesInc.EastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" name="AlconLaboratoriesHoldingCorporationFortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesInc.FortWorthTXMember" name="AlconLaboratoriesInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconRefractivehorizonsLLCFortWorthTXMember" name="AlconRefractivehorizonsLLCFortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconResearchLtd.FortWorthTXMember" name="AlconResearchLtd.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLensxInc.AlisoViejoCAMember" name="AlconLensxInc.AlisoViejoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozInc.PrincetonNJMember" name="SandozInc.PrincetonNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EonLabsInc.PrincetonNJMember" name="EonLabsInc.PrincetonNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" name="FougeraPharmaceuticalsInc.MelvilleNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeVenezuelaS.A.CaracasMember" name="NovartisDeVenezuelaS.A.CaracasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalC.A.CaracasMember" name="AlconPharmaceuticalC.A.CaracasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBiocienciasS.A.SaoPauloMember" name="NovartisBiocienciasS.A.SaoPauloMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" name="SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" name="NovartisDeColombiaS.A.SantafeDeBobotaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" name="LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" name="NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" name="NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" name="AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozFarmaceuticaLda.PortoSalvoMember" name="SandozFarmaceuticaLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaceuticaS.A.BarcelonaMember" name="NovartisFarmaceuticaS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozFarmaceuticaS.A.MadridMember" name="SandozFarmaceuticaS.A.MadridMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" name="NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" name="SandozIlacSanayiVeTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" name="SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsAdditionalDisclosureAbstract" name="FinancialInstrumentsAdditionalDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsCarryingValueLevel3" name="FinancialInstrumentsCarryingValueLevel3" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" name="GainsRecognisedInProfitOrLossFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" name="LossesRecognisedInProfitOrLossFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" name="FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisposalsFairValueMeasurementAssets" name="DisposalsFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReclassificationFairValueMeasurementAssets" name="ReclassificationFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" name="FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" name="MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" name="ReconciliationOfChangesInFairValueMeasurementAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MaturityOfNetDebtLineItems" name="MaturityOfNetDebtLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketableSecuritiesAndTimeDepositsMember" name="MarketableSecuritiesAndTimeDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommoditiesMember" name="CommoditiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="DeriviativeFinancialInstrumentsAndAccruedInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialDebtMember" name="FinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialDebtUndiscountedMember" name="FinancialDebtUndiscountedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" name="DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" name="PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" name="PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" name="DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContractualInterestOnNoncurrentLiabilities" name="ContractualInterestOnNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TenDayLossFairValueVARModelTable" name="TenDayLossFairValueVARModelTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TenDayLossFairValueVARModelLineItems" name="TenDayLossFairValueVARModelLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputation" name="FinancialInstrumentsValueAtRiskComputation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" name="FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" name="FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" name="FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_WorstCaseLossScenarioMember" name="WorstCaseLossScenarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" name="CashReceiptsAndPaymentsFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" name="AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForward" name="ScheduleOfUnvestedRestrictedStockUnitsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsMember" name="EquityBasedParticipationOtherShareAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareMovements" name="ShareMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NetInvestmentHedgeMember" name="NetInvestmentHedgeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsHeldByMarketMaker" name="WrittenCallOptionsHeldByMarketMaker" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsContractualLive" name="WrittenCallOptionsContractualLive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsContractualLiveRemaining" name="WrittenCallOptionsContractualLiveRemaining" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsWeightedAverageExercisePrice" name="WrittenCallOptionsWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PurchaseFairValueMeasurementAssets" name="PurchaseFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_StockRepurchaseProgramAuthorizedAmount1" name="StockRepurchaseProgramAuthorizedAmount1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" name="TaxRateEffectOfIncomeTaxedAtReducedRates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementsOfPropertyPlantAndEquipmentRollForward" name="MovementsOfPropertyPlantAndEquipmentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherAssetsProvisionsAccrualsMember" name="OtherAssetsProvisionsAccrualsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSingaporePteLtd.SingaporeMember" name="NovartisSingaporePteLtd.SingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" name="NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" name="NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" name="NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" name="AlconSingaporeManufacturingPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" name="CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPteLtdSingaporeMember" name="AlconPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" name="AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" name="SpinifexPharmaceuticalsInc.WilmingtonNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionInc.NewYorkNYMember" name="EncoreVisionInc.NewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInvestmentLtd.HamiltonMember" name="NovartisInvestmentLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceServicesLtd.HamiltonMember" name="NovartisFinanceServicesLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisB2Ltd.HamiltonMember" name="NovartisB2Ltd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisB3Ltd.HamiltonMember" name="NovartisB3Ltd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CibaGeigyJapanLimitedTokyoMember" name="CibaGeigyJapanLimitedTokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" name="NovartisInternationalPharmaceuticalInvestmentAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBioventuresAGBaselMember" name="NovartisBioventuresAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisForschungsstiftungBaselMember" name="NovartisForschungsstiftungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" name="NovartisMitarbeiterbeteiligungsstiftungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" name="FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" name="ZiarcoGroupLimitedFrimleyCamberleySurreyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VivactaLimitedFrimleyCamberleySurreyMember" name="VivactaLimitedFrimleyCamberleySurreyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUSFoundationNewYorkNYMember" name="NovartisUSFoundationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CortheraInc.SanMateoCAMember" name="CortheraInc.SanMateoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" name="CoStimPharmaceuticalsInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ClarVistaMedicalInc.AlisoViejoCAMember" name="ClarVistaMedicalInc.AlisoViejoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" name="TriangleInternationalReinsuranceLimitedHamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" name="TrinityRiverInsuranceCoLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisStiftungFuerKaderausbildungBaselMember" name="NovartisStiftungFuerKaderausbildungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" name="NovartisStiftungFuerMenschUndUmweltBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" name="StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" name="SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" name="DisclosureOfAssociatesNetIncomeEffectTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" name="DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" name="DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" name="DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" name="DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" name="GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" name="DebtSecuritiesBreakdownByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SummaryOfTreasurySharesMovementsTableTextBlock" name="SummaryOfTreasurySharesMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" name="USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" name="ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" name="ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDefinedContributionPlansTableTextBlock" name="ScheduleOfDefinedContributionPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" name="ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" name="DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" name="DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" name="DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" name="DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" name="DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" name="DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReprixysPharmaceuticalsCorporationMember" name="ReprixysPharmaceuticalsCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" name="TaxRateEffectOfReleaseOfContingentConsiderationLiability" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromNondeductibleLossesInRegion" name="TaxRateEffectFromNondeductibleLossesInRegion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeferredTaxAssetAndLiabilityValuationAbstract" name="DeferredTaxAssetAndLiabilityValuationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" name="ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" name="ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" name="ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" name="ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" name="ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactLocationAxis" name="ImpactLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactLocationMember" name="ImpactLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementMember" name="IncomeStatementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UndiscountedOperatingLeaseCommitments" name="UndiscountedOperatingLeaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContributionOfBusinessToJointVenture" name="ContributionOfBusinessToJointVenture" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" name="PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" name="ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" name="ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" name="ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" name="AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" name="PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherIntangiblePurchaseCommitments" name="OtherIntangiblePurchaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" name="ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OpenHedgesForAnticipatedTransactions" name="OpenHedgesForAnticipatedTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MostSignificantForeignExchangeLosses" name="MostSignificantForeignExchangeLosses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LongtermFinancialDebtWithACarryingAmount" name="LongtermFinancialDebtWithACarryingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" name="UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" name="NetInvestmentHedgeRecognizedInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_UpperLimitOnHoldingsOnUnrelatedCompany" name="UpperLimitOnHoldingsOnUnrelatedCompany" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" name="BorrowingsCommercialPaperMaximumBorrowingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DebtEquityRatio" name="DebtEquityRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_VAREstimateConfidenceInterval" name="VAREstimateConfidenceInterval" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" name="BorrowingsCommercialPaperMaximumAmountOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityCommitted" name="BorrowingsCreditFacilityCommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_CounterpartyRiskAbstract" name="CounterpartyRiskAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" name="CashAndCashEquivalentsHeldWithFinancialInstitution" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VendorAxis" name="VendorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VendorMember" name="VendorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LargestFinancialInstitutionMember" name="LargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SecondLargestFinancialInstitutionMember" name="SecondLargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThirdLargestFinancialInstitutionMember" name="ThirdLargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PreTaxProfitLossFromDivestmentOfBusiness" name="PreTaxProfitLossFromDivestmentOfBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" name="DivestmentDateFairValueOfTotalConsiderationTransferred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FuturePutOptionToSellBusiness" name="FuturePutOptionToSellBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentPutOption" name="PaymentPutOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestExchanged" name="InterestExchanged" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LiabilitiesToBanksAndOtherInstitutions" name="LiabilitiesToBanksAndOtherInstitutions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationReceivableCurrent" name="ContingentConsiderationReceivableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfDivestmentsOtherProvisions" name="ImpactOfDivestmentsOtherProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfFinancialInstrumentsNarrativeTable" name="DisclosureOfFinancialInstrumentsNarrativeTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CustomersWithNetSalesOverFivePercent" name="CustomersWithNetSalesOverFivePercent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" name="NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationReceivablesShorttermMember" name="ContingentConsiderationReceivablesShorttermMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OptionsExcludedFromTheCalculation" name="OptionsExcludedFromTheCalculation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MilestonePaymentAlreadyReceived" name="MilestonePaymentAlreadyReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_USCommercialPaperProgramsMember" name="USCommercialPaperProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JPCommercialPaperProgramsMember" name="JPCommercialPaperProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperNumberOfPrograms" name="BorrowingsCommercialPaperNumberOfPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsAAAMember" name="AdvancedAcceleratorApplicationsAAAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalInTenderOffer" name="PercentageOfShareCapitalInTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOfferPerOrdinaryShare" name="CashOfferPerOrdinaryShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOfferPerADS" name="CashOfferPerADS" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NumberOfOrdinarySharePerADS" name="NumberOfOrdinarySharePerADS" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ValueOfEquity" name="ValueOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MaximalAmountOfShareBuybackProgramm" name="MaximalAmountOfShareBuybackProgramm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAnnualIncentive" name="DescriptionOfAnnualIncentive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfBusinessUnits" name="NumberOfBusinessUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" name="RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonCurrentFinancialDebtsMember" name="NonCurrentFinancialDebtsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContractRightOfFirstNegotiationTerm" name="ContractRightOfFirstNegotiationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IntangibleAssetImpairmentChargesTextBlock" name="IntangibleAssetImpairmentChargesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" name="PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" name="AcquisitionFairValuePotentiallyRefundableContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentFairValueOfContingentConsiderationReceived" name="DivestmentFairValueOfContingentConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" name="AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" name="MaximumMarginPercentageImpactOfCommodityPriceChange" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MaximumHoldingInUnrelatedCompany" name="MaximumHoldingInUnrelatedCompany" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialReceivableFromDivestment" name="PotentialReceivableFromDivestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ChangeOverPeriodAxis" name="ChangeOverPeriodAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BasisOfPreparationAbstract" name="BasisOfPreparationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SelectedCriticalAccountingPoliciesAbstract" name="SelectedCriticalAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LegalProceedingsUpdateAbstract" name="LegalProceedingsUpdateAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LegalProceedingsUpdateTextBlock" name="LegalProceedingsUpdateTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" name="ImpactsOfAdoptionOfNewIFRSStandardsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" name="ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" name="DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" name="DescriptionOfAccountingPolicyForOtherRevenueTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" name="ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" name="ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" name="FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" name="DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" name="DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AveXisIncMember" name="AveXisIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OCIReservesMember" name="OCIReservesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetailGenericsMember" name="RetailGenericsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BiopharmaceuticalsMember" name="BiopharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AntiInfectivesMember" name="AntiInfectivesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SurgicalMember" name="SurgicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VisionCareMember" name="VisionCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsumablesMember" name="ConsumablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImplantablesMember" name="ImplantablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquipmentOtherMember" name="EquipmentOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OphthalmicOTCMember" name="OphthalmicOTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContactLensCareMember" name="ContactLensCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Top20ProductsMember" name="Top20ProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestOfPortfolioMember" name="RestOfPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProfitSharingIncome" name="ProfitSharingIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MilestoneIncome" name="MilestoneIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherRevenueOther" name="OtherRevenueOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" name="ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CanadaAndLatinAmericaMember" name="CanadaAndLatinAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" name="RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedMarketsMember" name="EstablishedMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EmergingGrowthMarketsMember" name="EmergingGrowthMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestOfTheWorldMember" name="RestOfTheWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.5EUR750Million20182023OfNovartisMember" name="A0.5EUR750Million20182023OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.375EUR750Million20182030OfNovartisMember" name="A1.375EUR750Million20182030OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.7EUR750Million20182038OfNovartisMember" name="A1.7EUR750Million20182038OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GalvusGroupMember" name="GalvusGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DiovanGroupMember" name="DiovanGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExforgeGroupMember" name="ExforgeGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImmunologyHepatologyAndDermatologyMember" name="ImmunologyHepatologyAndDermatologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AntiInfectivesSoldUnderSandozNameMember" name="AntiInfectivesSoldUnderSandozNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsOnFinancialAssetsSold" name="FairValueAdjustmentsOnFinancialAssetsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProductPortfolioAxis" name="ProductPortfolioAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherSharePurchasesValue" name="OtherSharePurchasesValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LutatheraMember" name="LutatheraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KymriahMember" name="KymriahMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" name="PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" name="ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" name="TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquityTextBlock" name="TransactionCostsRecordedInEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TransactionsWithRelatedPartiesAbstract" name="TransactionsWithRelatedPartiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionsWithRelatedPartiesTextBlock" name="TransactionsWithRelatedPartiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquityPaid" name="TransactionCostsRecordedInEquityPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquity" name="TransactionCostsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" name="OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPensionFundMember" name="NovartisPensionFundMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityUncommitted" name="BorrowingsCreditFacilityUncommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherNetAssets" name="OtherNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OcularHealthMember" name="OcularHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" name="AdvancedAcceleratorApplicationsInternationalSAGeneveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" name="AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AveXisInc.BannockburnILMember" name="AveXisInc.BannockburnILMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" name="AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisposalGroupHeldForSaleAbstract" name="DisposalGroupHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisposalGroupHeldForSaleLineItems" name="DisposalGroupHeldForSaleLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" name="ChangeInCashSettledShareBasedPaymentsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowNoncontrollingInterests" name="CashInflowOutflowNoncontrollingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountRecordedInEquityRelatedToHyperinflation" name="AmountRecordedInEquityRelatedToHyperinflation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsToInvestmentInAssociatedCompanies" name="AdditionsToInvestmentInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" name="FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" name="OtherComprehensiveIncomeNetOfTaxDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" name="GainOnDivestmentOfInterestsInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnDebtSecuritiesMember" name="FairValueAdjustmentsOnDebtSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnEquitySecuritiesMember" name="FairValueAdjustmentsOnEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" name="ReclassificationToPresentationRequiredUnderIFRS9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestatedValueAdjustmentsMember" name="RestatedValueAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsEquityInvestments" name="NoncurrentFinancialAssetsEquityInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsFundInvestments" name="NoncurrentFinancialAssetsFundInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ListedEquitySecuritiesMember" name="ListedEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonlistedEquitySecuritiesMember" name="NonlistedEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteMember" name="EndocyteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" name="DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" name="DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" name="DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" name="DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" name="DivestmentsAquisitionsOfInterestsInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherShareSales" name="OtherShareSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherShareSalesEquityImpact" name="OtherShareSalesEquityImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOtherShareSales" name="NumberOfOtherShareSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOtherShareSalesEquityImpact" name="NumberOfOtherShareSalesEquityImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeDebtSecurities" name="OtherComprehensiveIncomeDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeEquitySecurities" name="OtherComprehensiveIncomeEquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" name="NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" name="NovartisAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPtyLtdMacquarieParkNSWMember" name="SandozPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" name="AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaNVVilvoordeMember" name="NovartisPharmaNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozNVVilvoordeMember" name="SandozNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCouvreurNVPuursMember" name="AlconCouvreurNVPuursMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesBelgiumBVBAPuursMember" name="AlconLaboratoriesBelgiumBVBAPuursMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNVVilvoordeMember" name="AlconNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconAGFribourgMember" name="AlconAGFribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" name="AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionCorporationLLCDuluthGAMember" name="CIBAVisionCorporationLLCDuluthGAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" name="ReprixysPharmaceuticalsCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPolandSp.ZO.o.WarsawMember" name="NovartisPolandSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPolskaSp.ZO.o.WarsawMember" name="SandozPolskaSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPolskaSp.ZO.o.WarsawMember" name="AlconPolskaSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconHealthcareS.A.BarcelonaMember" name="AlconHealthcareS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOphthalmicsAGFribourgMember" name="NovartisOphthalmicsAGFribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozUkraineLLCKievMember" name="SandozUkraineLLCKievMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentCostToSell" name="DivestmentCostToSell" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountOfSettlementInPrinciple" name="AmountOfSettlementInPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" name="NavigateBioPharmaServicesInc.CarlsbadCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfProductsInPortfolioToBeSold" name="NumberOfProductsInPortfolioToBeSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CarryingValueOfTheDivestedBusiness" name="CarryingValueOfTheDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ShortTermLeasesAndLowValueLeases" name="ShortTermLeasesAndLowValueLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RemainingLeaseCommitments" name="RemainingLeaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesToBeRecognized" name="LeaseLiabilitiesToBeRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RightOfUseAssetsToBeRecognized" name="RightOfUseAssetsToBeRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" name="NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" name="NovartisInvestmentsS.aR.l.LuxembourgCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceS.A.LuxembourgCityMember" name="NovartisFinanceS.A.LuxembourgCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TearFilmInnovationsInc.FortWorthTXMember" name="TearFilmInnovationsInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TrueVisionSystemsInc.FortWorthTXMember" name="TrueVisionSystemsInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TranscendMedicalInc.LakeForestILMember" name="TranscendMedicalInc.LakeForestILMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBalticsSIARigaMember" name="NovartisBalticsSIARigaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOverseasInvestmentsAGBaselMember" name="NovartisOverseasInvestmentsAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JapatAGBaselMember" name="JapatAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconManagementSAGenevaMember" name="AlconManagementSAGenevaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteInc.LafayetteINMember" name="EndocyteInc.LafayetteINMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OrielTherapeuticsInc.DurhamNCMember" name="OrielTherapeuticsInc.DurhamNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_WaveLightInc.SterlingVAMember" name="WaveLightInc.SterlingVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBiosciencesPeruS.A.LimaMember" name="NovartisBiosciencesPeruS.A.LimaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesWithRestrictedUse" name="TreasurySharesWithRestrictedUse" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentForRepurchaseOwnShares" name="CommitmentForRepurchaseOwnShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAsstetsDebtSecurities" name="NoncurrentFinancialAsstetsDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" name="AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" name="DepreciationChargePriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProformaNetSales" name="ProformaNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SerelaxinMember" name="SerelaxinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CyPassMember" name="CyPassMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeStatementAdjustmentsOfPriorYear" name="IncomeStatementAdjustmentsOfPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeStatementAdjustmentsOfCurrentYear" name="IncomeStatementAdjustmentsOfCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PlansAndProgramRebatesAxis" name="PlansAndProgramRebatesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" name="AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" name="ImpairmentChargesRelatedToDisposalGroupHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" name="ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" name="AdditionsIncludedInDisposalGroupToTheDateOfReclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" name="NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentAssetsDivested" name="NoncurrentAssetsDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAssetsDivested" name="CurrentAssetsDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentLiabilitiesDivested" name="CurrentLiabilitiesDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssets" name="FinancialAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" name="CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradePayablesAndOtherLiabilities" name="TradePayablesAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" name="CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" name="LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" name="MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PlansAndProgramRebatesMember" name="PlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_USspecificHealthcarePlansAndProgramRebatesMember" name="USspecificHealthcarePlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" name="NonUSspecificHealthcarePlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" name="NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" name="UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice46.7Member" name="ExercisePrice46.7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice54.5Member" name="ExercisePrice54.5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.0Member" name="ExercisePrice57.0Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.6Member" name="ExercisePrice57.6Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice66.0Member" name="ExercisePrice66.0Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice46.4Member" name="ExercisePrice46.4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice53.7Member" name="ExercisePrice53.7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.1Member" name="ExercisePrice57.1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice58.3Member" name="ExercisePrice58.3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice66.1Member" name="ExercisePrice66.1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrepaymentsAndAccruedLeasePayments" name="PrepaymentsAndAccruedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" name="RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" name="AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" name="LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationPriorToClassificationToAssetsHeldForSale" name="AmortizationPriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" name="NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongTermFinancialInvestmentsMember" name="LongTermFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MarketableSecurities" name="MarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MajorPlansPercentageInGroupDBOPensions" name="MajorPlansPercentageInGroupDBOPensions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" name="MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" name="NoncurrentFinancialAssetsTotalFinancialInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" name="NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" name="DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDiscontinuedOperationsAbstract" name="DisclosureOfDiscontinuedOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YoYChangeMember" name="YoYChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PresentationOfLeasesForLessesTable" name="PresentationOfLeasesForLessesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PresentationOfLeasesForLesseeLineItems" name="PresentationOfLeasesForLesseeLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NewLeaseArrangements" name="NewLeaseArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UndiscountedFutureLeasePayments" name="UndiscountedFutureLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfDiscounting" name="EffectOfDiscounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentStatedMember" name="CurrentStatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOrIssueOfTreasurySharesNumberOfShares" name="SaleOrIssueOfTreasurySharesNumberOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DetailedInformationAboutSignificantTransaction" name="DetailedInformationAboutSignificantTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IFMTreInc.Member" name="IFMTreInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PowerVisionInc.Member" name="PowerVisionInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" name="AdjustmentsForPrepaymentsAndAccruedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialMilestoneMaximumPayments" name="PotentialMilestoneMaximumPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" name="NumberOfEmployeesAssociatedWithTheProductTransfer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionalBorrowings" name="AdditionalBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageOfEquityInterestSharesReceived" name="PercentageOfEquityInterestSharesReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" name="DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" name="DistributionOfDividendBearingSharesToConsolidatedFoundations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AimovigMember" name="AimovigMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" name="LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughExerciseOfOptionsShares" name="IncreaseDecreaseThroughExerciseOfOptionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" name="IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepaymentOfLeaseLiability" name="RepaymentOfLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateLeaseLiabilities" name="WeightedAverageInterestRateLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementsOfTheRightofuseAssetsRollForward" name="MovementsOfTheRightofuseAssetsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseContractTerminationsRightofuseAssets" name="LeaseContractTerminationsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" name="IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" name="SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesOnTreasuryShares" name="TaxesOnTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseIncentives" name="LeaseIncentives" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowForLeases" name="CashInflowForLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetAssetsDerecognized" name="NetAssetsDerecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionOfDividendToDividendBearingShares" name="DistributionOfDividendToDividendBearingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" name="DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" name="NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsAttributableToDivestedBusiness" name="CashFlowsAttributableToDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherNoncurrentAssets" name="FinancialAndOtherNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssets" name="TradeReceivablesAndOtherCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradePayablesProvisionsAndOtherLiabilities" name="TradePayablesProvisionsAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNoncurrentFinancialDebt" name="CurrentAndNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" name="RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" name="ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" name="DisclosureOfRightofuseAssetsRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" name="DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" name="DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" name="AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentLeaseLiabilitiesMember" name="NoncurrentLeaseLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentLeaseLiabilitiesMember" name="CurrentLeaseLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ApplicableTaxRateExcludingExceptionalItems" name="ApplicableTaxRateExcludingExceptionalItems" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" name="CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestedCashAndCashEquivalents" name="DivestedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CustomaryPurchasePriceAdjustment" name="CustomaryPurchasePriceAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepaymentOfIntercompanyBalances" name="RepaymentOfIntercompanyBalances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" name="TaxReformImpactOnDeferredTaxOnTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendPaidNoncashAssetsDistribution" name="DividendPaidNoncashAssetsDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" name="DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" name="ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" name="DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" name="DisclosureOfNetAssetsDerecognizedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" name="FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionByWayOfDivindendInKindToShareholders" name="DistributionByWayOfDivindendInKindToShareholders" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TheMedicinesCompanyMember" name="TheMedicinesCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PiqrayMember" name="PiqrayMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZolgensmaMember" name="ZolgensmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MayzentMember" name="MayzentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" name="DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" name="DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" name="DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" name="AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" name="NetDeferredTaxBalanceRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AspenGlobalIncorporatedMember" name="AspenGlobalIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" name="MinimumFinaceLeasePaymentsReceivableAtPresentValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" name="InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReclassificationFromNoncurrentToCurrentNet" name="ReclassificationFromNoncurrentToCurrentNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationPayable" name="ContingentConsiderationPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BorrowingsUSDMember" name="BorrowingsUSDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BorrowingsEURMember" name="BorrowingsEURMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinanceLeaseLiabilities" name="FinanceLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EquityBasedCompensationShares" name="EquityBasedCompensationShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" name="ExerciseOfOptionsAndEmployeeTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExerciseOfOptionsAndEmployeeTransactionsValue" name="ExerciseOfOptionsAndEmployeeTransactionsValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesDeliveredToDivestedBusinessEmployees" name="SharesDeliveredToDivestedBusinessEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" name="PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" name="NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" name="DerivativeFinancialInstrumentsOptionsOnEquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" name="EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionalAmountOfSettlementInPrinciple" name="AdditionalAmountOfSettlementInPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfResolvedAction" name="AmountOfResolvedAction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnoxaparinMember" name="EnoxaparinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozManufacturingInc.Member" name="SandozManufacturingInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" name="ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" name="SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CELLforCUREMember" name="CELLforCUREMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisManufacturingGmbHMember" name="NovartisManufacturingGmbHMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" name="NovartisHungaryHealthcareLimitedLiabilityCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" name="AdvacedAcceleratorApplicationsItalyS.r.l.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IDBHollandBVMember" name="IDBHollandBVMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" name="AdvacedAcceleratorApplicationsIbericaS.L.U.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImagingEquipmentLtdMember" name="ImagingEquipmentLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInflammasomeResearchInc.Member" name="NovartisInflammasomeResearchInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTechnologyLLCMember" name="NovartisTechnologyLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" name="PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" name="PartialReleaseOfDeferredTaxLiabilityRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesUndiscounted" name="LeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MostMaterialLeaseWithLeaseTermExtension" name="MostMaterialLeaseWithLeaseTermExtension" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsForShortTermAndLowValueLeases" name="CashOutflowsForShortTermAndLowValueLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsForPaymentsOfLeasesInterest" name="CashOutflowsForPaymentsOfLeasesInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" name="ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" name="ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LongTermReceivablesFromFinanceSubleases" name="LongTermReceivablesFromFinanceSubleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" name="DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityShortTerm" name="BorrowingsCreditFacilityShortTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_BeovuMember" name="BeovuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashOutflowsFromDivestments" name="NetCashOutflowsFromDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentLiabilitiesMember" name="CurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentLiabilitiesMember" name="NoncurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentLeaseLiabilitiesUndiscounted" name="CurrentLeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentLeaseLiabilitiesUndiscounted" name="NoncurrentLeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" name="ImpairmentChargePriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxOnTransactionCostsRecordedInEquity" name="TaxOnTransactionCostsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfWriteoffOfDeferredTaxAssets" name="EffectOfWriteoffOfDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromCurrentAndNoncurrentBorrowings" name="ProceedsFromCurrentAndNoncurrentBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" name="UncalledCapitalCommitmentsForInvestmentsInFunds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_LitigationCaseMember" name="LitigationCaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TennesseeClassActionMember" name="TennesseeClassActionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MassachusettsCaseMember" name="MassachusettsCaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossDeferredTaxAssets" name="GrossDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GrossDeferredTaxLiabilities" name="GrossDeferredTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountBorrowedUnderTheCreditFacility" name="AmountBorrowedUnderTheCreditFacility" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationLiabilities" name="ContingentConsiderationLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_XiidraMember" name="XiidraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfEntitysTradeReceivable" name="PercentageOfEntitysTradeReceivable" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowForSaleAndLeaseback" name="CashInflowForSaleAndLeaseback" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SaleAndLeaseBackMember" name="SaleAndLeaseBackMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" name="DerivativeFinancialInstrumentsCommodityPurchaseContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DisposalsAndRetirementsRightofuseAssets" name="DisposalsAndRetirementsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" name="EffectOfIncomeNotSubjectToTaxOnDivestmentGain" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" name="SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CELLforCURELesUlisMember" name="CELLforCURELesUlisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" name="AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNetherlandsB.V.AmsterdamMember" name="NovartisNetherlandsB.V.AmsterdamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaB.V.AmsterdamMember" name="NovartisPharmaB.V.AmsterdamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IDBHollandBVBaarleNassauMember" name="IDBHollandBVBaarleNassauMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSaudiLtd.RiyadhMember" name="NovartisSaudiLtd.RiyadhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.EspluguesDeLlobregatMember" name="AdvancedAcceleratorApplicationsIbericaS.L.U.EspluguesDeLlobregatMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUKLimitedLondonMember" name="NovartisUKLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsUKLimitedLondonMember" name="NovartisPharmaceuticalsUKLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGrimsbyLimitedLondonMember" name="NovartisGrimsbyLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImagingEquipmentLtdLondonMember" name="ImagingEquipmentLtdLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedLondonMember" name="ZiarcoGroupLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceCorporationEastHanoverNJMember" name="NovartisFinanceCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationEastHanoverNJMember" name="NovartisCapitalCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUSFoundationEastHanoverNJMember" name="NovartisUSFoundationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" name="AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" name="NovartisInflammasomeResearchInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" name="NovartisTechnologyLLCInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionInc.EastHanoverNJMember" name="EncoreVisionInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteInc.EastHanoverNJMember" name="EndocyteInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" name="NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" name="SpinifexPharmaceuticalsInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisManufacturingGmbHMarburgMember" name="NovartisManufacturingGmbHMarburgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfUSTaxReformLegislation" name="EffectOfUSTaxReformLegislation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquiredCashAndCashEquivalents" name="AcquiredCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" name="DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" name="ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BalanceSheetAdditionalInformationTableTextBlock" name="BalanceSheetAdditionalInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" name="CashFlowsUsedInInvestingActivitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" name="CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UltibroGroupMember" name="UltibroGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdakveoMember" name="AdakveoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReportedValueMember" name="ReportedValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" name="NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PoPChangeMember" name="PoPChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PoPYEChangeMember" name="PoPYEChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZPL389Member" name="ZPL389Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfOtherFinancialAssetsSold" name="FairValueOfOtherFinancialAssetsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RightOfUseAssetsAsOfAcquisitionDate" name="RightOfUseAssetsAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" name="CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" name="FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ReclassificationOfExportSales" name="ReclassificationOfExportSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrepaidSalesPriceForABusinessDivestment" name="PrepaidSalesPriceForABusinessDivestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" name="DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>logo.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X0O 17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  "OR    G
M$  *_(   "<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S #(P,3 Z,#<Z
M,34@,#DZ-#@Z,#       Z !  ,    !  $  * "  0    !    R* #  0
M   !    (P         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   J*
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ ' "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M         0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:  P# 0 "$0,1 #\ [[JG67]+ZCAUW /P\TFLN&CZ[ 6AK_Y=
M+_4]_P#HOYS_ (-<_P!?QP[_ !@=*@?SC:WGXUNO=_Z+4NHV/Z]]:Z<*J3C8
M3]KB.PK<U^6_^U8QF,M/JV.#]<.AW=S7E _V&-V_^?DWD\IEDS'] <48?X,/
M6R?$N7C'#RP(K)+AGD']663]7_A</S/1)*G=FG&RV57@"F_^:L'9PY99]_TU
M<0ADC,RB#ZH'AG']*/;_ !OT5LHD $[2%@J20<N\X^+=D!N\TUNL#9B=H+MN
MZ';55Z)UK$ZU@,S,8Q.EM1,NK?\ G5O_ -?>I.$UQ5ILLXAQ<-^HBZ=!)9F%
MU7+R>K9?3K,9E0PFUNLM;:7[A<'NI]-GHU_Z)WJ[W^S_ (1-F=:V9XZ7@4?;
M,\,%EK-XKKJ83[79-^VS8Y_^#JKJMM_ZVCP2NO"_HCW(U=]>'8_-Y.HDL+)^
MLE_3,JJKK6&,3&O=LJS:;?6IW<[+]U6-;1_VW_U%BG]8.OY'1/2M?B,MQ+K&
MU>OZI;L<X3-U?HV;:_:_WU^JB,<B0 /FVUW6G+  DGY?FT/I^CM)*CUCJ1Z7
MTN[J#F-L]!H<ZLN+9DANQCA79[W.=LK]B-3D6C#^T9];<5S6E]K _P!0, &X
M[K=E?T6_33>$U?2Z7<0OAZ@<7T\VPDLWH'6JNM]-9GUL]+<YS'U3N+2TZ!SH
M;]*O99_;0_K#UN[HN*W+&,W)I+VUN'J>FX.>=K(::WM<S_KB/!+BX*]5U2#D
MB(<=^FKMUDEC4?6"UO5Z^D=2PSB9&0TOQK&/%M5@:-SV^IMJ>RSV_0?7_P"B
MU8SL[JM66VC!Z?\ :V; ^R]]HI8TN<YK:V[J[/4=[-]FWZ'Z/_2)<$KK347N
M*_QE>Y$BQ>AX=I<5_P!WYG127-XOUFZOFT9-V)T@6C#M?1:P9(#C96 YXK'H
M?I/I>U:G6>J6],Z59U%M N%+0^VHO+#M/.P^F_<_=^:_TT3CD"!I9-;A RP,
M3(70%_+(:.@DJO3,NW-P*,NRMM)R&-M:QKB^&O >S<XLJ]^UWO\ :LUOU@SL
MFB_,Z=@-R<*BUU0>Z[T[7^F[T[[:L<4VM]-GOV>K?59;_HT!"1)';3=<<D0
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M,_X.JS]$NEZ#Z?[*Q_1];[/Z;?L_VC9O]+:WTOYC^1^_^E7.XO[,^PX'VO\
M:?[#]1GV;[7Z/V?G]3^T^C^O?9=_I_9_M?ZO_-^M^C1A\TSO'](']W_OOW49
M-88QJ)$>B0W$O^\_??_9_^T04%!H;W1O<VAO<" S+C  .$))300E       0
M                     #A"24T#[0      $ !(     0 " $@    !  (X
M0DE-!"8       X             /X   #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     TD    &               C    R     H 3@!6 %, ( !# $T 60!+
M "T 0P    $                          0              R    ",
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ",
M    4F=H=&QO;F<   #(    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<    C     %)G:'1L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     (X0DE-! P     "J8
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M_JW-Z#?;TWZU9?3KL=V%1U1OVK&H<YCMKVB+=OH.?4WU-MO_ &U6K7^,&?\
MF_IS]HICX[E+ZT?LO]H=*^U?:OMWJ/\ L/V/;NW35O\ 4]7V[?H?2]FSU?42
M^M_V#]DT?M?[7]EWMW_9_3W>I'Z+UH_E?Z#]'ZG_ %I&_P!;C-5+3BC^2TBL
M&4 W#U<$O#]+_%DA;DOL^M^/7URMN/=30?V4*W%]+WV>W+?ZKV5/^T;6M972
MZO\ ]$KJ5SOUD_8_[*Q_VWZ_K>H/LOI[?M?JSIZ'V7V>I_4_1?\ 7/36M@^O
M^SQO^T>IL.WU_2]?CV[O2_0>I_7_ .NJ/)1$3MIM^C7[T6;%8,AOK=_I7^[-
MQOJ/_1^K?^G/(_ZFI6_KE_XF.H_\5_WYJJ_5'[!NS/V=]M]+UW_:OM7I[?M$
M-]7Z/Z7U/H[MGZ-7?K3]D_8M_P!N]?['I]I^S;=^R?\ A/S-^S=Z?O\ [&].
M/\^/[T5D?]SG^[)L="_Y#Z=_X5I_\]L7,YM.;]5\H];Z7;]HZ'EV-MRL8$$-
M%I'Z6G\WW;OT-C/^#JL_1+I>@^G^RL?T?6^S^FW[/]HV;_2VM]+^8_D?O_I5
MSN+^S/L.!]K_ &G^P_49]F^U^C]GY_4_M/H_KWV7?Z?V?[7^K_S?K?HT8?-,
M[Q_2!_=_[[]U&36&,:B1'HD-Q+_O/WW_V3A"24T$(0      50    $!
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M  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8
M 0    #3+4A0("
M                 !%C<')T   !4    #-D97-C   !A    &QW='!T   !
M\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:
M   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V
M:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,
M  QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0
M9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="
M($E%0S8Q.38V+3(N,0
M                        6%E:(        /-1  $    !%LQ865H@
M                 %A96B        !OH@  ./4   .06%E:(        &*9
M  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE
M8RYC:
M      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M        9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG
M($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A9
M6B       $P)5@!0    5Q_G;65A<P         !
M     H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9
M !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8
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M949#!5M?20Y"&DKX)7A9Q(L<T;$:74FMY87^W2K!N%E-!,5U!9$9&*DD @,
M:5!%>%01Y=7VS>-HWNW>ZV;=+:[M5<H7AE25 X )4LC, P#*2I-:$&E".L._
M.R>NNK,(VYNSM_;*ZYVXLH@;<&_-TX+:&$6<H\@A;*[@K\?0"4QQLVGR7TJ3
M]![W8[=N&YS?3;;837%Q2NF)&D:G^E0$_P NJ[MO>S;#:F^WS=[6RLJT\2>5
M(4KQIKD95K^?2%V!\FOC=VQF3MSJSY!](=E[A6(SM@M@=K[#WEF1 JNS3'%[
M=S^1KA$JQL2VBP"G^A]KK_EOF+:H?J-SV"]MK>M-4L$L:U_TSJ!_/HJVCGCD
MKF"Y^BV'F_:[Z\I7P[>[@F>GKICD9J8/ETOMZ]B=?]:XRFS78V^=G; PU971
MXNDRV]=S87:N,JLG+3U-7%CJ:OSM;04L]=)2T<TJPJYD,<3L!96(066WW^XR
M-#M]E-/,%U%8T9R!4"I"@D"I KPJ1Z]&VY[SM&R0)=;SNMM:6S/I#S2I$I8@
MD*&=E!8@$T!K0$\ >FG9'<?479M574/6_:G7'8-=C*>.KR5'LC?&V-UU6/I9
MI/#%4UU/@<I7S4E/+,-"O(%5FX!O[>O=HW;;51]QVNXMT8T!DC= 3Z LHJ?L
MZ3[7S)R[ODDL6R[]97DJ"K"">*4J": L(V8@$XJ<5ZC[T[NZ8ZVRD&$[$[=Z
MPV#FJJBCR5-B-Z;^VIM;*5&.EFGIXJ^"@SF6H:N6BEJ*66-950QL\;*#=2!:
MSV7>-QB:;;]IN9X0U"T<3NH.#0E5(K0@TXY'5-SYHY9V6=+7>>8K&TN674$F
MN(HF*DD!@KNI*D@BM*5!'ET(.+RF,SF,QV:PN1H<QALQ0TF4Q.6Q=73Y#&93
M&9"GCJZ#(XZOI))J6MH:VEF26&:)VCDC8,I((/LOEBDADDAFC9)D8JRL""I!
MH00<@@X(.0>CB">"Z@ANK69)+:1 R.I#*RL*JRL*AE8$$$$@@U&.FG:F\=I[
MZQ!S^R]R8/=>#&4SF$.7V]DZ/+XW^+[9S-=MW<&-%;0S3TYK,-G<944E0@;5
M%/"Z-8J?;MU:75C+X%Y;/%/I5M+J5.EU#J:&AHRD,#Y@@])]OW+;]UM_J]LO
M8KBU\1TUQL'77$[1R+J4D51U9&'DP(/#J5N+<NW-GX7(;EW;G\+M;;F)B6?*
M9_<65H<)A<; \L<"39#*Y.>FH:.)YYD0-)(H+L!]2/=;>VN+N:.VM('EN'-%
M5%+,3QPH!)QZ#J]Y>V6W6LU[N%W%!91BK22.J(HK2K.Q"@5(%21D] XORN^+
M;LJK\D^@F9B%55[BZ[+,Q-@J@;C)))/ ]F_]5N9AD\N7]/\ GGE_Z Z#@Y_Y
M$) '.NT5_P">RW_ZV=#CC\AC\M0TN3Q5=1Y/&UT$=319#'U,-;0UE-*H:*HI
M:NF>2"H@D4W5T8J1]#[)9(Y(G:.5"LBFA!!!!]"#D'H4PS0W$4<]O*KPN*JR
MD,I!X$$5!!]1T%N[/D%T+L/<%5M/?/=W4.S-TT--15M;MK=G96S-N[@HZ/))
M))CJNJPV8S5'D:>FKXXF:&1XPLJJ2I(!]F=KL.^WT"W5ELMW-:L2 Z0R.I(X
M@,JD$CS%<>?1#N'-_*>TW<FW[KS1MUM?HJLT<MS#'( V5)1W# -0Z210TQTG
MO]FP^+7_ 'DKT!_Z./KK_P"R/VH_JMS/_P!,Y?\ _9/+_P! =(_]<#D/_IMM
MH_[++?\ ZV="KLW?>R.Q<*NY>OMY;5WWMQZNKH$S^S=PXC<^%>NH)3!742Y7
M"5E=0M5T4X*31B37&XLP!]E=Y8WNWS&VO[.6"XH#ID1D:AR#I8 T(X&F>C_;
M=UVO>;47NS[E;W=F6*^)#(DJ:E-&74A9:J<$5J#QZ#G'_)OXVY?)T.%Q/R$Z
M/R>9R=?38O&XG']L;"K<GD,G6U"4E'CJ&@IL_+55=?5U4JQ10QHTDDC!5!)
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MV0RO:?8%=3[1V+3XZBD(.0GH<WEHZZ6%;LU+22FUE/L(\C[$G,7,^U[=<8L
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M:DDY/J>L4?NY\J\L;USG[]6>\<N6%W:0;I$L236\4J1J;C<05171E12$4$*
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MG6VY7W/LO$;\KTT87*; W74)_=3=R9!XFIE@H<O18Y,N ZG'$3B1M,?KYO\
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M?]FT_O?_ '=\/V=1_P >)_<'_?X_WUU6T_P_]_[7R_V=7N&/?'Z?^J4?U?\
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M7R!^XOZY\L?NG^I.O0M?&_>_UM,_\DW]X]G^E\/.GY=;)OO'7K-7HD_\P_\
MA'^RE=C_ ,=_V7O^%_Q7KC[C_9I/[[_Z%=?^DO:/VO\ >C_1S_O\/N_N_'_#
MOM?1_$/#]Q_DWF]C/D#Q?ZU;?X'U_BZ9:?1>']1_8R5T>+^G2E=>K\%=/=3J
M,/>+Z?\ UOMY^K_<_@>);U_>GC_1?[DQ4\7Z?]:M:>'IQXFG7V:NCD9;P_PK
M)_<>7[?^'UOG\'WWG\/VTGE\/\,_W)>71?3]O^_?_-^NWL(15\6/335J%*T]
M?GC]N/7'4DW&GP)]==&@UIJK2AK33W5]-/=Z9ZIB^%?^CK_9R^X_X%_LJ/\
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MWS^&E.[HBG\MS_1O_LP>_/X+_LB7\4_B$GVG^R>_[-=_?K7HWCK_ -,O]_\
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K7;JTUSUCA[:_N#^N_)?[J_J7XW@9K^^?JJ4;_DE?O']*E>&GNT:Z8Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715734734520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVARTIS AG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001114448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732331576">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated income statements - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="nump">$ 11,764<span></span>
</td>
<td class="nump">$ 23,630<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,347<span></span>
</td>
<td class="nump">11,764<span></span>
</td>
<td class="nump">23,630<span></span>
</td>
<td class="nump">22,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">275<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,429)<span></span>
</td>
<td class="num">(3,406)<span></span>
</td>
<td class="num">(7,151)<span></span>
</td>
<td class="num">(6,657)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,193<span></span>
</td>
<td class="nump">8,618<span></span>
</td>
<td class="nump">17,179<span></span>
</td>
<td class="nump">16,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,368)<span></span>
</td>
<td class="num">(3,585)<span></span>
</td>
<td class="num">(6,854)<span></span>
</td>
<td class="num">(6,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,441)<span></span>
</td>
<td class="num">(2,051)<span></span>
</td>
<td class="num">(4,501)<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">432<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(464)<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
<td class="num">(1,421)<span></span>
</td>
<td class="num">(1,844)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,352<span></span>
</td>
<td class="nump">2,663<span></span>
</td>
<td class="nump">5,096<span></span>
</td>
<td class="nump">4,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,288<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">4,909<span></span>
</td>
<td class="nump">4,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(421)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
<td class="num">(797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">3,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution', window );">Net income/loss from discontinued operations before gain on distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income/loss from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">8,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">6,799<span></span>
</td>
<td class="nump">4,043<span></span>
</td>
<td class="nump">8,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding used in the basic earnings per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,289<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share, Continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings per share, Discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsPerShareAbstract', window );"><strong>Diluted earnings per share [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares in diluted earnings per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
<td class="nump">2,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share, Continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings per share, Discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsSalesToOtherSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732710648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of comprehensive income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,867<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,040<span></span>
</td>
<td class="nump">$ 8,567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income to be eventually recycled into the consolidated income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities', window );">Fair value adjustments on debt securities, net of taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges', window );">Fair value adjustments on deferred cash flow hedges, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments', window );">Total fair value adjustments on financial instruments, net of taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Associated companies' movements in comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">382<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Total of items to eventually recycle</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">369<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income never to be recycled into the consolidated income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="nump">319<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(293)<span></span>
</td>
<td class="num">(890)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="nump">173<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">99<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Total of items never to be recycled</a></td>
<td class="nump">492<span></span>
</td>
<td class="num">(408)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(816)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">2,702<span></span>
</td>
<td class="nump">6,890<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,215<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">2,703<span></span>
</td>
<td class="nump">6,888<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,219<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Comprehensive income, attributable to non-controlling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI', window );">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(358)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">$ 2,703<span></span>
</td>
<td class="nump">2,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,219<span></span>
</td>
<td class="nump">3,321<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,577<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In H1 2019, cumulative currency translation gains of USD 123 million were recycled into the consolidated income statement as a result of the Alcon spin-off (see Notes 2, 3 and 10).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in H1 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss pension plans that were previously recognized through other comprehensive income. This revaluation resulted from the Swiss canton Basel-Stadt tax reform, enacted in February 2019.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 39<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=39&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2019-01-01<br> -Paragraph 6.5.13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_6.5.13_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732565496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 11,955<span></span>
</td>
<td class="nump">$ 12,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">29,100<span></span>
</td>
<td class="nump">26,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">36,669<span></span>
</td>
<td class="nump">28,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in associated companies</a></td>
<td class="nump">8,575<span></span>
</td>
<td class="nump">8,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">8,601<span></span>
</td>
<td class="nump">7,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,475<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">99,881<span></span>
</td>
<td class="nump">88,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">6,904<span></span>
</td>
<td class="nump">5,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Current trade receivables</a></td>
<td class="nump">7,644<span></span>
</td>
<td class="nump">8,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax receivable</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">5,917<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other current assets</a></td>
<td class="nump">2,733<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Total current assets without disposal group</a></td>
<td class="nump">23,882<span></span>
</td>
<td class="nump">28,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">23,882<span></span>
</td>
<td class="nump">29,504<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">123,763<span></span>
</td>
<td class="nump">118,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">52,936<span></span>
</td>
<td class="nump">54,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Issued share capital and reserves attributable to Novartis AG shareholders</a></td>
<td class="nump">53,812<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">53,885<span></span>
</td>
<td class="nump">55,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Financial debts</a></td>
<td class="nump">23,955<span></span>
</td>
<td class="nump">20,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">7,499<span></span>
</td>
<td class="nump">5,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Provisions and other non-current liabilities</a></td>
<td class="nump">7,344<span></span>
</td>
<td class="nump">6,632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">40,496<span></span>
</td>
<td class="nump">34,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">4,820<span></span>
</td>
<td class="nump">5,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Financial debts and derivative financial instruments</a></td>
<td class="nump">8,875<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax liabilities</a></td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">2,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Provisions and other current liabilities</a></td>
<td class="nump">12,858<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Total current liabilities without disposal group</a></td>
<td class="nump">29,382<span></span>
</td>
<td class="nump">28,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">29,382<span></span>
</td>
<td class="nump">28,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">69,878<span></span>
</td>
<td class="nump">62,819<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">$ 123,763<span></span>
</td>
<td class="nump">$ 118,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.
Effective 2020-01-01: The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities other than liabilities included in disposal groups classified as held for sale. [Refer: Current liabilities; Disposal groups classified as held for sale [member]; Liabilities included in disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2019-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2019-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.
Effective 2020-01-01: The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 38<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2019-01-01<br> -Paragraph 22<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 38<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715729573992">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of changes in equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Equity attributable to owners of parent [member]</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Total value adjustments</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 78,692<span></span>
</td>
<td class="nump">$ 78,614<span></span>
</td>
<td class="nump">$ 944<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
<td class="nump">$ 82,191<span></span>
</td>
<td class="num">$ (4,452)<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Increase (decrease) due to changes in accounting policy required by IFRSs [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Restated Value Adjustments [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,695<span></span>
</td>
<td class="nump">78,617<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,194<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,692<span></span>
</td>
<td class="nump">78,614<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,191<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Increase (decrease) due to changes in accounting policy required by IFRSs [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Restated Value Adjustments [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,695<span></span>
</td>
<td class="nump">78,617<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,194<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,504<span></span>
</td>
<td class="nump">51,426<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">55,645<span></span>
</td>
<td class="num">(5,088)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period (Previously stated [member]) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,692<span></span>
</td>
<td class="nump">78,614<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,191<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period (Increase (decrease) due to changes in accounting policy required by IFRSs [member]) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period (Restated Value Adjustments [member]) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,695<span></span>
</td>
<td class="nump">78,617<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,194<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,567<span></span>
</td>
<td class="nump">8,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(667)<span></span>
</td>
<td class="num">(667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,511<span></span>
</td>
<td class="num">(613)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,645)<span></span>
</td>
<td class="num">(6,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DividendPaidNoncashAssetsDistribution', window );">Dividend in kind</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,434)<span></span>
</td>
<td class="num">(23,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,972)<span></span>
</td>
<td class="num">(2,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(2,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">447<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">Increase of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,289)<span></span>
</td>
<td class="num">(2,289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionCostsRecordedInEquity', window );">Transaction costs recorded in equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on financial assets sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(35,091)<span></span>
</td>
<td class="num">(35,089)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(35,060)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,504<span></span>
</td>
<td class="nump">51,426<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">55,645<span></span>
</td>
<td class="num">(5,088)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares', window );">Tax reform impact on deferred tax on treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,307<span></span>
</td>
<td class="nump">47,229<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="nump">51,518<span></span>
</td>
<td class="num">(5,170)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,504<span></span>
</td>
<td class="nump">51,426<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">55,645<span></span>
</td>
<td class="num">(5,088)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,307<span></span>
</td>
<td class="nump">47,229<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="nump">51,518<span></span>
</td>
<td class="num">(5,170)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">6,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,890<span></span>
</td>
<td class="nump">6,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,799<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DividendPaidNoncashAssetsDistribution', window );">Dividend in kind</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,927<span></span>
</td>
<td class="nump">2,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,770)<span></span>
</td>
<td class="num">(2,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(2,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">Increase of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,573)<span></span>
</td>
<td class="num">(2,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionCostsRecordedInEquity', window );">Transaction costs recorded in equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(301)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on financial assets sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,693)<span></span>
</td>
<td class="num">(2,691)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2,672)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,504<span></span>
</td>
<td class="nump">51,426<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">55,645<span></span>
</td>
<td class="num">(5,088)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares', window );">Tax reform impact on deferred tax on treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,504<span></span>
</td>
<td class="nump">51,426<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">55,645<span></span>
</td>
<td class="num">(5,088)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,551<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,885<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,551<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">4,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,215<span></span>
</td>
<td class="nump">4,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,987)<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">823<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">365<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on financial assets sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,881)<span></span>
</td>
<td class="num">(5,881)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="num">(5,811)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,885<span></span>
</td>
<td class="nump">53,812<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="nump">57,495<span></span>
</td>
<td class="num">(4,559)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,977<span></span>
</td>
<td class="nump">50,903<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="nump">55,356<span></span>
</td>
<td class="num">(5,321)<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,885<span></span>
</td>
<td class="nump">53,812<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="nump">57,495<span></span>
</td>
<td class="num">(4,559)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,977<span></span>
</td>
<td class="nump">50,903<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="nump">55,356<span></span>
</td>
<td class="num">(5,321)<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">835<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,702<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">203<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on financial assets sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">206<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,885<span></span>
</td>
<td class="nump">53,812<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="nump">57,495<span></span>
</td>
<td class="num">(4,559)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 53,885<span></span>
</td>
<td class="nump">$ 53,812<span></span>
</td>
<td class="nump">$ 913<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
<td class="nump">$ 57,495<span></span>
</td>
<td class="num">$ (4,559)<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in Q2 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 107<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReductionOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReductionOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DividendPaidNoncashAssetsDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DividendPaidNoncashAssetsDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsOnFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRelatedToDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRelatedToDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxesOnTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxesOnTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionCostsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionCostsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732142056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated cash flow statements - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">$ 1,867<span></span>
</td>
<td class="nump">$ 2,109<span></span>
</td>
<td class="nump">$ 4,040<span></span>
</td>
<td class="nump">$ 3,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Reversal of non-cash items and other adjustments</a></td>
<td class="nump">2,345<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
<td class="nump">5,202<span></span>
</td>
<td class="nump">4,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsReceivedClassifiedAsOperatingActivities', window );">Dividends received from associated companies and others</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
<td class="num">(406)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Other financial receipts</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities', window );">Other financial payments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Taxes paid</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="num">(960)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges', window );">Net cash flows from operating activities from continuing operations before working capital and provision changes</a></td>
<td class="nump">3,731<span></span>
</td>
<td class="nump">3,491<span></span>
</td>
<td class="nump">8,790<span></span>
</td>
<td class="nump">7,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities', window );">Payments out of provisions and other net cash movements in non-current liabilities</a></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(824)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems', window );">Change in net current assets and other operating cash flow items</a></td>
<td class="nump">650<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(1,477)<span></span>
</td>
<td class="num">(1,348)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations', window );">Net cash flows from operating activities from continuing operations</a></td>
<td class="nump">3,961<span></span>
</td>
<td class="nump">3,111<span></span>
</td>
<td class="nump">6,489<span></span>
</td>
<td class="nump">5,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash flows from operating activities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Total net cash flows from operating activities</a></td>
<td class="nump">3,961<span></span>
</td>
<td class="nump">3,111<span></span>
</td>
<td class="nump">6,489<span></span>
</td>
<td class="nump">5,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="num">(561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchases of intangible assets</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
<td class="num">(498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities', window );">Purchases of financial assets</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of financial assets</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Purchases of other non-current assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies', window );">Acquisitions and divestments of interests in associated companies, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Acquisitions and divestments of businesses, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(9,901)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities', window );">Purchases of marketable securities and commodities</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities', window );">Proceeds from sale of marketable securities and commodities</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">2,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations', window );">Net cash flows used in/from investing activities from continuing operations</a></td>
<td class="num">(334)<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="num">(10,461)<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(682)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash flows used in/from investing activities</a></td>
<td class="num">(425)<span></span>
</td>
<td class="num">(474)<span></span>
</td>
<td class="num">(10,566)<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">Dividends paid to shareholders of Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="num">(6,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2,368)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions', window );">Proceeds from exercised options and other treasury share transactions</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in non-current financial debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayment of non-current financial debts</a></td>
<td class="num">(1,002)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2,002)<span></span>
</td>
<td class="num">(3,008)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Change in current financial debts</a></td>
<td class="num">(1,169)<span></span>
</td>
<td class="num">(793)<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="num">(942)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities, net</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other financing cash flows, net</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations', window );">Net cash flows used in financing activities from continuing operations</a></td>
<td class="num">(2,172)<span></span>
</td>
<td class="num">(2,710)<span></span>
</td>
<td class="num">(1,146)<span></span>
</td>
<td class="num">(13,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows used in/from financing activities from discontinued operations</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Total net cash flows used in financing activities</a></td>
<td class="num">(2,185)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
<td class="num">(9,711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net change in cash and cash equivalents before effect of exchange rate changes</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
<td class="num">(5,249)<span></span>
</td>
<td class="num">(3,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations', window );">Cash and cash equivalents of discontinued operations at end of prior period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Total net change in cash and cash equivalents</a></td>
<td class="nump">1,389<span></span>
</td>
<td class="nump">3,184<span></span>
</td>
<td class="num">(5,195)<span></span>
</td>
<td class="num">(3,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,528<span></span>
</td>
<td class="nump">6,807<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
<td class="nump">13,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 5,917<span></span>
</td>
<td class="nump">$ 9,991<span></span>
</td>
<td class="nump">$ 5,917<span></span>
</td>
<td class="nump">$ 9,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from dividends received, classified as operating activities. [Refer: Dividends received]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents from discontinued operations. [Refer: Cash and cash equivalents; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire equity or debt instruments of other entities (other than payments for those instruments considered to be cash equivalents or those held for dealing or trading purposes), classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of equity or debt instruments of other entities (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 42A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 42B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796447688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BasisOfPreparationAbstract', window );"><strong>Basis of preparation [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Disclosure of basis of preparation of financial statements [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Basis of preparation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">These Condensed Interim Consolidated Financial Statements for the three-month and six-month period ended June 30, 2020, were prepared in accordance with International Accounting Standard 34 <i>Interim Financial Reporting </i>and accounting policies set out in the 2019 Annual Report published on January&nbsp;29, 2020. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715792202616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected critical accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedCriticalAccountingPoliciesAbstract', window );"><strong>Selected critical accounting policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Disclosure of significant accounting policies [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Selected critical accounting policies</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s principal accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2019 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of &#xfb01;nancial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of assets and liabilities, including any contingent amounts, the distribution liability recognized in connection with the distribution of Alcon Inc. to Novartis AG shareholders, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As disclosed in the 2019 Annual Report, goodwill, and acquired In-Process Research &amp; Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Group&#x2019;s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Group&#x2019;s results of operations and financial condition. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or&nbsp;held for distribution to owners</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are classified as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Distribution of Alcon Inc. </font> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"> </font> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">to Novartis AG shareholders</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&#x2019;s business (the &#x201c;Alcon business&#x201d;) to be reported as discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &#x201c;Other expense&#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&#x201d; in the income statement of discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &#x201c;Level 3&#x201d; in the fair value hierarchy. The section &#x201c;&mdash;Impairment of goodwill and intangible assets&#x201d; in Note 1 to the Consolidated Financial Statements of the 2019 Annual Report provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional disclosures, refer to Notes 3 and 10.</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">New IFRS standard effective as&nbsp;of&nbsp;January 1, 2020</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combination amendments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired or disposed of should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the entity may choose to consider the transaction an acquisition of an asset or set of assets. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedCriticalAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedCriticalAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796454440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsAbstract', window );"><strong>Disclosure of significant transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsTextBlock', window );">Significant transactions</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Significant transactions</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020</font> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of The&nbsp;Medicines Company</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 9.6 billion. The preliminary purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Results of operations since the date of acquisition were not material.</div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &ndash; acquisition of the Japanese business of Aspen Global Incorporated </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Aspen&#x2019;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consist of EUR 300 million (USD 331 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 120 million (USD 132 million), which AGI is eligible to receive upon the achievement of specified milestones. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was EUR 345 million (USD 381 million). The amount consisted of an initial cash payment of EUR 273 million (USD 301 million) and the fair value of contingent consideration of EUR 72 million (USD 80 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of approximately USD 309 million, consisting of USD 269 million intangible assets, USD 26 million other net assets, USD 14 million net deferred tax assets and goodwill of approximately USD 72 million. Results of operations since the date of acquisition were not material. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &ndash; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as regulatory approval from the US Federal Trade Commission was not obtained within the SAPA agreed timelines. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The cumulative amount of the depreciation on property, plant and equipment and amortization on intangible assets, not recorded in the consolidated income statement since the date of classification as held for sale, amounting to USD 38 million and USD 102 million, respectively, was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the Group&#x2019;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets of disposal group classified as held for sale</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 475</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities of disposal group classified as held for sale</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no cumulative income or expenses included in other comprehensive income relating to the disposal group. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2019</font> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG </font> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> shareholders</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April&nbsp;9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &#x201c;ALC.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&#x2019;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&#x2019;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> April 8, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net assets derecognized <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;025</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derecognition of distribution liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;434</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Difference between net assets and distribution liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;409</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Recognition of Alcon Inc. shares obtained <br></br>through consolidated foundations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;273 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation gains recycled into the <br></br>consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 123 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs recognized in the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;114</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> See Note 10 for additional information. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For additional disclosure on discontinued operations, refer to Note 10.</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of IFM Tre, Inc. </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&#x2019;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gutdirected molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangibles, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of </font> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;font-style:italic;">Xiidra</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with <i>Xiidra</i> (lifitegrast ophthalmic solution) 5% worldwide. <i>Xiidra</i> is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimated that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715734712680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of equity attributable to Novartis AG shareholders<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfEquityAbstract', window );"><strong>Disclosure of equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfEquityTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Summary of equity attributable to Novartis AG shareholders </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Number of outstanding shares (in millions) </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Issued share capital and reserves attributable to Novartis AG shareholders (in USD millions)</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;265.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;614</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in accounting policy <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated equity at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;617</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be cancelled</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;819</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;153</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 823</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 365</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 447</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase obligation under a share buyback trading plan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;289</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends to shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;987</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;645</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend in kind to effect the spin-off of Alcon Inc. <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23&nbsp;434</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income of the period attributable to shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;043</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;565</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income attributable to shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;667</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;253</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at June 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;289.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;291.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;812</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;426</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In H1 2019, the impact of change in accounting policy includes USD 3 million related to the implementation of IFRS 16 Leases. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Included in H1 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. <br></br>This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Fair value of the dividend in kind of Alcon Inc. shares to Novartis AG shareholders (see Notes 2 and 3 for further details). </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> In H1 2019, Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Impact of hyperinflationary economies </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715795778664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract', window );"><strong>Financial Instruments - additional disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of detailed information about financial instruments [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Financial instruments </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value by hierarchy</font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table illustrates the three hierarchical levels for valuing financial instruments at fair value as of June 30, 2020 and December&nbsp;31, 2019. For additional information on the hierarchies and other matters, please refer to the Consolidated Financial Statements in the 2019 Annual Report, published on January 29, 2020. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 1</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 2</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 3</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;443</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;557</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 235</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 235</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 444</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 444</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;189</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit or loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;059</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;065</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first half of 2020, there were no significant transfers from one level to the other and no significant transactions associated with level 3 financial instruments. During the second quarter of 2020, there were two non-significant transfers of equity securities from level 3 to level 1 for USD 26 million due to Initial Public Offerings. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of straight bonds amounted to USD 27.7 billion at June 30, 2020 (USD 23.7 billion at December 31, 2019) compared to the balance sheet value of USD 25.2 billion at June 30, 2020 (USD 22.2 billion at December 31, 2019). For all other financial assets and liabilities, the carrying amount is a reasonable approximation of the fair value. The carrying amount of financial assets included in the line total long-term financial investments of USD 2.1 billion at June 30, 2020 (USD 2.2 billion at December 31, 2019) is included in line &#x201c;Financial and other non-current assets&#x201d; of the consolidated balance sheets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In accordance with the consolidated foundations Alcon Inc. share divestment plans, Alcon Inc. shares with a fair value of USD 287 million were sold, or otherwise disposed of, in the first half of 2020 and the USD 16 million gain on disposal was transferred from other comprehensive income to retained earnings (second quarter : nil). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s exposure to financial risks has not changed significantly during the period and there have been no major changes to the risk management department or in any risk management policies. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current financial debt &ndash; issuance of bonds</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On February 11, 2020, Novartis issued the following straight bonds:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Coupon </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Currency </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Nominal amount <br></br> (USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Maturity year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issuer </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issue price </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Carrying value <br></br> Jun 30, 2020 <br></br> (USD millions) </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.75%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.852%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 996</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.00%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.909%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.20%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.869%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;492</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.75%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2050</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97.712%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;213</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35K<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796136264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract', window );"><strong>Disclosure of details to the consolidated statements of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Details to the consolidated statements of cash flows</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Details to the consolidated statements of&nbsp;cash&nbsp;flows </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.1. Reversal of non-cash items and other adjustments from continuing operations</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 319</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 371</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 601</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 958</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Losses/gains on disposal and other adjustments on property, plant and equipment; intangible assets; <br></br>financial assets; and other non-current assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;615 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 174</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;176</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 247</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 205</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;345</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;085</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 700</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 149</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;619</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 838</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;018</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets; <br></br>financial assets; and other non-current assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;55 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;684 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 377</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 372</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 493</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 387</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;101</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.2. Total amount of taxes paid </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first half of 2020, the total amount of taxes paid was USD 987 million (Q2 2020: USD 391 million), of which USD 899 million (Q2 2020: USD 303 million) was included within &#x201c;Net cash flows from operating activities from continuing operations&#x201d;, and USD 88 million (Q2 2020: USD 88 million) was included within &#x201c;Net cash flows used in investing activities from discontinued operations.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the first half of 2019, the total amount of taxes paid was USD 998 million (Q2 2019: USD 560 million), of which USD 960 million (Q2 2019: USD 560 million) was included within &#x201c;Net cash flows from operating activities from continuing operations&#x201d; and USD 38 million (Q2 2019: nil) was included within &#x201c;Net cash flows from operating activities from discontinued operations.&#x201d; </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.3. Cash flows arising from acquisitions and divestments of businesses, net</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of business combinations</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;407</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;030</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;486</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables and payables contingent consideration, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;367</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash flows from/used for divestments of businesses, net <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;286</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;901</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;382</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In the second quarter of 2020 and 2019, the USD 2 million represented the net cash inflows for previous years divestments. <br></br>During the first half of 2020, the USD 13 million included USD 15 million net cash outflows for previous years divestments (H1 2019: USD 15 million) and a prepaid sales price of USD 2 million for a business divestment. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 3 and 7 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.4. Cash and cash equivalents of discontinued operations at March 31, 2019</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents of discontinued operations at March 31, 2019,represents the amount of the Alcon business cash and cash equivalents included in the March 31, 2019, consolidated balance sheets in the line &#x201c;Assets related to discontinued operations.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For net cash flows used in investing activities from discontinued operations, see Note 10. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section Presentation of a statement of cash flows<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796861304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of businesses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract', window );"><strong>Disclosure of acquisition of businesses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Acquisition of businesses</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Acquisition of businesses</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fair value of assets and liabilities arising from acquisitions:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;602</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 449</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 470</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables, marketable securities <br></br>and other current assets </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 109 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;928</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;569</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 411</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;537</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 486</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 3 details significant acquisitions of businesses, specifically, The Medicines Company and the Japanese business of AGI in 2020, and IFM Tre, Inc. in 2019. The goodwill arising out of these acquisitions is attributable to the buyer specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. Goodwill of USD 59 million in 2020 (2019: nil) is tax deductible. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAcquisitionOfBusinessesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796569608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal proceedings update<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LegalProceedingsUpdateAbstract', window );"><strong>Legal proceedings update [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LegalProceedingsUpdateTextBlock', window );">Legal proceedings update [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Legal proceedings update </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings, including litigations, arbitrations and governmental investigations, that arise from time to time. Legal proceedings are inherently unpredictable. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F contains a summary as of the date of these reports of significant legal proceedings to which Novartis or its subsidiaries were a party. The following is a summary as of July 20, 2020 of significant developments in those proceedings, as well as any new significant proceedings commenced since the date of the 2019 Annual Report and 2019 Form 20-F. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Investigations and related litigations</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Government generic pricing antitrust investigations,</font> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> antitrust class actions</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2016, Sandoz Inc. received grand jury subpoenas and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) in connection with alleged price fixing and market allocation of generic drugs in the US market as well as alleged False Claims Act violations. Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. agreed to pay USD 195 million and entered into a deferred prosecution agreement. The Sandoz resolution related to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. is also in negotiations with the DOJ Civil Division to resolve potential related claims and has recorded a provision of USD 186 million. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Southern District of New York (S.D.N.Y.) marketing practices investigation and litigation</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, the US government filed a civil complaint in intervention to an individual <i>qui tam </i>action against Novartis Pharmaceuticals Corporation (NPC) in the United States District Court (USDC) for the S.D.N.Y. The complaint, as subsequently amended, asserted federal False Claims Act (FCA) and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications ( <i>Lotrel</i>,&nbsp; <i>Starlix</i>&nbsp;and&nbsp; <i>Valturna</i>) allegedly serving as mechanisms to provide kickbacks to healthcare professionals (HCPs). Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. In July 2020, Novartis finalized its settlement agreement with the S.D.N.Y, the New York State Attorney General and the individual relator to resolve their claims. As part of this settlement, Novartis will pay USD 0.7 billion, and has agreed to new corporate integrity obligations with the Office of Inspector General of the US Department of Health &amp; Human Services. As of June 30, a provision in the amount of USD 0.7 billion remained accrued in the Innovative Medicines Division for this matter. As of July 20, 2020, USD 0.6 billion have been paid out of this provision. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">U.S. Government Foreign Corrupt Practices Act (FCPA) investigations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In June 2020, Novartis reached settlements with the DOJ and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by Novartis and its subsidiaries. These investigations were previously disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the headings &#x201c;Greece investigation,&#x201d; &#x201c;South Korea investigation&#x201d; and &#x201c;Asia/Russia investigation.&#x201d; As part of the coordinated resolution of these investigations, Novartis and certain of its current and former subsidiaries agreed to pay USD 0.3 billion. As of June 30, 2020, a provision in the amount of USD 0.1 billion remained accrued. As of July 20, 2020, USD 0.1 billion have been paid out of this provisions. To resolve the DOJ investigation, Novartis Hellas S.A.C.I. entered into a deferred prosecution agreement (&#x201c;Novartis Hellas DPA&#x201d;) pertaining to inappropriate economic benefits provided to Greek healthcare professionals from 2012 to 2015 in connection with the ophthalmology product <i>Lucentis</i>. The Novartis Hellas DPA also covers books and records issues pertaining to the <i>Lucentis</i> conduct and to conduct related to a 2009 epidemiological study. The resolutions contain no allegations relating to any bribery of Greek politicians, which is consistent with what Novartis found in its own internal investigation. Alcon Pte Ltd, a former Novartis subsidiary, has entered into a separate deferred prosecution agreement with the DOJ (&#x201c;Alcon DPA&#x201d;) pertaining to inappropriate economic benefits provided to Vietnamese healthcare professionals and books and records violations from 2011 to 2014 in Vietnam. This conduct related to a consultancy program run by a distributor in Vietnam. To resolve the SEC investigation, Novartis AG reached an agreement pertaining to internal controls and books and records violations in Greece, Vietnam and South Korea. The violations in Greece pertain to the <i>Lucentis</i>-related conduct covered in the Novartis Hellas DPA as well as controls issues with Novartis Hellas post-approval studies identified by internal review in 2012 and resolved by 2013. In Vietnam, the violations relate to the activities involving an Alcon distributor that are the subject of the Alcon DPA. In South Korea, the violations relate to conduct for which Novartis has already taken responsibility in South Korea, where Novartis is in the final stages of resolving these issues with the local authorities. The SEC agreement also addresses certain internal controls and books and records issues related to Alcon China&#x2019;s placement of surgical devices. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In addition to the matters described above, there have been other developments in the other legal matters described in Note 20 to the Consolidated Financial Statements contained in our 2019 Annual Report and 2019 Form 20-F. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LegalProceedingsUpdateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LegalProceedingsUpdateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LegalProceedingsUpdateTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LegalProceedingsUpdateTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796859976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segmentation of key figures</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Segmentation of key figures </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments, Innovative Medicines and Sandoz. In addition, we separately report Corporate activities. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision maker which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The reporting segments are as follows:</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Novartis Oncology consists of the global business franchise Oncology, and Novartis Pharmaceuticals consists of the global business franchises Ophthalmology; Immunology, Hepatology and Dermatology; Neuroscience; Respiratory; Cardiovascular, Renal and Metabolism; and Established Medicines. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services. Corporate includes the costs of the Group headquarters and those of corporate coordination functions in major countries, and items that are not specific to one segment. Further details are provided in Note 3 to the Consolidated Financial Statements of the 2019 Annual Report. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following the February 28, 2019, shareholders&#x2019; approval of the spin-off of the Alcon business, the Group reported its financial results as &#x201c;continuing operations&#x201d; and &#x201c;discontinued operations&#x201d; (refer to Notes 2, 3 and 10 for further details). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Continuing operations comprise the activities of Innovative Medicines and Sandoz Divisions and the continuing Corporate activities. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discontinued operations included in 2019 the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (see Notes&nbsp;2, 3 and 10). </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Consolidated income statement </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;262</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;407</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;503</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;475</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;262</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 260</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;554</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;327</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;406</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;066</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;618</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;764</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;911</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;496</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;585</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;240</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;853</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;198</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;051</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 847</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 97</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 432</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 989</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;945</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;308</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;033</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;564</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;352</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;663</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 22.1%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 27.5%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 14.9%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11.6%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 20.7%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 22.6%</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;205</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;634</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;525</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;109</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;800</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;870</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 409</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;449</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;352</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;532</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;779</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;840</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;449</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;923</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 700</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 556</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;080</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;614</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;591</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 485</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;657</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;779</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;822</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;564</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;854</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;915</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;392</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;350</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 922</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 693</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;192</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;319</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;844</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;788</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 276</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 555</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;096</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;905</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 25.3%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 25.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 5.9%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11.6%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 21.6%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 21.4%</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;459</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;431</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;909</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;774</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;977</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain <br></br>on distribution of Alcon Inc. to Novartis AG shareholders </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;567</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Additional consolidated balance sheet and income statement disclosure</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 81&nbsp;373</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;225</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;229</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;468</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;161</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30&nbsp;677</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 123&nbsp;763</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;14&nbsp;690</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;332</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;681</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;804</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;51&nbsp;507</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;43&nbsp;683</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;69&nbsp;878</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;62&nbsp;819</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;885</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;537</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;537</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 66&nbsp;683</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;893</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;548</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;664</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;191</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;932</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 80&nbsp;422</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;489</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net operating assets are:</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;485</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;632</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;943</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;888</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 527</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 549</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;955</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;257</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;835</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;524</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&nbsp;877</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27&nbsp;586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;669</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the intangible asset impairment charges for continuing operations:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;500</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;509</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;466</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;478</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Q2 2020 and H1 2020 include an impairment of USD 485 million related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis. <br></br>H1 2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;D acquired through the 2015 Spinifex Pharmaceuticals Inc. acquisition. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region</font> <font style="font-family:arial,helvetica,sans-serif; font-size:6pt; color:#000000; font-weight:bold; vertical-align:super;">1</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change <br></br> cc <sup style="white-space: nowrap"> 2</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020 <br></br> % of total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019 <br></br> % of total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;964</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 666</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;909</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;130</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 52</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 508</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 333</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;796</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 538</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;094</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;978</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;439</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 766</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 860</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;817</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;897</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region</font> <font style="font-family:arial,helvetica,sans-serif; font-size:6pt; color:#000000; font-weight:bold; vertical-align:super;">1</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change <br></br> cc <sup style="white-space: nowrap"> 2</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020 <br></br> % of total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019 <br></br> % of total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;352</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;302</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;468</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;078</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;232</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 675</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 651</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 371</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;862</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;135</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;561</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;595</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;870</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;898</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;741</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by business franchise</font> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 468</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 422</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 349</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 371</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 340</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 310</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 253</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;548</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;606</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 944</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 858</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 937</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 825</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 886</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 580</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 580</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 427</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 289</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 290</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Ultibro</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 444</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Voltaren/Cataflam</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;749</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;640</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;720</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 902</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 825</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 715</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 795</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 628</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 380</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 215</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 545</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;927</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;874</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 413</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;965</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 974</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;591</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 375</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;045</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;683</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 778</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 790</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 596</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 571</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Ultibro</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 309</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 915</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 906</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 635</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 544</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 496</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 240</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 197</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Voltaren/Cataflam</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;747</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales of the top 20 Innovative Medicines Division products in 2020 </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD/cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="12%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right" width="1%"></td> <td width="12%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Immunology, <br></br> Hepatology and <br></br> Dermatology </div> </td> <td align="right" width="1%"></td> <td width="12%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis and <br></br> psoriatic arthritis <br></br> and non-radiographic <br></br> axial spondyloarthritis </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 614 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 15 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 330 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 2 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 6 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 944 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 10 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 12 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 416</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 322</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br></br> Renal and <br></br> Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 308 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 272 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 36 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 41 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 580 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 38 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 40 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Lucentis </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Ophthalmology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related <br></br> macular degeneration </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 401 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;25 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 401 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;25 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;24 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune <br></br> thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 212 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 25 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 210 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 422 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 23 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic <br></br> and adjuvant melanoma; <br></br> advanced non-small cell <br></br> lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 147 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 20 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 224 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 371 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 12 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Sandostatin </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors <br></br> and acromegaly </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 200 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 141 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;19 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 341 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;13 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycytomia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 310 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 310 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Gleevec/Glivec </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid <br></br> leukemia and GIST </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 70 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;27 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 218 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 288 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe Allergic Asthma (SAA) <br></br> and Chronic Spontaneous <br></br> Urticaria (CSU) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 289 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 289 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 4 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 234</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br></br> Hepatology and <br></br> Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, <br></br> SJIA, AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 95 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 105 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 19 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 200 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 23 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Zolgensma </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Neuroscience </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy <br></br> (SMA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 105 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 100 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 205 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Kisqali</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 743</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;084</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales of the top 20 Innovative Medicines Division products in 2020 </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD/cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="12%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right" width="1%"></td> <td width="12%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Immunology, <br></br> Hepatology and <br></br> Dermatology </div> </td> <td align="right" width="1%"></td> <td width="12%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis and <br></br> psoriatic arthritis <br></br> and non-radiographic <br></br> axial spondyloarthritis </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 1&nbsp;190 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 18 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 684 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 7 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 11 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 1&nbsp;874 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 14 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 15 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 804</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 706</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br></br> Renal and <br></br> Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 601 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 43 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 548 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 53 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 58 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 1&nbsp;149 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 48 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 50 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Lucentis </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Ophthalmology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related <br></br> macular degeneration </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 888 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 888 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune <br></br> thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 399 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 25 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 426 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 26 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 30 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 825 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 26 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 28 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic <br></br> and adjuvant melanoma; <br></br> advanced non-small cell <br></br> lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 279 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 458 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 13 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 737 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 19 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Sandostatin </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors <br></br> and acromegaly </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 413 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 302 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 715 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;10 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycytomia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 628 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 20 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 628 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 20 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Gleevec/Glivec </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid <br></br> leukemia and GIST </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 174 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 443 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 617 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe Allergic Asthma (SAA) <br></br> and Chronic Spontaneous <br></br> Urticaria (CSU) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 596 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 596 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 482</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 496</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br></br> Hepatology and <br></br> Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, <br></br> SJIA, AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 183 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 29 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 230 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 32 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 36 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 413 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 31 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 33 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Zolgensma <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Neuroscience </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy <br></br> (SMA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 231 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 144 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 375 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 257</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 192</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Kisqali</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;494</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;855</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;449</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;886</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Includes a reclassification of export sales from the US into rest of the world in the amount of USD 44 million that were in Q1 2020 classified within US net sales. This reclassification has no impact on the reported Q1 2020 total <i>Zolgensma</i> net sales. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales by business franchise </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc <sup style="white-space: nowrap"> 2</sup> </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;576</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;903</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Of which USD 134 million (2019: USD 186 million) represents Anti-Infectives sold under Sandoz name </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc <sup style="white-space: nowrap"> 2</sup> </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;545</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;753</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 916</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 752</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Of which USD 356 million (2019: USD 390 million) represents Anti-Infectives sold under Sandoz name </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2020 and 2019.</div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Other revenue </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit sharing income</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 209</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 209</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 182</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 251</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 260</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit sharing income</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 407</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 350</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 407</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 351</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 69</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 700</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 556</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796572136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDiscontinuedOperationsAbstract', window );"><strong>Disclosure of discontinued operations [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory', window );">Disclosure of discontinued operations [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Discontinued operations </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Discontinued operations included in 2019 the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Note 3 for further details). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon eye care devices business researched, discovered, developed, manufactured, distributed and sold a broad range of eye care products. Alcon was organized into two global business franchises, Surgical and Vision Care. Alcon also provided services, training, education and technical support for both the Surgical and Vision Care businesses. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Consolidated income statement </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from discontinued <br></br>operations </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;777 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;809</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;860</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 949</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;638</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;142</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 4.0%</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;159</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net loss from discontinued operations before gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> As the Alcon spin-off was completed on April 9, 2019, the Q2 2019 results of operations from the Alcon business were not material. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> See Note 3 for further details on the non-taxable non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders recognized on April 8, 2019, date of Distribution. </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Supplemental disclosures related to&nbsp;the Alcon business distributed to&nbsp;Novartis AG shareholders</font> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash flows </font> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">used in investing activities from&nbsp;discontinued operations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business in all periods. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments attributable to the spin-off of the Alcon business</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divested cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;628</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;628</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows attributable to the spin-off of the Alcon business</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;642</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other cash flows used in investing activities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;463</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in investing activities from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;682</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;105</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash flows from financing activities from&nbsp;discontinued operations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first half of 2020, the net cash outflows from financing activities from discontinued operations of USD 26 million (Q2 2020: USD 13 million) was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis shareholders. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the first half of 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (Q2 2019: USD 2.7 billion) included mainly USD 3.5 billion (Q2 2019: USD 3.2 billion) from Alcon borrowings, partly offset by USD 0.2 billion (Q2 2019: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis shareholders (see Note 3). </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transaction closed in 2019 </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately-held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the net present value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets, of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 3. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of discontinued operations. [Refer: Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796414616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Disclosure of events after reporting period [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Events subsequent to the June 30, 2020, consolidated balance sheet date</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In July 2020, Novartis paid USD 0.7 billion out of certain legal provisions. For additional information see Note 8. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715734974424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected critical accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements', window );">Description of other accounting policies relevant to understanding of financial statements [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s principal accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2019 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of &#xfb01;nancial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of assets and liabilities, including any contingent amounts, the distribution liability recognized in connection with the distribution of Alcon Inc. to Novartis AG shareholders, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As disclosed in the 2019 Annual Report, goodwill, and acquired In-Process Research &amp; Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Group&#x2019;s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Group&#x2019;s results of operations and financial condition. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory', window );">Non-current assets held for sale or held for distribution to owners</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or&nbsp;held for distribution to owners</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are classified as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DistributionByWayOfDivindendInKindToShareholders', window );">Distribution by way of dividend in kind to shareholders</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Distribution of Alcon Inc. </font> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"> </font> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">to Novartis AG shareholders</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&#x2019;s business (the &#x201c;Alcon business&#x201d;) to be reported as discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &#x201c;Other expense&#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&#x201d; in the income statement of discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &#x201c;Level 3&#x201d; in the fair value hierarchy. The section &#x201c;&mdash;Impairment of goodwill and intangible assets&#x201d; in Note 1 to the Consolidated Financial Statements of the 2019 Annual Report provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional disclosures, refer to Notes 3 and 10.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory', window );">Description of accounting policy for business combinations [text block]</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">New IFRS standard effective as&nbsp;of&nbsp;January 1, 2020</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combination amendments</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired or disposed of should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the entity may choose to consider the transaction an acquisition of an asset or set of assets. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of accounting policies relevant to an understanding of financial statements, which the entity does not separately disclose.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DistributionByWayOfDivindendInKindToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DistributionByWayOfDivindendInKindToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715797930440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsAbstract', window );"><strong>Disclosure of significant transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock', window );">Assets and liabilities of disposal group classified as held for sale</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets of disposal group classified as held for sale</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 475</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities of disposal group classified as held for sale</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock', window );">Net gain at completion of spin-off</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> April 8, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net assets derecognized <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;025</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derecognition of distribution liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;434</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Difference between net assets and distribution liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;409</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Recognition of Alcon Inc. shares obtained <br></br>through consolidated foundations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;273 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation gains recycled into the <br></br>consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 123 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs recognized in the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;114</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> See Note 10 for additional information. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796561048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of equity attributable to Novartis AG shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfEquityAbstract', window );"><strong>Disclosure of equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SummaryOfTreasurySharesMovementsTableTextBlock', window );">Summary of treasury shares movements [table text block]</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Number of outstanding shares (in millions) </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Issued share capital and reserves attributable to Novartis AG shareholders (in USD millions)</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;265.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;614</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in accounting policy <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated equity at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;617</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be cancelled</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;819</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;153</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 823</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 365</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 447</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase obligation under a share buyback trading plan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;289</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends to shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;987</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;645</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend in kind to effect the spin-off of Alcon Inc. <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23&nbsp;434</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income of the period attributable to shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;043</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;565</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income attributable to shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;667</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;253</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at June 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;289.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;291.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;812</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;426</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In H1 2019, the impact of change in accounting policy includes USD 3 million related to the implementation of IFRS 16 Leases. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Included in H1 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. <br></br>This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Fair value of the dividend in kind of Alcon Inc. shares to Novartis AG shareholders (see Notes 2 and 3 for further details). </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> In H1 2019, Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Impact of hyperinflationary economies </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SummaryOfTreasurySharesMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SummaryOfTreasurySharesMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796407864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract', window );"><strong>Financial Instruments - additional disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Fair value by hierarchy</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 1</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 2</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 3</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;443</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;557</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 235</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 235</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 444</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 444</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;189</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit or loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;059</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;065</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock', window );">Disclosure of detailed information about borrowings</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Coupon </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Currency </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Nominal amount <br></br> (USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Maturity year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issuer </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issue price </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Carrying value <br></br> Jun 30, 2020 <br></br> (USD millions) </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.75%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.852%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 996</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.00%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.909%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.20%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.869%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;492</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.75%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2050</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97.712%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;213</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796447560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract', window );"><strong>Disclosure of details to the consolidated statements of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock', window );">Adjustments for non-cash items from continuing operations</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 319</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 371</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 601</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 958</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Losses/gains on disposal and other adjustments on property, plant and equipment; intangible assets; <br></br>financial assets; and other non-current assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;615 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 174</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;176</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 247</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 205</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;345</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;085</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 700</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 149</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;619</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 838</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;018</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets; <br></br>financial assets; and other non-current assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;55 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;684 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 377</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 372</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 493</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 387</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;101</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock', window );">Cash flows arising from acquisitions and divestments of businesses</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of business combinations</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;407</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;030</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;486</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables and payables contingent consideration, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;367</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash flows from/used for divestments of businesses, net <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;286</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;901</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;382</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In the second quarter of 2020 and 2019, the USD 2 million represented the net cash inflows for previous years divestments. <br></br>During the first half of 2020, the USD 13 million included USD 15 million net cash outflows for previous years divestments (H1 2019: USD 15 million) and a prepaid sales price of USD 2 million for a business divestment. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715729522440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of businesses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract', window );"><strong>Disclosure of acquisition of businesses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock', window );">Fair value of assets and liabilities arising from acquisitions</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;602</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 449</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 470</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables, marketable securities <br></br>and other current assets </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 109 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;928</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;569</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 411</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;537</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 486</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAcquisitionOfBusinessesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732598296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segmentation - Consolidated income statements</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;262</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;407</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;503</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;475</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;262</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 260</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;554</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;327</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;406</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;066</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;618</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;764</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;911</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;496</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;585</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;240</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;853</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;198</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;051</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 847</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 97</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 432</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 989</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;945</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;308</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;033</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;564</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;352</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;663</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 22.1%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 27.5%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 14.9%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11.6%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 20.7%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 22.6%</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;205</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;634</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;525</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;109</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;800</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;870</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 409</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;449</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;352</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;532</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;779</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;840</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;449</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;923</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 700</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 556</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;080</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;614</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;591</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 485</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;657</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;779</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;822</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;564</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;854</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;915</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;392</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;350</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 922</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 693</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;192</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;319</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;844</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;788</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 276</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 555</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;096</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;905</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 25.3%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 25.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 5.9%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11.6%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 21.6%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 21.4%</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;459</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;431</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;909</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;774</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;977</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain <br></br>on distribution of Alcon Inc. to Novartis AG shareholders </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;040</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;567</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock', window );">Segmentation - Consolidated balance sheets and income statement</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 81&nbsp;373</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;225</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;229</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;468</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;161</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30&nbsp;677</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 123&nbsp;763</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;14&nbsp;690</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;332</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;681</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;804</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;51&nbsp;507</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;43&nbsp;683</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;69&nbsp;878</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;62&nbsp;819</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;885</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;537</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;537</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 66&nbsp;683</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;893</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;548</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;664</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;191</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;932</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 80&nbsp;422</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;489</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net operating assets are:</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;485</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;632</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;943</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;888</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 527</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 549</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;955</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;257</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;835</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;524</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&nbsp;877</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27&nbsp;586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;669</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the intangible asset impairment charges for continuing operations:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;500</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;509</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;466</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;478</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Q2 2020 and H1 2020 include an impairment of USD 485 million related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis. <br></br>H1 2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;D acquired through the 2015 Spinifex Pharmaceuticals Inc. acquisition. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock', window );">Net sales by region</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region</font> <font style="font-family:arial,helvetica,sans-serif; font-size:6pt; color:#000000; font-weight:bold; vertical-align:super;">1</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change <br></br> cc <sup style="white-space: nowrap"> 2</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020 <br></br> % of total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019 <br></br> % of total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;964</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 666</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;909</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;130</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 52</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 508</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 333</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;796</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 538</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;094</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;978</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;439</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 766</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 860</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;347</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;764</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;817</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;897</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region</font> <font style="font-family:arial,helvetica,sans-serif; font-size:6pt; color:#000000; font-weight:bold; vertical-align:super;">1</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change <br></br> cc <sup style="white-space: nowrap"> 2</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020 <br></br> % of total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019 <br></br> % of total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;352</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;302</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;468</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;078</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;232</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 675</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 651</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 371</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;862</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;135</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;561</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;595</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;870</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;898</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;741</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales from operations by location of third-party customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock', window );">Other revenue</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit sharing income</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 209</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 209</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 182</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 251</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 260</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit sharing income</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 407</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 350</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 407</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 351</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 69</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 700</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 556</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock', window );">Net sales by business franchise</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 468</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 422</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 349</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 371</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 340</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 310</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 253</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;548</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;606</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 944</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 858</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 937</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 825</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 886</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 580</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 580</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 427</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 289</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 290</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Ultibro</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 444</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Voltaren/Cataflam</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;749</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;640</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;720</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 902</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 825</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 715</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 795</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 628</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 380</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 215</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 545</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;927</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;874</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 413</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;965</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 974</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;591</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 375</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;045</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;683</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 778</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 790</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 596</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 571</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Ultibro</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 309</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 915</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 906</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 635</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 544</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 496</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 240</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 197</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Voltaren/Cataflam</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;747</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div> </td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock', window );">Net sales of Top 20 products</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales of the top 20 Innovative Medicines Division products in 2020 </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD/cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="12%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right" width="1%"></td> <td width="12%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Immunology, <br></br> Hepatology and <br></br> Dermatology </div> </td> <td align="right" width="1%"></td> <td width="12%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis and <br></br> psoriatic arthritis <br></br> and non-radiographic <br></br> axial spondyloarthritis </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 614 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 15 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 330 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 2 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 6 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 944 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 10 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 12 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 416</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 322</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br></br> Renal and <br></br> Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 308 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 272 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 36 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 41 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 580 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 38 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 40 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Lucentis </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Ophthalmology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related <br></br> macular degeneration </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 401 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;25 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 401 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;25 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;24 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune <br></br> thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 212 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 25 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 210 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 422 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 23 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic <br></br> and adjuvant melanoma; <br></br> advanced non-small cell <br></br> lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 147 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 20 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 224 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 371 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 12 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Sandostatin </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors <br></br> and acromegaly </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 200 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 141 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;19 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 341 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;13 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycytomia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 310 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 310 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Gleevec/Glivec </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid <br></br> leukemia and GIST </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 70 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;27 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 218 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 288 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe Allergic Asthma (SAA) <br></br> and Chronic Spontaneous <br></br> Urticaria (CSU) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 289 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 289 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 4 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 234</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br></br> Hepatology and <br></br> Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, <br></br> SJIA, AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 95 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 105 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 19 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 200 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 23 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Zolgensma </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Neuroscience </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy <br></br> (SMA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 105 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 100 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 205 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Kisqali</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 743</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;084</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales of the top 20 Innovative Medicines Division products in 2020 </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD/cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br></br> change <br></br> cc <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="12%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right" width="1%"></td> <td width="12%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Immunology, <br></br> Hepatology and <br></br> Dermatology </div> </td> <td align="right" width="1%"></td> <td width="12%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis and <br></br> psoriatic arthritis <br></br> and non-radiographic <br></br> axial spondyloarthritis </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 1&nbsp;190 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 18 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 684 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 7 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 11 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 1&nbsp;874 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 14 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 15 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 804</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 706</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br></br> Renal and <br></br> Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 601 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 43 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 548 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 53 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 58 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 1&nbsp;149 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 48 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 50 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Lucentis </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Ophthalmology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related <br></br> macular degeneration </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 888 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 888 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune <br></br> thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 399 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 25 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 426 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 26 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 30 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 825 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 26 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 28 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic <br></br> and adjuvant melanoma; <br></br> advanced non-small cell <br></br> lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 279 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 458 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 13 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 737 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 19 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Sandostatin </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors <br></br> and acromegaly </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 413 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 302 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;17 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 715 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;10 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycytomia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 628 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 20 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 628 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 20 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Gleevec/Glivec </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid <br></br> leukemia and GIST </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 174 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 443 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 617 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe Allergic Asthma (SAA) <br></br> and Chronic Spontaneous <br></br> Urticaria (CSU) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 596 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 596 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 482</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 496</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br></br> Hepatology and <br></br> Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, <br></br> SJIA, AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 183 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 29 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 230 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 32 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 36 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 413 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 31 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 33 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Zolgensma <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Neuroscience </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy <br></br> (SMA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 231 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 144 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 375 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> nm </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 257</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 192</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Kisqali</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;494</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;855</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;449</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;886</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;943</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Includes a reclassification of export sales from the US into rest of the world in the amount of USD 44 million that were in Q1 2020 classified within US net sales. This reclassification has no impact on the reported Q1 2020 total <i>Zolgensma</i> net sales. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock', window );">Net sales by business franchise</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>Second quarter</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc <sup style="white-space: nowrap"> 2</sup> </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;576</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;903</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Of which USD 134 million (2019: USD 186 million) represents Anti-Infectives sold under Sandoz name </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> <b>First half</b> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change</div> </td> <td></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> cc <sup style="white-space: nowrap"> 2</sup> </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;545</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;753</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 916</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 752</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;687</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;764</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Of which USD 356 million (2019: USD 390 million) represents Anti-Infectives sold under Sandoz name </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 54. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2020 and 2019.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715796565384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations (Tables) - Discontinued operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock', window );">Consolidated income statement, discontinued operations</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from discontinued <br></br>operations </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;777 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;809</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;860</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 949</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;638</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;142</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 4.0%</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;159</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net loss from discontinued operations before gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> As the Alcon spin-off was completed on April 9, 2019, the Q2 2019 results of operations from the Alcon business were not material. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> See Note 3 for further details on the non-taxable non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders recognized on April 8, 2019, date of Distribution. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock', window );">Cash flows used in investing activities</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments attributable to the spin-off of the Alcon business</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divested cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;628</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;628</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows attributable to the spin-off of the Alcon business</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;642</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other cash flows used in investing activities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;463</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in investing activities from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;682</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;105</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715722704264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 07, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 09, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 06, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,030,000,000<span></span>
</td>
<td class="nump">$ 486,000,000<span></span>
</td>
<td class="nump">$ 10,030,000,000<span></span>
</td>
<td class="nump">$ 486,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Profit (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,669,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,669,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,787,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,347,000,000<span></span>
</td>
<td class="nump">11,764,000,000<span></span>
</td>
<td class="nump">23,630,000,000<span></span>
</td>
<td class="nump">22,923,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,877,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,877,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,586,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,407,000,000<span></span>
</td>
<td class="nump">9,503,000,000<span></span>
</td>
<td class="nump">19,352,000,000<span></span>
</td>
<td class="nump">18,532,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,202,000,000<span></span>
</td>
<td class="nump">2,475,000,000<span></span>
</td>
<td class="nump">4,779,000,000<span></span>
</td>
<td class="nump">4,840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (262,000,000)<span></span>
</td>
<td class="num">(214,000,000)<span></span>
</td>
<td class="num">$ (501,000,000)<span></span>
</td>
<td class="num">$ (449,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DetailedInformationAboutSignificantTransaction', window );">Detailed information about significant transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval. In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as regulatory approval from the US Federal Trade Commission was not obtained within the SAPA agreed timelines. The cumulative amount of the depreciation on property, plant and equipment and amortization on intangible assets, not recorded in the consolidated income statement since the date of classification as held for sale, amounting to USD 38 million and USD 102 million, respectively, was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement. As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated. In the Group&#8217;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following: There are no cumulative income or expenses included in other comprehensive income relating to the disposal group.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember', window );">Sandoz | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DivestmentDateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, divestment-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember', window );">Aspen Global Incorporated | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DetailedInformationAboutSignificantTransaction', window );">Detailed information about significant transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020. Aspen&#8217;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace. The purchase price consist of EUR 300 million (USD 331 million) upfront payment, less customary purchase price adjustment of EUR 29 million (USD 32 million), plus potential milestone payments of up to EUR 120 million (USD 132 million), which AGI is eligible to receive upon the achievement of specified milestones. The fair value of the total purchase consideration was EUR 342 million (USD 377 million). The amount consisted of an initial cash payment of EUR 271 million (USD 299 million) and the fair value of contingent consideration of EUR 71 million (USD 78 million), which they are eligible to receive upon the achievement of specified milestones. The preliminary purchase price allocation resulted in net identifiable assets of approximately USD 308 million, consisting of USD 269 million intangible assets, USD 26 million other net assets, USD 13 million net deferred tax assets and goodwill of approximately USD 69 million. Results of operations since the date of acquisition were not material.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="nump">$ 381,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="num">(301,000,000)<span></span>
</td>
<td class="num">&#8364; (273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="num">(331,000,000)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="nump">309,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">269,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="nump">132,000,000<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CustomaryPurchasePriceAdjustment', window );">Customary purchase price adjustment</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">&#8364; 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember', window );">The Medicines Company | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DetailedInformationAboutSignificantTransaction', window );">Detailed information about significant transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#8217;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#8217; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels. The fair value of the total purchase consideration was USD 9.6 billion. The preliminary purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. Results of operations since the date of acquisition were not material.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,600,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashOfferPerOrdinaryShare', window );">Cash offer per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DetailedInformationAboutSignificantTransaction', window );">Detailed information about significant transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with Xiidra (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. The fair value of the total purchase consideration is USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimates that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,500,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueOfAcquiree', window );">Revenue of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueOfAcquireeFullYear', window );">Revenue of acquiree full year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CustomaryPurchasePriceAdjustment', window );">Customary purchase price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_IFMTreInc.Member', window );">IFM Tre, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DetailedInformationAboutSignificantTransaction', window );">Detailed information about significant transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&#8217;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gutdirected molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule. The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangibles, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_IFMTreInc.Member', window );">IFM Tre, Inc. | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Divested interest in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate', window );">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination', window );">Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_PowerVisionInc.Member', window );">PowerVision, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DetailedInformationAboutSignificantTransaction', window );">Detailed information about significant transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately-held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the net present value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets, of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition are not material. For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 3.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Profit (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,590,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPayable', window );">Dividend in kind distribution liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,434,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed', window );">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,409,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | Alcon [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RepaymentOfIntercompanyBalances', window );">Repayment of intercompany balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPayable', window );">Dividend in kind distribution liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners', window );">Decrease of distribution liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionalBorrowings', window );">Additional borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PercentageOfEquityInterestSharesReceived', window );">Percentage of equity interest shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | Alcon [member] | Borrowings, USD [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | Alcon [member] | Borrowings, EUR [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | Alcon [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DetailedInformationAboutSignificantTransaction', window );">Detailed information about significant transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.). The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets. The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April 9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &#8220;ALC.&#8221; The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019. On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates. At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&#8217;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets. Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&#8217;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income. The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of: For additional disclosure on discontinued operations, refer to Note 10.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | PowerVision, Inc. | Alcon [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(289,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph p<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_p_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of difference between the carrying amount of dividends payable and the carrying amount of non-cash assets distributed when settling the dividends payable. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 15<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_15&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends payable by means of the distribution of non-cash assets to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) recognised as result of remeasuring to fair value the equity interest in the acquiree held by the acquirer before the business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph p<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_p_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in dividends payable through a change in the fair value of non-cash assets held for distribution to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph IG63<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 40<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOfferPerOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOfferPerOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomaryPurchasePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomaryPurchasePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DetailedInformationAboutSignificantTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DetailedInformationAboutSignificantTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestmentDateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestmentDateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfEquityInterestSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfEquityInterestSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialMilestoneMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialMilestoneMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RepaymentOfIntercompanyBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RepaymentOfIntercompanyBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueOfAcquireeFullYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueOfAcquireeFullYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_IFMTreInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_IFMTreInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_PowerVisionInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_PowerVisionInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsUSDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsUSDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsEURMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsEURMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715724563448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant transactions (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract', window );"><strong>Assets of disposal group classified as held for sale [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 11,955<span></span>
</td>
<td class="nump">$ 12,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">36,669<span></span>
</td>
<td class="nump">28,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">8,601<span></span>
</td>
<td class="nump">7,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">6,904<span></span>
</td>
<td class="nump">5,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other current assets</a></td>
<td class="nump">2,733<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract', window );"><strong>Liabilities of disposal group classified as held for sale [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">7,499<span></span>
</td>
<td class="nump">5,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Provisions and other non-current liabilities</a></td>
<td class="nump">7,344<span></span>
</td>
<td class="nump">6,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Provisions and other current liabilities</a></td>
<td class="nump">$ 12,858<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember', window );">Assets and liabilities classified as held for sale [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract', window );"><strong>Assets of disposal group classified as held for sale [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract', window );"><strong>Liabilities of disposal group classified as held for sale [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Provisions and other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Provisions and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 38<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 38<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732569112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement', window );">Cumulative currency translation gains/losses recycled through income statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetAssetsDerecognized', window );">Net assets derecognized</a></td>
<td class="num">$ (20,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPayable', window );">Derecognition of distribution liability</a></td>
<td class="nump">23,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed', window );">Difference between net assets and distribution liability</a></td>
<td class="nump">3,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DistributionOfDividendToDividendBearingShares', window );">Distribution of dividend to dividend bearing shares</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement', window );">Cumulative currency translation gains/losses recycled through income statement</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionCosts', window );">Transaction costs recognized in the consolidated income statement</a></td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution</a></td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_AlconMember', window );">Alcon | Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPayable', window );">Derecognition of distribution liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of difference between the carrying amount of dividends payable and the carrying amount of non-cash assets distributed when settling the dividends payable. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 15<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_15&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends payable by means of the distribution of non-cash assets to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DistributionOfDividendToDividendBearingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DistributionOfDividendToDividendBearingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetAssetsDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetAssetsDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715724629848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of equity attributable to Novartis AG shareholders (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="nump">$ 50,977<span></span>
</td>
<td class="nump">$ 47,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 55,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">823<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation, equity impact</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">365<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">30<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">Increase of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,573)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,987)<span></span>
</td>
<td class="num">(6,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DividendPaidNoncashAssetsDistribution', window );">Dividend in kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,927<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">8,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">175<span></span>
</td>
<td class="num">(667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionCostsRecordedInEquity', window );">Transaction costs recorded in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="nump">53,885<span></span>
</td>
<td class="nump">51,504<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 53,885<span></span>
</td>
<td class="nump">51,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember', window );">Increase (decrease) due to changes in accounting policy required by IFRSs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember', window );">Restated Value Adjustments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember', window );">Equity attributable to owners of parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,265.0<span></span>
</td>
<td class="nump">2,311.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="nump">50,903<span></span>
</td>
<td class="nump">47,229<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 55,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredToBeCancelled', window );">Shares acquired to be cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredForCancellationValue', window );">Shares acquired for cancellation, equity impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherSharePurchases', window );">Other share purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherSharePurchasesValue', window );">Other share purchases, equity impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (150)<span></span>
</td>
<td class="num">$ (153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares', window );">Exercise of options and employee transactions shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 823<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_EquityBasedCompensationShares', window );">Equity based compensation shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation, equity impact</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployees', window );">Shares delivered to divested business employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">30<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">Increase of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,573)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,987)<span></span>
</td>
<td class="num">(6,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DividendPaidNoncashAssetsDistribution', window );">Dividend in kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,927<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">6,799<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,043<span></span>
</td>
<td class="nump">8,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">176<span></span>
</td>
<td class="num">(667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionCostsRecordedInEquity', window );">Transaction costs recorded in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period</a></td>
<td class="nump">2,289.0<span></span>
</td>
<td class="nump">2,291.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,289.0<span></span>
</td>
<td class="nump">2,291.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="nump">$ 53,812<span></span>
</td>
<td class="nump">$ 51,426<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 53,812<span></span>
</td>
<td class="nump">$ 51,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember', window );">Equity attributable to owners of parent [member] | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember', window );">Equity attributable to owners of parent [member] | Increase (decrease) due to changes in accounting policy required by IFRSs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember', window );">Equity attributable to owners of parent [member] | Restated Value Adjustments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,617<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in Q2 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares that are recognized through retained earnings. This revaluation resulted from the Swiss Federal tax reform enacted in May 2019, effective January 1, 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Transaction costs directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 107<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DividendPaidNoncashAssetsDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DividendPaidNoncashAssetsDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityBasedCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityBasedCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ExerciseOfOptionsAndEmployeeTransactionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherSharePurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherSharePurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherSharePurchasesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherSharePurchasesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxesOnTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxesOnTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionCostsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionCostsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesAcquiredForCancellationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesAcquiredForCancellationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesAcquiredToBeCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesAcquiredToBeCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715722592792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments (Details) - Recurring fair value measurement [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Long term financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">2,122<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Long term financial investments [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Long term financial investments [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Long term financial investments [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Long term financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">904<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Long term financial investments [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">904<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Long term financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">1,218<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_FundInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_FundInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_TotalAvailableforsaleMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_TotalAvailableforsaleMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_LongTermFinancialInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_LongTermFinancialInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_AvailableforsaleFinancialInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_AvailableforsaleFinancialInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715763742056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">$ (27,700)<span></span>
</td>
<td class="num">$ (23,700)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(1,185)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member] | Contingent consideration payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(1,039)<span></span>
</td>
<td class="num">(1,036)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member] | Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(1,059)<span></span>
</td>
<td class="num">(1,065)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Contingent consideration payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(1,039)<span></span>
</td>
<td class="num">(1,036)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715794568824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets', window );">Transfers out of Level 3 of fair value hierarchy, assets</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">27,700<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">25,200<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_AlconMember', window );">Alcon [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GainLossOnSaleOfOtherFinancialAssets', window );">Gain (loss) on sale of other financial assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueOfOtherFinancialAssetsSold', window );">Fair value of other financial assets sold</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfOtherFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfOtherFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainLossOnSaleOfOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainLossOnSaleOfOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715763686040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Details 4)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member', window );">Novartis Capital Corporation, New York, United States, 1.75%, 2025 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.852%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member', window );">Novartis Capital Corporation, New York, United States, 2.00%, 2027 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.909%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member', window );">Novartis Capital Corporation, New York, United States, 2.20%, 2030 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.869%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member', window );">Novartis Capital Corporation, New York, United States, 2.75%, 2050 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">97.712%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsOriginalCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The currency in which the borrowings are denominated. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsOriginalCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsPremiumDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsPremiumDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715763685224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities', window );">Non-cash change in provisions and other non-current liabilities</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(615)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(684)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Equity-settled compensation expense</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Net financial expense</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total</a></td>
<td class="nump">2,345<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
<td class="nump">5,202<span></span>
</td>
<td class="nump">4,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember', window );">Financial assets impaired [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">$ (166)<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">$ (127)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss; Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 14<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715725350472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Income taxes paid (refund)</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid (refund), classified as operating activities</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid (refund), classified as operating activities</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities', window );">Income taxes paid (refund), classified as investing activities</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid (refund), classified as operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as investing activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715724433496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (286)<span></span>
</td>
<td class="num">$ (9,901)<span></span>
</td>
<td class="num">$ (382)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowFromNetIdentifiableAssets', window );">Net assets recognized as a result of business combinations</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="num">(10,030)<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate', window );">Fair value of previously held equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ReceivablesAndPayablesContingentConsiderationNet', window );">Receivables and payables contingent consideration, net</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherPaymentsAndDeferredConsiderationNet', window );">Payments, deferred consideration and other adjustments, net</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="num">(9,888)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember', window );">Divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetCashOutflowsFromDivestments', window );">Net cash outflows from divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PrepaidSalesPriceForABusinessDivestment', window );">Prepaid sales price for a business divestment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowFromNetIdentifiableAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow (outflow) from Net identifiable assets (acquired) or divested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowFromNetIdentifiableAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetCashOutflowsFromDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetCashOutflowsFromDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherPaymentsAndDeferredConsiderationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherPaymentsAndDeferredConsiderationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrepaidSalesPriceForABusinessDivestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrepaidSalesPriceForABusinessDivestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReceivablesAndPayablesContingentConsiderationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReceivablesAndPayablesContingentConsiderationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715734897128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of businesses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RightOfUseAssetsAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Currently marketed products</a></td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Acquired research and development</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate', window );">Deferred tax assets</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FinancialAndOtherAssets', window );">Financial and other assets</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventories</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate', window );">Trade receivables and other current assets</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities</a></td>
<td class="num">(1,928)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate', window );">Current and non-current financial debts</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate', window );">Current and non-current lease liabilities</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TradePayablesAndOtherLiabilities', window );">Trade payables and other liabilities</a></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IdentifiableAssetsAcquired', window );">Net identifiable assets acquired</a></td>
<td class="nump">7,569<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AcquiredCashAndCashEquivalents', window );">Acquired cash and cash equivalents</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="nump">2,537<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets recognized as a result of business combinations</a></td>
<td class="nump">10,030<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GoodwillExpectedDeductibleForTaxPurposes', window );">Goodwill expected to be deductible for tax purposes</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for financial liabilities assumed in a business combination. [Refer: Financial liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillExpectedDeductibleForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill in a business combination that is expected to be deductible for tax purposes. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_k&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillExpectedDeductibleForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquiredCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquiredCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IdentifiableAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IdentifiableAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RightOfUseAssetsAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RightOfUseAssetsAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradePayablesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradePayablesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715725350216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details) - Legal proceedings provision [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AmountOfSettlementInPrinciple', window );">Amount of settlement in principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions', window );">Product liability, government investigations, other legal matters provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments', window );">Product liability, government investigations, other legal matters provisions, payments</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_LegalProceedingsProvisionMember', window );">US | Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent', window );">Product liability, government investigations, other legal matters provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AmountOfSettlementInPrinciple', window );">Amount of settlement in principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_LegalProceedingsProvisionMember', window );">US | NPC and others [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AmountOfSettlementInPrinciple', window );">Amount of settlement in principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions', window );">Product liability, government investigations, other legal matters provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments', window );">Product liability, government investigations, other legal matters provisions, payments</a></td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountOfSettlementInPrinciple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountOfSettlementInPrinciple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_LegalProceedingsProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_LegalProceedingsProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NPCAndOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NPCAndOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715763715208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NumberOfBusinessUnits', window );">Number of Business Units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NumberOfFranchises', window );">Number of Franchises</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfBusinessUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfBusinessUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfFranchises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfFranchises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732012808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="nump">$ 11,764<span></span>
</td>
<td class="nump">$ 23,630<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="nump">11,347<span></span>
</td>
<td class="nump">11,764<span></span>
</td>
<td class="nump">23,630<span></span>
</td>
<td class="nump">22,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(3,429)<span></span>
</td>
<td class="num">(3,406)<span></span>
</td>
<td class="num">(7,151)<span></span>
</td>
<td class="num">(6,657)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="nump">8,193<span></span>
</td>
<td class="nump">8,618<span></span>
</td>
<td class="nump">17,179<span></span>
</td>
<td class="nump">16,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(3,368)<span></span>
</td>
<td class="num">(3,585)<span></span>
</td>
<td class="num">(6,854)<span></span>
</td>
<td class="num">(6,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="num">(2,441)<span></span>
</td>
<td class="num">(2,051)<span></span>
</td>
<td class="num">(4,501)<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(464)<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
<td class="num">(1,421)<span></span>
</td>
<td class="num">(1,844)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="nump">$ 2,352<span></span>
</td>
<td class="nump">$ 2,663<span></span>
</td>
<td class="nump">$ 5,096<span></span>
</td>
<td class="nump">$ 4,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales', window );">Profit (loss) from operating activities, as a percentage from net sales</a></td>
<td class="nump">20.70%<span></span>
</td>
<td class="nump">22.60%<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
<td class="nump">21.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes from continuing operations</a></td>
<td class="nump">2,288<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">4,909<span></span>
</td>
<td class="nump">4,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes</a></td>
<td class="num">(421)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
<td class="num">(797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">3,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution', window );">Net income/loss from discontinued operations before gain on distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income/loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">8,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">9,188<span></span>
</td>
<td class="nump">9,326<span></span>
</td>
<td class="nump">18,943<span></span>
</td>
<td class="nump">18,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="nump">9,407<span></span>
</td>
<td class="nump">9,503<span></span>
</td>
<td class="nump">19,352<span></span>
</td>
<td class="nump">18,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(2,554)<span></span>
</td>
<td class="num">(2,327)<span></span>
</td>
<td class="num">(5,080)<span></span>
</td>
<td class="num">(4,551)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="nump">7,104<span></span>
</td>
<td class="nump">7,426<span></span>
</td>
<td class="nump">14,779<span></span>
</td>
<td class="nump">14,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(2,764)<span></span>
</td>
<td class="num">(2,911)<span></span>
</td>
<td class="num">(5,621)<span></span>
</td>
<td class="num">(5,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="num">(2,240)<span></span>
</td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(4,106)<span></span>
</td>
<td class="num">(3,958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">847<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(945)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="num">(1,219)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="nump">$ 2,033<span></span>
</td>
<td class="nump">$ 2,564<span></span>
</td>
<td class="nump">$ 4,788<span></span>
</td>
<td class="nump">$ 4,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales', window );">Profit (loss) from operating activities, as a percentage from net sales</a></td>
<td class="nump">22.10%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="nump">25.30%<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">2,159<span></span>
</td>
<td class="nump">2,438<span></span>
</td>
<td class="nump">4,687<span></span>
</td>
<td class="nump">4,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="nump">2,202<span></span>
</td>
<td class="nump">2,475<span></span>
</td>
<td class="nump">4,779<span></span>
</td>
<td class="nump">4,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(1,158)<span></span>
</td>
<td class="num">(1,315)<span></span>
</td>
<td class="num">(2,614)<span></span>
</td>
<td class="num">(2,591)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(496)<span></span>
</td>
<td class="num">(550)<span></span>
</td>
<td class="num">(1,016)<span></span>
</td>
<td class="num">(1,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="num">(395)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="num">(562)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales', window );">Profit (loss) from operating activities, as a percentage from net sales</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsSalesToOtherSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732167976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segmentation of key figures (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">$ 123,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(69,878)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">53,885<span></span>
</td>
<td class="nump">$ 50,977<span></span>
</td>
<td class="nump">55,551<span></span>
</td>
<td class="nump">$ 51,504<span></span>
</td>
<td class="nump">$ 47,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">26,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">80,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">11,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">36,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">81,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(14,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">66,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">9,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">34,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">16,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(3,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">12,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">26,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(51,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">26,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">1,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.
Effective 2020-01-01: The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2019-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2019-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.
Effective 2020-01-01: The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732159496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 4) - Accumulated depreciation, amortisation and impairment - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">$ (500)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (551)<span></span>
</td>
<td class="num">$ (478)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Spinifex | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">ZPL389 [member] | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Innovative Medicines | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
<td class="num">(466)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Sandoz | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SpinifexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SpinifexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZPL389Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZPL389Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715721361816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="nump">$ 11,764<span></span>
</td>
<td class="nump">$ 23,630<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember', window );">Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 4,094<span></span>
</td>
<td class="nump">$ 4,487<span></span>
</td>
<td class="nump">$ 8,924<span></span>
</td>
<td class="nump">$ 8,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 4,023<span></span>
</td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 8,135<span></span>
</td>
<td class="nump">$ 7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,464<span></span>
</td>
<td class="nump">$ 2,439<span></span>
</td>
<td class="nump">$ 4,976<span></span>
</td>
<td class="nump">$ 4,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember', window );">Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">$ 1,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember', window );">Canada and Latin America [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember', window );">Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 8,530<span></span>
</td>
<td class="nump">$ 8,867<span></span>
</td>
<td class="nump">$ 17,732<span></span>
</td>
<td class="nump">$ 17,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember', window );">Established Markets [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember', window );">Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,817<span></span>
</td>
<td class="nump">$ 2,897<span></span>
</td>
<td class="nump">$ 5,898<span></span>
</td>
<td class="nump">$ 5,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember', window );">Emerging Growth Markets [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 9,188<span></span>
</td>
<td class="nump">$ 9,326<span></span>
</td>
<td class="nump">$ 18,943<span></span>
</td>
<td class="nump">$ 18,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,964<span></span>
</td>
<td class="nump">$ 3,218<span></span>
</td>
<td class="nump">$ 6,366<span></span>
</td>
<td class="nump">$ 6,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Europe [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 3,515<span></span>
</td>
<td class="nump">$ 3,336<span></span>
</td>
<td class="nump">$ 7,057<span></span>
</td>
<td class="nump">$ 6,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="nump">$ 2,106<span></span>
</td>
<td class="nump">$ 4,301<span></span>
</td>
<td class="nump">$ 4,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Asia/Africa/Australasia [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">$ 666<span></span>
</td>
<td class="nump">$ 1,219<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Canada and Latin America [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 6,909<span></span>
</td>
<td class="nump">$ 7,071<span></span>
</td>
<td class="nump">$ 14,266<span></span>
</td>
<td class="nump">$ 13,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Markets [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,279<span></span>
</td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="nump">$ 4,677<span></span>
</td>
<td class="nump">$ 4,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Emerging Growth Markets [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,159<span></span>
</td>
<td class="nump">$ 2,438<span></span>
</td>
<td class="nump">$ 4,687<span></span>
</td>
<td class="nump">$ 4,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,130<span></span>
</td>
<td class="nump">$ 1,269<span></span>
</td>
<td class="nump">$ 2,558<span></span>
</td>
<td class="nump">$ 2,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Europe [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 1,078<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | US | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="nump">$ 651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Asia/Africa/Australasia [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Canada and Latin America [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,621<span></span>
</td>
<td class="nump">$ 1,796<span></span>
</td>
<td class="nump">$ 3,466<span></span>
</td>
<td class="nump">$ 3,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Established Markets [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Emerging Growth Markets [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715727169576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 6) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="nump">$ 11,764<span></span>
</td>
<td class="nump">$ 23,630<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember', window );">Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 9,188<span></span>
</td>
<td class="nump">9,326<span></span>
</td>
<td class="nump">$ 18,943<span></span>
</td>
<td class="nump">18,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 3,548<span></span>
</td>
<td class="nump">3,606<span></span>
</td>
<td class="nump">$ 7,196<span></span>
</td>
<td class="nump">6,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">$ 967<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Tasigna [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Sandostatin [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Afinitor/Votubia [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(33.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Promacta/Revolade [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Gleevec/Glivec [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Jakavi [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Exjade/Jadenu [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(36.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(35.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Votrient [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Kisqali [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Lutathera [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Lutathera [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Kymriah [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">103.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">103.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Piqray [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Adakveo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Other [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 5,640<span></span>
</td>
<td class="nump">5,720<span></span>
</td>
<td class="nump">$ 11,747<span></span>
</td>
<td class="nump">11,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(25.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Xiidra [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Beovu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Other [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(32.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="nump">$ 2,045<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Aimovig [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Aimovig [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Mayzent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Other [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(26.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Ultibro Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Other [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">$ 1,149<span></span>
</td>
<td class="nump">778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Other [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">$ 3,217<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">$ 542<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Other [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,144<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">$ 2,287<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 944<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="nump">$ 1,874<span></span>
</td>
<td class="nump">1,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessUnitAxis=nvs_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessUnitAxis=nvs_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessUnitAxis=nvs_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessUnitAxis=nvs_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_OphthalmologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_OphthalmologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_RespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_RespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_CardioMetabolicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_CardioMetabolicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_EstablishedMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_EstablishedMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715716850440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 7) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="nump">$ 11,764<span></span>
</td>
<td class="nump">$ 23,630<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember', window );">Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 4,023<span></span>
</td>
<td class="nump">3,978<span></span>
</td>
<td class="nump">$ 8,135<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 9,188<span></span>
</td>
<td class="nump">9,326<span></span>
</td>
<td class="nump">$ 18,943<span></span>
</td>
<td class="nump">18,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 7,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Top 20 products [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of portfolio [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 3,548<span></span>
</td>
<td class="nump">3,606<span></span>
</td>
<td class="nump">$ 7,196<span></span>
</td>
<td class="nump">6,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">$ 967<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Tasigna [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Promacta/Revolade [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Sandostatin [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Jakavi [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Gleevec/Glivec [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Afinitor/Votubia [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(33.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Exjade/Jadenu [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(36.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(35.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Votrient [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Kisqali [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 5,640<span></span>
</td>
<td class="nump">5,720<span></span>
</td>
<td class="nump">$ 11,747<span></span>
</td>
<td class="nump">11,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(25.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="nump">$ 2,045<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ReclassificationOfExportSales', window );">Reclassification of export sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">$ 1,149<span></span>
</td>
<td class="nump">778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">$ 3,217<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">$ 542<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,144<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">$ 2,287<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 944<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="nump">$ 1,874<span></span>
</td>
<td class="nump">1,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 3,515<span></span>
</td>
<td class="nump">$ 3,336<span></span>
</td>
<td class="nump">$ 7,057<span></span>
</td>
<td class="nump">$ 6,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Top 20 products [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Rest of portfolio [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Sandostatin [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(37.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(71.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Votrient [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(50.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 5,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 4,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Top 20 products [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Rest of portfolio [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Sandostatin [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(19.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Votrient [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(25.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReclassificationOfExportSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReclassificationOfExportSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_Top20ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_Top20ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessUnitAxis=nvs_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessUnitAxis=nvs_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessUnitAxis=nvs_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessUnitAxis=nvs_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_OphthalmologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_OphthalmologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_RespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_RespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_CardioMetabolicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_CardioMetabolicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_EstablishedMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_EstablishedMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715732699736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 8) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="nump">$ 11,764<span></span>
</td>
<td class="nump">$ 23,630<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember', window );">Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,159<span></span>
</td>
<td class="nump">2,438<span></span>
</td>
<td class="nump">$ 4,687<span></span>
</td>
<td class="nump">4,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Retail Generics [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,576<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">$ 3,545<span></span>
</td>
<td class="nump">3,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Retail Generics [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Biopharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Biopharmaceuticals [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Anti Infectives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Anti Infectives [member] | Change over period [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc', window );">Net sales, change in %, cc</a></td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Anti Infectives [member] | Anti Infectives sold under Sandoz name [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_RetailGenericsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_RetailGenericsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_AntiInfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_AntiInfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715730170056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 407<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MilestoneIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MilestoneIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherRevenueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherRevenueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProfitSharingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProfitSharingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715729505912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="nump">$ 11,764<span></span>
</td>
<td class="nump">$ 23,630<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,347<span></span>
</td>
<td class="nump">11,764<span></span>
</td>
<td class="nump">23,630<span></span>
</td>
<td class="nump">22,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,429)<span></span>
</td>
<td class="num">(3,406)<span></span>
</td>
<td class="num">(7,151)<span></span>
</td>
<td class="num">(6,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,193<span></span>
</td>
<td class="nump">8,618<span></span>
</td>
<td class="nump">17,179<span></span>
</td>
<td class="nump">16,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,368)<span></span>
</td>
<td class="num">(3,585)<span></span>
</td>
<td class="num">(6,854)<span></span>
</td>
<td class="num">(6,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,441)<span></span>
</td>
<td class="num">(2,051)<span></span>
</td>
<td class="num">(4,501)<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(464)<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
<td class="num">(1,421)<span></span>
</td>
<td class="num">(1,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,352<span></span>
</td>
<td class="nump">$ 2,663<span></span>
</td>
<td class="nump">$ 5,096<span></span>
</td>
<td class="nump">$ 4,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales', window );">Profit (loss) from operating activities, as a percentage from net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
<td class="nump">22.60%<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
<td class="nump">21.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (220)<span></span>
</td>
<td class="num">$ (205)<span></span>
</td>
<td class="num">$ (459)<span></span>
</td>
<td class="num">$ (431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">4,909<span></span>
</td>
<td class="nump">4,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (421)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="num">$ (869)<span></span>
</td>
<td class="num">(797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution', window );">Net income/loss from discontinued operations before gain on distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income/loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(860)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales', window );">Profit (loss) from operating activities, as a percentage from net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution', window );">Net income/loss from discontinued operations before gain on distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution</a></td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income/loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsSalesToOtherSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715725363432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="num">$ (91.0)<span></span>
</td>
<td class="num">$ (682.0)<span></span>
</td>
<td class="num">$ (105.0)<span></span>
</td>
<td class="num">$ (1,105.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows used in/from financing activities from discontinued operations</a></td>
<td class="num">(13.0)<span></span>
</td>
<td class="nump">2,682.0<span></span>
</td>
<td class="num">(26.0)<span></span>
</td>
<td class="nump">3,299.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Transaction cost payments</a></td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">532.0<span></span>
</td>
<td class="num">(142.0)<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents', window );">Payments out of provisions for transaction costs attributable to the divested business</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DivestedCashAndCashEquivalents', window );">Divested cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(628.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(628.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsAttributableToDivestedBusiness', window );">Cash flows attributable to divested business</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(642.0)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(642.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities', window );">Other cash flows used in investing activities, net</a></td>
<td class="num">(88.0)<span></span>
</td>
<td class="num">(40.0)<span></span>
</td>
<td class="num">(88.0)<span></span>
</td>
<td class="num">(463.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="num">$ (13.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProceedsFromCurrentAndNoncurrentBorrowings', window );">Cash inflow from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Transaction cost payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsAttributableToDivestedBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsAttributableToDivestedBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProceedsFromCurrentAndNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProceedsFromCurrentAndNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715725330744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="num">$ (91.0)<span></span>
</td>
<td class="num">$ (682.0)<span></span>
</td>
<td class="num">$ (105.0)<span></span>
</td>
<td class="num">$ (1,105.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows used in/from financing activities from discontinued operations</a></td>
<td class="num">(13.0)<span></span>
</td>
<td class="nump">2,682.0<span></span>
</td>
<td class="num">(26.0)<span></span>
</td>
<td class="nump">3,299.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Transaction cost payments</a></td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">532.0<span></span>
</td>
<td class="num">(142.0)<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents', window );">Payments attributable to the spin-off of the Alcon business</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DivestedCashAndCashEquivalents', window );">Divested cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(628.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(628.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsAttributableToDivestedBusiness', window );">Cash flows attributable to divested business</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(642.0)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(642.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities', window );">Other cash flows used in investing activities, net</a></td>
<td class="num">(88.0)<span></span>
</td>
<td class="num">(40.0)<span></span>
</td>
<td class="num">(88.0)<span></span>
</td>
<td class="num">(463.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="num">$ (13.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProceedsFromCurrentAndNoncurrentBorrowings', window );">Cash inflow from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Transaction cost payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsAttributableToDivestedBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsAttributableToDivestedBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProceedsFromCurrentAndNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProceedsFromCurrentAndNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140715737793688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,669<span></span>
</td>
<td class="nump">$ 28,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | PowerVision, Inc. | Alcon [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="num">(289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="nump">418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 40<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_PowerVisionInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_PowerVisionInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;W)K<VAE971S+W-H965T,BYX;6RE6EUOVS84_2N$L8<-:&R1U&>0!&C\T75
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MZYMX^J;H@ZC55J)YO>(KP'X>MD\#]A/MAZ,SR),SIB38X&^'>HQH] :1B$3
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MZZ7:L#.NOI+[2-72)DS.%F!H=#:%&J#J6Z[ZP<AU=<GR+(V11?5SQ2A4'TL
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MGN?JE6V/TM,P)OH"0D5C>1-BA)H#E*/P4=!A3T^'3U.V/4ILQ\1CBI'9Q\P
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M,P+'(U&F0AC-5'!LDV8J(),T4T&%*%.!+92IX-BF*E,%?XV,7N-D=,)0,4T
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M-0#1.0F R)R$:B/G75!MRMX7)"LV?8;F]"UP##1%L+' ,+*Q #"ZL0 @NK%
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M1Y9L^T8/$$4YZ0TJRJ[3_*FEK0"4)@3-'*#B(:5A5!4+I;71"G0LC1S[2,*
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M5IR:3<Y/$W##Q \&V39.V<H2SVQ<UOQ(H@L![*^LI9T1",9GM_@+4$L#!!0
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M-OQGI22B@@[@_<*BB*0OQ*#_'PJN_@=02P,$%     @ T4SU4+JV=&V<$@
M8SD  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6R]6VESV[B6_2LH3_64
M727+VKQEJW(GG;3SDK0K3F;ZU=1\@$A(PC-%J G2BOK7S[D7  E2RTO2Z?F0
M6!2QW/7<!="SM2D>[$*I4GQ99KE]?K0HR]63LS.;+-12VKY9J1QO9J98RA*/
MQ?S,K@HE4YZTS,Y&@\'%V5+J_.C%,_[NKGCQS%1EIG-U5PA;+9>RV/RL,K-^
M?C0\"E]\U/-%25^<O7BVDG-UK\K/J[L"3V?U*JE>JMQJDXM"S9X?W0R?_#RA
M\3S@O[1:V^BS($ZFQCS0PVWZ_&A !*E,)26M(/'G4;U4648+@8P__)I']98T
M,?X<5G_-O(.7J;3JI<G^6Z?EXOG1U9%(U4Q66?G1K']5GI]S6B\QF>7_Q=J-
M/1\<B:2RI5GZR:!@J7/W5W[Q<H@F7.V;,/(31DRWVXBI?"5+^>)98=:BH-%8
MC3XPJSP;Q.F<E')?%GBK,:]\<:_GN9[I1.:E* N96\G2LL_.2JQ.8\X2O]+/
M;J71GI4NQ'N3EPLK?LE3E;;GGX&JFK11(.WGT<$%WU9Y7XP'/3$:C 8'UAO7
MK(YYO?&>]5YIFV3&5H429B;L'L;%_\BIQ1=)^;\']IS4>TYXS\D/$._!E<@Y
MG]B53-3S(WB?5<6C.GHQ[HM].^Q_H7.6J+C-<_,HR2G$>Y7J!!M:\9__<34:
M#I_"6_ZHM-7L.9#6IT4\Z*59KF2^$;_EXH-Y5,NI*L1H3(H:7O?H*UF4V@J5
MEZI0*38LC9#PP'FA%!RZQ$,J5IGDI9>JF&/^<<E;\.>;,/ $WE N=N_>$U)\
MOC\EE\1B"PD73515@N%,))[ !6#JCPK4>#K$G2RL7KGI'P 9;U5AU0;KW/3%
M7578BJ5EQ"YB>@*R>*42Q^]YE]T>)A6FFB] EZVF5J<:*-<C6C [P?Y2E J^
M48#K&?XGH9"488\RRP00TY80C,[GPH(=<+I7\ !CT/Q*7)V+%5;BX2"OH"U,
MR0( ;&(K&10H5ZO"?-& ,95M>.YU_T),=9;1 $@FD79!#$HQJS(,2756E2 :
M\B7>=)YD%=-&HE$@^U%FI$K>6^"A4@#I3-(<<+:3;C:NRZ>6R'M4$-HT4R(W
MI>(-((W$%*F$K)S:L9.&F%2QM'U>L"4^]66E2:N@^:W,H>2-&#NLZ+%]1=]?
MA.^)=B=SEG*M)6>$J=N6)K/)[C$[: :03PN YMWZF2IHG49(DFT*.I-2K!>&
M!&O6.7:*]H9V@@WU&^>9Z5RRU1#-D?\V5O8H=29)@J0ZQ[-=F*(\Y8^9R>>G
M)#LQ-050"]1X*6Z32]L9!!LG3=HP58^(URMV5M!'V@<:@ KRNA4TEI=:$C<S
M7=CR5.>G228M^<!:0WT;)0N\Q$J%7-%?69*-F[45,H5@-"$L<Y-6K(H5GK"F
M]18BP"(D#+LB#++>(V$,<.BL7"1D<K#GF;*4',C,,LMK6'.+.)A96>@I[)A6
MT$M,>22P<)N!%-!'KNEDAV"+)$:1Z-:PKW>OWIV^%!D)P@MN)D&!LW3(A/7"
MSK:JBF0!&.IXW5K:KJ.Y=8#?F8842/GUW%5!@B,A)6ZZ,S,'6SFR,RP,OF::
M50Y9J]+N=NS+_C#LUW,D6;96#&;,Z)]'?@_$F>MFQ1X/&?8G]1#:&EF.*LC7
M2OE%9*! 9X@,RDE];DS*DM])S*C9K2\^,DM,-K)*)R:+2$PJ8*O#/%XF"CY0
M!6.$H$4+Z!4A#]N:/_>%*EKHK81=(TB*:67)TGG+&XM,5KS)S!0ZN\V!-2M3
M,%[%<6PX#,#NM]D?Q0B%:T3Y2P0<W[RY/2'7.H 1;O:="W3D +^:C #9BG<P
M)JS2%Y\9'IFD)FAY-GRH<7CBXPLLRZW*Y(I_]/_19Y7"%DRBF3)O: N5(11L
M!.CT4!PA$F55'2 >.L3MN_5KW >_Y<S &&AKMZDW4&<4L]DIG)-DNZQ!RF&R
M R@.4/@2/"#0._O#!J U*X&ZH"GUOMHR(;).E;/C>&E E8@?C/38FA,J,D+M
MT*]<Z"(]S21B@BVIK,A@X:D2<Y7#!+$OZI<'52*#291WZ;8;>Z:(IU\^?T02
M.T#N[OSIF+QB/!Z&+TY$M9H5 "K TL9I+"-[<;G_+HA(_X57 9EI^=%E9_5Z
M-]C4*JML XKT CP90*O?C@5?K4@BM-9PU"%U.!Y%JZT7.EF0%5#, (HY[,!<
M1#A%F62U\A%$)@L-[ QTLI9F&F924_#]J,HRG9QWN+YJ9.IM8&DJ[.Z5018Z
M<P%9LR@XX_%2:$0Y[LHRTA392[E%,D49^*$*6\5I%ZUY.6HO>37X>P7Z-X24
M\> ZT+PKI(PNZM?[0LKHHAYA*"W@_5LQ9U(/V HYGK1_'VT:4?]=P:90[$E.
MNY_O02>U!DQFYIL&ZYE0AQ4T!B"?"0O82R,$[!'J/&I36=!.M5#N$N<I*(/>
MK8]+]VI5NL#$2>SP*JJO, <&[G)$)%BZ[,0J :M('@*B0ZBU930Q[/C^YN[&
MEUDW56&F2%>-CS)4%E&<ZB,^A5<G==2SR/_9$+G#0FD56&,94\((P7O)00 1
MT]YL$\[/:)EFU%\09:B'!OVKK9J&:\T:_Y"8YE1I.5>AR$5V3* "LT[9"C"*
MU#NE;)!>%FI>H:XQ@&*VN$<RB]M<O)>0IB\L:IV4QCSX##K1W+EB7Z:U.NP&
MKF*6B-9=8O"I5D>]RZJL,+=19D>+E#5C,22:I>J6$8[_FD@20"D?D K@PPZ&
M!4+4DM< Y:\505PF/A4201%%Q%+;>A7R'B<[7T\%QF%GCE28JUXJZF\$+51+
MVH_0SD.V#P2I@H]0(L+^EE/*#T\N-SUV&-=&H%)T53<5,!]J^+.>L0.-B$"L
MBDK3 2%M1)!&&I .'%&\P;Y+//'"VYC!Q0Z;L6LM^@2)S)#<HN?YX'+9. 2]
MJN&-Z&3$&XP:4 4TKQ1W*#.PMV8M)&:>ZS^_EDH_B LRX9L>1*O+PV"O,G7V
MW>,@B,I/%R&8)!6P-B_ADBZS(6\N3%HE#C^)VDD3Q793MW/CPS13>BB 7,Z3
M0M+HR_0&\^.*PUO&=[L1(SR(]PJDI*!B$>S?+]5V9:!6,4=5NFIK.A1T&L]4
M] JD]MS <!UU;;VYA=R;\1VZ)@FDK!7BY@TM'#='&I&UUX.LZ@;4N"Y4#H@K
MXA-*ZW"R9TZ+P7;VQ'HV5,C#M)\0+4S&39TZ='9H;]]>^.Z@,P^14MQVG=>G
M#HAV>9,(3"[/0<AVMC <BM]<IF'R4V_@X=T(:S_BV13$\/ J#.T,&XM/G(I>
M388HL@X9Q2%&7^VKGD<D@T<&8*<%LT5O/'RR>_BNH:-S3SGJC$_4Y!"2$YL8
M:KTS&NZDJ=QR/4A-/N?2?G&S! 0OZ!"FF<)M/H]MC(HM61QH27/G>7C-?:=,
MQ?6R7>G\%.5?>+[)8'=-%M!T5I$;4=;*)#YH\G/J)5&/Q\?:.A+?O'%E+BIJ
M8(&E9.IMA;IG='T@D:*\!3'#IWA8SBKU$*\31<20!QTF/:1B:B4+EZB6%#93
MP<U>F5$IEH368NU;'N]93 28!:"X8H1SZT2BV[/?UNJNP]X9#1[<-Y3F^;)I
MKP0=ZZ&%<)AM(!5]R^J^R7/*4]X04N/O>R 9L<A>@CFOU;3@KL'H*B":K:;_
MHI8I6$E:MI( ,2B5JI,U+MZA.=7T[6.+Z(O/5#_M4F!O%]DNM%%F62.F*^\J
M L"ZC.CM*05WK*B^)$AYO- 2610;XKV>00;7E$(^'SK 7"UV#F1+589>]PV"
M$)#*2?!K-$2LJMG,Y>[3#9ZYS23;'N6_Z3@=M:-JLPG=I$/.1T3>O/J(0F))
MT5K200HP0Y>D]X]4ZJ[*$Q%&LZ6^BLBH"V675[E(RF7E.&I5<CNGE9J 18EG
M2F1:J3A>42$0>N(.7+J;]C &6^[A*13H)'RU)0U&!U3K!77('W?XE#V#. C8
MU*9VA)8*>ZZM1J(.*N-TB43/XZ[C\-\<&$64$!V9C]T^";_]7=ROD:V+7[Z@
M$LSG"@7@[>\GP8AH#!V+_=,4#^*>J\=FX(=_WO]R(JJZQV@WRZG)N#(>#9[>
MO'O9YX\HDKFT. C4(5AMN!/'5O@U-GO<]>]FH9-MV[B(;:.=99+<@/C,6>J*
M&P?]KC7D32A4$3L0BL\;)(<T\G!;9Z;;+KZ#C\;CR40Q9L\.[F6;<(<1T0I[
M 'C;4X:--+;2;EKWMU#37@0:W)JMLM.=2_'95E&0^%P3T7=I[0;0E?@J:2KS
M!^L-QKFO+OUIE(H,?E1S[#M_31'(E5-_U#H^H:9Z?:+5:>[M.'ZX:L%#Y_#2
M;S&(# 4*I:8=_DP+G<Y5E&GQ:5IFD-!XIFQ%O3N6T4PF]:%(J,>[5=<6=8/^
MN-Z7Y-6PY=:7(J\XU\=+:N)E-)HZ4Y1^-!N"UE33F:AK059TZ$5'JN$0581.
MMH.F]DZA$=_SI9'4EBJ33PM&TJ9?&)2#' _6E:III*#SKH+BL^QHKY:E9FI.
M_1@$5V8B%&:MNKQ3_4 3C?EQ<V>&=,FY[YY(W4?23,59)WRV#NM5X9-ZROR*
MD"[%F6MO-\THH=-=W=+(TT(7*@Z.X=A!SF90(>81LCO\:T?Q=C3:G6[L@=6O
M!H5)<U8HJ1]4*.FBCN-D4'/"4NY"!@+2TB7+%&VGR Y[OAK^6P2. J3B4BIX
M%5X2$GJKP!,;)K?\?IQNV!<Z.];[M J<ML/4TJ1S-F*G+O$C] Z:&$2B]LES
MZ#9U$Y-&]9T0>R@#Z^87O@&XVWI 0"<9*=32Y4U; 0__4*]^6]3KBY=-(M\T
M.V:PSM0WZLTZ;S$3F#V=(G.+[LA0,P499>F+)KB'OQCA.*$\K**0L6DZ+0&E
MMI,R3IGH&HKS$II,C5'28H7@[ 8=RAA+7CCFHTX3MQ/F0KF#Q]+?%(FL54SZ
MES]QI (/["6$W\&.W"J?P\E09IPV^+J#R3I98'F(V,AS=$ZG#J&5&"W0:??Q
M28.-D<A=P?+$T'51UH6O<A?NK@:=1+7IJ@W2)[+B6(IW=-M"#,5" [^!-!O>
M@25YPABY(T'K=<GQV#6,@FNKK#/?VG2C(J*1$UMP'TB82Y?\B 45BHHN%+K;
M3P07D30AL(BZH([]_15_P,[1EGI!I?Q"!W0]UQ@BP)J3Y[15LA4*8O#X=[5Z
M)RK ]FK)M0[[GC2H\*%!,,!+0\HPG)3AS_#Z\NEH( 8C:M"U4NK9/N 9C<5D
M/(&=NG0&.IBJ<JU4WDJ9]U<3F#ZXIH(RWFO;\^H#BI?</$M\\,E<8X7$RR:_
M2;*0]I+8/L5W'@S=6?C6'GU;-L/A1+PA59*Z.O@>._ !5)^(B^LAA/Z:D*J)
M4&ETU37?W\0HE+^'^,' 6(9\3/#U=T)O7[^'2&"73"47#QMQN74+M+YXTAK/
M]\@*Y.$<F:D"[C6W.:?:[+G0&5U3\U?4'':6^E3GLTPNE^[<JKD^4E+N&Z*#
M^/#NX]U8A*&V]K:8M3D=OT87\:H,>$.7NSE8M[C8<;&%;O/Q)B!*S@U==?-M
MG:VOHUFM6S#4L\N =,0X(L*\D$N7:JP--X0Z[^P3(NIT-!E=]ABIVC?RPO!3
MF.&<JG942TN=1(2X.)=S0<>98P*,PAS1$BFLB'+SHG495!**&1@;_>_3IYQ,
M,#$P42R!S3!]H>C.'4GS^,/-_:\G3UG[JD/:O"K=54FZU& RE529JMNL%(3+
MYCYB1-@4Y22;/.5:3UW=O&/U!',+SMZ*1U-9+PAQ_/+#_<DI@I8B""CKC>NK
M>N&,GKLT=2@&$=<_<5QQ]W$<>NZ.1./F3DD<C ]#!=V8C(R21M55V9+S$3>N
MG7)R9 @!<-)<AOB.BS9L%/5=61I^/?R)"'R(,J=4IWS")3/Z10A?7-L*)^.+
M89N0;[R7P^GQU7ES5KJ_]WKH*@[?#VENH:25"C5*&\AB? UM1V[342+S?3=T
MXMNT1#Q?"2\HFPA'U3_\#@\+_CP2&J7OV28Z$/=-[/A"#4^Z;BN+4[/BQ]RE
M^9;H\KO6:2%#6+GZAA\7N)\,P$Q3&:Y+AC 2+CS[&Y/BV T[B>_BQZ>IS3U(
M7M33Y/]\AT^%*\'C)L/:Y1+V*SPBZKK\%8\8--VU8.Q>=-]]'^W_P;IWU?47
M.R\]>[-WO8;N:?)L>VK+)6(DV]6]&S9*O,V]@=8797;XA"NYZKR;KRZP=1&K
M=%9L=ZBE56I C$R"O_+5S MADL15N OX[@X&O'=M*H2NA:SOUS38''4@>QB1
MM@F<4N)=YV^^RIBJN<YS?_NO;!""KW_157XXNTE_/'CL^C766?3#-_X)!_V\
MS[H>J/L-7/UM_0O"&_?#N6:X^_GA>^2)E/9G:H:I@_[E^9'+^L)#:5;\,[JI
M*4NSY(_T\R)5T "\GQDDT?Z!-JA_5_GB_P!02P,$%     @ T4SU4$(?+&E9
M!    0H  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULG59;;]LV%/XK
M!QHP;$!KZ^I+:AM(FFQ-@69!TG8/PQXHZ=@B0I$J2=GQO]\A9:MVG*3; ,,2
MJ7/YSG<NY&RC](.I$"T\UD*:>5!9VYP-AZ:HL&9FH!J4]&6I=,TL+?5J:!J-
MK/1*M1C&83@:UHS+8#'S>[=Z,5.M%5SBK0;3UC73VPL4:C,/HF"_<<=7E74;
MP\6L82N\1_NEN=6T&O962EZC-%Q)T+B<!^?1V47JY+W 5XX;<_ .+I)<J0>W
MN"[G0>@ H<#".@N,'FM\CT(X0P3CV\YFT+MTBH?O>^N_^=@IEIP9?*_$G[RT
MU3R8!%#BDK7"WJG-!]S%DSE[A1+&_\.FD\VF 12ML:K>*1."FLONR1YW/!PH
M3,(7%.*=0NQQ=XX\RDMFV6*FU0:TDR9K[L6'ZK4)')<N*?=6TU=.>G9QWR4#
MU!+P6\OM%IBUFN>M9;E L INU)IIRPV<_PZF8AHK)4K49C:TY-]9&18[7Q>=
MK_@%7R/XI*2M#%S)$LMC_2'A[L''>_ 7\:L&/[9R $GX!N(P#E^QE_1D)-Y>
M\H*]2VX*H4RK\8"/OUANK*;J^?L5#VGO(?4>TA<\7'F;SU'WJIYKS3/3L +G
M ?6>0;W&8)$.X/^G#V[:.D?M-*E7C66RY'+5B1CXA4NJ-B&H<<RO<&U,BV7W
M#0K6<,L$D +LH)A_[]49_G)_>6#<Y8[^HBE\B+J%?]+Z@@DF"R3CD..*2^D
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M*TM7!O]:T1T-M1.@[TNE['[A'/2WOL4_4$L#!!0    ( -%,]5#^#?GT  <
M '<2   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*58^V_;MA;^5P@/
MO=B U-;#\B,OH$V6K<.V%NUZAXMA/] 2;?.&(E62BI/__GZ'M&4[=I*N%T@L
MB3SG.^_#(YVOC+UU2R$\NZ^5=A>]I??-Z6#@RJ6HN>N;1FCLS(VMN<>C70Q<
M8P6O E.M!EF2C 8UE[IW>1[6/MC+<]-Z);7X8)EKZYK;A[="F=5%+^UM%C[*
MQ=+3PN#RO.$+\4GXS\T'BZ=!AU+)6F@GC696S"]Z;]+3MT.B#P3_EF+E=NX9
M63(SYI8>WE47O804$DJ4GA X+G?B2BA%0%#CRQJSUXDDQMW[#?I-L!VVS+@3
M5T;]*2N_O.A->JP2<]XJ_]&L?A9K>PK"*XURX9>M(NUXU&-EZ[RIU\S0H)8Z
M7OG]V@\[#)/D"89LS9 %O:.@H.4U]_SRW)H5LT0--+H)I@9N*"<U!>63M]B5
MX/.7-U)S74JNF-3.VQ;^]NY\X %-!(-R#?,VPF1/P(S8;T;[I6,_ZDI4^_P#
MJ-3IE6WT>IL]"_A+J_LL3TY8EF3),WAY9V<>\/(7[7RWM9.]9KRJ)*4'-BKI
M2F5<:P7[B\] A(SY^QG1PT[T,(@>/B'Z>HMKYL@8SZ42%?P=2RKDY@SUPN;'
M8L'^\N+>LYDRY>W?QP+SK'"JZ5/7\%)<]%"T3M@[T;LL^NQHW-D-EY;=<=4*
M-GM@2RDLM^7R@?VQ%&QN%"I8Z@7S?*8$DTJUY"0O'//8]TLK1,<C2T K<2>4
M V<$)=[C-G(8OQ7-'3D*&2"Z#&!<5^Q:E**>"<ORE%;3*<P ]$X(=WV*/U*K
M4PAJ$HC!HD4%>2^L.V&-$JAI:B]8]2:P7!GMC)(53*MV'/7)8R'J*R,VZ<#>
M:-UB]Z-HC/4 ;&=*HAXK4N 7CCW[P+)I-*//?B67L'1]S=;7G/UA/$!@<S 9
ME@8C_^GS;]S>BA@>)\K6PB\P^UK,_.YS-MS^W;2:4O%..!]-RW.6C]>_4:GZ
M*&BDB"#%F(U2B+'RCE.3?2+*:3YB:9)UU^?@*5352X!1AW24L#0#Y#3'?<Y^
M-7KQ&M&M][BV%@9W$+[XTDK_L"MUF@S9=#QB13YEQ21%G(9#@+("%AYX*LL+
M_.?=%6GCD>+88R4R2$+]F(D6>0M#8*$#WI#ETVEWC3Y0+ZB\T2ME63H)OQ +
MHS/ZG2 'G3-@HGPM3=UP'5RX5U0H3],NEJRQ9BX]0]V@)R$FXP((H^[ZI!$-
M?X@6_.N[29:F9[BDT_%9RA+XZG!M]-5T[T-!;NU6DL^DBO'8IT<;>+3P&/$8
MQ8MI^4BI[$#U2?%5-#&4QPW9C\4W2&1)<<1]HT.Z8[Q9D;!KY#CU;NKDTCK/
MEES-J<]27SJA=9Q/*_K1ACFYT'*.'HXT0(O7#MT1?=R:&EU-Q+Z^Z9:QH5(]
M'6/D8?B" [89NI)^N8;(CX>DOZLMRM, _ L:*2KDJ,9^92!<OSZN-C@.*SW8
MLE$"EJAU7Z:SZO.G:X:8U#CA*/,KJAZ#N0&<T/,#-?B2O9\#'#I"V7 Z;J,+
M>70NTCC(9E =QM>FU60Z8 +XN#]FLS4\4F/_J/L^D.3[) =GWP^QTFU$)4?-
MN((KX; PS'>Z!+2BG[TD,-LG.12X/FV56H=\&SH$5_C8LW>2/H2(E=S:!XIE
M= *3H$-'Y X'-O5\WJ CW<O-H3V/&=IY,WKW,0C(#J1+7:JV"H-5P*!)"*[Y
MFO:Z\5(_?<E)+_F(S-M5)"A!Y9@E9]M)8CN'4-8B)RWUVVA'($[/-IXH=V>1
MO0@C\=[16TUI;!560UT=\,SAL(K'(GRCL 6NL@\(I Y&WHT3, BA7DX.2%R$
MY8\2/#AC,NYJ))0AA%8G=+($VU;2D0#7&$?#T/QD$YC#]A,<0EL$FVXK;X&7
M2AJC(@H<M\)HN"ELROS8D8(GJ1JL6-+K(CH]8F#J4+:6YFT-6L&MIGIEWS_J
M**=,2_5#3+2?<$@VH7V.SQP3]TV<VX&SS1PKW:V#_@[1PRFYY#@NJ]W.IQ[0
M,[K^U:!-F&IC(L"6' K.A-#4,&O^7S@L@KA-)9,$[&B\%8?85 *%'L,$8OB$
MZX<#H@8A+U%V??;[3E)MU:YH[%F?#$A3UX:D001BCWJOV8V8V3"NING)NLG^
M;NX@F9(:#"(&:?LBL-_F3MG5IDQCGJ3]<?$JQI0E24*0Q1;QBC>2BO/*6$S.
M(4,A#Z_Q_\%K_ G[C'8+@6'HQ@ T[4^*[!6N(Q1ADFQ@Z60#[/C;8:?)]!4!
M#0NJ[@ZX"/KFR?^A[R@ #Z<8TG8<$34NOAD81T>:O5K/@,?>3@<['P-J81?A
MDX=#?:!QQN\"W6KW5>5-_)BP)8^?9/ ZL<"QC,-Q#M8$5O20=N$S1WSPI@F?
M%F;&>U.'VZ7@F!F) /MS8_SF@01TWYHN_P=02P,$%     @ T4SU4)^KBOT+
M!@  =Q(  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULQ5A;;]LV%/XK
M!QXPM(!CZV+KDAN0R[)V6(LL;;>'80^T1-M<:=(E*3OIK]\YE*S8:IRT1;8!
MB25>SOWC1U+':VT^VCGG#FX74MF3WMRYY>%P:(LY7S [T$NN<&2JS8(Y;)K9
MT"X-9Z476LAA% 3)<,&$ZIT>^[YK<WJL*R>%XM<&;+58,'-WSJ5>G_3"WJ;C
M1LSFCCJ&I\=+-N/ON/NPO#;8&K9:2K'@R@JMP/#I2>\L/#P?T7P_X7?!UW;K
M'2B2B=8?J?&Z/.D%Y!"7O'"D@>%CQ2^XE*0(W?C4Z.RU)DEP^WVC_<K'CK%,
MF.476OXA2C<_Z64]*/F45=+=Z/4KWL0S)GV%EM;_PKJ>F^+DHK).+QIA]& A
M5/UDMTT>M@2R8(] U A$WN_:D/?RDCEV>FST&@S-1FWTXD/UTNB<4%24=\[@
MJ$ Y=WK)'1/2@M/@YAP*K:R6HF2.EV =/K  SH*>0L'L'*981'L\=&B9Y(=%
M8^6\MA+ML9+ &ZW<W,)/JN3EKOP0/6[=CC9NGT>/*ORE4@.(@SY$010\HB]N
MTQ![??&^- A;2&TKPRG4\CN2 G^RB74&4?;7(_Z,6G]&WI_1OUR61ZW0@C^T
M2U;PDQZN:,O-BO=.DP%\CW5(!N$ ;OB*&\LDC2FM#ORX0 $+3)6@49T!5OZ-
MP*YU3(U>D $G5"74#)!M#*/U:N'%AW>7"'DIJ?42?HM\L>MGF*.3Z',A_.0^
ML(4V3GQF]5)'4V*Q9,(TCJI#N#:DVMWU82F9<GX._U2))4V!&!7&:0B>E [T
M]*"R')BU'*73#-(1O%:.J9F8R+8_1  FD 0A7 G%%+HB[X=^_"&+PO ('V&>
M'H5)TNF)([B8HT(.0L'2Z)6P/NC[+/GT5<:0>U*PB9#""8ZZPPSR<0:_:K1E
MAS,D7HH02F&7FE+_<**U-[,_!4?H2"?"(_@)1]W= 3:<Q-H7>H&;@:V3S&_I
MG4.8YQ#Z!.$PKPN*\II*T\@P18YW4I+%W9XT@??L%F>.HA#&T1C>XJ8T;7.[
M,1B-4D3 &-YKA[T1Q*,Q_@;9&-/>P<RKL,:,?SXW9M(@@!25/H29<#R"<)0_
M@!I$[Q@3!@E*/HV;*.WT8##?B9LLSE!_@.CY^?^&3)RF^!]]*V1HN76R,=Y
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M%5J!P7P172>SFX&7#P)_"MS9HV_PGJRT?O&+AVP1Q9X02N3.(S!Z;?$6I?1
M1./' 3-J37K%X^\&_3[X3KZLF,5;+?\2F=LLHDD$&>:LDNZKWGW"@S]#C\>U
MM.$)NUIV2!9Y99TN#LJT+H2JW^SU$(<CA4E\1B$]**2!=VTHL+QCCBWG1N_
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M+"NX7"=9<?;R.1_[5+U\7K9-GA7R4R7J=KU.JNTKF9=W+\[LL_[ YVRY:NC
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M6G;UD;1]RK\^4C#G0<K",+SO!\<SK"^L2!?"PZ4F! >VF9-\N)T/.WB1CIA
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M&]T8(X$S_USF35+)XO(Z:9)%GJQI]<58U3$6Y>R^T$_;*/R)+1@FFBLS31O
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MXTIPF( V8#W7$+1^(0;MI?'UWU!+ P04    " #13/508Z%]&W\"  !C!0
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M50SE HXCL+VE^PF9-M@H-\2F#,.:NR!:'\#[E6&AP\0G&/MJ]@=02P,$%
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MPV ?+J>3=PKI(_Q2,!ZV[Q)$?+6)A&\5-T1[\I(GQNCX,\HAO19=T\&:=/7
M?&\*UH,ILS'B@WA)81T:! 14(L!U Q<[J^Q.N\J$(%,BIGS,V$LY699_=CDM
M]N+O:WBG/HHJ'54U;-FQ'L CJHVAZ#L::I_TH?;)\=Y@[+ZH43=(.8SU6[BN
M84:^:,->,BZ4IL+K44('PNN;GRK3Q)NA%%UI="GB:X>-,710Y33/ 2554.]0
M9CA\?@""Z.#]JW<?'M#FPX4@6QB\O%5+A\NW8O%LGNZFBP^R)EM$N5O%(;)5
MG!S+:1W+22VKH9SVK38/[6JUIQ@"_ 17(RX2$R!-$-VYJD<H:X<O?0,N?/81
MGWMS;FDH"%(TM@Y?R3-XH)&"0(A",:#!.%_6%PW+SI-7HQ$B0O1X<?8BTLM+
M_/#\Q8,^0^7FP1\*R%'V24$)GY!1D(R#:#T7LO9V5_;D;!EX\E"KD8 T2CYV
MBD)DC0LGD55(_1>JZ5B$'>QEOI. ,*JO'@*Z.@[M$KG?IGQZZ/X-5:=#9!E2
M/C31Q5S/A2JUB%A'^#5P$2I(0SJ;M<9FBI$MIFPET6I,-(N<ARI4U;$8U6 Y
MMS_C-#X74%:*CJ.X>Z>DV/&OS/\$PU>'LG^Z=T!#4B,+U%/#79NA3%XJ97XT
M(K.T">M_X^8B]8P)ZJF*F()V'[&R(C1A$\#>P^D1(%GNWT<U0LGMYJ 1;CJR
M78[?1?:1L9Z_2I$4Z;D6*=KL'H,R0QU'#D0R%Q29[!IVRL," E3R"79TVJF^
M<>\Z).YC,E*S2.OXAZ)ZI]?+1T>.LF_XD:WG^XZ1>A_*6]F&[VAJ@N<_-TS(
M1D_(V0?+$3!$?_Y^R^\$MLZS)GH+HILL*J._TAB#'+/M$,Q]1("^VW-.!I\4
MU@\[#M?G*=<D^XX][VYPFY:$!0?_/?-^4K;1C&LT2(E#FG[,,JKO#PN4>N1"
M^DJLT'W #]&A?P&"&D)OBT:#DW*Z%?@&!@&0M"F%L30I#,[6-+)K=-?P,62G
M. 9(YW/-LA?9!^UD^4?Z&FF3YB]W^L8$U=]IU",N]C WNJ?20)<KJFU*HFE@
MEHZS/A8OWN_$S)UAR9TQR8C4C\Y<$P8F9JZ4S5$2P99EG"=@29OX'HC] (42
M=8XCJ_-\@\KGU&1Z>GO#K4!20E9^=*-!)5Z0 =:3G@(EC7KAU&D2(;9 "4 6
M-.'9KX'N(/M^+KP>#'$C[>O#QMX D@=N1(ES$<^H-AJ8&+*2O+70$44PE;H&
M;F*X'BC[I,[1GIR'W.HM)8=!I6G<"%R!HE,TJN1 1GYSP2R<GYT<Z2Z>]MW%
MTQ]Y\[ _OM]RS.C] /%QJ4WR^__U9N$HX4/#'+41-)<7/@W;4[7-?2/#\C=I
MN*P^CV]ZXNX+<9U9?#VPB(2%TCT"FCSJ_=7-=1[VCY:@UR.7Y.FF0@F>8ERI
M5GI<EV;U]/-V.#\Z'AH&<AW>C[S5 &0<Y*&0--%9J3:(4XM1QYGGQW&(T_+T
M&<N^8N MU7B (W<*7>VCA-0Y9TW2$#2B$T%/I[@[^) GAODJG@?$ 9-<4<^V
MI_,\LMV[7]84GGE03))OA_B*1[9-P.;Y, )Q]F<?YD1+CEEYN-P^'$^ZEA(*
MG7.8CQI4I#PNWZB8 @-I[,I3[T,)#>H=*LM>M]J/6(I5I*1IPYH&(R5)LM*R
MCZD[9O*ZT;5T$]L\3X0"F>&(X$2['^\DG=% N:@LO8^ N-F^L: ::81@,\RF
M&3,C(/''JF>%K57:=JA3IN"!M7W?*G7)4Y@TE=X?:L=QM.WVID&3KR$Y0<7!
M$%7<N?LZ?#/LD%)_'*1!CE_MAEY%S*, G/=*U5)W;G,R+1*I0KL"*3Y0W\-A
M(X_:QWAGGE;#/)W?:Y1J5!C0TE$#1KJD:.]S4L[0S#8BE&6+C)KS87))*'%9
M.V,_GHKOIZ.W^HUR:_[M K_4,B&^X.^?]C^/N(J_"ABVQ]]6?)!NK:&'6JUP
M].SDZ>.9</'W"O%+L"W_1F!I0[ -_UDI"3S2!JRO+/)1^D($^A^-7/X74$L#
M!!0    ( -%,]5!,(B5JI ,  )<(   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;)U6VV[C-A#]E8$*%"V0C2Z^Q,[:!IRDW4W1W09)VCX4?:"ID40L
M16I)RH[[]1U2LF.WL8'VQ>+ES,R9PR''LXTV7VR%Z."EELK.H\JYYCJ.+:^P
M9O92-ZAHI]"F9HZFIHQM8Y#EP:B6<98DX[AF0D6+65A[,(N9;IT4"A\,V+:N
MF=G>H-2;>91&NX5'45;.+\2+6<-*?$+W:_-@:!;OO>2B1F6%5F"PF$?+]/IF
MY/$!\)O C3T8@\]DI?47/[G/YU'B":%$[KP'1I\UWJ*4WA'1^-K[C/8AO>'A
M>.?]QY [Y;)B%F^U_%WDKII'DPAR+%@KW:/>?,0^GT"0:VG#+VPZ['@: 6^M
MTW5O3 QJH;HO>^EU.#"8)"<,LMX@"[R[0('E'7-L,3-Z \:CR9L?A%2#-9$3
MRA_*DS.T*\C.+9Y$J40A.%,.G&'*LJ"6A>^>V4JB_7X6.PKCP3'O7=YT+K,3
M+L?P22M76?A!Y9@?V\=$;\\QVW&\R<XZ_*E5ES!(+B!+LN2,O\$^YT'P-SCA
M[TY8+K5M#8(NP)Y2X ^VLK3 W9]G8@[W,8<AYO!$S*6UZ"PPE8,4;"6D< *M
MCY\+VVC+))1&MPUPR:PE/I@#LU"AS(&N'A  WSJ*LU']C;ZV#>,XC^C*6C1K
MC!9PAQP&Z07TG/X3!W@P]" 8M[V 1GK)?$;XM14-W50'Z7@*]\HQ50JJ'K+N
M(K@*#;B**2BUSC="2AA>C8A(@<90%,=>=M@TA5\"7&GUCK>T[8-T>QGY7M-<
M&Z]=.ME!_P$;P+-VE,QDF,+/_U?L8W*'9Y9Y#=;"AB+QZ>M_\3V$#]^&OP7-
M1CWS00IG:FZTK[G1V9K[3&]Z2>\R, =<UXW$\!#ZFF^$>J>+XJV*.NOS1$4M
M&R-([POP(?M3R-$@UW2W_B(-4_CVFTF6IN_IDTZOWF<)))DO@!ZS(T;GXXQ8
MM6&^DV8+V0"&@R'<B8+.!!5'6*';("I0KP&]MB?LR3R9PN-QK*7D-+A7_!)L
MQ8POD)4CN8CN;3@<ONT>!,F"B9?24B/B6RX)(Z@.J:81GE\?#9+9NH#9)4[J
M>PQ%LEJ*G+FP1J>!8!W-PJTYUB9-A_#!'QOY.\KGF#-%_ZS7S#AA8?FA2Z'2
MDF3W-3>>IO!V$<4'S:)&4X:6:(EAJUS7-_:K^ZZ[[)K-*[QKV9^8*;TF$@LR
M32ZOJ'9,UP:[B=--:#TK[:B1A6%%_QS0> #M%UJ[W<0'V/\76?P-4$L#!!0
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M"$YXIA\)&9PE.,JS$&>\L^@1?8OW[[<D2^NZ'&<6[W%RF18$<7+]!]7(" B
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M=I_B!=,BA:"LHT,.1"^_N%UOG]/!K$T2%:1R>R"5DM_HM9?RN. G;,L=^G
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MG* "75_5ZXU5.W\772N+-UN_+/#S!K03P/<;I>S3QEUOVP^FY;]02P,$%
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M6@'S?".$OA_88[7R&'7^/U!+ P04    " #13/50Q.$8H_@"  !E"   &0
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MC=(1R,@&[W/UF1]^)@VAR(RWYKFL?L&AP?HCL-Y+Q8LF6%=04%;_X\=&B*,
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M.,NTDO+C3R5JU38UL?F\5?]J@E?!/"&!9RS[26*9CJW @A@G:)W)![;YAJN
M^EHO8IDP5]A46,>":"TDRRNR\B GM+RCURH1#8+2Z29X%<';)_0.$/R*X)]J
MH5<1>J=:Z%<$$[I=QFX2-T<234:<;8!KM%+3#R;[AJWR1:ANE*7DZBU1/#F9
M8XE()D RD"F&B%'!,A(CB6,04MU44T@!+($(B102U5@"SK<L[P*^P.-R#N=G
M%W &A,(=R3+5 &)D2^6=MF%'E2?3TA/O@"<^W#$J4P$+&N.X@S\_SA\<X=LJ
M*W5JO&UJIMY1P>]K>@6^<PF>XSD=_LQ.IKMA5SC_9WWQ;NL[R?#K/O&-GG]
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MR^B_4 6P1!C6$BJO+@/K0H*8E% J\C5EV&)5&;;RK*CAR: 5. MFX(U:@;.
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M08G0 'B_X5R=%OJ >JB=_P=02P,$%     @ T4SU4+HA=IE>!   6P\  !D
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M\?>":UY2*O=D5V@4T!HT>7T+AG&AWY I^79_2UZ_>D->$9Z1SUP(%-=KSR
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M#WC[!64%\/M>2G-^L/>KYCZ]^0%02P,$%     @ T4SU4#Q6<G'_ @  VPH
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MYL%90'(H:,OU@]Q^@;Z@4\N728[NEVR[LY-I0+(6M:Q[L'%0,]$]Z5,?Q![
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M:'0R,_]AU372;J)EXYK72FK3"MVP,A\?4/: V2^DU+N)%?"?L_0O4$L#!!0
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MP00L]Y7@>2N6#O*T.+XF/]I$] 30)D"M (T5X%: QPJ"5A",%82M(!PK(*V
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MA- /+=!$HBR_!;:!)/:V%@L0U.@&K-@'6CI;1"32)2D['?;C=Z04^4U6@R5
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M5>6#IAP8N78W]H4T>/]WGRD^ D%9 5Q?2FF>!M9 _:R<_ =02P,$%     @
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M,"](4I#K0916F1S%%59QFDG'XH7**HDT!]XQ9]+X(IE(Q"O1QG!78.X*+!R
M^V/)UP@QDHE$;AKG.!X+]3U^-K8Q)Z[X7*E)Q)$A["%(+&41<QJ,SYF:1)SI
MI[(9AZW#8\ZQL9G@?EFMFN_E6"H;?*KF]=WPY\[DF/-=[&?'QS@A,4^I2G:8
M.,P@E:+M3&5%B73,DBNL(,TB*>]9*,T@9.K8S3A_LHLD*Q&OAG(^9V3NC"Q<
MD/OCR5<'S+PZ4-TNSC&;<0IF?C:SC!,5.U<*$W%D*)%#D!CK,DYY[)Q)3,29
M]CP?P6$'>DRH*S63F682VE<",LYVS,^FCW%"8IY2F4R1I,P.4ID**TI +CA1
M6#$J'ZD72JM84PG(.).RBZ0R$:]4F\K$@-I%"P;4%IPXM+A?,\W7"(EYC6!W
MZSA'](03<^)G8YMPZDK.E=!$'$U2;41'D!@/)YP0DW.F-!%GRF/Z;8>0&E6L
M0YQO$S/9:2:FL6XPX028^-GS)9RC$D_)S.0PN4ACD%*0,Y45I?)B7&&5A+%T
MV%(HK!C5'84GPO,:%TEG(EZUY=4S#*BK!,\QH#:CB0'1,,X7"<GQN];UW>(>
MN3D=)WXVMBDGK?1<J4S$D9:Y$1PHU@K[?>&\EYXSC8DXT_<'V1&B_>&LFCIM
M"$^H,TPY":9^=H4I9ZG44XHS/<PW$CBH!E=:A7)45UA%- 0IJJNLQ!;W1X0S
M:WJ1!"?BE2@6%MLA<03FKL#" ;@_EGS-D#KM:R]6?IAR[DX]/6PI/&UYML<M
MS8ZTQQ4(#LM\IIPPTW-F/A%GVO)#!(>5'V:<C3.G+>0I58D9I\_,S[8QXP27
M><J'9JH<IER5J#!B\CE+KC " E+Y>:&RHJ'F-";CI)M=)!N*>-56)2(X[2+>
M$5<<_SWWQY$O)3*G#>_EBA4SSNF9G]URQIDO.U>&%'$TV2QMU4^D(U#58Y+[
M_>%\F9TS28HXTZ[R$1SVU%#&R3ASVFXZUC!F@E*!GZTFA**<@*<LZFM#>[$\
M"Z4P/5.9)6$B+=]SE1E$Y. ,7FE'&4W5<1]"010AO$@N%7.K+V9$D=KH[]QF
MX8*41I0((^JT>;Y(H2.$@O1"Z&=C#:$@41">*^&*>9KH*0"#XA=74$ (SYET
MQ;P9.V6&XEHK@LA"Z)9Z=:^%A%!010C];$,A%(0+0D_YV->&]O6JDD,^4)G%
M\0$?*)X;98E\EJ\TBYB6#00EAO B65G,K;XL$D5JA0"<VRQ<D)+FD+#R0)2,
M'.\M=T;8$T3RI(@D2B+9:B+AC(!XTIX!84#\\@JD:BMH9,<'B#=%!>1KE\Q
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MX(FM 02N ;9TC?.OK+[4"M7=O5?]4<.=N]J=<T.N3%W<K4VY@"*LAA\*@70
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M'<<( R.00!%M\\YYF?WO>X8U@2+2+AY#AH""#!ESWRL=T=AWWVNV>F,+8XI
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MD>V_T*(@-^/S6<3SOV!?Q-H#X.^X8'$!EG<0A\GA/_E1#,010/+H :@ H#K
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MH#E;9-M"?N;W/[.64*#]S7@AZG_1?8.-Z #-MD+R=6NL1K#.R^9O]M F8L\
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #13/50V,P2C1X$  "!(@  #P
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MH+V6IK[U(GV,?\E4J_2P]- ;\Q[:_K0?G6S.;U"<W_YX]R]02P,$%     @
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MVMS32A?U,9^U?Z"GGU!+ 0(4 Q0    ( -%,]5 '04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " #13/50TS;M7?8&  #A'P  &
M    @($_&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MT4SU4 S"S&\O#P  "F(  !@              ("!:R$  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( -%,]5#9Z7QW(PH  &LT   8
M          " @= P  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " #13/50;/$KDWL"  ""!0  &               @($I.P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ T4SU4'\YAB:!"P  7"
M !@              ("!VCT  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( -%,]5"ZMG1MG!(  &,Y   8              " @9%)  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #13/500A\L:5D$
M   !"@  &0              @(%C7   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( -%,]5#^#?GT  <  '<2   9              "
M@?-@  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ T4SU
M4)^KBOT+!@  =Q(  !D              ("!*F@  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " #13/50!%EST2L$  !Q"0  &0
M        @(%L;@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( -%,]5#+L59SDP@  -44   9              " @<YR  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ T4SU4,^A2U4#&   WU(
M !D              ("!F'L  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " #13/50H)&7ML@'  ! %@  &0              @('2DP
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -%,]5!CH7T;
M?P(  &,%   9              " @=&;  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ T4SU4&3Z19G!"P  0"(  !D
M ("!AYX  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #1
M3/503"(E:J0#  "7"   &0              @(%_J@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -%,]5 ?NS6"9P0  /X)   9
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M970R-"YX;6Q02P$"% ,4    " #13/50EB0_ P($   ^"P  &0
M    @(%AU   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M -%,]5#D9M XSAT  .J,   9              " @9K8  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ T4SU4,5_! ='!   [!(  !D
M             ("!G_8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " #13/50&H =\[0#   \#0  &0              @($=^P  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( -%,]5"-S!=KTPD
M ",R   9              " @0C_  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ T4SU4# A-94_!@  &3$  !D              ("!
M$@D! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #13/50
M^9:(-<0#  !2%0  &0              @(&(#P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( -%,]5#$X1BC^ (  &4(   9
M      " @8,3 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ T4SU4'NG%<V !   T!<  !D              ("!LA8! 'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #13/50CNTV@PT%  #V%@
M&0              @(%I&P$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( -%,]5!+)C\6- ,  ,4+   9              " @:T@ 0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ T4SU4(&J]H<@
M!   X X  !D              ("!&"0! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " #13/50NB%VF5X$  !;#P  &0
M@(%O* $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -%,
M]5 \5G)Q_P(  -L*   9              " @00M 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ T4SU4"O15%]S @  V@8  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( -%,]5!BD!'P31<  /;=   9
M  " @5Q5 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MT4SU4%DOS:4-(0  8ET! !D              ("!X&P! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " #13/50OX =VCH%  !E'0  &0
M            @($DC@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( -%,]5 22 :VN00  !X7   9              " @963 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ T4SU4,>*4&Q'!@
M1R   !D              ("!A9@! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " #13/50(%L$@_X#  "7#P  &0              @($#
MGP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( -%,]5"D
MR_GQ^0,  'P/   9              " @3BC 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ T4SU4)I2*:?A P  B@P  !D
M     ("!:*<! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
M" #13/50N(;37E,"  !:"P  #0              @ & JP$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( -%,]5"7BKL<P    !,"   +              "
M ?ZM 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -%,]5#8S!*-'@0  ($B   /
M              "  >>N 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #1
M3/50H9?JE,D!  "@'@  &@              @ $RLP$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #13/50*+1H$\,!  ")'@  $P
M            @ $SM0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .P [
+ !00   GMP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>818</ContextCount>
  <ElementCount>384</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>113</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated income statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/StatementOfIncome</Role>
      <ShortName>Consolidated income statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated statements of comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/StatementOfComprehensiveIncome</Role>
      <ShortName>Consolidated statements of comprehensive income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/BalanceSheet</Role>
      <ShortName>Consolidated balance sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated statements of changes in equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/StatementOfChangesInEquity</Role>
      <ShortName>Consolidated statements of changes in equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated cash flow statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/StatementsOfCashFlow</Role>
      <ShortName>Consolidated cash flow statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2010100 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureBasisOfPreparationQ</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2010200 - Disclosure - Selected critical accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesQ</Role>
      <ShortName>Selected critical accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2010300 - Disclosure - Significant transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSignificantTransactionsQ</Role>
      <ShortName>Significant transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2010400 - Disclosure - Summary of equity attributable to Novartis AG shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersQ</Role>
      <ShortName>Summary of equity attributable to Novartis AG shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2010500 - Disclosure - Financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsQ</Role>
      <ShortName>Financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2010600 - Disclosure - Details to the consolidated statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsQ</Role>
      <ShortName>Details to the consolidated statements of cash flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2010700 - Disclosure - Acquisition of businesses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesQ</Role>
      <ShortName>Acquisition of businesses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2010800 - Disclosure - Legal proceedings update</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureLegalProceedingsUpdateQ</Role>
      <ShortName>Legal proceedings update</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2010900 - Disclosure - Segmentation of key figures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresQ</Role>
      <ShortName>Segmentation of key figures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2011000 - Disclosure - Discontinued operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsQ</Role>
      <ShortName>Discontinued operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2011100 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSubsequentEventsQ</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2020200 - Disclosure - Selected critical accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSelectedCriticalAccountingPoliciesPoliciesQ</Role>
      <ShortName>Selected critical accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2030300 - Disclosure - Significant transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSignificantTransactionsTablesQ</Role>
      <ShortName>Significant transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSignificantTransactionsQ</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2030400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersTablesQ</Role>
      <ShortName>Summary of equity attributable to Novartis AG shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersQ</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2030500 - Disclosure - Financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsTablesQ</Role>
      <ShortName>Financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsQ</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2030600 - Disclosure - Details to the consolidated statements of cash flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ</Role>
      <ShortName>Details to the consolidated statements of cash flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsQ</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2030700 - Disclosure - Acquisition of businesses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesTablesQ</Role>
      <ShortName>Acquisition of businesses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesQ</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2030900 - Disclosure - Segmentation of key figures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</Role>
      <ShortName>Segmentation of key figures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresQ</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2031000 - Disclosure - Discontinued operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ</Role>
      <ShortName>Discontinued operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsQ</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2040300 - Disclosure - Significant transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetailsQ</Role>
      <ShortName>Significant transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSignificantTransactionsTablesQ</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2040301 - Disclosure - Significant transactions (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails1Q</Role>
      <ShortName>Significant transactions (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSignificantTransactionsTablesQ</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2040302 - Disclosure - Significant transactions (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSignificantTransactionsDetails2Q</Role>
      <ShortName>Significant transactions (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSignificantTransactionsTablesQ</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2040400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersDetailsQ</Role>
      <ShortName>Summary of equity attributable to Novartis AG shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSummaryOfEquityToShareholdersTablesQ</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2040500 - Disclosure - Financial instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetailsQ</Role>
      <ShortName>Financial instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsTablesQ</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2040501 - Disclosure - Financial instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails2Q</Role>
      <ShortName>Financial instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsTablesQ</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2040502 - Disclosure - Financial instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails3Q</Role>
      <ShortName>Financial instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsTablesQ</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2040503 - Disclosure - Financial instruments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsDetails4Q</Role>
      <ShortName>Financial instruments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureFinancialInstrumentsTablesQ</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2040600 - Disclosure - Details to the consolidated statements of cash flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ</Role>
      <ShortName>Details to the consolidated statements of cash flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2040601 - Disclosure - Details to the consolidated statements of cash flows (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q</Role>
      <ShortName>Details to the consolidated statements of cash flows (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2040602 - Disclosure - Details to the consolidated statements of cash flows (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q</Role>
      <ShortName>Details to the consolidated statements of cash flows (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2040701 - Disclosure - Acquisition of businesses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesDetailsQ</Role>
      <ShortName>Acquisition of businesses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureAcquisitionOfBusinessesTablesQ</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2040800 - Disclosure - Provisions and other non-current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q</Role>
      <ShortName>Provisions and other non-current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2040900 - Disclosure - Segmentation of key figures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetailsQ</Role>
      <ShortName>Segmentation of key figures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2040901 - Disclosure - Segmentation of key figures (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails2Q</Role>
      <ShortName>Segmentation of key figures (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2040902 - Disclosure - Segmentation of key figures (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails3Q</Role>
      <ShortName>Segmentation of key figures (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2040903 - Disclosure - Segmentation of key figures (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails4Q</Role>
      <ShortName>Segmentation of key figures (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2040904 - Disclosure - Segmentation of key figures (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails5Q</Role>
      <ShortName>Segmentation of key figures (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2040905 - Disclosure - Segmentation of key figures (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails6Q</Role>
      <ShortName>Segmentation of key figures (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2040906 - Disclosure - Segmentation of key figures (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails7Q</Role>
      <ShortName>Segmentation of key figures (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2040907 - Disclosure - Segmentation of key figures (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails8Q</Role>
      <ShortName>Segmentation of key figures (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2040908 - Disclosure - Segmentation of key figures (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresDetails9Q</Role>
      <ShortName>Segmentation of key figures (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureSegmentationOfKeyFiguresTablesQ</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2041000 - Disclosure - Discontinued operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetailsQ</Role>
      <ShortName>Discontinued operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2041001 - Disclosure - Discontinued operations (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails1Q</Role>
      <ShortName>Discontinued operations (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2041002 - Disclosure - Discontinued operations (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails2Q</Role>
      <ShortName>Discontinued operations (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nvs-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2041003 - Disclosure - Discontinued operations (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsDetails3Q</Role>
      <ShortName>Discontinued operations (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20200630/role/DisclosureDiscontinuedOperationsTablesQ</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nvs-20200630.xml</File>
    <File>nvs-20200630.xsd</File>
    <File>nvs-20200630_cal.xml</File>
    <File>nvs-20200630_def.xml</File>
    <File>nvs-20200630_lab.xml</File>
    <File>nvs-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001370368-20-000069-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001370368-20-000069-xbrl.zip
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M6H![X!ZXKZ;'1QTK\*]M)4*L#YXB$=C2<0H:  V !A /(#-IA@CT&WEMZ*E
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M39>LT>QF\V$V1,RF-90VF^0KE+CFUO''P?^J9R>;<H%1<C(*C .\<< TGL-
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M\/ $>$C#8U>KJ]=N*U1MB'7 ?M;.9]-T3%4A2"8DRJQ"6&)14(5 'H0UK'4
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M#;1FG-8V,8%PJT"X18Q<$&R!E>K!2@BU2@^U"/ 9: FTE(^6Z@=7TKO' "P
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M=?,G> @6.S?L,?"<,8,/!PO(LH#8AN#,"SAS*K"$5P>>%9; P[UK=N])RV+
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MU0Z;M@Z_7:A<B1AM*+\=''P#OM'*-PB/"(9'AM+0B)' 6=:DW1$H64<@B);
M/!5@'H1,I8=,!,@*G /.J3<(]>P3 H: (?8US>UK(F8'<*G$[(B:-2<:SX*(
M?_?I!YD4P2'6N)S-%O[2VGYC<R=>_HF+=<[XC\464PD91&=5L,:E^;9QUJHJ
MUI*(Q$*"41[/5)69$.34@A(1<FD.N2X])R14P0): ZT9I[5-3"#<*A!N$2,7
M!%M@I7JP$D*MTD,M GP&6@(MY:.E^L&5].XQ  O 8IE1Z7UF0!P01\Q.+ A(
MSV!<N![SGS2>1YXS@OC,%F$0C5SFC]#9;RF1[,^AQNS"EJ$C&BF0]*1&&<I#
M&7 -N$8?UR L(A@6G;JSX-%](,-QH"I052E4M67H"(OJ=I8 ^ /\48@_<)*
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MPJU+P!*P/ ;+/?,!(HLB\G?GF_/H HP HRP8-RT'."R*PPN/L4<VNO"X_8P
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MDH1;%\[3611!D.Z0D 9/@B=1)D&/F$WFH@D2=9WX%@18,0+$RMS.7"]!'D3
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M"$YYI QF!#-6G1D1<)((.-7F,,A1<Z49MC8\@.PMLK?$L[?DF ]!:87!#.]
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M!-TBL(I0"WPQ5@/69]DI<C<6!K79XP3O4N5=\E&$T@587;R,]KV!]S\F0?C
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MTF$]!*.@2] E<J"V\W-JAJ  KX(C:7*DW:M+S?D0,$:!B [D ?) \ $J 1&
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MIUGH.E-@$5B4]HN;I@,D%BZ+=_\*G2< $4"4+H;?L!S@L/ >Q]CY]L@" !%
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MA9G;IH?H1Y(U=K%X-V7_#+@&)4I(0"#*"*0>B$XES->W;YLCZ(0.G8 ,0 ;
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MVL- Y#P*#'YG4_8T_N"XX1^.M]@WCB)[O\E)JK=LM B78UG%G]M/?$Q"D.3
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M3F,F,!\27E04P1F? <G3&30;41G<U,F/!/E61IU+A+Z(=#6T:^K=&3KIFVD
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MIA>N0:&AG<6-_VYT#YAROH_9IAA&"D]8WV5XN*EG0$;-(J;B>*QYR,:PVNF
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M/<>HST7!YG]V\YZ!)*TBMI_?A;SJ6;]0VWHW#_[B-Y,); ;NM.?OZ,CE-/%
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M/1-K0]#0R!TEWVT\88J*P:GH](4[RUSW__SW"\+LK;#;GBA #>/#C@M,@V\
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MA&6(@A%IHP)8(BOL\J-T1(Z!N2F'EQ+4_&P;_X6[N)PB$AA5@88"RNA0V%/
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M)M9$A-CE=>G$#A%9#&.Z[7@NT0XSKP391B-\\?*!^1=<X(]$,H#%+-$[G]A
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M7.P_T*MB,/>;^S-DU9V3&ON+PUJ&A#)$.)R"$DLLJ*0@,5!@:$ 5:7G1T.+
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MZW,9A?5_IX3_]/?=$)M,,^ANR)(P9,+KA/!'YH2@;F*\/_@*DP+B^'_WPI!
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M+1.SVPVJO^!\WF\=U,U\[:8KZ?I8:V\KM+><Z1V*$EH^U6#_'@/*GOK-+<-
MJFQN6]5M4$#VM+)(;/4KJ<@L609F2KQT;CBLH!"@5Y4<7N)Z2\L.%WF@'AVZ
M(-C_G!'N4Q[F'@MA'R>+8KY9,TJ<Y-C^TH.7PRF!OSIA9B1S D48CHXP'FK,
M*>%>\N"X$.M<*JS/D0N-RS"CY.0X6U-\WXF^C];CSOP\"S)>!5E(;Q:>]%J
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M $\H7#<H$/@G0 :H>W)F4/C*G5.XD\,J([)Q84TN]H)**&')EPQ=>:33&+E
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MXIP4TWGI<0>&21E^C>)(@L@JN $3@)EA],#=Z;4YQ3@]'LC)P[\/B77F;N8
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MHFC7)_?$C>#MO>ST]U^#=V2SMM-7>EM/(965%O=%1(:PYV[#%%(?X/R^)@
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M.-N[ZFP,A0V%U8#<4!@6A4W29&O21$RAYH5WX9SZ-EKRXKOFVKVS:,OK2N'
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MB5]$T!]W9RA.A9RA_R9!2'RF2D5-Z!GZ%3-2GZ$DI4WC9,E7\H#^3;##?KY
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M@%RF/[Q"#]0.Y_RJM%Z_JGO;.B\H'.(?CV(XC*K;#9_;J-/:&4\Z+N1%IJB
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M^PS!U5JU.]JD^;3A(G#5^SIU>VB3ON^:A.4A39H_O="GQ W5MQ'@6#/?"8\
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MG@(PB<#;=%]XC\>43L1(%/3FR\?2-/O2<U8\(\]SZ_?$Q^C-MS]U"E :+-3
M8M!$ZDH)3+2)A'1T4?*&MY1#I G>,@9670/KDT/(/;'>?7(H^P\ .P6\H;79
M5%N,4-IJ*X)HGV[O?FARR]MUIY$JBTFI(ZP)?CU]YKZ431_4!#]=.&Z@?3Q3
MEW"F,=6:(S%_L*@&_(2=^RB>1AM7!W[RO6BIOD'S(>"KNVDP)_9ZN;GZ8-]0
M/"%A(Y >_48:> \'+]-"T$ N-7"@(=*&!K!A%LC,<IHVR#[AHO_Q'$Q] %&6
M$KN\\+??2;"D/@X]'T+\Z"[N<KUR'.+/J(6N@G"^D+M<BPNQTK#3W9*] [O$
MB\K*MO[P.5@^[YR]OOM#I\R>KIFRT\.M/]8E[5'\6VV"I(6_U27W9GA3/^Q,
MF==!S<JK*74IL[3>_>F%T:214;('9AXXXWI_\0D.PJ1S]-V/NVMH][3;[4 #
MN=2;!N=.=[K@1@Z7IF!'VF ";D1Q?Z#-'>YH$]OK[+^U[C2-FFWYNAN^!<H5
M<)M\W>'!_KQ:$C\D;D ]%]J]'(!3K?#LE]Y(&\4#CO;@*-_O@0,9G @Q>S2;
MMSD^/$X]?T:,T6&,CMU&!S2 2YU@<-N;>F-PTKJ,^-IP$3BCJC?6AO;:!%+V
M9Z+3M&GVJ3FZ==B+(&Q:$J/L1:ZHK'7^,UGB,&Y4*U\-?D/\1?HI]9&^BD+O
MG+I3!R\6<0G5F^NK;W=E%/CQ7?SQ\^W-W;LO_[HY0Q^_?"S[[-VOMU=GZ.KW
MNQM!K9D7A7I7([5'NK0D%?^VH_=$UX[FD^"[NK0OE:"G>=F./H/KBH]/ES;(
M$O0:.#UC>]:U/?_M.3/B!@LL_AQ$RQ26ASD-R3FCF44ND>L]^'@9DX,["^XD
M6+Z/ \SL*VO2*&W(%;/=5Q+Y7F!1XEH0EF3=+:F+';2(@G@9* Y];SE?E2#W
MYNZ+-INA.MK(/W>A"2+MGBZELMH<B3:(=(>Z#!35YDB:0,18:.46VH?'O[!-
MWOW*_L>-U#=%X-2-IZV!E/T'>??$=SQL0[N30VUJ?@?@TCZ=OC8)'G 3", !
MW.V"JVDOS0:"*R(KQ<0,4SBDZ?*G%_J4N*'ZM@ <J^4[X9$>L4;1BO?1+)KH
M)CRN\.Z"T_6E+2;@%%%[K(WXUL;V!6<:=#O:T!Y>F64I)OM?;&/-;$F5_8L&
M?[._JF\CP+%F/G__Q[O/'[YWSN7-TQ.YH1_:Y6SWP57<=L&%,=H#<""/P)F\
M8W T[G; ]1_TP=E1 Z4:W#K K(P'\>C+B>?8A>3]X2WY2IBE[]F1%08H])A!
MHKX>/PD(#W;-*G$&ZJ^+K'H#I8V,:OB,=4 A.Y)6 ['D%\=':5>X&@I*Z]-J
M*+1[TDT?:W F2IN^QV*KTS1Z"FCYG3#GWINBI>>'4X:7=Q+&@_H0'CE_GXFX
MOMHBKK#R0VE=7SRJ)J/WJ \NW:!]@S6X&R";*#VE+7DMJH=,S.6@,9<0.XB]
MC/)Y-RC CFHS>JK9J"<*\PM[!D,I!J!V06A%[U/I\I"*.$CFY4CMS$M%A."C
MH+316?$41FNV&O<T",%J<";[2]P&+:/N\RRC0CNHM7Q\E8.@$=*.MHQ:+*5B
M=>B/ >\"^S/JGCMD&B:<$I+'\)RZ-G'#RW/QJ_7+DT[T]<655(/ +6U5O_;<
M(,1NB*S(]XEK41*@-Y;U%M$ 8>1Z[OGMQ^]W:$%P$/GD ETAFXBM'MQF]*9/
M/A&@*" VFJS05^\>^R%[C(5=-"&,L2/79A3AOW1GB'U]B6<$]7L7V\TAK8ZA
M4W(,MZ[E1#;A-/>)Y> @H%,&5DIE\LC#AK&-CJ:^MT#AG* _[A!U0X]](PXM
M\M\]>+YCLU^+?^ %H[GXTQ]W-ZC70PQUAS\RG.,0/?#-<NR3_]5&G5:GA=+7
MLN-[H.&<_86]P"7):R_0CSD[S"?0S7' F #1Q1);(?+B%_N$P\L>E#Y;)'0%
M2<0@TVS2@B!"/-M4>M/I\$.."1I"^X5DJ;M _V2<$'))X+(;/HVV9_!EA-[Q
M>;&DF @2K$MLV^S)J1IB^+VO"#[:'FYXJG77M.)_JDFLY[WM#KNV]Q]TDWKD
MV87@TG02!7R(+K_]V+7834P&=/!'[:1;,V +QA9L=_E7%(1TNGJ/UF2:"!2(
MY3$A_W?$A'Q2Q#BI?*JAM^3O?7R/-LZYVTH-C)C%.:^@V"+YYZO6*]$6PH>S
ML*]D_TX>(?Z=MV$84@Y>!N0R_>$5$W=V..<7IO7Z5=U+]I(62OSC48S3477;
M]+\Z0N8K!7D"YT#\/QG.]JXHKHH4?HVL.7:3R> G _HS-*"YG)OTYX;@0BFX
MBZZF>E!6IBY J"TK-4YW#3Q#M>:</3/LT'ZBLL$G9 KK04),'?2)N.P;5E#U
M!&2/OL91Y!DL,WA>5XINI1\?OSXP37+U$<-Z 6R5<,K),@FG<:M>]%0EG/+Y
MJ[)>O'IQ27CXU<M([\"O05D(J.VP@-Z_4&\YQ_Z"";N(?]UI(A%]W$H%$'-\
M<G*IUU(ZO5;<  <.XOV+A(R42(AYY8;T_-:=$BND]XW4JAR7%6HJ1P5$1+L+
MKD*O5',KG;=6;]Z!AD[8<ZKBLAB\RMQ3S<N74H_MOM*UJZ7XY(23A$^OJT'_
M4^E]5]I,VP\WI:RC9XJR0L&53[TR"!HA^;'*6 X([X'*6'Z?HH<YM>8B<LS,
MEJS2X0U/\5S&OQX-TE^_Y14*/@G8.P.T85=RKK!1Q #R49*2=?%BQSX$K8A<
M5J0"JU:H8DW!T7+C'ZD?A&B.G:D Q^3%3RWU]KD-(R\NX#1Y<3"@F[RXR8NK
M3UV 4)N\>('H,'GQ%\A'=J6\>*]>^XI*..5DF833L.;T2)5PJA3G@%O*4 F]
M1D_/Y+NTR8J/021L<U)IV%>Z$;@PL \/XOT[,(V4T",KWNF $Q$=M;-G)YH5
M/\I.(PU=L!//BDL3G08CI0MTJF7%)7R&#<RL?O'S*;OO2ML\U5#306(5RB>3
M_'[!Y'>W/RA*?G?'+9/\-LGO#7IO))3;_<8ZZDL3XC_F))WSOYZ%RPF4L!NC
MPP.UB;-" 6-2+&99B!$2[,\B+WE1 R'=)@20V8(Q<3QX(^93&P=S)@'".;NP
M/KDG;F0& ZA1 ,&UX"Z:HYCHJ!+5,Z)/IXTD6BW&2L27-'7WU6$RQ-7,H5O7
M98*0:R'TA=C4XN,N=,(OEF\Z873M^4R"XW"_>@O%D/KD>TSCUT=HPPC*/'F1
ML"R4$-TRMR3#ONP#1:0R3]OQM')G:2<4M<#<*^1L7G:<EYG;JOC3U"MJ>R.*
MKV(7.GB[E\HS<YGTG,MD*&PH;"BL.H6K1,U'VN7Y"L[ZF^]-:8B".7N,.T/4
MM;S%+E^ND4JU_L$KU3JM>CEZE1#)M^"/ZJ6)5$(DG\B#BL7&,">H:&AX&&"Q
MT%54U4O*-U '7%%-PZ[P^^ZML!.NGJ.?CV:F;6%OI8M0"OE8Z?T@132& /!&
ME9+Z .>Y& # .0I#J*K-45CM1>+%=<![0VQT7'+\7ZA#@M!S"5 M!T\"*UWK
M6E@N"4Y  (#W^5ZAH:^>XTN;EA)&Q27'']?H\<<?JYU=!9:'T&"4;P % '".
MQ."$"@0]#ELO0NR9*90>$!HM&W:[3S,[62DW'7<A>G*MNP8=B)V^T@*Q%(F-
M6,BNB@$UD<B?A-("LMI!*&T-5#P&D"C B6]7/(6ATC&MBF)IL+]8:E A'VY1
M.H.@$>(>K<GV</ >JLE6F!TTW=.=]MJ)9=R8-\_2D+>$!I$U1SA "^Q&4_;[
M2)16>7YBMC#X[ZDEOL][;(E]AD)/K,QF,!+>1LB_GSZ<!F*ALD\LSE5I7^YS
M%F6;8<BF%Q!0$Y;I!82&D>D%+%>(IKM(M:>97D#S,G-;H3S-] *:710*P6DH
M;"AL**P'A4\SVW9:O8"]UE&VTA^^P:9;,\FF$B+/+ZA0"0O3"Z@0%AKV FHD
MJAJ]'::(5(M>P+[2>?'"1#Z$"K0<C4W%[>%)W%=ZW7BAK0*!*S:*L92N/RFL
MO3K..O.34'30&P+A<>\8@E#+RV&E"V<+Z]' B6$ \(+N">PJ7;!;:$ITCK.X
MY"34W$DV!3; 0,?F>0B.*W#=:%3CH56C+FV!70@0Y^6'4J-B &4J*^6I]>P+
M[-?,!:B"1([Q^VKKH6HGT57:EZ]V$%VE+9AJYZ!XW+7:0>AP(88MF-V^>='4
M5ZI9W_0&FMY I7H#_]<[.O6#\VGD.)<W-+ <CZ^M_'WZP0UIN J^$[Z]D7\S
MV4H8?'A<.MC%H>>O_O?_^_\@]+^*O\]_9F=$&1+V[TOBBVV&\I<1_S-#^3N9
M_O/5?_W_-^?_Y\?-^;78NAG^'X+]5__[>9PA]] -GO)&3FR@6&XD_)+<V YO
M,4Q^Q?L0URV'[=8%DO%"7H;8TW,X7K]E&4@)IR:[-=MCP639WYDM[9,@<L(@
MYF#^QRN'/0B1%4$6]@FR2<RIDRC@K7F!6,YI$<8/[(E9*YC,^S@,?3J)XK;,
MA*WCAV;/6/J4W87D;\&2$=F;3L_$OV;\N>RS-@WBQR1+5>,GW+K6!?]>MDCU
MZI,H9"1S=HC$#\YRX,67C3PNB1N(R^8P4.WTO3?R&][X9$K\^-$,G2X[!Q]-
M(U\\P2;L<4[PMN"F%?2M'F?#JBS-.JV+3)S]J'"$?",P]JTYESLV9YS[6 :Q
M#Q*',0?[<2VXD@_%I&+4XP06JX,QFO@>MI&/W1GA1Y2],%GZRB13#,D#DX2>
M/\,N0Y!S(C^ !P_-'&_".# #:\J>9,TI.ZHS=!>QNV>QO_+7_1GOHK_&8MNN
M>"1V H^_YYYRYD[E*6,AGQT\.X4S1!@(\?I4_HB06'-7/)!)<B[.Q &SHYH+
M7BA[709<H9C=[WJW=PBF]3)8OI"86Q"">^,D*7LO^Q<7QI5X$F8O]>FV]A19
ML<D:G*HI!%0K<_#RZ!VTLG]PFN&RKZF-&.L\ZMOL_OM"2PM];\M6 X=KXF?8
MQS]NLVX.4*[:[C5:KUK-/2Q$_-30E1R>X7#8*/;-W4_8&>"[]"8F=XZ[A$'B
M4:D<9 %:?)$/BNZ?2#)J9K>:>:I5U@I$99:I+CEA8R!)^5'-951&LI=+]FLO
M"+D'//,\.Q#>L<JL HVUZU0XC(XS!O!$!?TGWQ/1.]% ;&2]VAB,&^AH,@(^
M,=V)XXBHXHRXC,?C."&V%]3ED5'!\RHS##0&KR/Q!]W]2P4,FR<]ITEB0+!W
MD@W@[BDX7H$&;PEOMWLJN:VP>3O+W,-H,0/-S\<I@CTAMDURV-#X !R\97*X
M@:9JXU66>95):5 VB\IXEHIC,#Q*6Z"FMT$\XI*&#!RK\#K@ +WFP<2LP$]E
MA@')X(5'D$.A=]%Z;7B\(1/FED]Z)T%HK)@7MF)4"HWK8)5/J8M=BSTG-5QX
MV,0P^8LRN3'4#V>HW\9</B%3SR<HQ(\FXZ\\!@TTTAFAGY36<X97F2.@<7 M
MXZ6O4C93-\G.*[@<+]@NSE/!OU^+#CB&5!C>BDJLU!\P<9RF=,.GO>Z$@*O6
M6*@X+PAH+%0^O+)&9#!6NDO^"-"?Y!6JK)4JI 1TOCW5)#R<^U0;G_Y8I:C5
MX48W-'2[RGH=MS/Y,T8W' [> TUNN JD3O2TYURT)C,!LW0([ZUE?[E:^M1!
MXS/1C!BWI*>-EVFK/%/KDO#9:)S/NID?"#.5^=R&!0X))T6-.0W0SZ!3<@9W
MA&SIK^?DYX1T/?<\Q(^B%9G_;.%@OJ?3(89GS.+^\^R01^DA\\9J_BQY(D#S
M&[<W6Z]1.]][S0]DCW;R7N5V\KMHR?B=U_5A1^C4>%Z'/"!A?7X%G"U/ Y _
MNM7CXZ#L)-$&A5J-35 HH403=*_^MFO.QU/'>TAZ:7,D.1H441!/ Z'N/0E$
MU84TNX,+L_6!;@OK5CK/9A I'7HB$70G5J7&8S(A14B>PF\SP5!P"2B?0>$@
M]ASJV3N&0Y@I##"G,%1R4F+S ,#JQ,2,40K.:A0VRRE=?G>U"P(4G/4WO!+]
M\(53I#*KO5 DUW(3GSFP87SX'7V-Y+550J]BIP-8_"H=7_LHV_YT.;\&Q2'L
ME/,-Y08I,UB%#RQFV_$?R-\190 #&1Q2/0ZE!KS5V@X[2D\H-J3?.R2LH<%5
MR=R6O.H#&V%'YK%JSL;A"@M?/*U2>J$::#-5]MQJ6EZJX':T@SM-25A:TVU5
MBRF>\?8<E1FKSA4903!E*EV(GM+;"D[T3 9'J<G74$A5+I*I*+3T*]:O=)5T
MJ(@IM0!&.IMN+0W6,94B)Y6L-(!G@Q*R4I'3CJ*'[.>7R*X+,9<TYT'.;]_$
M:V.XESVE?A"B.7:$W\VS87%MDIM*?R\*JR!?F@9G3^6)V,X@S<6B-TEB\U+\
MH=U-__!6%$WQ^IW09SCR%[!/6WP$YC+-WMC4)U;HK HC"+D2GC=I/.%M2:)=
MKNJ1JTH@+./8<H!I<5EV@-1MXORZ%UTTR1U@>QP?8.=BF/[E[7HMS )3EQU3
M_-5^R5>[%YWU5P44R1EYON\],"B9.\3GRK,'L8,,&$:3^)&M]1<W'MFZ:*\?
M^:)\Q+Z95:7MV/"B3@47XSXZ98]B[\L1S_$":=>/,H+LUD5?Q%RYF.^3%2[6
MWQ$[7AM]\QZ('R]=.8LK^=Y(OWI[AC!?&'2/0^*LSAE<]AECH?,)YJ@NB"WV
MML0[;N29=:*L$[LK!K,EC&)>/!C_.;Y7[.\+SV;7YYZ<(;K@2ZEB]J(NHRG[
MDH-]Y(C501>(K]698BK<@HBD+!:*=:3+B*'&H.%SW0-J)U=22$G.ZKU.+Q6=
M\7/PPHL$?.S3(KG#GH:YQ<ZN.7N<D ;)#<C$\FB<R66QSB:1'$N^RH=]+ =5
M+!]F)'U'!E'RL':WGS[L#-F1N$\2P3<6*CW,J266Y+!+Z!-$V/'2Y!*RNTD8
M]5"T3"HWL36GC,0IY,&26(Q-&88^F3%RBI5?(HG%2$]\WCE/_Q.#QN!A[HKG
MIK3.:,I.GITK=APOV>835^'&7,Y)0+G496\11X<#)GTR8=AKC]:()N06>]BF
M_(RQ&R,2?^<L_5*_)5&'O\#FFZ$XGX;X$3GL/=3)"L/X%\;=]>?CC5/\6WE(
M!NN/</SYG.@']HLG?XZ1WU)MS(29%=>JI46K,=W950IHS'85ZHZ54Y0?F37!
M 4F6DC%=Z/F+]+QS6[N>+_2?K HCTRE3+OS1<]^+9G,F9QAA.#\)YOI)^1!,
M^77A'(=E%>-9,?'&(K$\]<LV[>W<E/=DS1X)+)\N^<=^GUXQ61:)._^-&?+6
MBE'SJ^=:\1Z]*\&(O_OL%4LOP,XGANLRN'88@XJ[>15\9B*5?86OI]AG-Y\R
MVO$KKQF/ 4VO(=<:PF3E Y60YZ]]@.PO^9/VD/?@UJI=/K *+4"*BV,K.T>^
M;K($6_D.E=F/#W,B9#CE(7#?7PD=&2LJ*N[1A(@B>K$JCDME9IXNF5A>2;='
MO$ZV1TK)&L]/SN K^1 -,@7&WCEGQ\Q>M_2]"9?U0E3&.DGL0F//"X4(<+@J
MX_)@$P_^3DF'.UQ <'-3H!<0)HX?:,BK+%:)\!4CZ9@107VAT=8]!!<HOE55
M""LPS92!G=Q"-./7<..D<"*Y;<+T.M..0L#X''PFP,1KA6H4RQ-7[ H*ZF2+
MX2:875VF'((Y(>%Z:6A,' A*X'8JJJI1$$T"\G?$21Z75\>>$I-W0J$)>J5\
MGZ[XVV3ZF)2,%Y@=Y#,K,8R?D7!P;"O$7,&-K^0^L9.2]3M_!OO"^H8Q'UOZ
M>/Z%\59#\0IN]G"K<N-$'*Z2SIY[?/SDK6C!K2C^Z#7P&;.DMF'"+O$O<HMC
M"XT'^H28#)$B%&/3);X=B>6.;7ZHL:N6H;])X4 F<4S2M!6'NJG!6K[?<(L"
M/;@.C+6N>Q]<RJU!OZS^&Z^XSKX73&S?NO]B/_SP[F2O$JSVO"EOL'JJ#(\&
MU4N^>]<P"Q7,@R>1IK\C!G"L!V.[--&.5ZX;,?7S*=EC\(4)&_[%-U>?O@@C
MNMQ<%L* L<)',O'9PU?,*96[)$M;[_"2[VDE0M]SAS!N.EOSV&3%;.J5$!)/
M[6]&^]A,?U)[M,F71Z?[M@V\!322:)*0A!%"1%%EQ#+1NG9FN)P)4N'.S)38
M9^$[;-/ GU5E#;-XV#H9,7XO+01^P]^V_IOU?J.H*_N+_?YM9@MR"&*SL\3T
M4?%@"D^!FW]+WEXZ+70BQ:[AW,$D*BP5D3C/T*D-L4KOW-/ 4?X-L7872@FE
MY\M@6A#,O<.G;F_M%\@1B1#_),)@PLSF]Q([NNSYW-F5]/7:U/?Y>F7Q8<I=
M=+YNF_V=*3:^?)DA=!LFWTVI)I@FMA=B4YU@:[YA] BK1%AW<[Y36C39408R
M3V0OA'&P1O0,,6*E,0$I%++I2N1$40I_ <!7959_\MPU-R1D% C)K; /7L0$
MY!QSPX\0MZZ=(["5[V!^\KMT!1,_HNC*96(^)4D:5-S@V"TLQ1V.4+;!^:,"
MB38B 9">T/9G\9/"<3?U5:)^Y&!)_FN,K&'<EBQ>F1KLZ6MY W@:C>2LE=P.
M(8#X)\FC)8XG,XRWX7A/8KG+_H_WER=^8NX&Y8-X.1:03OUL\XHDD5!N[.=.
M<[\!0;GC3[CIR2+P<K9041)7Y\B<Z(T"<4(99R6;W1FKQCG)9<1T81!SIG2+
M0Y*%?@N*EB6M6'Z_1?@@T=<)\\D"XJD,+D9'R%N&1(9!4(C@@KD@L_@%#*)H
ML5Q'$U)QF L_[,!J&H5<E:P+A<[8&_R?C,<7_'XMD\VTZ:/9#62WA+%P\J%$
MY,:Q>S?T/8>G'A8T6HBO,4WJK#A?)M]/3=$-+;0F44H$B6@229/A&?G8EGR9
M?N-Y'-0MNA72$^>4\;]OS6.2,_D2*RSY0>+GA<VH\OXV)_*S"#T6QNA&LF#S
MQ2+4VTZ/X5H6\Q^S&<%W:TF?,(B0@8E!_EW84SRZQ2W@H"P:SO[_3Q[UDEA"
M1*6Y8YT$R *F+Z@($B0D20\EOFAK O%BL53L;=XEY23&1HHX05OPR7.3Q#%W
M)I\KS V?)<DV_B:AW45^YX$RSEWK>7SOL1/CFH DT0T1;!$6EIV924)K\GO.
M)8#ZL;B-A(PT)60CPQ&@KB!2NW61C],\)VI2-\OQ2R)9KKW%A-VSS:0)W"#,
M5_* ;C]^O^/:W;6Q;R=>L C]!>OLA3==__PK=H7+V3Y;=\MO#4T<OT9+H-1%
MZ;$AZ=R8X<:88KT+O5)0Y;AW)3-=;J_N?D&4B6!^S3.P^8W8@F BL7S"O/E$
MU=MD2F4O,E64J9G+U1]?F\"87KCT(CTA)/I:9+,OBM0-=F/=Q.WW.+<@15W3
M2HLXU;(412(\/S\70FU"Y#0+SKFE-(@QY-'CE!7G.$@D'U/[-#$_UO(YX "+
M1XF8>)P&PE,>C-I@T;0<8N/Y/-G/F\_<&//5VL)@O_*6B4AB(%O$399O"OON
MC+\+RZ"<3U;G<CYJ@AE!SX2A$U.0<.()/XL[/ P [BSQ%\6Y^6*[;B:VX&[2
M-DY6)2#%/A_F$?<93PX\J5'('5- &;=BOZB4@7G2_*7LX5L0Y^_.4AP)S1;,
M@+/F'CMJCFYZOK'3(U$$N[GB@;@2)8-0_&>:@2).RXX!B8E1Q![L;QOGS)C.
M%ID(H30Y5=;E2]Q&MT+!)=%&1F2]7D%RDH4]%B='N&N<QDK*G\S.(3%^LUD]
MG[T'9D#Z9S$"PLRSR9*'';W4B+225UG4MYB1&_(HA;#;DF?E^%W %/-&',2Q
MB26,N(QQ^9^V'F!2/\,('02I#9JR)I9JI=(3D>)\Z_PBYQ(_I8Y\CY^;0=FA
M7W/ID:R6(4ZV7+GV;^M<FJAP6*=>2C(O/SCC_V"2]Q?'LW[6UMYFS-*N 9 3
M/ROKCG_,#U]ZJFO5GPU4B)9:B!1U!=P0"W69>"P&?UV]V?@8H1,=)7Q55H&1
M#S+D$MZU>C*>.;&EW3O\2!J#AOI,7#0*R^<!W'!UAD1I<ASZ8V9 _8W<IW&H
MQT4C)\W;@WK+2?8??W02"W=N-^.N27TU<Z3=+$);B_!'4_SZ3.'I#<TR[\;&
M><FM!$DJ07UV ,V^;946=,#FWK@@P7U2B Z )4"S\%%F_)P$!]^Z]XQM/9^"
MV.,'FFG;(R-X&YY,983N$?G7[!$^7##N!V^;5IDAJH>>P6&08_)13R4A_<SE
M6LJR^6_Y7O$#!9Z-;#\^O.HQY*Y@@]37>'*G9=PUH!S\C1?#!EF)A?<D_F"X
M^GAA8,/5A^1JP]''E],JY36,BZ>*@P2&IZNY>%UP'E[)9-&LHZ#Q0L/B,L:O
M).0]>U?A=3SL2=1(WBVIZTVGIE!Q?R;6IU"QZ-IE?:Z%V!RRP*^GG<(I&7J>
ME(3PKH6L^Y:_,(B6Z0L?YC0DY_RFD$OF.#SX>!GC+&T+YRBG^ZEKB<IGEB-U
M6B^VI*W36B/>JFG^[%^R5)$Q81OW-V2CK[FX"5AENZ+05NZN.:?7/8HOJ)\<
MJV1RWM#IE/$0'XHQ(>$#;[.2)A'@S9&4(#BJHJ4JL5BK7CVE8;%RB?0]+X^D
M>1.BTSE WB09AE)HJJ0C4_*=65[DVDE7H\J,5Z@<"PTR:1M#9]C='RFC#V.@
M8S?(6L4-<T[<\L9'N8BA*2O+2=M$Q02JHJ/9.C1'%^[K&)9KC.6>CHJH.8D)
M'$^5;9BIN939:-$ZAMJ> YT4YK%JYEIOK3$'#6S8>G%&*V2KUO+QE0Q (U0N
MBWQMI6%UX(\ [@+[,^J>.V0:)CPCSY$Y;V=C9-* C$!/"KID/PK4TO#+7;J(
MI=T2M3#%,Y *QN?L'4JN'NQ=!XOOH@6CP^KWZ0]?C*Y:B4DVP1<O7H 1G'20
MF%^<7=R'8O9#E>:S9 PXG5:Z+[N"P)884B)=[NZKPX2XJR6:OD:+23RMUXM"
M,4J#3^9*/+0WU&TJ]JT8VK?Q$!V!)[+PDO)].CS(P??:^/<%8VQ+QPQS(N62
M!,^@TX:0S4P/$4<N9/1NF7+.B%KV@:(34.)IY9IX)Q2UP-S+$U'K989OGF=>
M'3B5N)>D?)EQ)MGD-E7 +LP&M-J[XK,JTO9S&P9Y!9S/HK!9DUUZ^K\DD\9Q
MB":$.2]N,@V8+V*IY;P^,^T[;C3K6U&82$'M0?]B%^=#PG.CXCK#L]MN7]0K
MP%8;S]QY]OM2BFQ8+[BG-IJYXQR.I-!2S1CF_F4*C6[)5D- %G5")V,7I\DD
M?S&N,AL B)9B F :O5&YG.8E[B$\O,I242"QT/ LZG4;'T_(Z68%?D_VZ263
MV+DUF,VJA<=)1EJIC(6QZ4IMNJ&BX@ZV31?GG]:SHN,5-A9W>QV'V/!82V-I
M5E*RT>U<C,!B>$+G)$4<1CLC=2\ES6"7<<5#C^+,X#+RF9L: .R)+2O-NA@
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MJ0/@-##FOH'7P&O@-?!6*L1*C<&I85NGB6R7CFP7.-  & @:PQMX#;P&WCW
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MVD'5OL' 8& PT!4#X#:O:;IY8L9BIP/!M2^:L=AI*IT]RJ<],( A>/E9@"%
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MF5LLU@47F 21W<I";$*F.P^9'HH?DMK6U%3;-BD7.4WATU![WD#)\]$A1'I
M\LK$2(WG;3  @@%0"^7+;!).L#O5Q 0Q&!@,%,! 46%0HA?.)EX(+[H!8U!/
MMEU%GVD9(#91E\/$-.;O4KS\'Z4.O#Y;>-TM .#-4-B4K!M!D:'O.^+/P0T?
M S%BS\@):! ?IIS0I;6EK7;B(+<WM@6N2*-PM@4$D5P.$Z6*.O3,TVH6"QVT
M>B"1*,K!-GM*W^:2H<6BR(/2Y3G;X5;#+!DPLNO0<[;0$@(&7H#P K4R/I.(
M^8%-B6<KO3+7I/D,!F P4%06; QQ?J0N\1;PDB$@@@/9IA-]\I/PQBT786)F
M&N]2N/S;=\?$"Z;@Q(L%<*8Q!(A-&L6(BR=F"=*I/Z=C:%Q1PR:P/<N*&NJ+
M]DUC".9>-N-F=C?M4E9\PHO_ ES=!"(3F"T0!0"P,2L.4U3H4IT!PG;/>AM*
MYW0KQ3*4[D:ME+O=OI(?3'[SQ<:.:I4[R726*RV#RE5I]/M*-[.4/!0=<-A>
M/8 11:;4 E9"T, +$%Z@1L,E9@[UYSBP(Q>S8W1#/&Y$B(D[GTB(^<=HH+2W
M:M+_!@,P&"@J(S:&,M][(2-!"&Z'4J>O=+%PGH/0AC<9#V#F8WNV,.%,R.%,
M /":+8S@( 83$'BIV.1A.!N*6QWE I5M2^G\2;F34'MR4$D<3$^8"50:> V\
MF@<A-@G"&Q+,*,.ASS3H.#<8& P4P$!14;!Y/)[O8@HNZ&#UP<W'LP9*NS)Y
M5 8'L)FD61LMQ8.I^.&[&](AB_,5\@7TD?G1#!IK--O@)$:SJ[3/7:GN$IPH
M*<)$J5HGV"(&9+H#PI6$W=*A]E2J/4L],/'&E\J#:!7+:.NPP:S=5;KLHF0\
MH.!*PSR?FKTZ,$+))$%@Q>H,O #A!6H^O ]"/'1I,"&B9,*A-O6(TCN(3"C>
M8  & _6$PE,QSH_8G4?QY0<<XK3@+0UJ:>3L0Q@,5 H3I:JD8(<X5Q+F2M1J
M>N E3!="?T(V[=K7YEZ"B^0J%6G01)"\OQ_Y;$S 2Q(0G4Y92=)5.OAWF.E8
M,W=OE\5A__:9Z%8-SBX)$T_TH+%-LP$N7]N$-Z^S4,R LUAV.#?,R)EB.?.9
M^ R[9[?8<^AT&GFOR1MHG#. )VCTL0+TB;W4L&SA, 7-4S[3[[X;8D:\LTL<
MXI&+IVOO"1K?]"$,L,R(F8$^1H ^AIF1,H==Q=IN*UVCE5O'VM%&R6N4]#)3
MB'=>X:IIH4IJ''%';4^D7-EK"I^>VKU&VU7 JFT%;8>;4@OB $FS N=+52:!
M5K-EX 4([V%*@@IVS6=_CEE( _1U@MD4VR02#W<#-(P"8>($*/*HTCN?RBF;
MSMHPZ-8P+?/%#9T4/CVU/9DM#1WXJ#V-PF%**&.K&'@/"=[#O.45[!#^932@
MOH<\$J( NSH$5P9K'=WL*UUI5\[F2.'3JF'SV8N?C[$Y7DP:Y<H>T2B<@: 6
MLO6?8V^4AWX?\$XQ&U/OQ"6C<,D%(;D/3ZCG$"\\/Y$OK;\\B&82O[7P6?\H
M<5N^ 5WZ7A!B+T1VQ!CQ;$H"]-JVWR#N#F+D^=[)]8>;6S0E.(@8.447R"$C
MRMU!(:?]T:-W<%\Q( X:+M9>I8T]-"2<:2//X101+WICQ#\^PV.".NW3*FI3
M7R9Z(>B]*?J)GV(H#M#C!S.*W-((G8E\",FW?%*PSK#C\"<GTH/C][8D^ ^[
M_A\@\%@0KFDE_E216,_[MFO/XYP>TCE9)X70U2-31ER)53QEQ+!G3V@0=P^(
MYVXD8CTX2)DA>?#\SR@(Z6CQ%JUI-A0_?: L"-$$NR,)SK#T\8;^3'SG_5OT
MX,!;C41!Q+PNF ;%&N6G(ZYC;.(*9N>4&Z]^7SY"_I[501PA%\\"<I[\<(3N
MJ!-.Q%5IO#JJ>MNL%Q0.\8][,1SZY>V&GYO(:FR,)^T7\CQ35,+9W)0I4I'"
MKY ]P=YXTRI;S4!_ABHTE_,A_;_?7J%-ZT1>_FJJ!V5IZ@*$VK83FS_YMKL)
M#<F)T*GDG!MW=PS/TCYA8OQO?8E?PFU4-HCUQ1,OCJM-OUO9+J]*!1&2MP]>
M[1V]:L%8@Y?!"P!>BHJ:C7U:WW#  <7PCCB_8ZO:+&>5$,D&QQO5FD)40B1S
M(G#/XT'R96>B8BO+!U"?13EQ])7Y4VR'^.R&S'T7.YO<0^42MWT+0G-4=GUJ
M1^GT6_[4(G 0FQ%<M1;WT-AX&5'/Q7&O5CPZY^]H]==/Y ?U:!"N_PJ-:7HM
MI=>,Y@H3$"!GJ%Q#Q].^(5:JJP&0,"EGA(BA%7X0XI""FX[3 S&@)2,Q>AJU
MDRM=.UT%$V.M[%+ _()_X#F%QBO=&FS8/<N63AO"< W@UD@-'2-&6!0+BX\N
M(7-BGWUT*?\'&G-TFQ#\@0<NC#9J')ST,Z)DEZ+D0A;<^NSL=S^,AK1:UD<!
M[NAT(3!TUKOI*3U<H9(P@2#)RV&BU(P;[<3,^_L_L4/.?N'_\2)H/--J00A'
M9-<S#I1N,JIR,UL0!'PY3,Q OEW*&&[!,$H\I8=)Y(H7>$&45E\;?TCM25>5
M,#'CRW<I7OY%@[_X'Z%Q"XSE:]D=+!5+W12@<@>"",]&X;:7>T9:%$N+7Z,0
MBYG!X (J%KSHK 4BPYU-Z1P>P$9:/&%;+*;\D1-H3&'5,&)^S[*BV0 W8+S9
M@"?>:MC(9>3%$S7Q]"^&JS4#JL 5((;[9Q._  #.T-C;U!JM(\1&5#R1X'7P
MCSGQH7%%"\+-RX@* / :27&8DB)OH #$A4:=-@1+.%MN.M FOP NQ%F$B%*^
MB6Z32AZ,_4\&E^@V[[^7&G^I]E;80GP>.#HK? 9J5W65.Q^EI6XY% Y(3(FQ
MI)OHBV("HU*C*5?T'(W4GO]?8127P@@  Q<\O?>$ % 3Y%ILEY=6QS'ZF<QP
M&%L@V'/0%6'3Y>]J'N_.AE49# P&!R4E-D9&+_V >.'B7N4CS$_%KTSU/HA6
MDJ(-JEVU-ZCFTAX"O1\DW51R(P %3<L)D6N7/U+I74*YWG$37":V!:\+OH9^
MCWU#O#U;@(DYO%1H]%"\$VNMZ*T^S(ABD>$RZ"J=ARIW/FK+TY(X*#64R,1(
MX8>\3(Q4%WH?=O1CXT*)V22<8'>JB;%A,# 8*("!HL*@1+>:3;P07ARCK_;:
MXPUN1*,++OY9V'NNM(-7"1,3+]VEI/D_2AUX3;%-$#?5E*-#@]A(BF))\8[X
M<W"CPIH@1E<800$-XL,4%+KTK0Q EVE87:4S!56,>PM"VKL<)DH-Y- S4ZM9
MC#25D&W6D.A_\81L"A_%)[26C#X67'6E7<_M4-L^:@1&B)GT+=@4@DG?ZHL
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MV06G6N'9+^V^-HH''.W!4;[3!@<R.!%B]FC6;W.\OQ_Y;$R,T6&,CLU&!S2
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MWK]%R2M+ Z'52$R"F"D%]5!L0_QTU#B2C1QBG K_R.KWY2/D[UFK@R/EXEE
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MHA4%4(H$2Q-"EN!>>-P><E%\('$JV)=G'!LU<M*$AY>GOW[:Z@#%<ST',R=
MKZ\_W-R^$0N.:!"(* "WQL3W9)^Q/K[41]_Y_)^< M&]G$.Z$)<;A*M*W*6:
MFN&UKEP>TFC8:+Y-2!&L"<N(M&#EAB<\CK4@/Y4I_D%65TRX+$)8!XD=&TTE
M=W.M0JA4-#B49'LL9\2J*"=>&B7>L.#LFFAG/!H1._X<DT<C#&-I6\0*<JV/
M7*X\J;N,-L<KJV0XQUNDK83E9^-R[4R%</+Y1;H"F$HCV2/VTI@-)X\_6+JT
M^%BPT!WA*A-+X).5GNEA$%PR<:]/<"Z_ Z(&./YK4E#.68Q[ P[E5&%)/3GW
M (J)_S3O[5>(%_'C12"#;+$K4WB'CU<6QW&,9.)577LG7YEO"\-]-954\K/X
M'[I:SR85\O]/?I2QG.'4I^2.?U[XDG3*M0B3;^)<ZA(<")DAOIWKFZ7I&9#,
M 6(W6<T:QPY7(BC'[GKJ^^XFW+.9B^O![]!<VI>BSMV6B@KYMATQT8_ P6*8
M<@81#,GO''?&A-TC .,&<?9.<1^5+03S2SLY8Y O1\]+PTW@E6#P .2DP#Y'
M@C]A,W!;%S$.(U>A:W.,$Y!ZTJ#F7R^N-J<'UP+<=N$<EJR26QE^G&&OU[0)
MES'9*5Z(0W'$[5KY4_S3J:])DY0;W<)]3'AI%(61F$(A:!A?H GFMCU>V9;B
MC!U^!/PBB:=P>5.,?GYKAR#E>L8+)U%L6#QA/]2L_E,AH:<6V[V+S^M6'->%
M][#-H%I;@&9U^Z+):I-^1K% 1*4DXDH@CD:E-DIN*LFV93@LU0C6.MI-UT&Y
M*/2UYW$]%PHO^5,2,-()OV6T2B>4+I.P)WJ]-I"6X8IP^WX2Q;"5POLYY_<@
ML[G*9,INX5SAT2K*I:S0+WI#'JW,TS8\K3AYLQ&*2F!N53!MOFP_7V9NJ^)/
M>T;#^XY[*.6#'RVVS'96;J?X7Z;Q[Y?(D\'=7/1DV%0MK/+R_U?$ECG,(AR6
M:XV5P<&<C#D9<S+F9/9Y,F6*E_J'6=[Y3=8OQ$',#92MI86TLY^UW)F+T4_5
MPK5Z>^ETWA.:F;O32Z%I6=5*_M1&,W.:S6X:S6JC2]5&,W.::33;W6K5^FJC
MF3E-*X5FLUNMDEH)-//.KM5(38WK[:4U_T5NHM5:X]FKV(:A-I[9J]CLIQ5(
MM1Z@&D81'+1IDBI3T(B_RO4G9(9/ULIV*EVO0O0[J5O7JM:'HC;ZI4X_)5N[
M?8"*<;O#3V'?;^QE>(]*9]])F?*=!D #HE(#9X;3=;(B2IUU=Y!B]9Y.AG[)
M:2LI]#<.MS.V59VVE:A2#1<:<=RCI)4F>#U_;8;:>)GS@H47\/,ZI-/II"WH
MOD[1X,SQ=5).8J=3JYMTF.9#P0@0APRKS2-2@H>,V%(."W,6ZF!1F(GIM#2)
M.:1CB(,60.?:G)11Y#LT$X5J]Y.F)\W+0+JI:Z-7G+'0(NX/=$+S0?(Y)03;
M "5[R=QS"LUN5]M$2'I:6<5Y>DI@F7=T5EJA:9N^[*=J7=J63F@6%M>U^R9-
ML0O#]EKV6*Z'/#TT3,18@'-X#*:5XVNP,%@8+ P6!XD%""WZE0F]&2[$.$TQ
MYT4.2_HKHG*DCQYG.DC;8@!36WD&9@JG+D1O88-7-V@#C$3D.N3IM"K L$-N
MKMC2)(C<:0/L!\J].>FKT]%$Q*5C68VNJCXT[(V.'Y?#ZBH1MPR;[)CAK73S
M8D?IG5JYK)WJ$.IUP&T)ZJ646DOII1BYL;ET%QH$ULD&4 $ _(#<Z@.<E2TI
MV[K9@' YLWF$=+K?JI8",KKRR7CSHRFN<KIK.,'>:NHK &[),'LKU338K]A[
MK *SIX1YI]\% 'Z1Q]OM;7]5]VW%I.1DQ0$2*M"^"4^5@F/P5KJ(IJ(/IP#!
MK;2=WM]>.M:H2[=9B_9,BFVSJV+DNZY_)U<0R+'4P42LAQ1#P!\.1\^;-"YF
MNB^W1,IM/*O)X(_SNRFTS,#LS'&M3FO+@=D&*//U0(ZDFI^1>PUW/"LU.Q7U
M673>@4:L,$;P-TO."E0*\CQ5+N'<V#"N(H5_;L*@L(3S610^S'W:N2&&QTL?
MY+<%T2SY-CEX^T28)>0<>?X=P[,8X;4S)O'E'\DW_':0#!KLOBZC:/1)Q0"=
M2@B6&GBQ\>*KBU_) ]Q+#O;E#K#=K>:UUY"Z+"DK88=CXP4R6[OD>PZ(@$LG
M%,HE (B4$D!M")B4.I+F]I@<IB56R@Z7,Y!49I5RWD1=AI0JR)435DK?\2T/
MKN(8$U60*V<\59QPMV.95BKH7B&^FX&@=N\\S3Y/4K$\]/N =[EVW26C<,E#
MZ<VV)\W58MO$,W[H_:Y^S/C!RT"5+'!?AE26>XR)V V;RCKX([GOO-WO))$Y
MQ(@K%[(N=V7?,>&#._Z=7$]\_?7F?Y.%N%?IMXJEN:L=T+9+/4X&%SG9E;EC
MAJ?HWU]_;?4',L^!0W]&;?XNN2\]I,L=PX_66RS#+0D.00$2S>YSD%AM_PTG
MS(_&DV1I< ?=SC@:(W*/ODXPA] FD3A<-XC7,Z=6S>:L1M:6Y\H'7$IDY_YQ
M5NN>V=3J6A)BZA+^=K&H73+FA5AR?$M7:WZ_,4XP'*_CWK"?]J3Y'[%O5ZS;
M/1&,>+G*SW&(!/3Q[\3YLLK67=S3(/NA_/=](M,A8=EWIH"\7B^$OO8N@L"W
MJ=C-+9_.\3P15_LW2RX-CY]T],\OGMAWPUEX<"S8N'^\WB*./<^/.#$=1.6"
M:;G^6"PH]E% R(_TBG&$9_S"<E:5%U5<B8#?AA-_-!(W2/P>;RH?1H&(W,FG
M^0CSY\AE\,1=H)!AT;(JEPUCU^<@\:/CW+TX3J=()_'++@GY5X0LLL.(B97Q
MF:7R3WS?HZ>CUSGOYCBL-ZN_B?=8%RU77Z(N)<)&M)>;Z--+QC\2CP@4/G&.
M%2CR*^J(-= ?R)!%F"V0U9<GP\\GB(9_RJ7T?D*$1((2QAE8,F:\_SG@\I/P
MDY.[K/U'J^-/T?<9_V3> 1[G@7TG]FO+9>@<31QO34^8,Y5S/DXVEJ,1%[;Q
M$O "0I![FQ!G2;3LVG#Q"<%PHG,Y+B>+#^ IY%9DOR.,H"F)N[7X%U[,&'71
MDH)E3DB@2D8C3F:Q97S!?U^(=^(,_9)7YI0#(=NL?U#Q?:,4V\34#02$Q:S#
M/W1Q=8->7TRY).8W&%UQ*G,M(<[]AN-(9^$;E+Q;<NI5"HPWQ^AN0NW)<L=Z
MK,"$;K-:IVTT7"HW\254G)_M<T'QW_@$,?_=B>SD/C,A #W^)RZ^/'X2DN1K
M_9;^TF/^'OZ5!3C)?>M4W 9QQQY20TH'L7-^@48BE/_H(<$9)X>L?EBL+D+F
M"(^1D/V21Y(C.T47<BMZ_+Y!\CYYUO$19,]%P.%RA"2,\FVWU_^';N\H/_WW
M]_8$>V."7O/7WB1,)-[SF=RA/WSV ]V&8D7Y^HV?_[A]_P9%8E%Z_)V+*;?F
MT?]*F_WR[<6OEZ?QSU=O)1L_XIH,8R5;&A;B5&(^+,.UKQ_>\/6#WCSFCFZ:
M.T+T"3-^H&);6$PY+O,E;@X:,7^Z%/Y4;+Y/F"B^ [DR2I!,W"&.G;CC09!
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M.6RGG!?U=](>U@PD*WC!$Z3%7;;6\1[Z@532'D9_S-?219D>:X#_&XEQQ9<
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M^ XC7GP8DWRUUECZM&$BZ'=URDS<R &-Z2CSC<MV5 "?:B@]Q5.675SLAQ\
M#^35>NK&=4T$]FM58*KR#\_^CYR[+\SS8%+ "";^@H&R, D"&MH*I8VBB;5=
MLXBF)-7$81G1 Z*H_O R/*=S*@1U843'? ;67S/RR#P6VN^+751-9'E2E65*
M]B DKXD E5B]G/0/+U SE>2[Z#WF^L^)C?YS\+_2!D8MUTP@@XS-7DV8F* V
M$A_M40NU=*!GM7]+)M+?GAH\C@H#]6G0&.BF:^)M[ZV<C8(UU*<&"=>,MHF
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MW^<QO>17^2/UU$IZ0!Z#4! G_-M/H8CH3VIP^<_!_YQS1^71!FE?P/X<;JZ
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M;I+U=,T#)@^O!>"6<2=7T*!023$5"TBP;%-9MTL>W]*_9:SM&_]VZ>/<:CI
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M0W*ZU!:^I2,Q"-[JK((3MM[M#%-'\)9%/9P,F#Y3X48T.8X"/2U14W/AUC/
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M.'(5*RMYE5_QJ7-R,D8KFAP!:J<5]=\P@A!KF8^(ZOW7?\;0=3U;9Z9FJ"5
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M4;*7;OA(#H4X*T!A))D7WQ\6Q"?<A:=/7^7#RO<R.XK#O#B':?R&X)7_&3H
MRA'SH=2=3)%69,XV"*%;H4U J8/6@K.C#T-JZNXE#U+!7OA$;C!)&9NA4:&
MCA]-B>ME7L8Y]+OOPPSJHI0\S,N7$^I6%Y_OW^P>:99=S(%-7XVO<P9#4;X$
M*YE4N-.[)1D,;P8SS\ONK#0SCCR-*F:FJ_D=<4JZ8F_+/L7:+_B\BE,8@!Y?
M;+2<'OJO^#H>QS$[%/K@$*_<_89O^$!D3I;B#-!_1#S\LZYJ ?25G_&Q_I9&
M@@<.DZNL%O9<]P4?@'L:K!G4XT*;O'4?\'7_C B7\1N92YE[3+O U/01'XR+
M0'I[6;"4J>-K7U9N+8$/4!+P?<=%. ?><VUE;?J*#\C9].Y<&U7%7_!U.+FU
M]]%C31?ZM$_X(#R0@"TJ-^"T'_%U6ST='LC(<?T*:\T'?-V?@''&8+G_PL/H
ML9)"N.$C/A@7K_\D+OT[_,^/M"6T[@L^  \$>.T1<4.?@.=!J$^#AJ_X@, J
M#^IS2.[I,_> ZY4]H/XK/B#3]3)<$F]59^+4?L(' >:M %54&TR57_%U_._D
MB3RS<K>UW_!U^G<6_(MX6J_U'_%U.TXC$>MF=>DY*Y_P07@0Y)FOP? *50>T
MM;/A(SX8LXT\K:0U&&J_X /PP-?2:3+U^)J$Q&6U6+H*X8-UQ@/XO'G5LWQH
MO^+K^"WE@GA2$66K5>1?Z+Z*AJ_X@/P#;$9!@^",RO>ZB:9I-W[%!^0*E#BF
MK;+:;_@Z?;.9RXQ[FEU9^15?QS\RC_H;S:C1?\37[<]>R!X%/Q64?@,U4W]L
MH_DS/B@S2A\%:T+2^!4?D*G_*.BW)B"-7_$!N?#E6AEJOKG*K_@Z_H5[(1'4
M/P.M8>Z1E6[4-'S%!^3BE7K<C_][1T)GJ3LLFC[C@W(O;PDR_Y([\@_M**'^
M&P80S1F^SVG^?/+4/V?!F@=0&&P@:"9^=CF<^"IA][J8U'@8B?T)V2K@S /U
M@@+,^+U&ZO"%7X[1LJJ)F#&:&]4!<0KU^C0EPEDJ,,\PA96(-:^J65D,$T4#
M*=\@/Q5@,-P"$ U4_3<,(+0A#.T&0?)>@7Q,4V9/)4)LD@?"@X<E"3^19SH5
M\K^W/#RE<EM1%Z+E^QV3H/ 49SD8>C>D$4^"RGU&-<-E#AT5X^UL"@%(<7S8
M/74VC@< E]#UQ3+4TOEGQO4V*&$.:#(,(M/CG0N/Q\B<P*6@SX$T_@3<NB&5
M]Y6[F%-?!3,O*L<M\44!6&/.>?08SB,O?A%$ J@<OIB41;AF)Q>@80UP:=[C
M0-[%.?-X0+W-#5<GE3+C<_+(8'Z%0D;["C=_>65KU/!>NM;YEU^BR-V7Q9_V
M!LDT"F4M>5]&/9:2[)[9-&_\O#\Y\N+<%4G/;_AS:6-L^HAYQ3(3H8ZTN]@>
M858(0!D$XA[H++  )W#NJ3Q<8WEF>Z.2 R[D*_+;7Z$?A KZW\3=UV79^!4?
MD#A5@#119?+-4L?3?N?7;,S*[H\"/WFF@LBK,/&U17D-9@KJMKJRH;U>9E(2
MW?V9>UGGDKV"\0T=SA3A<_H8/O XA4SQM\R5U;L:MCNMM>(ZY4+P%_F&:*M4
M2\70B33/72A?B6-N<J'EEON)FI<K/-T%$2L)NA>_\/9.IIO><\]+? VY8[^[
M(+[T+O6];L>$6WQ& ._(IKR_=)7:(PVH82!"O6(J]<Y2^[.7UD/)$HJT(RX6
MVWLAPTI#V<*O\>3)BZ/2F]?.#*/Z>\\E;;OJ*K2G:YV\'>S&AV,9J#PG2"WX
MSBJ(66&R:U=?RM.3LUG4VY<]72:UD)?NSTBP!(M_[O&76_H:/KQP":QC8>BN
MC'AHV++G&I1R\; D?@KS- IEPD\& ^*9VG'-C.:?F9D9S@SY _4',K.5YI^0
MF9.Y!&[+-KTV8@;5WGK,GKDQ?KBS<*90-=RV3A7?CK %B%OD%NXAMWW6M:<;
MV64#>Z2J;X$-NE&_79(_%B]U=\%V2>Z/;V$+N"N.B"W3_+$&IKF+XWLU]F/Q
M7W.>;)7B#Z455'TQVR:Z/^S\"K-L"49*S:G8) BXC/'.MR+3PN@.T%HZ/O5/
MB?^4/D-;>S1J71L='QK.!].W-^1=M_P(RK0PXL'>$D>81IK(B+@D[;5Z<Z V
MD+"EL''VL>5&BC5ZI%>[,SX;\ ;I $UD5W@!KQZS007$N!NRV&?A*B7,IH51
MX:TD?J_#H'2F.<W=5-W%]L<Z4(&MZ2@%6U%%MZI;)MGE@L*@O8^OW 3R^L%T
MKBZGQ%F1SPMI=+=+$O&JJ,=BNO"9S9GL;I+8/KF]DP5DMI78F[!:Z8>]]/B+
M7,1O:5@%E6U\!@7WR_2HOY77/(19>FFB.#^V0&=_UI=DX_,V-T0\45#^TA0Q
MH/T1?\&RL="3B3N@NS],35>-&$+3[<"!'-YU(_O#[@?J+'V9OZMUNZIEHEW5
M_6&-VN,'#K2!-/:'69E9FRI',=0K/WGII7*ALR<C=TA_?Y@L'4V^S$G<DWD6
M]?:'*?KU-<TLM1IM6Z:Y/\R4:BV E7](U>V9>-*^[:N_#"2R1^Q*QH-?>,^K
MY."S5/VV0G"/S(]:L]IFSMK3P,PM+?V$SU;$^T2)%VHI<VJ_(+S&#/:,0ZD;
MY&\(IB]]%.S(YA+[LSY,5M(#_BW.@3,_Y;X;I&_;93)K+;(_4,LN?_E ?>WZ
MI2UT!L7W9V)^I#Y\!JOHGCM++>= PS>$DS-]O%8>[<@"@0S93%Y-TAY'-2N*
M\.';<A]3&!>OU(E4KA6^6D%O$C$5?.,]:^T-<IA]-(5QS@1UP%CH@-U4!2'F
MZLMK:=CM911&@J8?XFBR%';O6OOCS;]8K3V^H2*^AOZ)>N[II@HWBUPV+;W+
M2^Q6.),45/W@]JVT-V<;$W>E'DT0*I]4\HKJ+0W+J++X%F7D9EJ*75W,>W?%
M[QQ&1(#:47C$<2+ 6O 7*B&.>E0PN%*+@%#O6B7K(F"-5FL5^F/*S._2U/ZH
MCE>^(U-&T',:_YED,LOXD,3YI2\[RIB:%ORYTVO+5/=H,&\%>VG,;I4B9DYJ
M*>]K75GZ0VNM93"H^&50IS&S9DM*5?Q8Z>G0^F^(WT_4>ZP](=KT%9]8XBPZ
M>?X]+1URTU=\0"XCWRWD5-3>M6SXB ^&T2$ +'CQ =2=H.OD.DKEW96!9/"Q
MIB'LLX!2?R/$N#P^L!/'@7^[:4COU)>.J7PB@CP?8-$[IVL>,%WXEG7Q,:'8
M3>GEF0JV8+Z*<5=7[F]@_Y=W?3\<G9.-/@/LZN)CPC7W%R#(E<KO!;+3DV9&
M0<A75,A/L1>37DM=:>(^R[\'B=PW]4-E5\3QL3&[!^#*1+3$EQ,AO"1,*-,[
MT2SO!)<:H^]*^TB;5/;U\3'C' @\*ZNZD(]8QN#6;"6&9?&!5,T&TWD>Q:%V
MO4*H;%$'-2Z-6"OMQJ"=#YB7QR=>I>*D1ZXUVD_E$SX(Z0Y]2HGP84# QBV/
MX.2A<79K*8$A-_$5\5WM]:H!!/"QH_'&DFY==17#!TT>TU A.WI'UOH#1DT?
M$<)H/$"MBLFP+#Z0,_A5WJM3Q^+:FUFUG_!!*%Z+XG*^!)4)(_?PI).Z3FA9
M&1\;BBKK]-%++\MJOH&.0OA@-1BV%2DU[OM#".!CAXQ<\7@0"3J=MRNKIQO9
M3!XZ4+IO-YP,JIMX/13^6VD2 Y[\EZ)B;%<5L9;<$U /:ZBE,L)ITSK&"[9M
MFNHB.0_L8QT:4,''F#H@=S 2';8&"VFE%.SB!.E1'O&L,$%1MW$:UL GYG3U
MGHK//NR WD8YP@O=U_59\_+XP-Y)]YR<I.ETU&39\AT?F%NZ(&U@6K[C V.N
M=EPS7RD,07^-I5@57RK"]KZ;[33[%!/5CB1)&ED3VY!%O)JQQ(S0GX1KTV<J
MP'91[J_TF-/93..X)3-^=9' RRE[>RA%.=@B:B*$V"92;\?$M]UE%_,#TN+1
M8?PP;@MTA4)S/^^ ,+Z-J^XE2W7R53A1K&%._VKXH"L!ZR][U@F\9ESTJH8/
M>M9]V%9F1JA[U4 ,.)%7.E#KQG$#\#XU\3'@K.:&5*VG?U_.8AIN?6DV1$<A
M?+!,7AIN'Z![-C"5:>=.PN0RHPS,"#0IMA?!!ZG!,5]_RFU:&!],PV.*?3R,
M.%M"?V_YL[RW%J3'9%3:8J>,WU"7.?)-G3CQSQD_O [=PYFTRY:$:=+= B$,
M[.FX)'#E9UZ:&_6"IZI?C+I)(U?CH/^FJP$6=!#?5=$WK'@43")I"9&/J\=/
M7QCU?:)O65W%,(R'>FAW2R)6G<@:2^$#-O$<[D_7RW!)O!5[:H1F4 X?N!GQ
M7?ZM"5+C5WQ +DXOOEXDHXH&AZO#Q\-/M_/%X>\?ZX 9E\8'-)U!I[#X><2E
MP?*:R7OC[D?RC:TC43_?.DOC!9K;EKDR*_?(3V3%O)#[]8"-:^$%'H]/AT)?
M0$.0;YD3E\!N>7C.Q3/Q_C.BC]1I6UY-J^)C@5I+\U[?L"" _T^B!9GZL%U+
MM:FR]!H5QP?U[.IT\B5^E-(8;\\Z^$#'&TO>^5,>.:#1/4-/:=VX[E$>']AT
M4H(=X-'9X>00T(2,+/@Y53_53^'.TOB JFEX31XYU.5 *\:@[)DVQ/VKX8-^
M2MD_P8(OK[^),9=\TT*?>U3 ![=AG_GT>Z)=?.+^XG>N8^Y="Q_P6?1MR:,R
MD"R1[2:1GS),@V6DK6%651&R(/%-I$CD%0T8K<W^CSX5\,%5JU,Z,EN'MU%)
MI "5CRHS7ITD8WC; M:_&C[HB5HA0937I 3!/Y9<SD;BUVHC/:IAA7Y^R.'_
M+E,,P1-H5ZYR.OV3_(,L!'VL0]ZC%C[@F8%X* #$G2"+J$$#JRV!#Y":B+K!
M]TVF"J3KZ-%C3C-2NZKX6! /RV:<+=_Q@4F'7YR'U2&"3F9G?$W])5G0!F]'
M1UE\(-7(N^7"94XSNJY"^&#% ZT94<MW?&#2P77A1,3E0MJB_QFQD-</P<92
M>('%*Y_L\<7A&6&B 5ES,7S0X@%VL=BLPV*W;^F+ZOF93)=1,R+-*N"#FXKH
MDOD> )EN+H(U;Q!C0QF\H%3S]%*H!%0@E?N(,N\&%&W"@B:WMV$=O*#S03@S
M FQ0'A_8U-G%! W4)M>-MU\5?)!3%4QV^IH^$\_C(#SYYDI8KZNU%<0'+QV.
MY](><I9RH9''IE_ILN% KJT@7GCYL?VMC,N [K:Z^.H+8H>GO!A/ZJY NPR[
MB^.%FKZ',).G* [M0-I9&A_0@FTK>WLI*'N,Q.)J=0I_"Q8DJK$UC(KC@_J5
M/--KF<Q"]OQ">#(L2ML^VHO@@Y2?<,H.0R>"X 6V@B DKAZR;%(2'\!XFU-9
M?WQ5FWBR_Y^X]^V)"6=9;SD:E<<']M/%?TVN)Q\;P;5\QP=F1KPH)(4=[I0(
MCSY6!=95#!^TR?$D[^\4>KDDSK+J^>\JA1 8%7PM^RR[?!^YO&XEZ2J$#]:M
M?%\[)%=^$"F++XWM8H^">"$157._5PV4@!-_)W0MD$;"V>'5X0T-R8J+]9('
M+)B$L'SHU\A[5\,'78N2H F8/./81"9&CH]AB"<QWA#H:1"P.HYLC1H^1F7"
MCOP%$9O<-9Z,]2PG?YS]<W,:N61-]?LF@ZG@8TRL0B2 >C'#JB8^!N1W,%Q&
M$A@WT>I1#U@P*(<77#Y2[]2=9&H U+ ./M#QP.P&:E .'[B[A\/"2.1@?S/R
M=_($/VC1["8%4<++;;=3 GNQ^D\%6FLA?+ R20@JG7O)8#N7Q^D-+NS6DG@!
MWH/*3X(GYKKIEE#XY4RFWH#_BJ=ZS'TKXV-#18,JBU'VOJI^]ZV$#W8V: -!
MJ">CG>Y C7:6#^SIN>&N5WM1?!"GZY#[7'7XEC[3*T^/_VHK@ ].=OX9'Y2M
M09>7+R@L]$L%!N7P@5,3ZBHD'DNZ?,,JXNHH@P]4>@36**JV ECAY-9D$B4:
MQ/V_Y\]44#VJI&<=?* SU9I[,MCY[P1LI-\/?S]\X$^;AHG77A0OQ-@9V &N
MJ1 ^6&JY4$*0"WP-I+8"^.#$,ZE!.DT?\<'(KD5QL>9Q_1OBD0V8.C/7/SQ=
MNH>_1_##=;1JO 3;LRX^)E341QV&5+ \M89LZFZG]ZZ*CP6Y-?AWON2B4_8]
MRN,#6[D9)QVQY_3L\,OA#7UE3DT\7[\J^"#GX3_M. W*X0-7W@RE1]V93<Y(
M -TDOM.:*J.Y,%Z8MU2F:9'V;7 *(IH(?ZF_KVE6%"_$6#A=Z!I+X0,6Q]Q3
M-Q9&$[#.4OB Q0N&ZJJW NNA;CFI^8H/2#YE7OY!B?(>A>XD<IZ\RJ-29D41
M0^1B02>S:> U6!5U!?#"2>(%R9,\@O<3G]_O1,CPB=8(P_8:V %?\P5TGSF!
MS-QP1P AJ0U,Z%$%'^3X.BR4$!SP".:HF/0FM,:E\0&M.3-<,H^MUS) 5"4B
M(=#K!EW&M!(^V,D)8M[KDC%91=RC/#ZPU_1)!>"'8O/$7[2+"/7?\('(5A0N
MPFA!O-G'N]FU2P[EO_F,>,]-GJKN\HC!QM=ADC#M>VC,EU[O^\/KP]/(@8^-
M@2Z]:N)C@%I13?":%,0'+S5W97\?B%A$-Y'0DZQVE,$'2MOSK\]N>.#HZTU7
M(7RPU A+LB,\A^RI"9E!.7S@_C&9QN.L#E'31WPP<LOH6;)]%DK_)Q6!O//1
M9$.UE,0'<$8BEY53.YPS>9;VJ'J59"JY9QOB+O5EQ*(F/@9D63P\^,N37.ME
M]H=322GP2%.L0F=I?$!!(=-2>)P?NH?7_XP>_TGTO*>&9?&!3-5I0YSFQ?%!
MS88BC\+E9"Z-P[MP W/NAKFBT<7361H?T,J15 7#82UDBWKXP"?*FM[SW^E*
M!A?=$3UPKD=Y?&#30?H[%Y2HO&^41U[]0&XH@P^4&H9MB-H*X(.3A *TX&DM
M@0]0[&.+ B;=%:=$.-3CM3G;F\O@ ]4<%]6(L5\5?) GC\1EY)Z&$15AG.F#
M")?[Y_0<?N%?"/38Y1[3=XG>U?!!SS;W9Z"TH)/36<B=IR7W&LX96\KA!5>Z
MTSSY>$H"VK UM);$"S")ZVN%UE &+ZB2+,J*MKD,V^OA!1_WNQ5G?1'LD%+W
MKP&TIJ+H(3K+%\J^R5OKGD<G'V^B,*3^MU:H'5700PXI\R<?U1^M..O*H0<7
M"V?R\9X%SM) C'I)? #C_%XO+/P6Q]?,)C78N@HAA:7Y9*0A<2G8(Z_X78U+
MXP.:9/FL6T/K/V&%H+&_=HX9E<0',$M&3]@+29W:\(\U;0C%:2N(&-Y2/@R:
M73"4ST ]\88[F1UE\8&L. )-T/:MA!MV!*+SB& /3 ;5A#)IXI4,%7NL=4;U
MJ(0/=CI,;YCK>O2"!.'E/R[.H\:D!BWE\(+[G+Z% MO<RJ.;,R*[#'^IQ]A=
M'"]4;<OHB;QW;;R,^ A=#AXWO> ;UL$'6JU#%QMZ!BN/H<C[5<$'.=:0C*":
M%<4'\:-'7GD O5X^><RG\A7K:$5%'NZ9^+>"=).5S['/N7#C13J@KV4^;)$>
M/F;57$>4N]0GXLMKS;?_W7EYL;XT7J#QP]^T@."6OOPW%T]-6$TJX(5[1M8L
ME(\!F<(UJ8 7KOY^3*]1W;<R7C9T/.PN@]SE2BZ8NZ WDR;GN!6-/6 *X+F,
M?"=V^W^D/E\EESM@QSMG=,'/NEC2AP)>AGPACB-O TQ\]YR1A<^S6RZ=@Z-?
M5;PL2 \.9,\-5HCNXOB@5K-KQNI*87F#X1Q^A?\M'_ZKPS]A5G</F" E: Z[
MJ312H/=T+K^Q9[J$[G\#A?7Z^JP=K7$5M)#C;4EYY3N0MI=$"O":^L&K'(<3
MCP7\"Z/_K&Q3!N7P@4LC@IS#.\% SPY!X?Q[?=!0?1%\D"[4XA&T8NHH@P_4
M)8\65&AOC,;7):FGWC[7-\U>-? !SA_'^4)]^BVBG@K<.I,7GDE#3N^.LOA
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MP-"N)&'M'$*BYN4 [;Y5Y]B&Z*HH-S5E42P+OG!/,,NIN+Y*_%&?!B@CCC0
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M1?H*^T$O+780:=61\N. _NW<<5@(4/?A-F O\R06_WMDL"T*8\Y@.A>QU:H
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MJ)WV5NZT9? &V>A[JMZMT W5%?E./5+F2E>G".>9?_ KX[>'/(9!709[?_<
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ME/\$-MC\K#/D_9J\X5IA6!8@.]&43 'F9FFGV#;)[-03"P+8WKP0GJ^+^C3
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M[)CFD;[DV9_*=PDS09H>/]X"LGN1[G>@60U$D%?":1A&L42Z6G_8"BZT0IO
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M31'9A0P>;!-9CMV^C?&I052.\K?TU5CT=^#OW0H?\&:. \)ARMG9,B(8TAB
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M\GE)1)PQ47 XB^53!%%:':?GA2 4A !Q"7E$,O%K"]N)+1VO4FQKF\WF'*9
M!5G 2-KX#"PTKN_<#[]"/C,2TZN,/9IR6=.E+UW:JJ]'C9U'F9H#[J8 >0M#
M]S5-];S$418763F97,O/J_;JF:YL5<^"IQQH NN)9/.\C,4OV%\]HYR92,I%
M.3WET1.C;+:43SOY>"3GI???'Z=%EOVN6CS_[RAF_/?G)J7TY?=EBXN"<PG+
MF1Q]N5@SET7WD)T>9O>:WROF,S6],K[65 #FM5S;L+N%[1F/#QA/@)\>RM7O
M\. 1R,,T7WVH:$4\?@'[ZP5CU>)8%+-92?6(2--?]T\YF]7RR%KU+0D'U/57
M1N,66]$U<='_^T#Z;Y8A+ 35"G^6YYS<%WETG\&$C1^I=-C&Z4VD>*X!Q;P3
MEE']TI%Y)0KN4;W#(W,#(?Q09S27\LK'/8QH#AR$=L0WM'2!Z$,@B(Q$"8O+
M2(@"DHMH3O(HJT&C]G?,P\1H0+!6X<*B,LZGP&]! %] W1BI_1WGDFB/2H-P
M85&9<(CD1G-Y-Y5\U\%2WZ#SC'6$!)@F\<(BL_)PKTET3S*2DUIT](VP>"G-
M_%LS'FHBKF.4F6$0WDDQL:3&=CBGX09,#*1!L!H^<WE%:$1C$F7-(%GTPCF,
MFG%ACE*BV&[2I!F[IF8XP6KDF-5N$K1P!';5&F5 :E<WG,V!Y\N;+**YE$")
M,I_51R]:V^*T,&T4B5F)%1:GSXPECR2KVVGN_H1S'6U#H5Z*P'M\FD?T@4@/
MO^*Y7#,FTX@VH&'<!V<\I@TF2_%"XR<WPKD:RF=QS J:0W+%^#=!Z$,U97^!
M?,J26A2M>KI@^7<$6#H(B66CL7'8#$Y -&U=4/LN.&J&8J':>6@Q:FSG@L_W
MP?$Q$"DL-I>0@F0MF41/6ERT;5PP^2$X)BWBH,&C>7/7W!#[&M2P-S(1#%N<
M=./X;'TWHG%6))",Z"41<R:B[#-GQ5Q<9)$0)"60G(E?(%.K[%V400W$O3X'
MYWK7$-G4QCZ]*R6L=7DUH3!VTO^ZVVXG?PYC*&W[PCYB:] %9WRFW^'-7%2$
M8K%YN1JNOM2O&8W-<<:$!D'>7#UXQKWTFE+[H=_2"V? :?#1;Z2ET/D240)G
M-"G9OHF6*L= 3%CY]5TQGV<$>'T:A44_G/N%0<S!04]8PEZKJ"MW]0X[4L*2
M\&&5*7_2R?]Y]_;],#:_RZPF"=H),10.S<Z)@94X8[[Y*-M7J5=2H^O,JS83
MZ/6A3F;U_;!FI?&*!M-.^(,@*L&I]Z%J?D6]4QH"--:B&A032KE@WT(,9%$N
MX0V;(TU+U/NB 7$V4A.>_5'[X9]!:]0.\(#8&ZLJ\)B/Q%3Z[.J/.IU>2$%I
MO>_7V- %]7_\"5$WT1*> ;^]:3<:\_H.J$]! @W[-FV%-81;I7>6%@*TT.N:
MN(#],?AQ=;,T6$(1UQ ),,[WUS3&.1T;G5J;"H?"538 JZ4E3J2&/$+8 Y@W
M"2XFQT6U+5$?_@;8$36J"8&#]#P+61X:&7?$Z3"Y%/G8'OW\=+PKXK7\[.\N
M&NW%/5@NI+GA+"7Y-1/B2BK^@M&<T(+0A_$<>"ETG769=\)RFO#,<:,XN(.#
M-7PR-T""5R1M<:MN.ZL8AL3"ZIJ[X8SZF0)H(AL6",\A91SD(MJ(V*M6V$=8
MZSAZ!9Q&1"PX*8%68M"'LS@G"YWO8-P'^R![C4CM:&N5,"R$Y942X_29YW$J
M_54F/9P<Q!E-_L4(S?\M78R"R\^655#^B>/,03(PBKY4@6 '\=+UW-TFU#FF
M> =UVXAE+9(A@*,Z@EG=97K!1-T>OKDASH,M@T%F(E;@,FPN^:\DJ8&EYE><
MFV?K :.5#,& N84%2%]8-TQV?L8Y@]7IE[4)$?A4IF))&5 97DM5!7CMV4QC
M0YP>00,>)N+4(1/*M%KX;91J,B4\N5'A*UQ>;[4XR!7DT],<J ##R)1-M\[S
M1#^7S]GO0>V%#HUM==OGBMU:&&M;= X:](V8UN]I%"CT+"] <J!212[E%)&Q
M\F8</39&[9%>[&CM%5D(&_AT4+K1XU1-[+4'OZ]_13J6&I9EK1 (/-2519PO
MKPH:*_%TOJJVH1L>_T W8DRD- 'LU2LDY!<6/DRK=ZIW?$Q/JRPX+(UVPDK=
MW,'#3)/7:-\9IV_=Q2%MES9P.!;*&\L_ Y5#(9/KPEDR(U2E&TB-+$"_;MIU
M[)RD@60Z<)$Z+,#GD2#QIXA3R;90DMY(0U2Q88L#<F<:6,[+M0+8"(O[K*^=
M;>8%3,36;'STWH$*SFB<'_#QG]-?DJS((>DXG76@@F5":Q#!3F#<DYH)X\P3
MJ*@MVWAJZT0'Y^3FSP@L)[C!LBFU[UL,GU"YYJMTD+\)E9%NEG9CUQ'+O&K&
MM?%H]$$.YZ"TA)?YUD?XTLX=.:J[B5_(8>B.=">&,VSB0:YUX1+D&V(5H:TW
M *MDIDNROAA:;+\0>+NPHN;1F"RJ*FZ40I;%[/-<K.-(4J J&6O,+^$^'U&1
M\V(E:16<E/HK%6DF[*ORTP&>B;02RYM]#JQ(YWCS#6<Q0++-WD[]O+T1>:.)
M,_'(GY%X5E3P1.Q=879?M.#%E!R)(JT)[-.6.FD*CS&5L^(UHP\Y\)D/0W(G
MB//F^'Z,J*N6\!C0:CAHWY'D95KJ2AWG+0^]SD]^5+8/VS[G+1[N6*RE#/H=
MO]/F=A^ [Q(6LB:W-V$A;T:REV&AE8MO/S\T=,02+!W16+TG&BZA^CNBQE>>
MV7;%.25:2Z&W]U:X,67H>Y3;:<4/%='T*#?R*MU/:0IQ/DX_/<53N:V$VRB'
MB_)_8FP^RCM0P5D2Z&H G16!)#A]$RW+Z.6$E0%X#KV'IOM]8F<KZR<ML8?(
M]!!Z=(]+%UR."P$^PM$=23G>N+]')N%'0X$#/AL9/$2=N])R,ID!:D_Z,)E]
MCC)OA/ 38_9 SLER!JC9[,-R]CS"O)'#9V#9&U$G0QJ@0+$/0QHND%SKJ_2<
MB[)]%_$062^=JL.V&#A[YJQ<)<KR8/GXS9U#R06;S2-:+VHW0D[6OT_Y)3[4
MXVSPU3YU1)4Y;E]JNWX=V2:2L99W)+51&^3L1&AO<MQ,TB ]:,)]L[7:"8Z+
MO)Q,%]*>JOFDNGRVFG6^L$65FBRY;+JX=GLY\TIX?[;F!H#WH1KW ;T6H;K>
MX3?&_RA-;4[RLJ1QP]\J0M5T7F%)8F\2 6URF9UTL \'5>[YRY;$G!;P =YL
M9'=,8W6XLX<GWC52=#GQMB:W/VZ>-RO!?^0M75.2 $W$3422":NBRK^P3&I?
M)?U$?&=C9G8>[I$JTHMA/,P2K"==!8ZT[!Y4C/DM) "S\DAB*<IBOB;WTZPC
MTMO2_)F%BSJ\%!9\>@(>$P'C>;[MXT[4@6G!E^5S)SRB(HIUJX4/<GNS7W3%
MUYN.\.3N/N]ZSAGG[%'5\+:81U,7G#D$_9A NQ["PGP+\_4>.#6$V;1+YTTE
M]JG<3A'H]@TU23,&Z'<CM#?%9(XFX4,["'**1C150HR+O/I;7H-@OUWH3&MO
MZL4<S<63@IS]PRWG0UU[*6XA5EJ4 E7;%;5UJ<'5IMO>5&LY0FBO"QS[N/+R
MG2H".J+5FPNG9+YU<G57W N2D(@WGRHXT>E<9X7=-?"@'1QF,DYW7U9JOPQT
MIK5'R7\=[:6CBL+:C&D6MG%TV@]!G(=;KBGK/G6R92X#OJ%4)4)PF (59 $X
M7U=:I6>_YO,K2/[5FWP7$9%VFJD31B'UO9.QJW.%NU/TD!S4QLGFR5O9YPX"
M-9'!637622+6 \P(-H(-HJP7OU\@J4]&<". LWYV"-MHT@=N4UB73UV2-)6.
M+8U5^52Y,:J@<C .4Y)8:FYU\DRF4?X;R;)SD!O#C2LW8=4-YV.NKL)<RVRA
M)A>R^S7K.DEH.-+LC M3I6L(;;6OY(%#VWI_\L6[:5J\3FP#HXGA%N3<9P?<
MZ\SGB-#R\F U7F_E=D(=HZYOZKV$E%!(SH'*_^2J"L'%*7%]!)9UZ/6[WVM?
MN8W\-+[=]'6BX#;@RK4;I_)S57*P2BN^8ESJDS8&0[S3QGD,'V*%<U1=6%M;
MO4A<)YOS:\4[>JR8V,(9^>O#PO%I'>=$O);G*\M[VI%94G8+=_P0?@'N10_F
M6ZWP&U-; 0W7HFX.*,Y15R.;.C%[L=96LTZWF+,3_?T*. YG?;8:=$Y":>-)
MW81S!W'!FR\ELB6 <^LS1*"Y21\#'@FJ$\J,J=EMJWY^NV#^$O*(9.)7;*>#
MVIL.5.[/ R5"G=5+E^M9JDOI>-7OQSL0\G 6.$KDP^3T$6TNCED5)=1E?;4W
MQAE(,^";^</#O?RWR@K-EE\B_@=(?UQRDQ2QFGE?WNUC:V5^">-<+LTQ[D,;
MSIBOF:Q__WM7X'N@CG/1-$>_-Y5T\WZZ(NU.!&<0T!S0KI('KM*%%.1TE*C,
M$"?@W0C@C(N9@]Y%:N>!^IRJLRKCT^9ZM;3$60-CKGTC\4)GHBZD-(PO;<>3
M74><Y2GF2+I(VZ76)('R16P+Q=FF&O;%34NV>/DCBK-.Q1Q+WYH(7Z[X.J?9
M>N?C3@7GFX LMCE=14?C&&W50G3PCFRI8"TY<7*2W(0/:P$;+Z,#_LXTL%X=
M[>"D]8>]?I6_B98OUJ#F^PE-NV"]E=ERC3:6U!F#6R7M./TFUNP8#1:+7MVO
M-0X,A+6L7:.Z$NRO;%WXOUOB9Q7&=:74_2Z_T*/'BP("E;RM2X"K,U1L!UJZ
M T.+LU:W0ZG_)X4/EYB#R;D;($MY@'<J>LE2ULY"JQ_4/_=RDI/?_ ]02P,$
M%     @ T4SU4&T\9G+^8@  %R ' !0   !N=G,M,C R,# V,S!?9&5F+GAM
M;.V]79/C-I(V>G\BSG^8\'NQ5^UVV^/Q>&)]WE!]M6NFNU1;5>U9[XT#14(2
MQQ2A 4AUR;_^ *2^"Y])4DCU\F)WW*4$B,PGD4@D$HG__+\O\_Q/2\I%QHJ?
M_N/=U]_\QY]HD; T*Z8__<>GIYLW?_V/__O__;__SW_F6?'[W]3_>R:"_DDV
M*D3]SY^^FI7EXF]OWW[^_/GKEV>>?\WX].VWWWSSW=L-]5=K<O5K6FX;[!-_
M_[;Y<4OZJNO/W]6T[W[\\<>W]:];4I'I"&6G[][^]\</C\F,SLF;K! E*1(U
M%I']3=1__, 24BJVW2S\R4BA_O5F0_9&_>G-NV_??/?NZQ>1?B4%]Z<__:F1
M'6<Y?:"3/ZG__?1PN_UHP9:$EYGX.F%SV:7LX2_???-64;V]RD22,U%Q>D5+
MDN7BDA6"Y5E*2IH^EO+_SVE1BDLB9C<Y^RS65-_^E^2R_N:,T\E/7Q5+\6;3
ML1K6_TG;]ENN%O2GKT0V7^3TJ[>=<?F838MLDB6D*)\X*01)%#P MGP[BL)'
M5VSTS87Z+U:465'1=+R@G.Q__+L '?/K)P87(3/%KY\87+SKB(MW4;GHB(G>
MYS:=*N-8?W,\^0==W613^>?-YW\,F-V^/<7AY*^=<?+7R)S\T!DG/T3FY"^=
M<?*7R)Q\WQDGWT?FY,^=<?+GR)P$K.G>/<7A),15].TI#B>=,=(W'_><+3.U
MB12C(AV7,\KO6'%9<2[']"$CSUF>E1D%N"S0CGOB<Y3\NY+#::1\48FLH$(
MX/+LIR]/+&3?%^)?POK%P&5/3/;-XTU6D"+)2'Y;B))7]1C"5R:O7D[/0<"*
MY-7+Z3D(6(F\>CD]!YTPT/LJ6LWGA*_&DVMI5<O5$WN<$4YG+$\I!RRE(;U%
MB2$%F&3?CDZZYW\BSSEMO>4_ZN7$'EHH#Y[]=,K%;ET:3S8KDV/ PM*DG[')
M[\Q(,:7BMF@FG.\(C0T['><%R=7)P>.,TM(QLF<-:6\R8_.%-$JT$-F2WA:2
ME@;(S=RXK_&&#K''45VQI%Z=Y(;B6AJ5<G5;3!B?US/3-9T]FIK'2GBR&>[Z
M/_='O#U8RHKR;9K-WZYIU'\KI%CQ)J434N5':F@XF]J<J:E#J>_7MLC03Y\C
M9G.2%>T'?-!-Y^.=R0YY4CW3-]M/ H=LZ:E[*==">3.G\V?*H2+6]='Y2$F>
M \>WU](\*JG.65'OI3_(?Z[)U8<M1[OUN-8'R7O=TY>2%BG=G-UN/Y&S1,=
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MPK*GT\!0*>)4OT"Y 5RYP)YQ+)\(5*Z5_.+[=(84]R-?S)H('SL2[.=#65E
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M<ME(97L^L6:-^KEY8GKS;O7^DK0.K/G>/VK?*^1*4I0H9.<\1XY!'7O,8_Y
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M90WK1O/2JA^(OJ *HW3 _9X:G*I0S_:BTFTA_>>JOF2$M3[/QWK3;"O18*#
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M&U=@\\_H;EOL9'ZQNB-S:HJ.6LB&Z.@7&AUU8A[7?S@>GSG$:B5$$_NPRMN
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M=3S(82/&$:%M <FK:8P9O, YVM-L[./]M-8 =CO_AH/:,S^HW6[9J;@G6?I
M)U6ABUI9Z7 8MX#XA)D)A&C4Z7O9)*/I2-P62RK4.TFCI,R6I@.A-MW@L'-
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M9O,ZGLA_PI;(P!XA8&':?G8J!C"\=2;A'2V-MX#T!!#A8]J VKB*Z\I?T2:
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M41L3M4ED(AT/>2Z3OD?7YUDO0MHY_M P3S>Q3+^S)(WGA4%@SEBQJ(U8.N4
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MYPIG.?LF>N9UBDJZR1(LGLBK6F'JDF2'LM!C.7] \:X!\;7!\.;Y^@C!NP:
MJ.)V:%XBOHG>N#Z+I^H([: 5U(8G'D%NZ]XY]$,O<+P9'25?=BE1!0&S?6Z;
M.I!X>TGET>F[=PTRJ>Z3E? +7Y>C(I&*PJ_7YYL*:-K!@@YN+19R^2O3E[(.
M$[S)KYYPMN'FG7&HQ!OR/LMQ'F=X4U_9DXSCD)^C 2.YWQHDD8G34):H;TC3
MR^R&>"K.QMVP"[IENH=WT%XS;*\Y.*,D;.$$RH([]WTII>&CHP< N@3P3<\*
M;9D/:N;1'V9\!1CC#_68_[%ET-,=J(%N)Q]A/\#2.LJ-P]?T M.US1DC*$\C
MSH]ZLJ\;P4O+[W8#S:WLZ:Y@'X<['\:V*9GPF5&\;KBY/0^[)3'X/>O//^/@
MTT[.@/>JH>5+@[8&@;LE/ZHW3)2_SW_-48FY%<-G1!S@LMS=RV4R ;]0]E[B
MIQ/2#!ZE&D4!EEG>Q=BNL QY#R(Y.#^X3WP["&3>*;D0ZBYC<>]R=2W?Z3.N
M[SG/K-62KH\1F^ZZVP6Y4UW[*0(](K$=8ED!?#Z:AISCE'*0^KE^Y-@!ZKO4
M)K<[:RIAQ^0ZIS("!#%>E'HJYA#@$O4<3B&HD@:V16)9Z._\#%;."*<^8:(T
M\(+(DB8&.>KOIRS/'K8/M5T@'WE^O"_X6:2Y655O'VI<S21*C(W((/G80)M9
M>\%"F4JX>FKR</@2?58E&-0W0UPKB(GL-L=2-%=0[D^=[ :OB3$B;I"TG]CZ
M@6G[]JPGMK69FLWE4B<8!_I5^A]>7[\ &&GG$$(])+X365X@K:=T/MV=P'GW
MXY$-,)?/ J53)$NU:7P@RR2'Z)3>&,GKP]?AD-O6=$"6@8_EB6M'5I]39&I^
M*R_DU!9Q5AJ2-(AE%OZR9PNOU^26?_)U65\_%42CCW:!D5*E08?NC&([\2U'
MEEI^!I8MK4)6F/I>),O\T?1+1+%>)4E3$"DFV1/OX_SG=4W[QI.(F<8<05,'
M:(]!BRFO1T[#):N/ D*!4A7&@(-V"/;-0):Q:'J&*FC?7ZYNC4.CX,U)0)#?
M<5QL6HX5^N&<E_1XRO)[NDE$2:U:K^@3*?IZ 9F5CEY=#\GNQ9+^]CZ[OAKT
M0Z2=8P>^S&/[)+5;;VZ&INNY'AJ6A$F!T5\*\HBS9%?&LC1>&]5]5B1L!U[
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M7:=9XXWJJ5CFO3)P\L2=FLV!>WWB\SPXJLS"28Q"6Q8I(3[ZO-*K[S@SQN9
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MEE$8V<0.8U.6Q)XOR$G!W_@%/S)XHHY6,K_"[)ME]IFW6U>J&V*;YU,;N4S
MPM-'>7KPT0$4@#KY4\;+!,M"Z2=CFF(1H(9N=>/@>W->DKB1-*+L]'[T3;K;
MRJXP[?1F.M1#K7H%IB1EC=0-CI4J<@BZ/'+=(+:P;$<Y"VU'W#UKX:[:1&=[
M44!<UY3TN_94HL ,O'#.?<EU09*L.MHTOSK*4Z"''@J$1QO'76((&5OZGM5
MZWHATBX&0 ]C<!@Z/I8Q2[(%/RI ,?_U*)E[YJBZBA:<ZY;18*'JPSX@3JI
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MBQ:_&[_E&0\#_%;QZZ=GNF/9T^J.PW"S9=3I*".3/WH8Y0;N$5J&E4.MD=9
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M#\#*0+V_9WT6CX//.GD'/>$A+Z"1VW["LSTWL$TGF#$J/XC0FA8&NKB,D+I
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M%V_YV;;@Z/E''V^V? 8T7R#9!&8 9-F( SP1*BGQO0U+T"+<"=?I#=F&2S.
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MY?$;BY^H\7>V(<+WN_Z%TPCG'.)4_)'?7WW]]2_RN]O;)UWZW?59<ADBZUQ
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M$UELTJWE2!8B;#UP?:SA(T_&WK9)]9B_/JR^B)#U6DDHVUV+8CM1.:$34F8
M\Q6\@:I!&,?$)RJ':7'VWTU/>@#9]27Y)7)/0VK?3QSB*M_LK4/FN]X<=A#&
M9JBLK5V>.I&)/,]R^SVFZT?>^_B)DMV&JF)697"*[%]>3!:HJ@=59F\?7GJT
MAJ<&?7Y]Q1@&FW4R JHM9H1"JJR7L6^.?6AYS0%R-.(226:#+.'PEA :7:HE
M(2L49?J6%GE9EZ4U2,3ZD+0'UM-6\% "06N\F-2BQ&EQTJ?G[! 'IDE0<.ES
M*W!,,P'KHDABCPM*Y+QNDVJ?J7,@UM-.6N$JM;-\YU+>:J0U-GU5]H)0)UH;
MS=4:BKY+T?NQ$YP^@$,:V6#5GUY%AB3V-/5!I0Y@OS#Q$T2PJG@*9/;W>(.S
M5QWM0RZ1O4'S<"+2:1;F;1F'-O ];$,W,:%!\SBVH@BISGW+*,<4EN%$$< !
MZ@@G2:RLO@*9>_TJ[G9[C[^GV\?\.I;>BT868O\FCO]"7H(464L"Y01A\,$2
MFEC@;TOS+\ZBAPD 4A#J)G@TPD@#=1A3P*@?TYO3]QS/\JQ890J/ PP'(7Q-
M$UJ* 6_CUU_Q9O[&UZ<IB0T3L.%H*B,@X%P9SQS0M+F(75,?)3=]='@ 9F7.
M80^60$_P5F"%D;)^]JP$'?S8J#BEI$S6PX;G_O1*<?83VY"+'&T*@(0D5/:@
MATW_"WW634,3NIR.EM,?*;VWIJ<GJ'MIJI(OT+W411XA2-61<&:RSJJME_EZ
M)(00!80&K8]HD!,Z 2>S$\ZHC4=ERG(10RC2[[*LS!9O7O,T+Z>I\*F'7- L
M4Z_L_C"-ZVH67UBF\-):[WPF^#8-3, $DV"=?(2^%PY"8KNN*L!6?K'/[8%M
M6]Z<C8I&$9V/08VTH,^]<IEU8_M7/HL;,8G)&'_VC6^5]><389T$A?JD%&'N
MDZDR1\HO-AT46F%@S=C3114/R?LGYB\:$\U;,OPO_>KZ]+N(D'4N/S0NZ=L^
MH5[KBT?/]4/?"IP9<SE::-4_)VE98G5EIE[X93W)I4Y[4K, G+^1>-1#X"NA
MH[OPY=*6 5D<VO-1*;P1<M>:J]V(P0D>8Q+Y4(1<FT8JPSDCM9=*]O ]9)NA
MLMGB2:AK&27]>G)BGBIC5349X)SU49!.= R\:M"(B^7'B:\D_D34&$#R$WZ
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MB $-*D><+ OL=!* >>I#ZU9D#+1"4#I'7F#'YDP4&!*)//  ?.U@4N0DH;*
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M:U.35N/K968ZA=17J/J8%QA,UI\HT".J;6(<*JLY3$W+ 9IWRDUXP1LSBL-
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MA- 8F>-@WT&JC ?Y8^!SZ^%XR)V/&A\J=12U:J-TBZLG4GV?7LZ75U\#_-C
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MGBFW#7L>#Y)FS=LEPM_Q ZF91X"S<E0[(-KMFM700/W9'%B@04>ULC(-UO(
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M&3L6S*U(DMB7F=67XQ3FZ'@;,XJN48YEQ_!B@69L79.->.!$S5?3M&@5BF9
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M1%;9S[PAX(@ZO,Z*G]<WU"%;2#O%0AZWJ&;!T2-F=5P9S8?I8PR"CLU9TPH
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MPN#KZ8EA I)JQ6B\PA 8PEA=K,7W?! QWED\M+Z]+RJ+]!#-F[+C\,?3D\,
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M<;V'HGW\]KG\OH; OKI: Y#,XFAM3F^5QAL*U3',T!Y%;+N98IF;O;X1<:/
MLZF.QL1M8RQP]L]5=W9Z"J(*]V.Q[7,@-U7-O TZ*M%3'55,'4\7A($7*X-]
M AA!"%G+,Z#@UG:2$HN;T?67IS2:']J^NV^.M);RQMX&+P^,@>I89/QN% <
M!,JB+2#TW<!'+H+VZ-EN@7@"O(K<,U=LAZ@\IHQ?US,6WK%EHOZ]]5OX$5Q%
M'@BN5_P?7=*8C+!M%.-L0DKV4R-"B7FB[:5(L-?0(<Z=";<%_O-=^*U,OQ%^
M2X]_?N+(OPC@E^7U'NS+_*(%_;[%S*.QZ^L6\2V]V,&KW;I,A&!Z+9IJX%2K
M(J8!9W'H^1 KGPN!,(J#* Q\BT^>S'2/_.Q6AJQ@9HN7!6IUL*G8G"W;M6-Z
M/?O0H;S8@KPL;[<0Q]>KD7J<OQZ--5"JI;?IZU'LPB")E$X]VZKZ'@H#BVJS
M>1^X*ME"\]^X9]E!*;W7;?(GAXJZ@JI/IB>0$AG5"<;TO4"6DS (9#< XD</
M !AYOAM9=%)>2/R!\">%H\K\JVCR@-3W/YJ7W%]@HUH)F>IZ&F$B3]O>4@I%
M40A]FQOX2V8)E_3N>32AKQM4"ES^P?3"5N"B.GD8AP8P@H1(ELZ[72Q0'/H^
MV$G@8B'3W3VN'G!*5DV1XN5HXMYO5BETW6?3BUZ+CFH%96KD8>8A#&1ISKJC
M<Q\"Q%80B\OZYH'X2$OZICW%>B[]_?3"EL.B6F&8[GE0E(,P4^NYS[S"./"B
M^"12'DG%-RTJM5OQQ8QDK=/I5T(QU6D,DR2,U(Z;&[!M,PQCB]*^?+QO[O'R
MP7P-WSL?B],T :[LO;3X$;G B]P V,Q*0E85K=."[[I&8^QNHTK2JC^:GK<:
M;%0G'U._,W%!#'+EJ;T?0#="R&9E^VM2/Q85G^#Q7,^=-I525WXSO=#5T*A.
M-J8Q>1"##.=J#P1 9@C="%C<;)SC*BOH$Z[3U1)79\XU*;NZS5])@Q.Z+.J'
MT=C0=K9N.%4R0OO=]*S0PZ-:"9HF78DAP1%49BR+0]=WT4Y*,PN7>#7/O"5>
M\3 N9$7*]]VC46&G]4WC2CX<_GAZ4AA@I#H!FOJS2<[F$2C] Q#XGA^Y86CQ
M>O>JHCRNQ^')V7*F 72DW4O7[M6Z6<4F1O?9]#S0HJ-:29G:ABCQ\D!:/*>E
M5@"\P/-M'D=+&##6X<6+Z5,?7V@_G!\/=+;@I<!,=SLH\4$,-;L=-_)B$,+
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M-XRLWSS,YX2Q89+W75=;:V(2,Q!%^HQP((Q"' +LL.C=%X,%S$8SW3M%498
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M-24LTOM!@#@$01@&TV6../.6,NF10NGVIR-ED#;._Q=%]S+?_D3S'GE$+S.
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M# N"(/91A+!#CYHO[)8Z@T3;N04D#GTZ/20.<LB-2V>+B302_\P-KP=270H
M<:@L]S/1>O\4O3)5+FL$6Y>UW?&3("H+4'7:NH;W,CW.CF&>&Y%B:^P"49A"
MK(VZE/[F.(08.72VL,JR.@QWTZ5:M86L5=MY =6.96Y$D:V$C$B> E]O_P)!
M""$ )P^+G 4&NQ;"=!OL^&QZ9!FYX\:UM@41ADF6:5^4",!Q&+L,&3ED075K
M&.UM^)P/-BSYY(;5M#4#Q"2+L/[9,0X1!@3Y#K7SPW;VG)??:9G)/UEQNY3E
MY^Y$#\PKZ8IM7LP=P^E]S<3[FH=W#0O7@H/VJMT?<3WZG#LH^PR%FP!F"=P$
M4I9%VJJ90204PP"X=+L_C%O^R,I7JSOV2H6R;,HHID\>?U".66X1>RG("^H-
M\?8-Y+(FW1NK5KW-':5V@^ F(%E;PBA+J?Z"$08807%Y=OF8WM\+:0/0*=V0
MVF49TQ')V.<,4#O:4+@)8[9*009!0@U)8GVQ'R BY'27X^TS^SVC\J?*\:..
MU90I+V9;C62;2G7#M@II%$Q;526Q;3\O#-NSS8VXLG[, AC02!L[$?@X1F(H
M+I,)[HQT3DG;=MC2/,9KOI@>4#K&N'%E;0V L;CV!$C__HG]((J)#QS:H,]O
M;TMI<&?9GE2;58J>+8\[RZ$O)'?XZ^EQ9<,D-T+!MFH#\M,L2/27E)!$. Q(
MX% L7<MZC*5\5M><H;-"VX;;K@-$B[H>K:9'7Q]FN1$LUK5#<@R23.N9%D0(
M$:$DNDSY_YF6WYA2T7:*:)\]JZ MXW8./\2-E:B%KV05WY:M;6WIW8J_Y\O,
MK(VKQ$;Z-"^N:$R/8G=#XT9HVIJ^PSB+*-#?8$3/!,0A/)$[YB.K5C5^ZS*P
M^_64'?C.;0BJ:J<[%7W-B!W8P_1X',HX-X+"]OK! DJRW'!?1D$,('9Y7U8;
MTJ./M%C(#?DJY^6KB@IY>]\E>L<5H^<M54%4TNR2"V8AV;^'Z2$WE'%N1,:1
M:04W_+SGY4W?I>C?>/I5&,#S_@N]3!,5C9;6\3D>6@'4)9\.KT/O3F:T'OUY
MWWL6"B"&$;!R-^R1LL8NT]7ACZ>?9PL>]\^VY[DNCYS0;3H<NSFU^G[Z:;5C
M<R_Q^?/4F[8&*)R"*,[UCK$(1E$ PM!A;:#SE^I"WJFUCJ4N/)<.1XG%'U$<
M]A2#+T%@>P&BN<Q)9G @$Y@E/@A=.G;T?,)9S-G5T?"@\<G6Y;%/']-#=SCK
MW @T6_F81#Y)F#Y[,X8X$/?\R.$57@TYV^;3_[O)IS^:/*P)M"G@_SY0+]GB
MZ^EA8\,D-ZZCK5TS"&$.F/[6'4(8([&Y'0+D0I8JK<LWS;5H4\WA96Y1J.G
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MY&*61FFD@QE&!!#BNTS=W7$S^4EML9]?@DU6UZ4+7O8O_@F2-$WT[AD(QX"
MP&$(='/^N]X_-9E>>\:VR?3[Q)I3;EA:6YW1QR&BL;Z(0B %.W;Y%';U];6W
M>W#S):L*>N;]@WX3/[-+ZFB#&4%GYVRKJ30TM*"Q;C,]:NQ9Y:;UM<1-DM+
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M&9YS,  D#DEX"I>8C\MJ5:S68E0Y+[VO)7]HY2BC%1MEO,C'.:.&QV8_\GU
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MR12./J]7*[;\VQ62]@B>?VBHV2+*IO7LD&7%-#<!P3;??11%61QK/=/%V@
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M+NT[S//!Y:=K)CY>Z9-)ID\'<TT>@]0@S?D9=&2 -EB69WJ^X<_EN['Q/\,
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M.:3=H>PY"5&N&DOE>-5P@P E_>YZ4"5/,NY%@"RT/$(D"+M]*-=R?,/3W7-
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M"9-BUM<#U#8QN&MJY"]*:3%?86OR4=,]PAJ1@:1;;5JN:SJ!Z%CQ:G,F<LE
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M7-=V1"(PBV:(\]IUO!]8V.*?;$=@H7TG$CBQ77ESY7T.I3W?I*X>=3^7^5A
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M79#>HJI)S#;8)0^,ZF\IH7_#_GQY> E@^ =5"5K.FD#M3,=;)=74,SB^3B5
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M61Z,4XC'O4"11"#TO"#6NX-=7<<U3=]1V-RSPM\CWK$*- DM4=.8?R*)='(
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M[H%XW2\(9K^@=#@O4:A;HEBGKZB@X8&E2508]T-[9)'-PY ,)76.0,EUMSS
M>@S.&XIP[\S)IKGYCA\*NX),0,2(55(&%L<G7D!WK4AD'<<0/OG:?BC]ENM
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MP-'(M0S8:3<,TS  ^7\*9_Y+0C;(!4[13)->?Z]SPCN>6'ZRNPC#?3,BNU\
M,';M4!3&U4Z(8S^K#VEHI\"5B9Z3]XRON9#A=#USWTT:EILEZ<P#RS6%H0!S
MP&!L.J1\'TAD1< 6D<\M)>WN3E?*.NMS0R_16#_S3;ZY080&LB5[8*MIE0.N
M'.[EXO:7'2'NK[PP8Y/O#&L"+V@#=T@#WTLB^:-U\81YEL,Q$II5W.O1N1EX
MP#.#3]::(SL(+&MQ/1BC[S7R^7I/0?]?O)2Z!,Z/A. Z(/"$47K\&LWP@0V
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M5+;IV@YP=86S_8^7?9; Q]GFNOQ>YTP+_[[\/(O)PKV3(1WH85N!%W??P7O
MI?#1%=8?:A*9Z"+ XZ)"^)049"4H$#WAI5O@@H5?YH<@)RLIW3ECXG&R//.R
MR4P9H,G?X'^=G&Q74[:-F1F]XF3=EU1MBOM'=%>3M"TIX@U-6$@D?Y+]02!B
M)=]?'J]JV,*]L)3$.S0<'WB=FU[R1</W794;!EI*,(E8^AQ.M2>8E#[.BF!_
M1.(-H9#Z@PK@KW2<Y=5 +7NX#[;29Z? #8*P.\S/-W7?M V51:3O,07\D]0:
M$)/MQ0+ZP$@\:=0H<=/T0>DXR^N#6O9P+VYEG5X71J$E=(?N,YCFD#4NN\)Y
MD=^BD,HJNDX_L##W\S5=;U&BA904+2MIH4=-G)JQM[YB_,NR/D5L*\+I8)+Q
M-(C(IL%X((XC8?47E> <<:0C@U#I:B%A2#P]6Y0D>XIKNN8NK(UE"@QU\V09
M=J/8#O6P,RK. , T;-=Q%.9UM)C*M>])\4B8VK'VLF7^NO8O&.1%1AZ9T[KD
MOY.A;OE(99KSIARF?_HE7ER579&A%_?.N>R"%H+(CF#W_IXLE, Q7%WA+9\$
MF-0L5@(I2RY5,F^N'5"=RU3'Q$^,=I8QQB-M^"HE?II:2:] L$K)*G>$3,_R
M13<^IP9=Q;*HVB\=(9>?!VI#838.8L"V8FAWEY8T3,LQ55[X\"J#(=X_9>@1
MI7GR7-68I(!Z"7DD;('9II^(-,>[)&*+2_E43ONUTZ"S66X0K]J$\ J/MR49
MUX0*LC>]:M' '[BK*.BZ:YSEH\LC=D9>< _&9,^V0A_J/NJ.;])]W7)\SSY'
M< C!9T;#>%."2P2S-$D?<@UF24X/KEBQJ#C)\D*#3T^[).1'PSBNFGG'AY3"
M^1F5T9-SM?:]Q[<E41]*FC:<)%IVZ",E:-/0LXU9[^>/A);KAA2!=!5\?7EL
MJV *]Z)1-@3*B9!%D-X%<Y_F?[NVKC _82:4EUOE'(6'C-4X7!+F?,V\JVF9
M&>==G_^Y@=[)%>X#I'25*-<(8&>+!!/XAFL A6<B=2+X#5W<"'2I7L\6FE!]
MO?PX_79GF,+)9Y>'T6D2<<_DR08O1+YO6%'G21GP3,^U#=]5F.UWB;,,?V>6
MCBA.E!1:#,-D1RW9@3HW^Z0H^LO_2'7'K4>Y8H-\+,?XU@PA$,* MY9'S!!B
M<>\D2[?;@"BRO>[.6XYAZ*[N. K+3_#=#2V:R_- 9MFC?$5EF&?7?N/- \O/
M?@==N'<^9.]-;-MQ;&&+M1OXPGPRNJC5H;O;[RG*\L?DB6Q8$)F\@OR.7D<F
M44*<F7.4&B^IXCY3*XP<5Y31+2\GC?XZ;Q%']L&PT"*LI;B@/>8/NX(^0JN6
M4U^+3$-!*%I%C/DHX<\UB>N!_C3R\7Q E@X:"9&-A$WKE*O3]')MK!8=TX2Z
M>FVC55Q!FB,DPLO)G<C1DN(9NH?"[IA9E^SQ' NH;.2Z#0\[F&F/".Z*^2)G
M^5=_91_M[N78^=#R6M9#&^Z=(5FMB!S;LIWN8GQ -UW/\U4&TNKO;%V7K<?'
M,[>0=O=N\^Y"^WSX081"/OS0_EE+\OS HQ!]_YUCV_\U:QD_73]1V:ZDD9+8
M$-7\=,VHVQ2<MMZJ?RJ'6A[<RCG$O4B6C;T%@>6#SAT\<'S;T4VUU=X&E!0<
MKB"^[<ZH(#)E^>3GE- VK6SAA*%6H""J.<1]0)8]X8J!!3IS60FMCJORL@*\
M<WM6CU?%$(<KAP'F50Y7:/#:907EYY/0UEMR4>50JU .M1SB;AC+GM68 8P]
M)"J+7:J<:P+?]51VM]Q$SU0"D;8)0[2C8?TXTUJ'X+G&-CB\$@_<:7>;"^T3
M2M'SC+6^2A):%+0).!K_;L,'[P;VY(^M +K3><"],)+-O0Y"SS3B;GP:+K'M
MM +9DOB\^YX4?Z)L1ZL;GA^=K=&G8O/DIU:/S-,<X%[XR!Y].K:'(KOSC-NQ
M3-,Q@*EP4[IY1O^=Y!?$.(;$4[B$:8K#/X)#EI)??9X/>VP4.D9KA.O/W0"3
M>7X%*)(B$_?-J&P<@>U%"'36S;0=0$_159;-/&V^F*]Y!Y.TH*:+WL3B _%7
MYBO/>DII"0%L>#9Z.?AH&W;Z8RO WW0>< ^*9%=73P]"5[2X7L(\":L !=HN
M\Z:L=W&>/!<V?!/J\H3*/%[9\V):5M%S/=&AX?MD=RB:X(OS\U82,($[V_5#
MUT4B[JZ.JM'0N[_[1Y@.*DZSS>I_DN>++ D.%)/WF-\W*+^DNWI5P(_=Y!:$
M"RV=6MZ//M[^7=3BCP99\0N+5=SAJ9_(1="S'@M\1E[Q0KHI>P: +&B;2!2+
MODIS4M!TYV$VE^?"O[(=-&.*5G<^-B#22TSHHLBW1?6K2ZE]3F! (VT2U(BN
M]3OB?.X.+(]@'<53*[N[:TAL&]_VKY.2='K)^[-55U4R.><"P>K,IR+V\/D4
M2=9(QHX;>9;(2*Y8IS__ARCMK)KYGZ!^\^G8N17) BCV]5"T>3FK(HW8N;6U
M:4)5S:.K23L*41B(@HS7XD5,=K?:GL,TG\L)D&W$XA:F= .]C;M2Y;8Q<5IQ
MF, "Y9LT^CM.TN(W0MR!=7QE%659R]=O-!.#IUM\0834B(B[^#W9[2YIMETM
MTWM\D^$X*;89/3_XBFB;7OA#N3EG3%+HX>[D3?)76+/*^BW]FS*K/9?<5B63
MR\:R!Y9#5*8([1G+/-+U.V&:=MK-6FS3/?(38YSNI&GHZP6+L::EH>"/5:P4
M:\#!2N&YGM5K5=+ ZZ%I9/FB,+1C*Q99Q2YN*J*^XF(5AJTG&;TQ1C3P_N<S
M2#--@;K)78]9F)LAK%()9-U= HP0F>M2SC&5QYA+1_0J*= ^U^B]>D:U+VC*
M1<AZ<29Q5P,DS*R^0SORJP=Z;Y_!';&SFVB?I/38$-+6=!]^/!%!#7)B)R<V
ME"1=: ^<*.92P1996+JOO&$A9-NBK,I-2%:,/&%W?_>/Q"5^>!1U(2/3_X2R
MXN6&4%@0Z=!UYHDFAB@WT&T"B4EF%(K;XEU0@\RH)#]1.IG 4$7I*FSR5'$K
MF,'U6.'9.,%*L"U;PDD/ POHHNJ&"RC;"(/;)%0)U4S>Y@30"(/.2L0.<("G
M^X;"0*7W/><D,Y8[/#K_:!UY]!0ZE'UE>:64IA3WS:WLA@+9(/2A2'?8CZ[K
M @"49O^7O6OHTM$^/J);@+[[_56U>N(\$,O1.JXC/EW'R5QWN-.$SRP/W$G4
MXS[0R2X$5F##H#O] UBT2QKP56: =*#YIT;R'##^B3$\',!O@29[]6CHT'6@
MZ"J+?]BQ+,\V?* P!E[0677%>'W=EDT&G]+O+(]'>5)Q+TRD(Y@#X/L]$<PF
MF0=787;I^P$1?JO"H=257"<B1[R]/#;'$(U[T"1;)<"U@R 0ULY@/Q(6#)NP
MX9W?9^U%*_R1Y.O ZH!%;D.(GK;"M[^P/&;'$HY[ 2:+7">R=%WO+FU"3*^C
MV\!4F('9OT,GWT#\V%?9'OTS&>*:CC!@D_[FG>6!)$\J[IUAV:T- *%A=Q;B
M]6S=(I]6OZ]Y&PO3;_-D3GR.'!#H$0<8=)YA^9X!;,,U%;H@_:$_\[+KHB *
MS4BTEFVB?Q_*:K<TGKILD%R5%KU.^952VS=4?S/0D,1S*E#5MSM)J[[=M!84
MO^$]VD*L8]T;+-)9YF4]1FL"[7@F5,K6\?"=2#?@8HHQXA3_JBF&-E !C@YD
M==V",HR_;IU^S'C+B"W+?<L]7J$-D!;B?-.Q5FLPG &A21@+2_E>3(;CA,NJ
MQ[15LUHKM;]4ZZ=@U914FR.3&5@6LH6IHHSU%AVT,#D%1[)#/,R$!IF<*?(+
MML3!BMV7A%3!77^AH5U_786MD!+;6'&OQPX,(Q>/AY3L-MDVD6E;/=MDQ]4!
M );*#M/U<A;"_%$C*WA!N^3PIKH!T5G:>*VL,#QNB1-WC6;#7J=79- [/B8+
M5KVD(U:58?N7I;&?6!Z'HRG'O>"0/?J. T\'Y[2>([RL-R:4Q<!*Y[':P+-"
M7;1X4IE?I_$.?]\>"OH?>O' ZUR31Q_JLL/J4U.INB6,$NTOF-/RUPN-74HU
M]#2UNR=KG"3C$V2V(@T;2C&>A Y9S4-.:#F^,+U:'2Q':-\H$!Y?79@! F9W
MNP3/-@Q3-PQ?G8)M]C2!0=1@M^HH2KRRQQ?:"9X(_F30JU1)(#;DZV9Z9:?-
M>_SKT6 BSW[,^\MKVSBR<2\>I.O+1S8"W96TR8?)/LK3578=W$11%42,6YW7
M*.#JK+6()8+ = ;7J1[N'C>-PJ[3.I4GNJI&$NX=A[Z\ G@-IQGW0D"^>:VZ
M+=?K;7L9M/LACE%8;..Z(0+9X:/D(?WP@[<@N*6Y6BW7\*C/%BVZ2OZQ"8OD
M^50CLK.,*X&=>E-O6B *8E'![[.0K-S?NQ:<AE1)!XBQTC2:8(U:8LZ.ADI^
MM(PR='%T#_^J7U[)E09KMDXMV(I5][QHP\OA1=8#M)S ]&W1CG^M*!]S1,[.
M]L(7K:!MAOFR7V)<VH.T @ C2UC J4-2VX"V("3LLE0R\M\K[L%NXW8#F6W&
MMI95<L3/8B%PQ5R9$TI_*CUT:C:.FCJ1)_@9:U S.:/56'J%5#W-ZP'<>CRP
MI070;]C/K/BR"2=Q"&/=%NU,UL''NG.\@ N %UBB%(?.)#:Z WU(DYS&MVWC
M5DK<>[)(JF_$UY<BRHXA.&TTG(86-&G(TV@#L578W'&BG6V.UF/Q)M*/9T2J
M;"!)Y-G(#$49Z&=3F!'FHE=KY)U%+W8C2W2P6MI!EGC/[S=8E HO,47,XWL4
M(^*M1O?P!__+LD:D)I<)@KMQ96Y*4I&L127-M!Y(]=<Y[8OPV&E>02J?J?68
M$D5\X3/@6];5\8&'+%/]I)[')(W50>E2YS"(0R<4N3;UT"VG;BT&J;V#_#F\
MF<'2G&-&5FAX!I/^VK:,1*-L.2'=-RS@GUT?)I?1J:OZ$S/1KN,?USH3H6#
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MF*3;]'U2Q4YNXSJ>7!A&J1P?E"#F&M4DL2K,%5&J(F>'RF$&4:X'A:,IQ[.
M2';7;NNZ9?NB]JUG0/&(%>XME*4C''Q/=^U85.J$;B9^HWN)5C(68?W(D>?U
MIM2?_\ON:V;KJRS/_"3)K4<S1]",)^)$.E70=X$=BH*RE4)4Y?Y;.H7)B3P0
M"'U-,>_<UUV1@I8>]ME45"R B?);NYJ>H+I74:40(WM<Y@8A HXH_$<Q7&=5
MUC>8E5Y-X\!Q(]19.,PV#=TVK>9V;7Y-;-J:\([WO)$/R@EO_-\98O<+D79(
M"4JUZX^W=YH_FU*^'IYV5FD&ORW'_D:'IB/[G>HY[4/+*^I$^G$?:F33$H$%
MC:BSV#P GDOV:H;"XFZWQ!MENR>F^5J[-LM\@.-#O+8M/<"2>6$- )*B$_?-
MJ&SL@^VY 7)$IWK\N[9O6[H#+(65,K\*0Q=X3%-S3E=G7D[>AC>EGIOH,#88
M7Y*:'$_1!GSXR\OC:03-N!<#LIOIP(%>*#P28C]ZMF=8OM&DZ9\;6S%9",^"
MK(]DH)&XZGAUQ:CJHACW3;ULW7YBK*)(V.>,8]4#.C6#*O/MWR=YN,/Y@;>-
MC1M?DITAUGRW"CXD:5YD!_[;".7)0\J61EBTWZY3[;K[-HYJ[*.T%'LIB&U<
M._GT6*R6056+X;H1P/N:_PU9T"!].]H4]>M5+E+'I7)_XZ&EJ5E>*=<@!-RK
MCY**CJ %8T-T#LM^-"S;<4W75=B>8T$U+VC@PO]:';^GW*]#P8](^5^IW<<2
MP'TJ*%V# " 8" ]UN6O@6I9A&[Y"KW!!U=Z-*OS_'Z7?G_L;$RQ.SO]*/7\K
M!=RGD])!T+'C!K;H(.I,?)TAQD:AO5B%B3C33"V'D?4H_KD9?GT]=%9=E#Y%
M"F+']X3)U:NU(:-C%4=</=D!<J 3=.Z5@&T!SS(<H/!,1*D57%-+KWZ<C=@]
MB_M^J1QF>3.GE#O<"WW9Z^P A(%N=_<'M0W/T1T/*+S/5:Q3:VKJ.#<@.J\
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M7EXESLTP[E4!2=T*=0N&;F?1'$%^'V&3;$?@#\IG3AE&^4<B@Q9'@D9\Y\F
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M%6;E"<Y]BM0R_;+TN6_=:EE (.Y:MA4A^03I'^ZOI*UE(_*A\/JQ4<#UO&[
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M\GVIA&VIPEIUK=O1*S3Z6\LOTW@6#FX// -0NZ6OO6R"$)INV!H&ZYFV:3K
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M**S;N37JP/ZS\ X.JLW5DB8Z9IXFG_@5H7L:/K ".,HZ3EP?.HZP:,OLTC'
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MZI<J/P#//6J1Q\)>+<N*V@ 71]%.*==HG!@[0YTH;W)<*H(6..E5+N)@(N/
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M\D2'OC\137]'T?D;,3V>T?5WE(5)$:AR%[-+WCN6#T'[YY"#5DJ3)&Y2]H<
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M?\U^W4QG(!7C-H9MCLK&Y".V=XX8]H7EH3>4<-P)#5D#*8:1[UKMY6(<W38
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MG<[6&B?C ]?NS55$2;;,BOS\K4=\3A&(^^! -K(W]E%H1,)C\61X&R!!]=4
MV[DC%.U#[B]CKE/:MR+=2[N/7,^(H"^L03$=EZ\H2W#TN(/93@6O9QK<:0%Z
M3M*4Q@11[SD;4-Y*BPW'%[K0IIZ#:Z)V5<T HFUL^_)NND[D>W9K(RC?\,G_
M3-U4IT7)J9B</%CID=K7GZ3Y+F,!_/D9J]")(WK_\4J^\=*\D1UK8=2#?RK'
MOJF'OBP'OB_&+>^GA=?SH[ZTO)(=RP#N@HWL<3$$KND8(JN%]]^#&]KPMHY:
M'!4=, RN)1W,C*EC"_O' TCA4X[KX?.U(OSU)!B/P85LF03#,VTC%(;C3(_'
M"0-G&W<"TK%YT#<#"$5>ONDZN/7CYW:8VP7XP'7;<_D,QP2Z;2CL(US?U!1!
MRRG>T7:Q_T-_N\,L5!FGC472GF'2Y]30V4V!7VQ^P;M'/N(39MTNZENMW\A@
M@LD9]/[R>F,8V;@#$+(G!-VP82""V63.O?%7'*,<?0?<6D;LDIENO01P/-TS
M+=M2F%+]N/_[!>^U+_B-!C#DVA,*7](D)/;B%3&$-Y@%3&N7^-<S[787D?]G
M%V_YRWXZCQ2CH"2@&K\Q/!F=CEV.W.ZR&O>EY>5N+ .X$SRRM;"L.#2A*<J_
M93^2W5MW+4-EGO_E]>TM$:W+KP_7!'8HU[YNDNE:QC>^3KY-/]V*J%./+@^9
MDQ3BKJ63M=E< WJ&V5KQR3=LVS1<E?O_>?1&#E HTL[#$&WHK3)1O>>OKYLB
MBR+7?KK9P<W[S]KCK]FO&Z*H[O'??R>;33(9;DH2&A0T"6##\\'+H=NSI$=^
M:GG<C>8 =^%'NAD%-(%GMY9[-8'AN)[E*VVY76R<7Q"METG^%N7:Q:]_$ ">
M;_,=RB*XG0R!Y6"-L>A0U4"M>.OWXO+HZDDO[EIS63^);T>6"SL*3YNZ1[/*
M%=8KJ<!T_P*S+52.(SY,/PB=?&<]Z#E-*NY<8-G=,;!MZ ;M#E_?MAS?,!6&
M\MQ<76B_XPT5%.WBCS/M L)L@W[Y0ML\3&>IDU&*02[^X"/P 5HQ(_?"\H"1
MI!-W+:HL6$S/LX)V4\IS+-O5&STM%6J91[B/DN)8]Y"\P^AE<@W#AJ C\.^?
MU"Z=SR\/%#DR<==ZRE;/,HR 7L^WX<1V3</S@<JBA:=-[AO"-?F7,V)SW_[Z
ME:#H.G_=[)_WB 9%:K<;'&34S3*;!<[)X<14I%RABI#!]GB_#R^/TXGYP5W
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M27)8(N5\/&V"/H-EV]:G7G<>%='>JPFM0\2:4H0./C^7O/;VJV]C@=A-J3K
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M!XX728"X,\>1^W^^1G!_5PO[UL)@+\A#=D_"/-6]ZP8; &A/?.BGQ+1J39H
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M1OMU6"11;;^Z*T$<R;*'0:+U2]48"/JN;:^.%$U A/"<<:2,ZY1Q<!X.)CF
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M5G06>6/H$\0J@3XNY-K%_?CF,47GRW%U/RQ@0],'3%2!D3]X#YT&L8TP6_;
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M1)X&.A4B>WY8KM]52)H;M*OBMR<E0$W#[SEU(N#25)?_D=Z'51"3*CPU(:G
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M21I2+D 8+W6U/5V[ O,X$=U$PH4#AA5*T2CH?1!_CS8UL"=ID/ @=!03JV&
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M5*1'Z& >*M([Q(UAL*V'BO38*]);9HW)0D"RLMPNCMB0,5;1MO_FK[E"OB4
M*F;TP6 T$]_";K<-<]/?>&M:]-_6,V-M)-M!O%K(8>OE&Q)G+$W9-WEX.5M_
M#A9$LTN;FL'#AQ'LUM6$X>*/5A^8&V+9Q8UP:UC2J&+=#_[E_L("S*-66)%4
M:YU*0AH \O++G0601ZVP% ER!5)#B%\U@?_9B%^0*/P6GXU0UX4N*H+*UXZG
M+%V4J#RP/%,7$%6Q!S0 %C4%K[U<@VR_:W$4_I533N6T(F&H7@4T_2V(<P%
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M\&[HBWI)H?4&@O$-DX^E"?KK7[>7R5SR$O&IW)BNUZOZP'B#R1WB2&H#B^F
M_QIWVS;MSKB4W(>!,0N3SZ,^]6#^?:*Q^#1+R";%<12G)(C6!E99]H!Q!9,G
MPHE0, .N<NG0N,TW#JX)NR=Q;# /K-K#P,?D5W @$[Z%E'S=?42U8VB:P #&
M%/!AI@R,Z=;O<_D8SJ6G5IE]JFL#0Q538$8%:9Z#DX--!!9)[^>"?J6\JYO
MJ@E@.I>;*6O$:5R,>QXL:2:?()^01* PGD[5[]*X](.AC^FX#2 7'NT7\'DQ
MGOCH.(W$W-*U3MXKV\*@QW2ZMB2Q$;A'%_<5(!^T@$&+Z0!L) P,Z.=<UK0;
M3Y\P2PNN16L8T)A.L]9$@D%_DLRK@%GY.PQ83"=/ UF-;XFEIB?1*)O,R>7C
MDI8'VO%4_!6V63J."&,7IB-IHT" &5Q$/WXFF3:/2=T !C^F0ZF)+K^F_<7F
M<G,2/&Z+V:R+6:I\;55M88S"=+BU)-%WL% FCHAT5XUH%U1LJ.UCW0?&0V1'
M:1=2&_!@RXOTTM%D]% ?-X,]<(/I=%Q-'3P(1%X&56Y<TTPRE\B +_)77ES[
MB25,DYGH25ED822T^AT8AS&=P#N IUV+L89HM#(^3"0P>09:A 7N37A>JU-6
M?VA!)%K]#DPT4'DVVH>GAL,I3=?B(]M@@SDI=R\2&:[-[#O!F(?)6^)*:VU/
MU6W*HCR4 =NRYNZ4Q91-V!FY9['J^L>A%XP7F!PLSL3ZCQ%,\B)4I$S$D,:V
M+D)0WQ#&-TR>%AOZ:D0'LN(IA<\DDX/K*@*IFL"0Q>1$,5/F5_R+,^;^@1F=
M:^NX!8PMF%PF1L(\.[?H2M@B2<1O@_7A0S)/3^?*)C"^G$9]7#,F?EEJ7&,-
M+:^?,3E8<*ZLZR1,2<#)!2G_>YT\%YK)/&7Y;'Y>1+-<)P?QB;*,GWPSH7#.
M;>KT"7C*9*\B9&O\+1&K0NG%[.ZS,-%!]>!K#1=JUSC[%>?=U<Q!07_5 <30
M#"8NF+PZU=3Y9=*5H" ):1!ORG 8R]=4-X8Q#).OQ99&WT:8=.&0)"1G)/M&
M2++U,I3U4L;3YZJE>$SG:9,G.F6G3#0) >U_#B8ZF#P]W:%4XWJMO2E^5M]O
M=_-%F/2\<S<L8E0V1:?H-B=U!Y;-H16SCPY(HMW&63BU94K;T[8VHM;@9V#R
MA<F'UCXZ< _<-CUNE^3S*7BDBWRQ28M0O_1HV0?&.50^.C=2:U\@7"Z6,5N3
MXOFMLJA+]"^:S84$;/SFV_Q1PW6"\Q@P-F'RV=4D'<RV_=M;1C^.J1D,?$SQ
M2=74-1(/\;2<3G$'RPW9F:Y=8:_Z8?*LP2BN85GL-Z.]L7-& GGO77YQPN3U
M.8NI?"DJNF*RQG5!@]*"J#\<C(>8@I.:0\%SAEW*EMM79TOWV)PN]^\J[<J9
MJ3(,G/O"V([)504D&1XYD@M;9B'&N\W3<!YPL3W2D(RB/W-MR0C;+C!F8')#
MN5'J.]Q=(!J6I>FE$)$T6]_&09*)$X3< Y8:;CKU@[$4E7O(G5R_?!TMI#K@
MQ80AX?&@_E ^OT'#YQID@W7I'5F69\'QM-#8(5LL@V1]%@CY"I77+I8]8%?V
MIU3BSPDHSQ?(3XJG[5^<O$[*<E[C5/[[<YD4ZL>4X]+4F-"%_>YT1*EA+ ^$
M[;]>'J$H9O%U\Z/RM\U03Q!)V"J0NNM'(>0OMTJF1'5/M/J)N N2!33F;_[[
MZ1S)8R9#CJ._@8IWB]D6U:4GFD C=0.SI-F>*W<L5M,[>N#%$SWJ4Z1C9]@;
M..W:-I8S9]6<\*L4R\I=N;SPT+U9.7JDRBAUMYY8F*AA!:M!E&<[=#9+"YUN
M,?=/1#IA5<8H>! L?'7E'&N&<-^!#DY<;I>?6$+0:K"4N>+DE_WW=%8^$)ID
M3YXBV#\WH-'=;AUAE<R[5MT0FORR[U*(6+;F1;;K%4OW$]4N8,L>6'2R(TL8
M@$CXO6 LEKA^/SS^M?^*T1985H$!&//= CXZ ZI.+<<'15#)Q<[U4,7\:]SF
ME8F1LI)7$:C$Y](QN@IB31"(70>X=D?F>#  S]P!@5_<B%&O8O:-C[+RGK"(
M76=6>;]./=$M!RWN(,(09-==)U,YZW&>E?^=2D+.XX!SL:N1:,3+74T:F&%&
M5[H8_MICP0KD8-IZJF6D(9 \>U.V@BYS<;\4ODO%C-7'"Y-"J#%<ZU<4&]E9
MD?2!>9.>YI!")T";E(NF!,AY.-C-1+^43W,XP>/H4A82$A4S.,]328\,,69)
M6/[%&+WHWAG$59?GY%"H!2@N?; ]% (*MCT,8X$$!9"4[E=0&H*I[4/#&9FR
ME#@?!%L8O2MO"!*SHFG@/%U."WVXHKRX"TFBLD(L2S:*\2 %=W-;_1IX6]WN
M?<?V!K:8_IX@W26X;9>FK\4+"*4A4120*1;" \NS)QS8;T0'X-M>G3?V 2S>
MXI:H8Q Y\'^MIYFKR7/JTJT!<=_DZ^PRXCXRH:P3J4\W1Z]9:2 74[DALR#^
M%&32RM]/:\]!M5';_/C]]^([<9FU#B7\ F:38'M/LBPFY5QN4RKLJZ52D5NU
MQW)5"6&2 X&>G132)":\*!2XU<::&"%SRQYP2QTE9$,6@C/D?GK:BTYC.RR6
M017>S)H6OTPI-.O&)R&=#KNY:MECV0,+H\P<8 ":_#+L(V&S-%C.:1C$(UF6
M2J/GC.VPW-.Y:CD+HI!Q1[N,*EIB63YFQ'5L:6+9<!+^.&.KEZ$T0=*"+>^W
M?WDA__+BU>L7;U\7#-C\\Q]?5$]\[?\1+O98+.TJI)F:Y"$FT'@E[5>I#5&"
MZ+0>YBC!^R")V+^U2*M^QK(R'*/]]*2HP#/%#?A=X.Y.L#I7MG6]*J823LV/
MWE4<4>M5X#KT>S5<1:J!&;4C*UV;;:<D(PW)QN?;\^VUG'YSUS>"1WIYW7BJ
M",*8Q_L6]<VH*NO:YGJTLI_;I9$_8BVO4&VZ8C&2G>>M,(<L^3LD).LYZZ$B
MU9"G/.0I]SU/>3]I"QY7-^[_)7[]'&5;E/Q'LF!(4'?)5^L!\YM?]_SY34!$
M:,%Y^8<7)7]W-P#BG\I;O-+4U^S'FA98_&.@?==(4VM8EQ^\8(N JBJ[JW[&
MLMWI &-54X=[6-@WDOY6',ROD_!'K:XQMH,I&51;C!):9DT[/*ZKV<3Z#F_.
MR*SP].GNQQ0_PRJ#(]%E>H(\WV!NYJ6_=5$VP*+QE+"RZID[7+.TL!MJ9M9$
M*0A_?J CGZ^#(^C87PS.F$.PUH'4>O88A'_E8H^2$Y2%U ]>9"E\RT_>?=^^
M&I$J7QJH.5)?7$7'7&0-TN]7&&ZWQ=>?3/8VH-'VT83BAR+CN\S<LTJ-:W+8
MUJ_.T)=P;1Y-#'ZKV=,,HWUEVA$?3P^6EGP!2NO/@@S2%_-2*P]U2??+_>M(
M3)Q.:; O-BPG*Y?I0;X9Y_E"N>E NL.++2#A.)QHS[;&[H6DC7C*OYBJ]]NT
M[XO)J+<;[*D$^PO*-.3M4WH*J-4-8&Y$3$O%1)?G<]7&&ID$C_OW#N4L5>>H
MJK8P1F%:!98D>MZL $^0M/OLR$^87L"#/S729=#102AT<0P+PH*J)E\-.$10
M\SG+\!G+W@T75M!\=2) .1.#?85-^JA[_V\9(:Q2>(O< /.U;DA,0EEZ)146
MBLS6"8LD)7'TN&4Q#87)B3I@[SY?R,?,GH!]3,+EXS(.$BF/JB?Y&AFO@;5:
MS0J#>G'OC,?K[SQSU6*KQSA?JV\[Z_))TPDK7L&<LUB W=K>M?F6I=K7M&YX
M;RJ_8KE]JAOW/[3)@D:%Y!L9Y$FN-^7>@O@Z$03DQ?T8ZGU$5S5)18C];E)S
MU ;6F.I+>]?$?JZ&E0<= LO^ IZ_8JTUPE!?:1EE L;A^\J[,GY\5ZX/]2K=
MSG(W;_NE:-.UE4)V?,(F<W*(^M%4W K7008\K;VQ!@Z*-6TO&9X6[L$]S]YU
M@_Q<IO(PV2]6R]X-KU<-SI:+T[+W::U$6Z(M8VFPK;Q-:%=0TO=/LKZB,_'/
MN)?>)HGTCBQ96E3=W0:HV:\_ER&PQ* ^26 N _N3V2ZBT&X-5_8[K=5;3:[J
MN.DL&ZC2D%$O7?64'<Z;MOV;MG2'EXRK7S*NP2A$7IR-[?T3[G6D.:;O'ZVP
M2>IW' 7C1EA-0LV:Z?J!4"Y8=RH<G$!&N? ;XK"?VMGZ<[ @FD0=4[-^\E,9
MTE]-)BYN:=-YS VQ<,P(MX8EC>;5?=YL=N?!DA8Q^ZFP70O"/Y-OO[/TZY>$
M;KVA_/6/[]^)$=[IRPC5'PTK9S1EAIHBN!L&OOGQE>C_YGTS#%2/AB6MI04&
MF@CNBH&R_]M733%0-1J6RM*M,%!/<%<,E#K@76,,5(V&I19"*PS4$XPG:[3:
M]KJQS"$%C(1%_S9@C#:"!!9[]3K)B  _NU/G<YD;GL+#>'6Y>60.ZX'"PO-Q
M2F<T$4JM>.,H5/DHJQOW<T%;\,],L%\>?F9E#$SY?))RGU8UP&([-<0K$Y%@
M>^E@ 7.>!TE(-"FNYH9=E9WN,FZCKD+4PH1%(7X*LCREF5D1/F\$+T%\LIQ6
M0]3 DKR15Q5F?]K3)O!L\I-EC@J@!EASFY(%S1?%_9AZ3ZIL"T\$/UEF&9'R
MK3:3J-#IRD( BE_AF>$GQUX--OANBW$7?1]NBX?;XN&VN']N/CO3(HCE:>%^
M3D@FQ];=?!N:]?.\J[[YKB03;L,]&UI_:6ULB$41&)'2H-GL^VE"L]#9/"NV
M>7U!3WTK+(_:5*#$+ E1 >FGY/7WZ^COJL[OVQ_?(63@4/47?=5?'V6VATK#
M1NG<%D7EXSP;3V_(BL1OQ]-='=5?*4G%!.=K;1$SV  G=J%4!P2__-^Y!0ZK
M&&:[F2L8;MFCGV:YEL-.5.-CJ24?L:G4%IG7T&[U,:#)#>-\G-P'\?9QSMWW
MM%K3I1N6DT)#S' G'<R<@W+@JJ_<LUCEU7;HA;&.<9UUXDJYM\3?JII4-:NC
MJ8_\IM)5IMI?+OW0.)X)#U.Z+%.KGTU[?<72SRP)BYB93977<2K8LV0\B#^F
M+%_R\SC@7% M:V'_2N)(=)'+O2)9LK./ME[1OO5K*C>I8GX !FMN\=DLI0^Y
MG.G9^E_!6B9EKJA8NXE0;/\4?WA:C$WMW 8-T?^@'IAHU(++\XU(A5@#RITT
M,R(6TZT590$M$>);0 K3YAB&.V%4K&0Q6/9%QL[P+$BBXC6/G16T+UQ4)3$-
M?@*+IZ2^"#4.BB_K4U,X6#JEAXK6A^6'RF<RDL,7,HKB"GN+0F-0%%C:ED!M
M^C/]-P :JI#=#K!U;,+=U#Z33/H11IG8?)8Q*17,_9(F;#IU$A[W@4XK%+B&
M>$"A\Z6V3<6<FU?>N\]-4A*([Z^+S_%/;%5N9952"AO@1 H_ ]1I[+?F<QUV
M(0H);7XAH*UQ["=B;^=C_52(B6.=7,O>_3=AFBP+[01:(^:)90B+K9$"':[_
MIDH7U<'M4/2DH^W*@C>OM4?1GSG/BJ]L_,+B6\6ET95@3OG\92Z/Z;OR>)42
MW=200QWP?M0OK5\'O%F) 6OVW3(;I92+S\F/'Y16EB?D"[HBFYD>5EJN7!--
M#]W_>ZUF):@=?#WM!9IRWBV8[/LX )4/2(-EI; W.>Q07-[WXG0L+M\\\[T%
MGZBKSK?@0MJJ-UV"H[H!QE,OPI+O[:T,Z\+M)O[A2%IH.Y6DC80%-:A#ELA)
M98E<)U)99\)V^T0B&LK-1PM=9=O^;\SFW!-+ .#)D$$2L7_K15?Q,YJP!B-P
M^IG72!S=J*<;0V*VOA$:W,Q:MF+^>!+HC_9J>U^\3=<3T"QZ5BI\K/:8-.)G
M/_K<83:SDXL=,!)\*9X(;VTA:BKB0T:6\+.U^/S&Z9-$=V1FY7JH.5+_+U+<
M6 V&J)U5O9_.UL]PE0K)FU/N%BE6?^#^EYJKN>:!B+4C%T5$Z1U9D22O*0C5
M(_6_;EU-SMM"U*X*&$\G;/GFU6W*HCRTB*)J;E#@TG]W,@( 0*M](V\DLU-"
MMB!/#R2-F'VV8_?_TJU!0] --%]1%<H'_GKJP1_>?VSB_4>\OOA]G$-Q6ZTD
M2NVF=^R)A8EFWQ*(*+\<',UF*9D)HBSFKJ]\!!X$"U]=.<>:(=R_L]&!R^WR
M$XN]48.ES!6GP5/?MJ=>'31W$*_US" T6%_&6+EF1NS_ZJFVUAN%JG[<Y!<N
MIW&=R$ [N=3#C*Z*J!_[^$C'(?J? &'!Y%K8((N>VH1Z?D!=BO[HX&M3>=[<
M:0C6\GQ*M [6<N4IBGBB_48@0"VTB#FBR]R^%_PSA7W9D.>7;Y=B:\[6?,*R
M();)]+IY:P\0L &P<-:.3ZP^J7ZY?"2T6G96M,3"-R KF .1?CGV25AC*0WB
M.R*LYY"*;\[,Z]"N Y9#8CW^N="*8EML/:ZYY5+53IL>NCUNB'5V.T</L<Y*
M_+^#6.=^0-Y"E/0Y2Y=,J#BB!5K3X@3NXHU8&\GV?].AW:".O%BV/H1C]Q?"
MAP7L]F,(G> 5=)NR*<UD$2)IC14^8 7TAE98MEM'U)@E87[7RB:.3J:[WK%U
M$&O>:# UZX5=JN5/-65@R?]$8\(S)CZLDWI-BUYH%BVB1J+ 8!Y&?19_5ODH
M=&WZ?PL#8T4%()Y]3P>3JV!F+3ZB2G^HS\<^W)[],MR>(21SN#T;;L]ZP[_A
M]FRX/1MNSSKFV\G?G@W7+HB8,%R[X/+TMXA59_[Z71*P9H4K?^^%OT6YQ WD
MU(=0*W&:%EB$3@W*<\0:%;N[XMS[D20DI:%>L9F:H4-/O6:K20"#>$;9<AZD
MBR D>?&<IA[(JJ98-NT*,.W(  ,Z$N;<=3(E,@[;<%5O:H9%-58 64U"G?LK
MF5Y^R])L*JQ@IME83,W@[F??^TLU58WAJA5/<T,L:M.(E ;-%A>[?"*Y>,:N
MM+$^!PO]=N[8$ROB-IK!DCAXN,@\2&9DO"+IK=@?6:3+AS8T@]]Q^%86U535
ML*^6@LTDVKR>HC6OM*VP"*T1(V9)!ESGLMO?+\LIZ-6MK@T6"$WP,"L:ZN!7
MC5YCV+5@C]IA5P^Y[S.PZV<,&KC3P*Z#R!E9CFD\_<A8Q"=SFD:W\@:Y*I"H
MHE/_XX-K!R19(=0B_TH]<)V(K2H4<P:Q4S-&_T.1V^*N$;#NF'T>-L'N_2C]
MCX?NB.'/(<,9X?-^B/!!2.80X3-$^/2&?T.$SQ#A,T3X=,RW(<)GB/ 9(GRP
M1?@,B=5*_%M/K&YO!7PD;)8&R[F\U!^E)-#I(V,[+)?O[HK)@BQD_-&NMXJ6
M6'26&7$=6YI8.)R$/\[8ZF7(\B1+"[:\W_[EA?S+BU>O7[Q]73!@\\]_?+E7
M(+W_Q_ZKL"JDF9KD&OX]GHVGDSGY%TOCR'!#JF^&Q0RRA*Z:%'@@VN9%F2\)
MS31Z6]>DOZ$^9HH:P5(?SJ=MA$6]:M%1H->H+(Z3D,5LMM8?/)4-,.*F.5,:
MY@^_J'\25:F_K3<TPZ(.JQ&LIJ('X?0H(IB&<'H<X?3CY3R;!_&B0O/I6Z'#
M3N=/JZ  C.!GDJ>,AY0DH5[P](VP*+\*_*H(J&-.+VE:O!9KLJ75;; <VRLS
M.8SSA\? !FDDHW&SX('%--073C.UPV)'5V!H00,8QTLN1HTIGY.HVBM8W1C+
MKER!J"TA<%_K8I$GA<+]E2P%%O)/\LT7(FRHS+SAN';%$DA8 3F,++AM[BFA
M!D6$YI!0TYN$FB>/BVK!-+3"BJ1:"U024M,W62V7QG98+%([,"U(\7O_L66T
MT//W)%W1D.ANJ"I:@OCR'I$J-A.&CDM56EW?%IDZTN*N9T_#E9TEO>M'0V%G
M50/$*.H*->O) (/WD<8D60?Z2U/5[\A4>#5T!BK@I[HD2V5Y5%-<H*(!%I^"
M-78F,N F6<#I+-&+G?)W+*X$:^@,5("1N\EE;@'5;Q_J!EB<!M;8F<BH<[):
M!&$6W)$5BX/(D/UI;(CEU&H-I@TY-=;RE"9QD'XB7VE"N?YRV-P0B_WIL+JK
MR0&#6I0UX)+>1!][J6L#@O(7CU!64 )&\1_!UV!%M0"J?@9A]\$C=GHBX$9A
M3,B*A!]C*OY?;QKJ6\%LZU<^+<0J8N!@!O$JYQ]3EB_U4.K:P(#T>4JI( 4,
MX_^(C8NF6@15/\/ \WE.T5,!QFTD-BDJZ/^-9?D#U5O<QG8P)'V>6BS( 4-Z
M0=DJ2,PK6ML&!J7/4TP%*? #].-43)F8<=0W@@'I\TA310O\)E18H883H>IG
M&'H^SS!Z*L"X_2^+9R3A"[U6U+2 H>?SL&(DI,82_E.<)O\A_I?DAB6L:P2#
MT>=!I8H6,))BGTJIF*$6174#&((^CRLF.L#H_9/ROX)8?]!3_@[S8OL\I!C(
M@-^>>"ITV,(J'@H=#H4.44(X%#H<"AWB*W38@A4P%#J$J1LLR:Y#H<.AT*$[
M=X="AT.APX98'L8!YW1*PTVYPLM'N?O+::A5LT5[>-2(&QMC3!RTQN6 5XB*
M4OX\%*5$2.90E!+ 4[_GCZ$HY1/F#44IAZ*4B+@\%*5\PLBA*.50E'(H2CD4
MI3R5HI0H2I*AJ"(YE"0;2I(-)<GP7:Y])R7)4)1E'$J2#27)VL%.=YH:2I(-
M)<F&DF1#2;*A)-E0DFPH2=9J23(416^'DF2]*4EV/KZ]T&]>1S]BQ4VS<6GF
M[]=K[+=0%J::A4.A+#_+QG>AK.Z*[OA,0&^CZ$[WU3A\9J&W58W#7RKZJ6:B
M^ZQGY#,E_63K&?E,3V^UGI&?DC(^\]7;JRC3554CG_GJ+50U\I&L/N2JUP1P
M2%6'&^&GEJI^DPL:Y^*@JP5/TZ)_5;2,A,!E;[U(:3#7RY[J]_Y5T3*0 ;>T
MZ5]IH/?>JW[N7]$L/17P,U\4?%T1O;]8^7O_:F09R*BA[KJK].NU+E8KI7XG
M:;!BRY3QS%Q@S-BN?U6R+,@!0_H_E$:&S5?U<_\*9>FI .-V1MA*?^)0_-J_
MNEA:(N .@\X>)O!:#JN-EPFZ+6OGM2)6.V7M1G3!5G2F-UI4O\/ \WG(,) !
MANY3L/ZWR36@_!T&G<\CAH$,>$Q A^_8O/%YS&CE(9NN:J"^\7G,:*$&ZI<X
MHP\I,QO)^D8P#'V>-JIH@9O''54H?^/S?-%"A?++#A]2>N/S:&&B VXG=_Z\
MP!N?!XVVGA?HOJ;[&Y_'CE.JZ?[6YP&DM9KN_\M2J2WX.4EEZIT^[LC<$(:H
MSU.)#3TUKB[C3$[S/,B":1PL#%>8IH8P5'T>6&SH :/ZF; TB&78&)7A_I=:
M5,T-8:CZ/,G8T ,/.ESS+$@J=*F^$0Q-GZ>;*EK@=P%L*;.7QS%;"O&/:!6H
M5NUA^'H-\+(G"^[_68O],#-DYJD;P,#T>1 RT5'#?"(Q2\K_OPVR4']57]$2
MAJ?7PY$-06!@[V@6B#97 I#8$,-M:@:#U.=9J9H:,)YC&9RRG8@63D,K&)H^
MCTR5Q, =OYZ>X&AAN0]/< Q/<*"$<'B"8WB" ]\3'"@>01J>X,!4G7!X@F-X
M@L.=N\,3',,3'!J6(WK6X=WPK -",H=G'0 \]6O3=E6&'-.C#>A*E0QER-VL
MB:$,N1)_3:1?RV7(BQH?_]:+KN+G_EO?9LCU--<(Z4V73*@XO>M'TZ+_AJ\9
M:R/9?M7Z1\)F:;"<RZO244H"W29K;(?%=>>^VUJ0A8P_^K!'<TLL&[$9<1U;
MFE@XTX _%+/E:5;PY"6),R[_]J*$__6+MZ\+^,4__7&9IVRIUV2JG[O:I5MY
M>[$*<E9%MRL[. E_G+'5RY#E2986J^3]]B^2(>\/&++YYS^^W"M8L?_'_N_9
MEEQX3C)XRQYQ&HRFJ?C<*)='Q3C@IE)EU:VQ%"RS!-*:(KA1%"1!%(P2(5EB
M-QHMB/R8WD"J;HVE?)DEPM84P<.(#NI<!^E78CBC5C7%4L7,5AE;D0,'5C!K
M)BRHCRG[ELTKL:UNC:6JF2V\MA3U+A8&Q3-90RQ,#V)A.HSE\!8'TTX43,=1
M1-XB8>I&$7V?L3 H'ND:8F$PG?UZ'PLSXIO[^?&T>!/Y,\ED2QA?JP;K_UF_
M+7[;(?<=Q42ANBD88J+:CXGZZ3MD>#]BHGY"'1-U1T*6A#2FF^F7$//KY%I0
ME,RH,*%&G),B?4;RXQN-8YNPJ=KC8HRL.IJ[76!553<L1T>G.2OLZ89X[O<$
M=1ZDZ5JHJ]%"7L",PC!?Y'$@CH071' B+&D3/TJU4/XYB:X7RX"F4@E(RE+&
M^;-1-#ZNEC^%4:[JRPCK$CQ,LFBX0=$WPR(#K;-+*1;X'#0*,O3A#55M^^\
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M_P%02P$"% ,4    " #13/50D9KI74?1 0"<IBL $               @ $
M    ;G9S+3(P,C P-C,P+GAM;%!+ 0(4 Q0    ( -%,]5 Q;@G6((H  )1[
M!P 0              "  771 0!N=G,M,C R,# V,S N>'-D4$L! A0#%
M  @ T4SU4)"AW%5.#P  R_L  !0              ( !PUL" &YV<RTR,#(P
M,#8S,%]C86PN>&UL4$L! A0#%     @ T4SU4&T\9G+^8@  %R ' !0
M         ( !0VL" &YV<RTR,#(P,#8S,%]D968N>&UL4$L! A0#%     @
MT4SU4 ]_A>RE9P( V7T: !0              ( !<\X" &YV<RTR,#(P,#8S
M,%]L86(N>&UL4$L! A0#%     @ T4SU4+5"^WST9   ,WX' !0
M     ( !2C8% &YV<RTR,#(P,#8S,%]P<F4N>&UL4$L%!@     &  8 A $
' '";!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
